PROGRAMME

THE INTERNATIONAL LIVER CONGRESS™
APRIL 13-17, BARCELONA, SPAIN

2016

See you next year in AMSTERDAM
19-23 April 2017

www.ilc-congress.eu
DOWNLOAD THE INTERNATIONAL LIVER CONGRESS™ 2016 APP ON YOUR MOBILE DEVICE!

The ILC 2016 app provides full-access to the scientific programme, posters and abstracts, as well as maps of the halls and exhibition area.

See who’s attending, search the full programme, save your favourite sessions, create notes, and interact with speakers while they are presenting.

Download the ILC 2016 app now!

Discover all the features of our Congress app at ilc-congress.eu/mobile-app
Follow the colour codes and pictogrammes throughout this book to find the sessions of interest to you!

What’s your colour?
# TABLE OF CONTENTS

**General Information** .................................................................................................................. 5
  Maps................................................................................................................................. 6
  Opening Hours.................................................................................................................... 12
  Ribbons & Badges .............................................................................................................. 14
  Welcome Messages ............................................................................................................ 15
  Congress Information/Venue ............................................................................................. 18
  Scientific Programme Overview .......................................................................................... 22

**EASL** ........................................................................................................................................ 27
  Mission & Vision ................................................................................................................. 28
  EASL Governing Board & Honorary President ................................................................. 30

**Awards** .................................................................................................................................. 33
  Hall of Fame ....................................................................................................................... 34
  Recognition Awards .......................................................................................................... 39
  EASL Fellowship Awards ................................................................................................... 40
  EASL Young Investigator Awards ....................................................................................... 42
  EASL Registry Grant Awards ............................................................................................. 42
  EASL Mentorship Awards ................................................................................................. 43
  Award Ceremonies ............................................................................................................. 43

**Travel Information** .................................................................................................................. 45
  Congress Shuttles .............................................................................................................. 47
  Public Transport ............................................................................................................... 48

**Technical Information for Presenters** .................................................................................... 51

**Scientific Programme** ............................................................................................................. 55
  What’s New? ....................................................................................................................... 56
  Session Format Descriptions ............................................................................................... 62
  Programme Week at a Glance .............................................................................................. 66
  Daily Programme at a Glance ............................................................................................. 68
  Wednesday 13 April ............................................................................................................ 79
  Thursday 14 April ............................................................................................................... 93
  Friday 15 April .................................................................................................................... 111

---

**VIEW THE PROGRAMME & ABSTRACTS ON YOUR MOBILE DEVICE!**

Download the ILC 2016 congress app.
TABLE OF CONTENTS (CONT.)

Saturday 16 April ................................. 133
Sunday 17 April ..................................... 153

Posters ................................................. 161
  Late-Breaker Posters ......................... 161
Thursday 14 April ............................... 169
Friday 15 April..................................... 259
Saturday 16 April ............................... 347

Acknowledgements .............................. 433
  Abstract Reviewers ............................ 434
  Sponsors ............................................. 436

Industry .............................................. 439
  Industry Satellite Symposia ................. 440
  Exhibition Info .................................. 450
  Exhibition Floor Plan ....................... 451
  Exhibitor’s List ................................. 452
  Company Profiles ............................. 454
  Associations’ Profiles ....................... 477
  National Associations’ Village ............. 480

Is your name on the list?
GENERAL INFORMATION

EASL THE HOME OF HEPATOLOGY
GENERAL SITE PLAN
CONGRESS CENTRE AND MAP

NORTH ENTRANCE
- Registration
- Speakers’ ready room
- Executive lounge
- Press office

HALL 8.0
- Plenary hall 8.0 (A1-E8)
- The Home of Hepatology

HALL 8.1
- Exhibition
- Poster areas
- CCS meeting rooms

HALL 6.0
- Plenary hall 6.0
- Tibidabo suite
- CCA meeting rooms
<table>
<thead>
<tr>
<th>Hall 8.0</th>
<th>Ground Floor</th>
</tr>
</thead>
<tbody>
<tr>
<td>A1</td>
<td>B1</td>
</tr>
<tr>
<td>B2</td>
<td>C1</td>
</tr>
<tr>
<td>D1</td>
<td>E3</td>
</tr>
<tr>
<td>D2</td>
<td>E2</td>
</tr>
<tr>
<td>E1</td>
<td>Press Office</td>
</tr>
</tbody>
</table>

**Wednesday - Sunday**

- **Hall 8.0**
  - General Information
  - Program Information
  - Congress Material
  - Poster Area
  - Press Room
  - Exhibition

---

**HALL 8.0**

**Ground Floor**

- **A1**
  - Paying Catering Outlet
  - ILC Sponsored Coffee & Lunch Breaks

- **B1**
  - A1

- **B2**
  - B1

- **C1**
  - C1

- **D1**
  - D1

- **D2**
  - D2

- **E1**
  - E1

- **E2**
  - E2

- **E3**
  - E3

**Registration**

- **1**
  - Hall 8.0: Exhibition, Poster Area, CC8 Meeting rooms
  - Hall 8.0: Paying Catering Outlet

- **2**
  - Hall 8.0: Registration
  - Hall 8.0: Exhibition, Poster Area, CC8 Meeting rooms

- **3**
  - Hall 8.0: Registration
  - Hall 8.0: Exhibition, Poster Area, CC8 Meeting rooms

- **4**
  - Hall 8.0: Registration
  - Hall 8.0: Exhibition, Poster Area, CC8 Meeting rooms

---

**EASL THE HOME OF HEPATOLOGY**
## OPENING HOURS

### GROUP BADGE PICK-UP
- Monday 11 April  14:00-18:00
- Tuesday 12 April  08:00-14:00

### REGISTRATION
- **Tuesday 12 April**  16:00-20:00
- **Wednesday 13 April**  07:00-19:00
- **Thursday 14 April**  07:00-19:00
- **Friday 15 April**  07:00-19:00
- **Saturday 16 April**  07:00-19:00
- **Sunday 17 April**  07:00-14:00

### EXECUTIVE LOUNGE & FACULTY REGISTRATION
- **Tuesday 12 April**  16:00-19:00
- **Wednesday 13 April**  07:00-19:00
- **Thursday 14 April**  07:00-19:00
- **Friday 15 April**  07:00-19:00
- **Saturday 16 April**  07:00-19:00
- **Sunday 17 April**  07:00-14:00

### CLOAKROOM
- **Wednesday 13 April**  07:00-19:00
- **Thursday 14 April**  07:00-19:00
- **Friday 15 April**  07:00-19:00
- **Saturday 16 April**  07:00-19:00
- **Sunday 17 April**  07:00-14:00

### SPEAKERS’ READY ROOM
- **Tuesday 12 April**  16:00-20:00
- **Wednesday 13 April**  07:00-19:00
- **Thursday 14 April**  07:00-19:00
- **Friday 15 April**  07:00-19:00
- **Saturday 16 April**  07:00-19:00
- **Sunday 17 April**  07:00-13:30

### THE HOME OF HEPATOLOGY – HALL 8.0
- **Wednesday 13 April**  07:00-18:30
- **Thursday 14 April**  07:00-18:30
- **Friday 15 April**  07:00-18:30
- **Saturday 16 April**  07:00-18:30
- **Sunday 17 April**  08:00-14:00

### PRESS OFFICE
- **Tuesday 12 April**  16:00-20:00
- **Wednesday 13 April**  07:00-19:00
- **Thursday 14 April**  07:00-19:00
- **Friday 15 April**  07:00-19:00
- **Saturday 16 April**  07:00-19:00
- **Sunday 17 April**  07:00-14:00
POSTER AREA – HALL 8.1
open to the public
- Thursday 14 April 08:00-18:00
- Friday 15 April 08:00-18:00
- Saturday 16 April 08:00-18:00
open to presenters
- Poster set-up:
  - Thursday to Saturday 07:00-08:00
- Removal of posters:
  - Thursday to Saturday 18:00-19:00
- Poster help desk:
  - Thursday to Saturday 07:00-19:00

EXHIBITION – HALL 8.1
Thursday 14 April 09:30-16:30
Friday 15 April 09:30-16:30
Saturday 16 April 09:30-16:30

SET-UP
- Monday 11 April 08:00-22:00
  (Booths 50m² and larger)
- Tuesday 12 April 08:00-22:00
- Wednesday 13 April 08:00-16:00

DISMANTLE
- Saturday 16 April 18:00-24:00*
- Sunday 17 April 07:00-18:00
*No truck loading will be permitted after 21:30.

MEETING ROOMS – CC7 & CC8
- Wednesday 13 April 07:00-19:00
- Thursday 14 April 07:00-19:00
- Friday 15 April 07:00-19:00
- Saturday 16 April 07:00-19:00
- Sunday 17 April 07:00-14:00

PRAYER ROOM – HALL 8.1
- Wednesday 13 April 07:00-19:00
- Thursday 14 April 07:00-19:00
- Friday 15 April 07:00-19:00
- Saturday 16 April 07:00-19:00
- Sunday 17 April 07:00-14:00
## COLOURED RIBBONS

The coloured ribbons attached to the congress badges indicate the following:

<table>
<thead>
<tr>
<th>Colour</th>
<th>Role</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blue</td>
<td>EASL member</td>
</tr>
<tr>
<td>Blue</td>
<td>EASL Governing Board or EASL staff</td>
</tr>
<tr>
<td>Green</td>
<td>New EASL member</td>
</tr>
<tr>
<td>Yellow</td>
<td>Faculty</td>
</tr>
<tr>
<td>Orange</td>
<td>Young investigator</td>
</tr>
<tr>
<td>Black</td>
<td>EASL Secretary General, EASL Vice-Secretary, ILC Honorary President</td>
</tr>
</tbody>
</table>

## COLOURED BADGE HOLDERS

<table>
<thead>
<tr>
<th>Colour</th>
<th>Role</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blue</td>
<td>Delegates</td>
</tr>
<tr>
<td>Blue</td>
<td>Exhibitors</td>
</tr>
<tr>
<td>Black</td>
<td>Media</td>
</tr>
</tbody>
</table>
Dear Colleagues,

Welcome to Barcelona and thank you for joining us at The International Liver Congress™ 2016 (ILC) for the 51st annual meeting of the European Association for the Study of the Liver (EASL), The Home of Hepatology!

We’re delighted to have you with us at the Fira Barcelona Gran Via, North Entrance, Spain, for the congress week, 13-17 April 2016.

This year, the readability of the ILC scientific programme is enhanced and the poster format enables even better interactivity, efficient discussions, and easier access, bringing you the best science and increased exposure to authors. Traditional paper posters will be on display in addition to electronic data to ensure that all attendees have the experience they desire.

The 2016 scientific programme will comprise:

• management of liver tumours

• scientific advances in the growing field of ‘gut-liver axis’

• a clinical hepatology lecture addressing novel approaches to cure hepatitis B

• challenging case-studies and animated debates/workshops on NAFLD, cirrhosis, hepatitis, hepatocellular carcinoma, and autoimmune liver disease

• updates on diagnostic, prognostic and therapeutic procedures across a broad range of liver-related topics, tissue engineering and animal models, public health issues, and imaging and interventional medicine.

Selected sessions and posters will be webcast of course and made available on the LiverTree™ for EASL members to view.
Accepted abstracts will be published as a supplement to the Journal of Hepatology.

The Journal of Hepatology is the fastest growing and most consistently impactful hepatology publication globally. Its Impact factor marks our success and EASL’s commitment to providing the liver community with the most up-to-date work and data of the highest quality.

Young investigators, clinicians, basic scientists, nurses, and researchers – ILC 2016 will broaden your horizons in Hepatology by giving you access to the latest data in your specialty. Enjoy this exciting week of liver discoveries and exchange!

Warmest regards,

LAURENT CASTERA
EASL Secretary General

TOM HEMMING KARLSEN
EASL Vice-Secretary
WELCOME MESSAGE FROM THE HONORARY PRESIDENT

On behalf of EASL – The Home of Hepatology, it’s my pleasure to welcome you to Barcelona for the 51st annual meeting of our Association – The International Liver Congress™ 2016.

During the past 50 years, our society has grown into a world leader in hepatology, attracting a growing number of scientists and clinicians from five continents to annual gatherings with over 10,000 delegates at last year’s meeting in Vienna. Over the years, efforts made in leadership by the EASL Governing Board, together with the academic excellence promoted by the Editors and Associate Editors of the Journal of Hepatology, have led to new and high standards affecting hepatology worldwide and our membership in particular.

Barcelona is known for its rich cultural heritage, pre-dating Roman times, and extends into the 21st century. This marvellous metropolis is renowned for treasures such as the architectural works of Antoni Gaudí and Lluís Domènech i Montaner as well as for its outstanding soccer team...

Last, but not least, we all cherish the significant scientific contributions to hepatology made during the past decades by our hosts in Spain in general, and in Barcelona in particular, by a growing number of brilliant scientists and clinicians.

These are exciting times for hepatologists witnessing recent progress made in understanding and controlling viral, metabolic and neoplastic liver diseases. It is therefore a great pleasure to welcome you all to Barcelona as Honorary President of The International Liver Congress™ 2016 which is expected to reach new heights in terms of scientific quality, as well as professional and social interaction.

Daniel Shouval, MD
Honorary President of The International Liver Congress™ 2016

Prof. DANIEL SHOUVAL
MD
CONGRESS INFORMATION

CONGRESS VENUE

Fira Barcelona Gran Via, North Entrance
Carrer del Foc, 37
08038 Barcelona, Spain

Metro station Fira: 8 min walk
Metro station Europa Fira: 20 min walk

IMPORTANT: Taxi – Ask the taxi driver to take you to the Fira Barcelona Gran Via NORTH ENTRANCE – Hall 8 (Carrer del Foc 37).

CONGRESS SHUTTLES

EASL congress shuttles will transport ILC delegates to the North Entrance of the Fira Barcelona Gran Via (Hall 8.0).

On the journey to the congress venue, the shuttles will stop at:

• Metro station “Europa/Fira” (at Joan Carles I street)
• SB Plaza Europa Hotel (at Alumini Street, just round the corner from the hotel entrance- turn right when you exit the hotel)
• North Entrance (Hall 8.0) (at Alumini Street)
• Metro station “Fira”

The shuttles will depart every 15 minutes and the journey to the venue will take approximately 5-10 minutes depending on where you got on. The shuttles will do repeat journeys of the same circuit.
The shuttles are free of charge and are operating from 13-17 April 2016 during the following times:

**Wednesday 13 April** 06:45-20:15  
**Thursday 14 April** 06:45-20:15  
**Friday 15 April** 06:45-20:15  
**Saturday 16 April** 06:45-20:15  
**Sunday 17 April** 06:45-14:45

**WI-FI INTERNET CONNECTION**

Select the “ILC Free Wi-Fi” network and click on “connect”. Enter the password: barcelona2016. The Wi-Fi connection will be available throughout the congress centre.

We ask you to avoid downloading heavy files, movies or music during the congress as it will affect the connection speed for other attendees.

**REGISTRATION**

The congress venue will be accessible at the same times as the registration opening hours.

**Tuesday 12 April** 16:00-20:00  
**Wednesday 13 April** 07:00-19:00  
**Thursday 14 April** 07:00-19:00  
**Friday 15 April** 07:00-19:00  
**Saturday 16 April** 07:00-19:00  
**Sunday 17 April** 07:00-14:00

On-site registration, congress material pick-up, and badge collection will be available at the registration area.

**YOUNG INVESTIGATOR BURSARIES**

The payment of YI bursaries depends on the day of your presentation, and will be processed as follows:

- Oral presentations: bursary payment as of Friday 15 April 14:00
- Poster presentations on Thursday 14 April & Friday 15 April: bursary payment as of Friday 15 April 14:00
PROGRAMME

• Poster presentations on Saturday 16 April: bursary payment as of Saturday 16 April at 14:00

Note: Bursaries will only be paid to young investigators who attend the congress and display their research on the assigned presentation day (before 08:00), and also submitted their ePoster prior to the congress. Kindly note that a passport, driving license or other official identification proofs will be requested to verify your identity.

BADGES

All delegates and exhibitors are requested to wear their congress badges at all times. Delegates not wearing the congress badge will not be granted access past the registration area.

Delegates

Delegates are admitted into the lecture halls and other scheduled activities, as well as the catering areas. Only delegates who have pre-booked hands-on sessions or early morning workshops (EMW) will be admitted to those sessions.

Exhibitors

Exhibitors are admitted into the exhibition as well as the catering areas, but have no access to the lecture halls (in Hall 8.0 & Hall 6.0).

They can however attend the industry satellite symposia of their respective company.

Badges for the exhibitor’s build-up and dismantling staff will be given on-site by congress centre staff.

Lost badges

EUR 25.00 (+21% VAT) will be charged for replacing a lost badge and for re-printing due to incorrect submission of names and/or company names or addresses.
POSTER AREA – HALL 8.1

Poster area open to the public:

Thursday 14 April     08:00-18:00  
Friday 15 April       08:00-18:00  
Saturday 16 April    08:00-18:00

Poster area open to presenters:

Poster set-up Thursday to Saturday  07:00-08:00  
Removal of posters Thursday to Saturday  18:00-19:00  
Poster help desk Thursday to Saturday  07:00-19:00
SCIENTIFIC PROGRAMME

Please check the scientific programme section for detailed information on all sessions.

Opening ceremony & General session I

The opening ceremony and general session 1 will take place in Hall 6.0 on Thursday 14 April at 13:30.

Early morning workshops

Pre-registration is compulsory if you wish to attend the early morning workshops (EMW). A fee of EUR 24.20 (21% VAT included) is applied. Only delegates registered to the ILC may sign-up for early morning workshop sessions.

Pre-registration to EMW on-site may be processed at the additional service booking desk in the registration area.

Hands-on sessions

Pre-registration is compulsory if you wish to attend the sonography and ultrasound courses. A fee of EUR 24.20 (21% VAT included) is applied. Only delegates registered to the ILC may sign-up for the hands-on sessions.

Pre-registration to hands-on sessions on-site may be processed at the additional service booking desk at the registration area.

Posters

At ILC 2016, EASL is returning to paper poster format for presentation, but will also be making all posters available electronically via ePoster kiosks in the congress hall and online via the LiverTree™.

Paper posters

From Thursday to Saturday EASL will present the latest scientific data in the field on poster boards in the poster area (Hall 8.1).

ePosters

Each poster presenter is also required to submit an electronic version of their paper poster. Throughout the congress week, this electronic version will be
accessible on plasma screens at The Home of Hepatology (EASL booth – Hall 8.0) and in the paper poster area (Hall 8.1).

Unlike the paper posters which are only displayed for 1 day, ePosters are available every day (Wednesday 13 April to Sunday 17 April) on multiple screens in Hall 8.1 and Hall 8.0, and simultaneously on the LiverTree™.

**SPEAKERS’ READY ROOM / EXECUTIVE LOUNGE & FACULTY REGISTRATION**

Faculty registration will take place at the executive lounge, located on the left-hand side when entering the Fira Barcelona Gran Via, North Entrance.

The speakers’ ready room will be available every day throughout the congress for invited speakers and oral presenters.

<table>
<thead>
<tr>
<th>Day</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tuesday 12 April</td>
<td>16:00-20:00</td>
</tr>
<tr>
<td>Wednesday 13 April</td>
<td>07:00-19:00</td>
</tr>
<tr>
<td>Thursday 14 April</td>
<td>07:00-19:00</td>
</tr>
<tr>
<td>Friday 15 April</td>
<td>07:00-19:00</td>
</tr>
<tr>
<td>Saturday 16 April</td>
<td>07:00-19:00</td>
</tr>
<tr>
<td>Sunday 17 April</td>
<td>07:00-13:30</td>
</tr>
</tbody>
</table>

Technicians will be available to assist speakers during the above hours.

Access to the speaker’s ready room is strictly restricted to invited speakers and oral presenters.

**CME ACCREDITATION**

“The International Liver Congress™ 2016” is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS), www.uems.net.

“The International Liver Congress™ 2016” is designated for a maximum of 27 hours of European external CME credits. Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME credits
to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME credit to AMA credit can be found at www.ama-assn.org

Live educational activities, occurring outside of Canada, recognized by the UEMS-EACCME for ECMEC credits are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of The Royal College of Physicians and Surgeons of Canada.

Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity. The EACCME credit system is based on 1 ECMEC per hour with a maximum of 3 ECMECs for half a day and 6 ECMECs for a full-day event.

ATTENDANCE AND CME CERTIFICATE

CME evaluation form

A link directing to the CME evaluation form will be sent to you by e-mail after the congress. In order to receive your certificate of attendance, the congress survey and CME evaluation form must be completed online.

Certificate of attendance

Please note that a completed CME evaluation form is a pre-requisite in order to receive your certificate of attendance. Upon completion of all mandatory online evaluations, the ILC registration agency will send you an electronic version of your certificate of attendance by e-mail.

**IMPORTANT:** No printed certificate of attendance will be available on-site.

Contact update stations

Contact update stations will be available in the registration area. **It is highly recommended to check that the email address entered in the system corresponds to your personal email** and not a group email address, otherwise you will not receive your certificate of attendance.
EXHIBITION

The exhibition is located in Hall 8.1. Please refer to the list of Exhibitors on page 452 for further information.

Opening hours

Thursday 14 April 09:30-16:30
Friday 15 April 09:30-16:30
Saturday 16 April 09:30-16:30

THE HOME OF HEPATOLOGY

For information on all EASL has to offer, come and visit us in Hall 8.0 at The Home of Hepatology (EASL booth): Science and Education, EASL Membership, the Journal of Hepatology, EU Affairs, Events, ePosters, and our National Association Village!

Opening hours

Wednesday 13 April 07:00-18:30
Thursday 14 April 07:00-18:30
Friday 15 April 07:00-18:30
Saturday 16 April 07:00-18:30
Sunday 17 April 08:00-14:00

CATERING

Business lunches and coffee/tea during breaks, are included in the registration fee. The serving times are indicated in the weekly overview on page 66.

Catering locations

Wednesday 13 April
Lunch & coffee breaks: Hall 8.0 and Hall 6.0

Thursday 14 April – Saturday 16 April
Lunch: Hall 8.1 and Hall 8.0
Coffee breaks: Hall 8.1

Sunday 17 April
Lunch & coffee breaks: Hall 8.0
FUTURE MEETINGS AND CONFERENCES

Information on future EASL and non-EASL meetings, conferences, and events, may be found at The Home of Hepatology, EASL’s booth, in Hall 8.0.

SMOKING POLICY

Smoking is prohibited at all times in all congress centre areas.

MOBILE PHONES

Mobile phones must be switched to silent mode during all sessions.

CLOAKROOM

Cloakroom facilities are available in the registration area (North Entrance) at the following times:

- Wednesday 13 April 07:00-19:00
- Thursday 14 April 07:00-19:00
- Friday 15 April 07:00-19:00
- Saturday 16 April 07:00-19:00
- Sunday 17 April 07:00-14:00

ACCOMMODATION

b network is the official housing agency for The International Liver Congress™ 2016 (ILC) and is offering special reduced rates for sponsors, exhibitors, and attendees.

The b network team will be happy to answer any questions on-site at the accommodation desk in the registration area.
EASL MISSION & VISION

EASL is a renowned community of clinicians and scientists striving to promote liver research and improve the treatment of liver diseases worldwide.

EASL VISION

Many Ways, One Aim: Beating Liver Disease.

OUR MISSION

• To be the Home of Hepatology so that all who are involved with liver disease can realize their full potential to cure and prevent it
• To promote research in the science of liver disease (Hepatology)
• To promote state-of-the-art education for physicians and scientists
• To foster public awareness of liver diseases and their management, and act as an advisor to European Health authorities
• To facilitate scientific exchanges and catalyse European multi-centre controlled trials
• To support young investigators to ensure that the liver remains at the forefront of research

OUR GOAL

To reduce the burden of liver disease in Europe by advocating for more research funding and effective prevention policies.

CONTRIBUTE TO ILC

Join the liver community on Facebook and Twitter.

HAVE YOUR SAY!

@EASLnews #ILC2016 #EASL

Like us on EASL facebook
EASL is delighted to announce the Perspectives Art Exhibition during the International Liver Congress™ 2016 in Barcelona.

The pieces can be viewed and purchased at the gallery during the Congress.

For further information go to: ilc-congress.eu/perspectives
EASL GOVERNING BOARD

SECRETARY GENERAL

Dr. Laurent Castera
*Paris, France*

Prof. Tom Hemming Karlsen
*Oslo, Norway*

Prof. Mauro Bernardi
*Bologna, Italy*

VICE-SECRETARY

TREASURER

SECRETARY GENERAL

VICE-SECRETARY

TREASURER

SCIENTIFIC COMMITTEE MEMBERS

Dr. Alessio Aghemo
*Milan, Italy*

Dr. Alejandro Forner
*Barcelona, Spain*

Dr. Helen Louise Reeves
*Newcastle-upon-Tyne, United Kingdom*

Prof. Cecilia Rodrigues
*Lisbon, Portugal*

Prof. Frank Tacke
*Aachen, Germany*
EDUCATIONAL COUNCILLORS

Prof. Francesco Negro  
*Geneva, Switzerland*

Prof. Massimo Pinzani  
*London, United Kingdom*

Prof. Patrizia Burra  
*Padua, Italy*

EU POLICY COUNCILLOR

Prof. Daniel Shouval  
*Jerusalem, Israel*

EXECUTIVE DIRECTOR

Grégoire Pavillon  
*Aclens, Switzerland*

ILC 2016 HONORARY PRESIDENT
2 day Post-Graduate Course Management of liver tumours

Wednesday 13, 11:30-17:30
Thursday 14, 08:30-12:00

Download the app

Test your knowledge

Take part in our interactive session
HALL OF FAME

EASL IS EXCELLENCE!

A decade ago, EASL introduced the Recognition Awards to acknowledge the men and women who are writing the history of EASL. The awards are our way of saying ‘Thank You’ to the scientists in the liver research field who dedicate their lives and careers to hepatology by providing major scientific contributions.

EASL Recognition Awardees

2006, Vienna

Prof. Jaime Bosch
“Developed one of the most famous research centres for the study of portal hypertension.”

Prof. Mario Rizzetto
“A source of pride for Italian research and a scientific and clinical reference for international hepatology.”

2007, Barcelona

Prof. Michael P. Manns
“30 years on the frontline of the war against hepatitis.”

Prof. Christian Trépo
Science is a joy for me. Lyon is the place to be.
2008, Milan

Dr Andrés T. Blei
“Andy was an excellent clinician and a productive researcher with profound curiosity.”

Prof. Peter Ferenci
“An accomplished, internationally-renowned clinical researcher in hepatology with a brilliant and exciting academic career.”

Prof. Juerg Reichen
“One of the most brilliant and hard-working colleagues I have ever met.”

2009, Copenhagen

Prof. Ding-Shinn Chen
“Accomplished scientist, physician, role model, mentor and teacher, medical administrator, public health specialist, highly respected colleague, and dear friend.”

Prof. Raoul Poupon
“Inspiring with creative thinking, provocative questions, and deep interest in basic mechanisms of unresolved clinical problems in our field.”

Prof. Daniel Shouval
“A truely global player and highly successful scientific mentor.”

2010, Vienna

Prof. Massimo Colombo
“Awarded for his outstanding medical and scientific contribution. A former Editor-in-Chief of the Journal of Hepatology.”

Dr. Jenny Heathcote
“Acknowledged as a senior scientist who has changed the world of health and healthcare.”
### 2010, Vienna (Cont.)

**Prof. Howard Thomas**

“Proud owner of a large collection of research medals and distinction awards accumulated over a 50 year career.”

### 2011, Berlin

**Prof. Vicente Arroyo**

“Fostered outstanding advancements in the pathophysiology and clinical management of chronic liver failure.”

**Prof. Stephen Locarnini**

“His substantial input has shaped clinical practice in most parts of the world.”

### 2012, Barcelona

**Prof. Scott L. Friedman**

“Talent, passion, and honesty.”

**Prof. Peter L.M. Jansen**

“A brilliant physician scientist, bridge builder, and creative thinker.”

**Prof. Helmer Ring-Larsen**

“A scientific reference.”

### 2013, Amsterdam

**Prof. Andrew K Burroughs**

“One of the most influential and inquisitive hepatologists worldwide.”

**Dr Didier Lebrec**

“A career full of creative scientific thoughts spanning over four decades.”
### 2013, Amsterdam (Cont.)

**Prof. Yun-Fan Liaw**
“One of the major hepatologist gentlemen.”

**Prof. Jesus Prieto**
“A visionary academic leader and pioneer.”

### 2014, London

**Prof. Geoffrey M. Dusheiko**
“One of the world's most requested KOLs in the development of new therapies for viral hepatitis B and C.”

**Prof. Guadalupe Garcia-Tsao**
“Lupe makes a clear difference in the lives of all who have had the privilege to work with her.”

**Prof. Tilman Sauerbruch**
“A successful academic physician, a superb mentor to trainees, and a wonderful clinician to his patients.”

### 2015, Vienna

**Prof. Dominique Charles Valla**
“A complete hepatologist; brilliant, comprehensive, enthusiastic, generous, an excellent teacher and leader.”

**Prof. Shiv Kumar Sarin**
“Intense dedication, vision and work – he is a role model for his country and represents the future of Asia.”

**Prof. Roberto de Franchis**
“Commitment to excellence and special pride for clinical research.”

Discover the Recognition Awardees 2006-2016

www.ilc-congress.eu/ilc-2016-barcelona/hall-of-fame
Visit
The Home
of Hepatology
HALL 8.0

THE PLACE TO BE
EASL RECOGNITION AWARDS

EASL’s annual award recognises the outstanding contribution of an individual to liver diseases care and research in Europe.

The following awards will be presented during general session 2, Friday 15 April between 08:30 and 10:30 in Hall 6.0.

Antonio Craxi, Italy

Jordi Bruix, Spain

Roberto Groszmann, United States

EASL photographers and film crew will be present throughout The International Liver Congress™ 2016 - you can find all official footage at the ILC website.
EASL FELLOWSHIP PROGRAMME

Physician Scientist

**Philipp Lutz, Germany**
Role of peritoneal T-lymphocytes in cirrhosis-associated immune dysfunction

Post-Doc

**Pedro Melgar Lesmes, United States**
Boosting liver regeneration via stimulation of M2 pathways in macrophages using matrix-embedded endothelial cells and gene therapy with nanoparticles

**Patricia Muñoz, Spain**
Characterization of non-coding RNAs in cholangiocarcinoma (CCA): consequences in tumour heterogeneity and drug resistance

**Eric Trepo, Belgium**
Hepatocellular carcinoma germline mutations impact (HEGEMONIC)
Entry Level

**Graziella Privitera, Italy**
Assessment of glucocorticoid resistance in acute-on-chronic liver failure: clinical relevance

**Muhammed Yuksel, Belgium**
Investigation of mechanisms of pregnancy-mediated tolerance in autoimmune hepatitis in mice and women

**Davide Roccarina, Italy**
Markers of cardiovascular morbidity and their association with liver disease severity in patients with NAFLD
EASL YOUNG INVESTIGATOR AWARDS

EASL introduced the Young Investigator Award in 2015 to recognize the international liver research achievements of young fellows. The EASL Governing Board and Young Investigator Concerted Action Group has selected the following awardees to receive the 2016 YI award.

EASL YI awards

Jordi Gracia-Sancho, Spain
Veronika Lukacs-Kornek, Germany

EASL Registry Grants

Jesus M. Banales, Spain
European registry data collection on cholangiocarcinoma

Ken Simpson, United Kingdom
European study of the epidemiology, management and outcome of acute liver failure

Deirdre Anne Kelly, United Kingdom
Long term graft outcome
EASL Mentorship programme

Nina Kimer, Copenhagen University Hospital Hvidovre, Denmark
Mentor: Marsha Y Morgan – UCL Institute for Liver & Digestive Health, University College London, United Kingdom

Sharat Varma, Cliniques universitaires Saint-Luc, Belgium
Mentor: Ulrich H.W. Beuers – Academic Medical Centre of the University of Amsterdam, The Netherlands

EASL AWARD CEREMONIES

FRIDAY 15 APRIL 2016
09:15-09:45
HALL 6

Award ceremony I
EASL Recognition Awards

SATURDAY 16 APRIL 2016
09:15 – 09:45
HALL 6

Award ceremony II
EASL Sheila Sherlock Fellowships
EASL Physician Scientist Fellowships
EASL Registry Grants
Best Basic and Best Clinical Oral Abstract Awards
Best Poster Presentation Awards
Young Investigator Awards
NEW PERSPECTIVES IN HEPATITIS C VIRUS INFECTION - THE ROADMAP FOR CURE

23–24 SEPTEMBER 2016
PARIS, FRANCE

Scientific Organising Committee
Thomas Berg, Germany
Raymond Chung, United States
Xavier Forns, Spain
Norah Terrault, United States

REGISTER OR SUBMIT YOUR ABSTRACTS TODAY!

KEY DEADLINE:
Abstract submission: 27 June 2016

SPONSORSHIP OPPORTUNITIES
industry@easloffice.eu

www.easl.eu
TRAVEL INFORMATION

13-17 APRIL 2016
BARCELONA, SPAIN

NEW PERSPECTIVES IN HEPATITIS C VIRUS INFECTION - THE ROADMAP FOR CURE
23-24 SEPTEMBER 2016
PARIS, FRANCE

Scientific Organising Committee
Thomas Berg, Germany
Raymond Chung, United States
Xavier Forns, Spain
Norah Terrault, United States

Co-organised by:

SPONSORSHIP OPPORTUNITIES industry@easloffice.eu

REGISTER OR SUBMIT YOUR ABSTRACTS TODAY!

KEY DEADLINE:
Abstract submission: 27 June 2016

www.easl.eu
www.easl.eu/_events
TRANSPORTATION

The International Liver Congress™ 2016 is to be held at the Fira Barcelona Gran Via, North Entrance. The venue is easily accessible by bus or metro.

Arriving by plane

Barcelona International Airport (El Prat Airport) is located only 8 miles from the city centre. Barcelona airport is one of the busiest airports in the world, since the opening of terminal T1 in 2009. Most European airlines and a significant number of intercontinental airlines have direct connections to Barcelona.

From Barcelona Airport (BCN) to the city centre

The aerobus is the direct bus from Barcelona Airport, El Prat, to Barcelona city centre. It is approximately a 35-minute direct trip that will cost EUR 5.90.

By taxi, it is approximately 20 minutes to Plaça de Catalunya and will cost around EUR 20.00. However, traffic can be dense in the city centre and it might take much longer to reach your destination.

Bus 46 is approximately a 40-minute trip to Plaça de Catalunya and will cost EUR 4.00.

From Barcelona Airport (BCN) to the congress centre

Option 1: Take the TMB Bus, line 46 from El Prat to Plaça Europa.

Option 2: Take train (FGC) to Plaça Espanya. Then take the train (Line R6) direction Igualada, from Plaça Espanya to Europa Fira.

Option 3: Take the Orange Metro Line L9, direction Zona Universitaria to the Fira. Line L9 extends from both airport terminals, Aeroport T1 and Aeroport T2, directly to the Fira stop.
**IMPORTANT:** Please note that there are two metro stations that stop near the Fira Barcelona Gran Via, North Entrance.

The first station ‘Europa/Fira’ is a 20-minute walk from the North Entrance.

**The second station ‘Fira’ is only 8 minutes walk from the North Entrance. We highly recommend to take the L9 line to the Fira stop and exit at the North Entrance. This is the most direct route to the venue.**

Tickets may be purchased at any metro station.

**Congress shuttles**

EASL congress shuttles will transport ILC delegates to the North Entrance of the Fira Gran Via (Hall 8.0).

The shuttles are free of charge and are operating from 13-17 April 2016 during the following times:

- Wednesday 13 April 06:45-20:15
- Thursday 14 April 06:45-20:15
- Friday 15 April 06:45-20:15
- Saturday 16 April 06:45-20:15
- Sunday 17 April 06:45-14:45

On the journey to the congress venue, the shuttles will stop at:

- Metro station “Europa/Fira” (at Joan Carles I street)
- SB Plaza Europa Hotel (at Alumini Street, just round the corner of the hotel entrance)
- North Entrance (Hall 8.0) (at Alumini Street)
- Metro station “Fira”

The shuttles will depart every 15 minutes and the journey to the venue will take approximately 5-10 minutes depending on where you got on. The shuttles will do repeat journeys of the same circuit.
Public transport

From the city centre to the congress centre:

*By metro (Fira stop)*

**Option 1:** Red Metro Line. L1 direction Hospital de Bellvitge to Espanya – take the metro line S8 direction Martorell Enllac.

**Option 2:** Green Metro Line. L3 at Plaça de Catalunya direction Zona Universitària – stop at Espanya. Then, take the FGC train or bus to the Fira.

**Option 3:** Red Metro Line. L1 at Plaça de Catalunya direction Zona Universitària- stop at Torrassa. Then, take the Orange Metro Line L9 direction Aeroport T1- Stop at the Fira.

Single journey tickets as well as multiple day transportation cards may be purchased at any metro station.
Taxi

Taxi zones are located throughout the city centre. However, we recommend booking a taxi directly using one of the phone numbers below:

+34 93 225 0000  +34 93 300 2314  +34 93 284 8888
+34 93 433 1020  +34 93 300 1100  +34 93 330 0300
+34 93 357 7755  +34 93 303 3033  +34 93 339 9262

**IMPORTANT:** Ask the taxi driver to take you to the **Fira Barcelona Gran Via NORTH ENTRANCE – Hall 8** (Carrer del Foc 37).

Car

Drive to the **Fira Barcelona Gran Via, North Entrance**.

GPS: Carrer del Foc 37, 08038 Barcelona, Spain.

The venue is located in a new business development area connected to the main motorways and roads to Barcelona: AP-7, AP-2, A-2, C-16, C-58, C-31, C-32, C-33.

**TRAVEL, HEALTH & LIABILITY INSURANCE**

The congress organisers/EASL cannot accept liability for personal injuries sustained, or for loss or damage of property belonging to congress delegates, either during, or as a result of the meeting. In case of sickness, the congress organisers/EASL will apply the official cancellation fees.

Delegates are therefore advised to take out their own personal travel and health insurance for their trip.

**LANGUAGE**

The language spoken in Barcelona is Castilian and Catalan. The official language of the congress is English. Simultaneous translation will not be provided.

**CLIMATE**

Barcelona’s climate is generally moderate and mild. Average spring temperatures range from 17°C to 25°C.
CURRENCY & BANK/ATM

The currency used in Spain is the Euro. Banks and currency exchange offices are located around the city, and cajeros automatico (ATMs) are found in various places throughout Barcelona, including the train stations and airport.

An ATM machine is located in the registration area (North Entrance) of the congress centre. You will also find a bank right in front of the North Entrance, in the MSC building.

RESTAURANTS

Barcelona and its surrounding areas have become renowned internationally for food and eating. Its location on the Mediterranean coast offers a generous and varied selection of meals.

Barcelona’s eateries range from traditional Catalan restaurants to the luxurious gourmet temple. Typical Catalan food includes Pa amb tomàquet, Sarsuela, Fideua, Calçotada and Crema catalana.

TIPPING

The only service providers that should receive tips are restaurant or bar staff. When leaving a tip, it is polite to add 5-15% to the bill to round-up to a convenient number.
ORAL PRESENTATION

IMPORTANT: It is mandatory that all oral presenters prepare a disclosure slide as the second slide in their presentation (after the title slide) indicating all personal conflicts of interest, not only conflicts related to the presentation. If you do not have anything to disclose, this slide must be included indicating “nothing to disclose”.

SPEAKERS’ READY ROOM

The speakers’ ready room is located in the executive lounge on the left when entering the venue Hall 8.0 (Fira Barcelona Gran Via, North Entrance), and will be available every day throughout the congress for invited speakers and oral presenters.

Technicians will be available to assist speakers during the following hours:

- Tuesday 12 April: 16:00-20:00
- Wednesday 13 April: 07:00-19:00
- Thursday 14 April: 07:00-19:00
- Friday 15 April: 07:00-19:00
- Saturday 16 April: 07:00-19:00
- Sunday 17 April: 07:00-13:30

PRESENTATION TECHNOLOGY

The lecture halls will be equipped with a laptop and data projector. To ensure high service quality and a near seamless transition between different talks and speakers, a network-based presentation system will be used along with a conference specific interface.

PRESENTATION FORMAT

Only presentations in MS-PowerPoint 2013 or earlier versions (*.ppt and *.pptx) will be accepted. The screen ratio is 16:9 in landscape format.

Please note that presentations attached to e-mails cannot be processed.

If you are using PowerPoint 2007 or older versions do not forget to upload your video files as well as they cannot be embedded into the presentation.

All uploaded material will pass through a technical check and detailed online support is available during the upload process.
You may send additional files, make changes to files sent, and download files again from any computer you use at any time.

Once on-site, you may check, change or upload your presentation in the speakers’ ready room at least 3 hours before the start of the session. Our staff will take a final look at your material with you and will assist you in uploading it.

**Please note that personal notebooks cannot be connected in the lecture halls.**

For technical questions related to your presentation contact:

ilc2016@m-events.com

**POSTER PRESENTATION**

If your abstract is accepted for poster presentation, you will be required to:

- Design and print your poster (paper version)
- Submit an electronic version on the EASL ePoster platform.
- Set-up the poster before 08:00 on the day and board you have been assigned.

Note: For presenters who have been granted a bursary: bursaries will only be paid once above conditions have been fulfilled

**PAPER POSTER RULES**

Poster board size: 190 cm wide x 90 cm high (landscape format only). Your poster must not exceed the stated size!

- Each poster will be on display for 1 day only. Poster presenters will need to check the online programme (as of January 2016) and the poster identification number (the first 3 letters indicate the day of the presentation. E.g. THU-0001 = Thursday, board number 1).

- Posters should be mounted between 07:00-08:00 on the day on which they are scheduled to be presented and must be removed by the end of the same day between 18:00-19:00. All unremoved posters will be dismantled and destroyed by on-site staff after 19:00.

- Presenters are required to stand next to their posters during the designated lunch-time as well as during the morning and afternoon coffee breaks on their scheduled day for informal discussions.
Authors have the possibility to print their posters on-site. Please do not mail them to the Secretariat or EASL Office.

Late-breaker posters will be on display for 3 days (Thursday 14 April – Saturday 16 April). Posters should be set up by Thursday 14 April at 08:00 and removed on Saturday 16 April by 19:00. All unremoved posters will be dismantled and destroyed by on-site staff after 19:00.

ePOSTERS

Submission of the poster in electronic format (ePoster) is mandatory. Your electronic poster will be available for continuous viewing throughout the congress at The Home of Hepatology (EASL booth – Hall 8.0) and in the paper poster area (Hall 8.1).

Note: You will not be allowed to display your paper poster if you have not submitted your ePoster format prior to the congress.

If you need support, please contact us at: eposter@easl.eu

ePOSTER CONNECT LOUNGE

What is the ePoster connect lounge?

You will find a new feature in the ILC 2016 app allowing delegates to contact you if they are interested in discussing a poster with you. This option allows you to plan a meeting date and time at The Home of Hepatology (EASL booth – Hall 8.0) in the ePoster connect lounge.

Please ensure that your abstract is linked to your personal profile so that you are reachable via the congress app. If you have any questions please go to the congress app help desk at the registration area where staff will be happy to help.

Tips for presenters

• Respond quickly to all presentation requests

• Make sure to arrive 5 minutes before the scheduled time

• You do not need to bring anything other than your notes. You will be able to view your ePoster on the screen

• Ideally, you should dedicate 10 minutes to the presentation and 5 minutes for questions.
WHAT’S NEW IN THE PROGRAMME?

For ILC 2016, we have improved the readability of the ILC scientific programme, and are offering formats for the posters enabling better interactivity, discussions and easier access, providing the best exposure to science.

The 2016 programme was redesigned in order to highlight the fields and specialties, enabling delegates to make choices on sessions of interest based on the scientific content.

The programme will be organised in specialties and fields:

**SPECIALTIES**

- General hepatology
- Liver tumours
- Cholestatic & autoimmune
- Metabolic, alcohol & toxicity
- Cirrhosis & complications
- Viral hepatitis
POSTERS

At ILC 2016, EASL is returning to paper poster format for presentation, but will also be making all paper posters available electronically as ePosters.

From Thursday to Saturday, paper posters will be accessible in the Exhibition area (Hall 8.1).

About 500 paper posters will be exhibited each day and taken down every evening. We encourage the poster presenters to be present next to their board during the breaks for interaction and discussions.

Unlike the paper posters which are only displayed for one day, all ePosters are available every day (Wednesday 13 April to Sunday 17 April) on multiple screens in Hall 8.0 and Hall 8.1, and simultaneously on the LiverTree™.
**POSTER TOURS**

During lunch and coffee breaks, Key Opinion Leader guides appointed by the EASL Governing Board will tour the paper poster area (Hall 8.1) with a group of delegates to present 3-5 paper posters and discuss data with the respective presenters.

**Join us at the poster help desk (Hall 8.1) and take part in the tour!**

No pre-registration is required.
# POSTER TOUR SCHEDULE

## Thursday 14 April

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Guide</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:00-10:30</td>
<td>Viral hepatitis: Hepatitis A, B, D, E – clinical (except therapy)</td>
<td>Jörg Petersen, Germany</td>
</tr>
<tr>
<td>10:00-10:30</td>
<td>Cirrhosis and its complications: Clinical aspects (1)</td>
<td>Emmanuel Tsochatzis, United Kingdom</td>
</tr>
<tr>
<td>10:00-10:30</td>
<td>Genetic and paediatric liver diseases</td>
<td>Heinz Zoller, Austria</td>
</tr>
<tr>
<td>12:00-12:30</td>
<td>Liver transplantation: Experimental + Acute liver failure-clinical &amp; experimental</td>
<td>Rajiv Jalan, United Kingdom</td>
</tr>
<tr>
<td>12:00-12:30</td>
<td>Viral hepatitis: Hepatitis C – clinical (new compounds, resistance)</td>
<td>Darius Moradpour, Switzerland</td>
</tr>
<tr>
<td>12:00-12:30</td>
<td>Cirrhosis and its complications: Clinical aspects (2)</td>
<td>Dominique Thabut, France</td>
</tr>
<tr>
<td>12:30-13:00</td>
<td>Alcoholic liver disease and drug induced liver disease</td>
<td>Raul Andrade, Spain</td>
</tr>
<tr>
<td>12:30-13:00</td>
<td>Viral hepatitis: Hepatitis C – experimental (virology)</td>
<td>Thomas Baumert, France</td>
</tr>
<tr>
<td>15:30-16:00</td>
<td>Viral hepatitis: Hepatitis B &amp; D – experimental</td>
<td>Massimo Levrero, Italy</td>
</tr>
<tr>
<td>15:30-16:00</td>
<td>Liver tumours: Clinical (epidemiology, diagnosis)</td>
<td>Arndt Vogel, Germany</td>
</tr>
<tr>
<td>15:30-16:00</td>
<td>Molecular and cellular biology: Cell cycle control / apoptosis and regeneration</td>
<td>Jessica Zucman-Rossi, France</td>
</tr>
</tbody>
</table>

## Friday 15 April

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Guide</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00-11:30</td>
<td>EU and public health</td>
<td>Daniel Lavanchy, Switzerland</td>
</tr>
<tr>
<td>11:00-11:30</td>
<td>Liver immunology including Viral Hepatitis</td>
<td>Mala Maini, United Kingdom</td>
</tr>
</tbody>
</table>
# POSTER TOUR SCHEDULE (CONT.)

## Friday 15 April (Cont.)

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Guide</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00-11:30</td>
<td>Viral hepatitis: Hepatitis B &amp; D – clinical (therapy, new compounds, resistance)</td>
<td>Cihan Yurdaydin, Turkey</td>
</tr>
<tr>
<td>12:30-13:00</td>
<td>Fatty liver disease: Clinical</td>
<td>Andreas Geier, Germany</td>
</tr>
<tr>
<td>12:30-13:00</td>
<td>Liver transplantation / surgery: Clinical</td>
<td>Didier Samuel, France</td>
</tr>
<tr>
<td>13:00-13:30</td>
<td>Autoimmune and hepato biliary disease (1)</td>
<td>Roger Chapman, United Kingdom</td>
</tr>
<tr>
<td>13:00-13:30</td>
<td>Liver tumours: Experimental</td>
<td>Malu Martinez-Chantar, Spain</td>
</tr>
<tr>
<td>15:30-16:00</td>
<td>Cirrhosis and its complications: Pathophysiology</td>
<td>Agostin Albillos, Spain</td>
</tr>
<tr>
<td>15:30-16:00</td>
<td>Viral hepatitis: Hepatitis C – clinical (except therapy)</td>
<td>Geoffrey Dusheiko, United Kingdom</td>
</tr>
</tbody>
</table>

## Saturday 16 April

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Guide</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00-11:30</td>
<td>Non-invasive markers of liver fibrosis</td>
<td>Thierry Poynard, France</td>
</tr>
<tr>
<td>11:00-11:30</td>
<td>Cirrhosis and its complications: Bleeding, hepatorenal syndrom and ascites</td>
<td>Andrea De Gottardi, Switzerland</td>
</tr>
<tr>
<td>11:00-11:30</td>
<td>Viral hepatitis: Hepatitis C – clinical (therapy) (1)</td>
<td>Robert Flisiak, Poland</td>
</tr>
<tr>
<td>13:30-14:00</td>
<td>Fatty liver disease: Experimental</td>
<td>Ali Canbay, Germany</td>
</tr>
<tr>
<td>13:30-14:00</td>
<td>Liver tumours: Management</td>
<td>Helen Reeves, United Kingdom</td>
</tr>
<tr>
<td>15:30-16:00</td>
<td>Viral hepatitis: Hepatitis C – clinical (therapy) (2)</td>
<td>Savino Bruno, Italy</td>
</tr>
</tbody>
</table>
POSTER TOUR SCHEDULE (CONT.)
Saturday 16 April (Cont.)

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Presenter, Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:30-16:00</td>
<td>Molecular and cellular biology: HSCs and fibrosis</td>
<td>Fabio Marra, Italy</td>
</tr>
<tr>
<td>15:30-16:00</td>
<td>Autoimmune and hepato biliary disease (2)</td>
<td>Christoph Schramm, Germany</td>
</tr>
</tbody>
</table>

ePOSTER CONNECT LOUNGE

Where?

The ePoster connect lounge is located in Hall 8.0 at The Home of Hepatology (EASL booth).

What’s new?

ePoster connect is a unique feature allowing you to request or join a presentation with a poster presenter in an intimate and relaxed setting. This feature is designed to boost your learning and network experience during The International Liver Congress™ 2016.

How does it work?

Registered ILC 2016 delegates may, at any time, request a presentation at the eConnect area. Simply browse “ALL POSTERS” in the ILC 2016 app and tap on “REQUEST PRESENTATION” on the poster you would like to see presented. You will be prompted for a preferred date and time for the presentation. The presenting author will then receive your request and upon his/her acceptance the Poster Lounge Team will assign an ePoster screen and send a confirmation to you and to the presenting author.

Please make sure that you arrive on time for the presentation you have requested.

You may also browse the list of existing presentations that have already been confirmed and join any presentation at your convenience.
SESSION FORMAT DESCRIPTIONS

POST-GRADUATE COURSE

Each year, the post-graduate course highlights many clinical practice dilemmas and engages the audience with world-renowned experts on how to make the best management decisions to help patients with liver disease. A printed course syllabus is distributed at the congress and made available in pdf format on the congress website.

The post-graduate course is divided into 5 sessions. At the beginning of each session, a case is presented and questions (with multiple choice answers) are presented to the audience. The audience can select the answer they consider most appropriate through the ILC 2016 mobile app and the correct answer is discussed at the end of the session.

In 2016, the post-graduate course is dedicated to all the current key clinical areas relative to liver tumours and will focus on a number of open issues requiring further scientific effort.

The post-graduate course sessions will be webcast and published on the LiverTree™.

BASIC SCIENCE SEMINAR

The basic science seminar aims to foster interaction with the audience and is organised like a workshop, with no classical lectures. The purpose of this seminar is to attract more people from the basic science field and to discuss specific topics where invited speakers have the opportunity not only to present their success stories, but also failures, generating a lively and informative discussion.

Another objective is to showcase young investigator presentations selected by the invited speaker (typically one of their fellows).

The usual format is as follows:
• 10-minute presentation by a senior speaker (lecture format)
• 10-minute presentation by a young investigator (abstract format)
• 10-minute discussion

In 2016, the basic science seminar will provide an overview of the rapid scientific advances in the growing field of the gut-liver axis.

The basic science seminar sessions will be webcast and published on the LiverTree™.
STATE-OF-THE-ART LECTURES

There are two 30-minute lectures (one clinical and one basic) running without sessions in parallel.

The State-of-the-art lectures will be webcast and published on the LiverTree™.

SONOGRAPHY AND ULTRASOUND COURSES €

Hands-on sessions will take place with machines (simulators or live exams on healthy patients). Places are limited to 4-6 persons per machine with one tutor dedicated to one machine.

Pre-registration is compulsory if you wish to attend the sonography and ultrasound courses. A fee of EUR 24.20 (21% VAT included) is applied. Only delegates registered to the ILC may sign-up for the sonography and ultrasound courses sessions.

Pre-registration to sonography and ultrasound courses on-site may be processed at the additional service booking desk at the registration area.

GRAND ROUNDS

The EASL Governing Board has decided to modify the grand round concept for 2016. This year, senior members of major European institutions will present an interesting or challenging case together with a junior member of his/her team. Each case presented will represent a challenge of broad interest to the audience and aims to nurture discussions. A co-chair from another institution will be present with the intention of animating the debate. The objective of this new concept is to foster interaction with a broad audience of clinicians through lively discussion around interesting clinical cases. The Grand Rounds will be webcast and published on the LiverTree™.

FORUMS

Various dedicated forums are planned; nurses and associates forum, young investigators forum, EU session. Lectures in these forums will address the specific needs of the target groups.
EARLY MORNING WORKSHOPS

Instead of providing you with a conventional lecture, early morning workshops (EMW) allow for active interaction with all attendees (limited number of seats per workshop). Speakers will present a short introduction of the field exposing the major points of research and controversies in order to initiate the debate with the audience.

Discussions will be co-chaired enabling delegates to gain knowledge from different experts in the field, and EASL encourages the participation of young investigators (YI) allowing YI poster presenters to present their data during these workshops.

Pre-registration is compulsory if you wish to attend the EMW. A fee of EUR 24.20 (21% VAT included) is applied. Only delegates registered to the ILC may sign-up for EMW sessions.

Pre-registration to EMW on-site may be processed at the additional service booking desk at the registration area.

JOINT WORKSHOPS

Joint workshops with sister associations or consortia are organised as sessions for groups to meet and present their latest achievements.

LITERATURE HIGHLIGHTS

Three literature sessions are offered this year.

Basic science highlights

This session runs in parallel to the Grand Rounds and offers a basic science alternative where speakers present selected publications on a current research topic.

Highlights from the literature

A chair will select 4 recent publications on hot topics and invite the author to present and discuss with the audience.

Journal of Hepatology session

The editor in chief and the co-editors of the Journal will present an overview of the 2015 publications.
SYMPOSIA

Symposia will provide the audience with a comprehensive, updated, and balanced summary of the diagnostic, prognostic, and therapeutic procedures related to the relevant topics.

Symposia sessions will be webcast and published on the LiverTree™.

PARALLEL SESSIONS

These are typical presentations based on selected abstracts.

FELLOWSHIP AND REGISTRY GRANT SESSIONS

EASL Fellowship awardees and Registry Grant recipients are invited to present their research and findings made possible thanks to the funding provided by EASL.

ORAL ePOSTER SESSIONS

ePoster sessions are discussion groups based on presentations from selected abstracts chosen by the EASL Scientific Committee. Each session will have a chairperson who will select 7 accepted poster abstracts. The presenting authors will be invited to give a 6-minute presentation of the poster displayed on a screen.

Selected ePosters will be presented during the lunch breaks as shown below:

- Thursday 14 April 12:00-13:00
- Friday 15 April 12:30-13:30
- Saturday 16 April 13:00-14:00

POSTER TOURS

During the lunch and coffee breaks, KOL guides will tour the paper poster area (Hall 8.1) with a group of delegates to present 3-5 paper posters and discuss data with the respective presenters.

The poster tour schedule is available on pages 59-61.
# Programme Week at a Glance

## Wednesday 13 April

<table>
<thead>
<tr>
<th>Time</th>
<th>Activities</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:30-08:00</td>
<td>Joint Workshops</td>
</tr>
<tr>
<td>08:00-08:30</td>
<td>Industry sponsored satellite symposas</td>
</tr>
<tr>
<td>08:30-09:00</td>
<td>Joint Workshops</td>
</tr>
<tr>
<td>09:00-09:30</td>
<td>Café</td>
</tr>
<tr>
<td>09:30-10:00</td>
<td>Joint Workshops</td>
</tr>
<tr>
<td>10:00-10:30</td>
<td>Joint Workshops</td>
</tr>
<tr>
<td>10:30-11:00</td>
<td>Post-graduate course</td>
</tr>
<tr>
<td>11:00-11:30</td>
<td>Basic science seminar</td>
</tr>
<tr>
<td>11:30-12:00</td>
<td>Post-graduate course</td>
</tr>
<tr>
<td>12:00-12:30</td>
<td>Basic science seminar</td>
</tr>
<tr>
<td>12:30-13:00</td>
<td>Oral ePoster sessions</td>
</tr>
<tr>
<td>13:00-13:30</td>
<td>Post-graduate course</td>
</tr>
<tr>
<td>13:30-14:00</td>
<td>Oral ePoster sessions</td>
</tr>
<tr>
<td>14:00-14:30</td>
<td>Nurse and associates forum</td>
</tr>
<tr>
<td>14:30-15:00</td>
<td>Post-graduate course</td>
</tr>
<tr>
<td>15:00-15:30</td>
<td>Basic science seminar</td>
</tr>
<tr>
<td>15:30-16:00</td>
<td>Oral ePoster sessions</td>
</tr>
<tr>
<td>16:00-16:30</td>
<td>Nurse and associates forum</td>
</tr>
<tr>
<td>16:30-17:00</td>
<td>Post-graduate course</td>
</tr>
<tr>
<td>17:00-17:30</td>
<td>Basic science seminar</td>
</tr>
<tr>
<td>17:30-18:00</td>
<td>Oral ePoster sessions</td>
</tr>
<tr>
<td>18:00-18:30</td>
<td>Major sponsor industry satellite symposas</td>
</tr>
<tr>
<td>18:30-19:00</td>
<td>Abdominal sonography course / €</td>
</tr>
<tr>
<td>19:00-19:30</td>
<td>Major sponsor industry satellite symposas</td>
</tr>
<tr>
<td>19:30-20:00</td>
<td>Major sponsor industry satellite symposas</td>
</tr>
</tbody>
</table>

## Thursday 14 April

<table>
<thead>
<tr>
<th>Time</th>
<th>Activities</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:30-08:00</td>
<td>Post-graduate course</td>
</tr>
<tr>
<td>08:00-08:30</td>
<td>Basic science seminar</td>
</tr>
<tr>
<td>08:30-09:00</td>
<td>EASL-WHA Joint Workshop</td>
</tr>
<tr>
<td>09:00-09:30</td>
<td>Café</td>
</tr>
<tr>
<td>09:30-10:00</td>
<td>Poster tours</td>
</tr>
<tr>
<td>10:00-10:30</td>
<td>Post-graduate course</td>
</tr>
<tr>
<td>10:30-11:00</td>
<td>Basic science seminar</td>
</tr>
<tr>
<td>11:00-11:30</td>
<td>EASL-WHA Joint Workshop</td>
</tr>
<tr>
<td>11:30-12:00</td>
<td>Oral ePoster sessions</td>
</tr>
<tr>
<td>12:00-12:30</td>
<td>CPG session AIH+NAFLD</td>
</tr>
<tr>
<td>12:30-13:00</td>
<td>Oral ePoster sessions</td>
</tr>
<tr>
<td>13:00-13:30</td>
<td>Fellowship &amp; Registry grant results</td>
</tr>
<tr>
<td>13:30-14:00</td>
<td>Oral ePoster sessions</td>
</tr>
<tr>
<td>14:00-14:30</td>
<td>Poster tours</td>
</tr>
<tr>
<td>14:30-15:00</td>
<td>Poster tours</td>
</tr>
<tr>
<td>15:00-15:30</td>
<td>Poster tours</td>
</tr>
<tr>
<td>15:30-16:00</td>
<td>Poster tours</td>
</tr>
<tr>
<td>16:00-16:30</td>
<td>Poster tours</td>
</tr>
<tr>
<td>16:30-17:00</td>
<td>Parallel sessions</td>
</tr>
<tr>
<td>17:00-17:30</td>
<td>Fusion Hepatology</td>
</tr>
<tr>
<td>17:30-18:00</td>
<td>Parallel sessions</td>
</tr>
<tr>
<td>18:00-18:30</td>
<td>Parallel sessions</td>
</tr>
<tr>
<td>18:30-19:00</td>
<td>Parallel sessions</td>
</tr>
<tr>
<td>19:00-19:30</td>
<td>Parallel sessions</td>
</tr>
<tr>
<td>19:30-20:00</td>
<td>Parallel sessions</td>
</tr>
</tbody>
</table>

---

**EASL THE HOME OF HEPATOLOGY**
### SCIENTIFIC PROGRAMME

#### WEDNESDAY 13 APRIL

<table>
<thead>
<tr>
<th>Event</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Early Morning Workshops / Industry sponsored satellite symposia</td>
<td>07:30-08:00</td>
</tr>
<tr>
<td>General session 2 and awards 1</td>
<td>08:00-08:30</td>
</tr>
<tr>
<td>Post-graduate course, Basic science seminar, EASL-WHA Joint Workshop</td>
<td>09:00-09:30</td>
</tr>
<tr>
<td>Journal of Hepatology session, Best poster, WHO Symposium</td>
<td>10:00-10:30</td>
</tr>
<tr>
<td>State of the Art Post-graduate course, Basic science seminar, EASL-WHA Joint Workshop</td>
<td>11:00-11:30</td>
</tr>
<tr>
<td>Oral ePoster sessions, WHO guidelines, Poster tours, YI Seminar</td>
<td>14:00-14:30</td>
</tr>
<tr>
<td>Symposia (parallel sessions), Oral ePoster sessions, Poster tours</td>
<td>14:30-15:00</td>
</tr>
<tr>
<td>Abdominal sonography course / Industry sponsored satellite symposia</td>
<td>16:30-17:00</td>
</tr>
</tbody>
</table>

#### THURSDAY 14 APRIL

<table>
<thead>
<tr>
<th>Event</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Early Morning Workshops / Industry sponsored satellite symposia</td>
<td>07:30-08:00</td>
</tr>
<tr>
<td>General session 3 and awards 2</td>
<td>08:00-08:30</td>
</tr>
<tr>
<td>Post-graduate course, Basic science seminar, EASL-WHA Joint Workshop</td>
<td>09:00-09:30</td>
</tr>
<tr>
<td>Journal of Hepatology session, Best poster, WHO Symposium</td>
<td>10:00-10:30</td>
</tr>
<tr>
<td>State of the Art Post-graduate course, Basic science seminar, EASL-WHA Joint Workshop</td>
<td>11:00-11:30</td>
</tr>
<tr>
<td>Oral ePoster sessions, WHO guidelines, Poster tours, YI Seminar</td>
<td>14:00-14:30</td>
</tr>
<tr>
<td>Symposia (parallel sessions), Oral ePoster sessions, Poster tours</td>
<td>14:30-15:00</td>
</tr>
<tr>
<td>Abdominal sonography course / Industry sponsored satellite symposia</td>
<td>16:30-17:00</td>
</tr>
</tbody>
</table>

#### FRIDAY 15 APRIL

<table>
<thead>
<tr>
<th>Event</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Early Morning Workshops / Industry sponsored satellite symposia</td>
<td>07:30-08:00</td>
</tr>
<tr>
<td>General session 2 and awards 1</td>
<td>08:00-08:30</td>
</tr>
<tr>
<td>Post-graduate course, Basic science seminar, EASL-WHA Joint Workshop</td>
<td>09:00-09:30</td>
</tr>
<tr>
<td>State of the Art Post-graduate course, Basic science seminar, EASL-WHA Joint Workshop</td>
<td>11:00-11:30</td>
</tr>
<tr>
<td>Oral ePoster sessions, WHO guidelines, Poster tours, YI Seminar</td>
<td>14:00-14:30</td>
</tr>
<tr>
<td>Symposia (parallel sessions), Oral ePoster sessions, Poster tours</td>
<td>14:30-15:00</td>
</tr>
<tr>
<td>Abdominal sonography course / Industry sponsored satellite symposia</td>
<td>16:30-17:00</td>
</tr>
</tbody>
</table>

#### SATURDAY 16 APRIL

<table>
<thead>
<tr>
<th>Event</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Early Morning Workshops / Industry sponsored satellite symposia</td>
<td>07:30-08:00</td>
</tr>
<tr>
<td>General session 3 and awards 2</td>
<td>08:00-08:30</td>
</tr>
<tr>
<td>Post-graduate course, Basic science seminar, EASL-WHA Joint Workshop</td>
<td>09:00-09:30</td>
</tr>
<tr>
<td>Journal of Hepatology session, Best poster, WHO Symposium</td>
<td>10:00-10:30</td>
</tr>
<tr>
<td>State of the Art Post-graduate course, Basic science seminar, EASL-WHA Joint Workshop</td>
<td>11:00-11:30</td>
</tr>
<tr>
<td>Oral ePoster sessions, WHO guidelines, Poster tours, YI Seminar</td>
<td>14:00-14:30</td>
</tr>
<tr>
<td>Symposia (parallel sessions), Oral ePoster sessions, Poster tours</td>
<td>14:30-15:00</td>
</tr>
<tr>
<td>Abdominal sonography course / Industry sponsored satellite symposia</td>
<td>16:30-17:00</td>
</tr>
</tbody>
</table>

#### SUNDAY 17 APRIL

<table>
<thead>
<tr>
<th>Event</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Early Morning Workshops / Industry sponsored satellite symposia</td>
<td>07:30-08:00</td>
</tr>
<tr>
<td>General session 4</td>
<td>08:30-09:00</td>
</tr>
<tr>
<td>Post-graduate course, Basic science seminar, EASL-WHA Joint Workshop</td>
<td>09:00-09:30</td>
</tr>
<tr>
<td>Journal of Hepatology session, Best poster, WHO Symposium</td>
<td>10:00-10:30</td>
</tr>
<tr>
<td>State of the Art Post-graduate course, Basic science seminar, EASL-WHA Joint Workshop</td>
<td>11:00-11:30</td>
</tr>
<tr>
<td>Oral ePoster sessions, WHO guidelines, Poster tours, YI Seminar</td>
<td>14:00-14:30</td>
</tr>
<tr>
<td>Symposia (parallel sessions), Oral ePoster sessions, Poster tours</td>
<td>14:30-15:00</td>
</tr>
<tr>
<td>Abdominal sonography course / Industry sponsored satellite symposia</td>
<td>16:30-17:00</td>
</tr>
</tbody>
</table>

See next pages to view the daily scientific programme.
DAILY PROGRAMME AT A GLANCE

**Joint Workshops**
- Hall 8.0-D1 EASL – ELITA – ILTS – LICAGE – Post graduate course liver transplant
- Hall 8.0-E8 EASL – CHBG
- Hall 8.0-E3 EASL – ESPGHAN
- Hall 8.0-B1 EASL – Baveno
- Hall 8.0-C2 EASL – CLIF
- Hall 8.0-E5 EASL – ESGAR

08:00-09:30

<table>
<thead>
<tr>
<th>Time</th>
<th>Location</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00-09:00</td>
<td>Hall 6.0 Foyer and Hall 8.0</td>
<td>Coffee break</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Location</th>
<th>Details</th>
</tr>
</thead>
</table>
| 09:30-10:00 | Hall 8.0-D1 EASL – ELITA – ILTS – LICAGE – Post graduate course liver transplant
- Hall 8.0-E8 EASL – CHBG
- Hall 8.0-E3 EASL – ESPGHAN
- Hall 8.0-B1 EASL – Baveno
- Hall 8.0-C2 EASL – CLIF
- Hall 8.0-E5 EASL – ESGAR

10:00-11:00

<table>
<thead>
<tr>
<th>Time</th>
<th>Location</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00-11:30</td>
<td></td>
<td>Break</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Location</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:30-13:30</td>
<td>Hall 6.0</td>
<td>Epidemiology, oncogenesis and population at risk</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Location</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:30-14:00</td>
<td>Hall 6.0 and 8.0</td>
<td>Lunch</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Location</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00-15:30</td>
<td>Hall 6.0</td>
<td>Surveillance and diagnosis for HCC</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Location</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:30-16:00</td>
<td>Hall 6.0 and 8.0</td>
<td>Coffee break</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Location</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:00-17:30</td>
<td>Hall 6.0</td>
<td>Blending evidence based medicine and personalized approach: stratified medicine</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Location</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>17:30-18:00</td>
<td>Hall 6.0 Foyer, Hall 8.0 and 8.1</td>
<td>Break</td>
</tr>
</tbody>
</table>

18:00-19:30

**Major sponsor industry satellite symposia**

*To refer to colour code, see page 58*
WEDNESDAY 13 APRIL 2016

**Joint Workshops**

- **Hall 8.0-B3** EASL – ILCA – New horizons in HCC
- **Hall 8.0-E2** EASL – ESBRA
- **Hall 8.0-B2** EASL – FLIP/EPoS
- **Hall 8.0-E4** EASL – INHSU – Enhancing HCV treatment access and outcomes for people who inject drugs in the interferon-free era
- **Hall 8.0-E1** EASL – MSF – PROLIFICA – TAG – Responding to viral hepatitis: Limited resources and marginalised populations
- **Hall 8.0-A1** EASL – Viral hepatitis group

**Basic Science Seminar**

- **Hall 8.0-A1** From microbiota to immunity

**Joint Workshops**

- **Hall 8.0-D1** EASL – ELITA – ILTS – LICAGE – Post graduate course liver transplant

**Nurse and associates forum**

- **Hall 8.0-C1** Contemporary issues in caring for people with liver disease

**Basic Science Seminar**

- **Hall 8.0-A1** Gut microbiota and liver disease

**Nurse and associates forum**

- **Hall 8.0-C1** Contemporary issues in caring for people with liver disease
DAILY PROGRAMME AT A GLANCE

07:30-08:30  Industry satellite symposia

08:30-10:00  Post Graduate Course

08:30-10:00  Hall 8.0 Intrahepatic cholangiocarcinoma (ICC): the emerging clinical challenge

08:30-10:00  Hall 8.0-C2 EASL – WHA

10:00-10:30  Hall 8.1 – Coffee break

10:00-10:30  Hall 8.0-B1 Registry grant presentations

10:00-10:30  Hall 8.0-C1 Fellowship presentations

10:00-10:30  Hall 8.0-B3 EU and public health session: Liver, lifestyle and EU policy

10:30-12:00  Post Graduate Course

10:30-12:00  Hall 6.0 Benign liver tumours

12:00-13:30  Hall 8.0-B1 Registry grant presentations

12:00-13:30  Hall 8.0-C1 Fellowship presentations

12:00-13:30  Hall 8.0-B3 EU and public health session: Liver, lifestyle and EU policy

12:00-13:30  Hall 8.1 – Poster tours

12:00-13:30  Hall 8.1 – Poster tours

12:00-13:30  Hall 8.1 – Poster tours

12:00-13:30  Hall 8.1 – Poster tours

13:30-15:40  Hall 6.0 – General session I and Opening Ceremony

13:30-15:40  Hall 6.0 – General session I and Opening Ceremony

15:30-16:00  Hall 8.1 – Poster tours

15:30-16:00  Hall 8.1 – Poster tours

15:30-16:00  Hall 8.1 – Poster tours

15:30-16:00  Hall 8.1 – Poster tours

15:30-16:00  Hall 8.1 – Poster tours

18:00-18:30  Break

18:30-20:00  Hall 8.0-E4 – Sonography course / € for beginners

To refer to colour code, see page 58
## THURSDAY 14 APRIL 2016

### Mini-workshop

**Basic Science Seminar**
**Hall 8.0-A1** Gut microbiota and liver disease

### Hall 8.1 – Poster tour

<table>
<thead>
<tr>
<th>Time</th>
<th>Hall 8.1 – Poster tours</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:00-12:30</td>
<td>Viral hepatitis: Hepatitis C – clinical (new compounds, resistance)</td>
</tr>
<tr>
<td></td>
<td>Liver transplantation: Experimental, acute liver failure-clinical &amp; experimental</td>
</tr>
<tr>
<td></td>
<td>Cirrhosis and its complications: Clinical aspects</td>
</tr>
</tbody>
</table>

### Hall 8.0-A1 Diagnosis and therapeutic strategies

<table>
<thead>
<tr>
<th>Time</th>
<th>Hall 8.0-A1</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:00-12:30</td>
<td>Viral hepatitis: Hepatitis C – experimental (virology)</td>
</tr>
</tbody>
</table>

### Hall 8.1 – Poster tours

<table>
<thead>
<tr>
<th>Time</th>
<th>Hall 8.1 – Poster tours</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:30-13:00</td>
<td>Alcoholic liver disease and drug induced liver disease</td>
</tr>
<tr>
<td></td>
<td>Viral hepatitis: Hepatitis C – experimental (virology)</td>
</tr>
</tbody>
</table>

### Hall 8.1 – Coffee break

### Fusion hepatology

**Hall 8.0-D2** The global picture of NAFLD

### Major sponsor industry satellite symposia
# Daily Programme at a Glance

## EMWs – Early Morning Workshops / €
- **Hall 8.0-E1** Evaluating interventions and health outcomes in liver disease
- **Hall 8.0-E3** Hepatotoxicity: modes of cell death and survival (apoptosis, necrosis, autophagy)
- **Hall 8.0-E5** Liver regenerative medicine: cell transplant, organoids and repopulated scaffolds
- **Hall 8.0-E8** New diagnostic approaches in genetic liver disease
- **Hall 8.0-B2** What is the best second line therapy for AIH

### 07:30-08:30

<table>
<thead>
<tr>
<th>Time</th>
<th>Location</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:30</td>
<td>Hall 8.0-E1</td>
<td>Evaluating interventions and health outcomes in liver disease</td>
</tr>
<tr>
<td>07:30</td>
<td>Hall 8.0-E3</td>
<td>Hepatotoxicity: modes of cell death and survival (apoptosis, necrosis, autophagy)</td>
</tr>
<tr>
<td>07:30</td>
<td>Hall 8.0-E5</td>
<td>Liver regenerative medicine: cell transplant, organoids and repopulated scaffolds</td>
</tr>
<tr>
<td>07:30</td>
<td>Hall 8.0-E8</td>
<td>New diagnostic approaches in genetic liver disease</td>
</tr>
<tr>
<td>07:30</td>
<td>Hall 8.0-B2</td>
<td>What is the best second line therapy for AIH</td>
</tr>
</tbody>
</table>

## 08:30-10:30
- **Hall 6.0 – General session 2 and awards I**
- **Hall 8.0-E4** – Sonography course / € for advanced

## 10:30-11:00
- **Hall 8.0 – J.P. Benhamou State of the Art Session: New treatment paradigm to cure chronic hepatitis B virus infections**

## 11:00-11:30
- **Hall 8.0-D1** Cholestatic/autoimmune liver diseases
- **Hall 8.0-D2** Cirrhosis
- **Hall 8.0-C1** HCC
- **Hall 8.0-B3** NAFLD
- **Hall 8.0-A1** HBV-HDV
- **Hall 6.0** HCV

### 11:00-12:30

<table>
<thead>
<tr>
<th>Time</th>
<th>Location</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00</td>
<td>Hall 8.0-D1</td>
<td>Cholestatic/autoimmune liver diseases</td>
</tr>
<tr>
<td>11:00</td>
<td>Hall 8.0-D2</td>
<td>Cirrhosis</td>
</tr>
<tr>
<td>11:00</td>
<td>Hall 8.0-C1</td>
<td>HCC</td>
</tr>
<tr>
<td>11:00</td>
<td>Hall 8.0-B3</td>
<td>NAFLD</td>
</tr>
<tr>
<td>11:00</td>
<td>Hall 8.0-A1</td>
<td>HBV-HDV</td>
</tr>
<tr>
<td>11:00</td>
<td>Hall 6.0</td>
<td>HCV</td>
</tr>
</tbody>
</table>

## 12:30-14:00
- **Hall 8.0-C2** – EASL members’ general assembly
- **Hall 8.0 – Oral ePosters**
  - **Booth 1** Complication of cirrhosis
  - **Booth 2** HCV
  - **Booth 3** Alcohol and Public Health
  - **Booth 4** Genetic and metabolic liver disease

## 14:00-15:30
- **Hall 8.0-B1** Liver tissue engineering
- **Hall 8.0-D2** Disease staging and prognosis: non-invasive versus invasive methods

## 15:30-16:00
- **Hall 8.0-C2** – EASL members’ general assembly
- **Hall 8.1 – Poster Tours**
  - **Hall 8.0-B3** Non-invasive tests for evaluation of liver disease severity and prognosis
  - **Hall 8.0-C1** Biliary pathophysiology
  - **Hall 8.0-D1** Fatty Liver Disease: Experimental
  - **Hall 8.0-A1** Cirrhosis (2)

## 16:00-18:00
- **Hall 8.0-B3** Non-invasive tests for evaluation of liver disease severity and prognosis
- **Hall 8.0-C1** Biliary pathophysiology
- **Hall 8.0-D1** Fatty Liver Disease: Experimental
- **Hall 8.0-A1** Cirrhosis (2)

## 18:00-18:30
- **Hall 8.0 and Hall 8.1 – Break**

## To refer to colour code, see page 58
FRIDAY 15 APRIL 2016

Hall 8.0-B1 Management of sepsis in patients with liver cirrhosis
Hall 8.0-C1 Downstaging of HCC before LT
Hall 8.0-D2 Assessment of NAFLD: when do we need biopsy?
Hall 8.0-C2 How to detect and manage alcohol liver disease in early phases
Hall 8.0-D1 How are DAAs and NUCs modifying the management of liver cancer?
Hall 8.0-A1 Management of HCV patients with DAA failures
Hall 8.0-B3 When can we stop NUCs in patients with chronic hepatitis B?

Hall 8.0-B1 – Young Investigator seminar
Liver diseases and the vascular system

Hall 8.0-B2 – Basic science highlights
Human protein atlas

Hall 8.0 and Hall 8.1 – Lunch

Hall 8.1 – Poster tours
12:30-13:00
| Fatty liver disease: Clinical
| Liver transplantation / surgery: Clinical
13:00-13:30
| Liver tumours: Experimental
| Autoimmune and hepatobiliary disease 1

Hall 8.0-B3 New therapies for autoimmune liver disease
Hall 8.0-D1 Immune therapy to cure HBV
Hall 8.0-A1 WHO

Hall 8.1 – Coffee break

Hall 8.0-D2 Alcoholic liver disease and drug induced liver disease
Hall 6.0 Viral hepatitis B and D

Recent highlights
Hall 8.0-C2 Recent highlights from the literature: ask the authors

The European Association for the Study of the Liver
Barcelona, Spain

13-17 April 2016

Major sponsor industry satellite symposia

18:30-19:30 Mini-workshop

To refer to colour code, see page 58

FRIDAY 15 APRIL 2016
## DAILY PROGRAMME AT A GLANCE

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:30-08:30</td>
<td>Industry satellite symposia</td>
</tr>
<tr>
<td>08:30-10:30</td>
<td>Hall 6.0 – General session 3 and awards 2</td>
</tr>
<tr>
<td>10:30-11:00</td>
<td>Hall 6.0 – State-of-the-art: Mechanisms Responsible for Malignant Conversion</td>
</tr>
<tr>
<td>11:00-11:30</td>
<td>Hall 8.1 – Poster tours</td>
</tr>
<tr>
<td>11:00-11:30</td>
<td>Viral hepatitis: Hepatitis C – clinical (therapy) (1)</td>
</tr>
<tr>
<td>11:00-11:30</td>
<td>Cirrhosis and its complications: Bleeding, hepatorenal syndrome and ascites</td>
</tr>
<tr>
<td>11:00-11:30</td>
<td>Non-invasive markers of liver fibrosis</td>
</tr>
<tr>
<td>11:30-13:30</td>
<td>Parallel Sessions</td>
</tr>
<tr>
<td>11:30-13:30</td>
<td>Hall 8.0-C1 EU and public health</td>
</tr>
<tr>
<td>11:30-13:30</td>
<td>Hall 8.0-B3 Molecular and cellular biology: cell death, fibrosis and regeneration</td>
</tr>
<tr>
<td>11:30-13:30</td>
<td>Hall 8.0-D2 Autoimmune and hepatobiliary disease</td>
</tr>
<tr>
<td>11:30-13:30</td>
<td>Hall 8.0-A1 Fatty liver disease: Clinical</td>
</tr>
<tr>
<td>11:30-13:30</td>
<td>Hall 8.0-D1 Liver tumours: Clinical</td>
</tr>
<tr>
<td>11:30-13:30</td>
<td>Hall 6.0 Vital hepatitis C (2)</td>
</tr>
<tr>
<td>13:30-14:00</td>
<td>Hall 8.1 – Poster tours</td>
</tr>
<tr>
<td>13:30-14:00</td>
<td>Liver tumours: Management</td>
</tr>
<tr>
<td>13:30-14:00</td>
<td>Fatty liver disease: Experimental</td>
</tr>
<tr>
<td>14:00-15:30</td>
<td>Symposia</td>
</tr>
<tr>
<td>14:00-15:30</td>
<td>Hall 8.0-D2 Animal models for study of liver disease</td>
</tr>
<tr>
<td>14:00-15:30</td>
<td>Hall 8.0-D1 Antiviral treatment of patients with decompensated cirrhosis</td>
</tr>
<tr>
<td>14:00-15:30</td>
<td>Hall 8.0-A1 ALD: from epidemiology to clinical management</td>
</tr>
<tr>
<td>14:00-15:30</td>
<td>Hall 8.0-B3 NAFLD and diabetes – cause or consequence</td>
</tr>
<tr>
<td>15:30-16:00</td>
<td>Hall 8.1 – Poster tours</td>
</tr>
<tr>
<td>15:30-16:00</td>
<td>Autoimmune and hepatobiliary disease 2</td>
</tr>
<tr>
<td>15:30-16:00</td>
<td>Viral hepatitis: Hepatitis C – clinical (therapy) 2</td>
</tr>
<tr>
<td>15:30-16:00</td>
<td>Molecular and cellular biology: HSCs and fibrosis</td>
</tr>
<tr>
<td>16:00-18:00</td>
<td>Hall 6.0 – Late-breaker session</td>
</tr>
<tr>
<td>18:00-18:30</td>
<td>Break</td>
</tr>
<tr>
<td>18:30-20:00</td>
<td>Hall 8.0-E4 – Sonography course / € for “acute medicine” in hepatology</td>
</tr>
</tbody>
</table>

To refer to colour code, see page 58
SATURDAY 16 APRIL 2016

Hall 8.0-BI – EASL – EFSUMB workshop
Lecture: Ultrasound Elastography in liver disease of different etiology

Hall 8.1 – Oral ePosters
Booth 1 Liver fibrosis, nanomedicine and new technologies
Booth 2 Transplantation and acute liver failure
Booth 3 Autoimmune and cholestatic liver disease
Booth 4 Molecular and cellular biology

Hall 8.0 and hall 8.1 – Lunch

Hall 8.0-CI – Young Investigator forum
How to become an independent researcher

Hall 8.1 – Coffee break

Hall 8.0-EI Ultrasound hands on sessions / €
Session 1

Hall 8.0-EI Ultrasound hands on sessions / €
Session 2

Hall 8.0-EI Ultrasound hands on sessions / €
Session 3

Hall 8.0-EI Ultrasound hands on sessions / €
Session 4

18:30-19:30
Hall 6.0 EASL recommendations on treatment of hepatitis C 2016: Update coming
## DAILY PROGRAMME AT A GLANCE

### EMWs – Early morning workshops / €

- **Hall 8.0-E3** Making the best use of CRISPR-Cas9 technology
- **Hall 8.0-E8** Operational tolerance implications for management of immunosuppression after liver transplantation

### 07:30-08:30

- **Hall 8.0-E2** EASL–ISHEN: Hepatic encephalopathy EASL/AASLD guidelines: 1 year on
- **Hall 8.0-B2** Beyond UDCA in cholestatic diseases
- **Hall 8.0-E4** Anticoagulation and cirrhosis
- **Hall 8.0-D2** Beta-blockers in liver cirrhosis: when to start, when to stop?

### Symposium

- **Hall 8.0-C1** WHO-EASL – New directions and innovations in hepatitis testing

### 08:30-10:30

- **Hall 8.0-A1** The best of Journal of Hepatology, 2015 Editor’s picks
- **Hall 8.0-B1** Best poster summary

### 10:00-10:30

- **Hall 8.0** – Coffee break

### 10:30-11:30

- **Hall 8.0-D1** Cholangiocyte biology
- **Hall 8.0-D2** Systemic inflammation in advanced chronic liver disease
- **Hall 8.0-B3** Liver biopsy in HCC
- **Hall 8.0-A1** Optimal therapy for challenging HCV patients (Kidney, DAA failures)

### 11:30-13:00

- **Hall 8.0-A1** – General session 4 and closing

### 13:00-14:00

- **Hall 8.0** – Lunch

*To refer to colour code, see page 58*
SUNDAY 17 APRIL 2016

- **Hall 8.0-E5** Epigenetics in human liver disease and HCC
- **Hall 8.0-C1** Screening of HCC in special populations (including fatty liver disease, cured HCV)
- **Hall 8.0-G2** New treatment options on the horizon in patients with NAFLD
- **Hall 8.0-B1** Diagnosis and optimal management of HEV infection
- **Hall 8.0-E1** HCV treatment prioritization when resources are limited
- **Hall 8.0-B3** Management of HCV patients with impaired kidney function
- **Hall 8.0-D1** Optimal management of chronic hepatitis delta

**Hall 8.0-B1 – Best poster summary**

**Hall 8.0-B2 – EASL clinical practice guidelines**

- Benign liver tumour – vascular liver disease – liver transplantation

Look out for the LiverTree™ symbol indicating that the session will be webcast and available for viewing after The International Liver Congress™.
Find out what EASL members already know! The LiverTree is the home of online hepatology education

All ILC2016 congress materials:
- Seminars
- Abstracts
- ePosters
- Slides

EASL monothematic material

More than 34,000 indexed slides

821 Learning quizzes

Resource exploration by topic

Become an EASL member and access the LiverTree!

www.easl.eu/livertree
Joint workshop: EASL – ELITA – ILTS – LICAGE – Hall 8.0-D1
Post graduate course liver transplant

**Chairs:**
Gianni Biancofiore, Italy
Elizabeth Pomfret, United States

08:00-08:20  **Hepatorenal syndrome and renal replacement therapy at the time of transplant**
Miquel Navasa, Spain

08:20-08:40  **Infections management in liver transplant candidate: which do contraindicate liver transplant?**
Ali Canbay, Germany

08:40-09:00  **Sarcopenia in liver transplant candidates**
Francois Durand, France

09:00-09:20  **Critical care in the pre-transplant setting**
Fuat Saner, Germany

09:20-09:30  **Discussion**

09:30-10:00  **Coffee Break**

10:00-10:20  **Outcomes in MELD>40 liver transplant**
James Trotter, United States

10:20-10:40  **Donor and recipient gender in liver transplantation: data from the European Liver Transplant Registry (ELTR)**
Giacomo Germani, Italy

10:40-11:00  **Discussion**

11:00-11:30  **Break**

**Chairs:**
Patrizia Burra, Italy
Paolo Muiesan, United Kingdom

11:30-11:50  **Immunosuppression after LT in PSC with IBD**
Kirsten Boberg, Norway
11:50-12:10  **Machine liver perfusion: where do we stand?**  
Costantino Fondevila, Spain

12:10-12:30  **Transition from adolescence to adulthood**  
Pietro Vajro, Italy

12:30-12:50  **Living donor related liver transplantation**  
Yaman Tokat, Turkey

12:50-13:10  **Multi-substance abuse and liver transplantation**  
Michael R. Lucey, United States

13:10-13:30  **Results from anti-HCV treatment in the setting of liver transplantation: In patients in the waiting list and in patients after liver transplantation**  
Xavier Forns, Spain

13:30-13:45  **Discussion and closing remarks**

---

**Joint workshop: EASL – CHBG  Hall 8.0-E8**

**Chairs:**  
Christian Gluud, Denmark  
Cecilia Rodrigues, Portugal

08:00-08:05  **Welcome**  
Christian Gluud, Denmark, Cecilia Rodrigues, Portugal

08:05-08:35  **Direct acting antivirals: do they work beyond sustained virological response in chronic hepatitis C patients?**  
Ronald Koretz, United States

08:35-09:05  **The effects of nutrition to hospitalized liver patients – a systematic review**  
Joshua Rose-Hansen Feinberg, Denmark

09:05-09:30  **Ursodeoxycholic acid for primary biliary cholangitis – a systematic review**  
Jelena Nincevic, Republic of Serbia

09:30-10:00  **Coffee Break**

10:00-10:30  **Non-invasive diagnostic tests for oesophageal varices – a systematic review**  
Agostino Colli, Italy
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30-11:00</td>
<td><strong>Nonabsorbable disaccharides for hepatic encephalopathy – a systematic review</strong></td>
</tr>
<tr>
<td></td>
<td>Lise Lotte Gluud, <em>Denmark</em></td>
</tr>
</tbody>
</table>

**Joint workshop: EASL – ESPGHAN**  
Hall 8.0-E3

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00-08:30</td>
<td><strong>Differences between adult and adolescent NAFLD – Implications for follow up and therapy</strong></td>
</tr>
<tr>
<td></td>
<td>Valerio Nobili, <em>Italy</em></td>
</tr>
<tr>
<td>08:30-09:00</td>
<td><strong>Small molecules in metabolic liver disease? – Novel therapeutic agents in α-1-ATD</strong></td>
</tr>
<tr>
<td></td>
<td>Nedim Hadzic, <em>United Kingdom</em></td>
</tr>
<tr>
<td>09:00-09:30</td>
<td><strong>Biliary atresia in adulthood – with and without liver transplantation</strong></td>
</tr>
<tr>
<td></td>
<td>Loreto Hierro, <em>Spain</em></td>
</tr>
<tr>
<td>09:30-10:00</td>
<td><strong>Coffee Break</strong></td>
</tr>
<tr>
<td>10:00-10:30</td>
<td><strong>Familial cholestasis syndromes</strong></td>
</tr>
<tr>
<td></td>
<td>Henkjan Verkade, <em>Netherlands</em></td>
</tr>
<tr>
<td>10:30-11:00</td>
<td><strong>Cystic fibrosis liver disease in the adolescent</strong></td>
</tr>
<tr>
<td></td>
<td>Dominique Debray, <em>France</em></td>
</tr>
</tbody>
</table>

**Joint workshop: EASL – Baveno**  
Hall 8.0-B1

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00-08:20</td>
<td><strong>Welcome and Introduction: from the Baveno meeting to the Baveno cooperation</strong></td>
</tr>
<tr>
<td></td>
<td>Roberto De Franchis, <em>Italy</em></td>
</tr>
<tr>
<td>08:20-08:50</td>
<td><strong>The Baveno cooperation: what it is, how it works, what are the goals</strong></td>
</tr>
<tr>
<td></td>
<td>Jaime Bosch, <em>Spain</em></td>
</tr>
</tbody>
</table>
### Areas of research

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker / Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:50-09:10</td>
<td>Translational</td>
<td>Jonel Trebicka, Germany</td>
</tr>
<tr>
<td>09:10-09:30</td>
<td>Evaluation and risk stratification</td>
<td>Annalisa Berzigotti, Switzerland</td>
</tr>
<tr>
<td>09:30-10:00</td>
<td>Coffee Break</td>
<td></td>
</tr>
<tr>
<td>10:00-10:20</td>
<td>Therapy</td>
<td>Guadalupe Garcia-Tsao, United States</td>
</tr>
<tr>
<td>10:20-10:40</td>
<td>Non cirrhotic portal hypertension / vascular liver diseases</td>
<td>Dominique-Charles Valla, France</td>
</tr>
<tr>
<td>10:40-11:00</td>
<td>Election of steering committee and closure</td>
<td></td>
</tr>
</tbody>
</table>

### Joint workshop: EASL – CLIF  
Hall 8.0-C2

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker / Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00-08:05</td>
<td>Introduction</td>
<td>Mauro Bernardi, Italy</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Richard Moreau, France</td>
</tr>
<tr>
<td>08:05-08:30</td>
<td>Natural history of ACLF</td>
<td>Thierry Gustot, Belgium</td>
</tr>
<tr>
<td>08:30-09:00</td>
<td>Identifiable triggers for ACLF</td>
<td>Pere Gines, Spain</td>
</tr>
<tr>
<td>09:00-09:30</td>
<td>Assessing prognosis</td>
<td>Rajiv Jalan, United Kingdom</td>
</tr>
<tr>
<td>09:30-10:00</td>
<td>Coffee Break</td>
<td></td>
</tr>
<tr>
<td>10:00-10:25</td>
<td>Role of bacterial and/or PAMP translocation in ACLF</td>
<td>Reiner Wiest, Switzerland</td>
</tr>
<tr>
<td>10:25-10:50</td>
<td>Pathophysiology of end organ dysfunction(s)/failure(s)</td>
<td>Paolo Angeli, Italy</td>
</tr>
<tr>
<td>10:50-11:00</td>
<td>Areas of future research</td>
<td>Richard Moreau, France</td>
</tr>
</tbody>
</table>
Joint workshop: EASL – ESGAR
Hall 8.0-E5

**Chairs:**
Alejandro Forner, Spain
Luis Marti-Bonmati, Spain

08:00-08:30 **Surveillance of HCC: can be it improved?**
Fabio Piscaglia, Italy

08:30-09:00 **Diagnosis criteria among the different guidelines**
Luis Marti-Bonmati, Spain

09:00-09:30 **Role of diffusion weighted imaging in HCC**
Valérie Vilgrain, France

09:30-10:00 **Coffee Break**

10:00-10:30 **Recent advances with hepatobiliary contrast media**
Filipe Caseiro-Alves, Portugal

10:30-11:00 **Evaluation of tumour response by imaging: A unique criteria for all treatment options?**
Wolfgang Sieghart, Austria

Joint workshop: EASL – ILCA
New horizons in HCC
Hall 8.0-B3

**Chairs:**
Peter Galle, Germany
Helen L. Reeves, United Kingdom

08:00-08:30 **Bridging the gap between basic science and clinical practice**
Peter Schirmacher, Germany

08:30-09:00 **Immunotherapy in HCC – checkpoint inhibition and beyond**
Tim Greten, United States

09:00-09:30 **The impact of novel HCV therapies for PLC development**
Peter Ferenci, Austria

09:30-10:00 **Coffee Break**
### Joint workshop: EASL – ESBRA

**Chairs:**  
Helena Cortez Pinto, Portugal  
Felix Stickel, Switzerland

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 08:00-08:30   | **Alcohol interactions with the inflammasome**  
Jan Petrasek, United States       |
| 08:30-09:00   | **Functional implications of PNPLA3 variation in alcoholic and non-alcoholic liver disease**  
Stefano Romeo, Sweden     |
| 09:00-09:30   | **Design of genetically modified rodents for experimental alcoholic liver disease**  
Thorsten Buch, Switzerland |
| 09:30-10:00   | **Coffee Break**                                                      |
| 10:00-10:30   | **Alcoholic hepatitis – current and future treatments**  
Christophe Moreno, Belgium |
| 10:30-11:00   | **Treatment of alcoholism in alcoholic cirrhosis – efficacy and safety**  
Lorenzo Leggio, United States    |

### Joint workshop: EASL – FLIP/EPoS

**Chairs:**  
Quentin Anstee, United Kingdom  
Jean-François Dufour, Switzerland

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 08:00-08:30   | **NAFLD Natural History**  
Mattias Ekstedt, Sweden       |
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30-09:00</td>
<td><strong>Non-invasive testing and risk-stratification in NAFLD</strong></td>
</tr>
<tr>
<td></td>
<td>Stuart McPherson, <em>United Kingdom</em></td>
</tr>
<tr>
<td>09:00-09:30</td>
<td><strong>Microbiota in NAFLD Pathogenesis</strong></td>
</tr>
<tr>
<td></td>
<td>Judith Aron, <em>France</em></td>
</tr>
<tr>
<td>09:30-10:00</td>
<td><strong>Coffee Break</strong></td>
</tr>
<tr>
<td>10:00-10:30</td>
<td><strong>Metabolomics &amp; Lipidomics</strong></td>
</tr>
<tr>
<td></td>
<td>Matej Oresic, <em>Denmark</em></td>
</tr>
<tr>
<td>10:30-11:00</td>
<td><strong>NAFLD Therapeutics</strong></td>
</tr>
<tr>
<td></td>
<td>Stephen Harrison, <em>United States</em></td>
</tr>
</tbody>
</table>

**Joint workshop: EASL – INHSU**
Enhancing HCV treatment access and outcomes for people who inject drugs in the interferon-free era  
Hall 8.0-E4

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00-08:05</td>
<td><strong>Introduction</strong></td>
</tr>
<tr>
<td></td>
<td>Philip Bruggmann, <em>Switzerland</em></td>
</tr>
<tr>
<td>08:05-08:30</td>
<td><strong>HCV diagnostics and point of care testing – tools to enhance screening and diagnosis</strong></td>
</tr>
<tr>
<td></td>
<td>Teri Roberts, <em>Switzerland</em></td>
</tr>
<tr>
<td>08:30-08:55</td>
<td><strong>Interferon-free treatment of HCV infection among people receiving opioid substitution therapy and people who inject drugs</strong></td>
</tr>
<tr>
<td></td>
<td>Gregory Dore, <em>Australia</em></td>
</tr>
<tr>
<td>08:55-09:20</td>
<td><strong>Is HCV treatment and care a priority in settings with high drug-related morbidity and mortality?</strong></td>
</tr>
<tr>
<td></td>
<td>Niklas Luhmann, <em>France</em></td>
</tr>
<tr>
<td>09:20-09:30</td>
<td><strong>Video: The Change Project</strong></td>
</tr>
<tr>
<td>09:30-10:00</td>
<td><strong>Coffee Break</strong></td>
</tr>
<tr>
<td>10:00-10:25</td>
<td><strong>Challenges to provide access to HCV screening and treatment to PWID in Eastern Europe</strong></td>
</tr>
<tr>
<td></td>
<td>Marieta Simonova, <em>Bulgaria</em></td>
</tr>
</tbody>
</table>
10:25-11:00  Where to from here? – Future research and clinical priorities for the management of HCV infection among people who inject drugs

Joint workshop: EASL – MSF – PROLIFICA – TAG
Responding to viral hepatitis: Limited resources and marginalised populations  Hall 8.0-E1

Chairs:
Isabelle Andrieux-Meyer, Switzerland
Markus Peck-Radosavljevic, Austria

08:00-08:20  Strategy for HCV treatment scale-up
Tracy Swan, United States

08:20-08:40  Strategy for rolling out HCV testing and treatment programs for key populations in Ukraine
Ludmila Maistat, Ukraine

08:40-09:00  Comprehensive packages of care for people who use drugs in resource limited settings
Nathan Ford, Switzerland

09:00-09:20  HCV diagnostic and treatment strategies in children and adolescents: the Egyptian experience
Manal Hamdy El-Sayed, Egypt

09:20-09:30  Discussion

09:30-10:00  Coffee Break

Chairs:
Tracy Swan, United States
Mark Thursz, United Kingdom

10:00-10:20  Epidemiologic estimates of hepatitis viruses
Jördis Ott, Germany

10:20-10:40  HBV testing in HIV facilities: coverage and consequences
Gibril Ndow, Gambia

10:40-11:00  Viral hepatitis testing in immigrants: ethics and acceptability
Graham Foster, United Kingdom
Joint workshop: EASL – Viral hepatitis group  

**Chairs:**
- Alessio Aghemo, Italy
- Jean-Michel Pawlotsky, France

**08:00-08:30**  
Hepatitis delta update  
Heiner Wedemeyer, Germany

**08:30-09:00**  
Insights from the pathobiology of HBV: new definitions for clinical phases of the disease and treatment endpoints  
Fabien Zoulim, France

**09:00-09:30**  
Interferon-free treatment failures and HCV resistance  
Jean-Michel Pawlotsky, France

**09:30-10:00**  
Coffee Break

**10:00-10:30**  
Improving worldwide access to HCV care  
Jason Grebely, Australia

**10:30-11:00**  
The challenges of hepatitis C treatment in patients with chronic kidney disease  
Jordan Feld, Canada

Post graduate course – Management of liver tumours  

**Chairs:**
- Jordi Bruix, Spain
- Markus Peck-Radosavljevic, Austria
- Massimo Pinzani, United Kingdom

**Epidemiology, oncogenesis and population at risk**

**11:30-11:50**  
Case presentation with Q&A  
Massimo Iavarone, Italy

**11:50-12:10**  
Epidemiology: current status and expected trends. Expected impact of HCV treatment and SVR. Is ICC incidence increasing?  
Massimo Colombo, Italy
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 12:10-12:30  | **Oncogenic mechanisms: is it all inflammatory damage? Or mutations by HBV? Or what?**
|              | Tom Luedde, Germany                                                       |
| 12:30-12:50  | **Molecular classification and profiling: is there a clinical link for prognosis and treatment**
|              | Josep Llovet, Spain                                                      |
| 12:50-13:10  | **Clinical profiling: high-low risk populations; risk prediction in different etiologies...**
|              | Kwang-Hyub Han, Korea, South                                             |
| 13:10-13:30  | **Q&A answers and discussion**                                           |
| 13:30-14:00  | Lunch                                                                    |
|              | **Surveillance and diagnosis for HCC**                                   |
| 14:00-14:20  | **Case presentation with Q&A**                                           |
|              | Alvaro Diaz, Spain                                                      |
| 14:20-14:40  | **Whom, how and when to start/stop screening (e.g. follow-up post SVR)** |
|              | Peter Galle, Germany                                                    |
| 14:40-15:00  | **Diagnosis of nodules detected by surveillance: current criteria, LIRADS, and future developments in imaging and tumor markers** |
|              | Claude Sirlin, United States                                            |
| 15:00-15:20  | **Prognosis evaluation and staging: is the BCLC enough? Should it be replaced? Refined? What is the ultimate goal of staging?** |
|              | Alejandro Forner, Spain                                                  |
| 15:20-15:30  | **Q&A answers and discussion**                                           |
| 15:30-16:00  | **Coffee Break**                                                         |
|              | **Blending evidence based medicine and personalized approach: stratified medicine** |
| 16:00-16:20  | **Different options for very early HCC (BCLC 0, T1): resection vs transplant vs ablation** |
|              | Alessandro Vitale, Italy                                                 |
16:20-16:40  TACE and loco-regional approaches: for whom? How? When to stop? Expected survival if following guidelines  
Bruno Sangro, Spain

16:40-17:00  Systemic therapies: the sorafenib realm and the emerging competitors  
Tim Meyer, United Kingdom

17:00-17:20  Evaluation of response to treatment and progression by imaging. Is there evidence to decide the optimal criteria?  
Ricardo Lencioni, United States

17:20-17:30  Discussion

Basic science seminar – Gut-liver axis  
Hall 8.0-A1

**Chairs:**  
Cecilia Rodrigues, Portugal  
Robert Schwabe, United States  
Antonio Zorzano, Spain

**From microbiota to immunity**

11:30-11:35  Introduction and aims  
Robert Schwabe, United States

11:35-12:00  Gut-liver axis: functional links and key pathways  
Robert Schwabe, United States

12:00-12:30  Immune regulatory mechanisms in the gut  
Lecture: Oliver Pabst, Germany  
Phenotype and function of mucosal dendritic cells: Vuk Cerovic, Germany

12:30-13:00  Mechanisms of immune-mediated liver disease  
Lecture: David Adams, United Kingdom  
Platlets: Critical players in immune mediated liver damage: Abhishek Chauhan, United Kingdom

13:00-13:30  Microbiome and immunometabolism  
Lecture: Karine Clement, France  
Systemic and intestinal immunity in human obesity: Sébastien André, France
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:30-14:00</td>
<td><strong>Lunch</strong></td>
</tr>
<tr>
<td>13:30-14:30</td>
<td><strong>From microbiota to metabolism</strong></td>
</tr>
<tr>
<td>14:00-14:30</td>
<td>Inflammatory and stress pathways of metabolic disorders</td>
</tr>
<tr>
<td></td>
<td>Lecture: Michael Karin, United States</td>
</tr>
<tr>
<td></td>
<td>Immunosuppressive B cells control NASH development:</td>
</tr>
<tr>
<td></td>
<td>Shabnam Shalapour, United States</td>
</tr>
<tr>
<td>14:30-15:00</td>
<td>Drug metabolism beyond the liver – the gut microbiota partnership</td>
</tr>
<tr>
<td></td>
<td>Lecture: Francisco Guarner, Spain</td>
</tr>
<tr>
<td></td>
<td>Development of a new metatranscriptomic tool to investigate microbial metabolic activity within the human gut: Chaysavanh Manichanh, Spain</td>
</tr>
<tr>
<td>15:00-15:30</td>
<td>Tissue-specific actions of nuclear receptors in metabolism and cancer</td>
</tr>
<tr>
<td></td>
<td>Lecture: Antonio Moschetta, Italy</td>
</tr>
<tr>
<td></td>
<td>Long term FXR activation in liver disease:</td>
</tr>
<tr>
<td></td>
<td>Marica Cariello, Italy</td>
</tr>
<tr>
<td>15:30-16:00</td>
<td><strong>Coffee Break</strong></td>
</tr>
<tr>
<td>16:00-16:30</td>
<td><strong>Gut microbiota and liver disease</strong></td>
</tr>
<tr>
<td>16:00-16:30</td>
<td>Dysbiosis in the course of chronic liver injury</td>
</tr>
<tr>
<td></td>
<td>Lecture: Gianluca Svegliati-Baroni, Italy</td>
</tr>
<tr>
<td></td>
<td>Functional pathways linking dysbiosis to progression of chronic liver injury: Irene Pierantonelli, Italy</td>
</tr>
<tr>
<td>16:30-17:00</td>
<td>Gut microbial regulation of bile acid metabolism in cholestasis</td>
</tr>
<tr>
<td></td>
<td>Lecture: Michael Trauner, Austria</td>
</tr>
<tr>
<td></td>
<td>Bile acid transporter modulation and bile acid metabolism in cholestasis: Claudia Fuchs, Austria</td>
</tr>
<tr>
<td>17:00-17:30</td>
<td>Host-microbial interaction in alcoholic liver disease</td>
</tr>
<tr>
<td></td>
<td>Lecture: Bernd Schnabl, United States</td>
</tr>
<tr>
<td></td>
<td>Experimental dysbiosis promotes alcoholic liver disease:</td>
</tr>
<tr>
<td></td>
<td>Cristina Llorente, United States</td>
</tr>
</tbody>
</table>
Nurse and associates forum: Contemporary issues in caring for people with liver disease

**Chairs:**
Lynda Greenslade, United Kingdom
Markus Reiss, Germany

14:00-14:20  **Burden of hepatic encephalopathy with ELPA**
Tatjana Reic, Belgium

14:20-15:00  **Hepatic encephalopathy**
Elizabeth Farrington, United Kingdom

15:00-15:30  **Discussion: Leading European Liver Nursing Forward**

15:30-16:00  Coffee Break

16:00-16:30  **Are cohort data of value to improve HCV therapy?**
Stefan Mauss, Germany

16:30-17:00  **Managing cirrhosis and ascites in the outpatient setting**
Eva Lopez, Spain

17:00-17:30  **Addiction due to alcohol and drugs and assessment of these patients for liver transplantation**
Kerry Webb, United Kingdom

**Closing remarks**

**Major sponsor industry satellite symposia**

18:00-19:30  Please refer to the industry section for more details
Industry satellite symposia and mini workshop

07:30-08:30 Please refer to the industry section for more details

Joint workshop: EASL – WHA

Chairs:
Patrizia Burra, Italy
Raquel Peck, Switzerland

08:30-08:35 Welcome and introduction
Laurent Castera, France

08:35-08:45 The Glasgow declaration
Charles Gore, United Kingdom

08:45-09:00 The WHO draft global strategy
Gottfried Hirnschall, Switzerland

09:00-09:15 Progress Towards HCV Elimination in Georgia
Amiran Gamkrelidze, Georgia

09:15-10:45 Panel one: Regional baseline positions:
Where are we in 2016

09:15-09:30 AFRO region: Danjuma Adda, Nigeria
09:30-09:45 EURO region: Francesco Negro, Switzerland
09:45-10:00 Latin America: Fernando Contreras, Dominican Republic
10:00-10:15 EMRO region: Ayman Yosry, Egypt
10:15-10:30 Asia Pacific region: Shiv Sarin, India
10:30-10:45 North America region: Anna Lok, United States
10:45-11:30 Panel discussion: What is needed to reach the SDGs targets on viral hepatitis and national responses towards eliminating hepatitis
### Intrahepatic cholangiocarcinoma (ICC): the emerging clinical challenge

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30-08:50</td>
<td>Case presentation with Q&amp;A</td>
</tr>
<tr>
<td></td>
<td>Alvaro Diaz, Spain</td>
</tr>
<tr>
<td>08:50-09:10</td>
<td>The pathological diagnosis of ICC and mixed hepatocellular carcinoma? Do we have consensus criteria? Do liver stem cell cancers exist? How to distinguish ICC from HCC with stem cell profile</td>
</tr>
<tr>
<td></td>
<td>Tania Roskams, Belgium</td>
</tr>
<tr>
<td>09:10-09:30</td>
<td>Molecular profiling of ICC: are we identifying therapeutic targets or prognostic indicators?</td>
</tr>
<tr>
<td></td>
<td>Diego Calvisi, Germany</td>
</tr>
<tr>
<td>09:30-09:50</td>
<td>Treatment of ICC. From surgery to ablation, transplant, locoregional and systemic approaches</td>
</tr>
<tr>
<td></td>
<td>Olivier Farges, France</td>
</tr>
<tr>
<td>09:50-10:00</td>
<td>Q&amp;A answers and discussion</td>
</tr>
<tr>
<td>10:00-10:30</td>
<td>Coffee Break</td>
</tr>
</tbody>
</table>

### Benign liver tumours

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30-10:50</td>
<td>Case presentation with Q&amp;A</td>
</tr>
<tr>
<td></td>
<td>Martha Kirstein, Germany</td>
</tr>
<tr>
<td>10:50-11:10</td>
<td>Is it possible to achieve diagnosis by imaging?</td>
</tr>
<tr>
<td></td>
<td>Valérie Vilgrain, France</td>
</tr>
<tr>
<td>11:10-11:30</td>
<td>Molecular profiling of adenoma: are we there?</td>
</tr>
<tr>
<td></td>
<td>Jessica Zucman Rossi, France</td>
</tr>
<tr>
<td>11:30-11:50</td>
<td>EASL clinical practice guidelines</td>
</tr>
<tr>
<td></td>
<td>Helen L. Reeves, United Kingdom</td>
</tr>
<tr>
<td>11:50-12:00</td>
<td>Q&amp;A answers and discussion</td>
</tr>
</tbody>
</table>
### Basic science seminar – Gut-liver axis

**Chairs:**
Cecilia Rodrigues, Portugal  
Robert Schwabe, United States  
Antonio Zorzano, Spain

#### Gut microbiota and liver disease

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Lecture</th>
</tr>
</thead>
</table>
| 08:30-09:00 | **Identification of the gut vascular barrier linking the gut with the liver**  
|         | Lecture: Maria Rescigno, Italy  
|         | The gut vascular barrier in disease: Ilaria Spadoni, Italy             |                                                                        |
| 09:00-09:30 | **Gut-liver-brain axis and encephalopathy**  
|         | Lecture: Debbie Shawcross, United Kingdom  
|         | The pathogenic relationship of the host microbiota with the gut-liver-brain axis: Vishal Patel, United Kingdom |                                                                        |
| 09:30-10:00 | **Obesity, the gut microbiome and liver cancer**  
|         | Lecture: Eiji Hara, Japan  
|         | The mechanism of obesity-associated liver carcinogenesis: a co-operation between gut microbial metabolites and lipid: Naoko Ohtani, Japan |                                                                        |
| 10:00-10:30 | **Coffee Break**   |                                                                        |

#### Diagnosis and therapeutic strategies

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Lecture</th>
</tr>
</thead>
</table>
| 10:30-11:00 | **Bacteria as biosensors to detect liver disease**  
|         | Lecture: Jasmohan S. Bajaj, United States  
|         | Use of bio-informatics to determine microbial changes in liver disease: Naga Betrapally, United States |                                                                        |
| 11:00-11:30 | **GI surgery and microbiota metabolites**  
|         | Lecture: Elaine Holmes, United Kingdom  
|         | The role of the microbiome in fatty liver disease: Jia Li, United Kingdom |                                                                        |
| 11:30-12:00 | **Regulation of obesity-related insulin resistance with gut anti-inflammatory agents**  
|         | Lecture: Shawn Winer, Canada  
|         | Treatment of obesity associated insulin resistance by targeting the gut immune system: Sue Tsai, Canada |                                                                        |
### Poster tours  
**Hall 8.1**

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Guide</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:00-10:30</td>
<td><strong>Genetic and paediatric liver diseases</strong></td>
<td>Heinz Zoller, Austria</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Viral hepatitis: Hepatitis A, B, D, E – clinical (except therapy)</strong></td>
<td>Jörg Petersen, Germany</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Cirrhosis and its complications: clinical aspects (1)</strong></td>
<td>Emmanuel Tsochatzis, UK</td>
<td></td>
</tr>
</tbody>
</table>

**Meeting point: poster help desk**

### Fellowship presentations  
**Hall 8.0-C1**

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Authors</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:00-12:15</td>
<td>Effects of liver sinusoidal endothelial phenotype amelioration through cox-1 silencing in cirrhotic portal hypertension</td>
<td>Dinesh Mani Tripathi, Spain</td>
<td></td>
</tr>
<tr>
<td>12:15-12:25</td>
<td>Urine biomarkers in the assessment of clinical outcomes in cirrhosis</td>
<td>Salvatore Piano, Italy</td>
<td></td>
</tr>
<tr>
<td>12:25-12:40</td>
<td>Characterization and predictive role of hepatitis C quasispecies evolution in the development of fibrosing cholestatic hepatitis after liver transplantation</td>
<td>Martina Gambato, Spain</td>
<td></td>
</tr>
<tr>
<td>12:40-12:55</td>
<td>Genetically engineering CD8+T cells to withstand the HBV infected liver milieu</td>
<td>Itziar Otano, UK</td>
<td></td>
</tr>
<tr>
<td>12:55-13:10</td>
<td>Functional characterization of long non-coding RNAs in liver regeneration under normal and pathological conditions</td>
<td>Simon Manuel Schultze, Austria</td>
<td></td>
</tr>
</tbody>
</table>
Molecular epidemiology and virus-host interaction of hepatitis E virus
Tong Hoang, Germany

Registry grant presentations

Hall 8.0-B1

Chairs:
Mario Mondelli, Italy
Helen L. Reeves, United Kingdom

12:00-12:15 Polycystic liver disease (PLD) Registry
Joost PH Drenth, Netherlands

12:15-12:30 Prospective European Drug-Induced Liver Injury Registry (Pro-Euro-DILI Registry)
Raul J. Andrade, Spain

12:30-12:45 Hepatitis Delta International Network
Heiner Wedemeyer, Germany

12:45-12:55 European registry for vascular disorders of the liver: the VALDIREG project
Andrea de Gottardi, Switzerland

12:55-13:05 A European repository of patients with IGG4 related disease
Ellie Barnes, United Kingdom

13:05-13:15 Non-HFE hemochromatosis registry
Heinz Zoller, Austria

EU and public health session:
Liver, lifestyle, and EU policy

Hall 8.0-B3

Chairs:
Andrew Amato Gauci, Sweden
Patrizia Burra, Italy

12:00-12:20 Alcohol
Nick Sheron, United Kingdom

12:20-12:40 HBV/HCV
David Goldberg, United Kingdom
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:40-13:00</td>
<td>Obesity</td>
<td>Christina Westphal, Germany</td>
</tr>
<tr>
<td>13:00-13:20</td>
<td>Advocacy &amp; policy</td>
<td>Fiona Godfrey, Belgium</td>
</tr>
<tr>
<td>13:20-13:30</td>
<td>Discussion</td>
<td></td>
</tr>
</tbody>
</table>

### Oral ePosters

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Chair(s)</th>
<th>Booth</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:00-13:00</td>
<td>HCC clinical and experimental</td>
<td>Guido Gerken, Germany</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>HBV and HDV</td>
<td>Pietro Andreone, Italy</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td>NASH</td>
<td>William Alazawi, UK</td>
<td>3</td>
</tr>
<tr>
<td></td>
<td>Non-invasive assessment of liver disease</td>
<td>Mirella Fraquelli, Italy</td>
<td>4</td>
</tr>
</tbody>
</table>

### Poster tours

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Guide</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:00-12:30</td>
<td>Cirrhosis and its complications: Clinical aspects (2)</td>
<td>Dominique Thabut, France</td>
</tr>
<tr>
<td></td>
<td>Liver transplantation: Experimental, acute liver failure-clinical &amp; experimental</td>
<td>Rajiv Jalan, UK</td>
</tr>
<tr>
<td></td>
<td>Viral hepatitis: Hepatitis C – clinical (new compounds, resistance)</td>
<td>Darius Moradpour, Switzerland</td>
</tr>
<tr>
<td>12:30-13:00</td>
<td>Alcoholic liver disease and drug induced liver disease</td>
<td>Raul Andrade, Spain</td>
</tr>
</tbody>
</table>
Viral hepatitis: Hepatitis C – experimental (virology)
Guide: Thomas Baumert, France

Meeting point: poster help desk

EASL clinical practice guidelines:
Autoimmune hepatitis and NAFLD
Hall 8.0-A1

12:15-12:45  Autoimmune hepatitis
Ansgar Lohse, Germany

12:45-13:15  NAFLD
Giulio Marchesini, Italy

General session I and opening ceremony
Hall 6.0

Chairs:
Laurent Castera, France
Daniel Shouval, Israel

13:30-13:50 Opening Ceremony – Part 1: Secretary General’s report

13:50-14:05 ABSTRACT GS01
TREATMENT OF HEPATITIS C VIRUS IN PATIENTS WITH ADVANCED CIRRHOSIS: ALWAYS JUSTIFIED? ANALYSIS OF THE HEPA-C REGISTRY
Carlos Fernández-Carrillo, Spain

14:05-14:20 ABSTRACT GS02
FIVE-YEAR ON-TREATMENT SYSTEMATICALLY MONITORING OF DYNAMIC CHANGES OF LIVER STIFFNESS MEASUREMENT WITH TRANSIENT ELASTOGRAPHY COMPARED WITH PAIRED LIVER BIOPSIES IN A RANDOMIZED CONTROLLED TRIAL IN CHRONIC HEPATITIS B PATIENTS
Jinlin Hou, China
A GENOME-WIDE ASSOCIATION STUDY IDENTIFIES PNPLA3 AND SLC38A4 AS RISK LOCI FOR ALCOHOLIC HEPATITIS
Stephen Atkinson, United Kingdom

14:35-14:55
Opening Ceremony – Part 2

14:55-15:10
THE MULTIKINASE INHIBITOR REGORAFENIB IMPROVES PORTAL HYPERTENSION IN PRESENCE AND ABSENCE OF CIRRHOSIS IN RATS
Robert Schierwagen, Germany

15:10-15:25
SAF SCORE AS A MARKER FOR MORTALITY IN NAFLD AFTER UP TO 41 YEARS OF FOLLOW-UP
Hannes Hagström, Sweden

15:25-15:40
A PHASE 3 STUDY OF TENOFOVIR ALAFENAMIDE COMPARED WITH TENOFOVIR DISOPROXIL FUMARATE IN PATIENTS WITH HBEAG-NEGATIVE, CHRONIC HEPATITIS B: WEEK 48 EFFICACY AND SAFETY RESULTS
Maria Buti, Spain

Poster tours

15:30-16:00
Liver tumours: Clinical (epidemiology, diagnosis)
Guide: Arndt Vogel, Germany

Molecular and cellular biology: Cell cycle control / apoptosis and regeneration
Guide: Jessica Zucman-Rossi, France

Viral hepatitis: Hepatitis B & D – experimental
Guide: Massimo Levrero, Italy

Meeting point: poster help desk
Parallel session: General hepatology

Hall 8.0-D1

Chairs:
Jaime Bosch, Spain
Frank Tacke, Germany

16:00-16:15

ABSTRACT PS017
COMPARISON OF DAILY NORFLOXACIN VERSUS WEEKLY CIPROFLOXACIN FOR THE PREVENTION OF SPONTANEOUS BACTERIAL PERITONITIS IN CIRRHOTIC PATIENTS: A RANDOMIZED CONTROLLED TRIAL
Hyung Joon Yim, Korea, South

16:15-16:30

ABSTRACT PS018
SHOULD WE KEEP USING RIBAVIRIN TO TREAT HEPATITIS C RECURRENCE AFTER LIVER TRANSPLANTATION? RESULTS FROM THE CO23 ANRS CUPILT STUDY
Pauline Houssel-Debry, France

16:30-16:45

ABSTRACT PS019
A NOVEL INNATE IMMUNOTHERAPY AGAINST HCC VIA AUGMENTATION OF NK CELL CYTOTOXICITY BY ENHANCING GWAS-IDENTIFIED HCC SUSCEPTIBILITY GENE EXPRESSION
Naoya Kato, Japan

16:45-17:00

ABSTRACT PS020
AN ONGOING PHASE 2, MULTI-CENTRE, OPEN-LABEL, STUDY OF WTX101 IN NEWLY DIAGNOSED WILSON DISEASE PATIENTS – EARLY OBSERVATIONS
Karl Heinz Weiss, Germany

17:00-17:15

ABSTRACT PS021
HIGH EFFICACY OF SOFOSBUVIR/VELPATASVIR/GS-9857 WITH OR WITHOUT RIBAVIRIN FOR 12 WEEKS IN DIRECT ACTING ANTIVIRAL-EXPERIENCED PATIENTS WITH GENOTYPE 1 HCV INFECTION
Eric Lawitz, United States

17:15-17:30

ABSTRACT PS022
STATINS REDUCE ESOPHAGEAL VARICEAL BLEEDING IN CHRONIC HEPATITIS B PATIENTS WITH CIRRHOSIS: A NATIONWIDE COHORT STUDY
Sien-Sing Yang, Taiwan
17:30-17:45
ABSTRACT PS023
PLPNA3 STATUS IN NASH IS ASSOCIATED WITH INCREASED HISTOLOGICAL SEVERITY AT BASELINE BUT NOT WITH RESPONSE TO THERAPY IN THE GOLDEN-505 ELAFIBRANOR TRIAL
Vlad Ratziu, France

17:45-18:00
ABSTRACT PS024
SOFOSBUVIR/VELPATASVIR IN COMBINATION WITH RIBAVIRIN FOR 24 WEEKS IS EFFECTIVE RETREATMENT FOR PATIENTS WHO FAILED PRIOR NS5A CONTAINING DAA REGIMENS: RESULTS OF THE GS-US-342-1553 STUDY
Tarik Asselah, France

Parallel session: Liver immunology and inflammation  Hall 8.0-B1

Chairs:
David Adams, United Kingdom
Gisa Tiegs, Germany

16:00-16:15
ABSTRACT PS025
HCV T CELL RE-VACCINATION STRATEGIES USING SIMIAN ADENO AND MVA VIRAL VECTORS TO ENHANCE AND MAINTAIN ANTIVIRAL IMMUNITY
Felicity Hartnell, United Kingdom

16:15-16:30
ABSTRACT PS026
RNA INTERFERENCE MEDIATED SUPPRESSION OF HBV TRANSCRIPTS RESTORES HBV-SPECIFIC IMMUNITY AND ENHANCES THE EFFICACY OF THERAPEUTIC VACCINATION
Thomas Michler, Germany

16:30-16:45
ABSTRACT PS027
PRIMARY AND ADAPTIVE IMMUNE RESPONSE INVERSELY CORRELATE WITH ANTIGEN DENSITY IN THE LIVER
Marcin Cebula, Germany

16:45-17:00
ABSTRACT PS028
IL-2 THERAPY RESTORES THE IMPAIRED FUNCTION OF REGULATORY T CELLS INDUCED BY CALCINEURIN INHIBITORS IN LIVER TRANSPLANTATION
Gavin Whitehouse, United Kingdom
17:00-17:15  | TREM-2 PROTECTS THE LIVER FROM IMMUNE-MEDIATED HEPATOCELLULAR DAMAGE  
ABSTRACT  
PS029  
María Jesús Perugorria, Spain

17:15-17:30  | PTX3 IS A NOVEL MARKER OF DISEASE PROGRESSION IN ALCOHOLIC HEPATITIS AND ATTENUATES LPS-INDUCED LIVER INJURY AND INFLAMMATION  
ABSTRACT  
PS030  
Luis Perea, Spain

17:30-17:45  | CHARACTERISATION OF THE SPECIFICITY, FUNCTIONALITY AND DURABILITY OF HOST T-CELL RESPONSES AGAINST THE FULL HEV GENOME  
ABSTRACT  
PS031  
Anthony Brown, United Kingdom

17:45-18:00  | IMMUNOTHERAPY USING T CELLS REDIRECTED AGAINST HBV RESULTS IN REDUCED VIRAL LOADS AND ENHANCED IMMUNE RESPONSES IN HUMANIZED MICE  
ABSTRACT  
PS032  
Janine Kah, Germany

Parallel session: Liver transplantation  
Hall 8.0-B3

Chairs:  
Patrizia Burra, Italy  
Frederik Nevens, Belgium

16:00-16:15  | THE DECISION FOR LIVER TRANSPLANT IN ACUTE ON CHRONIC LIVER FAILURE (ACLF) – FIRST WEEK IS THE CRUCIAL PERIOD – ANALYSIS OF THE APASL ACLF RESEARCH CONSORTIUM (AARC) PROSPECTIVE DATA OF 1021 PATIENTS  
ABSTRACT  
PS33  
Ashok Choudhury, India

16:15-16:30  | CTLA-4 IS A NEGATIVE REGULATOR OF T CELL ACTIVATION IN ACUTE LIVER FAILURE  
ABSTRACT  
PS34  
Wafa Khamri, United Kingdom
16:30-16:45
ABSTRACT PS35
IMPACT ON RENAL FUNCTION OF STEPWISE WITHDRAWAL OF TACROLIMUS COMBINED WITH EVEROLIMUS AND EC-MPS VS STANDARD TREATMENT COMBINING TACROLIMUS AND EC-MPS IN DE NOVO LIVER TRANSPLANT RECIPIENTS: RESULTS OF THE SIMCER STUDY
Filomena Conti, France

16:45-17:00
ABSTRACT PS36
IMPACT OF DIRECT ANTI-VIRAL AGENTS ON INACTIVATION/DE-LISTING OF LIVER TRANSPLANT CANDIDATES LISTED FOR DECOMPENSATED C CIRRHOSIS: A EUROPEAN STUDY
Luca Belli, Italy

17:00-17:15
ABSTRACT PS37
LIVER TRANSPLANTATION IN SEVERE NEUROLOGICAL FORMS OF WILSON DISEASE; THE FRENCH EXPERIENCE
Rodolphe Sobesky, France

17:15-17:30
ABSTRACT PS38
LONG-TERM OUTCOME OF LIVER TRANSPLANTATION IN CHILDHOOD: A STUDY OF 100 PATIENTS SURVIVING FOR 20 YEARS OR MORE
Josefina Martinelli, France

17:30-17:45
ABSTRACT PS39
MOUSE LIVER REPOPULATION WITH HUMAN LIVER STEM CELLS
Rodrigo Gutierrez Jauregui, Germany

17:45-18:00
ABSTRACT PS40
LONG-TERM OUTCOMES IN LIVER TRANSPLANT RECIPIENTS TRANSPLANTED FROM HCV-POSITIVE DONORS
Zobair Younossi, United States
### Parallel session: Cirrhosis I

**Hall 8.0-A1**

**Chairs:**
Pere Gines, *Spain*
Jonel Trebicka, *Germany*

<table>
<thead>
<tr>
<th>Time</th>
<th>Abstract</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:00-16:15</td>
<td>THE GUANYLYL CYCLASE STIMULATOR RIOCIGUAT REDUCES LIVER FIBROSIS AND PORTAL PRESSURE IN CIRRHOTIC RATS</td>
</tr>
<tr>
<td></td>
<td>Philipp Schwabl, <em>Austria</em></td>
</tr>
<tr>
<td>16:15-16:30</td>
<td>THE EFFECT OF TESTOSTERONE THERAPY ON MUSCLE MASS, BONE MASS AND HAEMOGLOBIN IN HYPOGONADAL MEN WITH CIRRHOSIS</td>
</tr>
<tr>
<td></td>
<td>Marie Sinclair, <em>Australia</em></td>
</tr>
<tr>
<td>16:30-16:45</td>
<td>IN TOXIC CIRRHOTIC RATS, THE FXR AGONIST OBETICHOLIC ACID REDUCES LIVER FIBROSIS INDIRECTLY VIA AN ANTI-INFLAMMATORY EFFECT IN LIVER SINUSOIDAL ENDOTHELIAL CELLS AND KUPFFER CELLS</td>
</tr>
<tr>
<td></td>
<td>Len Verbeke, <em>Belgium</em></td>
</tr>
<tr>
<td>16:45-17:00</td>
<td>DIFFERENT PROBIOTIC STRAINS IN EXPERIMENTALLY INDUCED LIVER CIRRHOSIS IN RATS: INTESTINAL BARRIER HOMEOSTASIS AS A KEY POINT TO ATTENUATE FIBROSIS?</td>
</tr>
<tr>
<td></td>
<td>Ding Shi, <em>China</em></td>
</tr>
<tr>
<td>17:00-17:15</td>
<td>EARLY USE OF TIPS AND OUTCOMES IN PATIENTS WITH CIRRHOSIS AND ACUTE ESOPHAGEAL VARICEAL BLEEDING: ANALYSIS OF THE U.S. NATIONWIDE INPATIENT SAMPLE DATABASE, 2000-2010</td>
</tr>
<tr>
<td></td>
<td>Basile Njei, <em>United States</em></td>
</tr>
<tr>
<td>17:15-17:30</td>
<td>HYPERTONIC SALINE VERSUS MANNITOL IN THE MANAGEMENT OF CEREBRAL EDEMA IN ACUTE LIVER FAILURE: A RANDOMIZED OPEN LABEL CONTROL TRIAL</td>
</tr>
<tr>
<td></td>
<td>Chetan Kalal, <em>India</em></td>
</tr>
</tbody>
</table>
17:30-17:45
ABSTRACT
PS015
MER TYROSINE KINASE REGULATES THE ACTIVATION OF MYELOID CELLS AND INNATE IMMUNE RESPONSES IN ACUTE-ON-CHRONIC LIVER FAILURE
Arjuna Singanayagam, United Kingdom

17:45-18:00
ABSTRACT
PS016
PORTAL VEIN THROMBOSIS RELEVANCE ON LIVER CIRRHOSIS: ITALIAN VENOUS THROMBOTIC EVENTS REGISTRY
Valeria Raparelli, Italy

Parallel session: Liver tumours: Experimental  Hall 8.0-C1
Chairs:
Sabine Colnot, France
Maria Martinez-Chantar, Spain

16:00-16:15
ABSTRACT
PS041
METABOLIC REPROGRAMMING TOWARD A WARBURG PHENOTYPE CHARACTERIZES EARLY PHASES OF HEPATIC CARCINOGENESIS
Marta Kowalik, Italy

16:15-16:30
ABSTRACT
PS042
ACTIVATED FIBROBLASTS RECOVERED FROM THE CIRRHOTIC LIVER PROVIDE MALIGNANCY-PRONE PHENOTYPES TO CANCER CELLS AND MACROPHAGES: COMPARABLE CAPACITY WITH CANCER-ASSOCIATED FIBROBLASTS IN HEPATOCELLULAR CARCINOMA
Yohei Mano, Japan

16:30-16:45
ABSTRACT
PS043
THE “FIBROUS NEST”: A BIOTYPE INCLUDING WNT SIGNALS, EXTRACELLULAR MATRIX REMODELING AND STEMNESS IN HEPATOCELLULAR CARCINOMA
Romain Désert, France

16:45-17:00
ABSTRACT
PS044
SPECIFIC AP-1 (FOS/JUN) DIMERS EXERT DISTINCT FUNCTIONS IN LIVER CANCER
Latifa Bakiri, Spain
### SCIENTIFIC PROGRAMME / THURSDAY 14 APRIL 2016

**EASL  THE HOME OF HEPATOLOGY**

**PROGRAMME**

<table>
<thead>
<tr>
<th>Time</th>
<th>Abstract ID</th>
<th>Title</th>
<th>Speaker, Nationality</th>
</tr>
</thead>
<tbody>
<tr>
<td>17:00-17:15</td>
<td>PS045</td>
<td><strong>LKB1 ACTIVATES RAS PATHWAY IN HEPATOCellular CARCINOMA</strong>&lt;br&gt;BY TRANSCRIPTIONAL AND POST-TRANSLATIONAL REGULATION OF RASGRP3</td>
<td>Teresa Cardoso Delgado, Spain</td>
</tr>
<tr>
<td>17:15-17:30</td>
<td>PS046</td>
<td><strong>CHOLANGiOCARCinOMA STEM-LIKE SUBSET SHAPES TUMOR-INITIATING NICHE BY EDUCATING ASSOCIATED MACROPHAGES</strong></td>
<td>Chiara Raggi, Italy</td>
</tr>
<tr>
<td>17:30-17:45</td>
<td>PS047</td>
<td><strong>NOVEL TUMOUR SUPPRESSOR GENES SORBS3 AND SH2D4A REPRESS IL-6 SIGNALLING IN HEPATOCellular CARCINOMA</strong></td>
<td>Carolin Ploeger, Germany</td>
</tr>
<tr>
<td>17:45-18:00</td>
<td>PS048</td>
<td><strong>RE-EXPRESSION OF FETAL IGF2 AS EPIDRIVER AND TARGET FOR THERAPY IN HCC</strong></td>
<td>Roser Pinyol, Spain</td>
</tr>
</tbody>
</table>

**Parallel session: Viral hepatitis C (I)  
Hall 6.0**

**Chairs:**
Alessio Aghemo, Italy  
Jean-Michel Pawlotsky, France

<table>
<thead>
<tr>
<th>Time</th>
<th>Abstract ID</th>
<th>Title</th>
<th>Speaker, Nationality</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:00-16:15</td>
<td>PS001</td>
<td><strong>PREVALENCE AND CLINICAL IMPORTANCE OF HEPATITIS C VIRUS GENOTYPE 2K/1B CHIMERAS</strong></td>
<td>Simone Susser, Germany</td>
</tr>
<tr>
<td>16:15-16:30</td>
<td>PS002</td>
<td><strong>C-EDGE HEAD-TO-HEAD: EFFICACY AND SAFETY OF ELBASVIR AND GRazOPREVIR COMPARED WITH SOFOSBUVIR/PEGYLATED INTERFERON/RIBAVIRIN: A PHASE 3 RANDOMIZED CONTROLLED TRIAL</strong></td>
<td>Jan Sperl, Czech Republic</td>
</tr>
<tr>
<td>16:30-16:45</td>
<td>PS003</td>
<td><strong>CYCLOPHilIN INHIBITORS REMODEL THE ENDOPLASMIC RETICULUM OF HCV-INFECTED CELLS IN A UNIQUE PATTERN RENDERING CELLS IMPERVIOUS TO A SECOND INFECTION</strong></td>
<td>Philippe Gallay, United States</td>
</tr>
</tbody>
</table>
16:45-17:00
ABSTRACT PS004

THE REAL-WORLD ISRAELI EXPERIENCE OF TREATING CHRONIC HEPATITIS C, GENOTYPE 1 PATIENTS WITH ADVANCED FIBROSIS WITH PARITAPREVIR/ritonavir/ombitasvir, dasabuvir with or without ribavirin: A LARGE MULTI-CENTER COHORT
Eli Zuckerman, Israel

17:00-17:15
ABSTRACT PS005

THE EVOLUTION OF PORTAL PRESSURE AFTER VIRAL SUPPRESSION WITH INTERFERON-FREE THERAPIES AND ITS CORRELATION WITH THE CHANGE IN LIVER STIFFNESS
Mattias Mandorfer, Austria

17:15-17:30
ABSTRACT PS006

HCV REINFECTION INCIDENCE AND OUTCOMES AMONG HIV INFECTED MSM IN WESTERN EUROPE
Thomas Martin, United States

17:30-17:45
ABSTRACT PS007

EUROPEAN RAVS DATABASE: FREQUENCY AND CHARACTERISTICS OF RAVS IN TREATMENT-NAÏVE AND DAA-EXPERIENCED PATIENTS
Julia Dietz, Germany

17:45-18:00
ABSTRACT PS008

HIGH EFFICACY OF SOFOSBUVIR/Velpatasvir plus GS-9857 FOR 12 WEEKS IN TREATMENT-EXPERIENCED GENOTYPE 1-6 HCV-INFECTED PATIENTS, INCLUDING THOSE PREVIOUSLY TREATED WITH DIRECT-ACTING ANTIVIRALS
Eric Lawitz, United States

Fusion hepatology – The global picture of NAFLD
Hall 8.0-D2

Chairs:
Laurent Castera, France
Masatoshi Kudo, Japan
Moon Seok Choi, Korea, South

Metabolic, alcohol and toxicity

16:00-16:05 Welcome from chairs
16:05-16:25  Solving NASH – the challenge and the opportunity  
Arun Sanyal, United States

16:25-16:40  Epidemiology and characteristics of NAFLD in Korea  
Dae Won Jun, Korea, South

16:40-16:50  A current research project related to NAFLD epidemiology/diagnosis/therapy in Korea  
Hye Won Lee, Korea, South

16:50-17:05  NASH and new therapeutic approach  
Hitoshi Yoshiji, Japan

17:05-17:15  DPP4 Inhibitor Suppresses Steatohepatitis and HCC Progression with Glucose Re-Programing in a Mouse Model of NASH  
Takumi Kawaguchi, Japan

17:15-17:30  NASH: challenges and opportunities from a European perspective  
Vlad Ratziu, France

17:30-17:40  Histological classifications in NASH and their clinical relevance  
Fabio Nascimbeni, Italy

17:40-18:00  Q&A panel discussion

Sonography course for beginners  Hall 8.0-E4

Pre-registration is compulsory if you wish to attend the sonography course. A fee of EUR 24.20 (21% VAT included) is applied. Only delegates registered to the ILC may sign up for the sonography course sessions. Check availability and purchase your seat at the registration desk.

18:30-20:00  Tutors:  
Robert De Knegt, Netherlands  
Michael Gebel, Germany  
Andrej Potthoff, Germany  
Dave Sprengers, Netherlands  
Jeoffrey Schouten, Belgium  
Christoph Terkamp, Germany

Major sponsor industry satellite symposia

18:30-20:00  Please refer to the industry section for more details
Early morning workshops (EMW)

Pre-registration is compulsory if you wish to attend the EMW. A fee of EUR 24.20 (21% VAT included) is applied. Only delegates registered to the ILC may sign up for the EMW sessions. Purchase your seat at the registration desk.

EMW – Evaluating interventions and health outcomes in liver disease

07:30-08:30

Moderators:
Andres Cardenas, Spain
Paul Kind, United Kingdom

EMW – Hepatotoxicity: modes of cell death and survival (apoptosis, necrosis, autophagy)

07:30-08:30

Moderators:
José Fernandez Checa, Spain
Claus Hellerbrand, Germany

EMW – Liver regenerative medicine: cell transplant, organoids and repopulated scaffolds

07:30-08:30

Moderators:
Stuart Forbes, United Kingdom
Giuseppe Mazza, United Kingdom

EMW – New diagnostic approaches in genetic liver disease

07:30-08:30

Moderators:
Uta Merle, Germany
Richard Thompson, United Kingdom
EMW – Endoscopic management of PSC

07:30-08:30

Moderators:
Tim Lankisch, Germany
Cyriel Ponsioen, Netherlands

EMW – What is the best second line therapy for AIH

07:30-08:30

Moderators:
Giorgina Mieli-Vergani, United Kingdom
Christoph Schramm, Germany

EMW – Management of sepsis in patients with liver cirrhosis

07:30-08:30

Moderators:
Francois Durand, France
Javier Fernandez, Spain

EMW – Downstaging of HCC before LT

07:30-08:30

Moderators:
Ulf Neumann, Germany
Fabio Piscaglia, Italy

EMW – Assessment of NAFLD: when do we need biopsy?

07:30-08:30

Moderators:
Marco Arrese, Chile
Manuel Romero-Gomez, Spain

EMW – How to detect and manage alcohol liver disease in early phases

07:30-08:30

Moderators:
Philippe Mathurin, France
Ramon Bataller, United States
EMW – How are DAAs and NUCs modifying the management of liver cancer?  Hall 8.0-D1
07:30-08:30  Moderators:
Seng Gee Lim, Singapore
Maria Reig, Spain

EMW – Management of HCV patients with DAA failures  Hall 8.0-AI
07:30-08:30  Moderators:
Tarik Asselah, France
Sandra Ciesek, Germany

EMW – When can we stop NUCsin patients with chronic hepatitis B?  Hall 8.0-B3
07:30-08:30  Moderators:
Markus Cornberg, Germany
Patrick Kennedy, United Kingdom

General session 2 and awards I  Hall 6.0
Chairs:
Tom Karlsen, Norway
Anna Lok, United States

08:30-08:45  ABSTRACT GS07
REAL-WORLD SAFETY AND EFFECTIVENESS OF OMBITASVIR/PARITAPREVIR/R WITH DASABUVIR AND/OR RIBAVIRIN IN THE GERMAN HEPATITIS C REGISTRY
Holger Hinrichsen, Germany

08:45-09:00  ABSTRACT GS08
RG-101 IN COMBINATION WITH 4 WEEKS OF ORAL DIRECT ACTING ANTIVIRAL THERAPY ACHIEVES HIGH ViroLOGIC RESPONSE RATES IN TREATMENT NAÏVE genotype 1 AND 4 CHRONIC HEPATITIS C PATIENTS: INTERIM RESULTS FROM A RANDOMISED, MULTI-CENTER, PHASE 2 STUDY
Gabor Horvath, United States
09:00-09:15  ABSTRACT GS09  
NOSOLOGY AND MOLECULAR CLASSIFICATION OF HEPATOCELLULAR ADENOMAS  
Jean Charles Nault, France

09:15-09:45  
Award ceremony 1

EASL Recognition Awardees
Antonio Craxi, Italy
Jordi Bruix, Spain
Roberto Groszmann, United States

09:45-10:00  ABSTRACT GS10  
THE DUAL CCR2/CCR5 ANTAGONIST CENICRIVIROC AMELIORATES STEATOHEPATITIS AND FIBROSIS IN VIVO BY INHIBITING THE INFILTRATION OF INFLAMMATORY MONOCYTES INTO INJURED LIVER  
Tobias Puengel, Germany

10:00-10:15  ABSTRACT GS11  
HIGH EFFICACY OF ABT-493 AND ABT-530 IN HCV GENOTYPE 1 INFECTED PATIENTS WHO HAVE FAILED DIRECT-ACTING ANTIVIRAL-CONTAINING REGIMENS: THE MAGELLAN-I STUDY  
Fred Poordad, United States

10:15-10:30  ABSTRACT GS12  
A PHASE 3 STUDY OF TENOFVIR ALAFENAMIDE COMPARED WITH TENOFVIR DISOPROXIL FUMARATE IN PATIENTS WITH HBEAG-POSITIVE CHRONIC HBV: WEEK 48 EFFICACY AND SAFETY RESULTS  
Henry L Y Chan, Hong Kong, China

J.P. Benhamou State of the Art Session  
Speaker: Fabien Zoulim, France

10:30-11:00  New treatment paradigm to cure chronic hepatitis B virus infections
Poster tours

11:00-11:30

**EU and public health**
Guide: Daniel Lavanchy, Switzerland

**Liver immunology including**
**Viral Hepatitis**
Guide: Mala Maini, United Kingdom

**Viral hepatitis: Hepatitis B & D – clinical**
**(therapy, new compounds, resistance)**
Guide: Cihan Yuyardin, Turkey

**Meeting point: poster help desk**

**Young investigator seminar**
Liver diseases and the vascular system

**Chairs:**
Upkar Gill, United Kingdom
Didier Lebrec, France

11:30-11:50  **EASL CPGs: Vascular disease of the liver**
Juan-Carlos Garcia-Pagan, Spain

11:50-12:10  **Vascular changes in liver disease**
Jonel Trebicka, Germany

12:10-12:30  **Betablocker in cirrhosis: Pro and cons**
Pierre-Emmanuel Rautou, France
Marco Senzolo, Italy

**Basic science highlights – Human protein atlas**

**Chair:**
Fernando Corrales, Spain

11:30-11:50  **Quantitative population analysis of the proteome**
Evan Williams, Switzerland

11:50-12:10  **Proteomics for study of liver diseases**
Barbara Sitek, Germany
12:10-12:30  **Self-assembled protein arrays for biomarker and drug discovery**
Manuel Fuentes, Spain

---

**Grand rounds – Cholestatic/autoimmune liver diseases**
Hall 8.0-D1

11:30-12:30  Ulrich Beuers, Netherlands
Sem Aronson, Netherlands
Michael Manns, Germany

---

**Grand rounds – Cirrhosis**
Hall 8.0-D2

11:30-12:30  Pere Gines, Spain
Elsa Solà, Spain
James O’Beirne, United Kingdom

---

**Grand rounds – HCC**
Hall 8.0-C1

11:30-12:30  Massimo Colombo, Italy
Massimo Iavarone, Italy
Jordi Bruix, Spain

---

**Grand rounds – NAFLD**
Hall 8.0-B3

11:30-12:30  Christopher Day, United Kingdom
Timothy Hardy, United Kingdom
Vlad Ratziu, France

---

**Grand rounds – HBV-HDV**
Hall 8.0-A1

11:30-12:30  George Papatheodoridis, Greece
Spyridon Siakavellas, Greece
Pietro Lampertico, Italy
## Grand rounds – HCV  Hall 6.0

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:30-12:30</td>
<td>Jean-Michel Pawlotsky</td>
<td>France</td>
</tr>
<tr>
<td></td>
<td>Isaac Ruiz</td>
<td>France</td>
</tr>
<tr>
<td></td>
<td>Stefan Zeuzem</td>
<td>Germany</td>
</tr>
</tbody>
</table>

**IMPORTANT:** Access restricted to active EASL members

## EASL Members’ General Assembly  Hall 8.0 – C2

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:30-14:00</td>
<td>EASL Members’ General Assembly</td>
<td>Hall 8.0 – C2</td>
</tr>
</tbody>
</table>

**Chair:** Gottfried Hirnschall, Switzerland  Karine Lacombe, France

## Launch of updated WHO guidelines for the screening, care and treatment of persons with hepatitis C infection  Hall 8.0-A1

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:30-12:50</td>
<td>Review of updated WHO HCV screening, care and treatment guidelines</td>
<td>Hall 8.0-A1</td>
</tr>
<tr>
<td></td>
<td>Stefan Wiktor</td>
<td>Switzerland</td>
</tr>
<tr>
<td>12:50-13:00</td>
<td>Network meta-analysis as a method to assess the relative safety and efficacy of hepatitis C treatments</td>
<td>Hall 8.0-A1</td>
</tr>
<tr>
<td></td>
<td>Ed Mills</td>
<td>Canada</td>
</tr>
<tr>
<td>13:00-13:10</td>
<td>The promise and the challenge of generic direct-acting antivirals for the treatment of hepatitis C infection: The Pakistan experience</td>
<td>Hall 8.0-A1</td>
</tr>
<tr>
<td></td>
<td>Saeed Hamid</td>
<td>Pakistan</td>
</tr>
<tr>
<td>13:10-13:20</td>
<td>How to overcome the barriers to providing hepatitis C treatment with direct-acting antivirals in Africa</td>
<td>Hall 8.0-A1</td>
</tr>
<tr>
<td></td>
<td>Olufunmilayo Lesi</td>
<td>Nigeria</td>
</tr>
<tr>
<td></td>
<td>Niklas Luhmann</td>
<td>France</td>
</tr>
<tr>
<td>13:30-14:00</td>
<td>Discussion</td>
<td></td>
</tr>
</tbody>
</table>
### Oral ePosters

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Chair</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:30-13:30</td>
<td><strong>Complication of cirrhosis</strong></td>
<td>Aleksander Krag, Denmark</td>
<td>Oral ePoster booth 1</td>
</tr>
<tr>
<td></td>
<td><strong>HCV</strong></td>
<td>Christophe Hezode, France</td>
<td>Oral ePoster booth 2</td>
</tr>
<tr>
<td></td>
<td><strong>Alcohol and Public Health</strong></td>
<td>Felix Stickel, Switzerland</td>
<td>Oral ePoster booth 3</td>
</tr>
<tr>
<td></td>
<td><strong>Genetic and metabolic liver disease</strong></td>
<td>Sabine Colnot, France</td>
<td>Oral ePoster booth 4</td>
</tr>
</tbody>
</table>

### Poster tours

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Guide</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:30-13:00</td>
<td><strong>Fatty liver disease: Clinical</strong></td>
<td>Andreas Geier, Germany</td>
<td>Hall 8.1</td>
</tr>
<tr>
<td></td>
<td><strong>Liver transplantation / surgery: Clinical</strong></td>
<td>Didier Samuel, France</td>
<td>Hall 8.1</td>
</tr>
<tr>
<td>13:00-13:30</td>
<td><strong>Autoimmune and hepatobiliary disease 1</strong></td>
<td>Roger Chapman, United Kingdom</td>
<td>Hall 8.1</td>
</tr>
<tr>
<td></td>
<td><strong>Liver tumours: Experimental</strong></td>
<td>Maria Martinez-Chantar, Spain</td>
<td>Hall 8.1</td>
</tr>
</tbody>
</table>

**Meeting point: poster help desk**
Symposium – Liver tissue engineering  
Hall 8.0-B1

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00-14:30</td>
<td><strong>Mechanisms controlling differentiation of pluripotent stem cells into</strong> <strong>definitive endoderm</strong></td>
<td>Ludovic Vallier</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>14:30-15:00</td>
<td><strong>Liver in a chip for disease modelling and drug screening</strong></td>
<td>Nicola Elvassore</td>
<td>Israel</td>
</tr>
<tr>
<td>15:00-15:30</td>
<td><strong>Liver tissue engineering in vitro and in vivo</strong></td>
<td>Alejandro Soto-Gutiérrez</td>
<td>United States</td>
</tr>
</tbody>
</table>

Symposium – Disease staging and prognosis: non-invasive versus invasive methods  
Hall 8.0-D2

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00-14:30</td>
<td><strong>Assessing fibrosis in patients with non-alcoholic liver disease: performance of elastographic methods and serum markers</strong></td>
<td>Vincent Wong</td>
<td>Hong Kong, China</td>
</tr>
<tr>
<td>14:30-15:00</td>
<td><strong>Assessing portal hypertension in patients with cirrhosis: can we skip HVPG measurement and diagnostic endoscopy?</strong></td>
<td>Annalisa Berzigotti</td>
<td>Switzerland</td>
</tr>
<tr>
<td>15:00-15:30</td>
<td><strong>Liver biopsy: still a place for staging and prognosis of chronic liver disease in the era of non-invasive markers and new antiviral drugs?</strong></td>
<td>Pierre Bedossa</td>
<td>France</td>
</tr>
</tbody>
</table>
Symposium – New therapies for autoimmune liver disease  
Hall 8.0-B3

**Chair:**
Gideon Hirschfield, United Kingdom

14:00-14:05  
The unmet clinical needs of patients  
Gideon Hirschfield, United Kingdom

14:05-14:33  
What causes autoimmune liver disease and what roadblocks remain to understanding disease pathogenesis?  
Ansgar W. Lohse, Germany

14:33-15:02  
What approaches can we take to effectively modulate the immune system in autoimmune liver disease?  
David Adams, United Kingdom

15:02-15:30  
Bile acid based therapies for autoimmune liver disease and it’s associated symptoms  
Peter L.M. Jansen, Netherlands

Symposium – WHO  
Hall 8.0-A1

**Chair:**
Stefan Wiktor, Switzerland

14:00-14:15  
Linkage to care – Introduction  
Stefan Wiktor, Switzerland

14:15-14:40  
Providing testing and treatment services to people who inject drugs  
Julie Bouscaillou, France

14:40-15:05  
Providing HCV treatment in prisons  
Maia Butsashvili, Georgia

15:05-15:30  
Reaching migrant populations for hepatitis treatment  
John Dillon, United Kingdom
Symposium – Immune therapy to cure HBV  

**Chair:**  
Ulrike Protzer, Germany

14:00-14:30  
**From understanding immune responses to HBV to therapeutic vaccination**  
Mala Maini, United Kingdom

14:30-15:00  
**Activating pattern recognition receptors to treat hepatitis B**  
Fabien Zoulim, France

15:00-15:30  
**Redirecting T cells for immunotherapy of hepatitis B**  
Ulrike Protzer, Germany

**Poster tours**  

**Cirrhosis and its complications: Pathophysiology**  
Guide: Agostin Albillos, Spain

**Viral hepatitis: Hepatitis C – clinical (except therapy)**  
Guide: Geoffrey Dusheiko, United Kingdom

**Meeting point: poster help desk**

**Recent highlights from the literature: ask the authors**  

**Chair:**  
Michael Trauner, Austria

16:00-16:30  
**Vascular adhesion protein-1 promotes liver inflammation and drives hepatic fibrosis**  
J Clin Invest. 2015 Feb;125(2):501-20  
David Adams, United Kingdom
16:30-17:00  Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study
Lancet 2016 Feb 13;387(10019):679-90
Matthew Armstrong, United Kingdom

17:00-17:30  Development and validation of a scoring system to predict outcomes of patients with primary biliary cirrhosis receiving ursodeoxycholic acid therapy
Gastroenterology. 2015 Dec;149(7):1804-1812
Henk Van Buuren, Netherlands

17:30-18:00  Addition of Simvastatin to standard therapy for the prevention of variceal rebleeding does not reduce rebleeding but increases survival in patients with cirrhosis
Juan Abraldes, Canada

Parallel Session: Non-invasive tests for evaluation of liver disease severity and prognosis  Hall 8.0-B3

16:00-16:15  EASL-ALEH GUIDELINES FOR THE NON-INVASIVE EVALUATION OF LIVER DISEASE SEVERITY IN CHRONIC HEPATITIS B: AN INDEPENDENT VALIDATION
Vincent Leroy, France

16:15-16:30  MAGNETIC RESONANCE IMAGING MORE ACCURATELY CLASSIFIES STEATOSIS AND LIVER FIBROSIS IN NONALCOHOLIC FATTY LIVER DISEASE THAN TRANSIENT ELASTOGRAPHY
Kento Imajo, Japan
<table>
<thead>
<tr>
<th>Time</th>
<th>Abstract</th>
<th>Title</th>
<th>Authors</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:30-16:45</td>
<td>PS083</td>
<td>COMPARISON OF CLASSICAL AND NOVEL RELIABILITY CRITERIA FOR ACCURACY OF TRANSIENT ELASTOGRAPHY IN A MULTICENTER PROSPECTIVE COHORT OF PATIENTS WITH VIRAL HEPATITIS AND GOOD QUALITY LIVER BIOPSIES</td>
<td>Christiane Stern</td>
<td>France</td>
</tr>
<tr>
<td>16:45-17:00</td>
<td>PS084</td>
<td>LIVER FIBROSIS EVALUATION USING REAL-TIME SHEAR WAVE ELASTOGRAPHY: APPLICABILITY, ASSOCIATION WITH ACTIVITY AND STEATOSIS, AND DIAGNOSTIC PERFORMANCE. DIRECT COMPARISONS WITH TRANSIENT ELASTOGRAPHY USING BIOMARKERS AS REFERENCES</td>
<td>Thierry Poynard</td>
<td>France</td>
</tr>
<tr>
<td>17:00-17:15</td>
<td>PS085</td>
<td>MID-INFRARED SPECTROSCOPY HAS A HIGH SENSITIVITY AND SPECIFICITY FOR POINT-OF-CARE DIAGNOSIS OF NON-ALCOHOLIC STEATO-HEPATITIS</td>
<td>Rodolphe Anty</td>
<td>France</td>
</tr>
<tr>
<td>17:15-17:30</td>
<td>PS086</td>
<td>FIBROSCAN IMPROVES THE ABILITY OF THE NEW PROGNOSTIC SCORING SYSTEMS TO PREDICT OUTCOMES OF PBC</td>
<td>Christophe Corpechot</td>
<td>France</td>
</tr>
<tr>
<td>17:30-17:45</td>
<td>PS087</td>
<td>REAL-WORLD VALIDATION OF BAVENO VI RECOMMENDATIONS FOR SCREENING ENDOSCOPY IN PATIENTS WITH COMPENSATED ADVANCED CHRONIC LIVER DISEASE</td>
<td>Pik Eu Jason Chang</td>
<td>Singapore</td>
</tr>
<tr>
<td>17:45-18:00</td>
<td>PS088</td>
<td>NEW RECOMMENDATIONS OF BAVENO VI CONFERENCE FOR THE SCREENING OF PORTAL HYPERTENSION: AN INDEPENDENT SEQUENTIAL VALIDATION IN PATIENTS WITH COMPENSATED VIRAL CIRRHOSIS TAKING INTO ACCOUNT VIROLOGICAL STATUS (ANRS CO12 CIRVIR COHORT)</td>
<td>Dominique Thabut</td>
<td>France</td>
</tr>
</tbody>
</table>
Parallel Session: Cirrhosis 2

Hall 8.0-A1

**Chairs:**
Paolo Angeli, Italy
Claire Francoz, France

16:00-16:15
**Abstract PS057**
**Reversal of Minimal Hepatic Encephalopathy After a Probiotic Administration. A Prospective, Randomized, Placebo-Controlled, Double-Blind Study**
Jiannis Vlachogiannakos, Greece

16:15-16:30
**Abstract PS058**
The Non-Steroidal FXR Agonist GS-9674 Reduces Liver Fibrosis and Ameliorates Portal Hypertension in a Rat NASH Model
Philipp Schwabl, Austria

16:30-16:45
**Abstract PS059**
When Is Intensive Care Treatment Futile in Patients With Organ Failure and End-Stage Liver Disease?
Katrine Lindvig, Denmark

16:45-17:00
**Abstract PS060**
The Role of Toll-Like Receptor 4 in Modulating the Brain-Gut Axis in the Pathogenesis of Hepatic Encephalopathy
Yalda Sharifi, United Kingdom

17:00-17:15
**Abstract PS061**
Polymorphisms in the Interleukin (IL)-1 Gene Cluster Influence the Inflammatory Burden in Patients With Decompensated Cirrhosis and Acute-On-Chronic Liver Failure
José Alcaraz Quiles, Spain

17:15-17:30
**Abstract PS062**
Prevalence of Cardiomyopathy and Impact of the Use of Non Selective Beta Blockers in End-Stage Liver Disease
Valerio Giannelli, France
17:30-17:45
ABSTRACT PS063
TIPS VERSUS ENDOSCOPY PLUS PROPRANOLOL AND ANTICOAGULATION FOR VARICEAL REBLEEDING IN CIRRHOTIC PATIENTS WITH PORTAL VEIN THROMBOSIS: RESULTS OF A RANDOMIZED CONTROLLED TRIAL
Guohong Han, China

17:45-18:00
ABSTRACT PS064
LONG TERM OUTCOME OF SPLANCHNIC VEIN THROMBOSIS IN CIRRHOSIS
Marco Senzolo, Italy

Parallel Session: Biliary pathophysiology 
Hall 8.0-C1

16:00-16:15
ABSTRACT PS089
TREATMENT WITH GLUCOCORTICOIDS INTERFERES WITH BILE ACID HOMEOSTASIS BY AFFECTING FXR/FGF19-MEDIATED ILEUM-LIVER CROSSTALK
Jose Marin, Spain

16:15-16:30
ABSTRACT PS090
CD362+ HUMAN MESENCHYMAL STROMAL CELLS REDUCE HEPATIC INFLAMMATION AND INDUCE M2 MACROPHAGE POLARISATION IN MURINE MODELS OF PRIMARY SCLEROSING CHOLANGITIS
Vasanthy Vigneswara, United Kingdom

16:30-16:45
ABSTRACT PS091
CASPASE-8 IN LIVER PARENCHYMAL CELLS (LPC), BUT NOT RIP3, IS AN ESSENTIAL ORCHESTRATOR OF EXPERIMENTAL CHOLESTATIC LIVER DISEASE
Francisco Javier Cubero, Germany

16:45-17:00
ABSTRACT PS092
PROTEOMIC ANALYSIS OF LIVER FIBROTIC SEPTA AND PERIPORTAL SPACES IN PRIMARY SCLEROSING CHOLANGITIS, PRIMARY BILIARY CHOLANGITIS AND ALCOHOLIC LIVER DISEASE
Giuseppe Mazza, United Kingdom
<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Abstract</th>
</tr>
</thead>
<tbody>
<tr>
<td>17:00-17:15</td>
<td>GENOME-WIDE ASSOCIATION STUDY (GWAS) OF LIVER FIBROSIS PHENOTYPES IN</td>
<td>GENOME-WIDE ASSOCIATION STUDY (GWAS) OF LIVER FIBROSIS PHENOTYPES IN PATIENTS WITH PRIMARY</td>
</tr>
<tr>
<td></td>
<td>PRIMARY SCLEROSING CHOLANGITIS (PSC) REVEALS COMMON GENETIC VARIATION</td>
<td>PRIMARY SCLEROSING CHOLANGITIS (PSC) REVEALS COMMON GENETIC VARIATION INFLUENCING SERUM LEVELS</td>
</tr>
<tr>
<td></td>
<td>OF LIVER FIBROSIS PHENOTYPES IN PATIENTS WITH PRIMARY SCLEROSING</td>
<td>OF LIVER FIBROSIS PHENOTYPES IN PATIENTS WITH PRIMARY SCLEROSING CHOLANGITIS (PSC) REVEALS</td>
</tr>
<tr>
<td></td>
<td>DISCLOSING COMMON GENETIC VARIATION OF LIVER FIBROSIS PHENOTYPES</td>
<td>COMMON GENETIC VARIATION INFLUENCING SERUM LEVELS OF LYSYL OXIDASE-LIKE-2 (LOXL2)</td>
</tr>
<tr>
<td></td>
<td>IN PATIENTS WITH PRIMARY SCLEROSING CHOLANGITIS (PSC)</td>
<td>Patrick R. Shea, United States</td>
</tr>
<tr>
<td>17:15-17:30</td>
<td>GENERATION OF BIOENGINEERED BILIARY TISSUE USING PRIMARY IN VITRO</td>
<td>GENERATION OF BIOENGINEERED BILIARY TISSUE USING PRIMARY IN VITRO PROPAGATED EXTRA-HEPATIC</td>
</tr>
<tr>
<td></td>
<td>PROPAGATED EXTRA-HEPATIC CHOLANGIOCYTES AND BIODEGRADABLE SCAFFOLDS</td>
<td>CHOLANGIOCYTES AND BIODEGRADABLE SCAFFOLDS</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Fotios Sampaziotis, United Kingdom</td>
</tr>
<tr>
<td>17:30-17:45</td>
<td>EXPANSION AND POLARIZATION OF CHOLANGIOCYTES FROM HUMAN INDUCED</td>
<td>EXPANSION AND POLARIZATION OF CHOLANGIOCYTES FROM HUMAN INDUCED PLURIPOTENT STEM CELLS</td>
</tr>
<tr>
<td></td>
<td>PLURIPOTENT STEM CELLS (IPSC)</td>
<td>PLURIPOTENT STEM CELLS (IPSC)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Mariangela Amenduni, United States</td>
</tr>
<tr>
<td>17:45-18:00</td>
<td>PROLONGED USAGE OF H1 OR H2 HISTAMINE RECEPTOR ANTAGONISTS DECREASES</td>
<td>PROLONGED USAGE OF H1 OR H2 HISTAMINE RECEPTOR ANTAGONISTS DECREASES FIBROSIS AND LIVER</td>
</tr>
<tr>
<td></td>
<td>FIBROSIS AND LIVER DAMAGE IN MDR2-/- MICE: NOVEL EVIDENCE OF THE</td>
<td>DAMAGE IN MDR2-/- MICE: NOVEL EVIDENCE OF THE THERAPEUTIC BENEFITS OF ANTI-HISTAMINES</td>
</tr>
<tr>
<td></td>
<td>THERAPEUTIC BENEFITS OF ANTI-HISTAMINES</td>
<td>Heather Francis, United States</td>
</tr>
</tbody>
</table>

**Parallel Session: Fatty Liver Disease: Experimental**

**Hall 8.0-D1**

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Abstract</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:00-16:15</td>
<td>BROWN ADIPOSE TISSUE STIMULATION AS A NEW APPROACH TO FIGHT OBESITY</td>
<td>BROWN ADIPOSE TISSUE STIMULATION AS A NEW APPROACH TO FIGHT OBESITY AND METABOLIC SYNDROME</td>
</tr>
<tr>
<td></td>
<td>AND METABOLIC SYNDROME</td>
<td>Laurence Poekes, Belgium</td>
</tr>
<tr>
<td>16:15-16:30</td>
<td>FXR AGONISM BY GS-9674 DECREASES STEATOSIS AND FIBROSIS IN A MURINE</td>
<td>FXR AGONISM BY GS-9674 DECREASES STEATOSIS AND FIBROSIS IN A MURINE MODEL OF NASH</td>
</tr>
<tr>
<td></td>
<td>MODEL OF NASH</td>
<td>John Liles, United States</td>
</tr>
<tr>
<td>Time</td>
<td>Abstract</td>
<td>Title</td>
</tr>
<tr>
<td>--------------</td>
<td>----------</td>
<td>----------------------------------------------------------------------</td>
</tr>
<tr>
<td>16:30-16:45</td>
<td>PS067</td>
<td>IDENTIFICATION OF LIPIDOMIC SIGNATURES THAT DEFINE THREE SPECIFIC SUBTYPES OF NAFLD AND DIFFERENTIATE NASH FROM SIMPLE STEATOSIS</td>
</tr>
<tr>
<td>16:45-17:00</td>
<td>PS068</td>
<td>THE NEW GENERATION PAN-PPAR AGONIST IVA337 PROTECTS THE LIVER FROM METABOLIC DISORDERS AND FIBROSIS</td>
</tr>
<tr>
<td>17:00-17:15</td>
<td>PS069</td>
<td>THE EFFECT OF MTORC1 INHIBITION ON NAFLD AND SUBSEQUENT HCC DEVELOPMENT</td>
</tr>
<tr>
<td>17:15-17:30</td>
<td>PS070</td>
<td>REDUCTION OF LIVER STEATOSIS AND FIBROSIS WITH AN ASK1 INHIBITOR IN A MURINE MODEL OF NASH IS ACCOMPANIED BY IMPROVEMENTS IN CHOLESTEROL, BILE ACID AND LIPID METABOLISM</td>
</tr>
<tr>
<td>17:30-17:45</td>
<td>PS071</td>
<td>HSP72 OVEREXPRESSION PROTECTS FROM LIVER INJURY VIA ATTENUATION OF JNK SIGNALLING</td>
</tr>
<tr>
<td>17:45-18:00</td>
<td>PS072</td>
<td>EXENATIDE EXERTS ITS POSITIVE EFFECTS ON LIVER BY REDUCING BOTH HEPATIC AND ADIPOSE TISSUE INSULIN RESISTANCE</td>
</tr>
</tbody>
</table>

Parallel Session: Alcoholic liver disease and drug induced liver disease

**Hall 8.0-D2**

**Chairs:**
Philippe Mathurin, France
Mark Thursz, United Kingdom

<table>
<thead>
<tr>
<th>Time</th>
<th>Abstract</th>
<th>Title</th>
<th>Speaker, Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:00-16:15</td>
<td>PS073</td>
<td>LIGHT TO MODERATE ALCOHOL USE IS NOT ASSOCIATED WITH LONG-TERM PROGRESSION OF LIVER FIBROSIS IN HIV HCV COINFECTED WOMEN</td>
<td>Erin Kelly, Canada</td>
</tr>
<tr>
<td>Time</td>
<td>Abstract</td>
<td></td>
<td></td>
</tr>
<tr>
<td>-------------------</td>
<td>---------------------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:15-16:30</td>
<td><strong>TUBERCULOSIS TREATMENT AND</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>DEVELOPMENT OF HY’S LAW CRITERIA</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>DURING FOLLOW-UP INCREASE THE RISK OF LIVER INJURY AND OVERALL MORTALITY IN HIV MONO-INFECTED PATIENTS WITH NORMAL TRANSAMINASES AT BASELINE: A PROSPECTIVE STUDY</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Hugo Perazzo, <em>Brazil</em></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:30-16:45</td>
<td><strong>DRAMATIC ALTERATIONS OF ANTIBACTERIAL MAIT-CELL NETWORK IN ALCOHOLIC LIVER DISEASE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Antonio Riva, <em>United Kingdom</em></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:45-17:00</td>
<td><strong>STARD1 DEPLETION PROTECTS AGAINST VALPROIC ACID-INDUCED SENSITIZATION TO ACETAMINOPHEN HEPATOTOXICITY</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Anna Baulies, <em>Spain</em></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:00-17:15</td>
<td><strong>SEX DIFFERENCES IN ACETAMINOPHEN-INDUCED ACUTE LIVER INJURY AND ACUTE LIVER FAILURE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Jessica Rubin, <em>United States</em></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:15-17:30</td>
<td><strong>CIRCULATING MICROPARTICLES CORRELATE WITH SEVERITY OF ALCOHOLIC HEPATITIS, PREDICT EARLY NON-RESPONSE TO CORTICOSTEROID THERAPY AND TRIGGER STERILE INFLAMMATION</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Sukriti Sukriti, <em>India</em></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:30-17:45</td>
<td><strong>DYNAMIN RELATED PROTEIN-1 AS A NOVEL THERAPEUTIC TARGET FOR ALCOHOLIC LIVER DISEASE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Elena Palma, <em>United Kingdom</em></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:45-18:00</td>
<td><strong>INFECTION IN SEVERE ALCOHOLIC HEPATITIS: RESULTS FROM THE STOPAH TRIAL</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Stephen Atkinson, <em>United Kingdom</em></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Parallel Session: Viral hepatitis B and D

Hall 6.0

Chairs:
Anna Lok, United States
Fabien Zoulim, France

16:00-16:15
ABSTRACT
PS049
NUCLEOS(T)IDE ANALOGUE TREATMENT FOR IMMUNE TOLERANT PHASE OF CHRONIC HEPATITIS B PATIENTS PROLONGS OVERALL SURVIVAL AND REDUCES THE RISK OF HEPATOCellular CARCINOMA AND CIRRHOSIS: A REAL-LIFE STUDY
Young Chang, Korea, South

16:15-16:30
ABSTRACT
PS050
NOVEL CAPSID ASSEMBLY EFFECTORS INHIBIT HBV CCCDNA FORMATION IN AN HBEAG REPORTER CELL-BASED ASSAY
Leda Bassit, United States

16:30-16:45
ABSTRACT
PS051
DECAY OF CCC-DNA IS SLOW AND MARKS PERSISTENCE OF INTRAHEPATIC VIRAL DNA SYNTHESIS DURING LONG-TERM TENOFOVIR TREATMENT IN HIV-HBV CO-INFECTED PATIENTS
Anders Boyd, France

16:45-17:00
ABSTRACT
PS052
INCIDENCES OF ALL MALIGNANCIES IN PATIENTS WITH CHRONIC HEPATITIS B RECEIVING LONG-TERM ORAL NUCLEOS(T)IDE ANALOGUE TREATMENT – A STUDY OF 45,299 SUBJECTS
Grace Wong, Hong Kong, China

17:00-17:15
ABSTRACT
PS053
DOES ANTIVIRAL TREATMENT AFFECT THE CLINICAL LONG-TERM OUTCOME OF HEPATITIS DELTA?
Anika Wranke, Germany

17:15-17:30
ABSTRACT
PS054
COMBINATION OF THE HEPATITIS B/D ENTRY INHIBITOR MYRCLUDEX B AND TENOFOVIR: ASSESSMENT OF THE EFFECT ON PLASMA BILE ACID PROFILES AND TENOFOVIR PHARMACOKINETICS
Stephan Urban, Germany
17:30-17:45
ABSTRACT
PS055

COMPARISON OF ANTIVIRAL EFFICACY BETWEEN TENOFOVIR MONOTHERAPY AND TENOFOVIR-BASED COMBINATION THERAPY IN CHRONIC HEPATITIS B WITH RESISTANCE TO ANTIVIRAL AGENTS: A INTERIM RESULT OF MULTICENTER COHORT STUDY
Kyu Sik Chung, Korea, South

17:45-18:00
ABSTRACT
PS056

AN IMMUNOLOGICAL BIOMARKER TO PREDICT HEPATIC FLARES UPON NUC THERAPY DISCONTINUATION IN CHRONIC HEPATITIS B
Nina Le Bert, Singapore

Sonography course for the advanced Hall 8.0-E4

Pre-registration is compulsory if you wish to attend the sonography course. A fee of EUR 24.20 (21% VAT included) is applied. Only delegates registered to the ILC may sign up for the sonography course sessions. Check availability and purchase your seat at the registration desk.

18:30-20:00
Tutors:
Robert De Knegt, Netherlands
Michael Gebel, Germany
Andrej Potthoff, Germany
Dave Sprengers, Netherlands
Pavel Taimr, Netherlands
Christoph Terkamp, Germany

Mini-workshop

18:30-19:30 Please refer to the industry section for more details

Major sponsor industry satellite symposia

18:30-20:00 Please refer to the industry section for more details
How to meet an author?

1. Download the app
2. Go to ePoster Connect
3. Choose a poster and request presentation
4. Plan a meeting with the author
5. Meet at the ePoster Connect Lounge EASL booth - Hall 8.0
## General session 3 and awards 2  
**Hall 6.0**

**Chairs:**
Mauro Bernardi, *Italy*  
Osamu Yokosuka, *Japan*

### 08:30-08:45
**ABSTRACT GS13**  
**LEDIPASVIR/SOFOSBUVIR FOR 12 OR 24 WEEKS IS SAFE AND EFFECTIVE IN KIDNEY TRANSPLANT RECIPIENTS WITH CHRONIC GENOTYPE 1 OR 4 HCV INFECTION**  
Massimo Colombo, *Italy*

### 08:45-09:00
**ABSTRACT GS14**  
**TM6SF2 AND NCAN WILDTYPE TOGETHER WITH SEVERAL LONG-CHAIN PHOSPHATIDYLCHOLINES ARE LINKED TO A HEALTHY LIVER IN OBESE SUBJECTS**  
Alexandra Feldman, *Austria*

### 09:00-09:15
**ABSTRACT GS15**  
**A MULTICENTRE, PHASE II, OPEN-LABEL, RANDOMISED CONTROLLED TRIAL OF REPEATED AUTOLOGOUS INFUSIONS OF GRANULOCYTE COLONY STIMULATING FACTOR MOBILISED CD133+ BONE MARROW STEM CELLS IN PATIENTS WITH CIRRHOSIS**  
Philip Newsome, *United Kingdom*

### 09:15-09:45
Award ceremony 2  
(see Award section on page 33 for more details)

### 09:45-10:00
**ABSTRACT GS16**  
**DEVELOPMENT OF A NEW HEPATOPROTECTIVE AND PROREGENERATIVE MOLECULE BASED ON FIBROBLAST GROWTH FACTOR 15/19**  
Gloria Álvarez-Sola, *Spain*
10:00-10:15  
**ABSTRACT**  
**GS17**  
**HIGH RATES OF SVR12 IN ADOLESCENTS TREATED WITH THE COMBINATION OF LEDIPASVIR/SOFOSBUVIR**  
Kathleen Schwarz, *United States*

10:15-10:30  
**ABSTRACT**  
**GS18**  
**ALFAPUMP® SYSTEM VERSUS LARGE VOLUME PARACENTESIS IN THE TREATMENT OF REFRACTORY ASCITES; RESULTS FROM A MULTICENTER RANDOMISED CONTROLLED STUDY (RCT)**  
Rajiv Jalan, *United Kingdom*

**State-of-the-art session**  
**Hall 6.0**

**Speaker:**  
Michael Karin, *United States*

10:30-11:00  
**Mechanisms responsible for malignant conversion**

**Poster tours**  
**Hall 8.1**

11:00-11:30  
**Non-invasive markers of liver fibrosis**  
Guide: Thierry Poynard, *France*

**Viral hepatitis: Hepatitis C – clinical (therapy) 1**  
Guide: Robert Flisiak, *Poland*

**Cirrhosis and its complications: Bleeding, hepatorenal syndrom and ascites**  
Guide: Andreas De Gottardi, *Switzerland*
Parallel session: EU and public health

Hall 8.0-C1

Chairs:
Helena Cortez Pinto, Portugal
Jeffrey Lazarus, Denmark

11:30-11:45
ABSTRACT PS137
HEPATITIS B SEROPREVALENCE AND IMMUNIZATION STATUS OF REFUGEES SEEKING ASYLUM IN GERMANY IN THE CURRENT MIDDLE-EAST CRISIS
Philipp Solbach, Germany

11:45-12:00
ABSTRACT PS138
HIGH MORTALITY IN CHRONIC HEPATITIS C PATIENTS IN SWEDEN COMPARED TO MATCHED CONTROLS – A NATIONWIDE POPULATION-BASED REGISTER STUDY FROM 1997 TILL 2013
Jonas Söderholm, Sweden

12:00-12:15
ABSTRACT PS139
LIVER TRANSPLANT CARE ARRANGED THROUGH ‘HUB AND SPOKE’ NETWORKS DELIVERS COMPARABLE PATIENT OUTCOMES
David Tai, United Kingdom

12:15-12:30
ABSTRACT PS140
THE FEASIBILITY OF BLOOD BORNE VIRUS TESTING IN INNER-CITY EMERGENCY DEPARTMENTS
Lukasz Cieply, United Kingdom

12:30-12:45
ABSTRACT PS141
A NATIONWIDE SEROSURVEY OF HEPATITIS E VIRUS IN THE GENERAL POPULATION OF PORTUGAL
Sara Pereira, Portugal

12:45-13:00
ABSTRACT PS142
PILOT STUDY TO DETERMINE FEASIBILITY OF CONDUCTING HBV AND HCV ENTIRE POPULATION SCREENING IN MONGOLIA
Purevjargal Bat-Ulzii, Mongolia

13:00-13:15
ABSTRACT PS143
INTERVENTIONS AGAINST HCV & HIV INFECTIONS AMONG PEOPLE WHO INJECT DRUGS (PWID) IN EASTERN EUROPE & CENTRAL ASIA: A MODELING AND COST-EFFECTIVENESS STUDY
Guillaume Mabileau, France
13:15-13:30

ABSTRACT PS144

CAN TARGETED HCV DIRECT-ACTING ANTIVIRAL TREATMENT AS PREVENTION REVERSE THE HCV EPIDEMIC AMONGST MEN WHO HAVE SEX WITH MEN IN THE UK – EPIDEMIOLOGICAL AND MODELLING INSIGHTS
Natasha Martin, United States

Parallel session: Molecular and cellular biology: cell death, fibrosis and regeneration Hall 8.0-B3

Chair:

Cecilia Rodrigues, Portugal
Christian Trautwein, Germany

11:30-11:45

ABSTRACT PS129

THE DYNAMICS OF FAST- AND SLOW- CYCLING STEM CELLS IN LIVER HOMEOSTASIS AND INJURY
Wanlu Cao, Netherlands

11:45-12:00

ABSTRACT PS130

INDUCED PLURIPOTENT STEM CELLS (IPSCS) DERIVED HEPATOCYTES FUNCTION IS IMPROVED BY ELIMINATING TRANSGENE
Dongho Choi, Korea, South

12:00-12:15

ABSTRACT PS131

ALTERED LIVER REGENERATION AFTER PARTIAL HEPATECTOMY IN PML-KNOCKOUT MICE
Marta Varela-Rey, Spain

12:15-12:30

ABSTRACT PS132

NONINVASIVE IDENTIFICATION OF HEPATOCELLULAR CARCINOMA MUTATIONS IN PLASMA CIRCULATING DNA BY TARGETED DEEP SEQUENCING
Henghui Zhang, China

12:30-12:45

ABSTRACT PS133

FUELING CELLULAR DIVISION DURING LIVER REGENERATION: CDK1 REGULATES ENERGY METABOLISM BY DIRECTING THE FLUX OF PYRUVATE
Matias Caldez, Singapore
<table>
<thead>
<tr>
<th>Time</th>
<th>Abstract Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:45-13:00</td>
<td><strong>GENERATION OF 3D HEPATIC STRUCTURE USING INDUCED HEPATOCYTE-LIKE CELLS DIRECTLY CONVERTED FROM FIBROBLASTS</strong></td>
<td>Dongho Choi, Korea, South</td>
</tr>
<tr>
<td>13:00-13:15</td>
<td><strong>MIR-873 PROMOTES LIVER DE-DIFFERENTIATION AND FIBROSIS TARGETING GLYCINE-N-METHYL TRANSFERASE</strong></td>
<td>Pablo Fernandez-Tussy, Spain</td>
</tr>
<tr>
<td>13:15-13:30</td>
<td><strong>B1 INTEGRIN LOSS SWITCHES HEPATOCYTE REGENERATION FROM HEPATOCELLULAR TO HEPATIC PROGENITOR CELLS (HPCS) MEDIATED</strong></td>
<td>Alex Raven, United Kingdom</td>
</tr>
</tbody>
</table>

**Parallel session: Autoimmune and hepato biliary disease**

**Hall 8.0-D2**

**Chairs:**
Christoph Schramm, Germany  
Diego Vergani, United Kingdom

<table>
<thead>
<tr>
<th>Time</th>
<th>Abstract Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:30-11:45</td>
<td><strong>CLARITY: A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF LOPIXIBAT CHLORIDE (FORMERLY LUM001), A NOVEL APICAL SODIUM-DEPENDENT BILE ACID TRANSPORTER INHIBITOR, IN THE TREATMENT OF PRIMARY BILIARY CIRRHOSIS ASSOCIATED WITH ITCHING</strong></td>
<td>Marlyn J. Mayo, United States</td>
</tr>
<tr>
<td>11:45-12:00</td>
<td><strong>SINGLE-OPERATOR PERORAL CHOLANGIOSCOPY FOR DETECTION OF CHOLANGIOCARCINOMA IN PATIENTS WITH PRIMARY SCLEROSING CHOLANGITIS: A PROSPECTIVE EVALUATION AND COST ANALYSIS</strong></td>
<td>Nauzer Forbes, Canada</td>
</tr>
<tr>
<td>12:00-12:15</td>
<td><strong>SURVEILLANCE OF BILIARY DYSPLASIA IN PRIMARY SCLEROSING CHOLANGITIS</strong></td>
<td>Martti Färkkilä, Finland</td>
</tr>
<tr>
<td>Time</td>
<td>Abstract Number</td>
<td>Title</td>
</tr>
<tr>
<td>--------------</td>
<td>-----------------</td>
<td>----------------------------------------------------------------------</td>
</tr>
<tr>
<td>12:15-12:30</td>
<td>PS124</td>
<td>EFFICACY AND SAFETY OF INDUCTION DOSING OF VEDOLIZUMAB FOR REDUCING BILIARY INFLAMMATION IN PRIMARY SCLEROSING CHOLANGITIS (PSC) IN INDIVIDUALS WITH INFLAMMATORY BOWEL DISEASE</td>
</tr>
<tr>
<td>12:30-12:45</td>
<td>PS125</td>
<td>SEROLOGICAL BIOMARKERS OF EXTRACELLULAR MATRIX REMODELING PREDICT TRANSPLANT-FREE SURVIVAL IN PRIMARY SCLEROSING CHOLANGITIS PATIENTS</td>
</tr>
<tr>
<td>12:45-13:00</td>
<td>PS126</td>
<td>VALIDATION OF THE PROGNOSTIC VALUE OF HISTOLOGIC SCORING SYSTEMS IN PRIMARY SCLEROSING CHOLANGITIS; A MULTICENTER COHORT STUDY</td>
</tr>
<tr>
<td>13:00-13:15</td>
<td>PS127</td>
<td>FIBROSCAN AND MRI HAVE COMPLEMENTARY PROGNOSTIC VALUES IN PRIMARY SCLEROSING CHOLANGITIS</td>
</tr>
<tr>
<td>13:15-13:30</td>
<td>PS128</td>
<td>EFFECTS OF PLASMAPHERESIS ON PRURITUS IN PATIENTS WITH PBC: PROSPECTIVE ANALYSIS OF 121 PROCEDURES PERFORMED IN A SINGLE CENTER</td>
</tr>
</tbody>
</table>

**Parallel session: Fatty liver disease: Clinical**

**Chairs:**
Elisabetta Bugianesi, Italy
Lawrence Serfaty, France

<table>
<thead>
<tr>
<th>Time</th>
<th>Abstract Number</th>
<th>Title</th>
<th>Speaker</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:30-11:45</td>
<td>PS105</td>
<td>METABOLIC EFFECTS AND GOOD TOLERANCE OF IVA337 A PAN-PPAR AGONIST IN DIABETIC PATIENTS WARRANT FURTHER INVESTIGATION IN NASH</td>
<td>Jean-Louis Abitbol, France</td>
<td>Hall 8.0-A1</td>
</tr>
</tbody>
</table>
11:45-12:00
ABSTRACT
PS106
CHARACTERISTICS OF FECAL MICROBIOTA IN NONALCOHOLIC FATTY LIVER DISEASE (NAFLD) PATIENTS: A CONNECTION BETWEEN ENDOTOXIN AND NAFLD
Takaomi Kessoku, Japan

12:00-12:15
ABSTRACT
PS107
ENDOTOXAEMIA IS ASSOCIATED WITH HISTOLOGICAL SEVERITY OF NON-ALCOHOLIC FATTY LIVER DISEASE AND MAY BE INCREASED IN PATIENTS WITH THE TM6SF2 GENE VARIANTS
Vincent Wong, Hong Kong, China

12:15-12:30
ABSTRACT
PS108
NDI-010976, A POTENT, LIVER-DIRECTED, ORAL INHIBITOR OF ACETYL COA CARBOXYLASE FOR NON-ALCOHOLIC STEATOHEPATITIS: PHARMACODYNAMIC EFFECTS ON HEPATIC DE NOVO LIPOGENESIS IN OBSESE BUT OTHERWISE HEALTHY ADULT MALE VOLUNTEERS
William Westlin, United States

12:30-12:45
ABSTRACT
PS109
PREDICTORS OF IMPROVEMENT IN NAFLD ACTIVITY SCORE ON PLACEBO: A SECONDARY ANALYSIS OF THE FLINT TRIAL
Rohit Loomba, United States

12:45-13:00
ABSTRACT
PS110
LEAN-NON ALCOHOLIC FATTY LIVER DISEASE (NAFLD) WITH CENTRAL VISCERAL OBESITY IDENTIFIES PATIENTS WITH MORE SEVERE DISEASE
Rosa Lombardi, Italy

13:00-13:15
ABSTRACT
PS111
A POST-HOC ANALYSIS OF THE GOLDEN505 TRIAL DEMONSTRATES HISTOLOGICAL AND CARDIOMETABOLIC EFFICACY OF ELAFIBRANOR-120 MG IN PATIENTS WITH MODERATE OR SEVERE NASH THAT ARE ELIGIBLE FOR PHARMACOTHERAPY
Vlad Ratziu, France

13:15-13:30
ABSTRACT
PS112
SITAGLIPTIN VERSUS PLACEBO IN THE TREATMENT OF NONALCOHOLIC FATTY LIVER DISEASE: A RANDOMIZED CONTROLLED TRIAL
Jeffrey Cui, United States
Parallel session: Liver tumours: Clinical
Hall 8.0-D1

**Chairs:**
Jean-François Dufour, Switzerland
Alejandro Forner, Spain

11:30-11:45
**ABSTRACT PS113**
DEVELOPMENT AND VALIDATION OF AN ONLINE WEB CALCULATOR FOR SURVIVAL AFTER TRANS-ARTERIAL CHEMO-EMBOLIZATION FOR HEPATOCELLULAR CARCINOMA
Carlo Sposito, Italy

11:45-12:00
**ABSTRACT PS114**
PROPOSAL AND VALIDATION OF A NEW MODEL TO ESTIMATE SURVIVAL FOR HEPATOCELLULAR CARCINOMA PATIENTS
Po-Hong Liu, Taiwan

12:00-12:15
**ABSTRACT PS115**
EDN1 EXPRESSION AS A NOVEL BIOMARKER FOR PREDICTING SORAFENIB RESPONSIVENESS IN PATIENTS WITH HEPATOCELLULAR CARCINOMA
Su Jong Yu, Korea, South

12:15-12:30
**ABSTRACT PS116**
PROSPECTIVE EVIDENCE THAT HEPATOCELLULAR CARCINOMA SURVEILLANCE IN PATIENTS WITH COMPENSATED VIRAL CIRRHOSIS INCREASES THE PROBABILITY OF CURATIVE TREATMENT AND SURVIVAL TAKING INTO ACCOUNT LEAD-TIME BIAS (ANRS CO12 CIRVIR COHORT)
Charlotte Costentin, France

12:30-12:45
**ABSTRACT PS117**
INTEGRATION OF THE CANCER-RELATED PRO-INFLAMMATORY RESPONSE AS A STRATIFYING BIOMARKER OF SURVIVAL BENEFIT WITH SORAFENIB IN HEPATOCELLULAR CARCINOMA
Jessica Howell, Australia
<table>
<thead>
<tr>
<th>Time</th>
<th>Abstract Id</th>
<th>Title</th>
<th>Authors, Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:45-13:00</td>
<td>PS118</td>
<td>HIGH SERUM SOLUBLE INTERCELLULAR ADHESION MOLECULE 1 (ICAM-1) CONCENTRATION IS ASSOCIATED WITH HEPATOCellular CARCINOMA (HCC) DEVELOPMENT IN HBV, HCV, AND NON-VIRAL LIVER DISEASE: MULTIPLEX ANALYSIS OF 51 CYTOKINES AND OTHER SERUM MARKERS</td>
<td>Vincent Chen, United States</td>
</tr>
<tr>
<td>13:00-13:15</td>
<td>PS119</td>
<td>THE ALBI GRADE PROVIDES OBJECTIVE HEPATIC RESERVE PHENOTYPING ACROSS EACH BCLC STAGE OF HEPATOCellular CARCINOMA</td>
<td>David James Pinato, United Kingdom</td>
</tr>
<tr>
<td>13:15-13:30</td>
<td>PS120</td>
<td>PATIENTS WITH 18F-FDG NON-AVID HCC BEYOND UP-TO-SEVEN CRITERIA HAVE AN EXCELLENT PROGNOSIS AFTER LIVER TRANSPLANTATION</td>
<td>Arno Kornberg, Germany</td>
</tr>
</tbody>
</table>

**Parallel session: Viral hepatitis C (2)** Hall 6.0

**Chairs:**
- Graham Foster, United Kingdom
- Francesco Negro, Switzerland

<table>
<thead>
<tr>
<th>Time</th>
<th>Abstract Id</th>
<th>Title</th>
<th>Authors, Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:30-11:45</td>
<td>PS097</td>
<td>ANTIVIRAL TREATMENT IN PATIENTS WITH ADVANCED HCV CIRRHOSIS USING SOFOSBUVIR AND LEDIPASVIR/ DACLATASVIR WITH OR WITHOUT RIBAVIRIN – 6 AND 12 MONTH OUTCOMES COMPARED TO UNTREATED PATIENTS</td>
<td>Michelle Cheung, United Kingdom</td>
</tr>
<tr>
<td>11:45-12:00</td>
<td>PS098</td>
<td>HIGH SVR RATES WITH ABT-493 + ABT-530 CO-ADMINISTERED FOR 8 WEEKS IN NON-CIRRHTIC PATIENTS WITH HCV GENOTYPE 3 INFECTION</td>
<td>Andrew Muir, United States</td>
</tr>
</tbody>
</table>
12:00-12:15  ABSTRACT PS099
RESISTANCE ANALYSES FOR LEDIPASVIR/SOFOSBUVIR CONTAINING REGIMENS IN PATIENTS INFECTED WITH CHRONIC HCV WHO HAVE ADVANCED LIVER DISEASE OR ARE POST LIVER TRANSPLANT (SOLAR-1 & 2 STUDIES)
Michael Charlton, United States

12:15-12:30  ABSTRACT PS0100
HUMANIZATION OF A THERAPEUTIC CLAUDIN-1-SPECIFIC ANTIBODY TO CURE HEPATITIS C VIRUS INFECTION IN MONOTHERAPY
Che Colpitts, France

12:30-12:45  ABSTRACT PS0101
HUMAN LIVER FIBROGENESIS: THE PROOF OF CONCEPT OF HCV-, ETHANOL- OR PALMITATE-INDUCED LIVER FIBROSIS IN THE EX VIVO MODEL OF HUMAN LIVER SLICES CULTURE
Sylvie Lagaye, France

12:45-13:00  ABSTRACT PS0102
PREVALENCE AND IMPACT OF BASELINE RESISTANCE-ASSOCIATED VARIANTS (RAVS) ON THE EFFICACY OF LEDIPASVIR/SOFOSBUVIR OR SIMEPREVIR/SOFOSBUVIR AGAINST GT1 HCV INFECTION: HCV-TARGET INTERIM ANALYSIS
Gary Wang, United States

13:00-13:15  ABSTRACT PS0103
RETREATMENT OF PATIENTS WHO FAILED DAA-COMBINATION THERAPIES: REAL-WORLD EXPERIENCE FROM A LARGE HEPATITIS C RESISTANCE DATABASE
Johannes Vermehren, Germany

13:15-13:30  ABSTRACT PS0104
SOFOBUVIR/VELPATASVIR FIXED DOSE COMBINATION FOR 12 WEEKS IN PATIENTS CO-INFECTED WITH HCV AND HIV-1: THE PHASE 3 ASTRAL-5 STUDY
David Wyles, United States
EASL – EFSUMB workshop: Lecture:
Ultrasound elastography in liver disease of different etiology

Hall 8.0-B1

Chairs:
Annalisa Berzigotti, Switzerland
Fabio Piscaglia, Italy

11:30-11:50 Overview of ultrasound elastography technologies in 2016 thresholds with remarks on thresholds establishment
Fabio Piscaglia, Italy

11:50-12:10 Role of ultrasound elastography techniques in screening alcoholic patients for liver disease
Maja Thiele, Denmark

12:10-12:30 Ultrasound elastography in primary biliary cholangitis and primary sclerosing cholangitis
Mette Vesterhus, Norway

12:30-12:50 Ultrasound elastography in non-alcoholic fatty liver disease
Annalisa Berzigotti, Switzerland

Oral ePosters

Hall 8.1

13:00-14:00 Liver fibrosis, Nanomedicine and new technologies
Chair: Pau Sancho-Bru, Spain
Oral ePoster booth 1

Transplantation and acute liver failure
Chair: Daniel Gotthardt, Germany
Oral ePoster booth 2

Autoimmune and Cholestatic liver disease
Chair: Christian Strassburg, Germany
Oral ePoster booth 3

Molecular and cellular biology
Chair: Jelena Mann, United Kingdom
Oral ePoster booth 4
### Poster tours

**Hall 8.1**

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Guide</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:30-14:00</td>
<td>Fatty liver disease: Experimental</td>
<td>Ali Canbay, Germany</td>
</tr>
<tr>
<td></td>
<td>Liver tumours: Management</td>
<td>Helen Reeves, United Kingdom</td>
</tr>
</tbody>
</table>

**Meeting point: poster help desk**

### Young Investigator forum

**How to become an independent researcher**

**Hall 8.0-C1**

**Chairs:**
- Rodrigo Liberal, United Kingdom
- Massimo Pinzani, United Kingdom

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Chair</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00-14:10</td>
<td><strong>Who are the YI CAG members?</strong></td>
<td>Rodrigo Liberal, United Kingdom</td>
</tr>
<tr>
<td>14:10-14:30</td>
<td><strong>The roadmap to become independent</strong></td>
<td>Tom Karlsen, Norway</td>
</tr>
<tr>
<td>14:30-15:10</td>
<td><strong>Should you cut the umbilical cord with the mentor?</strong></td>
<td>Patrizia Burra, Italy</td>
</tr>
<tr>
<td>14:30-14:50</td>
<td>The mentor point of view</td>
<td>Patrizia Burra, Italy</td>
</tr>
<tr>
<td>14:50-15:10</td>
<td>The mentee point of view</td>
<td>Giacomo Germani, Italy</td>
</tr>
<tr>
<td>15:10-15:30</td>
<td>International mobility/International networking</td>
<td>Annalisa Berzigotti, Switzerland</td>
</tr>
</tbody>
</table>

### Symposium – Animal models for study of liver disease

**Hall 8.0-D2**

**Chair:**
- Ralf Weiskirchen, Germany

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Chair</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00-14:30</td>
<td>Legal issues and ethics in animal-based research: An update on the new animal welfare rules in the EU</td>
<td>René Tolba, Germany</td>
</tr>
</tbody>
</table>
14:30-15:00  Experimental models for liver fibrosis and resolution  
Neil Henderson, *United Kingdom*

15:00-15:30  Mice are not men. What can we learn from experimental liver models?  
Gloria Gonzalez-Aseguinolaza, *Spain*

---

**Symposium – Antiviral treatment of patients with decompensated cirrhosis**

*Hall 8.0-DI*

**Chair:**  
Heiner Wedemeyer, *Germany*

14:00-14:05  **Introduction**  
Heiner Wedemeyer, *Germany*

14:05-14:30  **Natural history of decompensated viral hepatitis**  
Gennaro D’amico, *Italy*

14:30-14:55  **Antiviral treatment option in decompensated cirrhosis**  
Xavier Forns, *Spain*  
Case presenter: Sabela Lens, *Spain*

14:55-15:20  **Clinical effects of antiviral treatment**  
Katja Deterding, *Germany*

15:20-15:30  **Summary and final discussion**  
Heiner Wedemeyer, *Germany*

---

**Symposium – ALD: from epidemiology to clinical management**

*Hall 8.0-Al*

**Chairs:**  
Ramon Bataller, *United States*  
Nick Sheron, *United Kingdom*

14:20-14:40  **Identifying patients with early forms of ALD**  
Peter Stärkel, *Belgium*

14:00-14:20  **The science, art and law of alcohol policy: Experience from Scotland**  
Peter Rice, *United Kingdom*
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speaker/s</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:40-15:00</td>
<td><strong>Treating the cause: management of alcohol use disorder in patients with ALD</strong></td>
<td>Michael R. Lucey, United States</td>
<td></td>
</tr>
<tr>
<td>15:00-15:20</td>
<td><strong>Management of alcoholic hepatitis: what is next after the STOPAH trial?</strong></td>
<td>Philippe Mathurin, France</td>
<td></td>
</tr>
<tr>
<td>15:20-15:30</td>
<td><strong>Conclusion</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**EASL & EASD (European Association for the Study of Diabetes) Symposium – NAFLD and diabetes – cause or consequence**

**Hall 8.0-B3**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speaker/s</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00-14:30</td>
<td><strong>NAFLD and type 2 diabetes: common pathophysiological mechanisms</strong></td>
<td>Amalia Gastaldelli, Italy</td>
<td></td>
</tr>
<tr>
<td>14:30-15:00</td>
<td><strong>Heterogeneity of NAFLD</strong></td>
<td>Hannele Yki-Jaervinen, Finland</td>
<td></td>
</tr>
<tr>
<td>15:00-15:30</td>
<td><strong>Treatment of NAFLD in the context of diabetes</strong></td>
<td>Vlad Ratziu, France</td>
<td></td>
</tr>
</tbody>
</table>

**Securing the future of liver research: funding and consortium strategies**

**Hall 8.0-E5**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speaker/s</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00-14:10</td>
<td><strong>Strategic directions in H2020</strong></td>
<td>Maria Vidal-Ragout, Belgium</td>
<td></td>
</tr>
<tr>
<td>14:10-14:20</td>
<td><strong>FP7: MERLIN – stem cell-based therapies in liver disease</strong></td>
<td>Philip Newsome, United Kingdom</td>
<td></td>
</tr>
</tbody>
</table>
14:20-14:30  H2020: HEP-CAR – understanding, prevention and management of HCC  
Robert Thimme, Germany

14:30-14:40  H2020: GALAXY – the gut-liver axis in alcoholic liver disease  
Aleksander Krag, Denmark

14:40-14:50  ERN – what is the relationship between research consortia and clinical reference networks?  
David Jones, United Kingdom

14:50-15:00  LiSyM – What does Systems Medicine mean for the Liver?  
Peter L.M. Jansen, Netherlands

15:00-15:30  Panel discussion: What can EASL do to support EU grant applications?

**Poster tours**

**Hall 8.1**

15:30-16:00  Molecular and cellular biology: HSCs and fibrosis  
Guide: Fabio Marra, Italy

Autoimmune and hepato biliary disease (2)  
Guide: Christoph Schramm, Germany

Viral hepatitis: Hepatitis C – clinical (therapy) 2  
Guide: Savino Bruno, Italy

**Meeting point: poster help desk**
Pre-registration is compulsory if you wish to attend the ultrasound hands on session. A fee of EUR 24.20 (21% VAT included) is applied. Only delegates registered to the ILC may sign up for the ultrasound course sessions. Check availability and purchase your seat at the registration desk.

14:00-14:50 | **Tutors:**
Veronica Salvatore, Italy
Horia Stefanescu, Romania
Deike Strobel, Germany
Mette Vesterhus, Norway

15:00-15:50 | **Tutors:**
Simona Bota, Austria
Robert de Knegt, Netherlands
Deike Strobel, Germany
Mette Vesterhus, Norway

16:00-16:50 | **Tutors:**
Simona Bota, Austria
Robert de Knegt, Netherlands
Veronica Salvatore, Italy
Horia Stefanescu, Romania
EASL – EFSUMB Ultrasound hands on session 4  Hall 8.0-E1

Pre-registration is compulsory if you wish to attend the ultrasound hands on session. A fee of EUR 24.20 (21% VAT included) is applied. Only delegates registered to the ILC may sign up for the ultrasound course sessions. Check availability and purchase your seat at the registration desk.

17:00-17:50  Tutors:  
Veronica Salvatore, Italy  
Horia Stefanescu, Romania  
Deike Strobel, Germany  
Mette Vesterhus, Norway

Late-breaker session  Hall 6.0

16:00-16:15  ABSTRACT LBO1  
100% SVR4 WITH ABT-493 AND ABT-530 WITH OR WITHOUT RIBAVIRIN IN TREATMENT-NAÏVE HCV GENOTYPE 3-INFECTED PATIENTS WITH CIRRHOSIS  
Paul Kwo, United States

16:15-16:30  ABSTRACT LBO2  
NORURSODEOXYCHOLIC ACID IMPROVES CHOLESTASIS IN PRIMARY SCLEROSING CHolangitis: RESULTS OF A PHASE II DOSE FINDING STUDY  
Michael Trauner, Austria

16:30-16:45  ABSTRACT LBO3  
HIGH SUSTAINED VIROLOGICAL RESPONSE RATES USING GENERIC DIRECT ACTING ANTIVIRAL TREATMENT FOR HEPATITIS C, IMPORTED INTO AUSTRALIA  
James Freeman, United Kingdom
16:45-17:00
ABSTRACT LBO4
PROSPECTIVE RANDOMIZED CONTROLLED PHASE III TRIAL COMPARING THE EFFICACY OF SORAFENIB VERSUS SORAFENIB IN COMBINATION WITH LOW-DOSE CISPLATIN/FLUOROURACIL HEPATIC ARTERIAL INFUSION CHEMOTHERAPY IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA
Masatoshi Kudo, Japan

17:00-17:15
ABSTRACT LBO5
EMRICASAN (IDN-6556) ORALLY FOR THREE MONTHS IN PATIENTS WITH CIRRHOSIS AND MELD SCORES 11-18 IMPROVES CLINICAL PARAMETERS OF CIRRHOSIS IN PATIENTS WITH BASELINE MELD SCORE ≥ 15
Catherine Frenette, United States

17:15-17:30
ABSTRACT LBO6
NVR 3-778, A FIRST-IN-CLASS HBV CORE INHIBITOR, ALONE AND IN COMBINATION WITH PEG-INTERFERON (PEGIFN), IN TREATMENT-NAIVE HBEAG-POSITIVE PATIENTS: EARLY REDUCTIONS IN HBV DNA AND HBEAG
Man-Fung Yuen, United States

17:30-17:45
ABSTRACT LBO7
RANDOMIZED CONTROLLED TRIAL OF RIFAXIMIN VERSUS NORFLOXACIN FOR SECONDARY PROPHYLAXIS OF SPONTANEOUS BACTERIAL PERITONITIS
Sherief Abd-Elsalam, Egypt

17:45-18:00
ABSTRACT LBO8
SIX WEEKS OF SOFOSBUVIR/LEDIPASVIR (SOF/LDV) ARE SUFFICIENT TO TREAT ACUTE HEPATITIS C VIRUS GENOTYPE 1 MONOINFECTION: THE HEPNET ACUTE HCV IV STUDY
Katja Deterding, Germany
Recommendations on treatment of hepatitis C 2016: update coming

**Hall 6.0**

**Chairs:**
Laurent Castera, *France*
Jean-Michel Pawlotsky, *France*

18:30-19:30 Panel:
Alessio Aghemo, *Italy*
David Back, United *Kingdom*
Geoffrey Dusheiko, *United Kingdom*
Xavier Forns, *Spain*
Massimo Puoti, *Italy*
Nancy Reau, *United States*
Christoph Sarrazin, *Germany*

Sonography course for “acute medicine” on hepatology  Hall 8.0-E4

Pre-registration is compulsory if you wish to attend the sonography course. A fee of EUR 24.20 (21% VAT included) is applied. Only delegates registered to the ILC may sign up for the sonography course sessions. Check availability and purchase your seat at the registration desk.

18:30-20:00

**Tutors:**
Robert De Knegt, *Netherlands*
Michael Gebel, *Germany*
Andrej Potthoff, *Germany*
Dave Sprengers, *Netherlands*
Pavel Taimr, *Netherlands*
Christoph Terkamp, *Germany*
Early morning workshops (EMW)

Pre-registration is compulsory if you wish to attend the EMW. A fee of EUR 24.20 (21% VAT included) is applied. Only delegates registered to the ILC may sign up for the EMW sessions. Purchase your seat at the registration desk.

EMW – Making the best use of CRISPR-Cas9 technology
Hall 8.0-E3
07:30-08:30
Moderators:
Quentin Anstee, United Kingdom
Sabine Colnot, France

EMW – Operational tolerance implications for management of immunosuppression after liver transplantation
Hall 8.0-E8
07:30-08:30
Moderators:
Kosh Agarwal, United Kingdom
Pierluigi Toniutto, Italy

EMW – EASL – ISHEN: Hepatic encephalopathy EASL/AASLD guidelines: 1 year on
Hall 8.0-E2
07:30-08:30
Moderators:
Sara Montagnese, Italy
Henrik Vilstrup, Denmark

EMW – Beyond UDCA in cholestatic diseases
Hall 8.0-B2
07:30-08:30
Moderators:
Jesus Banales, Spain
Ulrich Beuers, Netherlands
<table>
<thead>
<tr>
<th>Session Title</th>
<th>Hall</th>
<th>Time</th>
<th>Moderators</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EMW – Anticoagulation and cirrhosis</strong></td>
<td>8.0-E4</td>
<td>07:30-08:30</td>
<td>Andrea De Gottardi, <strong>Switzerland</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Pierre-Emmanuel Rautou, <strong>France</strong></td>
</tr>
<tr>
<td><strong>EMW – Beta-blockers in liver cirrhosis: when to start, when to stop?</strong></td>
<td>8.0-D2</td>
<td>07:30-08:30</td>
<td>Vincenzo La Mura, <strong>Italy</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Mattias Mandorfer, <strong>Austria</strong></td>
</tr>
<tr>
<td><strong>EMW – Epigenetics in human liver disease and HCC</strong></td>
<td>8.0-E5</td>
<td>07:30-08:30</td>
<td>Jelena Mann, <strong>United Kingdom</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Susanne Strand, <strong>Germany</strong></td>
</tr>
<tr>
<td><strong>EMW – Screening of HCC in special populations</strong></td>
<td>8.0-C1</td>
<td>07:30-08:30</td>
<td>Christiane Kuhl, <strong>Germany</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Angelo Sangiovanni, <strong>Italy</strong></td>
</tr>
<tr>
<td><strong>EMW – New treatment options on the horizon in patients with NAFLD</strong></td>
<td>8.0-C2</td>
<td>07:30-08:30</td>
<td>Jörn Schattenberg, <strong>Germany</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Luca Valenti, <strong>Italy</strong></td>
</tr>
<tr>
<td><strong>EMW – Diagnosis and optimal management of HEV infection</strong></td>
<td>8.0-B1</td>
<td>07:30-08:30</td>
<td>Nassim Kamar, <strong>France</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Sven Pischke, <strong>Germany</strong></td>
</tr>
</tbody>
</table>
EMW – HCV treatment prioritization when resources are limited  Hall 8.0-E1
07:30-08:30  Moderators:
Gamal Esmat, Egypt
David Goldberg, United Kingdom

EMW – Management of HCV patients with impaired kidney function  Hall 8.0-B3
07:30-08:30  Moderators:
Peter Ferenci, Austria
Maria Londono, Spain

EMW – Optimal management of chronic hepatitis delta  Hall 8.0-D1
07:30-08:30  Moderators:
Seyed Moayed Alavian, Iran
Alessia Ciancio, Italy

Best poster summary  Hall 8.0-B1
08:30-08:50  Viral hepatitis
Marc Bourliere, France

08:50-09:10  Metabolic and cholestatic
Frank Lammert, Germany

09:10-09:30  Basic and translational science
Marco Marzioni, Italy

09:30-09:50  Chronic liver failure
Markus Peck-Radosavljevic, Austria
The best of Journal of Hepatology, 2015:
Editor’s picks
Hall 8.0-A1

**Chair:**
Rajiv Jalan, *United Kingdom*

08:30-08:45  **Journal of Hepatology in 2015: facts and numbers**
Rajiv Jalan, *United Kingdom*

08:45-09:00  **Cancer/Basic science**
Jessica Zucman Rossi, *France*

09:00-09:15  **ALD/NAFLD**
Ramon Bataller, *United States*

09:15-09:30  **Viral**
Thomas Berg, *Germany*

09:30-09:45  **Cirrhosis/Liver failure**
Richard Moreau, *France*

09:45-10:00  **Discussion**

WHO-EASL Symposium – New directions and innovations in hepatitis testing
Hall 8.0-C1

**Chairs:**
Massimo Colombo, *Italy*
Philippa Easterbrook, *Switzerland*

08:30-08:45  **New directions in hepatitis testing: WHO guidelines on hepatitis testing**
Philippa Easterbrook, *Switzerland*

08:45-09:00  **What tests to use and how: Systematic reviews of evidence and modelling**
Rosanna Peeling, *United Kingdom*

09:00-09:15  **Innovations in hepatitis testing**
Teri Roberts, *Switzerland*

09:15-09:30  **Experiences from the field in hepatitis testing: a survey of 15 countries**
Niklas Luhmann, *France*

09:30-09:50  **Q&A Panel discussion**
## Hepatitis testing Innovation contest

<table>
<thead>
<tr>
<th>Time</th>
<th>Organisation</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:50-10:00</td>
<td>Organisation of contest and announcement of winners</td>
<td>Joseph Tucker, United States</td>
</tr>
<tr>
<td>10:00-10:05</td>
<td>National Nursing Centers Consortium, entry 046</td>
<td>Catelyn Coyle, United States</td>
</tr>
<tr>
<td>10:05-10:10</td>
<td>Community Network for Empowerment (CONE), entry 007</td>
<td>Rajkumar Nalinikanta, India</td>
</tr>
<tr>
<td>10:10-10:15</td>
<td>FIRE NGO, entry 043</td>
<td>Meredith Potts, United States</td>
</tr>
<tr>
<td>10:15-10:20</td>
<td>Public Health Service of Amsterdam, entry 61</td>
<td>Janke Schinkel, Netherlands</td>
</tr>
<tr>
<td>10:20-10:25</td>
<td>St. Vincent’s Hospital, entry 032</td>
<td>Alex Thompson, Australia</td>
</tr>
</tbody>
</table>

## EASL clinical practice guidelines: Benign liver tumour – vascular liver disease – liver transplantation

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30-10:50</td>
<td><strong>Benign liver tumours</strong></td>
<td>Massimo Colombo</td>
<td>Italy</td>
</tr>
<tr>
<td>10:50-11:10</td>
<td><strong>Vascular liver disease</strong></td>
<td>Juan-Carlos Garcia-Pagan</td>
<td>Spain</td>
</tr>
<tr>
<td>11:10-11:30</td>
<td><strong>Liver transplantation</strong></td>
<td>Patrizia Burra</td>
<td>Italy</td>
</tr>
</tbody>
</table>

## Symposium – Cholangiocyte biology

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30-10:50</td>
<td><strong>Structure and functions of the biliary epithelium</strong></td>
<td>Gianfranco Alpini</td>
<td>United States</td>
</tr>
<tr>
<td>10:50-11:10</td>
<td><strong>Frontieres of cholangiocyte biology: micro-RNAs and micro-particles</strong></td>
<td>Jesus Banales</td>
<td>Spain</td>
</tr>
</tbody>
</table>
11:10-11:30  Cholangiocyte biology: a source for the therapy of chronic cholestatic diseases
Peter Fickert, Austria

Symposium – Systemic inflammation in advanced chronic liver disease  Hall 8.0-D2

**Chairs:**
Richard Moreau, France
Shiv Sarin, India

10:30-10:35  **Introduction**
Richard Moreau, France

10:35-10:50  **Pathomechanisms of inflammation and infection in advanced chronic liver disease**
Percy A. Knolle, Germany

10:50-11:00  **Infection and sepsis in ACLF: Mechanisms and management**
Shiv Sarin, India

11:00-11:25  **New concepts for targeting inflammation and immune dysfunction in advanced chronic liver disease**
Philip Newsome, United Kingdom

11:25-11:30  **General discussion**

Symposium – Liver biopsy in HCC  Hall 8.0-B3

**Chair:**
Peter Schirmacher, Germany

10:30-10:45  **Liver biopsy from the clinicians perspective – do we need to change the guidelines**
Jean-François Dufour, Switzerland

10:45-11:00  **Liver biopsy from the pathologist’ perspective – do the guidelines meet reality?**
Dina Tiniakos, United Kingdom
11:00-11:15  Liver biopsy in clinical trials – needless or necessity?  
Josep Llovet, Spain

11:15-11:20  Liver biopsy – options to come  
Peter Schirmacher, Germany

11:20-11:30  Discussion

Symposium – Optimal therapy for challenging HCV patients (Kidney, DAA failures)  
Hall 8.0-A1

Chair:  
Alessandra Mangia, Italy

10:30-10:35  Introduction  
Alessandra Mangia, Italy

10:35-10:50  Treatment of patients who fail DAA  
Christoph Sarrazin, Germany

10:50-11:05  Treatment of patients with renal disease  
Stanislas Pol, France

11:05-11:20  Treatment of patients with genotype 3  
Alessandra Mangia, Italy

11:20-11:30  General discussion and closing remarks

General session 4 and closing  
Hall 8.0-A1

Chairs:  
Francesco Negro, Switzerland  
Massimo Pinzani, United Kingdom

11:30-12:00  General hepatology (Cirrhosis, transplantation and tumour)  
Jaime Bosch, Spain

12:00-12:30  Metabolic and cholestatic  
Michael Trauner, Austria

12:30-13:00  Viral hepatitis  
Antonio Craxi, Italy
LATE BREAKER POSTERS

LBP500 SAFETY AND EFFICACY OF DIRECTLY ACTING ANTIVIRALS IN 2432 HCV PATIENTS WITH ADVANCED FIBROSIS: AN INTERIM ANALYSIS OF THE LOMBARDIA REGIONAL NETWORK FOR VIRAL HEPATITIS
Alessio M Aghemo*, G Cologni, F Maggiolo, L Pasulo, G Rizzardini, C Magni, T Quirino, L Minoli, G Filice, M Zuin, A Colli, Mg Rumi, M Puoti, S Fagiuoli, M Colombo, Italy

LBP501 TNF MEDIATED LIVER DAMAGE IS PROTECTED BY RIPK1 IN HEPATITIS
Aveline Filliol*, Claire Piquet-Pellorce, Jacques Le Seyec, Valentine Genet, Catherine Lucas-Clerc, John Bertin, Peter J. Gough, Marie-Thérèse Dimanche-Boitrel, Peter Vandenabeele, Mathieu J. M. Bertrand, Michel Samson, France

LBP502 APPLICABILITY, RELIABILITY AND DIAGNOSTIC PERFORMANCE OF FIBROSCAN FOR LIVER EVALUATION IN SEVERE OBESE PATIENTS CANDIDATE TO BARIATRIC SURGERY
Charles Barsamian*, Sébastien Czernichow, Magali Sasso, Véronique Miette, David Parlier, Jean-Luc Bouillot, Jean-François Emile, Claire Carette, France

LBP503 EFFECT OF BASELINE RESISTANCE-ASSOCIATED VARIANTS ON SVR WITH THE 3D REGIMEN WITH AND WITHOUT RBV IN GT1A AND GT1B-INFECTED PATIENTS
Christoph Sarrazin*, Mark S. Sulkowski, Preethi Krishnan, Rakesh Tripathi, Gretja Schnell, Yan Xie, Daniel E. Cohen, Roger Trinh, Lino Rodrigues-Jr., Yan Luo, Nancy S. Shulman, Tami Pilot-Matias, Christine Collins, Germany

LBP504 MONITORING THE WHO-RECOMMENDED CORE INDICATORS FOR VIRAL HEPATITIS B AND C IN EU/EEA MEMBER STATES: SUPPORTING THE GLOBAL VISION OF ELIMINATION
Erika Duffell*, D. Hedrich, O. Mardh, Antons Mozalevskis, Sweden

LBP505 CLINICAL OUTCOMES IN HCV-INFECTED PATIENTS TREATED WITH DIRECT ACTING ANTIVIRALS – 18 MONTH POST-TREATMENT FOLLOW-UP IN THE FRENCH ANRS CO22 HEPATHER COHORT STUDY
Fabrice Carrat*, France
LBP506 DEVELOPMENT OF HEPATOCELLULAR CARCINOMA IN HCV CIRRHOTIC PATIENTS TREATED WITH DIRECT ACTING ANTIVIRALS
Federica Buonfiglioli*, Fabio Conti, Pietro Andreone, Cristina Crespi, Francesco Giuseppe Foschi, Marco Lenzi, Giuseppe Mazzella, Gabriella Verucchi, Stefano Brillanti, Italy

LBP507 CO-ADMINISTRATION OF CHIMPANZEE ADENOVIRAL VECTORS OF DIFFERENT SEROTYPES, FOR THE PREVENTION OF HCV AND HIV CO-INFECTION
Felicity Hartnell*, Anthony Brown, Emma Ghaifari, Beth Turner, Antonella Folgori, Stefania Capone, Alfredo Nicosia, Riccardo Cortese, Stefano Colloca, Tomas Hanke, Lucy Dorrell, Ellie Barnes, United Kingdom

LBP508 METABOLIC PATHWAY REPROGRAMMING BY CRISPR/CAS9 GENOME EDITING
Francis Pankowicz*, Mercedes Barzi, Julie Tomolonis, Beatrice Bissig-Choisat, Xavier Legras, Milan Ravishankar, Qin Sun, Malgorzata Borowiak, Sarah H. Elsea, Pavel Sumazin, Karl-Dimiter Bissig, United States

LBP509 DECREASING INCIDENCE OF CANCER AFTER LIVER TRANSPLANTATION – A NORDIC POPULATION-BASED STUDY

LBP510 ANALYSIS OF THE REAL-WORLD EFFECTIVENESS OF DIRECT ACTING ANTIVIRAL TREATMENTS FOR HEPATITIS C IN A LARGE POPULATION
Jeffrey McCombs*, Justin McGinnis, Steven Fox, Ivy Tonnu-Mihara, United States
**LBP511**

**EFFECTIVENESS AND SAFETY OF SOFOSBUVIR/LEDIPASVIR TREATMENT FOR MONOINFECTED GENOTYPE 1 HCV PATIENTS IN REAL-LIFE CLINICAL PRACTICE: RESULTS FROM SPANISH HEPA-C COHORT**

Javier Crespo, Inmaculada Fernandez, Joaquin Cabezas*, Agustin Albillos, Christie Perello, Javier Garcia-Samaniego, Miguel Angel Serra, Moises Diago, Juan Manuel Pascasio, Martin Prieto, Susana Llerena, Zoe Mariño, Conrado Fernandez, Maria Buti, Rafael Bañares, Miguel Angel Simon, Juan Turnes, BeGoña Sacristan, Francisco Jorquera, Carmen Lopez, Jose Ramon Salcines, Javier Ampuero, Juan Jose Sanchez-Ruano, Rosa Morillas, Carmen Alvarez Navascues, Juan de la Vega, Lucia Bonet, Maria Cuaresma, Raul Andrade, Jose Antonio Carrion, Federico Saez Royuela, Oreste L. Iacono, Gloria Sanchez-Antolin, Esther Molina, Juan Arenas Ruiz, Silvia Montoliu, Xavi Torras, Jose Maria Moreno, Pilar Sanchez Pobre, Jose Ramon Fernandez, Miguel Fernandez Bermejo, Francisco Gea, Mirian Romero, Desamparados Escudero Garcia, Maria Luisa Manzano, Jose Luis Calleja, Spain

**LBP512**

**EFFECTIVENESS AND SAFETY OF OMBITASVIR, PARITAPREVIR, RITONAVIR AND DASABUVIR PATIENTS WITH GENOTYPE 1 CHRONIC HEPATITIS C VIRUS INFECTION: RESULTS FROM THE SPANISH REAL WORLD COHORT**

Jose Luis Calleja*, Diego Rincon, Belen Ruiz-Antoran, Begoña Sacristan, Christie Perello, Sabela Lens, Inmaculada Fernandez, Francisco Gea, Rosa Maria Morillas, Joaquin Cabezas, Jose Manuel Pascasio, Martin Prieto, Juan Turnes, Miguel A Serra, Juan Arenas, Xavier Torras, Lucia Bonet, Conrado Fernandez, Javier Samaniego, Alicia Hernandez-Albujar, Javier Ampuero, Jose Maria Moreno, Federico Saez-Royuela, Carmen Alvarez-Navascues, Moises Diago, Gloria Sanchez-Antolin, Juan de la Vega, Juan Jose Sanchez-Ruano, Raul Andrade, Maria Butti, Jose A Carrion, Esther Molina, Miguel A Simon, Jose Ramon Salcines, Francisco Jorquera, Silvia Montoliu, Adriana Ahumada, Tania Hernaez, Javier Crespo, Spain

**LBP513**

**HIV COINFECTION IMPAIRS RESPONSE TO DAA-BASED HCV THERAPY**

Karin Neukam, Marta Suárez-Santamaria, Antonio Rivero-Juárez, Alberto Romero-Palacios, Enrique Ortega, Ignacio de los Santos-Gil, Josep Cucurull, Francisco Vera-Méndez, Juan A. Pineda*, Spain
LBP514  ANALYSIS OF THE IMPACT OF HIV CO-INFECTION ON HEPATITIS C TREATMENT EFFECTIVENESS FOR PATIENTS USING NEW DIRECT-ACTING ANTIVIRALS
Justin McGinnis*, Jeffrey McCombs, Darshan Mehta, Steven Fox, Ivy Tonnu-Mihara, United States

LBP515  PROSPECTIVE COMPARISON TO LIVER BIOPSY OF CONTROLLED ATTENUATION PARAMETER AND PROTON DENSITY FAT FRACTION FOR PREDICTING DEGREE OF STEATOSIS IN NON-ALCOHOLIC FATTY LIVER DISEASE
Katharine Roberts*, Angelo H. Paredes, Christopher Lisanti, Ryan Schwope, Katherine M. Cebe, Jennifer M. Aldridge Whitehead, James K. Aden, Stephen A. Harrison, United States

LBP516  SIMEPREVIR PLUS SOFOSBUVIR FOR HEPATITIS C VIRUS GENOTYPE 4 INFECTION: A PHASE 3, OPEN-LABEL STUDY
María Buti’, José Luis Calleja, Xavier Forns, Moisés Diago, Enrique Ortega, Javier Crespo, Ramón Planas, Bart Fevery, Darryl Kurland, Annemiek Buelens, Chris Corbett, Ronald Kalmeijer, Wolfgang Jessner, Spain

LBP517  ADD ON INTERFERON-ALPHA-2A FOR THE TREATMENT OF HBEAG NEGATIVE HEPATITIS B PATIENTS RECEIVING EFFECTIVE NUCLEOS(T)IDE THERAPY: INTERIM RESULTS OF THE PROSPECTIVE MULTICENTRE PADD-ON TRIAL
Martin F. Sprinzl’, Annette Grambihler, Gerlinde Teuber, Matthias Ebert, Stefan Zeuzem, Jürgen Lohmeyer, Marcus Cornberg, Frank Tacke, Hanns Lörhr, Thomas Berg, Frank Lammert, Eckart Schott, Renate Heyne, Christoph Berg, Mathias Dollinger, Anita Pathil-Warth, Fabian Geisler, Ulrich Spengler, Robert Thimme, Kilian Weigand, Ulrich Alshuth, Anne Ehrlich, Michaela Riedl, Jens Kittner, Marcus Schuchmann, Peter R. Galle, Germany
LBP518 | HCV ERADICATION RESULTS IN REDUCTION OF HEPATIC VENOUS PRESSURE GRADIENT 48 WEEKS AFTER END OF TREATMENT; FINAL RESULTS OF THE STUDY OF SOFOSBUVIR PLUS RIBAVIRIN IN PATIENTS WITH CIRRHOSIS AND PORTAL HYPERTENSION
Nezam Afdhal*, Tarik Asselah, Gregory T. Everson, Jaime Bosch, Shampa De-Oertel, Diana M. Brainard, John G. McHutchison, Yin Yang, Kymberly D. Watt, Michael Curry, Edward Gane, United States

LBP519 | NO EFFECT OF PROTON PUMP INHIBITOR (PPI) USE ON SVR WITH LEDIPASVIR/SOFOSBUVIR (LDV/SOF): REAL WORLD DATA FROM 2034 GENOTYPE 1 PATIENTS IN THE TRIO NETWORK
Nezam Afdhal*, Bruce Bacon, Michael Curry, Douglas Dieterich, Steven Flamm, Lauren Guest, Kris Kowdley, Yoori Lee, Naoky Tsai, Zobair Younossi, United States

LBP520 | IMPACT OF AETIOLOGY ON SURVIVAL AFTER SORAFENIB TREATMENT OF ADVANCED HEPATOCELLULAR CARCINOMA: A META-ANALYSIS OF THREE LARGE RANDOMISED TRIALS
Philip J. Johnson*, Richard Jackson, Eftychia-Eirini Psarelli, Harun Khan, Sarah Berhane, United Kingdom

LBP521 | ADD-ON PEGINTERFERON ALFA-2A SIGNIFICANTLY REDUCES HBSAG LEVELS IN HBEAG-NEGATIVE, GENOTYPE D CHRONIC HEPATITIS B PATIENTS FULLY SUPPRESSED ON NUCLEOT(S)IDE ANALOGUES TREATMENT: FINAL RESULTS OF THE HERMES STUDY
Pietro Lampertico*, Maurizia R. Brunetto, Antonio Craxi, Giovanni B. Gaeta, Mario Rizzetto, Antonella Rozzi, Massimo Colombo, Italy

LBP522 | DS102 - A BIOACTIVE LIPID FOR THE TREATMENT OF NASH
Robert V. Lumsden*, David Coughlan, Mehar Manku, John Climax, Ireland

LBP523 | EVIDENCE OF IMPRESSIVE REAL WORLD SVR FROM THE PORTUGESE LEDIPASVIR/SOFOSBUVIR AND SOFOSBUVIR UNIVERSAL COVERAGE PROGRAM TO ERADICATE (ELIMINATE) HEPATITIS C
LBP524  A NOVEL TASK SHIFTING MODEL TO EXPAND THE HCV CARE CONTINUUM: THE ASCEND INVESTIGATION

LBP525  NOVEL THERAPEUTIC TARGETS FOR PRIMARY SCLEROSING CHOLANGITIS-ASSOCIATED BILIARY TRACT CANCER IDENTIFIED BY TISSUE SEQUENCING
Benjamin Goeppert#, Trine Folseraaas#*, Stephanie Roessler, Volker Endris, Krzysztof Grzyb, Piotr Milkiewicz, Barbara Gornicka, Erik von Seth, Annika Bergquist, Andre Franke, Tor J. Eide, Kirsten Muri Boberg, Peter Schirmacher##, Tom H. Karlsen##, Norway

LBP526  PREVALENCE OF RECTAL COLONIZATION BY MDR BACTERIA AND RELATIONSHIP WITH BACTERIAL INFECTION DEVELOPMENT IN PATIENTS ADMITTED TO A LIVER ICU
Veronica E. Prado Gonzalez*, Francesc Marco, Mireya Arteaga, Enric Reverter, Angells Escorsell, Jose Mensa, Pere Gines, Alejandro Soriano, Josep Vila, Javier Fernandez, Spain

LBP527  SILYMARIN IMPROVES FIBROSIS IN NON-ALCOHOLIC STEATOHEPATITIS
Wah Kheong Chan*, Nik Raihan Nik Mustapha, Sanjiv Mahadeva, Malaysia

LBP528  SUMO-SPECIFIC PROTEASE 3 IS AN IMPORTANT REGULATOR OF LIPID METABOLISM IN NONALCOHOLIC FATTY LIVER DISEASE
Yuhan Liu*, Fudong Yu, Zhujun Cao, Xiaogang Xiang, Qing Li, Hui Wang, Yan Han, Wei Cai, Jie Lu, Xiaolin Wang, Shisan Bao, Qing Xie, China
Every day, paper posters will change

Poster Tours
Use your lunch break wisely

Key Opinion Leader guides will walk you through the paper posters in Hall 8.1
Meet at the Poster Help Desk!
Alcoholic liver disease and drug induced liver disease

THU-276 ASSESSING MECHANISMS OF KETOCONAZOLE AND AMIODARONE INDUCED STEATOHEPATITIS IN AN ORGANOYTIC HUMAN PRIMARY HEPATOCYTE LIVER MODEL
Robert Figler, Svetlana Marukian, Maria Collado, David Manka, Mark Lawson, Aaron Mackey, Brett Blackman, Brian Wamhoff, Ajit Dash*, United States

THU-277 A NOVEL IN VITRO TEST ALLOWS CAUSALITY ASSESSMENT OF DRUG INDUCED LIVER INJURY IN POLYMEDICATION
Andreas Benesic*, Sandra Ehrlich, Alexander Gerbes, Germany

THU-278 THE BILE ACID TAUROURSODEOXYCHOLIC ACID COOPERATES WITH N-ACETYLCYSTEINE IN THE TREATMENT OF EXPERIMENTAL ACETAMINOPHEN-INDUCED HEPATOTOXICITY
Annelies Paridaens*, Lindsey Devisscher, Sarah Raevens, Eliene Bogaerts, Yves-Paul Vandewynckel, Xavier Verhelst, Inge Mannaerts, Leo Van Grunsven, Hans Van Vlierberghe, Isabelle Colle, Anja Geerts, Belgium

THU-279 METHACETIN BREATH TEST IS SUPERIOR TO MELD IN PREDICTING MORTALITY IN PATIENTS WITH ACUTE ON CHRONIC LIVER FAILURE: RESULTS OF A PHASE II CLINICAL TRIAL
Ashok K. Choudhury*, Ankit Bhardwaj, Chandan K. Kedarisetty, Yaron Ilan, Shiv K. Sarin, India

THU-280 INFECTION IS COMMON IN PATIENTS WITH SEVERE ALCOHOLIC HEPATITIS TREATED WITH STEROIDS BUT NOT ASSOCIATED WITH POOR OUTCOME
Ashwin Dhanda*, Peter Collins, United Kingdom

THU-281 ORAL TREATMENT WITH PBI-4425 DECREASES FIBROSIS IN CARBON TETRACHLORIDE (CCL4)-INDUCED HEPATIC FIBROSIS MODEL
Brigitte Grouix*, François Sarra-Bournet, Kathy Hince, Alexandra Felton, Mikael Tremblay, Shaun Abbott, Jean-Simon Duceppe, Boulos Zacharie, Pierre Laurin, Lyne Gagnon, Canada
<table>
<thead>
<tr>
<th>Poster Number</th>
<th>Title</th>
<th>Authors</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>THU-282</td>
<td>HISTOLOGICAL ACTIVITY AND FIBROSIS PREDICT LONG-TERM SURVIVAL IN PATIENTS WITH COMPENSATED ALCOHOLIC LIVER DISEASE</td>
<td>Carolin Lackner*, Walter Spindelboeck, Florian Rainer, Johannes Haybaeck, Rudolf E. Stauber, Austria</td>
<td>Austria</td>
</tr>
<tr>
<td>THU-283</td>
<td>MACROPHAGE ACTIVATION ASSESSED BY SOLUBLE CD163 AND SOLUBLE MANNOSE RECEPTOR IS ASSOCIATED WITH LIVER INJURY IN PATIENTS WITH ACETAMINOPHEN OVERDOSE</td>
<td>Cecilie B. Siggaard*, Konstantin Kazankov, Sidsel Rødgaard-Hansen, Holger Jon Møller, Henning Grønbæk, Denmark</td>
<td>Denmark</td>
</tr>
<tr>
<td>THU-284</td>
<td>AKKERMANSIA MUCINIPHILA PROTECTS FROM ALCOHOLIC LIVER DISEASE</td>
<td>Christoph Grander*, Verena Wieser, Romana R. Gerner, Felix Grabherr, Alexandra Pfister, Lisa Lichtmannegger, Barbara Enrich, Alexander R. Moschen, Herbert Tilg, Austria</td>
<td>Austria</td>
</tr>
<tr>
<td>THU-285</td>
<td>ADMINISTRATION OF BIFIDOBACTERIUM SP. LI09 OR BIFIDOBACTERIUM SP. LI10 ATTENUATES ACUTE LIVER DAMAGE INDUCED BY D-GALACTOSAMINE IN RATS</td>
<td>Daiqiong Fang*, Ding Shi, Longxian Lv, Wenrui Wu, Feifei Guo, Lanjuan Li, China</td>
<td>China</td>
</tr>
<tr>
<td>THU-286</td>
<td>METABOLOMOMIC ANALYSIS OF THE DYNAMIC CHANGES OF FAECES IN THE ACUTE LIVER FAILURE PIGS</td>
<td>Ermei Chen*, Yini Wang, Jie Wang, Juan Lu, Danhua Zhu, Lanjuan Li, China</td>
<td>China</td>
</tr>
<tr>
<td>THU-287</td>
<td>CASPASE-8 DEFICIENCY AMELIORATES HEPATIC STEATOSIS, BUT NOT APOPTOSIS IN ALCOHOLIC LIVER INJURY</td>
<td>Fengjie Hao*, Francisco Javier Cubero, Lijun Liao, Pierluigi Ramadori, Ute Haas, Daniela Lambertz, Nikolaus Gassler, Mareike Hoss, Konrad Streetz, Johanna Reissing, Henning W. Zimmermann, Christian Trautwein, Christian Liedtke, Yulia A. Nevzorova, Germany</td>
<td>Germany</td>
</tr>
</tbody>
</table>
Alcoholic liver disease and drug induced liver disease (cont.)

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>THU-289</td>
<td>EXTRACELLULAR VESICLES AND THEIR MICRORNA CARGOS ARE NOVEL BIOMARKERS AND INTERCELLULAR COMMUNICATORS</td>
<td>Gyongyi Szabo*, Banishree Saha, Fatemeh Momen-Heravi, Shashi Bala, Karen Kodys</td>
<td>United States</td>
</tr>
<tr>
<td>THU-292</td>
<td>INDEPENDENT AND ADDITIVE INDUCTION OF HEPCIDIN BY HYPOXIA AND H2O2: EVIDENCE FOR NOX4-MEDIATED IRON SIGNALING</td>
<td>Inês M. Silva*, Vanessa Rausch, Teresa Peccerella, Gunda Millonig, Sebastian Mueller</td>
<td>Germany</td>
</tr>
<tr>
<td>THU-293</td>
<td>A METABO-TRANSCRIPTOMICS PAIRED ANALYSIS FOR IDENTIFICATION OF MOLECULAR MECHANISMS IN SEVERE ALCOHOLIC HEPATITIS NON RESPONSIVE TO GLUCO-CORTICOSTEROIDS THERAPY</td>
<td>Jaswinder S. Maras*, Sukanta Das, Md S. Hussain, S M. Shasthry, Shvetank Sharma, Cristophe Junot, Richard Moreau, Shiv K. Sarin</td>
<td>India</td>
</tr>
<tr>
<td>THU-294</td>
<td>ROOM-TEMPERATURE SUSCEPTOMETRY ALLOWS THE SENSITIVE AND NON-INVASIVE ASSESSMENT OF LIVER IRON</td>
<td>Johannes Mueller*, Hanna Raisi, Vanessa Rausch, Helmut Karl Seitz, William Avrin, Sebastian Mueller</td>
<td>Germany</td>
</tr>
</tbody>
</table>
THU-295  GROWTH DIFFERENTIATION FACTOR 15 (GDF-15) 
A SURROGATE MARKER OF ENDOTHELIAL 
DYSFUNCTION CORRELATES WITH SEVERITY AND 
PREDICTS SHORT-TERM SURVIVAL OF PATIENTS 
WITH ALCOHOLIC HEPATITIS 
Jose Altamirano’, Daniel Rodrigo-Torres, Mar Coll, Silvia Affò, 
Oriol Morales-Ibanez, Javier Michelena, Delia Blaya, Marta Llopis, 
Cristina Millán, Isabel Graupera, Luis Perea, Beatriz Aguilar, 
Ramón Bataller, Pere Gines, Pau Sancho-Bru, Juan Caballeria, Spain

THU-296  RIBOSOMAL PROTEIN GENES INCREASE THEIR 
OVERALL GENE EXPRESSION IN RAT LIVER 
AFTER LONG-TERM VOLUNTARY HIGH ALCOHOL 
CONSUMPTION 
José Fernando Leonardi Essmann’, Steven Dooley, Germany

THU-297  ANALYSIS OF MOLECULAR MECHANISMS OF 
5-FLUOROURACIL INDUCED STEATOSIS AND 
INFLAMMATION IN VITRO AND IN MICE 
Judith Sommer’, Abdo Mahli, Kim Freese, Wolfgang Thasler, 
Fulya Kucuekkoctay, Anja Bosserhoff, Martina Müller, 
Claus Hellerbrand, Germany

THU-298  THE INFLUENCE OF CHEMOTHERAPY-ASSOCIATED 
LIVER INJURY ON OUTCOME AFTER PARTIAL 
HEPATECTOMY FOR COLORECTAL LIVER METASTASES: 
A SYSTEMATIC REVIEW AND INDIVIDUAL PATIENT 
DATA ANALYSIS 
Junfang Zhao’, Kim van Mierlo, Sander Rensen, Frank Schaap, 
Cornelis Dejong, Steven Olde Damink, Netherlands

THU-299  EVOLUTION OF PORTAL HEPATIC HEMODYNAMICS 
AND C-REACTIVE PROTEIN AT 3 MONTHS IN PATIENTS 
WITH ALCOHOLIC LIVER DISEASE WITH OR WITHOUT 
ALCOHOLIC HEPATITIS 
Laurent Spahr’, Flavie Furrer, Laura Rubbia-Brandt, 
Cassandra Oropesa, Emiliano Giostra, Switzerland

THU-300  NUTRITIONAL, METABOLIC AND IMMUNOLOGICAL 
effects of INTRAVENOUS LIPID EMULSIONS IN 
PATIENTS WITH ADVANCED ALCOHOL RELATED 
LIVER DISEASE 
Lovkesh Anand’, Y.k Joshi, Jaya Benjamin, Paul David, Ashish Kumar, 
Vanshija Pandit, Nirupama Trehanpati, Vikram Bhatia, Shiv K. Sarin, 
India
<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>THU-301</td>
<td><strong>Alcoholic liver disease and drug induced liver disease (cont.)</strong></td>
<td>Lucia Barbier Torres*, Paula Iruzubieta, Daniel Taibo, Teresa Cardoso, Nicolas Navasa, David Fernández Ramos, Marta Varela Rey, Virginia Gutiérrez de Juan, Pablo Fernández Tussy, Imanol Zubiete Franco, Maria Isabel Hernández Alvarez, Raul Andrade, Inmaculada Medina, Maria Jesús Monte, José Juan García Marín, Javier Crespo, Antonio Zorzano, José María Mato, Juan Anguita, Mercedes Rincon, Maria Luz Martinez Chantar, Spain</td>
</tr>
<tr>
<td>THU-302</td>
<td><strong>Predicting mortality in alcoholic hepatitis using CLIF-ORGAN failure score</strong></td>
<td>Marco Silva*, Patricia Andrade, Susana Rodrigues, Armando Peixoto, Rui Gaspar, Susana Lopes, Hélder Cardoso, Guilherme Macedo, Portugal</td>
</tr>
<tr>
<td>THU-303</td>
<td><strong>The mechanisms underlying murine and human ibuprofen intoxication</strong></td>
<td>Miguel Eugenio Zoubek*, Marius Maximilian Woitok, Raul J. Andrade, M. Isabel Lucena, Christian Trautwein, Francisco Javier Cubero, Germany</td>
</tr>
<tr>
<td>THU-304</td>
<td><strong>Novel function of mitochondrial LON protease (LONP) in a drug-induced dual model of ER-stress and mitochondrial dysfunction in hepatic cells</strong></td>
<td>Miriam Polo, Fernando Alegre, Alberto Marti-Rodrigo, Ana Blas-Garcia, Juan V Esplugues, Nadezda Apostolova*, Spain</td>
</tr>
<tr>
<td>THU-305</td>
<td><strong>N-terminal pro-brain natriuretic peptide and prognosis of alcoholic liver cirrhosis course</strong></td>
<td>Nataliya Virstyuk*, Iryna Kobitovych, Nataliya Slyvka, Oleg Virstyuk, Ukraine</td>
</tr>
<tr>
<td>THU-306</td>
<td><strong>High frequency of inflammatory CD16+ monocytes in alcoholic hepatitis can be reduced by treatment with prednisolone</strong></td>
<td>Nikhil Vergis*, Wafa Khamri, Charalambos Antoniades, Mark Thursz, United Kingdom</td>
</tr>
</tbody>
</table>
THU-307 | NATURAL KILLER CELLS MODULATE ENDOTHELIAL PROGENITOR CELLS IN ALCOHOLIC CHRONIC LIVER DISEASE PATIENTS BY INCREASING PRO-INFLAMMATORY CYTOKINES AND CHEMOKINES
Pratima Srivastava, Rashi Sehgal, S S. Shastry, Emily Huang, Jenny Gamble, Savneet Kaur, Gayatri Ramakrishna, Geoff McCaughan, Shiv K. Sarin, Nirupma Trehanpati*, Devanshi Seth, India

THU-309 | EXPRESSION OF PRO-INFLAMMATORY AND HEPATOPROTECTIVE FACTORS AT EARLY STAGES OF ALCOHOLIC LIVER DISEASE IN HUMANS AND THE IMPACT OF SHORT TERM ABSTINENCE
Peter Stärkel*, Christine Desaeger, Nicolas Lanthier, Philippe de Timary, Isabelle Leclercq, Belgium

THU-310 | PREDNISOLONE PLUS S-ADENOSYLMETHIONINE IN SEVERE ALCOHOLIC HEPATITIS
Petr Tkachenko*, Inna Komkova, Marina Maevskaya, Vladimir Ivashkin, Russia

THU-311 | HEPATOTOXICITY ASSOCIATED WITH NON-Steroidal ANTI-INFLAMMATORY DRUGS. A COMPARATIVE ANALYSIS AMONG IBUPROFEN, DICLOFENAC AND NIMESULIDE FROM THE SPANISH AND LATIN-AMERICAN DILI REGISTRIES

THU-312 | UNIVERSAL SCREENING FOR ALCOHOL MISUSE IN ACUTE MEDICAL ADMISSIONS IDENTIFIES COHORT OF PATIENTS WITH HIGH RISK OF ALCOHOL RELATED LIVER DISEASE – AN ANALYSIS OF 50,000 HOSPITAL ADMISSIONS
Greta Westwood, Paul Meredith, Susan Atkins, Peter Greengross, Paul Schmidt, Richard Aspinall*, United Kingdom

THU-313 | IMPACT OF HEPATITIS C VIRUS INFECTION IN THE LIVER-RELATED MORTALITY OF PATIENTS WITH ALCOHOL USE DISORDER
Arantza Sanvisens, Ferran Bolao, Inmaculada Jarrin, Daniel Fuster, Paola Zuluaga’, Jordi Tor, Robert Muga, Spain
<table>
<thead>
<tr>
<th>POSTERS / THURSDAY 14 APRIL 2016</th>
</tr>
</thead>
<tbody>
<tr>
<td>EASL  THE HOME OF HEPATOLOGY</td>
</tr>
<tr>
<td>PROGRAMME</td>
</tr>
</tbody>
</table>

**Alcoholic liver disease and drug induced liver disease (cont.)**

<table>
<thead>
<tr>
<th>THU-314</th>
<th>PREDICTING SHORT AND LONG-TERM MORTALITY OF HOSPITALIZED PORTUGUESE PATIENTS WITH ALCOHOLIC HEPATITIS</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Samuel R. Fernandes, Pedro M. Costa, Sofia Vitor, Patricia Santos, Carlos M. Moura, Joana R. Carvalho, Helena Cortez-Pinto*, Fernando Ramalho, José Velosa, Portugal</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>THU-315</th>
<th>URINARY MICRO-ALBUMIN LEVEL AND ITS MODIFICATION STATUS SERVE AS AN NON-INVASIVE MARKER FOR OUTCOME PREDICTION IN ACUTE-ON-CHRONIC LIVER FAILURE (ACLF) PATIENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Shabir Hussain*, Sukanta Das, Jaswinder S. Maras, Shastry S M, Shvetank Sharma, Shiv K. Sarin, India</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>THU-316</th>
<th>SYSTEMS LEVEL ANALYSIS FOR CHARACTERIZATION OF GENES RESPONSIBLE FOR OUTCOME IN SEVERE ALCOHOLIC HEPATITIS PATIENTS ON STEROID THERAPY</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>THU-317</th>
<th>EFFECTS OF ALCOHOL ON TGF-BETA MEDIATED HEPATOCYTE APOPTOSIS</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Katja Breitkopf-Heinlein, Christoph Meyer, Maria Thomas, Franziska Wandrer, Heike Bantel, Steven Dooley*, Germany</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>THU-318</th>
<th>ASSOCIATIVE ROLE OF GENETIC ALTERATION IN ALCOHOL METABOLIZING GENES WITH ALCOHOL MEDIATED LIVER DISEASE SUSCEPTIBILITY AND SEVERITY IN ETHNICALLY DISTINCT NORTHEAST INDIAN POPULATION</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Tarun K. Basumatary, Sujoy Bose*, Anjan K. Saikia, Ramie H. Begum, India</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>THU-319</th>
<th>MOLECULAR ELLIPTICITY OF CIRCULATING ALBUMIN-BILIRUBIN COMPLEX IS A RELIABLE PROGNOSTIC MEASURE OF SEVERITY OF ACUTE ON CHRONIC LIVER FAILURE (ACLF)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Sukanta Das*, Jaswinder S. Maras, Shabir Hussain, Chidanand Sudarshan, Shastry S M, Shvetank Sharma, P Balaram, Shiv K. Sarin, India</td>
</tr>
</tbody>
</table>
THU-320
YI

IRREVERSIBLE MODIFICATION OF CIRCULATING ALBUMIN IN ACUTE ON CHRONIC LIVER FAILURE (ACLF) TRIGGERS NEUTROPHIL BURST VIA INDUCING GENES ASSOCIATED TO CYTOKINE RELEASE AND CELLULAR STRESS
Sukanta Das*, Jaswinder S. Maras, Shabir Hussain, Paul David, Shasthry S M, Nirupama Trehanpati, Shvetank Sharma, T P. Singh, Shiv K. Sarin, India

THU-321
YI

AN IMMUNE MODULATORY EFFECT BY ORAL CO-ADMINISTRATION OF SOY-DERIVED EXTRACTS WITH HIGH ALCOHOL OR SUGAR-SWEETENED BEVERAGES EXERTS LIVER AND SUGAR PROTECTIVE EFFECTS
Tawfik Khoury*, Devorah Rotnemer-Golinkin, Lidya Zolotarovya, Yaron ilan, Israel

THU-322
YI

PRIMARY LIVER INJURY AND DELAYED RESOLUTION OF LIVER STIFFNESS AFTER ALCOHOL DETOXIFICATION IN HEAVY DRINKERS WITH THE PNPLA3 VARIANT I148M
Vanessa Rausch*, Teresa Peccerella, Carolin Lackner, Eray Yagmur, Helmut-Karl Seitz, Thomas Longerich, Sebastian Mueller, Germany

THU-323
YI

HEPCIDIN REGULATION IN PATIENTS WITH ALCOHOLIC LIVER DISEASE WITH IRON OVERLOAD AND ANEMIA: THE ROLE OF HEMOLYSIS
Vanessa Rausch*, Teresa Peccerella, Gunda Millonig, Eray Yagmur, Helmut-Karl Seitz, Sebastian Mueller, Germany

THU-324
YI

THE MITOCHONDRIAL CHOLESTEROL TRANSPORTER STARD1 PROMOTES CHRONIC ALCOHOLIC LIVER DISEASE
Vicent Ribas*, Susana Núñez, Carmen García-Ruiz, Jose Carlos Fernández-Checa, Spain
<table>
<thead>
<tr>
<th>Poster Number</th>
<th>Title</th>
<th>Authors</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>THU-001</td>
<td><strong>Beta-Blocker Use in Hospitalized Cirrhotic Patients with Ascites Is Associated With a Lower MELD, Less Inflammation and an Improved Survival</strong></td>
<td>Abdul Q. Bhutta*, Guadalupe Garcia-Tsao, Rajender Reddy, Puneeta Tandon, Florence Wong, Jacqueline G. O’Leary, Chathur Acharya, Debolina Banerjee, Juan G. Abraldes, Ian Plener, Tiana M. Jones, Jawaid Shaw, Yanhong Deng, Maria Ciarleglio, Jasmohan S. Bajaj, United States</td>
<td></td>
</tr>
<tr>
<td>THU-002</td>
<td><strong>Efficacy and Safety of Simeprevir Plus Sofosbuvir Plus Ribavirin Flat Dose in a Population of Naive and Experienced HCV Genotype 1 Cirrhotic Elderly Patients: A Real World Experience from CLEO Group</strong></td>
<td>Adriano M Pellicelli*, Valeria Pace Palitti, Pascal Vignally, Alessandra Moretti, Pierluigi Tarquini, Gaetano Scifo, Vincenzo Messina, Antonio Ascione, Antonio Izza, Cecilia D’Ambrosio, Roberto Villani, Lucia Fondacaro, Luca Fontanella, Paolo Guarascio, Loredana Alessio, Emilo D’amico, Giuseppe Maria Ettorre, Massimo Marignani, Paola Begini, Giuseppe Cerasari, Angelo Barlattani, Orlando Armignacco, Giorgio Barbarini, Italy</td>
<td></td>
</tr>
<tr>
<td>THU-003</td>
<td><strong>Circulating Microparticles and Risk of Portal Vein Thrombosis in Patients with Liver Cirrhosis and Hepatocellular Carcinoma</strong></td>
<td>Alberto Zanetto*, Alberto Ferrarese, Elena Nadal, Ilaria Bortoluzzi, Elena Campello, Luca Spiezia, Umberto Cillo, Alessandro Vitale, Fabio Farinati, Giacomo Germani, Francesco Paolo Russo, Paolo Simioni, Patrizia Burra, Marco Senzolo, Italy</td>
<td>Italy</td>
</tr>
<tr>
<td>THU-004</td>
<td><strong>Whole Blood Coagulation Tests Are Not Equally Able to Detect Haemostatic Prothrombotic Alterations in Patients with Liver Cirrhosis and Hepatocellular Carcinoma: Rotational Thromboelastometry Versus Thrombingeneration Test</strong></td>
<td>Alberto Zanetto*, Alberto Ferrarese, Elena Nadal, Ilaria Bortoluzzi, Elena Campello, Luca Spiezia, Umberto Cillo, Alessandro Vitale, Fabio Farinati, Giacomo Germani, Francesco Paolo Russo, Sabrina Gavasso, Paolo Simioni, Patrizia Burra, Marco Senzolo, Italy</td>
<td>Italy</td>
</tr>
</tbody>
</table>
THU-005 SUSTAINED VIROLOGICAL RESPONSES (SVR) OF 97% IN GENOTYPE 2 (GT-2) PATIENTS WITH F3/4 STAGE OF FIBROSIS TREATED WITH SOFOSBUVIR (SOF) AND WEIGHT-BASED RIBAVIRIN (RBV): A REAL LIFE, SINGLE CENTRE EXPERIENCE
Alessandra Mangia*, Andrea Arleo, Valeria Piazzolla, Rosanna Santoro, Daniela Petruzzellis, Maria Miscio, Maria Maddalena Squillante, Italy

THU-006 SELECTIVE ENDOTHELIN-A BLOCKADE DECREASES PORTAL PRESSURE IN PATIENTS WITH CIRRHOSIS. A PILOT STUDY COMBINING A LOCAL INTRAARTERIAL AND SYSTEMIC ADMINISTRATION
Alexander Zipprich*, Enno Schenkel, Fleur Gittinger, Matthias Winkler, Patrick Michl, Cristina Ripoll, Germany

THU-007 HIGH LIPOPOLYSACCHARIDE BINDING PROTEIN LEVELS ARE RELATED TO INTERMEDIATE MORTALITY IN PATIENTS WITH DECOMPENSATED CIRRHOSIS
Danai Agiasotelli, Alexandra Alexopoulou*, Larisa Vasilieva, Emily Hadziyannis, Dimitrios Goukos, George Daikos, Spyridon Dourakis, Greece

THU-008 EXTENSIVELY DRUG RESISTANT BACTERIA AS AN INDEPENDENT PREDICTIVE FACTOR OF MORTALITY IN SPONTANEOUS BACTERIAL PERITONITIS AND SPONTANEOUS BACTEREMIA
Alexandra Alexopoulou*, Larisa Vasilieva, Danai Agiasotelli, Kyriaki Siranidi, Sophia Pouriki, Athanasia Tsiriga, Marina Toutouza, Spyridon Dourakis, Greece

THU-009 EARLY PREDICTION FOR COMMON COMPLICATIONS OF LIVER CELL FAILURE USING FECAL CALPROTECTIN CONCENTRATION
Amr M. Gawaly, Medhat Ghazy*, Said abdou, Egypt

THU-011 MULTISPECIES PROBIOTIC MAINTAINS HEALTH RELATED QUALITY OF LIFE IN CIRRHOSIS BETTER THAN PLACEBO
Angela Horvath*, Bettina Leber, Dietmar Fuchs, Bianca Schmerboeck, Monika Tawdrous, Oezlem Yueksel, Khalida Sherzay, Astrid Hartl, Sandra Lemesch, Walter Spindelboeck, Peter Fickert, Rudolf E. Stauber, Philipp Stiegler, Franziska Durchschein, Elisabeth Krones, Philipp Douschan, Gernot Zollner, Vanessa Stadlbauer, Austria
Cirrhosis: Clinical aspects (cont.)

THU-012

INFLUENCE OF DIABETES MELLITUS IN CHRONIC RESPONSE TO B-BLOCKERS
Angela Puente*, Jose Ignacio Fortea, Patricia Ruiz, Maria Teresa Arias Loste, Joaquin Cabezas, Angel Estebanez, Emilio Fabrega, Javier Crespo, Spain

THU-013 YI

HEPATIC ENCEPHALOPATHY IS AN INDEPENDENT RISK FACTOR FOR TRANSPLANT-FREE SURVIVAL IN PATIENTS AWAITING LIVER TRANSPLANTATION
Annarein J. Kerbert, Enric Reverter, Lara Verbruggen, Madelon Tieleman, Miguel Navasa, Marleen de Vree, Herold J. Metselaar, Fang W. Chiang, Hein W. Verspaget, Bart van Hoek, Jaime Bosch, Minneke J. Coenraad*, Netherlands

THU-014 YI

BREATH PRINT ANALYSIS BY E-NOSE IS ASSOCIATED WITH ADVERSE OUTCOMES OF CIRRHOTIC PATIENTS INDEPENDENTLY FROM THE OTHER PROGNOSTIC INDICES
Antonio De Vincentis*, Umberto Vespasiani-Gentilucci, Giovanni Galati, Paolo Gallo, Giorgio Pennazza, Marco Santonico, Chiara Vernile, Raffaele Antonelli-Incalzi, Antonio Picardi, Italy

THU-015 YI

ASSESSMENT OF THE CLINICAL IMPACT OF MULTIDRUG-RESISTANT ORGANISMS IN SPONTANEOUS BACTERIAL PERITONITIS
Artur Antunes*, Pedro Costa, Cristina Teixeira, Bruno Peixe, Sofia Santos, Ana Alves, Paula Oliveira, Cristina Chagas, Horácio Guerreiro, Portugal

THU-016

CORRELATION BETWEEN THE HEPATIC VENOUS PRESSURE GRADIENT AND ALPHA-SMOOTH MUSCLE ACTIN (SMA) EXPRESSION IN PATIENTS WITH COMPENSATED CIRRHOSIS DUE TO NONALCOHOLIC STEATOHEPATITIS
THU-017 PROGNOSTICATING AFTER VARICEAL BLEED IN CRYPTOGENIC CIRRHOSIS: NON CIRRHOTIC PORTAL HYPERTENSION CAN BE A CONFOUNDER
Ashish Goel*, Banumathi Ramakrishna, Uday Zachariah, K G Sajith, George Chandy, George Kurian, C E Eapen, India

THU-018 ACUTE KIDNEY INJURY AMONG LIVER TRANSPLANT LISTED PATIENTS NEGATIVELY IMPACTS WAIT LIST MORTALITY AND PREDICTS SECOND EPISODE OF ACUTE KIDNEY INJURY
Ashwani K. Singal*, Kirk Russ, Paul Fitzmorris, Donny Kakati, Glauber Pereira, Toni Seay, Gary Cutter, United States

THU-019 CLINICAL FEATURES AND OUTCOMES ACCORDING TO THE ETIOLOGY OF CIRRHOSIS: A 20-YEAR FOLLOW-UP STUDY IN A MONOCENTRIC COHORT
Astrid Marot*, Jean Henrion, Marie de Vos, Jean-François Knebel, Christopher Doerig, Pierre Deltenre, Switzerland

THU-020 PHASE ANGLE AS AN EARLY NUTRITIONAL MARKER OF SHORT-TERM OUTCOME IN HOSPITALIZED PATIENTS WITH CIRRHOSIS
Astrid Ruiz-Margáin*, Ricardo Macias-Rodriguez, Luis Chi-Cervera, Silvia Rios-Torres, Paola Rodriguez-Cordova, Gerladine Osalde-Solis, Osvely Mendez-Guerrero, Francisco Javier Cubero, Aldo Torre, Mexico

THU-021 IS PROTEIN MALNUTRITION A NEGATIVE PROGNOSTIC FACTOR IN COMPENSATED CIRRHOTIC PATIENTS? A RETROSPECTIVE ANALYSIS ANSWERING TO THE PROPOSAL OF THE ITALIAN CONSENSUS ON PORTAL HYPERTENSION (BAVENO VI)
Barbara Lattanzi*, Cristina Lucidi, Vincenza Di Gregorio, Silvia Nardelli, Stefania Gioia, Oliviero Riggio, Manuela Merli, Italy

THU-022 HEPACONTROL: A PROGRAM THAT REDUCES EARLY HOSPITAL READMISSIONS AND MORTALITY AMONG PATIENTS WITH DECOMPENSATED CIRRHOSIS
Betty P. Morales Arrieta*, Helena Masnou, Ramon Bartoli, Rosa M. Morillas, Marga Sala, Irma Casas, Ramon Planas, Spain

THU-023 DANGEROUS LIAISON: INFECTION – ACUTE KIDNEY INJURY – MORTALITY
Andreea Pop, Petra Fischer, Horia Stefanescu, Dana Matei, Marcel Tantau, Vasile Andreica, Bogdan D. Procopet’, Romania
**Cirrhosis: Clinical aspects (cont.)**

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>THU-024</td>
<td>Natural history and management of esophagogastric varices in chronic non-cirrhotic non-tumoral portal vein thrombosis</td>
<td>Carlos Noronha Ferreira*, Susana Seijo, Aurelie Plessier, Gilberto Silva-Junior, Fanny Turon, Pierre-Emmanuel Rautou, Anna Baiges, Cristophe Bureau, Jaime Bosch, Virginia Hernández-Gea, Dominique Valla, Juan Carlos Garcia-Pagan, Spain</td>
</tr>
<tr>
<td>THU-025</td>
<td>Vitamin D metabolic chemotyping in patients with chronic liver diseases</td>
<td>Caroline S. Stokes*, Miriam Müller, Dietrich Volmer, Frank Lammert, Germany</td>
</tr>
<tr>
<td>THU-026</td>
<td>Risk factors of candidemia in cirrhotic patient hospitalized in a non transplant hepatology-oriented intensive care unit</td>
<td>Cécile Zylberfajn*, Astrid Hoogvorst, Anthony Checinski, Stephane Charpentier, Philippe Cruaud, Mathilde Lescat, Pierre Nahon, Roland Amathieu, France</td>
</tr>
<tr>
<td>THU-027</td>
<td>Exercise capacity and survival after liver transplant in cirrhotic with hepatopulmonary syndrome</td>
<td>Claudio Augusto Marroni’, José Leonardo F. Pereira, Lucas H. Galant, Luis Henrique Telles da Rosa, Eduardo Garcia, Ajácio Bandeira de Mello Brandão, Brazil</td>
</tr>
<tr>
<td>THU-028</td>
<td>Assessment of prognostic scores in acute on chronic liver failure patients admitted to critical care units: a Canadian cohort study</td>
<td>Eric Sy, Juan Ronco, Constantine Karvellas’, Canada</td>
</tr>
<tr>
<td>THU-029</td>
<td>Viral suppression is not a risk factor for CKD in viral cirrhosis (ANRS CO12 CIRVIR prospective cohort)</td>
<td>Corinne Isnard Bagnis*, Richard Layese, Gillian Divard, Patrice Cacoub, Valerie Bourcier, Lynda Corvi, Ventzislava Petro-Sanchez, Patrick Marcellin, Dominique Guyader, Stanislas Pol, Dominique Larrey, Victor De Ledingen, Denis Ouzan, Fabien Zoulim, Gilbert Deray, Françoise Roudot-Thoraval, Pierre Nahon, France</td>
</tr>
</tbody>
</table>
THU-030 PROTON PUMP INHIBITORS INTAKE AND INFECTION IN CIRRHOTIC PATIENTS: A MULTICENTRIC EXPERIENCE
Cristina Teixeira*, Artur Antunes, Claudio Martins, Ana M. Vaz, Patricia Queiros, Ana L. Alves, Bruno Peixe, Horacio Guerreiro, Ana P. Oliveira, Portugal

THU-031 PREDICTORS OF MINIMAL HEPATIC ENCEPHALOOPATHY IN PATIENTS WITH CIRRHOSIS AND PREDICTORS OF OVERT HEPATIC ENCEPHALOOPATHY IN PATIENTS WITH MINIMAL HEPATIC ENCEPHALOOPATHY
Dhaval V. GUPTA*, Kaivan shah, Dattatray SOLANKE, Megharaj INGLE, Prabha SAWANT, India

THU-032 VARIATIONS IN THE PROMOTER REGION OF THE GLUTAMINASE GENE AND THE DEVELOPMENT OF HEPATIC ENCEPHALOOPATHY IN PATIENTS WITH CIRRHOSIS
Ee ‘Teng Goh’, Michael J. Way, Stephen R. Atkinson, Andrew McQuillin, Marsha Y. Morgan, United Kingdom

THU-033 ASSOCIATION BETWEEN THE HEPATO-ADRENAL SYNDROME AND FEATURES OF CIRRHOTIC CARDIOMYOPATHY
Eleni Theocharidou*, Sotirios Anastasiadis, Themistoklis Vasiliadis, Fotini Adamidou, Athanasios Fotoglidis, Efsthathios Pagourelas, Vasilios Vassilikos, Maria Kouskoura, Aikaterini Markopoulou, Aikaterini Balaska, Aristides Slavakis, Athanasios Notopoulos, Asterios Karagiannnis, Olga Giouleme, United Kingdom

THU-034 NEW APPROACHES TO THE DIAGNOSIS AND THE SYMPTOMATIC TREATMENT OF HEPATIC ENCEPHALOOPATHY
Elina Manzhalii*, Vitalii Kondratiuk, Marina Scherbinina, Olena Baka, Ukraine

THU-035 TREATMENT WITH RIFAXIMIN HIGH DOSE PLUS LACTULOSE VS RIFAXIMIN STANDARD DOSE PLUS LACTULOSE FOR ACUTE HEPATIC ENCEPHALOOPATHY IN ED
Emanuele Crisafulli*, Shirin Demma, Giuseppe Rigano, Gaetano Bertino, Italy
<table>
<thead>
<tr>
<th>Session Code</th>
<th>Title</th>
<th>Authors</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>THU-042</td>
<td>END-OF-LIFE HEALTHCARE COSTS AND UTILIZATION AMONG PATIENTS WITH END-STAGE-LIVER-DISEASE IN ONTARIO: A POPULATION-BASED STUDY</td>
<td>Erin M. Kelly*, Sanjay Murthy, Florence Wong, Tom Shaw-Stiffel, Linda Scully, Matieu Chalifoux, Peter Tanuseputro, Paul James</td>
<td>Canada</td>
</tr>
<tr>
<td>THU-043</td>
<td>COMPARISON OF CREATININE AND CYSTATIN C BASED GLOMERULAR FILTRATION RATE FORMULAE WITH 51CHROMIUM-EDTA CLEARANCE IN PATIENTS WITH DECOMPENSATED CIRRHOSIS</td>
<td>Evangelos Cholongitas*, Ioannis Goulis, Maria Ioannidou, Stergios Soulaïdopoulos, Parthenis Chalevas, Evangelos Akriviadis</td>
<td>Greece</td>
</tr>
<tr>
<td>THU-044</td>
<td>URINE ALBUMIN-TO-CREATININE RATIO IS ASSOCIATED WITH THE SEVERITY OF LIVER DISEASE, RENAL FUNCTION AND SURVIVAL IN PATIENTS WITH DECOMPENSATED CIRRHOSIS</td>
<td>Evangelos Cholongitas*, Ioannis Goulis, Maria Ioannidou, Stergios Soulaïdopoulos, Parthenis Chalevas, Evangelos Akriviadis</td>
<td>Greece</td>
</tr>
<tr>
<td>THU-045</td>
<td>PORTAL VEIN THROMBOSIS IN PATIENTS WITH CIRRHOSIS. INCIDENCE AND FACTORS ASSOCIATED WITH ITS DEVELOPMENT</td>
<td>Fanny Turon*, Anna Baiges, Angeles Garcia-Criado, Isabel Nuñez, Rosa Gilabert, Concepción Bru, Annalisa Berzigotti, Juan Carlos Reverter, Susana Seijo, Jaume Bosch, Virginia Hernández-Gea, Juan Carlos García-Pagan</td>
<td>Spain</td>
</tr>
<tr>
<td>THU-046</td>
<td>CLINICAL TRIAL TO EVALUATE THE EFFICACY OF PRIMARY PROPHYLAXIS WITH L-ORNITHINE L-ASPARTATE TO PREVENT THE DEVELOPMENT OF OVERT HEPATIC ENCEPHALOPATHY IN PATIENTS WITH CIRRHOSIS AND ACUTE VARICEAL BLEEDING</td>
<td>Fatima Higuera-de la Tijera*, Alfredo Israel Servín-Caamaño, Francisco Salas-Gordillo, Juan Miguel Abdo-Francis, Jaime Camacho-Aguilera, José Luis Pérez-Hernández, Fiacro Jiménez-Ponce</td>
<td>Mexico</td>
</tr>
</tbody>
</table>
THU-325  INADEQUATE NUTRITION IN PATIENTS WITH CIRRHOSIS: THE NEED OF A PERSONALIZED EDUCATIONAL PROGRAM
Ferdinando A. Giannone*, Paolo Caraceni, Marco Domenicali, Maurizio Baldassarre, Paola De Pasquale, Silvia Boffelli, Maristella Laggetta, Maurizio Biselli, Mauro Bernardi, Italy

THU-326  IN-HOSPITAL MORTALITY AND ECONOMIC BURDEN OF GASTROINTESTINAL BLEEDING IN CIRRHOSIS PATIENTS
Firew Wubiee*, Charles Howell, Blen Tesfaye, Angesom Kibreab, United States

THU-327  CLINICAL OUTCOME IN HOSPITALIZED CIRRHOTIC PATIENTS WITH BACTERIAL INFECTIONS TREATED WITH EMPIRICAL OR ANTIBIOMAP-GUIDED THERAPY
Gaia Caccamo*, Sergio Maimone, Roberto Filomia, Maria S. Franzè, Simona Tomeo, Rosaria Spinella, Tindaro Lembo, Angela Alibrandi, Placido Mondello, Carlo Saitta, Irene Cacciola, Giovanni Squadrito, Giovanni Raimondo, Italy

THU-328  PROTON PUMP INHIBITORS INCREASE THE RISK FOR INFECTIONS IN CIRRHOSIS PATIENTS WITH ASCITE
Gitte Dam*, Hendrik Vilstrup, Hugh Watson, Peter Jepsen, Denmark

THU-329  EMBOLIZATION OF A SPONTANEOUS PORTOSYSTEMIC SHUNT FOR POST-TIPS REFRACORY HEPATIC ENCEPHALOPATHY
Wenbin Wu, Luanluan Zheng, Mingwu Li, Chuangye He, Wengang Guo, Zhengyu Wang, Zhanxin Yin, Jing Niu, Daiming Fan, Guohong Han*, China

THU-330  HEPATIC MYELOPATHY AFTER TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT: PREVALENCE, RISK FACTORS, AND LONG-TERM OUTCOME
Shuyao Ren, Yong Lv, Zhengyu Wang, Ming Bai, Wen Zhang, Jing Niu, Zhanxin Yin, Chuangye He, Wengang Guo, Bojing Zhang, Xiangchen Meng, Jingzhi Cai, Guohong Han*, China
Cirrhosis: Clinical aspects (cont.)

**THU-331**

**USE OF NON-SELECTIVE BETA BLOCKERS (NSBB) IN CIRRHTIC PATIENTS WITH BACTERIAL INFECTIONS IS ASSOCIATED WITH LOWER FREQUENCY OF SEPSIS, BUT NOT OF ACUTE-ON-CHRONIC LIVER FAILURE (ACLF) OR SURVIVAL. RESULTS OF A PROSPECTIVE STUDY**


**THU-332**

**LIPOCALIN-2 GENE AND ITS PROTEIN NEUTROPHIL GELATINASE-ASSOCIATED LIPOCALIN ARE BIOMARKERS OF ACUTE-ON-CHRONIC LIVER FAILURE**

Isabel Graupera*, Mar Coll, Marta Llopis, Xavier Ariza, Elsa Solà, Patricia Huelin, Cristina Solé, Elisa Pose, Cristina Millán, Rebeca Moreira, Glòria de Prada, Delia Blaya, Daniel Rodrigo, Luis Perea, Beatriz Aguilar, Pau Sancho-Bru, Pere Ginès, *Spain*

**THU-333**

**HIGH LEVELS OF MONOCYTE CHEMOTACTIC PROTEIN-1 (MCP-1) ARE ASSOCIATED WITH READMISSION RATE AND MORTALITY IN DECOMPENSATED CIRRHOSIS**

Isabel Graupera*, Elsa Solà, Rebeca Moreira, Núria Fabrellas, Cristina Solé, Patricia Huelin, Glòria de Prada, Elisa Pose, Xavier Ariza, Alessandro Risso, Sonia Albertos, Manuel Morales, Wladimiro Jiménez, Pere Ginès, *Spain*

**THU-334**

**IN-HOSPITAL MORTALITY RELATED TO HEPATIC ENCEPHALOPATHY IS INDEPENDENT OF ACUTE-ON-CHRONIC LIVER FAILURE AND VARIES SIGNIFICANTLY ACROSS NORTH AMERICA: NACSELD EXPERIENCE**

THU-335 ELDERLY CIRRHOTIC PATIENTS WITH PRE-DEMENTIA MILD COGNITIVE IMPAIRMENT AND MINIMAL HEPATIC ENCEPHALOPATHY HAVE A DISTINCT COGNITIVE AND BRAIN MR PROFILE
Vishwadeep Ahluwahlia, James Wade, Frederick Moeller, Joel Steinberg, Melanie White, Ariel Unser, Andrew Fagan, Dinesh Ganapathy, Richard Sterling, R Todd Stravitz, Scott Matherly, Velimir Luketic, Arun Sanyal, Muhammad Siddiqui, Puneet Puri, Michael Fuchs, Douglas Heuman, Jasmohan S S. Bajaj*, United States

THU-336 COST EFFECTIVENESS OF COVERED TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT VERSUS ENDOSCOPIC TREATMENT FOR SECONDARY PREVENTION OF GASTRO-OESOPHAGEAL VARICEAL BLEEDING
Jihan Harki*, I. Lisanne Holster, Suzanne Polinder, Adriaan Moelker, Henk R. van Buuren, Ernst J. Kuipers, Eric T. T. L. Tjwa, Netherlands

THU-337 LACTULOSE TREATMENT MODULATES GUT MICROBIOME IN MINIMAL HEPATIC ENCEPHALOPATHY PATIENTS: RESULTS FROM A MULTI-CENTER, CONTROLLED TRIAL
Ji-Yao WANG*, Jiang-Bin WANG, Jia SHANG, Xin-Min ZHOU, Xiao-Lin GUO, Xuan ZHU, Li-Na MENG, Hai-Xing JIANG, Yu-Qiang MI, Jian-Ming XU, China

THU-338 SALIVARY CORTISOL DETERMINATION AFTER ACTH STIMULATION TEST FOR DIAGNOSIS OF ADRENAL INSUFFICIENCY IN PATIENTS WITH LIVER CIRRHOSIS
Joaquim Profitós*, Lara Albert, Olga Giménez-Palop, Mercedes Vergara, Blai Dalmau, Mireia Miquel, Meritxell Casas, Ismael Capel, David Subias, Mercedes Rigla, Eugenio Berlanga, Jordi Sánchez, Spain

THU-339 HEPATIQ MEASURE OF HEPATIC FUNCTION: RANGE IN FUNCTION FOR ASCITES AND DEATH IN PATIENTS WITH CHRONIC LIVER DISEASE
John C. Hoefs*, United States

THU-340 PORTAL HYPERTENSIVE ENTEROPATHY IS NOT RELATED TO PORTAL HYPERTENSION SEVERITY IN PATIENTS WITH CIRRHOSIS
Judith Gomez*, Pedro Menchen, Oscar Nogales, Alain Huerta, Diego Rincon, Marta Puerto, Luis Ibañez, Cecilia Gonzalez-Asanza, Rafael Bañares, Spain
<table>
<thead>
<tr>
<th>Poster Number</th>
<th>Title</th>
<th>Authors</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>THU-341</td>
<td>NON-TUMORAL PORTAL VEIN THROMBOSIS AND END-STAGE LIVER DISEASE IN PATIENTS WITH CIRRHOSIS: A LONGITUDINAL RETROSPECTIVE COHORT</td>
<td>Julia Roux*, Philippe Sultanik, Samir Bouam, Anaïs Vallet-Pichard, Hélène Fontaine, Marion Corouge, Vincent Mallet, Stanislas Pol, Philippe Sogni</td>
<td>France</td>
</tr>
<tr>
<td>THU-342</td>
<td>IMPACT OF DEPRESSION AND HEPATIC ENCEPHALOPATHY ON HEALTH-RELATED QUALITY OF LIFE IN CIRRHOTIC HEPATITIS C PATIENTS</td>
<td>Katherine Barboza*, Lilian Salinas, Farhad Sahebjam, Arun Jesudian, Ilan Weisberg, Samuel Sigal</td>
<td>United States</td>
</tr>
<tr>
<td>THU-343</td>
<td>A GLOBAL SURVEY IF AND WHEN TO STOP BETA-BLOCKERS IN END STAGE LIVER DISEASE</td>
<td>Katrine Holtz Thorhauge*, Katrine Prier Lindvig, Wim Laleman, Paolo Angeli, Shivaram P. Singh, Aleksander Krag</td>
<td>Denmark</td>
</tr>
<tr>
<td>THU-344</td>
<td>TOLVAPTAN AND RENAL RESISTANCE INDEX IN CIRRHOTIC PATIENTS WITH REFRACTORY ASCITES: A PRELIMINARY STUDY</td>
<td>Kazuhisa Nakashima*, Yasuji Komorizono, Katsumi Sako, Toshihiko shibatou</td>
<td>Japan</td>
</tr>
<tr>
<td>THU-345</td>
<td>PATIENTS WITH LIVER CIRRHOSIS HAVE SIMILAR PREVALENCE, BUT HIGHER BURDEN OF CORONARY ARTERY DISEASE COMPARED TO PATIENTS EVALUATED FOR ANGINA PECTORIS</td>
<td>Konstantin Kazankov, Kim Munk, Kristian A. Øvrehus, Jesper M. Jensen, Cecilie B. Siggaard*, Bjarne L. Nørgaard, Henning Grønbæk, Hendrik Vilstrup</td>
<td>Denmark</td>
</tr>
<tr>
<td>THU-346</td>
<td>HOW TO USE CROSS-SECTIONAL IMAGING TO ASSESS PROGNOSIS IN END-STAGE CIRRHOSIS WITH THE USE OF ELAAR (THE ENHANCED LIVERPOOL ABDOMINAL AREA RATIO) AND SOFTWARE ASSISTED LIVER VOLUME</td>
<td>Laura C. Smith*, Syed Alam, Catriona Farrell, Mirashini Swaminathan, Vijay Chidambaram, Tim Cross</td>
<td>United Kingdom</td>
</tr>
</tbody>
</table>
THU-347
PROGRESSIVE ALTERATIONS IN SYSTEMIC AND CARDIOPULMONARY HEMODYNAMICS OCCUR IN PATIENTS WITH CIRRHOSIS AND PREDICT DEATH IN DECOMPENSATED CIRRHOSIS
Laura Turco*, Guadalupe Garcia-Tsao, Ilenia Magnani, Marcello Bianchini, Martina Costetti, Rosario Rossi, Erica Villa, Filippo Schepis, Italy

THU-348
PROSPECTIVE ANALYSIS OF EARLY HOSPITAL READMISSIONS IN PATIENTS WITH DECOMPENSATED CIRRHOSIS AND ITS IMPACT ON MORTALITY
Lissa Franco*, José Ferrusquia, Sonia Antón, Adriana Ríos, Carmen A. Navascués, Juan de la Vega, Luisa Gonzalez-Diegez, Maria Varela, Valle Cadahía, Manuel Rodríguez, Spain

THU-349
HBV ASSOCIATED CIRRHOTIC PATIENTS MEETING APASL ACUTE-ON-CHRONIC LIVER FAILURE CRITERIA HAVE HETEROGENEOUS OUTCOME AND SHORT TERM SURVIVAL RATE
Hai Li*, Liu-Ying Chen, Qing Xie, Nan-Nan Zhang, Shan Yin, Shi-Jin Wang, China

THU-350
IMPACT OF INFECTIONS ON WAITING LIST SURVIVAL IN PATIENTS WITH END STAGE LIVER DISEASE
Loes Alferink*, Herold Metselaar, Carolina Schurink, Bettina Hansen, Netherlands

THU-351
A MORE INTENSIVE REGIMEN OF ALBUMIN DIALYSIS IMPROVES SURVIVAL IN PATIENTS WITH ACUTE ON CHRONIC LIVER FAILURE. RESULTS FROM AN INDIVIDUAL-PATIENT DATA META-ANALYSIS
Luis Ibáñez Samaniego*, Carmen Olmedo, Marco Pavesi, Josep Torner, Maria-Vega Catalina, Tarek Hassanein, Uwe Heemann, Frederik Nevens, Fin Larsen, Rajiv Jalan, Agustin Albillos, Harmut Schmidt, Richard Moreau, Vicente Arroyo, Rafael Bañares, Spain
**Cirrhosis: Clinical aspects (cont.)**

<table>
<thead>
<tr>
<th>Code</th>
<th>Title</th>
<th>Authors</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>THU-353</td>
<td>PLATELET COUNT AND LIVER STIFFNESS MEASUREMENT TO EXCLUDE HIGH-RISK GASTROESOPHAGEAL VARICES IN PATIENTS WITH HCV-CIRRHOSIS. A MULTICENTRIC STUDY</td>
<td>Marc Puigvehí*, María-Carlota Londoño, Rosa M. Morillas, Mireia Miquel, Adolfo Gallego, Sabela Lens, Zoe Mariño, Mercedes Vergara, Sara Lorente, Xavier Torras, Ramon Planas, Ricard Solà, Jose A. Carrión</td>
<td>Spain</td>
</tr>
<tr>
<td>THU-354</td>
<td>PREDICTIVE MODEL FOR IN-HOSPITAL MORTALITY FOR HEPATIC ENCEPHALOPATHY</td>
<td>Marco Silva*, Andreia Albuquerque, Armando Peixoto, Susana Rodrigues, Hélder Cardoso, Guilherme Macedo</td>
<td>Portugal</td>
</tr>
<tr>
<td>THU-355</td>
<td>DYNAMIC CONTRAST ENHANCED ULTRASOUND PERFUSION IMAGING AND CLINICALLY SIGNIFICANT PORTAL HYPERTENSION IN PATIENTS WITH LIVER CIRRHOSIS: A FEASIBILITY STUDY</td>
<td>Maria Elena Ainora*, M Garcovich, B E Annicchiarico, M Siciliano, L Riccardi, M Pompili, G L Rapaccini, A Gasbarrini, M A Zocco</td>
<td>Italy</td>
</tr>
<tr>
<td>THU-356</td>
<td>SERUM LEVELS OF LECTIN COMPLEMENT PATHWAY MOLECULES DO NOT PREDOMINANTLY DETERMINE THE RISK OF BACTERIAL INFECTIONS IN PATIENTS WITH CIRRHOSIS</td>
<td>Ildiko Foldi, David Tornai, Tamas Tornai, Zsuzsannanna Vitalis, Istvan Tornai, Tamas Dinya, Peter Antal-Szalmas, Maria Papp*</td>
<td>Hungary</td>
</tr>
</tbody>
</table>
THU-357 TRANSJUGULAR INTRA HEPATIC PORTO SYSTEMIC SHUNT PLACEMENT INDUCES MODIFICATIONS OF CEREBRAL MULTIMODAL MRI IN CIRRHOTIC PATIENTS, EVEN IN THE ABSENCE OF DEVELOPMENT OF HEPATIC ENCEPHALOPATHY
Marika Rudler*, Nicolas Weiss, Vincent Perlarg, Maxime Mallet, Simona Tripon, Romain Valabregue, Damien Galanaud, Dominique Thabut, France

THU-358 VENTILATORY THRESHOLD PREDICTS EPISODES OF SEPSIS IN END-_STAGE LIVER DISEASE PATIENTS AWAITING LIVER TRANSPLANTATION
Matthew P. Wallen*, Adrian Hall, Tina Skinner, Aidan Woodward, Jeff Coombes, Graeme Macdonald, Australia

THU-359 ELEVATED CARDIAC TROPONIN T LEVELS ARE COMMON AND ARE ASSOCIATED WITH MORTALITY IN CIRRHOTIC PATIENTS ADMITTED TO AN EMERGENCY DEPARTMENT
Mayada Elnegouly*, Wajima Safi, Andreas Umgelter, Germany

THU-360 QUALITY OF LIFE ASSESSMENT CAN BE USED TO DIAGNOSE COVERT HEPATIC ENCEPHALOPATHY
Mette Munk Lauridsen*, Hendrik Vilstrup, Ove B Schaffalitzky de Muckadell, Douglas M Heuman, Jasmohan S Bajaj, Denmark

THU-361 MULTI-PARAMETRIC MAGNETIC RESONANCE IMAGING OF THE SPLEEN: AN ACCURATE AND NON-INVASIVE BIOMARKER OF PORTAL PRESSURE
Michael Pavlides*, Christina Levick, Jane Phillips-Hughes, Jane Collier, Rajarshi Banerjee, Lai Mun Wang, Jeremy Cobbold, Matthew Robson, Stefan Neubauer, Eleanor Barnes, United Kingdom

THU-362 RAPID IMPROVEMENT IN LIVER AND SPLEEN STIFFNESS DURING TREATMENT WITH NEW ORAL ANTIVIRAL THERAPY FOR HCV
Monica Pons Delgado*, Begoña Santos García de Vicuña, Macarena Simón-Talero, Meritxell Ventura Cots, Salvador Augustín Recio, Joan Genescà Ferrer, Spain

THU-363 ACUTE-ON CHRONIC LIVER FAILURE: THE RELATIONSHIP WITH UNDERLYING LIVER DISEASE SEVERITY AND PORTAL HYPERTENSION
Moon Young Kim*, Yoo Li Lim, Soon Koo Baik, Yoon Ok Jang, Korea, South
### Cirrhosis: Clinical aspects (cont.)

<table>
<thead>
<tr>
<th>Poster No.</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>THU-364</td>
<td>Outcomes of Endoscopic Retrograde Cholangiopancreatography in Patients with Cirrhosis</td>
<td>Muzzaffar Gill*, Pakistan</td>
</tr>
<tr>
<td>THU-365</td>
<td>Does the Use of Non-Selective Beta-Blockers in Cirrhosis Patients with Ascites Result in Increased Mortality?</td>
<td>Nethmee Mallawaarachchi*, Rohit Sinha, Peter Hayes, United Kingdom</td>
</tr>
<tr>
<td>THU-366</td>
<td>Brain Water Content is Dependent on Plasmatic Ammonemia Levels in Hyperammoniemic Encephalopathy, A Quantitative CT-Scan Study</td>
<td>Nicolas Weiss*, Marika Rudler, Maxime Mallet, Simona Tripion, Sarah Mouri, Damien Galanaud, Fanny Mochel, Louis Puybasset, Dominique Thabut, France</td>
</tr>
<tr>
<td>THU-367</td>
<td>Incidence, Prevalence and Natural History of Minimal Hepatic Encephalopathy in Cirrhosis</td>
<td>Omesh Goyal*, Sandeep Sidhu, Harsh Kishore, India</td>
</tr>
<tr>
<td>THU-368</td>
<td>TLR-10 Single Nucleotide Polymorphism is Associated to Poor Short Term Survival in Cirrhotic Patients with Acute on Chronic Liver Failure Precipitated by Bacterial Infections</td>
<td>Paolo Caraceni*, Marco Domenicali, Maurizio Baldassarre, Ferdinando A. Giannone, Elena Marasco, Marco Pavesi, Vilma Mantovani, Paolo Angeli, Alexander Gerbes, Richard Moreau, Rajiv Jalan, Pere Gines, Vincente Arroyo, Mauro Bernardi, Italy</td>
</tr>
<tr>
<td>Poster</td>
<td>Title</td>
<td>Authors</td>
</tr>
<tr>
<td>--------</td>
<td>----------------------------------------------------------------------</td>
<td>------------------------------------------------------------------------</td>
</tr>
<tr>
<td>THU-370</td>
<td>RELATIONSHIP BETWEEN ALCOHOL USE DISORDERS AND RESPONSE TO ANTIVIRAL TREATMENT ON THE PROGNOSIS OF CIRRHOTIC PATIENTS WITH CHRONIC HEPATITIS C</td>
<td>Philippe Sultanik*, Laura Kramer, Samir Bouam, Anaïs Vallet-Pichard, Hélène Fontaine, Marion Corouge, Véronique Thepot, Béatrice Laveille, Philippe Sogni, Stanislas Pol, Vincent Mallet</td>
</tr>
<tr>
<td>THU-371</td>
<td>THE GOLDEN 24 HOURS: CHECKLIST BUNDLE IMPROVES QUALITY OF ACUTE CARE FOR PATIENTS WITH DECOMPENSATED CIRRHOSIS AND REDUCES 30-DAY MORTALITY</td>
<td>Prarthana Thiagarajan*, Charlotte Peal, David Gunn, Martin James</td>
</tr>
<tr>
<td>THU-372</td>
<td>A POTENTIAL ROLE OF SEX HORMONES IN THE PROGRESSION OF END STAGE LIVER DISEASE</td>
<td>Prowpanga Udompap*, Ajitha Mannalithara, Donghee Kim, W. Ray Kim</td>
</tr>
<tr>
<td>THU-374</td>
<td>A RAPID BEDSIDE SCREEN TO PREDICT UNPLANNED HOSPITALIZATION AND DEATH IN OUTPATIENTS WITH CIRRHOSIS: A PROSPECTIVE STUDY OF THE CLINICAL FRAILTY SCALE</td>
<td>Puneeta Tandon*, Navdeep Tangri, Lesley Thomas, Laura Zenith, Tahira Shaikh, Michelle Carbonneau, Mang Ma, Saumya Jayakumar, Kelly Burak, Amanda Brisebois, Juan G Abraldes, Thomas Ferguson, Sumit R Majumdar</td>
</tr>
<tr>
<td>THU-375</td>
<td>EXCLUSION OF VARICES VIA TRANSIENT ELASTOGRAPHY COMBINED WITH PLATELET COUNT ACCORDING TO THE BAVENO VI GUIDELINES CAN ONLY BE MADE FOR LARGE NOT SMALL VARICES</td>
<td>Rafael Paternostro’, Remy Schwarzer, Monika Ferlitsch, Philipp Schwabl, Thomas Reiberger, Mattias Mandorfer, Markus Peck-Radosavljevic, Michael Trauner, Arnulf Ferlitsch</td>
</tr>
<tr>
<td>Poster</td>
<td>Title</td>
<td>Presenters</td>
</tr>
<tr>
<td>--------</td>
<td>----------------------------------------------------------------------</td>
<td>---------------------------------------------------------------------------</td>
</tr>
<tr>
<td>THU-376</td>
<td>THE IMPACT OF RIFAXIMIN-ALPHA ON NHS HOSPITAL RESOURCE USE IN UK PATIENTS WITH HEPATIC ENCEPHALOPATHY: A RETROSPECTIVE OBSERVATIONAL STUDY (IMPRESS)</td>
<td>Richard Aspinall*, Amr Radwan, Gabriel Shaya, Hanna Sodatonou, Riccardo Cipelli, Mark Hudson, <em>United Kingdom</em></td>
</tr>
<tr>
<td>THU-378</td>
<td>A COMPARISON OF MELD, MELD-NA, MESO INDEX AND IMELD FOR EVALUATING THE PROGNOSIS OF CIRRHOSIS</td>
<td>Ruchir Patel*, Jatin Patel, Meghraj Ingle, Prabha Sawant, <em>India</em></td>
</tr>
<tr>
<td>THU-379</td>
<td>THE ALBICC MODEL: A NEW PROGNOSTIC TOOL FOR PREDICTION OF SHORT-TERM SURVIVAL IN PATIENTS WITH END-STAGE LIVER DISEASE</td>
<td>Rudolf E. Stauber*, Josef Haas, Doris Wagner, Daniela Kniepeiss, Vanessa Stadlbauer, Arnulf Ferlitsch, Valentin Fuhrmann, <em>Austria</em></td>
</tr>
<tr>
<td>THU-380</td>
<td>HANDGRIIP STRENGTH IN PATIENTS WITH CHRONIC LIVER DISEASE CORRELATES WITH INVASIVE ASSESSMENT OF MUSCULAR FUNCTION AND SURVIVAL</td>
<td>Sarah E. Brown*, Ziva Mrevlje, Natasha Vidas, Pauline A. Kane, Nigel Heaton, Michael Heneghan, William Bernal, <em>United Kingdom</em></td>
</tr>
<tr>
<td>THU-381</td>
<td>RELATION OF CT DETERMINED SARCOPENIA TO STEROID HORMONE LEVELS IN PATIENTS WITH CHRONIC LIVER DISEASE</td>
<td>Sarah E. Brown*, Lea Ghataore, Pauline A. Kane, Nigel Heaton, Michael A. Heneghan, Royce Vincent, William Bernal, <em>United Kingdom</em></td>
</tr>
<tr>
<td>THU-382</td>
<td>LECITHIN-CHOLESTEROL ACYLTRANSFERASE ACTIVITY AND APOLIPOPROTEIN A1 LEVELS PREDICT PROGRESSION TO ORGAN FAILURE IN ACLF PATIENTS AND 3 MONTH MORTALITY FOLLOWING ACUTE CIRRHOSIS DECOMPENSATION</td>
<td>Satinder Samra*, Karen Louise Thomsen, Ayrles F Brandao DaSilva, Rohit Sawhney, Helen Jones, Jim Owen, Rajeshwar P Mookerjee, <em>United Kingdom</em></td>
</tr>
</tbody>
</table>
THU-387

YI

SPONTANEOUS BACTEREMIA IN PATIENTS WITH CIRRHOSIS: CHARACTERISTICS AND OUTCOMES
Sebastian Marciano*, Carla Bermudez, Natalia Sobenko, Leila Haddad, Federico Genre Bert, Laura Barcán, Astrid Smud, Maria Lourdes Posadas-Martinez, Diego Giunta, Adrián Gadano, Argentina

THU-388

YI

EVALUATION OF PREVALENCE OF ERECTILE DYSFUNCTION AND ASSOCIATED RISK FACTORS IN PATIENTS WITH LIVER CIRRHOSIS
Sergio Maimone*, Giovanni Oliva, Antonino Di Benedetto, Roberto Filomia, Gaia Caccamo, Carlo Saitta, Irene Cacciola, Giovanni Squadrito, Giovanni Raimondo, Italy

THU-389

YI

HEPATIC ENCEPHALOPATHY IS ASSOCIATED WITH PERSISTENT LEARNING IMPAIRMENTS DESPITE ADEQUATE MEDICAL TREATMENT: A MULTI-CENTER, INTERNATIONAL STUDY
Silvia Nardelli*, Sanath Allampati, Oliviero Riggio, Kevin Mullen, Ravi Prakash, Stefania Gioia, Ariel Unser, Melanie White, Andrew Fagan, James Wade, Alessio Farcomeni, Edith Gavis, Jasmohan Bajaj, Italy

THU-390

YI

Top 10%

COGNITIVE IMPAIRMENT PREDICTS THE OCCURRENCE OF HEPATIC ENCEPHALOPATHY AFTER TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT
Silvia Nardelli*, Stefania Gioia, Chiara Pasquale, Ilaria Pentassuglio, Alessio Farcomeni, Manuela Merli, Leandra Nikolli, Valeria Nicoletti, Sabrina Torrisi, Francesca Greco, Oliviero Riggio, Italy

THU-391

YI

LIVER STIFFNESS ASSESSED BY TRANSIENT ELASTOGRAPHY CAN NOT PREDICT THE HEMODYNAMIC RESPONSE TO NON-SELECTIVE BETABLOCKERS
Simona Bota*, Mattias Mandorfer, Philipp Schwabl, Thomas Reiberger, Michael Trauner, Arnulf Feiltsch, Markus Peck-Radosavljevic, Austria
## Cirrhosis: Clinical aspects (cont.)

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>THU-392</td>
<td>SODIUM PHENYLBUTYRATE ADMINISTRATION TO AVOID NEUROLOGICAL WORSENING IN CIRRHOTIC PATIENTS WITH HEPATIC ENCEPHALOPATHY ADMITTED IN ICU</td>
<td>Simona Tripon*, Maxime Mallet, Marion Lodey, Elsa Guiller, Marika Rudler, Sarah Mouri, Nicolas Weiss, Dominique Thabut, France</td>
</tr>
<tr>
<td>THU-393</td>
<td>ROTATIONAL THROMBOELASTOMETRY AND CHILD CAN PREDICT 3-MONTH MORTALITY IN LIVER CIRRHOSIS</td>
<td>Sotiria Bedreli*, Jan-Peter Sowa, Sandra Blomeyer, Saraa Malek, Guntje Kneiseler, Lars Bechmann, Andreas Paul, Guido Gerken, Dominik Heider, Fuat Saner, Ali Canbay, Germany</td>
</tr>
<tr>
<td>THU-394</td>
<td>PREDICTIVE POWER OF CLINICAL STIGMATA IN DETECTING ADVANCED LIVER DISEASE</td>
<td>Stephen D. Bloom*, William Kemp, Anouk Dev, Amanda Nicoll, Stuart Roberts, Sally Bell, Ian Kronborg, Virginia Knight, Siddharth Sood, John Lubel, Australia</td>
</tr>
<tr>
<td>THU-395</td>
<td>EFFICACY OF NUTRITIONAL THERAPY ON COMPLICATIONS AND OUTCOME IN PATIENTS WITH CIRRHOSIS AND MINIMAL HEPATIC ENCEPHALOPATHY IN A RANDOMIZED TRIAL</td>
<td>Sudhir Maharshi*, Barjesh Chander Sharma, Siddharth Srivastava, Jatinder Pal Singh, India</td>
</tr>
<tr>
<td>THU-396</td>
<td>PREVALENCE AND CORRELATION OF DIABETES WITH SEVERITY OF CHRONIC LIVER DISEASE AND UTILITY OF HBA1C IN THESE PATIENTS AS COMPARED WITH ORAL GLUCOSE TOLERANCE TEST</td>
<td>Tejasav Sehrawat*, Paaras Kohli, Amit Thour, Ramaninder Nagra, Anurag Jindal, Jasbinder Kaur, Atul Sachdev, Yashdeep Gupta, India</td>
</tr>
<tr>
<td>THU-397</td>
<td>LIVER CIRRHOSIS IS CHARACTERIZED BY AN ACQUIRED LYSOSOMAL ACID LIPASE DEFICIENCY INDEPENDENT FROM THE ETIOLOGY OF LIVER DISEASE</td>
<td>Umberto Vespasiani-Gentilucci*, Paolo Gallo, Aldostefano Porcari, Ferruccio Vorini, Livia Piccioni, Giovanni Galati, Antonio De Vincentis, Chiara Dell’Unto, Fiorella Piemonte, Giulia Tozzi, Elisabetta Riva, Antonio Picardi, Italy</td>
</tr>
</tbody>
</table>
THU-398  EFFECTIVENESS OF BETA-BLOCKERS IN PRIMARY PREVENTION OF BLEEDING: A COMPARISON OF PROPRANOL VS. CARVEDILOL BY HVPG
Vincenza Calvaruso*, Ambra Bonaccorso, Fabio Simone, Giuseppe Butera, Vito Di Marco, Antonio Craxi, Piero L. Almasio, Italy

THU-399  INCREASED PLASMA LEVELS OF VON WILLEBRAND FACTOR AND FACTOR VIII (FVIII) DURING ACUTE BACTERIAL INFECTION DRIVE A PRO-HEMOSTATIC IMBALANCE AND HERALD SEVERE OUTCOME IN CIRRHOSIS
Vincenzo La Mura*, Armando Tripodi, Giulia Tosetti, Veena Chantarangkul, Luciano Baronciani, Flora Peyvandi, Massimo Iavarone, Angelo Sangiovanni, Massimo Primignani, Massimo Colombo, Italy

THU-400  CRITICAL ROLE OF HEPATOCYTE DEATH IN THE PATHOPHYSIOLOGY OF ACUTE ON CHRONIC LIVER FAILURE: ASSOCIATION BETWEEN THE EXTENT OF HEPATOCYTE DEATH AND TYPES OF PRECIPITATING EVENT
Zhujun Cao*, Yun Wang, Liwen Chen, Xiaogang Xiang, Yuhan Liu, Jie Lu, Lanyi Lin, Qing Xie, Hui Wang, China
Clinical trials in progress

THU-480 YI
MULTICENTRIC PROSPECTIVE STUDY OF VALIDATION OF ANGIOGENESIS POLYMORPHISMS IN HCC PATIENTS TREATED WITH SORAFENIB. INNOVATE STUDY
Andrea Casadei Gardini*, Luca Faloppi, Bruno Daniele, Giuseppe Francesco Foschi, Stefano Casinu, Giorgia Marisi, Gianluca Masi, Luchino Chessa, Francesca Negri, Emanuela Scarpi, Daniele Santini, Jody Corbelli, Nicola Silvestris, Emiliano Tamburini, Vittorina Zagonel, Mario Scartozzi, Italy

THU-481
PROGNOSIS OF ACUTE LIVER FAILURE PATIENTS DUE TO DIFFERENT ETIOLOGY TREATED WITH ARTIFICIAL LIVER
Dewi Andayani*, Lanjuan Li, China

THU-482
ENDURANCE-3: A PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY TO COMPARE EFFICACY AND SAFETY OF ABT-493/ABT-530 TO SOFOSBUVIR CO-ADMINISTERED WITH DACLATASVIR IN ADULTS WITH HCV GENOTYPE 3 INFECTION
Graham Foster*, Edward Gane, Armen Asatryan, Stanislas Pol, Fred Poordad, John Vierling, Jens Kort, Chih-Wei Lin, Sandra S. Lovell, Teresa I. Ng, Federico Mensa, United Kingdom

THU-483
PHARMACOKINETICS OF THE ANTIFIBROTIC DRUG PIRFENIDONE IN CHILD PUGH A AND B CIRRHOTIC PATIENTS COMPARED TO HEALTHY AGE-MATCHED CONTROLS
Jorge L. Poo*, Raúl Bernal, Juan R. Aguilar, Rosalba Alonso, Ramiro Balderas, Everardo Piñeyro, Magda Gómez, Jarod Escobar, Claudia Mora, Nadiel Hernandez, Rogelio Magaña, Pedro Peña, Mexico

THU-484
PROSPECTIVE STUDY TO ASSESS LONG-TERM OUTCOMES OF TREATMENT WITH TRIENTINE IN WILSON DISEASE PATIENTS WITHDRAWN FROM THERAPY WITH D-PENICILLAMINE
Karl Heinz Weiss*, Jan Pfeiffenberger, Wolfgang Stremmel, Ray Estall, Daniel N. Gotthardt, Germany
THU-485 RETROSPECTIVE STUDY TO ASSESS LONG-TERM OUTCOMES OF CHELATOR-BASED TREATMENT WITH TRIENTINE IN WILSON DISEASE PATIENTS WITHDRAWN FROM THERAPY WITH D-PENICILLAMINE
Karl-Heinz Weiss*, Agustin Albillos, Radan Bruha, Luigi Demelia, Anil Dhawan, William Griffiths, Gideon Hirschfield, Roderick Houwen, Nina Manolaki, Aurelia Poujois, Carmen Ribes, Giacomo C. Sturniolo, Massimo Zuin, Sabrina Chowdhury, Peter Ferenci, United Kingdom

THU-486 PRO-EURO-DILI REGISTRY: A COLLABORATIVE EFFORT TO ENHANCE THE UNDERSTANDING OF DILI

THU-487 A MULTICENTER, RANDOMIZED, OPEN LABEL, SINGLE- AND MULTIPLE-DOSE, DOSE FINDING STUDY AND OPEN-LABEL EXTENSION TO ASSESS THE EFFECTS OF OBETICHOLIC ACID IN PEDIATRIC PATIENTS WITH BILIARY ATRESIA
Saul Karpen*, Lise Eliot, Barbara Scholz, Maria M. Joshi, Michelle M. Merrigan, Cathi Sciacca, Tonya Marmon, Roya Hooshmand-Rad, Leigh MacConell, David Shapiro, United States

THU-488 REGENERATE: A PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED MULTICENTER STUDY OF OBETICHOLIC ACID THERAPY FOR NONALCOHOLIC STEATOHEPATITIS
Vlad Ratziu*, Arun J. Sanyal, Leigh MacConell, Reshma Shringarpure, Tonya Marmon, David Shapiro, Zobair M. Younossi, France

THU-489 A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PARITAPREVIR/RITONAVIR/OMBITASVIR AND DASABUVIR IN NON-CIRRHOTIC ADULT ASIANS WITH HCV GENOTYPE 1B
Jeong Heo, Lai Wei, Yan Luo*, Wan-Long Chuang, Linda Fredrick, Katia Alves, Rebecca Redman, Andrew Campbell, Niloufar Mobashery, United States
### Genetic and paediatric liver diseases

<table>
<thead>
<tr>
<th>Poster ID</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>THU-429</td>
<td><strong>LIVER TRANSPLANTATION FOR CHILDREN WITH ACUTE LIVER FAILURE ASSOCIATED WITH SECONDARY HAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS</strong></td>
<td>Achiya Amir*, Simon Ling, Ahmed Naqvi, Sheila Weitzman, Annie Fecteau, David Grant, Anand Ghanekar, Mark Cattral, Nadya Nalli, Binita Kamath, Nicola Jones, Maria DeAngelis, Vicky Ng, Yaron Avitzur, <em>Israel</em></td>
</tr>
<tr>
<td>THU-430</td>
<td><strong>DIAGNOSTIC ALGORITHM FOR HIGH LIVER IRON OVERLOAD: RESULTS FROM A PROSPECTIVE STUDY OF 312 PATIENTS WITH HYPERFERRITINEMIA</strong></td>
<td>Eva Zapata*, Agustin Castiella, Iratxe Urreta, Jose M. Alústiza, Emma Salvador, Pedro Otazua, Maria D. De Juan, Garazi Letamendi, Beatriz Arrizabalaga, Leire Zubiaurre, Usua Mendarte, Maria L. Rincon, Jose I. Empananza, <em>Spain</em></td>
</tr>
<tr>
<td>THU-431</td>
<td><strong>SUCCESSFUL TREATMENT WITH 4-PHENYLBUTYRATE WITH RIFAMPICINE REFRACTORY BENIGN RECURRENT INTRAHEPATIC CHOLESTASIS TYPE 1: FIRST REPORT OF 2 CASES</strong></td>
<td>Akin Inderson*, Bart van Hoek, <em>Netherlands</em></td>
</tr>
<tr>
<td>THU-432</td>
<td><strong>THERAPEUTIC EFFICACY OF TRIENTINE NANOPARTICLES IN WISTAR RAT MODEL OF COPPER TOXICOSIS</strong></td>
<td>Amit Pal*, Rajendra prasad, Babu R. thapa, Rakesh K. vasishta, <em>India</em></td>
</tr>
<tr>
<td>THU-433</td>
<td><strong>INHIBITION OF THE CA2+-INHIBITED ADENYLYL CYCLASE 5 REDUCES CYST GROWTH IN MICE WITH POLYCYSTIC LIVER DISEASE (ADPKD) CAUSED BY DEFECTIVE POLYCYSTIN-2</strong></td>
<td>Carlo Spirli*, Valeria Mariotti, Ambra Villani, Luca Fabris, Romina Fiorotto, Mario Strazzabosco, <em>United States</em></td>
</tr>
<tr>
<td>THU-434</td>
<td><strong>IN VITRO STUDY OF NOVEL COMPOUNDS TO TREAT FAMILIAL AMYLOID POLYNEUROPATHY BY USING PLURIPOTENT STEM CELLS</strong></td>
<td>Christoph Niemietz*, Vanessa Sauer, Gursimran Chandhok, Sarah Guttmann, Andree Zibert, Hartmut Schmidt, <em>Germany</em></td>
</tr>
</tbody>
</table>
THU-435
LIVER TRANSPLANTATION IN HUNGARIAN WILSON’S DISEASE PATIENTS, 1998-2015

THU-436
ACCUMULATION OF HEPATITIS B SURFACE ANTIGEN PROMOTES THE DEVELOPMENT OF ALPHA-1 ANTITRYPSIN MUTATION-RELATED LIVER DISEASE
Deniz Kuscuoglu*, Gökce Kobazi Ensari, Kanishka Hittatiya, Hans-Peter Fischer, Christian Trautwein, Pavel Strnad, Germany

THU-437
BENEFIT OF SEBELIPASE ALFA IN CHILDREN AND ADULTS WITH LYSOSOMAL ACID LIPASE DEFICIENCY BASED ON ANALYSIS OF EFFICACY BY BASELINE ALANINE AMINOTRANSFERASE LEVEL
Florian Abel*, Jean-Baptiste Arnoux, Maria Kostyleva, Anna Tylki-Szyma ska, Mark Friedman, Alejandra Consuelo, Radhika Tripuraneni, Germany

THU-438
URSODEOXYCHOLIC ACID IN ADVANCED POLYCYSTIC LIVER DISEASE: A MULTICENTER RANDOMIZED CONTROLLED PHASE 2 TRIAL (CURSOR)
Hedwig M. A. D’Agnolo*, Wietske Kievit, Bart Takkenberg, Ioana Riano, Luis Bujanda, Myrte Neijenhuis, Ellen Brunenberg, Ulrich Beuers, Jesus Banales, Joost Drenth, Netherlands

THU-439
POLYCYSTIC LIVER DISEASE PATIENTS WITH UNDERLYING DIAGNOSIS OF POLYCYSTIC KIDNEY DISEASE ARE MORE LIKELY TO UNDERGO LIVER TRANSPLANTATION THAN PATIENTS WITH ISOLATED POLYCYSTIC LIVER DISEASE
Hedwig M. A. D’Agnolo*, Wietske Kievit, Kim van Munster, Jouke van der Laan, Frederik Nevens, Joost Drenth, Netherlands

THU-440
VALIDITY OF NON-INVASIVE FIBROSIS SCORES IN A LARGE COHORT OF PAEDIATRIC NAFLD
Jake P. Mann*, Matthew J. Armstrong, Antonella Mosca, Anna Alisi, Massimiliano Raponi, Ulrich Baumann, Valerio Nobili, United Kingdom
### Genetic and paediatric liver diseases (Cont.)

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>THU-441 YI</td>
<td><strong>INDUCED PLURIPOTENT STEM CELLS (IPSCS) FROM A PATIENT WITH FAMILIAL HYPERCHOLESTEROLEMIA: A NOVEL MODEL TO STUDY LDL RECEPTOR FUNCTIONS AND TARGETED RECOMBINATION</strong></td>
<td>Jérôme Caron*, Sylvie Goulinet-Mainot, Samir Saheb, Eric Bruckert, Anne Weber, Tuan Huy Nguyen, Anne Dubart-Kupperschmitt, France</td>
</tr>
<tr>
<td>THU-442 YI</td>
<td><strong>POTENCY OF EXOSOMES FROM ADULT-DERIVED HUMAN LIVER STEM CELLS TO TREAT CRIGLER NAJJAR SYNDROME</strong></td>
<td>Jiun Pang Huang*, Joachim Ravau, Catherine Lombard, Etienne Sokal, Belgium</td>
</tr>
<tr>
<td>THU-443 YI</td>
<td><strong>IDENTIFICATION OF A NEW INBORN ERROR IN THE PEROXISOMAL STEPS OF BILE ACID SYNTHESIS RESULTING IN ACCUMULATION OF TOXIC BILE ACID INTERMEDIATES AND HEPATOCELLULAR DAMAGE</strong></td>
<td>Maria J. Monte, Marta Alonso, Oscar Briz, Elisa Herrera, Rocio R. Macias, Maria J. Perez, Elisa Lozano, Ruba Al-Abdulla, Maitane Asensio, Francisco Gonzalez-San Martin, Silvia Jimenez, Beatriz Castaño, Josep Argemi, Jesus Prieto, Jose J. Marin*, Spain</td>
</tr>
<tr>
<td>THU-444 YI</td>
<td><strong>DISEASE-RELATED VARIANTS IN GENES INVOLVED IN BILE FORMATION AND TRANSPORT DEMONSTRATED IN 12 OF 22 PATIENTS WITH “UNEXPLAINED CHOLESTASIS” BY THE USE OF A NOVEL PANEL FOR GENETIC TESTING</strong></td>
<td>Luise Aamann*, Nikolaj Ørntoft, Dorte Lildballe, Henning Gronbæk, Hendrik Vilstrup, Ida Vogel, Peter Ott, Denmark</td>
</tr>
<tr>
<td>THU-446 YI</td>
<td><strong>COMPREHENSIVE PROTEOMIC STUDY OF HEPATOBLASTOMA: IDENTIFICATION OF A PROGNOSTIC SIGNATURE AND DEREGULATED PATHWAYS</strong></td>
<td>Marina Simon*, Mikel Azkargorta, Laura Guerra, Lara Nonell, Manuel López-Santamaria, Marta Garrido, Maria Elena Mateos, Cristina Belendez, Diego Plaza, Francisco Hernandez, Marta Mendiola, Isabel Ojanguren, Margaret Childs, Piotr Czauderna, Rudolf Maibach, Bruce Morland, Marie Annick Buendia, Felix Elortza, Ramon Planas, Maria-Rosa Sarrias, Margarita Sala, Carolina Armengol, Spain</td>
</tr>
</tbody>
</table>
THU-447
YI
A PAIR OF BROTHERS WITH ACERULOPLASMINEMIA DUE TO A NOVEL NONSENSE MUTATION: UNUSUAL PHENOTYPE AND EFFECTIVENESS OF IRON-CHELATION THERAPY BY DEFERASIROX
Massimo Fiorini*, Francesca Ferrara, Stefania Scarlini, Davide Bocchi, Francesco Cavallieri, Franco Valzania, Angela Caleffi, Antonello Pietrangelo, Elena Corradini, Italy

THU-448
YI
AUTOPHAGY IN TUMOR-FREE LIVERS AND HEPATOCellular TUMORS IN A GLYCOGEN STORAGE DISEASE TYPE Ia MOUSE MODEL
Monika Gjorgjieva*, Margaux Raffin, Anne Stefanutti, Gilles Mithieux, Fabienne Rajas, France

THU-449
YI
AAV INTEGRATION IN THE LIVER IN A MODEL OF INDUCED GENOTOXICITY
Nerea Zabaleta*, Daniel Moreno-Luqui, Christine Kappel, Gloria González-Aseguinolaza, Manfred Schmidt, Rafael Aldabe, Spain

THU-450
NEXT GENERATION SEQUENCING IN THE STUDY OF HYPERFERRITINEMIA
Bekim Sadikovic, Alexander Levstik, Paul Adams*, Canada

THU-451
YI
ALLOGRAFT INFLAMMATION AND FIBROSIS AMONG MAINTENANCE PEDIATRIC LIVER TRANSPLANT RECIPIENTS – GENETIC PREDISPOSITION AND ANTIBODIES, CONNECTING THE MISSING LINKS
Sharat Varma*, Dominique Latinne, Mina Komuta, Jerome Ambroise, Françoise Smets, Raymond Reding, Xavier Stephenne, Etienne Sokal, Belgium

THU-452
DEFECTIVE PLASMA MEMBRANE TARGETING OF P.I661T-ATP8B1, ASSOCIATED WITH FAMILIAL INTRAHEPATIC CHOLESTASIS, CAN BE RESCUED IN VITRO BY CFTR CORRECTORS
Wendy van der Woerd, Catharina Wichers, Anna Vestergaard, Jens Peter Andersen, Coen Paulusma, Roderick Houwen, Stan Van De Graaf*, Netherlands
Genetic and paediatric liver diseases (Cont.)

THU-453  PELD SCORE AS A PROGNOSTIC FACTOR IN FULMINANT LIVER FAILURE CAUSED BY MUSHROOM POISONING IN CHILDREN
Tudor Lucian Pop*, Alina Grama, Ana Stefanescu, Dan Delean, Cornel Aldea, Aurel Bizo, Romania

THU-454  ANALYSIS OF TREATMENTS FOR WILSON DISEASE USING PATIENT-SPECIFIC INDUCED PLURIPOTENT STEM (IPS) CELLS DERIVED FROM URINE
Vanessa Sauer*, Christoph Niemietz, Sarah Guttmann, Jacqueline Stella, Gursimran Chandhok, Hans Zischka, Andree Zibert, Hartmut H.-J. Schmidt, Germany
Liver transplantation / surgery: Acute liver failure – clinical and experimental

THU-383 ELEVATED AMMONIA LEVELS AND INFECTION IN ACUTE LIVER FAILURE – CAUSE OR EFFECT?
Dr Shalimar*, Baibaswata Nayak, Saurabh Kedia, Subrat Kumar Acharya, India

THU-384 PORTAL HEMODYNAMICS PREDICTS THE OUTCOME IN SEVERE ALCOHOLIC HEPATITIS PRESENTING AS ACUTE-ON-CHRONIC LIVER FAILURE

THU-385 MIR-1224 IS UPREGULATED IN HEPATIC ISCHEMIA-REPERFUSION INJURY AND INDUCES CELL DEATH VIA SP1/NFIB INHIBITION
Christoph Roderburg*, Sanchari Roy, Fabian Benz, Frank Tacke, Christian Trautwein, Tom Luedde, Germany

THU-401 INCREASED TLR2 EXPRESSION IN PERIPHERAL CD4+ T CELLS PROMOTES TH17 CELLS RESPONSES AND IS ASSOCIATED WITH DISEASE AGGRAVATION OF HBV-RELATED ACUTE-ON-CHRONIC LIVER FAILURE
Jia Liu*, Chunli Xu, Xin Zheng, Mengji Lu, Dongliang Yang, China

THU-402 MAINTENANCE OF HEPATOCYTE PHENOTYPE IN VITRO: THE SINUSOIDAL MILIEU IS THE KEY
Martí Ortega-Ribera, Xavi Illa, Constantino Fondevila, Carmen Peralta, Rosa Villa, Jordi Gracia-Sanco*, Spain

CLIF-C ALF SCORE IS A NEW PROGNOSTIC TOOL TO IDENTIFY LIVER TRANSPLANT CANDIDATES IN PATIENTS WITH PARACETAMOL-RELATED ACUTE LIVER FAILURE AND IT CAN PREDICT THE FUTILITY OF LIVER TRANSPLANTATION
Francesco Figorilli*, Olivier Roux, Antonella Putignano, Pauline Houssel, Claire Francoz, Catherine Paugam, Banwari Agarwal, François Durand, Rajiv Jalan, Italy

YI Top 10%
Liver transplantation / surgery: Acute liver failure – clinical and experimental (Cont.)

**THU-403**  
**INFLUENCE OF ACUTE FAILURE ON THE STRUCTURE OF GUT MICROBIOME IN PIGS**  
Yimin Zhang, Zhou Ning, Baohong Wang, Lanjuan Li*, China

**THU-404**  
**EFFECTS OF HEALTHY- AND ACUTE LIVER FAILURE PLASMA ON DIFFERENTIATED HUMAN HEPARG PROGENITOR CELLS IN MONOLAYERS AND BIOARTIFICIAL LIVERS**  
Martien Van Wenum*, Robert Chamuleau, Aldo Jongejan, Philipp Treskes, Sander Meisner, Erik Hendriks, Thomas van Gulik, Perry Moerland, Ruurdtje Hockstra, Netherlands

**THU-405**  
**ELEVATED LEVELS OF PROCALCITONIN DURING ACUTE LIVER FAILURE ARE NOT ASSOCIATED WITH SEPSIS OR WORTH OUTCOME**  
Maxime Mallet*, Simona Tripon, Dominique Thabut, Marika Rudler, France

**THU-406**  
**THE ROLE OF THE INFLAMMATORY RESPONSE IN NON-POD ALF: ARE SERIAL MEASUREMENTS OF SIRS, SOFA SCORES AND NEUTROPHIL-LYMPHOCYTE RATIO CLINICALLY RELEVANT MARKERS OF PROGNOSIS?**  
Mhairi C. Donnelly*, Kenneth Simpson, United Kingdom

**THU-407**  
**THE SCOTTISH LOOK BACK ON ACUTE LIVER FAILURE: ARE WE AS GOOD AS THE BEST?**  
Mhairi C. Donnelly*, Janice Davidson, Kirsty Martin, Andrea Baird, Peter Hayes, Kenneth Simpson, United Kingdom

**THU-408**  
**INHIBITION OF CONNEXIN HEMICHANNELS ALLEVIATES ACETAMINOPHEN-INDUCED HEPATOTOXICITY IN MOUSE**  
Michaël Maes*, Sara Crespo Yanguas, Joost Willebrords, Tereza C. da Silva, Margitta Lebosky, Isabel V. Pereira, Hartmut Jaeschke, Bruno Cogliati, Mathieu Vinken, Belgium

**THU-409**  
**ANTI-INFLAMMATORY ACTION OF GLUTAMINE IN ACUTE LIVER FAILURE INDUCED BY THIOACETAMIDE IN RATS**  
Elizangela Gonçalves Schemitt, Josieli Raskopf Colares, Renata Minuzzo Hartmann, Francielli Licks, Mariana Do Couto Soares, Jéferson De Oliveira Salvi, Cláudio Augusto Marroni, Norma Anair Possa Marroni*, Brazil
THU-410

**HIGHER FERRITIN CONCENTRATIONS ARE ASSOCIATED WITH WORSE OUTCOME IN ACUTE LIVER FAILURE**
Olympia Anastasiou, Julia Kälsch, Mahdi Hakmouni, Jan-Peter Sowa, Fuat Saner, Andreas Paul, Guido Gerken, Lars P. Bechmann, Ali Canbay*, Germany

THU-411

**ESTABLISHING THE EDINBURGH MODEL: DOSE TO INJURY RESPONSE IN A LARGE ANIMAL INFUSION MODEL OF PARACETAMOL-INDUCED ACUTE LIVER FAILURE**
Philipp Treskes*, Guen Bradbury, Bastiaan Vliegenthart, Martien van Wenum, Karla Borland, Bryony Few, Alasdair Hay, Peter Hayes, Michael Eddleston, Eddie Clutton, John Plevris, United Kingdom

THU-412

**MODULATION OF THE NON-CANONICAL NFκB PATHWAYS MAY UNDERLIE ALTERNATIVE ACTIVATION OF CIRCULATING CD14HI MONOCYTES IN HYPERACUTE LIVER FAILURE**
R Daniel Abeles*, Charalambos Antoniades, Godhev Manakkat-Vijay, Debbie Shawcross, Wafa Khamri, Nikhil Vergis, William Bernal, Julia Wendon, Diego Vergani, United Kingdom

THU-413

**PARACETAMOL-INDUCED ACUTE LIVER FAILURE: THE BIRMINGHAM EXPERIENCE 2004-2013**
Damian Harding, Sarah Townsend*, Nick Murphy, Ahmed Elskarkawy, United Kingdom

THU-414

**ISCHEMIC POSTCONDITIONING (IPOSTC) PROTECTS HEALTHY AND FATTY RAT LIVERS FROM ISCHEMIA REPERFUSION INJURY**
Julia Schewe, Ingrid Liss, Alexander L. Gerbes, Christian Steib*, Germany

THU-415

**IKKALPHA/BETA REGULATE HEPATOCELLARINOCINOGENSE AND BILIARY HOMEOSTASIS BY CONTROLLING RIPK1 ACTIVITY**
Christiane Koppe*, Florian Reisinger, Patricia Verheugd, Jeremie Gautheron, Christoph Roderburg, Frank Tacke, Christian Preisinger, Bernhard Lüscher, Mihael Vucur, Christian Trautwein, Matthias Heikenwälder, Tom Luedde, Germany
Liver transplantation / surgery: Acute liver failure – clinical and experimental (Cont.)

THU-416 YI
SELECTIVE BLOCKADE OF METABOTROPIC GLUTAMATE RECEPTOR BY MPEP PROTECTS AGAINST HEPATIC COLD ISCHEMIA AND REPERFUSION INJURY
Clarissa Berardo*, Laura Giuseppina Di Pasqua, Vittoria Rizzo, Plinio Richelmi, Ferdinando Nicoletti, Andrea Ferrigno, Mariapia Vairetti, Italy

THU-417 YI
ISCHEMIA/REPERFUSION INJURY IN THE AGED LIVER: THE IMPORTANCE OF THE SINUSOIDAL ENDOTHELium IN DEVELOPING THERAPEUTIC STRATEGIES FOR THE ELDERLY
Diana Hide’, Marti Ortega-Ribera, Alessandra Warren, David Le Couteur, Jaume Bosch, Victoria Cogger, Jordi Gracia-Sancho, Spain

THU-418 YI
AMMONIA-INDUCED BRAIN OEDema AND IMMUNE DYSFUNCTION IS MEDIATED BY TOLL-LIKE RECEPTOR 9 (TLR9)
Godhev Manakkat Vijay’, Changyun Hu, Jian Peng, Irma Garcia Martinez, Rafaz Hoque, Xiaojun Zhang, Yun Ma, Wajahat Mehal, Debbie Shawcross, Li Wen, United Kingdom

THU-419 YI
URINARY METABOLOMIC ANALYSIS OR EARLY PREDICTION OF SEPSIS IN ACUTE-ON-CHRONIC LIVER FAILURE PATIENTS

THU-420 YI
THE IMPACT OF LIVER RESECTION ON BILE SALT AND FGF19 HOMEOSTASIS IN HUMANS
Kiran V. Koelfat’, Kim M. Van Mierlo, Johanne G. Bloemen, Albert K. Groen, Peter L. Jansen, Cornelis H. Dejong, Frank G. Schaap, Steven W. Olde Damink, Netherlands

THU-421 YI
THE FARNESOID-X-RECEPTOR AGONIST OBETICHOLIC ACID FURTHER INCREASES BILIARY EXCRETION OF ASYMMETRIC DIMETHYLARGININE DURING HEPATIC ISCHEMIA/REPERFUSION INJURY
Laura Giuseppina Di Pasqua’, Clarissa Berardo, Vittoria Rizzo, Luciano Adorini, Plinio Richelmi, Mariapia Vairetti, Andrea Ferrigno, Italy
THU-422  YI  RESISTIN PREVENTS VISFATIN HEPATIC RECAPTATION FROM ADIPOSE TISSUE IN HEPATIC SURGERY UNDER VASCULAR OCCLUSION
Maria Eugenia Cornide-Petronio*, Esther Bujaldon, Mariana Mendes-Braz, Monica Bibiana Jiménez-Castro, Elsa Negrete-Sánchez, Cindy Ávalos de León, Arani Casillas-Ramirez, Jose Gulfo, Jordi Gracia-Sancho, Juan Rodés, Carmen Peralta, Spain

THU-423  YI  EVALUATION OF METABOLIC PARAMETERS OF HEPATIC DYSFUNCTION IN SUBJECTS WITH HEPATOCELLULAR CARCINOMA AND THEIR CHANGE AFTER LIVER TRANSPLANTATION: A METABOLOMIC APPROACH
Melania Gaggini*, Chiara Saponaro, Paolo De Simone, Franco Filipponi, Giuseppina Basta, Amalia Gastaldelli, Italy

THU-424  YI  HMGB1 IN STEATOTIC AND NON-STEATOTIC LIVER TRANSPLANTATION FROM BRAIN-DEAD DONORS WITH PREVIOUS ISCHEMIC PRECONDITIONING
Monica B. Jimenez-Castro*, Elsa Negrete-Sanchez, Cindy Avalos de León, Arani Casillas-Ramirez, Maria Eugenia Cornide-Petronio, Esther Bujaldon, Mariana Mendes-Braz, Jose Gulfo, Jordi Gracia-Sancho, Juan Rodés, Carmen Peralta, Spain

THU-425  IMPAIRED LIVER REGENERATIVE RESPONSE FOLLOWING ADMINISTRATION OF ANTI-TLR4 ANTIBODY IN MICE

THU-426  THE XENOGRAFT OF ADIPOSE DERIVED-HUMAN MESENCHYMAL STEM CELLS ATTENUATES HEPATIC DAMAGE IN RATS WITH CHRONIC LIVER INJURY
Nathaly Enciso*, Jose Amiel, John Pando, Nancy Rojas, Carlos Cisneros, Ernesto Nava, Fredy Fabian, Javier Enciso, Peru

THU-427  MELATONIN MITIGATES THE NUTRITIONAL AND MORPHOLOGICAL CHANGES OF RAT TONGUE WITH SECONDARY BILIARY CIRRHOSIS INDUCED BY LIGATION OF THE COMMON BILE DUCT
Norma Anair Possa Marroni*, Josieli Raskopf Colares, Elizangela Gonçalves Schemitt, Renata Minuzzo Hartmann, Francielli Licks, Mariana Do Couto Soares, Sabrina Fernandes, Cláudio Augusto Marroni, Brazil
Liver transplantation / surgery: Acute liver failure – clinical and experimental (Cont.)

THU-428

LIVER REGENERATION AFTER PARTIAL HEPATECTOMY IS SEVERELY ATTENUATED IN COMPLEMENT COMPONENT C3A RECEPTOR ANTAGONISED LPS-HYPORESPONSIVE C3H/HEJ MOUSE

Rahiman S. Faiyaz*, Beth Mallard, Muhamad Marlini, Antony Wheatley, Ireland
## Liver tumours: Clinical (epidemiology, diagnosis)

<table>
<thead>
<tr>
<th>Abstract ID</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>THU-036</td>
<td>HEPATOCELLULAR CARCINOMAS DIAGNOSED DURING SURVEILLANCE HAVE A BETTER SURVIVAL REGARDLESS OF AGE AT DIAGNOSIS</td>
<td>Alberto Lué*, Elena Martínez, Estela Solanas, Sara Lorente, Maria Trinidad Serrano, Spain</td>
</tr>
<tr>
<td>THU-037</td>
<td>ANALYSIS OF THE FREQUENCY AND RISK FACTORS ASSOCIATED WITH FAILURE IN EARLY DETECTION OF HEPATOCELLULAR CARCINOMA IN A SURVEILLANCE PROGRAM IN PATIENTS WITH CIRRHOSIS</td>
<td>Alejo Mancebo*, Maria Luisa González-Diéguez, Valle Cadahía, Carmen A. Navascués, Andrés Castaño, Maria Varela, Manuel Rodríguez, Spain</td>
</tr>
<tr>
<td>THU-038</td>
<td>COMPLETE RESPONSE UNDER SORAFENIB TREATMENT FOR HEPATOCELLULAR CARCINOMA IS ASSOCIATED TO DEVELOPMENT OF DERMATOLOGY ADVERSE EVENTS</td>
<td>Álvaro DÍAZ-GONZÁLEZ*, Jordi Rimola, Reig Maria, Anna Darnell, María Varela, Fernando Pons, Manuel Hernández-Guerra, Manuel Delgado, Javier F. Castroagudín, Ana Matilla, Bruno Sangro, Carlos Rodríguez de Lope, Sala Margarita, Carmen González, Carlos Huertas, Beatriz Minguez, Carmen Ayuso, Jordi Bruix, Spain</td>
</tr>
<tr>
<td>THU-039</td>
<td>PROGNOSIS VALUE OF SKELETAL MUSCLE INDEX AND ALPHA FETOPROTEIN SCORE IN PATIENTS TREATED BY TRANS-ARTERIAL CHEMOEMBOLIZATION</td>
<td>Edouard Soum, Camille Teilhet, Geraldine Lamblin, Leon Muti, Laurent Poincloux, Louis Boyer, Pascal Chabrot, Bruno Pereira, Armando Abergel*, France</td>
</tr>
<tr>
<td>THU-040</td>
<td>CLINICAL FEATURES, DIAGNOSIS AND THERAPEUTIC ASSOCIATED OUTCOMES IN CLEAR CELL HEPATOCELLULAR CARCINOMA</td>
<td>Armando Peixoto*, Marco Silva, Pedro Pereira, Guilherme Macedo, Portugal</td>
</tr>
</tbody>
</table>
Liver tumours: Clinical (epidemiology, diagnosis) (Cont.)

**THU-041** RISK FACTORS AND CHARACTERISTICS OF HEPATOCELLULAR CARCINOMA OCCURRING IN HCV CIRRHOTIC PATIENTS AFTER SUSTAINED VIROLOGICAL RESPONSE
Audrey Payancé*, Nathalie Goutté, Emeline Clair, Valérie Paradis, Mohamed Bouattour, Marie-Pierre Vullierme, Corinne Castelnau, Nathalie Boyer, Olivier Farges, Tarik Asselah, François Durand, Pierre Bedossa, Patrick Marcellin, Laurent Castera, France

**THU-047** CIRCULATING TUMOR CELLS EARLY PREDICT PROGNOSIS OF HEPATOCELLULAR CARCINOMA TREATED WITH TRANSARTERIAL CHEMOEMBOLIZATION: A PROSPECTIVE STUDY
Bo Zhou*, Guowei Yang, Zhiping Yan, Jianhua Wang, China

**THU-048** LARGE SOLITARY HEPATOCELLULAR CARCINOMAS TREATED WITH TRANSARTERIAL CHEMOEMBOLIZATION: IN WHICH BCLC STAGE PATIENTS SHOULD BE ALLOCATED?
Bruno C. Odisio*, Tomas A. Figueira, Mohamed E. Abdelsalam, Sharjeel Sabir, Sharjeel Sabir, Armeen Mahvash, Michael J. Wallace, Jean-Nicolas Vauthey, Ahmed O. Kaseb, United States

**THU-049** COMPARISON OF PROGNOSTIC SCORING SYSTEMS FOR PREDICTION OF SURVIVAL IN HEPATOCELLULAR CARCINOMA
Bulent Baran*, Omer Ekinci, Ozlem M. Soyer, Asli C. Ormeci, Suut Gokturk, Sami Evirgen, Arzu Poyanli, Mine Gulluoglu, Filiz Akyuz, Cetin Karaca, Kadir Demir, Fatih Besisik, Sabahattin Kaymakoglu, Turkey

**THU-050** DIABETES IS NOT ASSOCIATED WITH AN INCREASED RISK OF HEPATOCELLULAR CARCINOMA IN PATIENTS WITH ALCOHOLIC, HBV OR HCV LIVER CIRRHOSIS
Carlos R. Escaja*, Carmen A. Navascués, Luísa González-Díezquez, Valle Cadahía, María Varela, Miguel Ángel De Jorge, Manuel Rodriguez, Spain
THU-051 CLINICAL CHARACTERISTICS OF INTRAHEPATIC CHOLANGIOCARCINOMA IN SPAIN. LIVER CIRRHOSIS AND HIGH AFP ARE NOT ALWAYS HEPATOCELLULAR CARCINOMA
Carlos Rodriguez-Lope*, Montserrat Forne, Javier Fuentes, Maria Reig, Victoria Andreu, Beatriz Minguez, Mercedes Iñarrairaegui, Cristina Fernández, Mercè Roget, Alberto Lue, Inmaculada Ortiz, Felipe Jimenez, Silvia Montoliu, M Carmen Garre, Paloma Rendón, Manuel Rodríguez, Javier Crespo, Jordi Bruix, Maria Varela, Spain

THU-052 CIRCULATING NEUTROPHILS – IMMUNOLOGICAL DRIVERS OF HEPATOCELLULAR CARCINOMA PROGRESSION?
Catherine E. Willoughby*, Laura F. Ogle, Stephen L. Chan, Charles Chan, Allen K. C. Chan, Tim J. S. Cross, Wern Y. Ding, David Jamieson, Helen L. Reeves, United Kingdom

THU-053 GALNT14 GENOTYPE PREDICTS PROGNOSIS OF MULTIPLE HEPATO-GASTROINTESTINAL CANCERS INCLUDING HEPATOCELLULAR CARCINOMA, CHOLANGIOCARCINOMA, COLORECTAL CANCER AND ESOPHAGEAL CANCER
Chau-Ting Yeh*, Kung-Hao Liang, Ta-Sen Yeh, Ren-Chin Wu, Chun-Nan Yeh, Wey-Ran Lin, Jy-Ming Chian, Yung-Kuan Tsou, Taiwan

THU-054 THE ROLE OF SERUM ALPHAFETOPROTEIN DETERMINATION IN HCV-CIRRHOSIS AFTER ANTIVIRAL TREATMENT
Cristina Della Corte*, Roberta D’ambrosio, Nicole Piazza O Sed, Angelo Sangiovanni, Alessio Michele Aghemo, Massimo Alberto Iavarone, Stella De Nicola, Massimo Colombo, Italy

THU-055 EFFECT OF LOCO-REGIONAL TREATMENT OF HEPATOCELLULAR CARCINOMA ON THE GENOMIC EXPRESSION IN CIRCULATING PERIPHERAL BLOOD MONONUCLEAR CELLS
Daniela Santovito*, Simona D’Amore, Giusi Graziano, Giuseppe Palasciano, Vincenzo O. Palmieri, Italy
Liver tumours: Clinical (epidemiology, diagnosis) (Cont.)

THU-056  DECREASING THE RISK OF HCC IN CAUCASIAN CHRONIC HEPATITIS B PATIENTS UNDER NUCS: RESULTS OF THE SPANISH CHRONIC HEPATITIS B REGISTRY (CIBERHEP)
David Tabernero*, Mar Riveiro-Barciela, José L Calleja, José M Sánchez-Tapias, María L Manzano, Víctor Moreira, Javier Crespo, Belén Piqueras, Juan M Pascasio, José C Erdozain, Conrado M Fernandez, Alberto Aguirre, Emilio Suárez, Francisco Gea, Miguel Rivero, Doroteo Acero, Miguel Fernandez-Bermejo, Diego Moreno, Pilar Sánchez-Pobre, Beatriz De Cuenca, José J Moreno, Rafael Esteban, Maria Buti, Spain

THU-057  THE VALIDATION OF A NEWLY UPDATED CHILD-TURCOTTE-PUGH SCORE USING INSULIN GROWTH FACTOR-1 FOR PREDICTING SURVIVAL OF PATIENTS WITH HEPATOCELLULAR CARCINOMA IN CHRONIC HEPATITIS B ENDEMIC AREA
Dong Hyeon Lee*, Jeong-Hoon Lee, Yuri Cho, Young Youn Cho, Eun Ju Cho, Su Jong Yu, Yoon Jun Kim, Jung-Hwan Yoon, Korea, South

THU-058  ADHERENCE TO GUIDELINES IN FIELD-PRACTICE: PROGETTO EPATOCARCINOMA CAMPANIA
Giovan Giuseppe Di Costanzo*, Maria Guarino, Giorgio De Stefano, Carmine Coppola, Raffaella Tortora, Filomena Morisco, Salomone Megna Angelo, Francesco Izzo, Gerardo Nardone, Guido Piai, Luigi Elio Adinolfi, Giuseppe D’Adamo, Giovan Battista Gaeta, Vincenzo Messina, Giampiero Francica, Vincenzo De Girolamo, Nicola Coppola, Italy

THU-059  EARLY EVALUATION OF ALPHA-FETOPROTEIN RESPONSE FOR PREDICTING OUTCOMES IN SORAFENIB TREATED PATIENTS MAY BE MISLEADING
Giovan Giuseppe Di Costanzo*, Raffaella Tortora, Gabriella Cordone, Maria Guarino, Maria Teresa Tartaglione, Massimo De Luca, Francesco Paolo Picciotto, Luigia Falco, Filomena Morisco, Nicola Caporaso, Italy
THU-060
HCC DERIVED CIRCULATING MICROPARTICLES DETECT HEPATOCELLULAR CARCINOMA AND DIFFER FROM OTHER CANCER RELATED MICROPARTICLES
Henrike Julich*, Marcin Krawczyk, Arnulf Willms, Markus Casper, Matthias Glanemann, Robert Schwab, Ines Richardsen, Sebastian Schaa, Christian Geis, Marek Krawczyk, Frank Lammert, Veronika Lukacs-Kornek, Detlef Schuppan, Miroslaw Kornek, Germany

THU-061
IN SITU ANALYSIS OF HTERT EXPRESSION IN ARCHIVAL HUMAN HEPATOCELLULAR CARCINOMA SPECIMENS
Hyunjin Park*, Hyejung Lee, Yangkyu Lee, Haeryoung Kim, Youngrok Choi, Jai Young Cho, Yoo-Seok Yoon, Ho-Seong Han, Korea, South

THU-062
RISK OF RECURRENCE IN HEPATITIS B VIRUS-RELATED HEPATOCELLULAR CARCINOMA PATIENTS FAILED IN NUCLEOS(T)IDE ANALOGUES (NUCs) SECONDARY PREVENTION – A NATIONWIDE COHORT STUDY
I-Cheng Lee*, Ti-Hao Wang, Yu-Wen Hu, Han-Chieh Lin, Yee Chao, Yi-Hsiang Huang, Taiwan

THU-063
NEUTROPHIL-LYMPHOCYTE RATIO CORRELATED WITH BCLC STAGING OF HCC PATIENTS, REGARDLESS OF CIRRHOTIC CONDITION
Irsan Hasan*, Imelda Loho, Arles Arles, C Rinaldi A Lesmana, Rino A Gani, Indonesia

THU-064
DIFFERENTIAL CYTOKINE PROFILES IN PATIENTS WITH HEPATOCELLULAR CARCINOMA RELATED TO HEPATITIS B VIRUS AND HEPATITIS C VIRUS INFECTION
Jacqueline Estevez*, Vincent L. Chen, Ondrej Podlaha, Biao Li, An Le, Philip Vutien, Ellen Chang, Zhaoshi Jiang, Stefan Pflanz, Dongliang Ge, Anuj Gaggar, Mindie H. Nguyen, United States

THU-065
AFRICAN AMERICANS WITH HEPATOCELLULAR CARCINOMA IN THE U.S. HAVE HIGHER RATES OF BEING UNINSURED AT TIME OF DIAGNOSIS, ARE LESS LIKELY TO HAVE HCC WITHIN MILAN CRITERIA, AND ARE LESS LIKELY TO RECEIVE ANY HEPATOCELLULAR CARCINOMA TREATMENT
Jennifer Wang*, John Ha, Melissa Yan, Maria Aguilar, Ramsey Cheung, Robert Wong, United States
Liver tumours: Clinical (epidemiology, diagnosis) (Cont.)

**THU-066 YI**

**INSURED PATIENTS WITH HEPATOCELLULAR CARCINOMA IN THE UNITED STATES ARE MORE LIKELY TO HAVE HEPATOCELLULAR CARCINOMA WITHIN MILAN CRITERIA, ARE MORE LIKELY TO RECEIVE TREATMENT, AND HAVE HIGHER SURVIVAL COMPARED TO UNINSURED AND MEDICAID PATIENTS**

Jennifer Wang*, John Ha, Michele Tana, Taft Bhuket, Benny Liu, Zobair Younossi, Robert Wong, United States

**THU-067 YI**

**THE IMPACT OF ETHNIC SUBGROUP ON TUMOR STAGE AT DIAGNOSIS, TREATMENT RECEIVED, AND OVERALL LONG-TERM SURVIVAL AMONG ASIAN ADULTS WITH HEPATOCELLULAR CARCINOMA IN THE UNITED STATES**

Jennifer Wang*, Melissa Yan, Joseph Ahn, Taft Bhuket, Benny Liu, Aijaz Ahmed, Robert Wong, United States

**THU-068 YI**

**THE EXTERNAL VALIDATION OF HONG KONG LIVER CANCER STAGING SYSTEM FOR PREDICTION OF SURVIVAL WITH KOREAN MULTICENTER HCC PATIENTS: COMPARING WITH BARCELONA CLINIC LIVER CANCER STAGING SYSTEM**

Young-Sun Lee, Ji Hoon Kim*, Hae Rim Kim, Yang Jae Yoo, Tae Suk Kim, Seong Hee Kang, Sang Jun Suh, Young Kul Jung, Yeon Seok Seo, Hyung Joon Yim, Jong Eun Yeon, Kwan Soo Byun, Korea, South

**THU-069 YI**

**ROOM-TEMPERATURE SUSCEPTOMETRY DETECTS HEPATOCYTE BUT NOT MACROPHAGE IRON**

Johannes Mueller*, Hanna Raisi, Vanessa Rausch, Helmut Karl Seitz, William Avrin, Sebastian Mueller, Germany

**THU-070 YI**

**VALIDATION OF THE GALAD SCORE FOR HEPATOCELLULAR CARCINOMA DIAGNOSIS IN A US COHORT**

Ju Dong Yang*, Jianliang Dai, Benyam Addissie, Mindie H. Nguyen, Alex S. Befeler, Rajender Reddy, Myron E. Schwartz, Denise M. Harnois, Gregory J. Gores, Ziding Feng, Jorge A. Marrero, Lewis R. Roberts, United States
THU-071
VALIDATION OF MESIAH SCORE SYSTEM IN PATIENTS WITH HEPATOCELLULAR CARCINOMA

THU-072
RACE DISPARITY IN CONDITIONAL SURVIVAL OF HEPATOCELLULAR CARCINOMA PATIENTS A COHORT STUDY OF THE NATIONAL CANCER INSTITUTE SURVEILLANCE, EPIDEMIOLOGY, AND END RESULTS (SEER)
Juan Li*, Maikel P. Peppelenbosch, Eleni-Rosalina Andrinopoulou, Dave Sprengers, Qiuwei Pan, Netherlands

THU-073
MITOTIC CHECKPOINT CHK2 UPREGULATION IS LINKED TO CHROMOSOMAL INSTABILITY IN HUMAN HEPATOCELLULAR CARCINOMA
Matteo Lulli, Stefania Madiai, Tommaso Mello, Mirko Tarocchi, Krista Rombouts*, Massimo Pinzani, Andrea Galli, Vinicio Carloni, United Kingdom

THU-074
THE IMPACT OF SOCIO-ECONOMIC DEPRIVATION ON MANAGEMENT AND OUTCOMES OF HEPATOCELLULAR CARCINOMA IN EAST YORKSHIRE
Mohammed Saleem Mohammed, Graham Ferrier, George Abouda, Lynsey Corless*, United Kingdom

THU-075
STRATIFYING THE RISK OF HEPATOCELLULAR CARCINOMA IN CIRRHOTIC PATIENTS USING LIVER STIFFNESS MEASUREMENT BY FIBROSCAN – A MULTICENTRE STUDY
Maciej Adler*, Licia Larocca, Francesca Trovato, Heather Marcinkowski, Yasmin Pasha, Simon Taylor-Robinson, United Kingdom

THU-076
HEPATOCELLULAR CARCINOMA RESPONSE TO LOCAL REGIONAL THERAPY; CORRELATIONS BETWEEN PRE-LIVER TRANSPLANTS IMAGING AND EXPLANT PATHOLOGY
Mansour Alghanem*, Karim Qumosani, Paul marotta, David driman, Bandar Aljudaibi, Nermal Kakani, Canada
Liver tumours: Clinical (epidemiology, diagnosis) (Cont.)

**THU-077**
PROGNOSTIC VALIDATION OF PROPOSED BCLC-B SUBSTAGING SYSTEM IN HEPATOCELLULAR CARCINOMA PATIENTS TREATED BY TRANSARTERIAL CHEMOEMBOLIZATION
Marco Biolato*, Giulia Gallusi, Massimo Iavarone, Giuseppe Cabibbo, Simona Racco, Adriano De Santis, Cristina Della Corte, Marcello Maida, Adolfo F. Attili, Angelo Sangiovanni, Calogero Cammà, Giuseppe La Torre, Antonio Gasbarrini, Antonio Grieco, Italy

**THU-078**
METABOLIC DISORDERS ACROSS HEPATOCELLULAR CARCINOMA IN ITALY
Filomena Morisco, Maria Guarino*, Rossella Valvano, Nicola Caporaso, Fabio Farinati, Edoardo G. Giannini, Francesca Ciccarese, Fabio Piscaglia, Gian Lodovico Rapaccini, Mariella Di Marco, Eugenio Caturelli, Marco Zoli, Franco Borzio, Rodolfo Sacco, Calogero Cammà, Martina Felder, Antonio Gasbarrini, Gianluca Svegliati Barone, Francesco G. Foschi, Gabriele Missale, Alberto Masotto, Roberto Virdone, Franco Trevisani, Italy

**THU-079**
VARIANTS ASSOCIATED WITH VITAMIN D METABOLISM AND PROGRESSION TO HEPATOCELLULAR CARCINOMA IN CHRONIC HEPATITIS C: DBGAP DATA FROM HALT-C TRIAL
Laura A. De Azevedo, Ursula D. S. Matte, Themis R. Silveira, Mario R. Alvares-da-Silva*, Brazil

**THU-080**
SURVIVAL IN PATIENTS WITH HEPATOCCELLULAR CARCINOMA AFTER TRANSARTERIAL CHEMOEMBOLISATION IS DETERMINED BY TUMOR BIOLOGY AND HEPATIC FUNCTION
Martha M. Kirstein*, Nora Schweitzer, Nazli Ay, Christina Boeck, Jan Hinrichs, Torsten Voigtländer, Michael Manns, Thomas Rodt, Arndt Vogel, Germany

**THU-081**
RISK OF HEPATOCELLULAR CARCINOMA IN CHRONIC HEPATITIS B PATIENTS TREATED WITH NUCLEOS(T) IDE ANALOGUES AND LONG-TERM VIROLOGICAL SUPPRESSION
Massimo Fasano*, Luigi Montrano, Marianna Ciarallo, Bruno Caccianotti, Adele Giammario, Angarano Gioacchino, Teresa Santantonio, Italy
THU-082  ACCURACY OF THE RADIOLOGICAL DIAGNOSIS OF HEPATOCELLULAR CARCINOMA OUTSIDE THE PERIODIC SURVEILLANCE WITH ULTRASOUND
Massimo Iavarone*, Cristina Della Corte, Mauro Vigano, Nicole O Sed Piazza, Lucia Miglioresi, Alessio Aghemo, Angelo Sangiovanni, Maria G. Rumi, Massimo Colombo, Italy

THU-083  THE IMMENDING ROLE OF STEREOTACTIC BODY RADIATION THERAPY IN HEPATOCELLULAR CARCINOMA – A CASE SERIES
Assaf Moore, Aharon Allen, Yulia Kundel, Ofer Benjaminov, Marius Broun, Assaf Issachar, Eytan Mor, Ana Tovar, Noa Gordon, Solomon M. Shtemer, Michal Cohen*, Israel

THU-084  ONLY ONE-THIRD OF PATIENTS WITH HEPATOCELLULAR CARCINOMA WERE DIAGNOSED BY SCREENING, SURVEILLANCE, OR WITHOUT SYMPTOMS: A META-ANALYSIS OF 40 STUDIES AND 20,349 PATIENTS WITH DIVERSE UNDERLYING LIVER DISEASE AND WORLD REGIONS
Michelle Q. Jin*, Richard H. Le, Mingjuan Jin, Changqing Zhao, Michael H. Le, Alexander Nguyen, Brian Kwan, Vincent L. Chen, Vincent Wong, Young-Suk Lim, Wan-Long Chuang, Ming-Lung Yu, Grace Wong, Mindie Nguyen, United States

THU-085  TUMOR-ASSOCIATED CIRCULATING MICROPARTICLES: A NOVEL CLINICAL TOOL FOR SCREENING AND THERAPY MONITORING OF HCC AND OTHER EPITHELIAL NEOPLASIA
Arnulf Willms, Clara Müller, Henrike Julich, Niklas Klein, Robert Schwab, Ines Richardsen, Sebastian Schaaf, Christian Geis, Marcin Krawczyk, Marek Krawczyk, Frank Lammert, Detlef Schuppan, Veronika Lukacs-Kornek, Miroslaw Kornek*, Germany

THU-086  RACIAL AND ETHNIC DISPARITIES IN ETIOLOGY OF LIVER DISEASE, TUMOR CHARACTERISTICS, AND LONG-TERM SURVIVAL OF PATIENTS WITH HEPATOCELLULAR CARCINOMA: RESULTS OF A SINGLE-CENTER U.S. COHORT OF 1998 PATIENTS
Nathan Kim*, Pauline Nguyen, Maya Ladenheim, Zachary Rosenthal, Helen Nguyen, Gabriel Garcia, Mindie Nguyen, United States
<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>THU-087</td>
<td>POPULATION-BASED FACTORS ASSOCIATED WITH EARLY DEATH AFTER LIVER CANCER DIAGNOSIS AND RESECTION IN QUEENSLAND, AUSTRALIA 1996-2011</td>
<td>Paul J. Clark*, Thomas R. O’Rourke, Jonathon Fawcett, Katherine A. Stuart, Graeme A. Macdonald, Darrell H. Crawford, Barbara A. Leggett, David C. Whiteman, Peter A. Baade, Patricia C. Valery, Australia</td>
</tr>
<tr>
<td>THU-088</td>
<td>TIME-TRENDS IN INCIDENCE AND SURVIVAL OF HEPATOCELLULAR CARCINOMA IN DENMARK: A NATIONWIDE REGISTER-BASED COHORT STUDY</td>
<td>Peter Jepsen*, Mette Winther Andersen, Gerda E. Villadsen, Peter Ott, Hendrik Vilstrup, Denmark</td>
</tr>
<tr>
<td>THU-089</td>
<td>IMPACT OF SMOKING ON SURVIVAL IN PATIENTS WITH HEPATOCELLULAR CARCINOMA</td>
<td>Philippe Kolly*, Marina Knöpfli, Jean-François Dufour, Switzerland</td>
</tr>
<tr>
<td>THU-090</td>
<td>INCIDENTALLY DETECTED SPACE OCCUPYING LESIONS ON LIVER IMAGING IN CHRONIC HEPATITIS C, WHAT IS OBSCURED INSIDE A FIBROTIC LIVER?</td>
<td>Ragesh B. Thandassery*, Maneesh Khanna, Madiha E. Soofi, Hamidullah Wani, Saad R. Al-Kaabi, Qatar</td>
</tr>
<tr>
<td>THU-091</td>
<td>VALIDATION OF CLINICAL SCORING SYSTEMS ART AND ABCR AFTER TRANSARTERIAL CHEMOEMBOLIZATION OF HEPATOCELLULAR CARCINOMA</td>
<td>Roman Kloeckner*, Michael Pitton, Christoph Dueber, Irene Schmidtmann, Peter Galle, Sandra Koch, Marcus Wörns, Arndt Weinmann, Germany</td>
</tr>
<tr>
<td>THU-092</td>
<td>ALANINE AMINOTRANSFERASE NORMALIZATION DURING ENTECAVIR TREATMENT AND THE HEPATOCELLULAR CARCINOMA RISK IN HEPATITIS B VIRUS-ASSOCIATED CIRRHOSIS</td>
<td>Seung Kak Shin*, Jong Eun Yeon, Oh Sang Kwon, Eui Joo Kim, Heon Nam Lee, Seong Hee Kang, Kwan Soo Byun, Jeong Han Kim, So Young Kwon, Sang Jun Suh, Hyung Joon Yim, Yun Soo Kim, Ju Hyun Kim, Korea, South</td>
</tr>
</tbody>
</table>
THU-094 YI  
**EFFICACY AND SAFETY OF PERCUTANEOUS LASER ABLATION THERAPY FOR TREATMENT OF LARGE HEPATOCELLULAR CARCINOMA**  
Silvia Camera’, Giovan Giuseppe Di Costanzo, Raffaella Tortora, Luigi Addario, Filippo Lampasi, Maria Teresa Tartaglione, Valentina Cossiga, Laura Donnarumma, Nicola Caporaso, Filomena Morisco, *Italy*

THU-095  
**THE RISK FACTORS OF DEVELOPING HEPATOCELLULAR CARCINOMA IN PATIENTS WITH CHRONIC HEPATITIS B TREATED WITH ORAL ANTIVIRAL THERAPY AND INACTIVE STAGE DISEASE**  
Yong Keun Cho, Gum Mo Jung, So Hee Yun*, *Korea, South*

THU-096  
**GADOXETIC ACID DISODIUM-ENHANCED MRI COMBINED SURVEILLANCE IMPROVES CLINICAL OUTCOME BY SENSITIVE DETECTION OF EARLY STAGE HEPATOCELLULAR CARCINOMA, COMPARED WITH ULTRASONOGRAPHY BASED SURVEILLANCE, IN PATIENTS WITH CIRRHOSIS**  
Su Jong Yu’, Jeong-Ju Yoo, Young Youn Cho, Won-Mook Choi, Minjong Lee, Dong Hyeon Lee, Yuri Cho, Eun-Ju Cho, Jeong-Hoon Lee, Yoon Jun Kim, Jeong Min Lee, Chung Yong Kim, Jung-Hwan Yoon, *Korea, South*

THU-097 YI  
**POSTABLATION DES-GAMMA-CARBOXY PROTHROMBIN: PREDICTION OF PROGNOSIS IN HEPATITIS B-RELATED HEPATOCELLULAR CARCINOMA**  
Sunyoung Lee*, Hyunchul Rhim, *Korea, South*

THU-098 YI  
**POPULATION-BASED CLINICAL COHORT ALLOWS MAPPING OF HEPATOCELLULAR CARCINOMA INCIDENCE AND RISK FACTORS TO ENABLE TARGETED SURVEILLANCE**  
Thai P. Hong*, Paul Gow, Michael Fink, Anouk Dev, Stuart Roberts, Amanda Nicoll, John Lubel, Ian Kronborg, Niranjan Arachchi, Marno Ryan, William Kemp, Virginia Knight, Helen Farrugia, Vicky Thursfield, Paul Desmond, Alexander J. Thompson, Sally Bell, *Australia*

THU-099 YI  
**SURVIVAL RATE IN A LARGE AUSTRIAN COHORT OF CHRONIC HEPATITIS C PATIENTS**  
Tuul Purevsambuu*, Simona Bota, Florian Huckle, Harald Hofer, Peter Ferenci, Wolfgang Sieghart, Markus Peck-Radosavljevic, *Austria*
Liver tumours: Clinical (epidemiology, diagnosis) (Cont.)

THU-100  GAMMA-GLUTAMYL TRANSPEPTIDASE-TO-PLATELET RATIO IS AN INDEPENDENT PREDICTOR OF HEPATITIS B VIRUS-RELATED LIVER CANCER
Yong Eun Park*, Seung Up Kim, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Sojung Han, Mi Young Jeon, Ja Yoon Heo, Korea, South

THU-101  ALBI GRADE VS. CHILD-PUGH GRADE AS A GRADING SYSTEM FOR LIVER FUNCTION IN PATIENTS WITH HEPATOCELLULAR CARCINOMA
Young Kul Jung*, Seong Kyun Na, Sang Jun Suh, Hyung Joon Yim, Seung Young Kim, Jong Jin Hyun, Sung Woo Jung, Ja Seol Koo, Ji Hoon Kim, Yeon Seok Seo, Jong Eun Yeon, Sang Woo Lee, Kwan Soo Byun, Soon Ho Um, Korea, South
Molecular and cellular biology: Cell cycle control / apoptosis and regeneration

**THU-455**

**LCA INDUCED LIVER DAMAGE IS MORE PRONOUNCED IN TGR5 KNOCKOUT MICE**
Caroline Klindt*, Kathleen Deutschmann, Maria Reich, Diran Herebian, Ertan Mayatepek, Dieter Häussinger, Verena Keitel, Germany

**THU-456**

**DE-DIFFERENTIATION OF HEPATOCYTIC PlACENTA DERIVED MESENCHYMAL STEM CELLS: GET A POPULATION OF DISTINGUISHABLE STEM CELLS**
Chenxia Hu*, Jinlin Cheng, Yini Wang, Lanjuan Li, China

**THU-457**

**3D PRINTING OF MOUSE PRIMARY HEPATOCYTES FOR GENERATING 3D HEPATIC STRUCTURE**
Sungho Jang*, Kyojin Kang, Hyereon Jeon, Jaemin Jeong, Su A Park, Wan Doo Kim, Seung Sam Paik, Dongho Choi, Korea, South

**THU-458**

**OBETICHOlIC ACID ACCELERATES LIVER REGENERATION IN A RABBIT MODEL OF PORTAL VEIN EMBOLIZATION**
Frank G. Schaap*, Pim B. Olthof, Cathy Van Himbeeck, Floor Huisman, Krijn P. Van Lienden, Rowan F. Van Golen, Michal Heger, Joanne Verheij, Isabelle A. Leclercq, Peter L. Jansen, Thomas M. Van Gulik, Steven W. Olde Damink, Netherlands

**THU-459**

**DELETION OF THE HIPPO CORE KINASES MST1 AND MST2 BY SIRNA RESCUED LIVER REGENERATION IN AGED MICE**
Giulio Loforese*, Switzerland

**THU-460**

**BILIARY TREE AND PERIBILIARY GLANDS AS A NICHE OF EXTRA-PANCREATIC PRECURSORS YIELDING INSULIN-PRODUCING CELLS IN EXPERIMENTAL AND HUMAN DIABETES**
Guido Carpino*, Vincenzo Cardinale, Rosa Puca, Anastasia Renzi, Gaia Scafetta, Lorenzo Nevi, Massimo Rossi, Pasquale B. Berloco, Stefano Ginanni Corradini, Lola Reid, Marella Maroder, Eugenio Gaudio, Domenico Alvaro, Italy
<table>
<thead>
<tr>
<th>Posters</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>THU-461</td>
<td>WILMS’ TUMOR SUPPRESSOR GENE IS THE KEY REGULATORY OF HEPATIC DIFFERENTIATION FROM BONE MARROW-DERIVED HUMAN MESENCHYMAL STEM CELLS VIA MESENCHYMAL-EPITHELIAL TRANSITION</td>
<td>Jung Hoon Cha*, Na Ri Park, Ho-Shik Kim, Jong Young Choi, Seung Kew Yoon, Si Hyun Bae, Korea, South</td>
</tr>
<tr>
<td>THU-462</td>
<td>ANALYSIS OF NRF2–KEAP1 PATHWAY AND METABOLIC REPROGRAMMING IN TWO DISTINCT MODELS OF RAT LIVER PROLIFERATION</td>
<td>Lavinia Cabras*, Claudia Orrù, Andrea Perra, Andrea Morandi, Giovanna Maria Ledda-Columbano, Amedeo Columbano, Marta Anna Kowalik, Italy</td>
</tr>
<tr>
<td>THU-463</td>
<td>ABLATION OF HISTONE DEACETYLASES 3 IN HEPATOCYTE INHIBITS LIVER REGENERATION AND INDUCES APOPTOSIS IN MICE</td>
<td>Lei Zhang*, Xufeng LU, China</td>
</tr>
<tr>
<td>THU-464</td>
<td>MOLECULAR MECHANISMS UNDERLYING THE UNPRECEDENTED LIVER REGENERATION INDUCED BY ALPPS SURGERY</td>
<td>Magda Langiewicz*, Andrea Schlegel, Bostjan Humar, Rolf Graf, Pierre-Alain Clavien, Switzerland</td>
</tr>
<tr>
<td>THU-466</td>
<td>TGR5 SIGNALLING IS ESSENTIAL FOR BILE ACID-DEPENDENT CHOLANGIOCYTE PROLIFERATION IN VIVO</td>
<td>Maria K. Reich*, Kathleen Deutschmann, Caroline Klindt, Diran Herebian, Ertan Mayatepek, Dieter Häussinger, Verena Keitel, Germany</td>
</tr>
<tr>
<td>THU-467</td>
<td>CONTROL OF HEPATIC CELLS GROWTH BY TOPOLOGICALLY MODULATED SUBSTRATES</td>
<td>Mariia Lunova*, Vitalii Zablotskii, Nora Dempsey, Dominique Givord, Thibaut Devillers, Milan Jirsa, Eva Syková, Šárka Kubinová, Oleg Lunov, Alexandr Dejneka, Czech Republic</td>
</tr>
</tbody>
</table>
THU-468 YI  RIP3 REGULATES ACUTE CHOLESTASIS-ASSOCIATED NECROPTOTIC SIGNALING AND CELL DEATH

THU-469 YI  SMALL MOLECULE FPH2 MEDIATES LONG-TERM HEPATOCYTE EXPANSION IN VITRO AND INDUCES LIVER REGENERATION IN MICE
Marwa Farid*, Qinggong Yuan, Asha Balakrishnan, Michael P. Manns, Michael Ott, Amar Deep Sharma, Germany

THU-470 YI  CHARACTERIZATION OF BILE ACID HOMEOSTASIS DURING LIVER REGENERATION UNDER NORMAL AND PATHOLOGICAL CONDITIONS
Michaela Mueller*, Simon Schultze, Nicole Auer, Florian Pauler, Michael Trauner, Austria

THU-471 YI  CDK1 KNOCK OUT GIANT HEPATOCYTES INDUCE LIVER PROGENITOR CELLS
Noëmi Van Hul*, Matias Caldez, Philipp Kaldis, Singapore

THU-472 YI  KERATIN 23 REPRESENTS A NOVEL LIVER INJURY MARKER REFLECTING THE SEVERITY OF DUCTULAR REACTION

THU-473 Top 10% OSTEOPONTIN: A KEY REGULATOR OF LIVER METABOLISM DURING REGENERATION AFTER PARTIAL HEPATECTOMY
Maitane Nuñez-Garcia, Beatriz Gomez-Santos, Xabier Buqué, Juan Luis García-Rodriguez, Marta R. Romero, José J G. Marín, Beatriz Arteta, Carmelo Garcia-Monzón, Wingkin Syn, Olatz Fresnedo, Patricia Aspichueta*, Spain

THU-475 YI  EGR1 MEDIATES INFLAMMATION AND REGENERATION IN CHOLESTATIC LIVER DISEASES
Sara Ibrahim*, Rania Dayoub, Michael Melter, Thomas Weiss, Germany
### Molecular and cellular biology: Cell cycle control / apoptosis and regeneration (Cont.)

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>THU-476</td>
<td>THE ROLE OF LNCRNA SNHG5 IN LIVER REGENERATION UNDER NORMAL AND PATHOLOGICAL CONDITIONS</td>
<td>Simon Schultze*, Michaela Müller, Florian Pauler, Michael Trauner</td>
<td>Austria</td>
</tr>
<tr>
<td>THU-477</td>
<td>IN SILICO CHARACTERIZATION OF LIVER PROGENITOR CELLS</td>
<td>Stefaan Verhulst*, Pau Sancho-Bru, Laurent Dollé, Leo van Grunsven</td>
<td>Belgium</td>
</tr>
<tr>
<td>THU-478</td>
<td>CAN REGULATED NECROSIS BE A POTENTIAL TARGET IN HEPATIC ISCHEMIC REPERFUSION INJURY?</td>
<td>Waqar K Saeed*, Dae Won Jun, Hyeontae Kang, Jae Yoon Jeong, Joo Hyun Sohn, Sang Bong Ahn</td>
<td>Korea, South</td>
</tr>
<tr>
<td>THU-479</td>
<td>VOLUNTARY DISTANCE RUNNING PREVENTS INFLAMMATORY LIVER INJURY IN MICE</td>
<td>Yvonne Alt*, Nadine Gehrke, Perikles Simon, Marcus Wörns, Peter Galle, Marcus Schuchmann, Jörn Schattenberg</td>
<td>Germany</td>
</tr>
</tbody>
</table>
Viral hepatitis: Hepatitis A, B, D, E – clinical (except therapy)

THU-102 YI
METABOLIC SYNDROME AND HEPATOCELLULAR CARCINOMA RISK IN HEPATITIS B: A PROSPECTIVE STUDY

THU-103
CHRONIC HBV INFECTION ALTERS MONOCYTES SUBPOPULATIONS, MONOCYTIC CD163 EXPRESSION AND PLASMA SCD163
Anna Parfieniuk-Kowerda*, Andrzej Eljaszewicz, Kamil Grubczak, Magdalena Świderska, Magdalena Maciaszek, Paula Miklasz, Jerzy Jaroszewicz, Robert Flisiak, Marcin Moniuszko, Poland

THU-104
COMPARATIVE PERFORMANCE OF THREE RAPID HBSAG ASSAYS FOR DETECTION OF HBS DIAGNOSTIC ESCAPE MUTANTS IN CLINICAL SAMPLES
Annabelle Servant-Delmas*, Thoai Duong Ly, Clémence Hamon, Ali Kassim Houdah, Syria Laperche, France

THU-105
A NOVEL APPROACH FOR HEPATITIS DELTA VIRUS VIREMIA QUANTIFICATION BY DROPLET DIGITAL PCR ASSAY
Antonella Olivero*, Maria Lorena Abate, Grazia Niro, Gian Paolo Caviglia, Chiara Rosso, Alessia Ciancio, Rossana Fontana, Antonina Smedile, Mario Rizzetto, Giorgio Maria Saracco, Italy

THU-106 YI
HBV-HDV CO-INFECTION CONSTRAINS HBV GENETIC EVOLUTION IN HBSAG
Luna Colagrossi, Rossana Scutari, Arianna Battisti*, Romina Salpini, Michela Pollicita, Ada Bertoli, Carmine Minichini, Pascale Trimoulet, Henry Fleury, Elena Nebuloso, Roberta Longo, Giuseppina Cappiello, Alberto Spanò, Vincenzo Malagnino, Loredana Sarmati, Terenzio Mari, Angelo Barlattani, Nerio Iapadre, Miriam Lichtner, Claudio Mastroianni, Ilaria Lenci, Leonardo Baiocchi, Caterina Pasquazzi, Giuseppe Maria De Sanctis, Alfonso Galeota Lanza, Maria Stanzione, Gianfranca Stornaiuolo, Massimo Marignani, Massimo Andreoni, Mario Angelico, Carlo-Federico Perno, Nicola Coppola, Valentina Svicher, Italy
Viral hepatitis: Hepatitis A, B, D, E – clinical (except therapy)

**THU-107**

**BETTER SURVIVAL IN PATIENTS WITH HEPATITIS E VIRUS C.F. TO OTHER ACUTE INSULTS CAUSING ACUTE-ON-CHRONIC LIVER FAILURE (ACLF) – APASL-ACLF RESEARCH CONSORTIUM (AARC) DATABASE**

Ashish Goel*, C E Eapen, Ashok Choudhary, Manoj Kumar Sharma, Rakhi Maiwall, Mamun Al Mahtab, Yogesh Kumar Chawla, Soek-Siam Tan, Qin Ning, Harshad Devarbhavi,

Deepak Narayan Amrapurkar, Chang Wook Kim, Saeed Sadiq Hamid,

Aamna Subhan Butt, Hasmik Ghazinyan, Zhongping Duan, Chen Yu, Ajit Sood, Guan Huei Lee, Zaigham Abbas, Gamal Shiha,

Laurentius A. Lesmana, Diana Alcantara Payawal, A. Kadir Dokmeci,

Man Fung Yuen, George K. Lau, Md. Fazal Karim, Jose D. Sollano,

Shiv K. Sarin, *India*

**THU-108**

**LONG-TERM RISK OF HEPATOCELLULAR CARCINOMA DURING FOLLOW-UP OF PATIENTS WITH CHRONIC HEPATITIS B WITH NORMAL ALANINE AMINOTRANSFERASE**

Blaise Kutala*, Emilie Estrabaud, Kevin Appourchaux, Nathalie Boyer,

Corinne Castelnau, Nathalie Guiuly, Michelle Martinot-Peignoux,

Patrick Marcellin, Tarik Asselah, *France*

**THU-109**

**DYNAMICS OF SERUM QUANTITATIVE HEPATITIS B SURFACE ANTIGEN TESTING IN ASSESSING NUCLEOS/TIDE ANALOG TREATMENT RESPONSE AND DISEASE PHENOTYPE IN CHRONIC HEPATITIS B PATIENTS IN CANADA**

Conar R. O’Neil, Stephen E. Congly, Samuel S. Lee,

Meredith Borman, Carmen L. Charlton, Carla Osiowy,

Mark G. Swain, Kelly W. Burak, Carla S. Coffin*, *Canada*

**THU-110**

**ASSOCIATION OF RHEUMATOID ARTHRITIS AND HEPATITIS B INFECTION: A NATIONWIDE NESTED CASE-CONTROL STUDY FROM 1999 TO 2009 IN TAIWAN**

Ching-Sheng Hsu*, Hui-Chu Lang, Kuang-Yung Huang,

Chien-Lin Chen, *Taiwan*
THU-111  DEEP SEQUENCING ANALYSIS OF HEPATITIS B VIRUS QUASISPECIES CHARACTERISTICS IN THE PRE-S REGION PRIOR TO DEVELOPMENT OF HEPATOCELLULAR CARCINOMA
Danny K. H. Wong*, An-Ye Zhang, Ching-Lung Lai, Fung-Yu Huang, Wai-Kay Seto, James Fung, Man-Fung Yuen, Hong Kong, China

THU-112  INCIDENCES OF ACUTE HEPATITIS D AMONG 15 TO 35 YEARS OLD MONGOLIAN YOUTHS
Delgerbat Boldbaatar, Oyungerel Lkhagva-Ochir, Maralmaa Enkhbat, Purevjargal Bat-Ulzii, Ganbolor Jargalsaikhan, Delgersaikhan Zulkhuu, Otgon Nasan, Naranbaatar Dashdorj, Naranjargal Dashdorj*, Mongolia

THU-113  POLYMORPHISMS OF IL28B IS ASSOCIATED WITH HBV SEROCONVERSION IN NATURE HISTORY OF HBV INFECTION
Dengming He*, Shiqi Tao, Shimin Guo, Maoshi Li, Xianghua Zeng, Zhaoxia Tan, Yuming Wang, China

THU-114  RISK FACTORS AND SEROPREVALENCE OF HEPATITIS E IN PREGNANT AND NON-PREGNANT WOMEN IN A SOUTHERN REGION OF BRAZIL
Dominique A. Muzzillo*, Svenja Hardtke, Rodrigo Rocco, Jony Ogata, Maira Barbosa, Simone Braga, Eliane Maluf, Giorgio Baldanzi, Elvira Doi, Dione Da Cunha, Leonardo De Oliveira Jr (in memorium), Almir Urbanetz, Denis Nascimento, Edison Tristão, Renato Sbalqueiro, Heiner Wedemeyer, Brazil

THU-115  THE HUMAN LEUKOCYTE ANTIGEN -DPA1 RS3077 TT POLYMORPHISM IS ASSOCIATED WITH SPONTANEOUS CLEARANCE OF HBS ANTIGEN IN CAUCASIANS WITH CHRONIC HEPATITIS B
Eleni Koukoulioti*, Janett Fischer, Stephan Böhm, Eckart Schott, Balazs Fülop, Renate Heyne, Thomas Berg, Florian van Bömmel, Germany

THU-116  HEPATITIS B DNA AND NOT QUANTITATIVE SURFACE ANTIGEN AS A PREDICTOR OF SEVERITY OF LIVER DISEASE IN UNTREATED GENOTYPE A E-ANTIGEN NEGATIVE DISEASE
Enoka Gonsalkorala*, Matthew D. Sadler, Matthew Bruce, Mary Horner, Anna Mrzljak, Suman Verma, Ivana Carey, Kosh Agarwal, United Kingdom
Viral hepatitis: Hepatitis A, B, D, E – clinical (except therapy) (Cont.)

THU-117 WHAT WOULD WE HAVE IF NAIVE HEPATITIS B PATIENTS WITH HBV-DNA LEVELS BELOW 2000 IU/ML WERE PERFORMED LIVER BIOPSY; THE RESULTS OF 85 YOUNG-MALE AND NAIVE PATIENTS
Ercan Yenilmez*, Riza A. Cetinkaya, Murat Afyon, Asim Ulcay, Vedat Turhan, Turkey

THU-118 EVALUATION OF A NEW COMMERCIAL ASSAY USING A ONE-STEP REAL TIME RT-PCR TECHNOLOGY FOR HDV RNA VIRAL LOAD QUANTIFICATION
Frédéric Le Gal*, Mirco Fabrice, Fernando Neri Pinto, Elhame Anouhal, Ségolène Brichler, Emmanuel Gordien, France

THU-119 PERINATAL TRANSMISSION HBV IN A WESTERN SETTING; WHAT IS THE MATERNAL VIRAL THRESHOLD AT WHICH ANTIVIRAL THERAPY SHOULD BE CONSIDERED?
Gabrielle Wark*, Scott Davison, Anne Glass, Kelly Somes, Miriam T. Levy, Australia

THU-120 NON-INVASIVE CLINICAL SCORES TO IDENTIFY LIVER FIBROSIS IN HEPATITIS DELTA PATIENTS
Gunnar Lewon Lutterkort*, Anika Wranke, Cihan Yurdaydin, Eva Budde, Ralf Lichtinghagen, Judith Stift, Svenja Hardtke, Ramazan Idilman, Onur Keskin, Armin Koch, Michael P Manns, Hans Peter Dienes, Heiner Wedemeyer, Benjamin Heidrich, Germany

THU-121 CORRELATION OF MUTATIONS WITHIN HDV-PROTEIN WITH HLA BACKGROUNDS OF PATIENTS LEADS TO IDENTIFICATION OF NOVEL CD8 T CELL EPITOPES
Hadi Karimzadeh*, Bettina Budeus, Anna Kosinska, Tanja Bauer, Andreas Heinold, Daniel Hoffmann, Ulrike Protzer, Michael Roggendorf, Germany

THU-122 EARLY EXPERIENCES FROM ONE OF THE FIRST TREATMENT PROGRAMS FOR CHRONIC HEPATITIS B IN SUB-SAHARAN AFRICA
Hanna Aberra*, Hailemichael Desalegn, Nega Berhe, Girmay Medhin, Svein Gundersen, Asgeir Johannoten, Ethiopia
THU-123
AUTOCHTHONOUS HEPATITIS E: A NEW RISK FACTOR FOR CIRRHOSIS DECOMPENSATION
Hélène Blasco Perrin*, Vincent Blasco-Baque, Florence Abravanel, Christophe Bureau, Marie Angèle Robic, Jean Pierre Vinel, Jean Marie Peron, France

THU-124
IMMUNE RECONSTITUTION IN PREGNANCY AND CHRONIC HEPATITIS B – IS POST-DELIVERY FLARE ASSOCIATED WITH EVOLUTION IN HBV DNA VIRAL REPLICATION AND HBSAG LEVELS IN UNTREATED PATIENTS POST PARTUM?
Ivana Carey*, Marie-Ange McLeod, Matthew Bruce, Mary Horner, Teresa Bowyer, Kath Oakes, Anna Mrzljak, Ron Basuroy, Suman Verma, Kosh Agarwal, United Kingdom

THU-125
LONG-TERM OUTCOME OF HEPATITIS B E-ANTIGEN SEROCLEARANCE IN CHRONIC HEPATITIS B – RESULTS FROM THE C.H.E.S.S. COHORT
James Fung*, Wai-Kay Seto, Danny Wong, Ching-Lung Lai, Man-Fung Yuen, Hong Kong, China

THU-126
ASSOCIATION OF A COMMON POLYMORPHISM IN THE TOLL-LIKE RECEPTOR (TLR) 3 GENE WITH SPONTANEOUS HBS ANTIGEN CLEARANCE
Janett Fischer*, Eleni Koukoulioti, Stephan Böhm, Eckart Schott, Balazs Fülöp, Renate Heyne, Thomas Berg, Florian van Bömmel, Germany

THU-127
SERUM LEVELS OF WISTERIA FLORIBUNDA AGGLUTININ-POSITIVE MAC-2 BINDING PROTEIN AS SHORT-TERM PREDICTORS OF HEPATOCELLULAR CARCINOMA IN CHRONIC HEPATITIS B

THU-128
CLINICAL EPIDEMIOLOGICAL INVESTIGATION OF DEATH CAUSES IN PATIENTS WITH HBV-ACLF
Xiaoyan LIU, Jinhua Hu*, Jing CHEN, Haibin SU, Haozhen YANG, Long XIAO, Jingjin TONG, China
Viral hepatitis: Hepatitis A, B, D, E – clinical (except therapy) (Cont.)

**THU-129**

**CLINICAL SERUM PREDICTORS FOR SIGNIFICANT MORPHOLOGICAL CHANGES OF COHORT OF CHINESE CHRONIC HEPATITIS B VIRAL (CHB) CARRIES WITH PERSISTENTLY NORMAL ALAMINE AMINOTRANSFERASE (ALT)**

Jinlin Cheng*, Chenxia Hu, Lanjuan li, *China*

**THU-130**

**HEPATITIS E IN HAEMATOLOGICAL PATIENTS IN EUROPE: A MULTICENTRE STUDY**

Johann Von Felden*, Laurent Alric, Paul Schnitzler, Dominik Bettinger, Jean Marie Peron, Heiner Wedemeyer, Ulrich Spengler, Stefan Schlabe, Christoph Hoener zu Siederdissen, Jan Cornelissen, Maria Teresa Giordani, Gabriella Par, Celia Aitken, Robert Thimme, Ansgar W Lohse, Robert A de Man, Sven Pischke, Vincent Mallet, *Germany*

**THU-131**

**RHEUMATOLOGICAL PATIENTS ARE AT RISK OF CHRONIC HEV INFECTION: A MULTICENTRIC EUROPEAN STUDY**

Sven Pischke, Johann Von Felden*, Jean Marie Peron, Laurent Alric, Heiner Wedemeyer, Ulrich Spengler, Paul Schnitzler, Dominik Bettinger, Stefan Schlabe, Jan Cornelissen, Christoph Hoener zu Siederdissen, Maria Teresa Giordani, Gabriella Par, Robert Thimme, Ansgar W Lohse, Celia Aitken, Robert A de Man, Vincent Mallet, *Germany*

**THU-132**

**HOSPITAL EPIDEMIOLOGY OF HEPATITIS B VIRUS INFECTION**

Jing Meng, Junqi Niu*, *China*

**THU-133**

**INCREASING ACCESS TO SPECIALIST CARE IN CHRONIC HEPATITIS B IN AUSTRALIA**

Kendall Williams*, Miriam Levy, Heidi Lord, *Australia*

**THU-134**

**PREVALENCE OF HEPATITIS E VIRUS IN SOLID ORGAN TRANSPLANT RECIPIENTS: A META-ANALYSIS**

Kessarin Thanapirom*, Paweena Susantitaphong, Sombat Treeprasertsuk, Kearth Praditpornsilpa, Piyawat Komolmit, *Thailand*
THU-135  HEPATITIS B VIRUS PRECORE-, BASAL CORE PROMOTOR- AND PRES-GENE VARIANTS: IMPORTANCE FOR REACTIVATION IN A LARGE COHORT OF HBS ANTIGEN CARRIERS
Lisa Sommer*, Kai-Henrik Peiffer, Johannes Vermehren, Viola Knop, Christoph Sarrazin, Stefan Zeuzem, Germany

THU-136  IMMUNE-ESCAPE MUTATIONS AND STOP-CODONS IN HBSAG CIRCULATES IN A RELEVANT PROPORTION OF PATIENTS WITH CHRONIC HBV INFECTION EXPOSED TO ANTI-HBV DRUGS IN EUROPE: IMPLICATIONS FOR HBV TRANSMISSION IN THE SETTING OF VACCINATION AND DISEASE PROGRESSION

THU-137  CHRONIC HEPATITIS B IS ASSOCIATED WITH INCREASED CARDIOVASCULAR RISK ASSESSED BY INTIMA-MEDIA THICKNESS
Mar Riveiro-Barciela*, Fernando Martinez-Valle, Isidro Sanz-Perez, Cristina Marcos-Fosch, David Tabernero, Maria Homs, Francisco Rodriguez-Frias, Rafael Esteban, Maria Buti, Spain

THU-138  HBSAG LEVELS NEED HBV GENOTYPING TO DIFFERENTIATE INACTIVE CARRIERS HBSAG CARRIERS FROM HBEAG NEGATIVE CHRONIC HEPATITIS B
Mar Riveiro-Barciela*, Marta Bes, Maria Homs, David Tabernero, Rosario Casillas, Silvia Sauleda, Leonardo Nieto, Francisco Rodriguez-Frias, Rafael Esteban, Maria Buti, Spain
Viral hepatitis: Hepatitis A, B, D, E – clinical (except therapy) (Cont.)

THU-139 PREVENTS HBV REACTIVATION WITH TENOFOVIR IN ANTI-HBC POSITIVE PATIENTS WITH HEMATOLOGIC MALIGNANCIES TREATED WITH RITUXIMAB. RESULTS FINAL VISIT 18-MONTHS (PREBLIN STUDY)
Maria Buti*, Maria L. Manzano, Rosa M. Morillas, Montserrat Garcia-Retortillo, Leticia Martin, Martin Prieto, Maria L. Gutiérrez, Emilio Suárez, Fernando Gil-Ares, Javier López, Pilar Castillo, Manuel Rodríguez, José M. Zozaya, Miguel A. Simón, Luis E. Morano, José L. Calleja, Rafael Esteban, Spain

THU-140 HEV GT3 INFECTION IN HUMAN CHIMERIC-LIVER MICE IS NOT ASSOCIATED WITH A POTENT INTRAHEPATIC INNATE IMMUNE RESPONSE
Martijn Van De Garde*, Suzan Pas, Lucio Gama, Andre Boonstra, Thomas Vanwolleghem, Netherlands

THU-141 NATURAL HISTORY OF CHRONIC HEPATITIS B VIRUS INFECTION IN INACTIVE CARRIERS AND IN “GRAY ZONE” PATIENTS
Martin S. Bonacci*, Sabela Lens, Zoe Mariño, Maria C. Londoño, Antoni Mas, Jose M. Sanchez-Tapias, Xavier Forns, Spain

THU-142 MOLECULAR CHARACTERIZATION OF HEPATITIS B VIRUS STRAINS IN RURAL SOUTH CAMEROON, 2010-2015
Mary Rodgers*, Barbara Harris, Vera Holzmayer, Jules Kemegne, Bih Awazi, Lazare Kaptue, Dora Mbanya, Gavin Cloherty, Nicaise Ndemb, United States

THU-143 HBSAG LOSS IS ENOUGH TO DISCONTINUE LONG-TERM NUCLEOS(T)IDE ANALOGUE THERAPY IN HBEAG-NEGATIVE CHRONIC HEPATITIS B PATIENTS IN REAL PRACTICE?
Massimo Fasano*, Marianna Ciarallo, Grazia Niro, Rossana Fontana, Raffaele Cozzolongo, Annamaria Maci, Imma Carraturo, Antonio Miglietta, Gioacchino Angarano, Teresa Santantonio, Italy

THU-144 ACTIVE HEPATITIS D VIRUS INFECTION IS POORLY IDENTIFIED WITH THE USE OF IMMUNOGLOBULIN M TITRE
Matthew D. Sadler*, Kate E. Childs, Dazhuang Shang, Suman Verma, Matthew Bruce, Mary Horner, Kosh Agarwal, Ivana Carey, Canada
THU-145  LONG-TERM FIBROSIS AND VIRAL LEVEL PROGRESSION AMONG TREATED AND UNTREATED PATIENTS WITH CHRONIC HEPATITIS B  
Jia Li, Stuart Gordon, Loralee Rupp, Talan Zhang, Joseph Boscarino, Connie Trinacty, Mark Schmidt, Anne Moorman, Scott Holmberg, Mei Lu*, United States

THU-146  ALTERED EXPRESSION OF STAT1, MX AND SOCS3 ASSOCIATED STRONGLY WITH OUTCOME OF THERAPY IN HBV INFECTION  
Meifang Han*, Yong Li, Yuanya Zhang, Xiaoping Luo, Qin Ning, China

THU-147  DEVELOPMENT AND VALIDATION OF A RISK SCORE SYSTEM INCLUSIVE OF ANTIVIRAL THERAPY FOR PREDICTING LIVER CIRRHOSIS RISK IN DIVERSE PATIENTS WITH CHRONIC HEPATITIS B INFECTION  
Mingjuan Jin*, Hwai-I Yang, An K. Le, Mei-Hsuan Lee, Joseph Hoang, Nghia H. Nguyen, Derek Lin, Huy Trinh, Jiayi Li, Jian Zhang, Chien-Jen Chen, Mindie Nguyen, United States

THU-148  HIGH SEROPREVALENCE OF HEPATITIS E ANTIBODIES AMONG PATIENTS WITH CHRONIC HEPATITIS C IN SWEDEN  
Miriam Karlsson*, Åsa Mellgren, Rune Wejstål, Hélène Norder, Sweden

THU-149  SPONTANEOUS LOSS OF HEPATITIS B SURFACE ANTIGEN AND ANTIBODY, BASED ON A LONG-TERM FOLLOW-UP STUDY IN JAPAN  
Naota Taura*, Kazuhiko Nakao, Japan

THU-150  HOMEOSTASIS MODEL ASSESSMENT–IR AND LEPTIN AS A PREDICTORS OF LIVER FIBROSIS AMONG PATIENTS WITH CHRONIC HEPATITIS B VIRUS INFECTION  
Nasser Mousa*, Ahmed Abdel-Razik, Niveen El-Wakeel, Sherif Elbaz, Narmin Effat, Wagdi Elkashef, Waleed Eldars, Egypt

THU-151  IMPACT OF OCCULT HBV INFECTION IN HEPATOCELULAR CARCINOMA PRESENTATION IN HCV-RELATED CIRRHOSIS  
Nicola Coppola*, Valentina Iodice, Mario Starace, Carmine Minichini, Nunzia Farella, Lorenzo Onorato, Giulia Liorre, Evangelista Sagnelli, Giorgio De Stefano, Italy
Viral hepatitis: Hepatitis A, B, D, E – clinical (except therapy) (Cont.)

**THU-152**

**ACUTE LIVER FAILURE CAUSED BY HEPATITIS A VIRUS (HAV) INFECTION IN JAPAN: RECENT STATUS BASED ON NATIONWIDE SURVEYS**

Nobuaki Nakayama*, Masamitsu Nakao, Yoshihito Uchida, Hirohito Tsubouchi, Hajime Takikawa, Satoshi Mochida, Japan

**THU-153**

**HEPATITIS E VIRUS GENOTYPE 3 IN SEWAGE AND GENOTYPE 1 IN SPORADIC ACUTE HEPATITIS CASES IN ISRAEL**

Daniela Ram, Yossi Manor, Yael Gozlan, Eli Schwartz, Ziv Ben-Ari, Ella Mendelson, Orna Mor*, Israel

**THU-154**

**HEPATITIS E ORF2 ANTIGEN LEVELS DIFFERENTIATE BETWEEN ACUTE AND CHRONIC COURSE OF INFECTION**

Patrick Behrendt*, Birgit Bremer, Daniel Todt, Richard J. Brown, Michael P. Manns, Eike Steinmann, Heiner Wedemeyer, Germany

**THU-155**

**EXTRA-HEPATIC REPLICATION AND INFECTION OF HEPATITIS E VIRUS IN NEURONAL-DERIVED CELLS**

Patrick Behrendt*, Svenja Drave, Yannick Debing, Daniel Todt, Martina Friesland, Michael Engelmann, Stephanie Walter, Heiner Wedemeyer, Johann Neyts, Eike Steinmann, Germany

**THU-156**

**SEROLOGICAL AND MOLECULAR STUDY OF HEPATITIS E VIRUS INFECTIONS OVER 2 YEARS (2013-2015) AT MARSEILLE UNIVERSITY HOSPITALS AND IN PROVENCE-ALPES-CÔTE D’AZUR REGION, SOUTHEASTERN FRANCE**

Philippe Colson*, Michael Huart, Jean-Dominique Poveda, Anais Selles, Marine Sicello, Catherine Dhiver, Rafael Tola, Sarah Aherfi, Anne Motte, Catherine Tamalet, Valérie Moal, René Gérolami, France

**THU-157**

**HIGH RATES OF HEPATITIS B VIRUS (HBV) FLARE AND REACTIVATION AMONG PATIENTS WITH CHRONIC INACTIVE HBV AND PRIOR RESOLVED HBV INFECTION TREATED WITH RITUXIMAB**

Kevin Junus, Maria Aguilar, Priya Patel, David Irwin, Stephen Yee, Benny Liu, Taft Bhuket, Robert Wong*, United States
THU-158 QUANTIFICATION OF HBSAG IN HBV PATIENTS WITH CHRONIC KIDNEY DISEASE: RELATIONSHIP WITH VIRAL LOAD AND HISTOLOGICAL FINDINGS
Alessandra S. N. Lima, Camila S. Ferreira, Isabela R. D. de Castro, Jardelina S. Bernardino, Rafael Alves, Genimari A. Silva, Christini T. Emori, Silvia N. Uehara, Isabel M. Carvalho-Mello, Valeria P. Lanzoni, Ana Cristina A. Feldner, Ivonete Sandra S. Silva, Antonio Eduardo B. Silva, Maria Lucia G. Ferraz, Roberto Carvalho-Filho*, Brazil

THU-159 A HIGH DENSITY OF MUTATIONS WITHIN HLA CLASS I AND II HBSAG/RT EPITOPES CHARACTERIZES HBV VARIANTS EMERGING DURING IMMUNE-SUPPRESSION DRIVEN HBV REACTIVATION
Romina Salpini*, Alba Grifoni, Alessandra Lo Presti, Antonella Minutolo, Arianna Battisti, Luna Colagrossi, Massimo Amicosante, Vittorio Colizzi, Aldo Marrone, Nicola Coppola, Loredana Sarmati, Massimo Andreoni, Mario Angelico, Massimo Ciccozzi, Carlo Federico Perno, Carla Montesano, Valentina Svicher, Italy

THU-160 VACCINE-ESCAPE HBSAG MUTATIONS CIRCULATING IN A RELEVANT PROPORTION OF HBV GENOTYPE D INFECTED PATIENTS CORRELATE WITH ATYPICAL SEROLOGICAL PROFILES, HIGH VIREMIA AND TRANSAMINASES: POTENTIAL IMPLICATION FOR VACCINE SUCCESS
Romina Salpini*, Arianna Battisti, Luna Colagrossi, Claudia Alteri, Ada Bertoli, Lavinia Fabeni, Cesare Sarrecchia, Domenico Di Carlo, Michela Pollicita, Miriam Lichtner, Claudio Mastroianni, Giuseppe De Sanctis, Maurizio Paoloni, Massimo Marignani, Caterina Pasquazzi, Daniele Di Paolo, Nerio Iapadre, Terenzio Mari, Giustino Parruti, Sara Romano, Michela Visca, Iacopo Vecchiet, Massimo Andreoni, Giuseppina Cappiello, Alberto Spanò, Mario Angelico, Carlo Federico Perno, Valentina Svicher, Italy

THU-161 CLEARANCE OF HBV DNA IN IMMUNIZED CHILDREN BORN TO HBSAG POSITIVE MOTHERS, YEARS AFTER BEING DIAGNOSED WITH OCCULT HBV INFECTION
Seyed Mohammad Jazayeri*, Seyed Moayed Alavian, Ahmad Reza Sadeghi, Iran
Viral hepatitis: Hepatitis A, B, D, E – clinical (except therapy) (Cont.)

THU-162 A TERRITORY-WIDE STUDY ON THE SEROPREVALENCE OF HEPATITIS B VIRUS IN THE GENERAL POPULATION AFTER UNIVERSAL HEPATITIS B IMMUNIZATION ERA IN HONG KONG, CHINA
Sze Hang Kevin Liu*, Wai-Kay Seto, Danny Ka-Ho Wong, John Chi-Hang Yuen, Yuk Fai Frank Lam, Ka Shing Michael Cheung, Wai Pan Elvis To, Kwan Lung Michael Ko, Lung Yi Loey Mak, Ching-Lung Lai, Man-Fung Yuen, Hong Kong, China

THU-163 THE ROLE OF CELLULAR IMMUNITY AND CYTOKINES IN THE PATHOGENESIS OF CHRONIC HEPATITIS B IN CHILDREN
Tatiana Raba*, Tatiana Kalinski, Moldova, Republic of

THU-164 QUANTIFICATION OF HBSAG (HBSAG-Q) IN HBEAG-NEGATIVE PATIENTS RECEIVING NUCLEOS(T)IDE ANALOGUES TO PREDICT THE LOSS OF HBSAG
Teresa Broquetas*, Montserrat García-Retortillo, Juan José Hernández, Marc Puigvéhi, Rosa Fernández, Nuria Cañete, Susanna Coll, Beatriz Cabrero, Maria Dolores Giménez, Felipe Bory, Ricard Solà, Jose A. Carrión, Spain

THU-165 HEPATITIS B REACTIVATION IN PATIENTS RECEIVING RITUXIMAB: AS CLINICIANS HOW GOOD ARE WE AT ASSESSING RISK AND PERFORMING SCREENING?
Victoria J. Appleby*, Sulleman Moreea, Ruth Bellwood, Carol Firth, Alison Haigh, United Kingdom

THU-166 IMPACT OF DYNAMIC VIRAL AND BIOCHEMICAL PARAMETERS ON PROGRESSION OF LIVER FIBROSIS IN A COHORT OF INACTIVE EUROPEAN HEPATITIS B (HBV) CARRIERS: A PROSPECTIVE LONGITUDINAL STUDY (ALBATROS STUDY)
Viola Knop*, Johannes Vermehren, Jörg Petersen, Peter Buggisch, Heiner Wedemeyer, Markus Cornberg, Stefan Mauss, Martin Sprinzl, Thomas Berg, Florian van Bömmel, Hartwig Klinker, Dietrich Hüppe, Jean-Pierre Bronowicki, Michael Rausch, Tania Welzel, Annika Vermehren, Simone Susser, Stefan Zeuzem, Christoph Sarrazin, Germany
THU-167 YI  POLYMORPHISMS OF HLA-DPB1 ARE ASSOCIATED WITH LONG-TERM CLINICAL OUTCOME IN A DIVERSE COHORT OF CHRONIC HEPATITIS B PATIENTS
Willem Pieter Brouwer*, Adriaan J. van der Meer, Andre Boonstra, Rob J. de Knecht, Rob A. de Man, Fiebo J. ten Kate, Harry L. Janssen, Bettina E. Hansen, Netherlands

THU-168 YI  EXPRESSION AND FUNCTION OF TOLL-LIKE RECEPTOR 7 IN CHRONIC HEPATITIS B PATIENTS LINKS TO ANTIVIRAL EFFECT OF PEG-IFN-A-2A THERAPY
Xiaoyong Zhang*, Jun Ge, Zuxiong Huang, Jian Sun, Mengji Lu, Jinlin Hou, China

THU-169 YI  HEPATITIS E VIRUS INFECTS NEURONS AND NERVOUS SYSTEM
Xinying Zhou*, Fen Huang, Lei Xu, Bart Jacobs, Wenshi Wang, Yijin Wang, Dave Sprengers, Herold Metselaar, Harry Dalton, Nassim Kamar, Maikel Peppelenbosch, Qiuwei Pan, Netherlands

THU-170 YI  MYELOID-DERIVED SUPPRESSOR CELLS ARE CLOSELY ASSOCIATED WITH DISEASE PROGRESSION IN PATIENTS WITH HBV-RELATED ACUTE-ON-CHRONIC LIVER FAILURE
Yingfu Zeng, Chaoshuang Lin*, Lirong Lu, Ying Liu, China

THU-171 YI  CLINICAL IMPACT OF ASYMPTOMATIC HEV INFECTION PROVEN BY SCREENING ON BLOOD DONATION IN HOKKAIDO, JAPAN
Jong-Hon Kang, Yoshiya Yamamoto*, Yoshiyasu Karino, Masao Watanebe, Naoto Yoshizaki, Sin-Ichi Katsuki, Keiji Matsubayashi, Japan

THU-172 YI  CLINICAL CHARACTERISTICS AND LONG-TERM OUTCOME OF ACUTE KIDNEY INJURY IN PATIENTS WITH HBV-RELATED ACUTE-ON-CHRONIC LIVER FAILURE
Xinxing Shi, Yuming Wang*, China

THU-173 YI  HLA-DP GENE AND PREVALENCE DISCREPANCY OF HEPATITIS B VIRUS INFECTION
Yun Liao, Qi Zhang*, Bei Cai, Jie Chen, Lanlan Wang, China
Viral hepatitis: Hepatitis A, B, D, E – clinical (except therapy) (Cont.)

**THU-174**

**ASSESSMENT OF HEALTH-RELATED QUALITY OF LIFE IN CHRONIC HEPATITIS B INFECTION PATIENTS IN TURKEY: A MULTICENTER STUDY**


**THU-175**

**VIROLOGICAL CHARACTERIZATION OF CHRONIC HEPATITIS B IN AUSTRALIA: HIGH PREVALENCE OF VARIANTS ASSOCIATED WITH DISEASE PROGRESSION**

Zina Valaydon*, Catherine Croagh, Peter Revill, Sally Bell, Paul Desmond, Alexander Thompson, *Australia*
Viral hepatitis: Hepatitis B & D – experimental

**THU-176**

**NK CELLS FROM CHRONIC HBV PATIENTS IN DIFFERENT CLINICAL PHASE EXHIBIT ALTERED GENE EXPRESSION PROFILES BY RNA-SEQ**

Jun Hou, Rik de Groen, Thomas Vanwolleghem, Gertine Van Oord, Zwier Groothuismink, Robert De Knegt, André Boonstra*, Netherlands

**THU-177**

**ACHIEVEMENT OF SURFACE ANTIGEN CLEARANCE IN THE LIVER BY COMBINATION THERAPY WITH REP 2139-CA AND NUCLEOSIDE ANALOGUES AGAINST CHRONIC HEPATITIS B**

Jonathan Quinet, Catherine Jamard, Andrew Vaillant*, Lucyna Cova, Canada

**THU-178**

**CO-SPECIATION OF HBV AND HDV GENOTYPES: STUDY OF PLASMA SAMPLES OF 826 INFECTED-PATIENTS**

Athenaïs GERBER*, Samira DZIRI, Ségolène BRICHLER, Frédéric LE GAL, Emmanuel GORDIEN, France

**THU-179**

**CHARACTERISATION OF A MOUSE MODEL FOR THE STUDY OF HDV CHRONIC INFECTION**

Carla Usai, Lester Suarez Amaran, Marianna Di Scala, Yi Ni, Stephan Urban, Rafael Aldabe, Gloria Gonzalez-Aseguinolaza*, Spain

**THU-180**

**VISUALIZATION OF MYRCLUDEX B BINDING TO THE MOUSE HOMOLOGUE OF HEPATITIS B VIRUS RECEPTOR SODIUM TAUROCHOLATE COTRANSPORTING POLYPEPTIDE (NTCP) IN MOUSE LIVER SECTIONS**

Christina Kaufman*, Max Sauter, Thomas Longerich, Walter Mier, Stephan Urban, Germany

**THU-181**

**EFFECT OF THE HEPATITIS B CORE PROTEIN C-TERMINAL DOMAIN MUTATIONS ON HBV TRANSCRIPTION**

Chun Kong Chong*, Serene Cheng, Jasmine Tsoi, Fung-Yu Huang, Wai-Kay Seto, Ching-Lung Lai, Man-Fung Yuen, Danny Wong, Hong Kong, China

**THU-182**

**HBV E ANTIGEN AND ITS PRECURSORS PROMOTE THE PROGRESS OF HCC BY INTERACTING WITH NUMB AND DECREASING P53 ACTIVITY**

Dan Liu*, Lei Cui, Yuan Wang, Guifang Yang, Jing He, Ruidong Hao, Chengpeng Fan, Mengmeng Qu, Zhepeng Liu, Min Wang, Lang Chen, Deyin Guo, China
THU-183 YI  EXPLORING CURRENT HEPATITIS B VIRUS THERAPIES IN SINGLE AND COMBINATION THERAPY IN INFECTED HEPATOCYTE CULTURES A 3D MICROFLUIDIC PLATFORM
Emma M. Large*, John C. Malone, Caroline A. Smith-Burchnell, Sophie A. Snow, David J. Hughes, *United Kingdom

THU-184 YI  BI- AND TRISPECIFIC ANTIBODY CONSTRUCTS MEDIATE SPECIFIC T-CELL RETARGETING TOWARDS AND ELIMINATION OF HBV-POSITIVE HEPATOCYTES AND TUMOR CELLS
Felix Bohné*, Oliver Quitt, Julia Hasreiter, Shanshan Luo, Jan-Hendrick Bockmann, Raindy Tedjokusumo, Frank Momburg, Ulrike Protzer, *Germany

THU-185 YI  CHARACTERIZATION AND FUNCTIONAL MODULATION OF HBV-SPECIFIC CD4+ T CELL RESPONSES
Felix J. Jacob*, Tobias Flecken, Robert Thimme, Tobias Boettler, *Germany

THU-186 YI  SCREENING AN FDA-APPROVED DRUG LIBRARY ON A CELL LINE THAT SUPPORTS THE FULL LIFECYCLE OF HEPATITIS DELTA VIRUS
Florian A. Lempp*, Lea Nußbaum, Lisa Rieble, Yi Ni, Stephan Urban, *Germany

THU-187 YI  THE HBX-DLEU2 LNCRNA COMPLEX REGULATES TRANSCRIPTION FROM THE HBV CCCDNA AND FROM CELLULAR GENES IN CIS AND IN TRANS
Francesca Guerrieri*, Letizia Chiodo, Debora Salerno, Safaa Jeddari, Giancarlo Ruocco, Massimo Levreco, *Italy

THU-188 YI  PARTIALLY RESTORED T CELL RESPONSES IN HBEAG-NEGATIVE CHRONIC PATIENTS AFTER STOPPING NA THERAPY
Franziska Rinker*, Christoph Höner zu Siederdissen, Birgit Bremer, Michael P. Manns, Heiner Wedemeyer, Anke R. M. Kraft, Markus Cornberg, *Germany

THU-189 YI  HEPATITIS E VIRUS ORF3 PROTEIN FORMS MEMBRANE-ASSOCIATED OLIGOMERS
Jérôme Gouttenoire*, Johann Mauron, Joël Oppliger, Maxime Matter, Viet Loan Dao Thi, Darius Moradpour, *Switzerland
THU-190 YI  
SINGLE CELL ANALYSES DEMONSTRATE NO UP-REGULATION OF HUMAN INNATE GENES IN HDV MONO-INFECTED HUMAN HEPATOCYTES  
Katja Giersch*, Tassilo Volz, Lena Allweiss, Janine Kah, Ansgar W. Lohse, Jörg Petersen, Maura Dandri, Marc Lütgehetmann, Germany

THU-191  
SIMILAR FREQUENCIES, PHENOTYPE AND ACTIVATION STATUS OF INTRAHEPATIC NK CELLS IN CHRONIC HBV PATIENTS AFTER LONG-TERM TREATMENT WITH TENOFOVIR DISOPROXIL FUMARATE (TDF)  

THU-192  
INNATE IMMUNE SENSING OF HEPATITIS B VIRUS AND RESPONSE TO INTERFERON STIMULATION ARE MOSTLY ELICITED IN NON HBV PRODUCING HUMAN HEPATOCYTES IN VIVO  
Lena Allweiss*, Jan Bockmann, Tassilo Volz, Katja Giersch, Janine Kah, Ansgar W. Lohse, Jörg Petersen, Marc Lütgehetmann, Maura Dandri, Germany

THU-193  
DIFFERENTIAL REDUCTIONS IN VIRAL ANTIGENS EXPRESSED FROM CCCDNA VS INTEGRATED DNA IN TREATMENT NAÏVE HBEAG POSITIVE AND NEGATIVE PATIENTS WITH CHRONIC HBV AFTER RNA INTERFERENCE THERAPY WITH ARC-520  
Man-Fung Yuen*, Henry Lik Yuen Chan, Kevin Liu, Bruce D. Given, Thomas Schluep, James Hamilton, Ching-Lung Lai, Stephen A. Locarnini, Johnson Y N Lau, Carlo Ferrari, Robert G. Gish, Hong Kong, China

THU-194  
QUANTIFICATION OF HEPATITIS B CORE-RELATED ANTIGEN IS MORE USEFUL THAN QUANTITATIVE HBSAG FOR IDENTIFICATION OF INACTIVE HBSAG CARRIERS  
Mar Riveiro Barciela*, Marta Bes, Maria Homs, David Taberner, Rosario Casillas, Silvia Sauleda, Leonardo Nieto, Francisco Rodriguez-Frias, Rafael Esteban, Maria Buti, Spain
<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>THU-195</td>
<td>HEPATITIS DELTA VIRUS EVOLUTION RATE IS HIGH IN PATIENTS WITH CHRONIC DELTA INFECTION, BUT TENDS TO STABILIZE OVER TIME&lt;br&gt;Maria Homs*, Francisco Rodriguez-Frias, Josep Gregori, Rosario Casillas, Pilar Reimundo, Alicia Ruiz, Cristina Godoy, David Tabernero, Josep Quer, Mar Riveiro-Barciela, Rafael Esteban, Maria Buti, Spain</td>
</tr>
<tr>
<td>THU-196</td>
<td>TOLL-LIKE RECEPTOR 4 PATHWAY MEDIATE LIVER FIBROSIS IN CHIMERIC MICE WITH HUMAN HEPATOCYTES PERSISTENTLY INFECTED WITH HBV&lt;br&gt;Masaya Sugiyama*, Tatsuya Kanto, Masashi Mizokami, Japan</td>
</tr>
<tr>
<td>THU-197</td>
<td>CALPROTECTIN AND MONOCYTE RESPONSES IN THE PATHOGENESIS OF VERTICAL HBV INFECTION&lt;br&gt;Michelle Hong*, Stefania Fieni, Barbara Amadei, Simonetta Urbani, Yap-Seng Chong, Antonio Bertolletti, Singapore</td>
</tr>
<tr>
<td>THU-198</td>
<td>IN VITRO AND IN VIVO ANTIVIRAL ACTIVITIES OF AB-423 A POTENT SMALL MOLECULE INHIBITOR OF HEPATITIS B VIRUS CAPSID ASSEMBLY&lt;br&gt;Nagraj Mani*, Andrew Cole, Janet Phelps, Andrzej Ardzinski, Kyle Cobarrubias, Andrea Cuconati, Bruce Dorsey, Ellen Evangelista, Troy Harasym, Salam Kadhim, Amy Lee, Hongyan Liang, Alice Li, Kevin McClintock, Sara Majeski, Stephen Reid, Rene Rijnbrand, Sunny Tang, Xiaohoe Wang, Michael Sofia, United States</td>
</tr>
<tr>
<td>THU-199</td>
<td>REPLICATION OF THE RNA GENOME OF HEPATITIS DELTA VIRUS (HDV) BY RNA POL II IDENTIFIES A NEW CELLULAR TARGET TO BLOCK HDV REPLICATION&lt;br&gt;Natali Aheywickrama Samarakoon*, Sébastien Violot, Dulce Alfaiate, Susanne Müller-Knapp, Philippe Merle, Camille Sureau, Jean-Claude Cortay, Paul Dény, France</td>
</tr>
<tr>
<td>THU-200</td>
<td>GENOMIC ANALYSES OF HOST-PATHOGEN INTERACTIONS IN CHRONIC HEPATITIS B VIRUS INFECTION&lt;br&gt;Nimisha Chaturvedi*, Istvan Bartha, Kathryn Kitrinos, Anuj Gaggar, Dongliang Ge, Mani Subramanian, David Goldstein, Peter Revill, Alex Thompson, Jacques Fellay, Switzerland</td>
</tr>
</tbody>
</table>
THU-201 APPLICATION OF MASS CYTOMETRY TIME OF FLIGHT (CYTOF) FOR SYSTEMATIC CHARACTERIZATION OF PBMC PHENOTYPES ASSOCIATED WITH HBSAG SERUM LEVELS IN CHRONIC HBV PATIENTS
Nina Le Bert*, Laura Rivino, Yang Cheng, Damien Tan, Evan Newell, Aaron Arvey, Patrick Kennedy, Stefan Pflanz, Antonio Bertoletti, Singapore

THU-202 CHRONIC HBV INFECTION DRIVES EXPANSION OF ADAPTIVE NK CELLS
Philipp A. Müller*, Anita Schuch, Robert Thimme, Maike Hofmann, Germany

THU-203 HEPATITIS B VIRUS ACTIVATES TOLL-LIKE RECEPTOR 2 SIGNALING UPON INFECTION OF PRIMARY HUMAN HEPATOCYTES
Ruth Broering*, Zhenhua Zhang, Martin trippler, Catherine Real, Melanie Werner, Guido Gerken, Joerg Schlaak, Mengji Lu, Germany

THU-204 NUCLEIC ACID-BASED POLYMERS EFFECTIVE AGAINST HEPATITIS B VIRUS INFECTION IN PATIENTS DO NOT HARBOUR IMMUNE STIMULATORY PROPERTIES IN PRIMARY ISOLATED BLOOD OR LIVER CELLS
Catherine Real, Melanie Werner, Andreas Paul, Guido Gerken, Joerg Schlaak, Andrew Vaillant, Ruth Broering*, Germany

THU-205 MICRORNA-150 DOWNREGULATION IS INVOLVED IN PATHOGENESIS OF HBV ASSOCIATED HEPATOCELLULAR CARCINOMA THROUGH HBX-MIR150-CXCR4 SIGNALING PATHWAY
Sadaf B. Dar*, Manish C. Choudhary, Chaggan Bihari, Nirupma Trehanpati, Gayatri Ramakrishna, Shiv K. Sarin, India

THU-206 PRO-FIBROGENIC HOST PROTEIN OSTEOPONTIN PARTICIPATES IN HBV REPLICATION AND HBSAG SECRETION
Sandra Phillips*, Jason Coombes, Sameer Mistry, Marieta Simonova, Slava Pavlova, Krum Katzarov, Tanya Hadzhiolova, Thiago A. Pereira, Fausto E. Pereira, Roger Williams, Wing Syn, Shilpa Chokshi, United Kingdom

THU-207 THE CGAS-STING PATHWAY EXHIBITS ANTIVIRAL ACTIVITY AGAINST HEPATITIS B VIRUS INFECTION
Seung-Ae Yim*, Laura Heydmann, Eloi Verrier, Sarah Durand, James Kozubek, Tom Croonenborghs, Mirjam Zeisel, Nathalie Pochet, Catherine Schuster, Thomas F. Baumert, France
**Viral hepatitis: Hepatitis B & D – experimental (Cont.)**

**THU-208**

**A NEW MODEL FOR STUDYING INTERACTION BETWEEN HEPATITIS B VIRUS AND HOST CELLS DERIVED FROM HUMAN INDUCED PLURIPOTENT STEM CELLS**

**THU-209**

**LOCAL STIMULATION OF LSEC WITH NOD-LIKE RECEPTOR AGONISTS INDUCES T CELLS ACTIVATION AND RECRUITMENT AND SUPPRESSES HBV REPLICATION IN THE MOUSE MODEL**
Shunmei Huang*, Mingfa Chen, Xiaoyan Gao, Liwen Chen, Xilang Yang, Meijun Li, Dongliang Yang, Jun Wu, *China*

**THU-210**

**LSEC EXPRESS FUNCTIONAL NOD1 AND NOD2 RECEPTORS: A ROLE FOR NOD1 IN LSEC MATURATION INDUCED T CELL IMMUNITY IN VITRO**
Shunmei Huang*, Jun Wu, Chan Sun, Xiaoyan Gao, Mingfa Chen, Meijun Li, Dongliang Yang, *China*

**THU-211**

**HLA-DRB1*1501/1502 ALLELE PREDICTS SPONTANEOUS CLEARANCE OF HEPATITIS B VIRUS INFECTION**
Vijay K. Karra*, Soumya Jyothi Chowdhury, Rajesh Ruttala, Sunil Kumar Polipalli, Anita Chakravarti, Premashis Kar, *India*

**THU-212**

**HEPATITIS B VIRUS INFECTION OF HUMAN STEM CELLS-DERIVED HEPATOCELLULAR-LIKE CELLS**
Yuchen Xia*, Arnaud Carpentier, Zhensheng Zhang, Ulrike Protzer, T. Jake Liang, *United States*

**THU-213**

**TREATMENT OF CHRONICALLY HBV-INFECTED CHIMPANZEES WITH RNA INTERFERENCE THERAPEUTIC ARC-520 LED TO POTENT REDUCTION OF VIRAL MRNA, DNA AND PROTEINS WITHOUT OBSERVED DRUG RESISTANCE**
Zhao Xu*, Deborah Chavez, Bernadette Guerra, Margaret Littlejohn, Ryan Peterson, Stephen Locarnini, Robert Gish, Christopher Anzalone, Steven Kanner, Jason Goetzmann, Robert Lanford, David Lewis, Christine Wooddell, *United States*
Viral hepatitis: Hepatitis C – clinical (new compounds, resistance)

THU-214  **CONSISTENT SIMEPREVIR RESISTANCE PROFILE IN HEPATITIS C VIRUS GENOTYPE 1-INFECTED PATIENTS FAILING SIMEPREVIR INTERFERON-FREE COMPARED WITH INTERFERON-CONTAINING REGIMENS**

Bart Fevery*, Leen Vijgen, Veerle Van Eygen, Wolfgang Jessner, Chris Corbett, Michael Schlag, Oliver Lenz, Sandra De Meyer, Belgium

THU-215  **DEEP SEQUENCING RESULTS FROM THE PHASE 2 IMPACT STUDY OF SIMEPREVIR IN COMBINATION WITH DACLATASVIR AND SOFOSBUVIR IN TREATMENT-NAÏVE AND -EXPERIENCED PATIENTS WITH CHRONIC HEPATITIS C VIRUS GENOTYPE 1 OR 4 INFECTION AND DECOMPENSATED LIVER DISEASE**

Christoph Sarrazin*, Veerle Van Eygen, Leen Vijgen, Mohamed Gamil, Maria Beumont, Eric Lawitz, Sandra De Meyer, Germany

THU-216  **RESISTANCE ANALYSIS IN 1284 PATIENTS WITH GENOTYPE 1 TO 6 HCV INFECTION TREATED WITH SOFOSBUVIR/VELPATASVIR IN THE PHASE 3 ASTRAL-1, ASTRAL-2, ASTRAL-3 AND ASTRAL-4 STUDIES**

Christophe Hezode*, Nancy Reau, Evguenia Svarovskaia, Brian P. Doehle, Krishna Chodavarapu, Hadas Dvory-Sobol, John Mcnally, Anu Osinusi, Diana M. Brainard, Michael D. Miller, Hongmei Mo, Stuart Roberts, Jacqueline G. O’leary, France

THU-217  **RETREATMENT OF HCV DAA FAILURES: HCV INFECTION MAY BE INCURABLE**

Christophe Hezode**, Slim Fourati, Giovanna Scoazec, Alexandre Soulier, Anne Varaut, Murielle Francois, Isaac Ruiz, Ariane Mallat, Stephane Chevaliez, Jean-Michel Pawlotsky, France

THU-218  **AVDLIB 2: NEWS DIRECT-ACTING ANTIVIRAL (DDA) IN HCV PATIENTS WITH ADVANCED LIVER DISEASE. FINAL RESULTS OF A THE SECOND MULTICENTER PROSPECTIVE OBSERVATIONAL STUDY IN REAL LIFE PRACTICE IN FRANCE**

Denis Ouzan*, Guillaume Penaranda, Patrick Delasalle, Christophe Renou, Michel Antoni, Pierre Toulemonde, Philippe Halfon, Solange Bresson-Hadni, Jacques Liautard, Marc Bourlière, France
**Viral hepatitis: Hepatitis C – clinical (new compounds, resistance) (Cont.)**

**THU-219 Efficacy and Safety of IFN Free, Direct-Acting Antiviral-Based Treatment Regimens in Patients with Advanced Liver Disease: Community Treatment of a Real World Population in France**

**THU-220 Resistance Analysis of Genotype 1 or 3 HCV-Infected Patients Treated with Sofosbuvir/Velpatasvir+GS-9857 for 6 or 8 Weeks**

**THU-221 Hepatitis C Virus Screening Project of Patients on Current Anti-HCV Therapy**
Elena Knops*, Prabhav Kalaghatgi, Maria Neumann-Fraune, Eva Heger, Eugen Schuelter, Thomas Lengauer, Verena Keitel, Tobias Goeser, Niels Schuebel, Thomas von Hahn, Iris Peuser, Nazifa Qurishi, Katja Römer, Stefan Scholten, Martin Daeumer, Julian Schulze zur Wiesch, Axel Baumgarten, Martin Obermeier, Hauke Walter, Rolf Kaiser, Saleta Sierra, *Germany*

**THU-222 In a 5-Day Monotherapy Trial, MK-8408 Demonstrates Potent Antiviral Activity and Improved Resistance Profile in HCV Patients with Genotypes 1, 2, and 3 Infections**
THU-223  NS3 GENETIC VARIABILITY IN HCV GENOTYPE 1A ISOLATES FROM LIVER TISSUE AND SERUM SAMPLES OF TREATMENT-NAÏVE PATIENTS WITH CHRONIC HEPATITIS C  
Deborah D’aliberti, Irene Cacciola, Salvatore Benfatto, Federica Mannino, Roberto Filomia, Concetta Beninati, Carlo Saitta, Giovanni Raimondo*, Teresa Pollicino, Italy

THU-224  GENOTYPIC AND PHENOTYPIC RESISTANCE IN CLINICAL SAMPLES SUBMITTED FOR HCV NS5B DRUG RESISTANCE TESTING IN THE US  
Jacqueline D. Reeves*, Joseph Volpe, Kristi Strommen, Elizabeth Anton, Sharon Martens, Dongmei Yang, Jeannette Whitcomb, Wei Huang, Christos J. Petropoulos, Charles Walworth, United States

THU-225  C-EDGE CO-STAR: FAVORABLE IMPACT OF ELBASVIR AND GRAZOPREVIR ON HEALTH-RELATED QUALITY OF LIFE IN TREATMENT-NAÏVE HCV-INFECTED PERSONS WHO INJECT DRUGS RECEIVING OPIOID AGONIST THERAPY  
Jean Marie Arduino*, Oren Shibolet, Alain H Litwin, Jason Grebeley, Frederick Altice, Chizoba Nwankwo, T Christopher Mast, Zhiwei Jiang, Isaiaas N Gendrano, Heather L Platt, Gregory J Dore, United States

THU-226  PAN-GENOTYPIC EVALUATION OF AL-335, A CLINICAL STAGE URIDINE ANALOGUE INHIBITOR OF HEPATITIS C VIRUS POLYMERASE  
Jerome Deval’, Amy Fung, Ishani Behera, Zhinan Jin, Antitsa Stoycheva, Lawrence M Blatt, Guangyi Wang, Natalia Dyatkina, Marija Prhavc, Julian A Symons, David B Smith, Leonid Beigelman, United States

THU-227  DIRECT ANTIVIRAL COMBINATION TREATMENT ACCORDING TO PRESENCE OF BASELINE RAVS IN NS3, NS5A AND NS5B LEADS TO HIGH SVR RATES IN NON-CIRRHOTIC AND CIRRHOTIC GENOTYPE 1 INFECTED PATIENTS  
Kai-Henrik Peiffer*, Simone Susser, Julia Dietz, Caterina Berkowski, Dany Perner, Sandra Passmann, Mirjam Raeder, Johannes Vermehren, Christian Lange, Stephanie Klein, Nina Weiler, Stefan Zeuzem, Christoph Sarrazin, Germany
Viral hepatitis: Hepatitis C – clinical (new compounds, resistance) (Cont.)

THU-228 AL-335, A ONCE-DAILY PANGENOTYPIC NUCLEOTIDE HCV POLYMERASE INHIBITOR, DEMONSTRATES POTENT ANTIVIRAL ACTIVITY OVER 7 DAYS IN TREATMENT-NAÏVE GENOTYPE 1-4 PATIENTS
Elina Berliba, Tengiz Tsertsvadze, Neli Ghicavii, Dominique Guyader, Tea Kakabadze, Christopher Westland, Sushmita Chanda, Alain Patat, Qingling Zhang, Dave Smith, Jeysen Yogaratnam, Matthew McClure, Leo Beigelman, Lawrence Blatt*, John Fry, United States

THU-229 ABT-493 AND ABT-530 COMBINATION DEMONSTRATED MINIMAL POTENTIAL FOR CYP-MEDIATED DRUG-DRUG INTERACTIONS
Matthew P. Kosloski*, Sandeep Dutta, Hong Li, Federico Mensa, Jens Kort, Wei Liu, United States

THU-230 PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF NEXT GENERATION DIRECT ACTING ANTIVIRALS ABT-493 AND ABT-530 IN SUBJECTS WITH RENAL IMPAIRMENT
Matthew P. Kosloski*, Sandeep Dutta, Weihan Zhao, David Pugatch, Federico Mensa, Jens Kort, Wei Liu, United States

THU-231 PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF NEXT GENERATION DIRECT ACTING ANTIVIRALS ABT-493 AND ABT-530 IN SUBJECTS WITH HEPATIC IMPAIRMENT
Matthew P. Kosloski*, Sandeep Dutta, Haoyu Wang, David Pugatch, Federico Mensa, Jens Kort, Wei Liu, United States

THU-232 SEQUENCE ANALYSIS FOR RESISTANCE MONITORING FOLLOWING A SINGLE DOSE OF RG-101, AN ANTI-MIR TARGETING MICRORNA-122, IN CHRONIC HEPATITIS C PATIENTS
THU-233  SB 9200, A NOVEL AGONIST OF INNATE IMMUNITY, SHOWS POTENT ANTIVIRAL ACTIVITY AGAINST RESISTANT HCV VARIANTS
Meleri Jones*, Morven Cunningham, Peter Wing, Sampath DeSilva, Anjaneyulu Sheri, Seetharamaiyer Padmanabhan, Radhakrishnan Iyer, Nezam Afdhal, Graham Foster, United Kingdom

THU-234  HIGH SUSTAINED VIROLOGIC RESPONSE RATES IN PATIENTS INFECTED WITH GENOTYPE 2 WITH BASELINE NS5A POLYMORPHISMS TREATED WITH DACLATASVIR-BASED REGIMENS
Nannan Zhou*, Zhou Han, Sandra Hartman Neumann, Brenda DeGray, Joseph Ueland, Vincent Vellucci, Dennis Hernandez, Fiona McPhee, United States

THU-235  PRE-TREATMENT REDUCTION IN SENSITIVITY TO SOFOSBUVIR AND RIBAVIRIN IN PATIENTS WITH GENOTYPE 3 HEPATITIS C VIRUS WHO RELAPSE FOLLOWING ALL ORAL ANTIVIRAL THERAPY
Peter Wing*, Ana Filipe, Morven E. Cunningham, Sampath De Silva, Michelle Cheung, Meleri Jones, Will Irving, John McLauchlan, Graham R. Foster, United Kingdom

THU-236  CHARACTERIZATION OF THE ANTI-HCV ACTIVITIES OF THE NEW CYCLOPHILIN INHIBITOR STG-175
Philippe Gallay*, Udayan Chatterji, Michael Bobardt, Zhengyu Long, Shengli Zhang, Zhuang Su, United States

THU-237  PREVALENCE AND CHARACTERIZATION OF NS5A RESISTANCE ASSOCIATED VARIANTS IN PATIENTS WHO RELAPSED FOLLOWING EXPOSURE TO NS5A INHIBITORS
Philippe Halfon*, Caroline Scholtès, Sofiane Mohamed, Guillaume Penaranda, Vincent Leroy, Marc Bourlière, Denis Ouzan, Laura Polverel, Marie-Ange Thélù, Fabien Zoulim, Hacène Khiri, Sylvie Larrat, France

THU-238  NO TRANSMITTED RESISTANCE AGAINST HCV PROTEASE INHIBITORS IN ACUTE HEPATITIS C
Sebastiaan Hullegie*, Mette Christiansen, Martin Schutten, Katja Einer-Jensen, Helena Tutil, Judith Breuer, Bart Rijnders, Netherlands
Viral hepatitis: Hepatitis C – clinical (new compounds, resistance) (Cont.)

THU-239  
**RG-101 DEMONSTRATES FAVORABLE IN VITRO ANTIVIRAL ACTIVITY AND CROSS RESISTANCE PROFILE TO SUPPORT CLINICAL COMBINATION STUDIES IN HCV PATIENTS**  
Steven Neben*, Scott Davis, Paul Grint, Amy Patick, United States

THU-240  
**ANALYSIS OF HCV GENOTYPE 2 AND 3 VARIANTS IN PATIENTS TREATED WITH COMBINATION THERAPY OF NEXT GENERATION HCV DIRECT-ACTING ANTIVIRAL AGENTS ABT-493 AND ABT-530**  
Teresa Ng*, Tami Pilot-Matias, Rakesh Tripathi, Gretja Schnell, Thomas Reisch, Jill Beyer, Tanya Dekhtyar, Stanley Wang, Federico Mensa, Jens Kort, Christine Collins, United States

THU-241  
**YI**  
**Virological failures to new direct acting antivirals in a real life setting may require unconventional regimens for re-treatment**  
Velia Chiara Di Maio*, Valeria Cento, Daniele Di Paolo, Ilaria Lenci, Marianna Aragri, Gabriella Verucchi, Michela Melis, Ada Bertoli, Francesco Paolo Antonucci, Simona Francioso, Adriano Pellicelli, Vincenza Calvaruso, Caterina Pasquazzi, Dante Romagnoli, Marco Biolato, Jacopo Vecchiet, Filomena Morisco, Manuela Merli, Giovanni Battista Gaeta, Stefano Brillanti, Francesca Donato, Massimo Puoti, Vincenzo Pisani, Maurizio Paoloni, Sergio Babudieri, Antonio Craxi, Mario Angelico, Carlo Federico Perno, Francesca Ceccherini-Silberstein, Italy

THU-242  
**“OTHELLO HYPOTHESIS” INVOLVED IN THE DEVELOPMENT OF RAVS TOLERANT TO NS5A INHIBITORS IN PATIENTS WITH GENOTYPE 1B HCV INFECTION**  
Yoshihito Uchida*, Jun-Ichi Kouyama, Kayoko Naiki, Kayoko Sugawara, Mie Inao, Yukinori Imai, Nobuaki Nakayama, Satoshi Mochida, Japan
### Viral hepatitis: Hepatitis C – experimental (virology)

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>THU-243</td>
<td>ARISEING OF SIMEPREVIR DRUG-RESISTANCE Q80K IN HEPATITIS C VIRUS SUBTYPE 1A CLADE 2 ISOLATES</td>
<td>Allan Peres-da-Silva’, Débora A. dos Santos, André L. Q. Torres, Ernesto R. Caffarena, Elisabeth Lampe</td>
<td>Brazil</td>
</tr>
<tr>
<td>THU-244</td>
<td>17B-ESTRADIOL IMPAIRS HCV INFECTION interfering with virus assembly/release</td>
<td>Andrea Magri’, Matteo Barbaglia, Elisa Boccato, Michela E. Burlone, Rosalba Minisini, Arvind H. Patel, Mario Pirisi</td>
<td>Italy</td>
</tr>
<tr>
<td>THU-245</td>
<td>ANG2/ANG1 RATIO AS NON-INVASIVE BIOMARKER OF CIRRHOSIS IN PATIENTS WITH CHRONIC HEPATITIS C</td>
<td>Ángel Hernández Bartolomé’, Rosario López-Rodriguez, Maria Jesús Borque, Yolanda Rodríguez-Muñoz, Luisa Garcia-Buey, Ricardo Moreno-Otero, Paloma Sanz-Cameno</td>
<td>Spain</td>
</tr>
<tr>
<td>THU-246</td>
<td>NEUTRALIZING ACTIVITY OF MONOCLONAL ANTIBODIES DIRECTED AGAINST THE HCV GLYCOPROTEIN E2 ISOLATED FROM PATIENTS WITH SPONTANEOUSLY RECOVERY FROM AN HCV INFECTION IN A SINGLE-SOURCE OUTBREAK</td>
<td>Anne Olbrich’, Hedda Wardemann, Thomas Berg, Che Colpitts, Thomas Baumert, Julia Benckert</td>
<td>Germany</td>
</tr>
<tr>
<td>THU-247</td>
<td>CHRONIC HEPATITIS C IS ASSOCIATED WITH DYSBIOSIS OF THE SMALL INTESTINAL MICROBIOTA AND ALTERED INTESTINAL PERMEABILITY</td>
<td>Ashok S. Raj’, Erin Shanahan, Gerald Holtmann, Ingrid Hickman, Linda Fletcher, Cuong Tran, Mark Morrison, Graeme Macdonald</td>
<td>Australia</td>
</tr>
<tr>
<td>THU-248</td>
<td>FITNESS-ASSOCIATED MECHANISM OF DRUG RESISTANCE IN HEPATITIS C VIRUS</td>
<td>Isabel Gallego, Julie Sheldon, Nathan Beach, Elena Moreno, Josep Gregori, Josep Quer, Juan Ignacio Esteban, Charles Rice, Esteban Domingo, Celia Perales'</td>
<td>Spain</td>
</tr>
<tr>
<td>THU-249</td>
<td>IL-6/STAT3 PATHWAY UP-REGULATE MIR-125B EXPRESSION IN HEPATITIS C VIRUS INFECTION</td>
<td>Chia-Yen Dai’, Chung-Feng Huang, Ming-Lun Yeh, Jee-Fu Huang, Ming-Lung Yu, Wan-Long Chuang</td>
<td>Taiwan</td>
</tr>
</tbody>
</table>
EDP-494 IS A POTENT PAN-GENOTYPIC CYCLOPHILIN INHIBITOR FOR HCV INFECTION, INCLUDING DAA RESISTANCE ASSOCIATED VARIANTS (RAVS)
Christopher Owens*, Alex Polemeropoulos, Michael Rhodin, Nicole McAllister, Guoqiang Wang, Lijuan Jiang, Yat Sun Or, United States

THU-251
EPIGALLOCHATECHIN GALLATE STIMULATES THE EXPRESSION OF THE MIRNAS, MIR-122, -200C, -155 AND -182 AND DECREASES VIRAL ENTRY IN HCV INFECTED CELLS THROUGH REPRESSING TIGHT JUNCTION PROTEINS, OCCLUDIN AND CLAUDIN-1
Sarah E. Riad, Dalia S. Elhelw*, Gamal Esmat, Ahmed I. Abdelaziz, Egypt

THU-252
SEQUENCING METHODS DEVELOPED FOR HEPATITIS C IDENTIFIES A NEW VIRUS, HUMAN HEPEGIVIRUS 1, IN PATIENTS WITH ADVANCED CIRRHOSIS
David G. Bonsall*, William F. Gregory, Camilla L. Ip, Sharyne Donfield, James Iles, M A. Ansari, Paolo Piazza, Amy Trebes, John Frater, Oliver Pybus, Philip Goulder, Paul Klenerman, Anthony Brown, Rory Bowden, Edward G. Gomperts, Eleanor Barnes, Amit Kapoor, Colin Sharp, Peter Simmonds, United Kingdom

THU-253
COMPARISON OF NEXT GENERATION SEQUENCING TECHNOLOGIES FOR THE COMPREHENSIVE ASSESSMENT OF FULL-LENGTH HEPATITIS C VIRAL GENOMES
Emma Thomson*, Camilla Ip, Anjna Badhan, Mette Christiansen, Walt Adamson, Azim Ansari, David Bibby, David Bonsall, Rory Bowden, Judith Breuer, Anthony Brown, Josie Bryant, Ana Da Silva Filipe, Chris Hinds, Emma Hudson, Paul Klenerman, Kieren Lythgow, Jean Mbisa, John McLauchlan, Richard Myers, Paolo Piazza, Sunando Roy, Amy Trebes, Sreenu Vattipally, Jeroen Witteveldt, Peter Simmonds, Eleanor Barnes, United Kingdom

THU-254
A SINGLE DOSE OF ANTI-MIR122 OLGONUCLEOTIDE RG-101 RESULTS IN A LESS ACTIVATED PHENOTYPE OF NK CELLS IN PATIENTS WITH CHRONIC HEPATITIS C
**THU-255**

**DIFFERENT PREVALENCE OF HCV RESISTANCE AND HCV RNA QUANTIFICATION WITHIN TUMORAL AND NON TUMORAL LIVER TISSUES IN HCC/TRANSPLANTED PATIENTS**

Maria C. Sorbo, Francesco P. Antonucci, Matteo Manuelli, Ilaria Lenci, Daniele Sforza, Luca Carioti, Maria C. Bellocchi, Valeria Cento, Daniele Di Paolo, Francesco De Leonardis, Martina Milana, Tommaso Manzia, Giuseppe Tisone, Mario Angelico, Carlo F. Perno, Francesca Ceccherini-Silberstein, **Italy**

**THU-256**

**GENETIC VARIABILITY OF AURORA B KINASE CODING REGION IN PATIENTS WITH CHRONIC HEPATITIS C WITH AND WITHOUT CIRRHOSIS**

Irene Francisco-Recuero, Ana Isabel Gil, Antonio Madejón, Aurora Sánchez-Pacheco, Miriam Romero, Araceli García, Celia Perales, Antonio Olveira, Pilar Castillo, José Carlos Erdozain, Esteban Domingo, Javier García-Samaniego, **Spain**

**THU-257**

**MIR135A-MEDIATED DOWNREGULATION OF PROTEIN-TYROSINE PHOSPHATASE DELTA IS A CANDIDATE DRIVER OF HCV-ASSOCIATED HEPATOCARCINOGENESIS**

Nicolaas Van Renne, Francois H. T. Duong, Claire Gondeau, Diego Calabrese, Nelly Fontaine, Armando A. Roca-Suarez, Patrick Pessaux, Markus H. Heim, Thomas F. Baumert, Joachim Lupberger, **France**

**THU-258**

**DAA-INDUCED HCV CLEARANCE DOES NOT RESTORE THE ALTERED CYTOKINE AND CHEMOKINE MILIEU IN PATIENTS WITH CHRONIC HEPATITIS C**

Julia Hengst, Verena Schlaphoff, Katja Deterding, Christine S. Falk, Michael P. Manns, Markus Cornberg, Heiner Wedemeyer, **Germany**

**THU-259**

**DETECTION OF THE NOVEL HUMAN PEGIVIRUS, HPGV-2, IN BLOOD**

Kelly Coller, Michael Berg, Matt Frankel, Kevin Cheng, Kenn Forberg, Marilee Marcinkus, Gavin Cloherty, Charles Chiu, John Hackett, George Dawson, **United States**

**THU-260**

**APPLICABILITY OF DRIED BLOOD SAMPLES FOR HEPATITIS C VIRUS DETECTION AND QUANTIFICATION**

Livia M. Villar, Brunna L. C. Marques, Marcia P. Espírito-Santos, Vanessa A. Marques, Cristiane A. Villela-Nogueira, Lia Laura Lewis-Ximenez, Elisabeth Lampe, **Brazil**
Viral hepatitis: Hepatitis C – experimental (virology) (Cont.)

**THU-261**  
**PRECLINICAL CHARACTERISATION OF JNJ-54257099 – A POTENT URIDINE-BASED NUCLEOTIDE POLYMERASE INHIBITOR IN PHASE I CLINICAL DEVELOPMENT FOR THE TREATMENT OF CHRONIC HEPATITIS C**  
Lotke Tambuyzer*, Leen Vijgen, Tim H. Jonckers, Sophie Lachau-Durand, Jan Snoeys, Laurent Leclercq, Jan Martin Berke, Jerome Deval, Pieter Van Remoortere, Kenny Simmen, Sandra De Meyer, Pierre Raboisson, Belgium

**THU-262**  
**YI GENOME-TO-GENOME VIRUS-HOST ANALYSIS REVEALS HCV GENOTYPE 3 VIRAL POLYMORPHISMS LINKED VIRAL LOAD AND TO HOST HLA CLASS-I/II AND IL28B ALLELES**  
M. Azim Ansari*, Vincent Pedergnana, David Bonsall, Nimisha Chaturvedi, Istvan Bartha, Jacques Fellay, David Smith, Rory Bowden, Camilla Ip, Amy Trebes, Paolo Piazza, Graham Foster, Graham Cooke, Paul Klenerman, Eleanor Barnes, Chris Spencer, United Kingdom

**THU-263**  
**YI IN THE ERA OF NEW DIRECT ACTING ANTIVIRAL AGENTS HCV SEQUENCING ALLOWS THE MOST ACCURATE SUBTYPE AND GENOTYPE ASSIGNMENT**  
Marianna Aragri*, Velia Chiara Di Maio, Daniele Di Paolo, Valeria Cento, Francesco De Leonardis, Laura Gianferrera, Monica Tontodonati, Valeria Micheli, Simona Landonio, Alessandra Manunta, Ada Bertoli, Marco Ciotti, Francesco Paolo Antonucci, Ilaria Lenci, Simona Franciosio, Laura Ambra Nicolini, Simona Marenco, Elisabetta Teti, Lara Lambiase, Martina Milana, Ivana Maida, Antonio Di Biagio, Adriano Pellicelli, Lorenzo Nosotti, S Grieco, Pierluigi Cacciatore, Daniele Romagnoli, Massimo Siciliano, Gabriella D’Ettorre, Sergio Babudieri, Miriam Lichtner, Umberto Vespasiani Gentilucci, Mario Romano, Cesare Sarrecchia, Antonio Grieco, Filomena Morisco, Claudio Mastroianni, Jacopo Vecchiet, Massimo Puoti, Emilio D’Amico, Antonio Gasbarrini, Savino Bruno, Carlo Magni, Maria Stella Mura, Gloria Taliani, Antonio Picciotto, Giuliano Rizzardini, Massimo Andreoni, Caterina Pasquazzi, Giustino Parruti, Mario Angelico, Carlo Federico Perno, Francesca Ceccherini Silberstein, Italy
THU-264 DISCOVERY OF A NOVEL HUMAN PEGIVIRUS IN BLOOD ASSOCIATED WITH HEPATITIS C VIRUS CO-INFECTION
Michael G. Berg, Deanna Lee, Kelly Coller*, Matthew Frankel, Andrew Aronsohn, Kevin Cheng, Kenn Forberg, Marilee Marcinkus, Samia Naccache, George Dawson, Catherine Brennan, Donald Jensen, John Hackett, Charles Chiu, United States

THU-265 DECIPHERING EPIGENETIC REPROGRAMMING IN PERSISTENT HEPATITIS C VIRUS INFECTION REVEALS CANDIDATE DRIVERS OF HEPATOCARCINOMAESIS
Simonetta Bandiera, Nourdine Hamdane*, Irwin Davidson, Christine Thumann, Mirjam B. Zeisel, Yujin Hoshida, Nabeel Bardeesy, Thomas F. Baumert, France

THU-266 DIMINISHED REPLICATION AND VIRAL COMPARTMENTALIZATION OF HEPATITIS C VIRUS IN HEPATOCELLULAR CARCINOMA TISSUE
Djamila Harouaka, Ronald E. Engle, Kurt Wollenberg, Giacomo Diaz, Ashley Tice, Fausto Zamboni, Sugantha Govindarajan, Harvey J. Alter, David E. Kleiner, Patrizia Farci*, United States

THU-267 TRANSCRIPTOMIC ANTAGONISM BETWEEN HCV INFECTION AND VITAMIN D
Noa Rapaport, Romy Zemel, Eteedal Morad, Daphna Wynstein, Marcela Karpuj, Amiram Ravid, IzhaK Haviv, Ran Tur-Kaspa*, Israel

THU-268 CC-31244, A NOVEL, PAN-GENOTYPIC, POTENT NS5B NON-NUCLEOSIDE POLYMERASE INHIBITOR FOR THE TREATMENT OF CHRONIC HEPATITIS C
Irina Jacobson, Michael Feese, Hong Xiao, Lothar Uher, Biing Lin, Emiliano Sanchez, Robert Tomkiewicz, Tony Whitaker, Tamara McBrayer, Luz Pascual, Judy Pattassery, Sam Lee*, United States

THU-269 PREEXISTING HEPATITIS C VIRUS (HCV)-SPECIFIC CD8+ T CELLS ARE ABUNDANT IN HCV-SERONEGATIVE INDIVIDUALS AND CAN SHOW CROSS-REACTIVITY TO COMMON PATHOGENS
Shihong Zhang*, Suneetha Pothakamuri Venkata, Verena Schlaphoff, Antoaneta Markova, Solomon Owusu Sekyere, Michael P. Manns, Heiner Wedemeyer, Markus Cornberg, Germany
THU-270 YI
MIR-146A-5P, A PROVIRAL FACTOR UP-REGULATED BY HEPATITIS C VIRUS INFECTION, DEREGULATES METABOLIC PATHWAYS RELEVANT FOR LIVER DISEASE PROGRESSION IN HEPATOCYTES
Sophie Pernot, Simonetta Bandiera*, Hussein El Saghir, Sarah C. Durand, Tao Ye, Christine Thumann, Emilie Crouchet, Catherine Schuster, Isabel Pofana, Markus H. Heim, Thomas F. Baumert, Mirjam B. Zeisel, France

THU-271
HEPATITIS C VIRUS CORE PROTEIN OF GENOTYPE 3A DOWNREGULATES PTEN EXPRESSION IN HEPATOCYTES THROUGH MICRORNAS-DEPENDENT MECHANISMS
Sophie Clément*, Cyril Sobolewski, Stéphanie Conzelmann, Francesco Negro, Michelangelo Foti, Switzerland

THU-272
REGULATION OF HEPATITIS C VIRUS INFECTION BY LONG NON-CODING RNA
Tetsuro Shimakami*, Masao Honda, Takayoshi Shirasaki, Naoki Ooishi, Shuichí Kaneko, Japan

THU-273
ASUNAPREVIR EVOKE HEPATOCYTES INNATE IMMUNITY TO RESTRICT THE REPLICATION OF HEPATITIS C AND DENGUE VIRUS
Wei-Lun Tsai*, Jin-Shiung Cheng, Kwok-Hung Lai, Hoi-Hung Chan, Tsung-Hsien Chang, Taiwan

THU-274 YI
CONVERGENT TRANSCRIPTION OF INTERFERON-STIMULATED GENES BY TNF-A AND IFN-A AUGMENTS ANTIVIRAL ACTIVITY AGAINST HCV AND HEV
Wenshi Wang*, Lei Xu, Johannes Brandsma, Yijin Wang, Mohamad Hakim, Xinying Zhou, Yuebang Yin, Gwenny Fuhler, Luc J. W. Van Der Laan, C. Janneke Van Der Woude, Dave Sprengers, Herold Metselaar, Ron Smits, Raymond Poot, Maikel Peppelenbosch, Qiuwei Pan, Netherlands

THU-275 YI
UNPHOSPHORYLATED ISGF3 DRIVES THE BASAL TRANSCRIPTION OF INTERFERON-STIMULATED GENES TO DEFEND HCV AND HEV INFECTIONS
Wenshi Wang*, Yuebang Yin, Lei Xu, Yijin Wang, Xinying Zhou, Luc J. W. Van Der Laan, Dave Sprengers, Herold Metselaar, Maikel Peppelenbosch, Qiuwei Pan, Netherlands
Autoimmune and hepato biliary disease I

FRI-344 DECREASED EXPRESSION OF VITAMIN D RECEPTOR MAY AFFECT AN IMMUNE RESPONSE VIA VDR – MIRNA155 – SOCS1 PATHWAY IN PRIMARY BILIARY CIRRHOSIS
Agnieszka Kempińska Podhorodecka*, Urszula Wasik, Piotr Milkiewicz, Małgorzata Milkiewicz, Poland

FRI-345 VALUE OF TRANSIENT ELASTOGRAPHY (FIBROSCAN®) IN PATIENTS WITH AUTOIMMUNE HEPATITIS ON IMMUNOSUPPRESSIVE TREATMENT
Albert F. Stättermayer*, Michael Eder, Sandra Beinhardt, Karin Kozbial, Clarissa Freissmuth, Rafael Stern, Fritz Wrba, Michael Trauner, Peter Ferenci, Harald Hofer, Austria

FRI-346 BOTH BIOCHEMICAL HEPATITIS AND CHOLESTASIS AT SIX MONTHS AFTER LIVER TRANSPLANTATION PREDICT RECURRENT PRIMARY BILIARY CHOLANGITIS
Aldo J Montano-Loza*, Davide Roccarina, Douglas Thorburn, Christophe Corpechot, Jerome Dumortier, Alexie Bosch, Emiliano Giostria, Yvon Calmus, Irene Franceschet, Annarosa Floreani, Andrew Mason, Canada

FRI-347 UTILITY OF UK-PBC RISK SCORES AS AN ALTERNATIVE TO TRANSIENT ELASTOGRAPHY IN ASSESSING RISK IN PRIMARY BILIARY CHOLANGITIS (CIRRHOSIS) PATIENTS
Vinod S. Hegade, Amardeep Khanna*, Greta Pells, Lin Lee Wong, Jessica K Dyson, David Jones, United Kingdom

FRI-348 YI CHOLESTASIS INDUCES EXPRESSION OF THE ONCOFETAL MARKER NOPE IN ADULT MURINE LIVER INDEPENDENT OF FXR
Andrea Bowe*, Vera Hoffmann, Harald M. Curth, Peter Fickert, Dirk Nierhoff, Germany

FRI-349 PRURITUS AND SERUM AUTOTAXIN IN PATIENTS WITH PRIMARY BILIARY CIRRHOSIS PARTICIPATING IN THE POISE TRIAL
Andreas E. Kremer*, A. Ruth Bolier, Elizabeth Smoot Malecha, Ulrich Beuers, Mary Erickson, Roya Hooshmand-Rad, David Shapiro, Germany
FRI-350  SERUM LYSYL OXIDASE-LIKE-2 (SLOXL2) LEVELS CORRELATE WITH DISEASE SEVERITY IN PATIENTS WITH PRIMARY SCLerosing CHOLANGITIS
Andrew J. Muir*, Zachary Goodman, Christopher L. Bowlus, Stephen Caldwell, Pietro Invernizzi, Velimir Luketic, Gerald Minuk, Gideon M. Hirschfield, Robert P. Myers, Dora Ding, Raul Aguilar, G. Mani Subramaniam, John G. McHutchison, Bertus Eksteen, Cynthia Levy, United States

FRI-351  RELIABILITY OF COMPUTED TOMOGRAPHY IN DIFFERENTIATING TYPE 1 AUTOIMMUNE PANCREATITIS FROM PANCREATIC CANCER
Angela C. Cheung*, Mashael Bandar, Jess Rhee, Hyun-Jung Jang, Korosh Khalili, Ravi Menezes, Tae Kyoung Kim, Canada

FRI-352  EVALUATION AND PREDICTORS OF MORTALITY IN PATIENTS WITH LIVER ABSCESS. AN ANALYSIS OF 943 CONSECUTIVE PATIENTS
Ankur Jindal*, Apurva Kumar, Shiv Kumar Sarin, India

FRI-353  BEZAFIBRATE ALLEVIATES PRURITUS AND DECREASES SPECIFIC CIRCULATING METABOLITES IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS
Anna Reig*, Miriam Pérez-Cormenzana, Pilar Sesé, Rebeca Mayo, Azucena Castro, Albert Pares, Spain

FRI-354  THE ALT/AST RATIO AND TOTAL PROTEIN LEVEL IDENTIFY THE AUTOIMMUNE ETIOLOGY IN PATIENTS WITH FULMINANT HEPATITIS
Anna Reig*, Veronica Prado, Hugo Úchima, Antoni Mas, Albert Parés, Spain

FRI-364  COLONIZATION OF GERM-FREE MICE WITH A HUMAN MICROBIOTA INDUCES FXR SIGNALING
Annika Wahlström*, Petia Kovatcheva-Datchary, Marcus Ståhlman, Hanns-Ulrich Marschall, Fredrik Bäckhed, Sweden

FRI-365  ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY INDUCED CHOLANGITIS: CLINICAL CHARACTERISTICS, SEVERITY INDICATORS AND PROGNOSIS
Armando Peixoto*, Marco Silva, João Santos-antunes, Eduardo Rodrigues-Pinto, Pedro Pereira, Guilherme Macedo, Portugal
### Autoimmune and hepato biliary disease I (Cont.)

<table>
<thead>
<tr>
<th>Session Code</th>
<th>Title</th>
<th>Authors</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>FRI-366</td>
<td>ENVIRONMENTAL RISK FACTORS AND SOCIOECONOMIC DISPARITY IN HISPANIC VERSUS NON-HISPANIC PATIENTS WITH PBC</td>
<td>Atoosa Rabiee*, Nathalie A. Pena polanco, Aymara Fernandez De La Vara, Kalyan R. Bhamidimarri, Cynthia Levy, United States</td>
<td>United States</td>
</tr>
<tr>
<td>FRI-367</td>
<td>INCIDENCE AND PREDICTIVE FACTORS OF DECOMPENSATING EVENTS IN PRIMARY BILIARY CHOLANGITIS - EXPERIENCES OF 3194 CASES IN JAPAN</td>
<td>Atsushi Tanaka*, Junko Hirohara, Hajime Takikawa, Japan</td>
<td>Japan</td>
</tr>
<tr>
<td>FRI-368</td>
<td>DEMOGRAPHICS, CLINICAL FEATURES, TREATMENT AND OUTCOME OF IGG4-RELATED SCLEROSING CHOLANGITIS - EXPERIENCES OF 495 CASES IN JAPAN</td>
<td>Atsushi Tanaka*, Susumu Tazuma, Hajime Takikawa, Japan</td>
<td>Japan</td>
</tr>
<tr>
<td>FRI-369</td>
<td>INCREASED LONG-TERM CANCER RISK IN AUTOIMMUNE HEPATITIS: RELATION TO IMMUNOSUPPRESSIVE DRUG TREATMENT</td>
<td>Barbara Hoeroldt*, Matt Barclay, Kate Shephard, Nina Farquarsson, Elaine McFarlane, Mohammed Karajeh, Jason Poole, Dermot Gleeson, United Kingdom</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>FRI-370</td>
<td>POPULATION-BASED PREVALENCE, INCIDENCE, AND DISEASE BURDEN OF AUTOIMMUNE HEPATITIS IN SOUTH KOREA</td>
<td>Bo Hyun Kim*, Hwa Young Choi, Moran Ki, Kyung-Ah Kim, Eun Sun Jang, Sook-Hyang Jeong, Korea, South</td>
<td>Korea, South</td>
</tr>
<tr>
<td>FRI-371</td>
<td>THE INCIDENCE OF RETHROMBOSIS IN PATIENTS WITH NON-CIRRHOTIC, NON-TUMORAL CHRONIC PORTAL VEIN THROMBOSIS- A PROSPECTIVE OBSERVATIONAL STUDY</td>
<td>Bogdan Procopet*, Gilberto Silva-Junior, Elba Llop, Anna Darnell, Maria Angeles Garcia-Criado, Fanny Turon, Anna Baiges, Jose Luis Calleja, Jaime Bosch, Virginia Hernandez-Gea, Juan Carlos Garcia-Pagan, Romania</td>
<td>Romania</td>
</tr>
</tbody>
</table>
FRI-372 YI  LIVER-INFLICTURING B CELLS PRODUCE AUTOANTIBODIES THAT POINT TOWARD NOVEL AUTOANTIGENS IN PRIMARY SCLEROSING CHOLANGITIS
Brian K. Chung*, Gupta Udatha, Anne Pharo, Michael Taussig, Claudia Fonseca, Oda Stoevesandt, Adi Mehta, Fridtjof Lund-Johansen, Gideon M. Hirschfield, Tom Hemming Karlsen, Evaggelia Liaskou, United Kingdom

FRI-373 YI  TREATMENT OUTCOMES AND DRUG-RELATED ADVERSE EFFECTS IN IGG4-RELATED DISEASE
Charis D. Manganis, Tamsin Cargill, John P. Corcoran, Antony J. Ellis, Roger W. Chapman, Jane D. Collier, Emma L. Culver*, Eleanor Barnes, United Kingdom

FRI-374 YI  TLR4 ACTIVATION DRIVES SYSTEMIC PLATELET-MONOCYTE AGGREGATE FORMATION AND MONOCYTE TNFA PRODUCTION AND IS CRITICAL FOR THE DEVELOPMENT OF FATIGUE-LIKE BEHAVIORS IN MICE WITH EXPERIMENTAL CHOLESTATIC LIVER DISEASE
Charlotte D'Mello*, Hongqun Liu, Mark G. Swain, Canada

FRI-375  LIVER STIFFNESS MEASUREMENT BY TRANSIENT ELASTOGRAPHY FOR THE PREDICTION OF FIBROSIS IN PATIENTS WITH PRIMARY SCLEROSING CHOLANGITIS IN A RANDOMIZED TRIAL OF SIMTUZUMAB

FRI-376  EFFECT OF FIBRATE-ADD-ON TREATMENT IN PRIMARY BILIARY CHOLANGITIS PATIENTS WITH AN INSUFFICIENT RESPONSE TO URSODEOXYCHOLIC ACID
Clarissa Freissmuth*, Karin Kozbial, Albert F. Stättermayer, Sandra Beinhardt, Rafael Stern, Emina Halilbasic, Peter Ferenci, Michael Trauner, Harald Hofer, Austria
### Autoimmune and hepato biliary disease I (Cont.)

<table>
<thead>
<tr>
<th>ID</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>FRI-377</td>
<td><strong>Allopurinol is safe and effective to achieve biochemical and histological remission in patients with autoimmune hepatitis with incomplete therapeutic response</strong></td>
<td>Debora Raquel Terrabuio*, Lydia Teofilo De Moraes Falcao, Suzane Kioko Ono, Marcio Augusto Diniz, Flair José Carrilho, Eduardo Cancado, Brazil</td>
</tr>
<tr>
<td>FRI-378</td>
<td><strong>Successful identification of high risk young adults with biliary atresia using the Mayo PSC risk score</strong></td>
<td>Deepak Joshi*, Anil Dhawan, John O’Grady, Mark Davenport, Nigel Heaton, Dino Hadzic, Michael Heneghan, Marianne Samyn, United Kingdom</td>
</tr>
<tr>
<td>FRI-383</td>
<td><strong>CYP3A11 is dispensable for the formation of murine bile acids</strong></td>
<td>Samer Al-Dury*, Annika Wahlström, Marcus Ståhlman, Fredrik Bäckhed, Hanns-Ulrich Marschall, Sweden</td>
</tr>
<tr>
<td>FRI-384</td>
<td><strong>A new mouse model of sclerosing cholangitis to unravel the interplay of T cell dependent liver inflammation and bile acid metabolism</strong></td>
<td>Fabian V. Glaser*, Bastian Engel, Clara John, Till Krech, Sören Weidemann, Antonella Carambia, Johannes Herkel, Ansgar W. Lohse, Jörg Heeren, Christoph Schramm, Dorothee Schwinge, Germany</td>
</tr>
<tr>
<td>FRI-387</td>
<td><strong>Autoimmune hepatitis is associated with significant alterations of the circulating innate lymphoid cell pool and displays elevated markers of bacterial translocation</strong></td>
<td>Felix Goeser*, Benjamin Krämer, Philipp Lutz, Dominik Kaczmarek, Claudia Finnemann, Sahar Fazeli, Marijo Parcina, Christian P. Strassburg, Achim Hörauf, Isabelle Bekeredjian-Ding, Ulrich Spengler, Jacob Nattermann, Germany</td>
</tr>
<tr>
<td>FRI-388</td>
<td><strong>Autoimmune hepatitis is associated with stable immunization against intestinal commensal bacteria</strong></td>
<td>Felix Goeser*, Benjamin Krämer, Philipp Lutz, Dominik Kaczmarek, Claudia Finnemann, Sahar Fazeli, Marijo Parcina, Christian P. Strassburg, Achim Hörauf, Isabelle Bekeredjian-Ding, Jacob Nattermann, Ulrich Spengler, Germany</td>
</tr>
</tbody>
</table>
FRI-389 ORAL BACTERIAL ACTIVITY IS SIGNIFICANTLY ASSOCIATED WITH AUTOIMMUNE LIVER DISEASES AND IT COULD BE INVOLVED IN THEIR PATHOGENESIS MECHANISMS Francesco Figorilli*, Germano Orrù, Simona Onali, Claudia Salustro, Sara Cappellini, Elisabetta Cocco, Sara Fais, Maria Melis, Alessia Gilardi, Luca Secci, Stefania Casu, Stefano Littera, Luchino Chessa, Italy

FRI-390 LARGE SCALE ALTERATIONS IN HEPATIC MRNA AND MIRNA EXPRESSION IN HUMAN EXTRAHEPATIC CHOLESTASIS Frank G. Schaap*, Zita Soons, Laura Fischer, Marlon J. Jetten, Danyel Jennen, Jos C. Kleinjans, Peter L. Jansen, Steven W. Olde Damink, Netherlands

FRI-391 THERAPEUTIC OPTIONS FOR LOW DOSE PROLEUKIN IN AUTOIMMUNE LIVER DISEASES THROUGH SELECTIVE INDUCTION OF PHOSPHO-STAT5, REGULATORY PHENOTYPE AND PROSURVIVAL BCL-2 IN TREG Hannah Jeffery*, Louisa Jeffery, Jane Birtwistle, David Adams, Ye H. Oo, United Kingdom

FRI-392 PRIMARY BILIARY CHOLANGITIS IN ELDERLY PATIENTS Irene Franceschet*, Nora Cazzagon, Chiara Mangini, Lisa Perini, Annarosa Floreani, Italy

FRI-393 IMPACT OF GENDER ON CLINICAL PRESENTATION, RESPONSE TO TREATMENT, AND LONG-TERM OUTCOMES IN AN ETHNICALLY DIVERSE POPULATION OF PATIENTS WITH AUTOIMMUNE HEPATITIS Jean A. Donet*, Erin F. Perlini, Dani Gilinsky, Michael Huang, Kalyan R. Bhamidimarri, Cynthia Levy, United States

FRI-394 EXPOSURE-RESPONSE RELATIONSHIP OF OBETICHOLIC ACID FOR ALKALINE PHOSPHATASE AND TOTAL BILIRUBIN IN PATIENTS WITH PRIMARY BILIARY CIRRHOSIS Jeffrey E. Edwards*, Carl LaCerte, Leng Hong Pheng, Thomas Peyret, Nathalie H. Gosselin, J. F. Marier, David Shapiro, United States

FRI-395 URSODEOXYCHOLIC ACID INCREASES OBETICHOLIC ACID STIMULATION OF FGF19 IN HUMAN ILEAL EXPLANTS Jenna Geers*, Richard Appleby, Julian Walters, Ireland
### Autoimmune and hepato biliary disease I (Cont.)

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>FRI-396</td>
<td>B-CELL ACTIVATING FACTOR IS ELEVATED IN AUTOIMMUNE HEPATITIS BUT DOES NOT DETERMINE DISEASE PHENOTYPE</td>
<td>Jessica K. Dyson*, Jeremy Palmer, Lin Lee Wong, Stuart Kendrick, David Jones, United Kingdom</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>FRI-397</td>
<td>SPECT TECHNIC IN EVALUATION OF PATHOGENESIS OF FATIGUE IN PATIENTS WITH PRIMARY BILIARY CIRRHOSIS – A PILOT STUDY</td>
<td>Joanna Raszeja-Wyszomirska*, Piotr Zorga, Marcin Kotulski, Bożena Birkenfeld, Poland</td>
<td>Poland</td>
</tr>
<tr>
<td>FRI-398</td>
<td>TGR5-DEPENDENT HEPATOPROTECTION THROUGH THE REGULATION OF BILIARY EPITHELIUM PERMEABILITY</td>
<td>José Ursic-Bedoya*, Hayet Simerabet, Isabelle Doignon, Noémie Péan, Zahra Tanfin, Julien Gautherot, Christoph Ulmer, Lydie Humbert, Dominique Rainteau, Doris Cassio, Thierry Tordjmann, France</td>
<td>France</td>
</tr>
<tr>
<td>FRI-399</td>
<td>MUCOSA ASSOCIATED INVARIANT T CELLS ARE PHENOTYPICALLY ALTERED AND FUNCTIONALLY IMPAIRED IN PATIENTS WITH AUTOIMMUNE LIVER DISEASE</td>
<td>Katrin Schölzel*, Krista Rombouts, Matteo Rosselli, Francesca Saffioti, Davide Roccarina, Aileen Marshall, Douglas Thorburn, Massimo Pinzani, United Kingdom</td>
<td>United Kingdom</td>
</tr>
</tbody>
</table>
Cirrhosis: Pathophysiology

FRI-001
THE EFFECT OF IMATINIB IN VARIOUS THIOACETAMIDE-INDUCED MOUSE LIVER FIBROSIS MODELS
András A. Rókus*, Katalin Dezső, Sándor Paku, Edina Bugyik, Vanessza Szabó, Armanda Szűcs, Péter Nagy, Hungary

FRI-002
ALTERATIONS IN THE CNS HEMICHANNEL FUNCTION AND NEUROCHEMICAL PHENOTYPE IN THE PATHOGENESIS OF HEPATIC ENCEPHALOPATHY
Anna Hadjihambi*, Alexander Gourine, Rajiv Jalan, United Kingdom

FRI-003
THE ‘IRON SCORE’ IS AN MELD-INDEPENDENT PREDICTOR OF SURVIVAL IN PATIENTS WITH LIVER CIRRHOSIS
Armin Finkenstedt*, Simon Krapf, André Viveiros, Benedikt Schäfer, Andrea Griesmacher, Wolfgang Vogel, Heinz Zoller, Austria

FRI-004
THE ASSOCIATION OF ALPHA-1-ANTITRYSIN DEFICIENCY WITH IRON OVERLOAD AND CIRRHOSIS
Benedikt Schaefer*, David Haschka, Richard Hilbe, Armin Finkenstedt, Ivan Tancevski, Igor Theurl, Wolfgang Vogel, Günter Weiss, Heinz Zoller, Austria

FRI-005
ROLE OF CIRCULATING PROPIONATE IN PORTAL HYPERTENSION IN CIRRHOSIS
Chelsea McDougall*, Andrea Davila-Cervantes, Puneeta Tandon, Andrew Mason, Juan Jose Lozano, Cintia Z Meireles, Stefania Casu, Esteban Ruiz, Joan Carles Garcia-Pagan, Jaime Bosch, Juan G Abraldes, Canada

FRI-006
PATHOLOGICAL ANALYSIS OF THE LIVER OF PATIENTS WITH CIRRHOSIS AND HEPATOPULMONARY SYNDROME REVEALS A VASCULAR PATTERN OF DAMAGES
Clement Lejealle*, Valérie Paradis, Claire Francoz, Olivier Soubrane, Didier Lebrec, Dominique Valla, François Durand, Pierre Emmanuel Rautou, France

FRI-007
BENEFICIAL EFFECTS OF ORNITHINE PHENYLACETATE TO ATTENUATE MUSCLE MASS LOSS AND TO PREVENT HEPATIC ENCEPHALOPATHY IN EXPERIMENTAL CIRRHOSIS
Cristina R. Bosoi, Mariana Oliveira, Marc-André Clément, Mélanie Tremblay, Gabriella A. Ten Have, Nicolaas E. Deutz, Christopher F. Rose*, Canada
**Cirrhosis: Pathophysiology (Cont.)**

**FRI-008**

**SYSTEMIC INFLAMMATORY RESPONSE PROFILE IN ACUTE-ON-CHRONIC LIVER FAILURE AND ITS RELATIONSHIP WITH PROGNOSIS**


**FRI-009**

**INTESTINAL BACTERIAL TRANSLOCATION IN RATS WITH CIRRHOSIS IS RELATED TO INTESTINAL IMMUNE DYSFUNCTION**

Haiyan Shi*, Haiyin Jiang, Lanjuan Li, *China*

**FRI-010**

**DETERMINATION OF STAGE SPECIFIC MARKERS FOR LIVER FIBROSIS IN HEPATITIS B: A COMPARATIVE TISSUE PROTEOMIC STUDY**

Seyma Katrinli, Kamil Ozdil, Abdurrahman Sahin, Oguzhan Ozturk, Gozde Kir, Ahmet Tarik Baykal, Omer Sinan Sarac, Mehmet Sokmen, Gizem Dinler Doganay, Hamdi Levent Doğanay*, *Turkey*

**FRI-011**

**NORADRENALINE POTENTIATES PORTAL HYPERTENSION THROUGH THE ALPHA 2A ADRENERGIC RECEPTOR- A TARGET FOR THERAPY IN PORTAL HYPERTENSION**


**FRI-012**

**CHRONIC OPIOID THERAPY IS ASSOCIATED WITH GUT DYSBIOSIS IN CIRRHOSIS INDEPENDENT OF CIRRHOSIS SEVERITY**


**FRI-013**

**THE BENEFICIAL IMPACT OF RIFAXIMIN ON SYSTEMIC AND INTESTINAL INFLAMMATION AND AMMONIA OCCURS EVEN WITHOUT MICROBIOTA: MORE THAN AN ANTIBIOTIC**

FRI-014 YI  SLEEP DISTURBANCES IN PATIENTS OF LIVER CIRRHOSIS WITH MINIMAL HEPATIC ENCEPHALOPATHY BEFORE AND AFTER LACTULOSE THERAPY
Jatinderpal Singh*, Barjesh Chander Sharma, Vinod Puri, Sanjeev Sachdeva, Sudhir Maharshi, India

FRI-015 YI  IN VIVO MYOFIBROBLAST SPECIFIC GENE SILENCING IN THE LIVER USING NOVEL SIRNA-LOADED BIODEGRADABLE NANOHYDROGEL PARTICLES
Leonard Kaps*, Lutz Nuhn, Misbah Aslam, Alexander Brose, Friedrich Foerster, Rudolf Zentel, Detlef Schuppan, Germany

FRI-016  GAP JUNCTION OPENER IMPROVES ENDOTHELIAL DYSFUNCTION AND DECREASES HEPATIC VASCULAR RESISTANCE IN CIRRHOTIC RATS
Manuel Hernandez-Guerra*, Dalia Morales-Arraez, Javier Gonzalez-Paredes, Ketil Haugan, Goretti Hernandez-Mesa, Raquel de la Barreda, Beatriz Abrante, Bjarne Larsen, Enrique Quintero, Spain

FRI-017  INHIBITION OF EETS PRODUCTION IN CIRRHOTIC RATS HAS BENEFICIAL EFFECTS ON PORTAL HYPERTENSION BY REDUCING SPLANCHNIC VASODILATION
Marco Di Pascoli*, Francesca Zampieri, Alberto Verardo, Paolo Angeli, David Sacerdoti, Massimo Bolognesi, Italy

FRI-018  VIGILANCE AND WAKE EEG ARCHITECTURE IN SIMULATED HYPERAMMONAEMIA: A PILOT STUDY ON THE EFFECTS OF LOLA AND CAFFEINE
Maria Garrido*, Jelena Skorucak, Daniela Raduazzo, Matteo Turco, Giuseppe Spinelli, Paolo Angeli, Piero Amodio, Peter Achermann, Sara Montagnese, Italy

FRI-019 YI  CHARACTERIZING MINIMAL HEPATIC ENCEPHALOPATHY: INFLAMMATION, METABOLISM AND MORPHOPHYSIOLOGICAL EFFECTS
Natalia Arias, Marta Mendez*, Eneritz Gómez-Lázaro, Arantxa Azpiroz, Jorge L. Arias, Spain

FRI-020  ADAR1 INHIBITS THE PROGRESSION OF HEPATIC FIBROSIS VIA IL6 EXPRESSION REGULATION
Shirley Oren, Polina Kagan, Maya Sultan, Michal Safran*, Ziv Ben-Ari, Israel
Cirrhosis: Pathophysiology (Cont.)

FRI-021 COAGULATION OF PATIENTS WITH CIRRHOSIS REVISITED USING AN ASSAY TAKING INTO ACCOUNT ENDOTHELIAL CELLS: THROMBIN GENERATION IS QUICKER BUT LESS ABUNDANT
Pierre-Emmanuel Rautou*, Charlène Kuadjovi, Laure Elkrief, Laurence Venisse, Larbi Boudaoud, François Durand, Dominique Valla, Nadine Ajzenberg, Emmanuelle De Raucourt, France

FRI-022 KINETICS OF PULMONARY ANGIOGENESIS IN MOUSE COMMON BILE DUCT LIGATION-INDUCED LIVER FIBROSIS
Sarah Raevens*, Lindsey Devisscher, Annelies Paridaens, Eliene Bogaerts, Sander Lefèvre, Yves-Paul Vandewynckel, Christophe Casteleyn, Ken Bracke, Tania Maes, Xavier Verhelst, Hans Van Vlierberghe, Christophe Van Steenkiste, Anja Geerts, Isabelle Colle, Belgium

FRI-023 DELTA-LIKE HOMOLOG 1 (DLK1), PROFIBROGENIC PROTEIN OVEREXPRESSED IN CCL4 RAT LIVER FIBROSIS
Silvia Carvajal*, Vedrana Reichenbach, Denise Oró, Santiago Marfà, Guillermo Fernández-Varo, Santiago Lamas, Wladimiro Jiménez, Spain

FRI-024 SPLENECTOMY AMPLIFY THE THERAPEUTIC POTENTIAL OF ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLS VIA STROMAL CELL-DERIVED FACTOR-1 AND HEPATOCYTE GROWTH FACTOR
Tang Wei-Ping*, Akahoshi Tomohiko, Hashizume Makoto, Japan

Top 10%

FRI-359 A DIET COMBINING HIGH FAT AND GLUCOSE-FRUCTOSE SYRUP INDUCES OBESITY, NON-ALCOHOLIC STEATOHEPATITIS AND PORTAL HYPERTENSION IN A NEW ANIMAL MODEL
Teresa García-Lezana*, María Martell, Nahia Ezkurdia, Manuel Torres-Arauz, María Teresa Salcedo, Joan Genescà, Salvador Augustín, Spain
FRI-360  YI  EFFECTS OF TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) ON BLOOD VOLUME DISTRIBUTION IN PATIENTS WITH CIRRHOSIS
Troels M. Busk*, Flemming Bendtsen, Jens H. Henriksen, Stefan Fuglsang, Fin S. Larsen, Jens O. Clemmesen, Søren Møller, 
Denmark

FRI-361  SILDENAFIL REDUCES NEUROINFLAMMATION AND RESTORES SPATIAL LEARNING IN RATS WITH HEPATIC ENCEPHALOPATHY. UNDERLYING MECHANISMS
Vicente Hernandez-Rabaza, Ana Agusti, Andrea Cabrera-Pastor, Lucas Taoro-Gonzalez, Carmina Montoliu, Marta Llansola, Vicente Felipo*, Spain

FRI-362  ALTERED GUT MICROBIAL PROFILE IS A PROONENT OF BACTERIAL TRANSLOCATION IN ACUTE-ON-CHRONIC LIVER FAILURE
Vishal C. Patel*, Lex E. X. Leong, Garrit Koller, Susanne Knapp, Glory Lai, Arjuna Siganayagam, Christine Bernsmeier, Mark J. W. McPhail, Debbie L. Shawcross, Charalambos G. Antoniades, Mark Thursz, Julia A. Wendon, Geraint B. Rogers, Kenneth D. Bruce, United Kingdom

FRI-363  AUTOMATED QUANTITATION OF CIRRHOTIC PATTERNS SHOWING THE EXCELLENT ACCURACY IN REFLECTING THE PATHOPHYSIOLOGIC EVOLUTION AND DISEASE SEVERITY IN CIRRHOTIC ANIMAL MODEL AND CHRONIC HEPATITIS B LIVER BIOPSIRES
Yan WANG*, Qianjin FENG, Wei HUANG, Jinlian YANG, Hailin LIU, Jinlin HOU, China
EU and public health

**FRI-382 YI**
SIMVASTATIN IMPEDES THE ENDOTOXIN-INDUCED AGGRAVATION OF HEPATIC MICROVASCULAR DYSFUNCTION IN TWO ANIMAL MODELS OF LIVER CIRRHOSIS
Dinesh M. Tripathi*, Erica Lafoz, Hector Garcia-Caldero, Juan C. Garcia-Pagan, Jordi Gracia-Sancho, Jaime Bosch, Spain

**FRI-385 YI**
MODELLING THE INCREASING BURDEN OF HCV IN PAKISTAN: THE CRUCIAL NEED TO ACT!
Aaron G. Lim*, Huma Qureshi, Charlotte Davies, Saeed Hamid, Adam Trickey, Nancy Glass, Hassan Mahmood, Quaid Saeed, Hannah Woodall, Christina Mukandavire, Margaret May, Francisco Averhoff, Peter Vickerman, United Kingdom

**FRI-386**
CO-INFECTION WITH HEPATITIS C, HEPATITIS B, HIV AND LATENT TB INFECTION AMONG HOMELESS PEOPLE IN LONDON
Alistair Story*, Andrew Hayward, Rob Aldridge, United Kingdom

**FRI-401 YI**
OCCULT LIVER DISEASE BURDEN: ANALYSIS FROM A LARGE GENERAL PRACTITIONERS DATABASE
Andrea Martini*, Elena Ceranto, Angelo Gatta, Patrizia Pontisso, Italy

**FRI-402 YI**
KNOWLEDGE OF HEPATITIS C ACQUISITION RISKS IS ASSOCIATED WITH IMPROVED BIRTH COHORT-BASED SCREENING PRACTICES AMONG PRIMARY CARE PHYSICIANS
Sandeep T. Samuel, Anthony D. Martinez, Sumeet Munjal, Elizabeth George, Miles Basil, Yang Chen, Rositsa B. Dimova, Andrew Talal*, United States

**FRI-404 YI**
ACCEPTANCE, YIELD AND FEASIBILITY OF ATTACHING HCV BIRTH CONTROL SCREENING TO COLORECTAL CANCER SCREENING IN SPAIN
Daniel Bonillo-Cambrordon*, Francisco-Javier Garcia-Alonso, Alicia Algaba, Andrea Bermejo-Abati, Jesús García-Martínez, Paz Valer, Belen Piqueras-alcol, Fernando Bermejo, Spain

**FRI-405 YI**
ASSESSMENT OF RAPID TEST KITS TO DETECT HBSAG AND ANTI-HCV
Ganbolor Jargalsaikhan*, Odgerel Oidovsambuu, Bekhhbold Dashtseren, Delgerbat Boldbaatar, Zulkhuu Genden, Alimaa Tuya, Andreas Bungert, Naranbaatar Dashdorj, Naran Gurjav, Naranjargal Dashdorj, Mongolia
FRI-406 HEPATITIS E IN A REGION OF ITALY: AN AUTOCHTHONOUS EMERGING INFECTION?
Giuseppe Tarantino*, Giulia Surace, Katia Marinelli, Marco Marzioni, Alisia Malena, Stefano Menzo, Antonio Benedetti, Italy

FRI-407 KNOWLEDGE AND PRACTICE OF CHINESE PHYSICIANS IN MANAGING HEPATITIS B VIRUS INFECTION
Hong Zhao*, Guiqiang Wang, China

FRI-408 AGE-STANDARDIZED LIVER-RELATED MORTALITY IN BRAZIL FROM 2008 TO 2012: A NATIONWIDE ANALYSIS OF MORE THAN 270,000 LIVER DEATHS
Hugo Perazzo*, Antonio Pacheco, Juliana Fittipaldi, Caroline Rigolon, Sandra Cardoso, Valdilea Veloso, Beatriz Grinsztejn, Brazil

FRI-409 A NATIONWIDE ANALYSIS OF AGE-STANDARDIZED CIRRHOSIS MORTALITY RATES IN BRAZIL FROM 2000 TO 2012
Hugo Perazzo*, Antonio Pacheco, Raquel De Boni, Paula Luz, Juliana Fittipaldi, Sandra Cardoso, Beatriz Grinsztejn, Valdilea Veloso, Brazil

FRI-410 THE IMPACT OF AGE ON FIBROSIS PROGRESSION IN CHRONIC HEPATITIS C PATIENTS
Ilias Gountas, Sypsa Vana*, Ioanna Delladetsima, Nikolaos Tassopoulos, George Papatheodoridis, Angelos Hatzakis, Greece

FRI-411 EVIDENCE OF RECENT HEPATITIS E VIRUS INFECTION IN PORTUGUESE BLOOD DONORS

FRI-412 IS HEPATITIS E VIRUS INFECTION IN SWINE SLAUGHTERHOUSE WORKERS AN OCCUPATIONAL RISK IN PORTUGAL?

FRI-413 ELEVEN-YEAR MORTALITY AND REFERRAL PRACTICES ASSOCIATED WITH ABNORMAL ALANINE AMINOTRANSFERASE RESULTS
James G. Orr*, Richard Thomas, Daniel Stow, Fiona Matthews, Barbara Hanratty, David E. J. Jones, Mark Hudson, United Kingdom
<table>
<thead>
<tr>
<th>POSTERS / FRIDAY 15 APRIL 2016</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EU and public health (Cont.)</strong></td>
</tr>
</tbody>
</table>
| **FRI-414** USE OF CANCER REGISTRATION DATA TO EXAMINE TRENDS AND VARIATION IN PRIMARY LIVER CELL CANCER IN ENGLAND – IMPLICATIONS FOR PUBLIC HEALTH AND HEALTH SERVICE ACTION  
Julia Verne*, Alex Ives, *United Kingdom* |
| **FRI-415** EARTH STUDY (PHASE 1): EXPANDING ACCESS TO RAPID TREATMENT FOR HEPATITIS C  
Julian Surey*, Alistair Story, Dee Menezes, Jim Conneely, Andrew Hayward, *United Kingdom* |
| **FRI-416** EFFECT OF COMBINED HARM REDUCTION STRATEGIES ON HCV INCIDENCE AMONG PEOPLE WHO INJECT DRUGS IN MONTREAL, CANADA  
Julie Bruneau*, Didier Jutras Aswad, Geng Zang, Élise Roy, *Canada* |
| **FRI-417** DOES ALCOHOL DEPENDENCY EXPLAIN DIFFERENCES IN RATES OF DECOMPENSATED CIRRHOSIS AMONG PEOPLE WITH A HEPATITIS C NOTIFICATION? AN INTERNATIONAL COMPARISON  
Maryam Alavi*, Naveed Janjua, Amanda Yu, Jason Grebely, Esther Aspinall, Hamish Innes, Heather Valerio, Peter Hayes, Mel Krajden, Janaki Amin, Matthew Law, Jacob George, David Goldberg, Sharon Hutchinson, Gregory Dore, *Australia* |
| **FRI-418** AN INTERIM ANALYSIS OF A NATIONAL PROGRAM FOR TREATING HEPATITIS C WITH NOVEL ANTIVIRAL AGENTS  
Michal Cohen*, Natan R. Kahan, Dan-Andrei Waitman, Ran Tur-Kaspa, *Israel* |
| **FRI-419** INEQUALITY AND ECONOMIC FACTORS IMPACT ON THE WEIGHT OF ALCOHOL IN CIRRHOSIS BURDEN AND DEATH RATE: A WORLDWIDE STUDY  
Monica Cruz-Lemini*, Eva Stein, Juan G Abraldes, Ramon Bataller, Jose Altamirano, *Mexico* |
| **FRI-420** COMPARING INDIVIDUAL AND POPULATION PREVENTION BENEFITS OF EARLY DIRECT-ACTING ANTIVIRAL TREATMENT FOR HCV  
Natasha K. Martin*, Peter Vickerman, Gregory J. Dore, Jason Grebely, Alec Miners, John Cairns, Graham R. Foster, Sharon J. Hutchinson, David J. Goldberg, Thomas C. S. Martin, Mary Ramsay, Matthew Hickman, *United States* |
FRI-421
YI

AN EVALUATION OF FEASIBILITY AND COST EFFECTIVENESS FOR OUTREACH SCREENING AND TREATMENT OF HEPATITIS C VIRUS IN A CENTRAL LONDON DRUG TREATMENT UNIT
Nowlan Selvapatt*, Tom Ward, Lorna Harrison, Jody Lombardini, Mark Thursz, Phil McEwan, Ashley Brown, United Kingdom

FRI-422
YI

COST-EFFECTIVENESS OF BIRTH COHORT SCREENING AND TREATMENT FOR HCV IN THE UK: AN EXPLORATORY ANALYSIS
Nowlan Selvapatt*, Tom Ward, Abbesega Ananthavarathan, Bilal Khan, Samantha Webster, Mark Thursz, Ashley Brown, Phil McEwan, United Kingdom

FRI-423
YI

STUDY ON KNOWLEDGE AWARENESS OF HBV AND HCV AMONG MONGOLIAN POPULATION
Oyungerel Lhagva-Ochir*, Purevjargal Bat-Ulzii, Delgerbat Boldbaatar, Maralmaa Enkhbat, Ganbolor Jargalsaikhan, Bekhbold Dashtseren, Bayarmagnai Bold, Naranjargal Dahdorj, Naranbaatar Dahdorj, Mongolia

FRI-424
YI

EARLY DETECTION AND CURATIVE TREATMENT OF HEPATOCELLULAR CARCINOMA: A COST EFFECTIVENESS ANALYSIS BASED ON PROSPECTIVE FRENCH COHORT (ANRS CO12 CIRVIR AND CHANGH)
Benjamin Cadier, Julie Bulsei, Pierre Nahon*, Olivier Seror, Alexis Laurent, Isabelle Rosa, Richard Layese, Isabelle Durand-Zaleski, Karine Chevreul, France

FRI-425
YI

SEROPREVALENCE OF HEPATITIS E VIRUS AMONG PORTUGUESE CHILDREN BORN IN THE 1990’S AND 2000’S: IS IT INCREASING?

FRI-426
YI

ECONOMIC EVALUATION OF A COMMUNITY BASED DIAGNOSTIC PATHWAY TO SCREEN ADULTS FOR NON-ALCOHOLIC FATTY LIVER DISEASE
Lukasz Tanajewski, Rebecca Harris*, David J Harman, Guru P Aithal, Timothy R Card, Georgios Gkountouras, Vladislav Berdunov, Indra Neil Guha, Rachel A Elliott, United Kingdom
<table>
<thead>
<tr>
<th>FRI-427</th>
<th>CASCADE OF CARE FOR PERSONS TESTING ANTI-HCV POSITIVE, 2002-2013, ENGLAND</th>
</tr>
</thead>
<tbody>
<tr>
<td>FRI-428</td>
<td>HOW MANY PATIENTS TREATED? THE HCV TREATMENT REALITY IN GERMANY</td>
</tr>
<tr>
<td>FRI-429</td>
<td>UNSAFE USE, KNOWLEDGE AND HCV INFECTION: RESULTS FROM A SERO-BEHAVIORAL SURVEY OF CURRENT INJECTORS IN GERMANY</td>
</tr>
<tr>
<td>FRI-430</td>
<td>CLINICAL AND SOCIAL PSYCHOLOGICAL PROFILES OF PATIENTS WITH CHRONIC HEPATITIS C TREATED WITH IFN-FREE REGIMENS IN FRANCE</td>
</tr>
<tr>
<td>FRI-431</td>
<td>INVESTMENT CASE FOR A COMPREHENSIVE PACKAGE OF INTERVENTIONS AGAINST HEPATITIS B IN CHINA</td>
</tr>
<tr>
<td>FRI-432</td>
<td>OPPOSITE TRENDS IN LIVER RELATED MORTALITY CONCERNING LIVER MALIGNANT NEOPLASIA AND CHRONIC LIVER DISEASE IN THE LAST 12 YEARS IN PORTUGAL (2002-2013)</td>
</tr>
</tbody>
</table>
FRI-433

DIET, PHYSICAL ACTIVITY, SEDENTARY BEHAVIOUR AND SLEEP IN 1289 ADULTS WITH LIVER DISEASE; A CROSS SECTIONAL STUDY OF DATA FROM THE UK BIOBANK
Sophie Cassidy*, Josephine Chau, Michael Catt, Quentin Anstee, Christopher Day, Adrian Bauman, Michael Trenell, United Kingdom

FRI-434

COST-EFFECTIVENESS AND BUDGET IMPACT OF INTERFERON-FREE DIRECT-ACTING ANTIVIRAL (DAA)-BASED REGIMENS FOR CHRONIC HEPATITIS C TREATMENT. THE FRENCH CASE
Sylvie Deuffic-Burban*, Dorothée Obach, Valérie Canva, Stanislas Pol, Françoise Roudot-Thoraval, Daniel Dhumeaux, Philippe Mathurin, Yazdan Yazdanpanah, France
# Fatty liver disease: Clinical

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Narmin Effat, Mohamed Refaey, Rasha Elzehery, Wagdi Elkashef, Mohamed Hafez, Mahmoud</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Awad, Khaled Zalata, Waled Eldars, <strong>Egypt</strong></td>
<td></td>
</tr>
<tr>
<td>FRI-273</td>
<td>LIPIDOMIC CONNECTIONS BETWEEN LIVER AND SERUM DURING THE ONSET OF NAFLD</td>
<td>Ainara Cano*, Borja Lanza, David Balgoma, Rebeca Mayo, Angel Rodriguez, Azucena Castro,</td>
<td>Spain</td>
</tr>
<tr>
<td></td>
<td>IN HUMANS</td>
<td>Antonio Martin-Duce, <strong>Spain</strong></td>
<td></td>
</tr>
<tr>
<td>FRI-274</td>
<td>RISING INPATIENT ENCOUNTERS AND HOSPITAL CHARGES FOR PATIENTS WITH</td>
<td>Alexander L. Nguyen*, Pauline Nguyen, Edward Sheen, Michelle Jin, Mingjuan Jin, Yoona</td>
<td>United States</td>
</tr>
<tr>
<td></td>
<td>NON-ALCOHOLIC FATTY LIVER DISEASE IN THE UNITED STATES</td>
<td>Kim, Mindie H. Nguyen, <strong>United States</strong></td>
<td></td>
</tr>
<tr>
<td>FRI-275</td>
<td>TRYPTASE+ SCF+ MAST CELL ACCUMULATION IN THE HUMAN LIVER CORRELATES</td>
<td>Anna Christina de la Cruz, Alborz Omidian, Mina Wilson, Mehmet Altintas, Nestor De La</td>
<td>United States</td>
</tr>
<tr>
<td></td>
<td>WITH FIBROSIS IN NON-ALCOHOLIC FATTY LIVER DISEASE</td>
<td>Cruz-Munoz, Mehrdad Nadji, Monica Garcia-Buitrago, Ali Nayer*, <strong>United States</strong></td>
<td></td>
</tr>
<tr>
<td>FRI-276</td>
<td>COMPLICATIONS OF NON-ALCOHOLIC FATTY LIVER DISEASE</td>
<td>Amitabh Suman*, Vikas Khullar, Alpana Limaye, <strong>United States</strong></td>
<td></td>
</tr>
<tr>
<td>FRI-277</td>
<td>NON-INVASIVE ASSESSMENT OF FIBROSIS PROGRESSION IN NON-ALCOHOLIC</td>
<td>Amr S. Hanafy*, <strong>Egypt</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>FATTY LIVER DISEASE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>FRI-278</td>
<td>THE AMOUNT OF PREADIPOCYTES IN VISCERAL ADIPOSE TISSUE DECREASES WITH</td>
<td>Angel Carazo*, Esther Pavón, Jesus García-Rubio, Jose Antonio Muñoz-Gámez, Antonio</td>
<td>Spain</td>
</tr>
<tr>
<td></td>
<td>NON-ALCOHOLIC FATTY LIVER DISEASE IN MORBID OBESITY</td>
<td>Côzar, Mercedes Caba-Molina, Trinidad Caballero, Ana Gila, Javier Salmerón, <strong>Spain</strong></td>
<td></td>
</tr>
<tr>
<td>FRI-279</td>
<td>ASSOCIATION OF CONTROLLED ATTENUATION PARAMETER (CAP) AND HBA1C IN</td>
<td>Anita Arslanow*, Ahmed Eid, Jürgen Geisel, Frank Lammert, <strong>Germany</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>PATIENTS WITH FATTY LIVER</td>
<td></td>
<td></td>
</tr>
<tr>
<td>FRI-280</td>
<td>PRIMARY CARE SEQUENTIAL USE OF FIB-4 AND THE ENHANCED LIVER FIBROSIS TEST TO STRATIFY PATIENTS WITH NON-ALCOHOLIC FATTY LIVER ACIDE DOUBLES CIRRHOSIS DETECTION AND REDUCES REFERRALS OF PATIENTS WITH MILD DISEASE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>---------</td>
<td>--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>FRI-281</th>
<th>NOCTURNAL INCREASE OF CIRCULATING FIBROBLAST GROWTH FACTOR 21 IS CORRELATED WITH SEVERITY OF NON-ALCOHOLIC FATTY LIVER DISEASE IN CHILDREN</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Annalisa Crudele*, Antonella Mosca, Claudia Della Corte, Nadia Panera, Valerio Nobili, Anna Alisi, <em>Italy</em></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>FRI-282</th>
<th>A SYSTEMATIC LITERATURE REVIEW OF THE EPIDEMIOLOGY AND ECONOMIC BURDEN ASSOCIATED WITH NON-ALCOHOLIC STEATOHEPATITIS</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Arun J. Sanyal*, Amber L. Martin, Sarah M. Cadarette, Meghan D. Burns, Deniz Guranlioglu, Bernt Kartman, Karin M. Henriksson, Mark Berner Hansen, <em>United States</em></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>FRI-283</th>
<th>THE DISCREPANCY BETWEEN TRANSCRIPTOME AND PHENOTYPE OF NON-ALCOHOLIC FATTY LIVER DISEASE: COULD ITS PHENOTYPE CROSS OVER TO THAT OF AUTOIMMUNE HEPATITIS?</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Atsumasa Komori*, Kazuyoshi Nagata, Yuki Kugiyama, Shigemune Bekki, Shinjiro Uchida, Satoru Hashimoto, Akira Saeke, Shinya Nagaoka, Kazumi Yamasaki, Seigo Abiru, Hiroshi Yatsuhashi, <em>Japan</em></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>FRI-284</th>
<th>ROLE OF 13C-OCTANOATE BREATH TEST FOR NON-INVASIVE DIAGNOSIS OF NON-ALCOHOLIC STEATOHEPATITIS</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Carmen Fierbinteanu-Braticevici*, Alexandru Moldoveanu, Laura Tribus, Ana Petrisor, Ana Necula, Octav Viasu, <em>Romania</em></td>
</tr>
<tr>
<td>Poster Number</td>
<td>Title</td>
</tr>
<tr>
<td>---------------</td>
<td>-----------------------------------------------------------------------</td>
</tr>
<tr>
<td>FRI-285</td>
<td>Adipose tissue insulin resistance is associated with macrophage activation in non-diabetic patients with non-alcoholic fatty liver disease</td>
</tr>
<tr>
<td>FRI-286</td>
<td>Angiopoietin-like4 is associated with lipid metabolism and severe fibrosis in non-diabetic patients with non-alcoholic fatty liver disease</td>
</tr>
<tr>
<td>FRI-287</td>
<td>Hepatocellular carcinoma in non-alcoholic steatohepatitis – histopathological aspects</td>
</tr>
<tr>
<td>FRI-288</td>
<td>From mice to men – Changes in FGF15/19 expression and bile acid levels as sensitive markers of pharmacological FXR activation; results from human phase I and animal studies using the potent and selective FXR agonist PX-102</td>
</tr>
<tr>
<td>FRI-289</td>
<td>A non-invasive lipidomic test accurately discriminates non-alcoholic steatohepatitis from steatosis: A blind validation study</td>
</tr>
</tbody>
</table>
FRI-290
YI
EXERCISE THERAPY IN PATIENTS CONSUMING MODERATE ALCOHOL: A RANDOMISED CONTROL TRIAL
David Houghton*, Kate Hallsworth, Christian Thoma, Sophie Cassidy, Timothe Hardy, Kieran Hollingsworth, Roy Taylor, Chris Day, Steve Masson, Stuart McPherson, Quentin Anstee, Michael Trenell, United Kingdom

FRI-291
PREDICTING FATTY LIVER DISEASE IN HEALTHY POTENTIAL LIVER DONORS
Dinesh Jothimani*, Sanjay Govil, Mukul Vij, David Sheridan, Matthew Cramp, Mohamed Rela, India

FRI-292
IMPACT OF CONTINUOUS POSITIVE AIRWAY PRESSURE TREATMENT ON NON-ALCOHOLIC FATTY LIVER DISEASE IN PATIENTS WITH OBSTRUCTIVE SLEEP APNEA
Donghee Kim*, Ajitha Mannalithara, Prowpanga Udompap, Clete Kushida, W. Ray Kim, United States

FRI-293
DEVELOPMENT AND VALIDATION OF A NON-INVASIVE MODEL FOR PREDICTING FIBROSIS RESOLUTION ONE YEAR AFTER LIFESTYLE INTERVENTION FOR BIOPSY-PROVEN NON-ALCOHOLIC STEATOHEPATITIS

FRI-294
YI
RELATIONSHIP BETWEEN PATTERN OF HEPATIC IRON DEPOSITION, DISEASE SEVERITY AND CLINICAL OUTCOMES IN NON-ALCOHOLIC FATTY LIVER DISEASE
Elena Buzzetti*, Roberta Manguerra, Andrew Hall, Laura De Luca, Pinelopi Manousou, Paul Dhillon, Massimo Pinzani, Antonello Pietrangelo, Emmanuel Tsocchatzis, United Kingdom

FRI-295
YI
DETERMINATION OF A NORMAL VALUE FOR HOMA-IR AND CUT-OFF VALUE FOR NON-ALCOHOLIC FATTY LIVER DISEASE
Elina M. Petäjä*, You Zhou, Markku Peltonen, Pekka Jouslahti, Satu Männistö, Sirkka Keinänen-Kiukaanniemi, Juha Saltevo, Hannele Yki-Järvinen, Finland
**Fatty liver disease: Clinical (Cont.)**

<table>
<thead>
<tr>
<th>FRI-296</th>
<th>PREVALENCE OF NON-ALCOHOLIC FATTY LIVER DISEASE AND FIBROSIS IN A LARGE POPULATION COHORT IN THE NORTH OF THE NETHERLANDS: A LIFELINES COHORT STUDY</th>
</tr>
</thead>
<tbody>
<tr>
<td>YI</td>
<td>Eline H. van den Berg*, Marzyeh Amini, Tim C. M. A. Schreuder, Robin P. F. Dullaart, Klaas Nico Faber, Behrooz Z. Alizadeh, Hans Blokzijl, Netherlands</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>FRI-297</th>
<th>QUANTIFICATION OF LIVER STEATOSIS USING THE NEW SCORE ULTRASOUND FLI (FATTY LIVER INDEX) AND CAP (CONTROLLED ATTENUATED PARAMETER): A COMPARATIVE ANALYSIS</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Fernanda V. Calcado*, Rodrigo Luz, Renata Leite, Nathalie Leite, Henrique Coelho, Cristiane Villela Nogueira, Brazil</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>FRI-298</th>
<th>PREDICTORS OF LATE RECURRENCE AFTER LIVER RESECTION FOR HEPATOCELLULAR CARCINOMA ON NON-ALCOHOLIC FATTY LIVER DISEASE</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Fiammetta Soggiu*, Carlo Sposito, Maria Flores, Sherrie Bhoori, Vincenzo Mazzaferro, United Kingdom</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>FRI-299</th>
<th>STEATOMETER: A NEW ULTRASOUND IMAGING SYSTEM FOR NON INVASIVE, NON-IONIZING FATTY LIVER MEASUREMENT</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Francesco Faita*, Nicole Di Lascio, Lorenzo Cini, Cinzia Avigo, Antonio Salvati, Nicola Martini, Dante Chiappino, Lorenzo Ghiadoni, Ferruccio Bonino, Maurizia R. Brunetto, Italy</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>FRI-300</th>
<th>ENDOSCOPIC DUODENAL MUCOSAL RESURFACING (DMR) IMPROVES METABOLIC MEASURES INCLUDING HEPATIC TRANSAMINASE LEVELS IN PATIENTS WITH TYPE 2 DIABETES (T2D): DATA FROM A FIRST-IN-HUMAN STUDY</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Manoel Galvao Neto, Harith Rajagopalan*, Pablo Becerra, Patricia Rodriguez, Paulina Vignolo, Jay Caplan, Leonardo Rodriguez, United States</td>
</tr>
</tbody>
</table>
FRI-301

YI

**EFFECTS OF ORAL HIGH-DOSE VITAMIN D SUPPLEMENTATION ON NON-ALCOHOLIC FATTY LIVER DISEASE IN PATIENTS WITH TYPE 2 DIABETES: A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL**

Ilaria Barchetta*, Francesco Angelico, Maria Del Ben, Michele Di Martino, Antonio Fraioli, Giuseppe La Torre, Sergio Morini, Claudio Tiberti, Riccardo Del Vescovo, Laura Bertocci, Flavia Agata Cimini, Carlo Catalano, Marco Giorgio Baroni, Maria Gisella Cavallo, *Italy*

FRI-302

YI

**SHARED GENE EFFECTS BETWEEN HEPATIC STEATOSIS AND FIBROSIS: A PROSPECTIVE TWIN STUDY**


FRI-303

**NON-INVASIVE TESTS FOR THE DIAGNOSIS OF LIVER FIBROSIS ARE ALSO PROGNOSTIC MARKERS IN NON-ALCOHOLIC FATTY LIVER DISEASE**

Jerome Boursièr*, Adrien Lannes, Sandrine Bertrais, Sophie Michalak, Frédéric Oberti, Isabelle Fouchard-Hubert, Paul Calès, *France*

FRI-304

**NOVEL SERUM LIPIDOMIC SIGNATURE CORRELATES WITH THE GRADE OF STEATOSIS MEASURED BIOCHEMICALLY AND BY MAGNETIC RESONANCE IMAGING**

Raul Jimenez-Agüero, Luis Bujanda, Enara Arretxe, David Balgoma, Maria J. Perugorria, Cristina Alonso, Emma Eizaguirre, Marcin Krawczyk, Frank Lammert, Azucena Castro, Jesús M. Banales*, *Spain*

FRI-305

**FUNCTIONAL HEPATIC VOLUME (FHV), PORTAL HYPERTENSION AND CIRRHOSIS ARE RELATED TO WEIGHT IN PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS**

John C. Hoefs*, *United States*

FRI-306

**LIVER AND SYSTEMIC IRON LOADING CHARACTERISE INITIAL DISEASE PROGRESSION IN NON-ALCOHOLIC FATTY LIVER DISEASE**

John D. Ryan*, Andrew Armitage, Rajarshi Banerjee, Stefan Neubauer, Lai Mun Wang, Jeremy Cobbold, Jane Collier, Eleanor Barnes, Michael Pavlides, *United Kingdom*
Fatty liver disease: Clinical (Cont.)

FRI-307 THE PREVALENCE OF NON-ALCOHOLIC STEATOHEPATITIS AMONG DIABETIC PATIENTS FOLLOWED BY PRIMARY CARE AND ENDOCRINOLOGY
Kartik Joshi*, Jasmine Thakkar, Anna Boron, Ann Moore, Ashley Hepner, James Deer, Monica Rodriguez, Robert Gish, Justin Reynolds, Richard Manch, Anita Kohli, United States

FRI-308 THE ROLE OF SYSTEMIC INFLAMMATION AND ENDOTHELIAL DYSFUNCTION IN PATHOGENESIS OF CARDIOVASCULAR DISEASE IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE
Kateryna Pivtorak*, Ukraine

FRI-309 NON-ALCOHOLIC STEATOHEPATITIS RESOLUTION IS ASSOCIATED WITH IMPROVEMENTS IN LDL SIZE AND PHENOTYPE
Kathleen Corey*, Laura Wilson, Raymond Chung, Ronald Krauss, Naga Chalasani, United States

FRI-310 EVALUATION OF EFFECTS OF CONCOMITANT MEDICATIONS FOR NON-ALCOHOLIC STEATOHEPATITIS AND ASSOCIATED COMORBIDITIES ON HISTOLOGICAL IMPROVEMENTS WITH OBETICHOLIC ACID
Kris V. Kowdley*, Manal F. Abdelmalek, Arthur J. McCullough, Rohit Loomba, Bilal Hameed, Naga P. Chalasani, Brent A. Neuschwander-Tetri, Saswati Hazra, Jianfen Chen, Reshma Shringarpure, David Shapiro, Arun J. Sanyal, United States

FRI-311 THE USE OF AN INULIN-TYPE PREBIOTIC IN NON-ALCOHOLIC STEATOHEPATITIS
Laura Iliescu*, Letitia Toma, Georgiana Minzala, Alina Tanase, Carmen Orban, Romania

FRI-312 THE ACCURACY OF TRANSIENT ELASTOGRAPHY AND COMPARISON OF NON-INVASIVE MARKERS FOR ASSESSING FIBROSIS IN KOREAN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE
Lee Hye Won*, Chung Kyu Sik, Kim Beom Kyung, Kim Seung Up, Kim Do Young, Ahn Sang Hoon, Park Young Nyun, Han Kwang-Hyub, Park Jun Yong, Korea, South
FRI-313 YI

THE SIGNIFICANT ASSOCIATION BETWEEN CONTROLLED ATTENUATION PARAMETER ASSESSED BY TRANSIENT ELASTOGRAPHY AND VISCERAL FAT, NOT BODY MASS INDEX
Lee Hye Won*, Kim Kwang Joon, Chung Kyu Sik, Chon Young Eun, Kim Beom Kyung, Kim Seung Up, Kim Do Young, Ahn Sang Hoon, Han Kwang-Hyub, Park Jun Yong, Korea, South

FRI-314 YI

SPLEEN DIMENSIONS EVALUATED BY ULTRASOUND ARE INVERSELY ASSOCIATED WITH LYSOSOMAL ACID LIPASE ACTIVITY IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE
Licia Polimeni*, Francesco Baratta, Daniele Pastori, Giulia Tozzi, Giancarlo Labbadia, Francesco Violi, Maria Del Ben, Francesco Angelico, Italy

FRI-315

NON-ALCOHOLIC FATTY LIVER DISEASE IS ASSOCIATED WITH AN EXCESSIVE CALORIE INTAKE RATHER THAN A DISTINCTIVE DIETARY PATTERN
Malte H. Wehmeyer*, Bettina Jagemann, Birgit-Christiane Zyriax, Eberhard Windler, Ansgar W. Lohse, Julian Schulze zur Wiesch, Johannes Kluwe, Germany

FRI-316 YI

THE COMMON PROSTEATOTIC PNPLA3 (ADIPONUTRIN) P.1148M VARIANT MIGHT PROTECT AGAINST GALLSTONE DISEASE
Marcin Krawczyk*, Raúl Jiménez-Agüero, María J. Perugorria, Lander Gallego, Luis Bujanda, Frank Lammert, Jesús M. Banales, Germany

FRI-317 YI

CHANGES OF THE GUT MICROBIOTA IN PATIENTS WITH OBESITY, METABOLIC SYNDROME AND NON-ALCOHOLIC FATTY LIVER DISEASE VERSUS HEALTHY CONTROLS
Esther Nistal, María Ballesteros Pomar, María Teresa Arias Loste*, Carmen Alonso, Marta Aparicio Cabezudo, Marcos Jimenez, Paula Iruzubieta, Monica Molina-Edesa, Emilio Fábrega, Juan Maria Garcia-Lobo, Jose Luis Olcoz, Javier Crespo, Spain

FRI-318 YI

THE FTO RS1421085 T>C POLYMORPHISM IS ASSOCIATED WITH THE SEVERITY OF NON-ALCOHOLIC FATTY LIVER
María Teresa Arias Loste*, Rocio Gallego-Duran, Carmen Alonso, Paula Iruzubieta, Javier Ampuero, David Ramos, Antonio Gil-Gomez, Javier Abad, Emilio Fábrega, Jose Luis Calleja, Raul Jesus Andrade, Carmelo Garcia-Monzón, Manuel Romero-Gomez, Javier Crespo, Spain
**Fatty liver disease: Clinical (Cont.)**

<table>
<thead>
<tr>
<th>FRI-319</th>
<th>PHYSICAL ACTIVITY REDUCE HEPATIC APOPTOSIS IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE AND VISCERAL OBESITY</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Nataliia Dynnyk*, Anatolyy Svintsitsky, Galyna Solovyova, Volodymyr Bogomaz, Olena Baka, Olena Gurbych, Yevgeniia Golovchanska, <em>Ukraine</em></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>FRI-320</th>
<th>EFFECTS OF OMEGA-3 POLYANSATURATED FATTY ACIDS AND METFORMIN ON NASH COURSE</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Nataliya Virstyuk*, Olena Deltsova, Sergyi Geraschenko, Oleg Virstyuk, <em>Ukraine</em></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>FRI-321</th>
<th>MATERNAL OBESITY AND DURATION OF BREASTFEEDING INFLUENCE THE RISK OF NON-ALCOHOLIC FATTY LIVER DISEASE IN ADOLESCENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Oyekoya T. Ayonrinde*, Wendy H. Oddy, Leon A. Adams, Trevor A. Mori, Lawrence Beilin, John K. Olynyk, <em>Australia</em></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>FRI-322</th>
<th>CIRCULATING PCSK9 LEVELS ARE ASSOCIATED WITH THE HEPATIC FAT IN NON-ALCOHOLIC FATTY LIVER DISEASE</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Paola Dongiovanni*, Massimiliano Ruscica, Nicola Ferri, Chiara Macchi, Claudia Lanti, Raffaela Rametta, Marco Maggioni, Anna Ludovica Fracanzani, Sara Badiali, Silvia Fargion, Paolo Magni, Luca Valenti, <em>Italy</em></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>FRI-323</th>
<th>CLINICAL VALIDATION OF A NON-INVASIVE LIPIDOMIC TEST FOR THE DIAGNOSIS OF NON-ALCOHOLIC FATTY LIVER DISEASE</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Patricia Salvador*, Sonia Blanco, Nahikari Maria Irazabal-Remuiñan, Ibon Martinez-Arranz, Luis Francisco Eraña-Ledesma, Itziar Mincholé, Fernando Menéndez, Rebeca Mayo, Pablo Ruiz, Raquel González-Monasterio, Elvira Delgado, Juan Ignacio Arenas, Maider Martos, Antxon Otegui, Gixane Arregui, Maria Carmen Eizmendi, Sagrario Urquiola, Ricardo San Vicente, Azucena Castro, Pablo Ortiz, Jose Ignacio Pijoán, Javier Bustamante, <em>Spain</em></td>
</tr>
</tbody>
</table>
FRI-324  PNPLA3 VARIANTS CONFER AN INCREASED RISK OF ADVANCED FIBROSIS DUE TO NON-ALCOHOLIC STEATOHEPATITIS

FRI-325  QUANTIFICATION OF LIVER FAT CONTENT: DIAGNOSTIC EVALUATION OF PROTON MAGNETIC RESONANCE SPECTROSCOPY COMPARED WITH HISTOLOGICAL METHODS
Patrik Nasr*, Mikael F. Forsgren, Simone Ignatova, Olof Dahlqvist Leinhard, Nils Dahlström, Mattias Ekstedt, Peter Lundberg, Stergios Kechagias, Sweden

FRI-326  A SYSTEMATIC REVIEW ON NON-INVASIVE DIAGNOSTIC METHODS FOR NON-ALCOHOLIC STEATOHEPATITIS: A META-ANALYSIS
Pauline Verhaegh*, Roisin Bavalia, Bjorn Winkens, Ad Masclee, Daisy Jonkers, Ger Kock, Netherlands

FRI-327  PERFORMANCE OF FIBROSCAN® IN THE ASSESSMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE/NON-ALCOHOLIC STEATOHEPATITIS PATIENTS: INTERIM RESULTS OF A PROSPECTIVE MULTICENTRE VALIDATION STUDY
Peter J Eddowes*, Quentin M Anstee, Indra Neil Guha, Emmanouil Tsochatzis, Valérie Paradis, Pierre Bedossa, Philip N Newsome, United Kingdom

FRI-328  ELEVATED MEAN PLATELET VOLUME IMPROVES CURRENT NON-INVASIVE MARKERS OF FIBROSIS AND PREDICTS ACUTE CARDIOVASCULAR EVENTS IN NON-ALCOHOLIC FATTY LIVER DISEASE PATIENTS
Maciej Adler, Pinelopi Manousou*, Iyer Rishi, Stephen Atkinson, Michael Yee, Shahid Khan, Josephine Lloyd, Robert Goldin, Mark Thursz, United Kingdom

FRI-329  SERUM BILE ACID PROFILES ARE ASSOCIATED WITH HISTOLOGICAL SEVERITY IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE
Raluca Pais*, Dominique Rainteau, Lydie Humbert, Thierry Poynard, Chantal Housset, Vlad Ratziu, France
Fatty liver disease: Clinical (Cont.)

**IMPACT OF GWAS-IDENTIFIED COMMON VARIANTS ON HISTOPATHOLOGICAL FEATURES OF NON-ALCOHOLIC FATTY LIVER DISEASE PATIENTS**

Rocío Gallego-Durán*, Javier Ampuero, Jose Antonio Del Campo, Helena Pastor-Ramírez, Eduardo Vilar-Gomez, Antonio Gil-Gómez, Maria Teresa Arias-Loste, Maria Jesús Pareja, Javier Abad, Maria Carmen Rico, Marta García-Valdecasas, Inmaculada Moreno, Jose Luis Calleja, Raúl Jesús Andrade, Javier Crespo, Carmelo García-Monzón, Manuel Romero-Gómez, Spain

**RELATIONSHIP BETWEEN APPENDICULAR SARCOPENIA AND NON-ALCOHOLIC FATTY LIVER DISEASE IN KOREAN POPULATION**

Sae Kyung Joo*, Won Kim, Sohee Oh, Korea, South

**FNDC5 RS3480 A>G POLYMORPHISM DISENTANGLES STEATOSIS FROM FIBROSIS SEVERITY IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE**

Salvatore Petta*, Luca Valenti, Rosaria Pipitone, Paola Dongiovanni, Calogero Cammà, Anna Fracanzani, Vito Di Marco, Marta Milano, Stefania Grimaudo, Silvia Fragion, Antonio Craxì, Italy

**SARCOPENIA IS ASSOCIATED WITH SEVERE LIVER FIBROSIS IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE**

Salvatore Petta*, Stefania Ciminnisi, Vito Di Marco, Calogero Cammà, Antonio Craxì, Italy

**CIRCULATING CD36 CORRELATES WITH INTRAHEPATIC LIPID CONTENT IN NON-ALCOHOLIC FATTY LIVER DISEASE PATIENTS**

Sara Hæbøll†, Marianne K Poulsen, Marie J Ørnsrøp, Thomas N Kjær, Steen B Pedersen, Søren Nielsen, Aase Handberg, Henning Grønbæk, Denmark

**CLINICAL DETERMINANTS OF FIBROSIS PROGRESSION IN AN ITALIAN PROSPECTIVE COHORT OF PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE**

Serena Pelusi*, Rosa Lombardi, Emirijana Hyseni, Vittorio Borroni, Anna Ludovica Fracanzani, Silvia Fargion, Luca Valenti, Italy
FRI-336  
**SERUM LEVELS OF ENDOCANNABINOIDS ARE INDEPENDENT RISK FACTORS FOR NON-ALCOHOLIC FATTY LIVER DISEASE**  
Shira Zelber-Sagi*, Shahar Azar, Alina Nemirovski, Muriel Webb, Zamir Halpern, Oren Shibolet, Joseph Tam, Israel

FRI-337  
**SCREENING FOR LIVER DISEASE IN THE GENERAL POPULATION: THE POTENTIAL UTILITY OF USING AST/ALT RATIO**  
Sofia Carvalhana*, Jorge Leitão, Ana Catarina Alves, Ana Paula Silva, Francisco Velasco, Isabel Medeiros, Armando Carvalho, Mafalda Bourbon, Helena Cortez-Pinto, Portugal

FRI-338  
**ACTIVITY OF COAGULATION FACTORS IX AND XIII AND FIBRINOGEN ARE INCREASED IN ‘OBESE NON-ALCOHOLIC FATTY LIVER DISEASE’ BUT NOT IN ‘PNPLA3 NON-ALCOHOLIC FATTY LIVER DISEASE’**  
Susanna Lallukka*, Marju Orho-Melander, Nina Lundbom, Vesa M Olkkonen, Hannele Yki-Järvinen, Finland

FRI-339  
**RELATIONSHIP BETWEEN BASELINE HEPATIC DISEASE SEVERITY AND THE CARDIOMETABOLIC AND ANTI-INFLAMMATORY EFFECTS OF ELAFIBRANOR IN PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS**  
Sven M. Francque*, Stephen A. Harrison, Arun Sanyal, Pierre Bedossa, Lawrence Serfaty, Manuel Romero-Gomez, Jérôme Boursier, Manal Abdelmalek, Stephen Caldwell, Joost Drenth, Quentin Anstee, Dean Hum, Remy Hanf, Alice Roudot, Sophie Megnien, Bart Staels, Vlad Ratziu, Belgium

FRI-340  
**EFFICACY OF GLUTATHIONE FOR THE TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE: AN OPEN-LABEL, MULTICENTER, PROSPECTIVE STUDY**  
Takaomi Kessoku*, Yoshio Sumida, Kento Imajo, Yasushi Honda, Yuji Ogawa, Masato Yoneda, Masafumi Ono, Yuichiro Egushi, Atsushi Nakajima, Japan

FRI-341  
**NON-INVASIVE ASSESSMENT OF STEATOSIS AND LIVER FIBROSIS IN OVERWEIGHT AND OBESE PATIENTS**  
Teresa Broquetas*, Marc Puigvehí, Susanna Coll, Montserrat Garcia-Retortillo, Nuria Cañete, Rosa Fernández, Beatriz Cabrero, Maria Dolores Giménez, Javier Gimeno, Felipe Bory, Juan Pedro-Botet, Ricard Solà, Jose A. Carrión, Spain
<table>
<thead>
<tr>
<th>Poster No.</th>
<th>Title</th>
<th>Authors</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>FRI-342</td>
<td>DUODENAL-JEJUNAL BYPASS LINER (ENDOBARRIER®) TREATMENT IMPROVES NON-ALCOHOLIC FATTY LIVER DISEASE</td>
<td>Thomas Karlas*, Jürgen Feisthammel, Tatjana Schütz, Matthias Blüher, Sebastian Beer, Tina Weiße, Franziska Lindner, Volker Keim, Albrecht Hoffmeister, Johannes Wiegand</td>
<td>Germany</td>
</tr>
<tr>
<td>FRI-343</td>
<td>LOW LEVELS OF NATURAL IGM ANTIBODIES TOWARDS OXIDATION-SPECIFIC EPITOPES ARE ASSOCIATED WITH HUMAN NON-ALCOHOLIC STEATOHEPATITIS</td>
<td>Tim Hendrikx*, Martin Watzenboeck, Sofie M. Walenbergh, Satish Kalhan, Ger H. Koek, Daisy Jonkers, Christoph J. Binder, Ronit Shiri-Sverdlav</td>
<td>Belgium</td>
</tr>
<tr>
<td>FRI-356</td>
<td>SARCOPENIA IS AN INDEPENDENT RISK FACTOR FOR BIOPSY-PROVEN NON-ALCOHOLIC STEATOHEPATITIS</td>
<td>Won Kim*, Bo Kyung Koo, Sae Kyung Joo, Jung Ho Kim, Su Cheol Park</td>
<td>Korea, South</td>
</tr>
<tr>
<td>FRI-357</td>
<td>THE CHARACTERISTICS OF NON-OBESE NON-ALCOHOLIC FATTY LIVER DISEASE: EFFECT OF GENETIC AND ENVIRONMENTAL FACTORS</td>
<td>Yasushi Honda*, Takaomi Kessoku, Yuji Ogawa, Kento Imajo, Masato Yoneda, Satoru Saito, Atsushi Nakajima</td>
<td>Japan</td>
</tr>
<tr>
<td>FRI-358</td>
<td>THE ECONOMIC AND CLINICAL BURDEN OF NON-ALCOHOLIC FATTY LIVER DISEASE IN THE UNITED STATES</td>
<td>Zobair M. Younossi*, Linda Henry, Maria Stepanova, Youssef Younossi, Andrei Racila, Sharon Hunt, Rachel Beckerman</td>
<td>United States</td>
</tr>
</tbody>
</table>
Liver immunology including viral hepatitis

**FRI-202**  
**Immune Response to Hepatitis B Vaccine Booster in Adolescents Who Received Active Immunization at Birth**  
Aezam Katoonizadeh*, Alireza Norouzi, Navid Khoshbakht, Maryam Sharaefkhah, Shahin Merat, Hossein Poustchi, Reza Malekzadeh, *Iran

**FRI-203**  
**Donor Liver Perfusate Non-Dominant B Cell Chimerism Correlated with Early Recurrence of Post Transplantation Hepatitis C**  
Akinobu Takaki*, Kazuko Koike, Ryuichiro Tsuzaki, Masashi Utsumi, Takahito Yagi, Hiroyuki Okada, *Japan

**FRI-204**  
**T Cell-Independent Hepatic Inflammation in Viral-Related Liver Cirrhosis and Hepatocellular Carcinoma**  

**FRI-205**  
**Long-Term Efficacy of Recombinant Hepatitis B Vaccination on Persistent HBS Antigenaemia, Recurrence of Viremia and Insulin Resistance After Off Treatment Response in Chronic Hepatitis B Patients**  
Amr S. Hanafy*, *Egypt

**FRI-206**  
**High Levels of Immunoglobulin A Anti-Tissue Transglutaminase Antibodies at Diagnosis Are a Predictive Factor for Celiac Hepatitis**  

**FRI-207**  
**Differential Contribution of Progenitor and Terminal Subsets of Exhausted CD8+ T Cells in Chronic HBV versus HCV Infection**  
Anita Schuch*, Dominik Wieland, Maike Hofmann, Robert Thimme, *Germany
Liver immunology including viral hepatitis (Cont.)

FRI-208  RETREATMENT OF SOFOSBUVIR-INCLUDING REGIMEN FAILURES IN THE REAL LIFE
Anne Laurain*, Philippe Sultanik, Laura Kramer, Jean-Francois Mertitet, Estelle Boueyre, Vincent Mallet, Philippe Sogni, Helene Fontaine, Arielle Rosenberg, Anais Vallet-Pichard, Stanislas Pol, France

FRI-209  THE GENERATION OF AN IMMUNOGENIC SECOND-GENERATION CONSERVED SEGMENT HCV T CELL VACCINE TO TARGET MULTIPLE HCV GENOTYPES
Annette Von Delft’, Timothy Donnison, Senthil Chinnakannan, Jose Lourenco, Claire Hutchings, Anthony Brown, Paul Klenerman, Eleanor Barnes, United Kingdom

FRI-210  NEUTROPHILS INDUCE EARLY HEPATOCYTE DEATH BY CONTACT DEPENDENT AND INDEPENDENT MECHANISMS AND POSITIVELY CORRELATE WITH THE DISEASE OUTCOME IN ACUTE-ON-CHRONIC LIVER FAILURE
Arshi Khanam*, Nirupma Trehanpati, Peggy Riese, Archana Rastogi, Carlos A. Guzman, Shiv K. Sarin, India

FRI-211  T FOLLICULAR HELPER CELLS OF THE MOTHER PREVENT VERTICAL TRANSMISSION OF HEPATITIS B TO THEIR BABIES
Ashish K. Vyas*, Paul David, Sharda Patra, Shiv K. Sarin, Nirupma Trehanpati, India

FRI-212  EFFECT OF SOFOSBUVIR/DACLATASVIR +/- RIBAVIRIN ON THE PHARMACOKINETICS OF CALCINEURIN INHIBITORS IN LIVER TRANSPLANT RECIPIENTS – FROM THE ANRS CO23 CUPILT STUDY
Aurélie Barrail-Tran’, Claire Laforest, Thibaut Gelè, Jérome Dumortier, Vincent Leroy, Rodolphe Anty, Georges-Philippe Pageaux, Jean-Charles Duclos-Vallée, Anne-Marie Taburet, Audrey Coilly, France

FRI-213  LET-7A; A SINGLE MICRORNA WITH OPPOSING CELL-SPECIFIC-TUMORIGENIC ACTION IN BOTH NATURAL KILLER CELLS AND THEIR TARGET HEPATOCYTES
Aya A. Bassiouni’, Mohamed M. Abdelrahman, Asmaa I. Gomaa, Imam Waked, Hend M. El Tayebi, Ahmed I. Abdelaziz, Egypt
FRI-214  
VA1 T CELLS DIFFERENTIATE INTO CYTOTOXIC EFFECTOR CELLS IN CHRONIC VIRAL HEPATITIS
Benedikt Binder*, Alexander Hoh, Robert Thimme, Maike Hofmann, Germany

FRI-215  
NOTCH SIGNAL REGULATES INFLAMMASOME NLRP3 ACTIVATION IN LIVER ISCHEMIA AND REPERFUSION INJURY
Shi Yue, Changyong Li, Michael Ke, Ling Lu, Ronald Busuttil, Qilong Ying, Jerzy Kupiec-Weglinski, Bibo Ke*, United States

FRI-216  
DO MUCOSAL-ASSOCIATED INVARIANT T (MAIT) CELLS IMPACT FIBROSIS IN HCV AND HIV/HCV CO-INFECTED PATIENTS?
Boris Beudeker*, Gertine Van Oord, Marieke Van der Heide, Robert De Knegt, Annelies Verbon, Andre Boonstra, Mark Claassen, Netherlands

FRI-217  
EFFICACY OF PROLONGED TENOFOVIR MONOTHERAPY FOR PARTIAL VIROLOGIC RESPONSE TO TENOFOVIR IN TREATMENT-NAÏVE CHRONIC HEPATITIS B PATIENTS
Byung Seok Kim*, Min Keun Kim, Sun Mi Kang, Si Hye Kim, Jeung Eun Song, Ga Young Kim, Sang Ah Back, Chang Hyeong Lee, Korea, South

FRI-218  
THE INTERPLAY OF THE MAPKAP KINASES 2 AND 3 COORDINATES LPS-INDUCED INFLAMMATION AND ACUTE PHASE REACTION BY CONTROLLING A LARGE SUBSET OF EXPRESSED GENES
Christian Ehlting*, Julia Sanwald, Maximilian J. Hahnel, Oliver Böhmer, Ute Albrecht, René Deenen, Karl Köhrer, Matthias Gaestel, Ronny Feuer, Oliver Sawodny, Dieter Häussinger, Johannes G. Bode, Germany

FRI-219  
PREVENTION OF VIRAL SPREAD, VIREMIA REDUCTION AND HBSAG CLEARANCE IN HEPATITIS B AND D COINFECTED HUMANIZED MICE BY A HUMAN NEUTRALIZING MONOCLONAL ANTIBODY
Davide Corti*, Tassilo Volz, Katja Giersch, Gloria Agatic, Elisabetta Camerini, Janine Kah, Lena Allweiss, Andreas Schulze, Ansgar W. Lohse, Joerg Petersen, Stephan Urban, Marc Lütgheatmann, Antonio Lanzavecchia, Maura Dandri, Switzerland
FRI-220  
**TREATMENT OF HCV-RECURRENT AFTER TRANSPLANTATION WITH SOFOSBUVIR/LEDIPASVIR: THE ROLE OF RIBAVIRIN**  
Dennis Eurich*, Brigitta Globke, Nathanael Raschzok, Eckart Schott, Johann Pratschke, Germany

FRI-221  
**IL-7 INDUCED TRAF1 UP-REGULATION RESTORES HCV-SPECIFIC CD8 T CELL REACTIVITY IN MID-LASTING HCV INFECTION FEATURED BY PRESENCE OF DIRECTLY EX-VIVO DETECTABLE PENTAMER BINDING CELLS**  
Elia Moreno-Cubero*, Dolores Subirá, Eduardo Sanz de Villalobos, Joaquin Miquel, Rodrigo Borobia, Alicia Lázaro, Alejandro González Pretorius, Juan Ramón Larrubia, Spain

FRI-222  
**THE SODIUM TAUCOCHOLATE CO-TRANSPORTING POLYPEPTIDE (NTCP) FACILITATES HCV ENTRY BY MODULATING BILE ACID TRANSPORT AND EXPRESSION OF INTERFERON-STIMULATED GENES**  
Eloi R. Verrier*, Che C. Colpitts, Laetitia Zona, Charlotte Bach, Laura Heydmann, Rajiv G. Tawar, Christine Thumann, Catherine Schuster, Camille Sureau, Yujin Hoshida, Mirjam B. Zeisel, Thomas F. Baumert, France

FRI-223  
**NK CELLS FUNCTIONAL SKEW: IMPLICATIONS IN INNATE IMMUNITY TO HCV INFECTION**  
Ester Badami*, Floriana Barbera, Serena Vella, Loredana Bruno, Alessia Gallo, Claudia Coronnello, Giovanna Russelli, Claudia Carcione, Bruno Gridelli, Pier Giulio Conaldi, Italy

FRI-224  
**SECRETORY LEUKOCYTE PROTEASE INHIBITOR DRIVES HEPATIC RESOLUTION RESPONSES IN ACUTE LIVER FAILURE THROUGH MODULATION OF THE MER TYROSINE KINASE PATHWAY**  
Evangelos Triantafyllou*, Annika Wilhelm, Lucia Possamai, Oltin Pop, Evaggelia Liaskou, Christine Bernsmeier, Wafa Khamri, Gemma Petts, Scott Davies, Robin Abeles, Zania Stamatakis, Kevin Woollard, Yun Ma, Alberto Quaglia, Julia Wendon, Mark Thursz, David Adams, Stuart Curbishley, Chris Weston, Charalampos Antoniades, United Kingdom
FRI-225
YI

**HUMAN LIVER CD8+ T CELLS HAVE A TISSUE RESIDENT PHENOTYPE WHICH IS ALTERED IN THE PRESENCE OF CHRONIC VIRAL INFECTION**
Femke Stelma*, Annikki de Niet, Marjan J. Sinnige, Karel A. van Dort, Ester M. M. van Leeuwen, Neeltje A. Kootstra, Hendrik W. Reesink, Netherlands

FRI-226
YI

**HUMAN LIVER NK CELLS ARE PHENOTYPICALLY DIFFERENT FROM PERIPHERAL BLOOD NK CELLS**
Femke Stelma*, Annikki de Niet, Marjan J. Sinnige, Ester M. M. van Leeuwen, Neeltje A. Kootstra, Hendrik W. Reesink, Netherlands

FRI-227
YI

**CELLULAR NEUTROPHIL DYSFUNCTION IS A FEATURE OF EARLY CIRRHOSIS AND ASSOCIATED WITH AN INCREASED RISK OF DECOMPENSATION AND BACTERIAL INFECTION**
Haw Lu*, Jane Macnaughtan, Rohit Sawhney, Helen Jones, Alba Moratalla, Francesco Figorelli, Marco Bondoc, Gavin Wright, Nathan Davies, Raj Mookerjee, Rajiv Jalan, United Kingdom

FRI-228
YI

**GENETICALLY ENGINEERING HBV-SPECIFIC CD8+T CELLS RESISTANT TO TRAIL-MEDIATED APOPTOSIS**
Itziar Otano*, Frederick Arce, Harsimran Singh, Anna Schurich, Dimitra Peppa, Richard Gilson, Giuseppe Fusai, Hans Stauss, David Escors, Mala K. Maini, United Kingdom

FRI-229
YI

**CAN PRE-CORE MUTATION STATUS HELP TO DETERMINE BETWEEN THE STAGE OF TRUE IMMUNE TOLERANCE AND EARLY IMMUNE ACTIVITY IN HBEAG POSITIVE PATIENTS WITH CHRONIC HEPATITIS B?**
Ivana Carey*, Sanjay Bansal, Mary Horner, Matthew Bruce, Diego Vergani, Kosh Agarwal, Giorgina Mieli-Vergani, United Kingdom

FRI-230
YI

**OSTEOPONTIN PROMOTES CHOLANGIOCYTE CHEMOKINE SECRETION AND MACROPHAGE ACCUMULATION IN MURINE LIVER FIBROSIS**
Jason D. Coombes*, Paul P. Manka, Marzena Swiderska-Syn, Danielle Reid, Antonio Riva, Lee C. Claridge, Laurent Dolle, Rasha Younis, Marco A. Briones-Orta, Naoto Kitamura, Kosha Mehta, Zhiyong Mi, Paul C. Kuo, Roger Williams, Anna Mac Diehl, Leo A. van Grunsven, Shilpa Chokshi, Bertus Eksteen, Ali Canbay, Wing-Kin Syn, United Kingdom
Liver immunology including viral hepatitis (Cont.)

**FRI-231**

HBV STRENGTHENS INTRAHEPATIC MYELOID-DERIVED CELLS MEDIATED T CELL TOLERANCE THROUGH TLR1/2 INDUCED KUPFFER CELL EXPANSION AND IL-10 PRODUCTION

Jia Liu*, Dongliang Yang, Mengji Lu, *China*

**FRI-232**

KIR3DL1 IN COMBINATION WITH HLA-BW4-80T IS ASSOCIATED WITH SUPERIOR FUNCTIONALITY OF NK CELLS AND SPONTANEOUS IMMUNE CONTROL OF HCV INFECTION IN PEOPLE WHO INJECT DRUGS

Christine Thoens, Tina Senff, Theresa J. Hydes, Falko M. Heinemann, Andreas Heinold, Martin Heilmann, Markus Uhrberg, Norbert Scherbaum, Salim Khakoo, Joerg Timm*, *Germany*

**FRI-233**

MODULATIONS IN VITAMIN D RECEPTOR (VDR) EXPRESSIONS IN LATE FIBROSIS MODEL OF BALB/C MICE INHIBITED 25-HYDROXY-VITAMIN-D3 ALLEVIATION OF LIVER NK CYTOTOXICITY

Ahmad Salhab, Johnny Amer*, Rifaat Safadi, *Israel*

**FRI-234**

INTERFERON SPARING DIRECTLY ACTING ANTIVIRAL (DAA) THERAPY FOR HCV IN DECOMPENSATED CIRRHOSIS: NATURAL KILLER CELL (NK) PHENOTYPE IS ASSOCIATED WITH NON-RESPONSE

Kate Childs*, Elliot Merritt, William Swanson, Alberto Sanchez-Fueyo, Marc Martinez-Llordella, Kosh Agarwal, Ivana Carey, United Kingdom

**FRI-235**

VACCINE-INDUCED HCV-SPECIFIC CD8+ T CELL RESPONSE RESTRICTED BY THE PROTECTIVE HLA ALLELE B*27: WIDE CROSS-RECOGNITION OF EVOLVING VIRAL VARIANTS

Katrin Frohmüller*, Leo Swadling, Katja Nitschke, Paul Kleenerman, Robert Thimme, Eleanor Barnes, Christoph Neumann-Haefelin, Germany

**FRI-236**

ROLE OF TYPE 2 INNATE LYMPHOID CELLS AND THE ALARMIN IL-33 IN A MOUSE MODEL OF IMMUNE-MEDIATED HEPATITIS

Katrin Neumann*, Khalil Karimi, Jana Meiners, Ruth Voetlause, Werner Dammermann, Stefan Lüth, Claudia Wegscheid, Andrea Horst, Gisa Tiegs, Germany
FRI-237  RISK ASSESSMENT OF HEPATOCELLULAR CARCINOMA IN CHRONIC HEPATITIS B PATIENTS WITH LONG-TERM ANTIVIRAL THERAPY  
Kyu Sik Chung*, Hye Won Lee, Do Young Kim, Beom Kyung Kim, Seung Up Kim, Jun Yong Park, Kwang-Hyub Han, Sang Hoon Ahn, Korea, South

FRI-238  AN UNEXPECTED ROLE OF HIGH MOBILITY GROUP BOX 1 (HMGB1) AND NEUTROPHILS IN NON-ALCOHOLIC FATTY LIVER DISEASE: INHIBITION OF T CELL ACTIVATION AND PROLIFERATION  
Laura Antonucci*, Mario Picozza, Anastasia Renzi, Eugenio Gaudio, Clara Balsamo, Italy

FRI-239  INTERFERON REGULATORY FACTOR 1 RESTRICTS HEPATITIS E VIRUS REPLICATION BY ACTIVATING STAT1 TO INDUCE ANTIVIRAL INTERFERON-STIMULATED GENES  
Lei Xu*, Xinying Zhou, Wenshi Wang, Yijin Wang, Yuebang Yin, Luc J. W. Van Der Laan, Dave Sprengers, Herold J. Metselaar, Maikel P. Peppelenbosch, Qiuwei Pan, Netherlands

FRI-240  RIG-I INHIBITS HEPATITIS E VIRUS REPLICATION BY SIMULTANEOUSLY ACTIVATING JAK-STAT AND NFKB PATHWAYS  
Lei Xu*, Wenshi Wang, Xinying Zhou, Yijin Wang, Yuebang Yin, Luc J. W. Van Der Laan, Dave Sprengers, Herold J. Metselaar, Maikel P. Peppelenbosch, Qiuwei Pan, Netherlands

FRI-241  MIR-155: A DOUBLE FACED MICRORNA WITH RESPECT TO ITS IMPACT ON TUMORIGENESIS IN BOTH NATURAL KILLER CELLS AND THEIR TARGET HEPATOCYTES  

FRI-242  LIVER DERIVED MIR-122 MEDIATES INFLAMMATION-INDUCED ANEMIA BY TARGETING ERYTHROPOIETIN IN THE KIDNEY  
Mila Rivkin*, Elina Zorde-Khvalevsky, Alina Simerzin, Chofit Chai, Jonathan Yuval, Ronen Schneider, Mathias Heikenwalder, Eithan Galun, Hilla Giladi, Israel

FRI-243  CYSTEINE CATHEPSINS ARE INVOLVED IN A DOUBLE CHECK-POINT DURING HEPATIC NKT ACTIVATION  
Alvaro de Mingo, Estefania de Gregorio, Shilpi Chandra, Albert Morales, Mitchell Kronenberg, Montserrat Mari*, Spain
Liver immunology including viral hepatitis (Cont.)

**FRI-244**

**HEPATITIS B VIRUS X PROTEIN STIMULATES HBV REPLICATION THROUGH REGULATING TRANSCRIPTION FACTORS ASSOCIATED WITH HISTONE METHYLATION**

Naoki Oishi*, Masao Honda, Tetsuro Shimakami, Shuichi Kaneko, *Japan*

**FRI-245**

**FUNCTIONAL VARIANTS AND ABERRANT METHYLATION IN THE SOCS3 PROMOTER REGION INFLUENCE THE PROGRESSION OF HBV-RELATED LIVER DISEASES**

Nghiem X. Hoan*, Hoang Van Tong, Dao Phuong Giang, Nguyen Linh Toan, Le Huu Song, C.-Thomas Bock, Peter G Kremsner, Thirumalaisamy P Velavan, *Germany*

**FRI-246**

**THE BREADTH OF CD8+ T CELL RESPONSES IN CHRONIC AND RESOLVED HEPATITIS B VIRUS INFECTION**

Philipp Ehrenmann*, Michael Kiraithe, Julia Lang, Felix Jacobi, Robert Thimme, Christoph Neumann-Haefelin, *Germany*

**FRI-247**

**IMPAIRED INDUCTION OF ACQUIRED IMMUNOLOGICAL TOLERANCE MAY PREDICT HBV-RELATED ACUTE LIVER FAILURE**

Po-Sung Chu*, Shingo Usui, Hiroko Murata, Rei Miyake, Hirotoshi Ebinuma, Hidetsugu Saito, Takanori Kanai, *Japan*

**FRI-248**

**EXPRESSION PROFILE OF MIR-183 AND MIR-191 IN ACUTE LIVER FAILURE**

Rajib K. Hazam*, Premashis Kar, *India*

**FRI-249**

**DISTINCT CELL-SPECIFIC TNFR1-SIGNALING DETERMINES LIVER DAMAGE IN EXPERIMENTAL HEPATITIS**

Raluca Wroblewski*, Marietta Armaka, Vangelis Kondylis, Manolis Pasparakis, Ansgar W. Lohse, Julian Schulze zur Wiesch, George Kollias, Hanno Ehlken, *Germany*

**FRI-250**

**RESTORING THE EXPRESSION OF ENDOGENOUS IGF-1 BY MIR-486 IN NK CELLS OF HCC PATIENTS AUGMENTS ITS CYTOTOLYTIC ACTIVITY AGAINST HEPATOMA CELL LINES**

FRI-251
YI

MIR 450B IS AN INDEPENDENT PROGNOSTIC MARKER FOR ACUTE LIVER FAILURE IN HEPATITIS E INFECTED PREGNANT FEMALES
Rashi Sehgal*, Ritu Khosla, Sharda Patra, Guresh K. Chibbar, Shyam Kottili, Shiv K. Sarin, Nirupma Trehanpati, India

FRI-252

GLOBAL GENOTYPE DISTRIBUTION OF HEPATITIS C VIRAL INFECTION AMONG PEOPLE WHO INJECT DRUGS.
Rob Bielen*, Geert Robaeys, Darush Ghezel Azar, Homie Razavi, Frederik Nevens, Belgium

FRI-253

RORGT INHIBITION IN THE LIVER PREVENTS HEPATIC FIBROSIS PROGRESSION, A PROOF OF CONCEPT STUDY WITH A POTENT, FIRST IN CLASS, HEPATOCENTRIC RORGT INVERSE AGONIST
Zouher Majd, Jean-François Delhomel, Philippe Delataille, Isabelle Delbaere, Maryse Le Parquier, Dean W. Hum, Bart Staels, Robert Walczak*, France

FRI-254

AGGRAVATION OF INFLAMMATION AND FIBROSIS BY THE ADDITIONAL KNOCKOUT OF HO-1 IN THE MDR2 KNOCKOUT MOUSE MODEL
Roja Barikbin*, Mareike Sandmann, Alexander Quaas, Khalil Karimi, Gabriele Sass, Gisa Tiegs, Germany

FRI-255

IMPACT OF GENETIC POLYMORPHISMS IN THE SCARB1 GENE ON HEPATITIS C VIRUS
Sandra Westhaus*, Maximilian Deest, Frauke Stanke, Dirk Heckl, Axel Schambach, Michael P. Manns, Thomas Berg, Christoph Sarrazin, Sandra Ciesek, Thomas von Hahn, Germany

FRI-256

HBSAG LOSS WITH TENOFOVIR DISOPROXIL FUMARATE PLUS PegINTERFERON ALFA-2A IN CHRONIC HEPATITIS B: LONG-TERM RESULTS OF A GLOBAL RANDOMIZED CONTROLLED TRIAL
### Liver immunology including viral hepatitis (Cont.)

<table>
<thead>
<tr>
<th>ID</th>
<th>Title</th>
<th>Authors</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>FRI-257</td>
<td>HEPATITIS C DIAGNOSIS AND LINKAGE TO CARE RATES IN AN URBAN EMERGENCY DEPARTMENT BLOOD BORNE VIRUS SCREENING PROGRAMME</td>
<td>Sarah O’Connell*, Darren Lillis, Aoife Cotter, Siobhan O’Dea, Ann Moriarty, Darragh Shields, Helen Tuite, Brendan Crowley, Suzanne Norris, Patrick K Plunkett, Colm Bergin</td>
<td>Ireland</td>
</tr>
<tr>
<td>FRI-258</td>
<td>EARLY IMMUNE CHANGES DURING HCV DAA THERAPY IN AN INCARCERATED POPULATION</td>
<td>Sharon A. Oldford*, Krista Arseneault, Lisa Barrett</td>
<td>Canada</td>
</tr>
<tr>
<td>FRI-259</td>
<td>IL-4RA SIGNALING REGULATES LIVER FIBROSIS PROGRESSION AND REVERSAL DIFFERENTLY BY MODULATING POLARIZATION OF M2 MACROPHAGE SUBSETS</td>
<td>Shih Yen Weng*, Santosh Vijayan, Xiaoyu Wang, Yilang Tang, Kornelius Padberg, Yong Ook Kim, Frank Brombacher, Jeff Crosby, Michael McCaleb, Ari Waisman, Ernesto Bockamp, Detlef Schuppan</td>
<td>Germany</td>
</tr>
<tr>
<td>FRI-261</td>
<td>CD56BRIGHT AND CD56DIM NK CELLS DIFFER IN THEIR PHENOTYPIC PROFILE IN REACTIVATION OF HEPATITIS B</td>
<td>Suvercha Bhardwaj*, Manoj Sharma, Meenu Baipai, Ankur Jindal, Gureash Kumar, Ankit Bhardwaj, Nirupma Trehanpati, Shiv Sarin</td>
<td>India</td>
</tr>
<tr>
<td>FRI-262</td>
<td>SIGNIFICANCE OF MUTATIONS IN THE REGION CODING FOR NS3/4 PROTEASE IN PATIENTS INFECTED WITH HCV GENOTYPE 1B</td>
<td>Tadeusz W. Lapinski*, Julita Nikolajuk-Stasiuk, Magdalena Rogalska-Plonska, Oksana Kowalczuk, Joanna Kisruk, Joanna Zurawska, Jacek Nikliński, Robert Flisiak</td>
<td>Poland</td>
</tr>
</tbody>
</table>
FRI-263  HEPATITIS B CORE RELATED ANTIGEN IN SERA IS THE SURROGATE MARKER FOR HBV COVALENTLY CLOSED CIRCULAR DNA
Takeshi Matsui*, Jong-Hon Kang, Yushi Kimura, Kazunari Tanaka, Kunihiko Tsuji, Hiroyuki Maguchi, Yasuhito Tanaka, Japan

FRI-264  DISTINCT NATURAL KILLER CELL POPULATIONS IN THE HUMAN LIVER EXPRESS MARKERS OF NK CELL MEMORY AND MIGRATION
Theresa J. Hydes*, Mohammed AbuHilal, Thomas Armstrong, Zaed Hamady, John Primrose, Arjun Takhar, Salim Khakoo, United Kingdom

FRI-265  INTERFERON-STIMULATED GENE 15 IN HBV INFECTION AND PROGRESSION OF HBV-RELATED LIVER DISEASES
Tong V. Hoang*, Nghien Xuan Hoan, Dao Phuong Giang, Nguyen Linh Toan, Le Huu Song, C.-Thomas Bock, Peter Kremsner, Thirumalaisamy Velavan, Germany

FRI-266  TLR4 SIGNALING DIFFERENTIALLY AFFECTS PROGENITOR CELL SUBSET EXPANSION AND ACTIVATION DURING LIVER INJURY
Christoph Eckert, Yong Ook Kim, Thomas Tschernig, Miroslaw Kornek, Frank Lammert, Detlef Schuppan, Veronika Lukacs-Kornek*, Germany

FRI-267  PKCA/AP-1 DRIVES TRANSCRIPTION OF INTERFERON-STIMULATED GENES AND MEDIATES CELL-AUTONOMOUS DEFENSE AGAINST HEPATITIS E VIRUS
Wenshi Wang*, Yijin Wang, Xinying Zhou, Yuebang Yin, Lei Xu, Yannick Debing, Elena Herrera Carrillo, Johannes Brandsma, Dave Sprengers, Raymond Poot, Herold Metselaar, Ron Smits, Ben Berkhout, Johan Neyts, Maikel Peppelenbosch, Qiuwei Pan, Netherlands

FRI-268  DEFICIENCY OF DJ-1 REDUCES LIVER FIBROSIS AND TUMOR DEVELOPMENT BY SUPPRESSING LIVER INJURY AND INFLAMMATION
Yingxue Yu, Bijun Qiu, Wenjun liu, Hai Li, Qiang xia, Xiaoni Kong*, China
Liver immunology including viral hepatitis (Cont.)

**FRI-269 YI**

**CROSSTALK BETWEEN NUCLEOTIDE SYNTHESIS PATHWAYS WITH CELLULAR IMMUNITY IN CONSTRAINING HEPATITIS E VIRUS REPLICATION**  
Yijin Wang*, Wenshi Wang, Lei Xu, Xinying Zhou, Krzysztof Felczak, Luc van der Laan, Krzysztof Pankiewicz, Dave Sprengers, Herold Metselaar, Maikel Peppelenbosch, Qiuwei Pan, *Netherlands*

**FRI-270**

**LCN2 SUPPRESSED INFLAMMATION THROUGH PI3K/AKT/MTOR SIGNALING PATHWAY**  
Ying Hu*, Feng Chen, Chunhong Huang, Zhi Chen, *China*

**FRI-271**

**HUMAN LIVER EXPLANTS HAVE ENRICHED PRO-INFLAMMATORY CD24- B CELL POPULATIONS**  
Sudha Purswani, Gary Reynolds, Yuxin Liu, Gwilym Webb, Benjamin Wiggins, Konstantinos Aliazis, Evangelos Triantafyllou, Scott Davies, Evaggelia Liaskou, Gideon Hirschfield, David Adams, Zania Stamatakis*, *United Kingdom*
Liver transplantation / surgery: Clinical

**FRI-435**

**YI**

**TRANSITION OF PEDIATRIC LIVER TRANSPLANTED RECIPIENTS TO ADULT HEALTHCARE SERVICE: A SINGLE CENTER COHORT**

Alberto Ferrarese*, Giacomo Germani, Mara Cananzi, Alberto Zanetto, Chiara Bergamo, Sarah Shalaby, Elena Nadal, Ilaria Bortoluzzi, Marco Senzolo, Francesco Paolo Russo, Umberto Cillo, Patrizia Burra, *Italy*

**FRI-436**

**YI**

**ANALYSIS OF HEMODYNAMIC EFFECTS OF BOSENTAN ON PORTOPULMONARY HYPERTENSION IN SHORT-TERM AND MEDIUM-TERM FOLLOW-UP: PROMISING PREDICTORS OF RESPONSE TO THERAPY?**

Alessandro Risso*, Walter Grosso Marra, Silvia Martini, Fulvio Orzan, Maria Torrani Cerenzia, Federico Balzola, Daniele Arrese, Marco Sacco, Silvia Strona, Davide Stradella, Daniela Libertucci, Pier Luigi Omedè, Arianna Bissolino, Domenica Zema, Giorgio Maria Saracco, Mario Rizzetto, Antonio Ottobrelli, *Italy*

**FRI-437**

**VALIDATION OF A METHOD FOR ESTABLISHING ALLOCATION EQUITY AMONG PATIENTS WITH AND WITHOUT HEPATOCELLULAR CARCINOMA ON A COMMON WAITING LIST**

Alessandro Vitale*, Anna Chiara Frigo, Patrizia Burra, Paolo Angeli, Umberto Cillo, *Italy*

**FRI-438**

**YI**

**AUTOIMMUNE LIVER DISEASES DO NOT RECUR MORE FREQUENTLY AFTER LIVING-RELATED COMPARED TO LIVING UNRELATED OR DECEASED DONOR LIVER TRANSPLANTATION**

Aloysious D. Aravinthan*, Adam Doyle, Max Marquez, David Peretz, Nazia Selzner, Leslie Lilly, Eberhard Renner, *Canada*

**FRI-439**

**LATE ACUTE REJECTION: HISTOLOGICAL APPRAISAL IN DIFFERENT TIME PERIODS FOLLOWING LIVER TRANSPLANTATION**

Archana Rastogi*, Viniyendra Pamecha, Gayatri Ramakrishna, Ashok Kumar, Chhagan Bihari, Guresh Kumar, Shiv K. Sarin, *India*
FRI-440 DEVELOPMENT OF A PROGNOSTIC SCORING SYSTEM FOR PATIENTS UNDERGOING LIVER RESECTION FOR HEPATOCELLULAR CARCINOMA
Carlo Sposito*, Stefano Di Sandro, Federica Brunero, Giacomo Concone, Carlo Battiston, Vincenzo Buscemi, Marco Bongini, Luciano De Carlis, Vincenzo Mazzaferro, Italy

FRI-441 VALIDATION OF 2 EXPLANT-BASED RECURRENCE PROGNOSTIC MODELS AFTER LIVER TRANSPLANTATION FOR HEPATOCELLULAR CARCINOMA IN AN EXTERNAL COHORT
Charlotte Costentin*, Andrea Notarpaolo, Karim Boudjema, Giulia Magini, Philippe Bachellier, Lucia Meglioresi, Fabrice Muscari, Martina Gambato, Ephrem Salame, Federico Manenti, Pierre Henri Bernard, Cécilia D’Ambrosio, Giuseppe Maria Ettore, Claire Francoz, Alessandro Vitale, Sébastien Dharancy, Patrizia Burra, Claire Vanlemmens, Stefano Fagiuoli, Alexis Laurent, Sylvie Radenne, Jérôme Dumortier, Marie Noelle Hilleret, Thomas Decaens, Julien Calderaro, Giuliana Amaddeo, Françoise Roudot-Thoraval, Christophe Duvoux, France

FRI-442 USE OF A SALINE-COUPLED BIPOLAR SEALER IN OPEN LIVER RESECTIONS FOR HEPATIC MALIGNANCIES: MEDICAL RESOURCE USE AND COSTS FROM A NATIONALLY-REPRESENTATIVE CLAIMS DATABASE
Christine I. Nichols*, Joshua Vose, United States

FRI-443 CORONARY ARTERY CALCIUM SCORE AND FRAMINGHAM SCORE IN EVALUATION OF CARDIOVASCULAR RISK AFTER LIVER TRANSPLANTATION
Livia Carone, Claudia P Oliveira*, Mario Reis Alvareys-da-Silva, Jose Tadeu Stefano, Debora Raquel B Terrabuio, Edson Abdala, Flair J Carrilho, Alberto Q Farias, Luiz Augusto Carneiro D’ Albuquerque, Brazil

FRI-444 DON’T JUDGE A BOOK BY ITS COVER: NORMAL LIVER ENZYMES AFTER TRANSPLANTATION CAN BE ASSOCIATED WITH PATHOLOGIES REQUIRING INTERVENTION
Czarina Sanchez*, Sean Kumer, Shelbi Olson, Richard Gilroy, Timothy Schmitt, Bart Kane, Ryan Taylor, United States
FRI-445  
YI

**ALL ORAL SOFOSBUVIR-BASED ANTIVIRAL THERAPY IN LIVER TRANSPLANT RECIPIENTS AFFECTED BY MODERATE-SEVERE HEPATITIS C RECURRENCE: PREDICTORS OF VIRAL RESPONSE AND SURVIVAL**

Silvia Martini, Daniele Arese*, Marco Sacco, Silvia Strona, Donatella Cocchis, Stefano Mirabella, Giorgia Rizza, Antonio Ottobrelli, Maria Rosaria Torrani-Cerenzia, Federico Balzola, Paola Magistroni, Pamela Moschini, Antonio Amoroso, Mauro Salizzoni, Mario Rizzetto, Giorgio Maria Saracco, Renato Romagnoli, *Italy*

---

FRI-446  
YI

**DONOR AGE IS AN INDEPENDENT RISK FACTOR FOR CALCINEURIN INHIBITOR-INDUCED NEUROTOXICITY AFTER LIVER TRANSPLANTATION**

Elena Martinez*, Alberto Lué, Mercedes Navarro, Guillermo Garcia, Maria Jose Domper, Sara Lorente, Juan Jose Araiz, Francisco Agustin Garcia-Gil, Maria Trinidad Serrano, *Spain*

---

FRI-447  

**IMPACT OF HEPATOPULMONARY SYNDROME ON PROGNOSIS AFTER LIVER TRANSPLANTATION**

Eva Dueñas*, Rosa Rota, Jesus Ribas, Alejandro Ruiz – Majoral, Emma González – Vilalartsana, Alba Cachero, Katja Serra, Carme Baliellas, Juan Fabregat, Xavier Xiol, Jose Castellote, *Spain*

---

FRI-448  

**REVERSIBILITY OF HEPATOPULMONARY SYNDROME AFTER LIVER TRANSPLANTATION**

Eva Dueñas*, Rosa Rota, Jesus Ribas, Alejandro Ruiz – Majoral, Emma González – Vilalartsana, Alba Cachero, Alberto Amador, Carme Baliellas, Juan Fabregat, Xavier Xiol, Jose Castellote, *Spain*

---

FRI-449  
YI

**DOES MULTIORGAN FAILURE IMPACT PROGNOSIS OF LIVER TRANSPLANTATION IN PATIENTS WITH END-STAGE LIVER DISEASE? RESULTS OF A FRENCH RETROSPECTIVE MULTICENTER CASE-CONTROL STUDY**

Florent Artru*, Alexandre Louvet, Isaac Ruiz, Eric Levesque, Julien Labreuche, Samir Jaber, Guillaume Lassailly, Sebastien Dharancy, Emmanuel Boleslawski, Gilles Lebuffe, Eric Kipnis, Philippe Ichai, Audrey Coilly, Eleonora De Martin, Eric Vibert, Astrid Herrerro, Didier Samuel, Georges-Philippe Pageaux, Philippe Mathurin, Faouzi Saliba, *France*
Liver transplantation / surgery: Clinical (Cont.)

FRI-450 YI

LIVER TRANSPLANTATION FOR CHRONIC HCV INFECTION IN THE UNITED STATES 2002-2014: AN ANALYSIS OF THE UNOS/OPTN DATABASE
Georg Dultz*, Barry Graubard, Paul Martin, Martin W. Welker, Brian Borg, Stefan Zeuzem, Katherine A. McGlynn, Tania M. Welzel, Germany

FRI-451 YI

INFLUENCE OF DONOR AND RECIPIENT GENDER ON LIVER TRANSPLANTATION OUTCOMES IN EUROPE: A ELTR STUDY
Giacomo Germani*, Alberto Ferrarese, Renè Adam, Vincent Karam, Luca Belli, John O’Grady, Darius Mirza, Jurgen Klempnauer, Daniel Cherqui, Johann Pratschke, Neville Jamieson, Mauro Salizzoni, Hernest Hidalgo, Jan Lerut, Andreas Paul, Juan Carlos Garcia-Valdecasas, Fernando San Juan Rodriguez, Patrizia Burra, Italy

FRI-452 YI

UNEXPECTED VERY EARLY ATHEROSCLEROTIC AND CARDIAC DAMAGE IN PATIENTS UNDERGOING LIVER TRANSPLANTATION
Giuseppina Pisano, Rosa Lombardi*, Michela Orlandi, Maria F. Donato, Stefania Zannoni, Cristina G. Bertelli, Giovanna Oberti, Lucio Caccamo, Massimo Colombo, Silvia Fargion, Anna Ludovica Fracanzani, Italy

FRI-453

SOFOSBUVIR AND SIMEPREVIR THERAPY FOR RECURRENT HEPATITIS C GENOTYPE 1, AFTER LIVER TRANSPLANTATION: EFFICACY AND SAFETY
Gloria Sanchez Antolin*, Milagros Testillano, Martin Prieto, Inmaculada Fernandez, Xavier Xiol, Maria Carlota Londoño, Lluis Castells, Juan Manuel Pascasio, Maria Luisa Gonzalez Dieguez, Alejandra Otero Ferreiro, Magdalena Salcedo, Isidoro Narvaez, Jose Antonio Pons, Jose Ignacio Herrero, Sonia Pascual Bartolome, Jose Luis Montero, Ana Arencibia, Emilio Fabrega Garcia, Sara Lorente, Esther Molina, Jose Ramon Fernandez, Carolina Almohalla Alvarez, Valentin Cuervas-Mons, Spain
FRI-454  SHORT-TERM OUTCOMES FOLLOWING HEPATECTOMY IN ELDERLY PATIENTS WITH HEPATOCELLULAR CARCINOMA: AN ANALYSIS OF 10,805 SEPTUAGENARIANS AND 2,381 OCTO-NONAGENARIANS IN JAPAN
Hiroko Okinaga*, Hideo Yasunaga, Kiyoshi Hasegawa, Kiyohide Fushimi, Norihiro Kokudo, Japan

FRI-455  LIVER TRANSPLANTATION FOR ACUTE HEPATIC DECOMPENSATION ACHIEVES EXCELLENT OUTCOMES WITHOUT INCREASED RECIDIVISM RATES: A SINGLE CENTER EXPERIENCE
Howard Monsour*, David Victor, Maha Boktour, Joseph Galati, John Ontiveros, Lisette Theriot, Robert McFadden, Constance Mobley, Ashish Saharia, Sherilyn Gordon-Burroughs, Mark Ghobrial, United States

FRI-456  RENAL DYSFUNCTION IN DONATION AFTER CIRCULATORY DEATH LIVER TRANSPLANTATION: UK SINGLE CENTRE STUDY
Ilaria Umbro*, Francesca Tinti, Felicity Evison, Adnan Sharif, Bridget Gunson, Anna Paola Mitterhofer, James Ferguson, Paolo Muiesan, Italy

FRI-457  EFFICACY AND SAFETY OF SIMEPREVIR AND SOFOSBUVIR WITH AND WITHOUT RIBAVIRIN FOR 12 WEEKS IN SUBJECTS WITH RECURRENT GENOTYPE 1 HEPATITIS C POST-ORTHOTOPIC LIVER TRANSPLANT: THE GALAXY STUDY

FRI-458  DEFINING SURGICAL DIFFICULTY ACCORDING TO THE PERCEIVED COMPLEXITY OF LIVER RESECTION: VALIDATION OF A COMPLEXITY CLASSIFICATION IN PATIENTS WITH HEPATOCELLULAR CARCINOMA
Jai Young Cho*, Youngrok Choi, Jae Seong Jang, Haeryoung Kim, Korea, South
Liver transplantation / surgery: Clinical (Cont.)

**FRI-459**

YI

**ALCOHOL SCREENING TESTS FOR LIVER TRANSPLANT (LT) CANDIDATES: A USEFUL ADJUVANT TO SOCIAL WORK EVALUATION OF RECIDIVISM RISK?**

Jeanne-Marie Giard*, Raymond Cogan, Pauline Rogers, Andrew Posselt, John Roberts, Francis Yao, Norah A. Terrault, United States

**FRI-460**

**OUTPATIENT LIVER TRANSPLANTATION ASSESSMENT IS AN EFFECTIVE TOOL WITH NO EVIDENCE OF DELAY IN DECISION MAKING**

Jeremy S. Nayagam*, Kushala Abeysekera, Kosh Agarwal, Nigel Heaton, Michael Heneghan, John O’Grady, Abid Suddle, Varuna Aluvihare, United Kingdom

**FRI-461**

**PATIENTS WHO UNDERWENT PERCUTANEOUS CORONARY INTERVENTION PRIOR TO LIVER TRANSPLANTATION DID NOT EXPERIENCE BLEEDING COMPLICATIONS WHILST ON DUAL ANTIPLATELET THERAPY**

Jeremy S. Nayagam*, Omair Raja, Kosh Agarwal, Nigel Heaton, Michael Heneghan, John O’Grady, Abid Suddle, Varuna Aluvihare, United Kingdom

**FRI-462**

**BIOCHEMICAL AND SEROLOGICAL MARKERS OF LIVER FUNCTION IN LIVER TRANSPLANT RECIPIENTS WITH PRIMARY BILIARY CHOLANGITIS**

Joanna Raczynska*, Leszek Paczek, Andrzej Habior, Bartosz Foroncewicz, Magdalena Zielenkiewicz, Alicja Bauer, Tomasz Cieciura, Monika Krajewska, Michal Florczak, Maria Mulka, Krzysztof Mucha, Poland

**FRI-463**

**LONG-TERM HEALTH-RELATED QUALITY OF LIFE IN THE LIVING LIVER DONORS**

Joanna Raszeja-Wyszomirska*, Maciej Janik, Aleksandra Ksiezopolska, Konrad Kostrzewa, Konrad Kobryn, Maciej Moskwa, Oskar Kornasiewicz, Waldemar Patkowski, Marek Krawczyk, Poland
FRI-464  INTERFERON (INF)-FREE ANTIVIRAL THERAPY IN CIRRHOTIC PATIENTS INFECTED WITH HEPATITIS C ON THE WAITING LIST FOR LIVER TRANSPLANTATION. EFFICACY AND IMPACT ON DELISTING AND LIVER FUNCTION  
Juan Manuel Pascasio*, Carmen Vinaixa, María Teresa Ferrer, Jordi Colmenero, Angel Rubin, Lluís Castells, Maria Luisa Manzano, Sara Lorente, Milagros Testillano, Francisco Xavier Xiol, Esther Molina, Luisa González-Dieguez, Elena Otón, Sonia Pascual, Begoña Santos, José Ignacio Herrero, Magdalena Salcedo, José Luis Montero, Gloria Sánchez-Antonilín, Isidoro Narváez-Rodríguez, Flor Nogueras, Alvaro Giráldez, Carlos Fernández-Carrillo, Xavier Forns, Martín Prieto, María Carlota Londoño, Spain

FRI-465  DE NOVO PLASMA CELL HEPATITIS FOLLOWING LIVER TRANSPLANTATION  
Jung Hyun Kwon*, Ibrahim Hanouneh, Daniela Allende, Lisa Yerian, Teresea Diago Uso, Bijan Eghtesad, Nizar Zein, Korea, South

FRI-466  SOLUBLE CD163, A MARKER OF MACROPHAGE ACTIVATION, IS INCREASED IN EARLY ALLOGRAFT DYSFUNCTION AFTER LIVER TRANSPLANTATION  
Karen Louise Thomsen*, Rajiv Jalan, Francis P Robertson, Peter Holland-Fischer, Brian R Davidson, Raj Mookerjee, Holger Jon Møller, Henning Grønbæk, Denmark

FRI-467  DONOR SPECIFIC ANTIBODIES POST LIVER TRANSPLANT: PREDICTORS AND PROTECTORS  
Katharina Willuweit*, Andreas Heinold, Peter Horn, Andreas Paul, Guido Gerken, Kerstin Herzer, Germany

FRI-468  DISSOCIATION BETWEEN CLINICAL EVALUATION AND PELD SCORE IN THE SETTING OF PEDIATRIC LIVING-RELATED LIVER TRANSPLANTATION IN JAPAN: A EIGHTEEN YEAR SINGLE CENTER EXPERIENCE  
Kazuhiko Bessho*, Yasuhiro Hasegawa, Hitomi Fukuda, Kuniko Hagiwara, Takehisu Ueno, Yoko Miyoshi, Hiroki Kondou, Sotaro Mushiake, Hiroomi Okuyama, Keiichi Ozono, Japan

FRI-469  THE PREVALENCE AND PREDICTORS OF CARDIOVASCULAR EVENTS POST-LIVER TRANSPLANTATION  
Laura De Luca*, Maria Kalafateli, Simone Bianchi, Norah Alasaker, Elena Buzzetti, Douglas Thorburn, David Patch, James O’Beirne, Rachel Westbrook, Emmanuel Tsochatzis, Italy
Liver transplantation / surgery: Clinical (Cont.)

**FRI-470 YI**

**PREVALENCE AND PREDICTORS OF THE METABOLIC SYNDROME POST LIVER TRANSPLANTATION**
Laura De Luca*, Maria Kalafateli, Simone Bianchi, Norah Alasaker, Elena Buzzetti, Douglas Thorburn, David Patch, James O’Beirne, Rachel Westbrook, Emmanuel Tsochatzis, *Italy*

**FRI-471**

**LONG-TERM OUTCOME IN LIVER TRANSPLANTATION CANDIDATES WITH PORTOPULMONARY HYPERTENSION**
Laurent Savale*, Caroline Sattler, Yvon Calmus, Christophe Duvoux, François Durand, Filoména Conti, Cyrille Feray, Claire Francoz, Philippe Hervé, Didier Samuel, Jean Charles Duclos-Vallée, Olivier Sitbon, *France*

**FRI-472 YI**

**IMPACT OF HISTOLOGICAL FEATURES OF HEPATOCELLULAR CARCINOMA ON MTOR PATHWAY EXPRESSION AFTER LIVER TRANSPLANTATION**
Manuel Rodríguez-Perálvarez*, Marta Guerrero-Misas, Gustavo Ferrín, Lydia Barrera, Marina Sánchez-Frias, Jose María Álamo, Rubén Ciria, Francisco Serrano, Carmen Bernal, Javier Briceño, Miguel Ángel Gómez-Bravo, Jose Luis Montero, Manuel De la Mata, *Spain*

**FRI-473**

**LACK OF IMPROVEMENT OF LIVER STIFFNESS DURING SOFOSBUVIR-TREATMENT IN DECOMPENSATED CIRRHOTIC PATIENTS LISTED FOR LIVER TRANSPLANT SEEMS TO BE ASSOCIATED WITH MORE SEVERE HISTOLOGICAL DAMAGE IN THE NATIVE LIVER**
Federica Invernizzi, Federica Malinverno, Marco Maggioni, Amedeo Sciarrà, Alessio Aghemo, Daniele Dondossola, Giorgio Rossi, Massimo Colombo, Maria Francesca Donato*, *Italy*
FRI-474  EFFICACY AND CLINICAL IMPACT OF DACLATASVIR-BASED ANTIVIRAL THERAPY IN SEVERE RECURRENT HEPATITIS C AFTER LIVER TRANSPLANTATION. RESULTS FROM A MULTICENTER SPANISH GROUP
Maria Magdalena Salcedo Plaza*, Carmen Vinaixa, Lluís Castells Fusté, Juan Manuel Pascasio Acevedo, Inmaculada Fernández, Diego Rincón, Gloria Sánchez-Antolín, Luisa González-Díéguez, Alejandra Otero, Sara Lorente, Milagros Testillano, María Londoño, Fernando Casafont, Jose Antonio Pons Miñano, Esther Molina, Jose Catellote Alonso, Sonia Pascual, Valentín Cuervas-Mons, Jose Ignacio Herrero, Isidoro Narváez, Miguel García González, Victoria Aguilera, Jordi Llaneras, Alejandro Manrique, Jose Manuel Sousa Martín, Carolina Almohalla, Valle Cadahia, Francisco Suárez, Trinidad Serrano, Rafael Bañares, Martin Prieto, Spain

FRI-475  YI  CLINICAL AND FUNCTIONAL CHANGES ASSOCIATED WITH THE ACHIEVEMENT OF SUSTAINED RESPONSE IN HCV GENOTYPE-1 INFECTED LIVER TRANSPLANT RECIPIENTS: DOES SOFOSBUVIR DIFFER FROM PEG-INTERFERON THERAPY?
Ilaria Lenci, Martina Milana*, Francesco Santopalo, Piera Rossi, Simona Francioso, Francesco De Leonardis, Daniele Di Paolo, Silvia Cucchiarelli, Chiara Masetti, Mario Angelico, Leonardo Baiocchi, Italy

FRI-476  SAFETY, ADHERENCE AND EFFICACY OF A 4-WEEK RANDOMISED-CONTROLLED TRIAL OF EXERCISE TRAINING IN PATIENTS AWAITING LIVER TRANSPLANTATION
Matthew P. Wallen*, Shelley Keating, Adrian Hall, Tina Skinner, Aidan Woodward, Graeme Macdonald, Jeff Coombes, Australia

FRI-477  YI  A BAD TEST FOR A DIFFICULT DECISION: 6 MONTHS OF PRETRANSPLANT ABSTINENCE DO NOT PREDICT MORTALITY OR UNFAVORABLE OUTCOME – A META-ANALYSIS 1982-2015
Moritz Tobiasch*, Alexander Hapfelmeyer, Andreas Umsgelter, Germany
Liver transplantation / surgery: Clinical (Cont.)

FRI-478 VALIDATION OF A NOVEL PREDICTION INDEX (RETREAT) FOR HCC RECURRENCE AFTER LIVER TRANSPLANT USING THE UNITED NETWORK FOR ORGAN SHARING (UNOS) DATABASE
Neil Mehta*, Jennifer Dodge, Monika Sarkar, Francis Yao, John Roberts, United States

FRI-479 FAILURE TO RESPOND TO SOFOSBUVIR AND RIBAVIRIN AFTER LIVER TRANSPLANTATION
Paola Carrai*, Paolo De Simone, Laura Coletti, Davide Ghinolfi, Laura Fascetti, Franco Filipponi, Italy

FRI-480 YI PREFERENCEAL ACCUMULATION OF GRAFT INFILTRATING T HELPER CELLS BUT NOT CYTOTOXIC T CELLS DISTINGUISHES SUBCLINICAL REJECTION FROM ACUTE CELLULAR REJECTION IN HUMAN LIVER ALLOGRAFTS
Richard Taubert*, Anna Baumann, Fatih Noyan, Matthias Hardtke-Wolenski, Jerome Schlue, Frank Lehner, Michael Manns, Elmar Jaeckel, Germany

FRI-481 RENAL DYSFUNCTION IN LIVER TRANSPLANT PATIENTS TREATED WITH SOFOSBUVIR BASED-REGIMEN FOR HCV RECURRENCE: RESULTS FROM A LARGE FRENCH PROSPECTIVE MULTICENTRIC ANRS CO23 CUPILT
Rodolphe Anty*, Audrey Coilly, Claire Fougerou, Victor De Ledinghen, Pauline Houssel-Debruy, Christophe Duvoux, Vincent Di Martino, Sylvie Radenne, Nassim Kamar, Louis D’Alteroche, Valérie Canva, Pascal Lebray, Christophe Moreno, Jérôme Dumortier, Christine Silvain, Camille Besch, Daniele Botta-Fridlund, Vincent Leroy, François Durand, Albert Tran, Hélène Montialoux, François Habersetzer, Guillaume Favre, Emilie Rossignol, A Rohel, A Renault, Sébastien Dharancy, H Danjou, Jean-Charles Duclos-Vallee, Georges-Philippe Pageaux, France

FRI-482 DONATION AFTER CARDIAC DEATH (DCD) LIVERS ARE ASSOCIATED WITH EARLIER VIRAL RECRUDESCENCE AND CLINICALLY SIGNIFICANT GRAFT INJURY THAN DONATION AFTER BRAINSTEM DEATH LIVERS IN HCV+ RECIPIENTS
Sarah Townsend*, Debashis Haldar, Muhammed Ali Monga, Andy Holt, Ahmed Elsharkawy, United Kingdom
FRI-483  
**SOFOSBUVIR-BASED-REGIMEN FOR HCV RECURRENT AFTER COMBINED LIVER-KIDNEY TRANSPLANTATION: RESULTS FROM THE ANRS CO23 CUPILT STUDY**

FRI-484  
**SELECTION CRITERIA OF SURGICAL RESECTION FOR PATIENTS WITH BARCELONA CLINIC LIVER CANCER CLASSIFICATION B HEPATOCELULAR CARCINOMA**
Sukwon Suh*, Yoo-Shin Choi, *Korea, South*

FRI-485  
**PATIENTS’ ATTITUDES TO IMMUNOSUPPRESSIVE THERAPY POST LIVER TRANSPLANT: WHY AREN’T WE LISTENING?**
Susanne O’Reilly*, Nathaniel Mc Hugh, Aaron Doherty, Cliona Farrelly, Cathal Harmon, Diarmaid Houlihan, Emir Hoti, *Ireland*

FRI-486  
**PERI-TRANSPLANT TREATMENT WITH DIRECT-ACTING ANTIVIRALS OF HIV-HCV COINFECTED PATIENTS**
Victoria Aguilera*, Carmen Vinaixa, Angel Rubin, Maria García-Eliz, Marino Blanes, Salvador Benlloch, Eugenia Pareja, Marina Berenguer, Martín Prieto, *Spain*

FRI-487  
**ARE THE EARLY QUALITY OF LIFE BENEFITS SUSTAINED LONG-TERM AFTER LIVER TRANSPLANTATION? A 10-YEAR LONGITUDINAL DIAGNOSIS STRATIFIED EVALUATION**
Vincent Karam*, Colette Danet, Didier Samuel, René Adam, Teresa Antonini, Faouzi Saliba, Denis Castaing, *France*

FRI-488  
**DECREASING MORTALITY IN LIVER TRANSPLANT CANDIDATES WITH HEPATITIS C VIRUS INFECTION IN THE UNITED STATES**
W. Ray Kim*, Nae-Yun Heo, Donghee Kim, Prowpanga Udompap, Ajitha Mannalithara, *United States*
Liver transplantation / surgery: Clinical (Cont.)

FRI-489

YI

COMPARISON OF TREATMENT OUTCOME BETWEEN LIVING DONOR LIVER TRANSPLANTATION AND SORAFENIB FOR PATIENTS WITH BCLC B OR C STAGE HEPATOCELLULAR CARCINOMA
Yuri Cho*, Jeong-Hoon Lee, Dong Hyeon Lee, Eun Ju Cho, Su Jong Yu, Nam-Joon Yi, Kwang-Woong Lee, Kyung-Suk Suh, Yoon Jun Kim, Jung-Hwan Yoon, Korea, South

FRI-490

LONG-TERM OUTCOMES OF HEART TRANSPLANT RECIPIENTS WITH HEPATITIS C INFECTION
Maria Stepanova, Leyla De Avila, Thomas Jeffers, Robert Wong, Aijaz Ahmed, Zobair M. Younossi*, United States
<table>
<thead>
<tr>
<th>Poster Number</th>
<th>Title</th>
<th>Authors</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>FRI-025</td>
<td>MOLECULAR CLASSIFICATION OF MIXED HEPATOCELLULAR-CHOLANGIOCARCINOMA TUMORS</td>
<td>Agrin Moeini*, Daniela Sia, Zhongyang Zhang, Genis Camprecios, Ashley Stueck, M. Isabel Fiel, Oriana Miltiadous, Iris M. Quetglas, Ke Hao, Augusto Villanueva, Swan N. Thung, Myron E. Schwartz, Josep M. Llovet, Spain</td>
<td>Spain</td>
</tr>
<tr>
<td>FRI-026</td>
<td>DICER PREVENTS HYPOXIA-INDUCED UP-REGULATION OF HIF-1A, HYPOXIC RESPONSE AND EPITHELIAL-MESENCHYMAL TRANSITION IN HEPATOCELLULAR CARCINOMA</td>
<td>Ahmed A. Ibrahim, Christian Schmithals, Eric Kowarz, Verena Köberle, Bianca Kacoschky, Thomas Pleli, Oliver Waidmann, Fabian Finkelmeier, Stefan Zeuzem, Horst W. Korf, Bernd Kronenberger, Rolf Marschalek, Albrecht Piiper*, Germany</td>
<td>Germany</td>
</tr>
<tr>
<td>FRI-027</td>
<td>THE CXCL12/CXCR7 SYSTEM MEDIATES MIGRATION AND SURVIVAL OF CHOLANGIOCARCINOMA (CCA) CELLS THROUGH INTERACTION WITH CXCR4 AND BARRESTIN-2</td>
<td>Alessandra Gentilini*, Krista Rombouts, Massimo Pinzani, Chiara Raggi, Pietro Invernizzi, Carlotta Raschioni, Fabio Marra, Italy</td>
<td>Italy</td>
</tr>
<tr>
<td>FRI-030</td>
<td>RNA INTERFERENCE SCREEN FOR COMBINATION THERAPY DISCOVERY FOR HEPATOCELLULAR CARCINOMA TREATMENT</td>
<td>Julien Bollard, Anu Venkatesh, Billie Bian, Veronica Miguela-Fernandez, Yujin Hoshida, Amaia Lujambio*, United States</td>
<td>United States</td>
</tr>
<tr>
<td>FRI-031</td>
<td>HEPATITIS B VIRUS ANTAGONIZES SORAFENIB IN HEPATOMA CELLS THROUGH INDIRECT INDUCTION OF THE RAF-MEK-ERK PATHWAY</td>
<td>Dvora Witt-Kehati, Romy Zemel, Amir Shlomai*, Israel</td>
<td>Israel</td>
</tr>
</tbody>
</table>
Liver tumours: Experimental (Cont.)

**FRI-032**
THE PROTEASE-INHIBITOR SERPINB3 ACTIVATES CANONICAL WNT PATHWAY IN MONOCYTES
Andrea Cappon*, Santina Quarta, Alessandra Biasiolo, Cristian Turato, Gianmarco Villano, Mariagrazia Ruvoletto, Stefano Fasolato, Giacomo Zanus, Umberto Cillo, Patrizia Pontisso, *Italy*

**FRI-033**
CROSSTALK BETWEEN TGF-B-INDUCED EPITHELIAL-MESENCHYMAL TRANSITION AND STEMNESS IN HEPATOCELLULAR CARCINOMA
Andrea Malfettone*, Jitka Soukupova, Joan Fernando, Petra Koudelkova, Esther Bertran, Àngels Fabra, Markus Grubinger, Bhavna Rani, Gianluigi Giannelli, Wolfgang Mikulits, Isabel Fabregat, *Spain*

**FRI-034**
ALTERATIONS IN TUMOUR-RELATED IMMUNITY IN PATIENTS WITH INTERMEDIATE STAGE HEPATOCELLULAR CARCINOMA UNDERGOING TRANSARTERIAL CHEMOEMBOLISATION – A SINGLE-CENTRE TRANSLATIONAL STUDY
Ankit Rao*, Miroslava Blahova, David H. Adams, Gary Middleton, Stuart M. Curbishley, Yuk Ting Ma, *United Kingdom*

**FRI-035**
TARGETING MITOCHONDRIAL FUNCTION WITH THE BCL-2 INHIBITOR ABT-263 INCREASES THERAPY EFFICACY AND EVADES SORAFENIB RESISTANCE
Albert Morales, Anna Tutusaus*, Jose C. Fernandez-Checa, Montserrat Mari, Milica Stefanovic, *Spain*

**FRI-036**
GALUNISERTIB (LY2157299) MODULATES STEMNESS IN HEPATOCELLULAR CARCINOMA
Bhavna Rani*, Francesco Dituri, Andrea Malfettone, Yuan Cao, Luigi Lupo, Isabel Fabregat, Gianluigi Giannelli, *Italy*

**FRI-037**
INHIBITION OF HYALURONIC ACID IN HEPATOCARCINOGENESIS: A NOVEL APPROACH TO TARGET CD44 AND OTHER CANCER STEM CELL POPULATIONS
Cecilia H. C. Sukowati*, Beatrice Anfuso, Susan Ie, Claudio Avellini, Oriano Radillo, Alan Raseni, Esteban Fiore, Guillermo Mazzolini, Claudio Tiribelli, *Italy*
FRI-038  APOPTOSIS SIGNAL-REGULATING KINASE 1 SUPPRESSES THE MALIGNANCY OF HEPATOCELLULAR CARCINOMA
Caifeng Jiang, Liangzhi Wen, Chuan Yin, Wenping Xu, Chenhong Ding*, Bin Shi, Xin Zhang, Weifen Xie, China

FRI-039  HSP-90 INHIBITION IS A PROMISING THERAPEUTIC STRATEGY IN CHOLANGIOCARCINOMA AND MIR-21 MAY SERVE AS A BIOMARKER OF SENSITIVITY
Andrea Lampis, Luciano Cascione, Rosemary Burke, Paul Clarke, Michele Simbolo, Aldo Scarpa, Else Bosma, Sijia Yu, Rebecca Cole, Mark Stubbs, Swee Sharp, Rob van Montfort, Jens Hahne, Matteo Fassan, Paul Workman, Nicola Valeri, Chiara Braconi*, United Kingdom

FRI-040  TARGETING THE UNFOLDED PROTEIN RESPONSE PROGRAM EXHIBITS POTENT CYTOTOXIC EFFECTS IN LIVER ANGIOSARCOMA CELLS
Christian Perez Shibayama*, Marianne Kraus, Christoph Driessen, David Semela, Switzerland

FRI-041  THE STRATEGY OF FIGHTING MYC ACTIVITY TO HINDER HEPATOCELLULAR CARCINOMA
Cristiana Porcu*, Barbara BARBARO, Sergio Nasi, Barbara Illi, Patrizia Pontisso, Clara Balsano, Italy

FRI-042  CYP51 LIVER KNOCKOUT MICE – A NEW MODEL OF SEX-DEPENDENT PROGRESSION TO NASH AND HEPATOCELLULAR CARCINOMA
Damjana Rozman*, Gregor Lorbek, Ursa Kovac, Ziga Urlep, Peter Juvan, Martina Perse, Jera Jeruc, Slovenia

FRI-043  TRANSIENT EXPANSION OF STEM-LIKE TUMOR-INITIATING CELLS CONTRIBUTES TO CHEMoresistance DURING ANTI-ANGIOGENIC THERAPIES IN HEPATOCELLULAR CARCINOMAS
Darko Castven*, Carolin Czauderna, Diana Becker, Marcus A. Wörns, Snorri S. Thorgeirsson, Hauke Lang, Peter R. Galle, Jens U. Marquardt, Germany

FRI-044  TARGETING OF MIR-518D REDUCES CHEMoresistance IN HEPATOCELLULAR CARCINOMA CELL LINES
David Fernández Ramos*, Pablo Fernández Tussy, María Jesús Perugorria, Jesús María Bañales, Óscar Briz, Elisa Herráez, José Juan García Marin, José Maria Mato, María Luz Martínez Chantar, Spain
Liver tumours: Experimental (Cont.)

FRI-045
YI
MOLECULAR NETWORKS IN HEPATOCELLULAR CARCINOMA: TELOMERASE EXTRATELOMERIC EFFECTS
Isabella Martinozzi, Natalia Rosso, Claudio Tiribelli, Devis Pascut*, Italy

FRI-046
YI
ADAPTIVE MECHANISMS LEADING TO MULTIDRUG RESISTANCE IN HEPATOCELLULAR CARCINOMA
Devis Pascut*, Petra Popovic, Claudio Tiribelli, Italy

FRI-047
YI
FUNCTION OF STROMAL-DERIVED JUNB IN HCC ONSET AND PROGRESSION
Doris Schneller*, Jochen Hess, Stephanie Rössler, Kai Breuhahn, Sergij Goerd, Marina Schorpp-Kistner, Peter Angel, Germany

FRI-048
YI
EXOGENOUS ADMINISTRATION OF SERPINB3 INHIBITS CELL REPROGRAMMING
Erika Torchio*, Santina Quarta, Stefano Giuliani, Cristian Turato, Alessandra Biasiolo, Camilla Luni, Mariagrazia Ruvoletto, Gianmarco Villano, Giovanni Giuseppe Giobbe, Patrizia Pontisso, Nicola Elvassore, Italy

FRI-049
YI
THE INTRA-TUMOR HETEROGENEITY OF C19MC MIRNA CLUSTER EXPRESSION MIRRORS THE PRESENCE OF THE SIDE POPULATION IN HEPATOCELLULAR CARCINOMA
Federico Colombo, Claudia Augello, Andrea Terrasi, Elena Trombetta*, Marco Maggioni, Marco Baccarin, Rosamaria Silipini, Silvana Guerrieri, Silvano Bosari, Laura Porretti, Valentina Vaira, Italy

FRI-050
YI
TGF-BETA INHIBITS IN VITRO TRANSENDOTHELIAL MIGRATION OF CD4+ TREG CELLS VIA MODULATING HUMAN HEPATOCELLULAR CARCINOMA STROMAL CELLS
Francesco Dituri*, Serena Mancarella, Cinzia Buccoliero, Luigi Lupo, Gianluigi Gianneli, Italy

FRI-051
YI
EFFICACY OF AKT INHIBITOR ARQ 092 COMPARED WITH SORAFENIB IN A CIRRHOTIC RAT MODEL WITH HEPATOCELLULAR CARCINOMA
Gaël Roth*, Zuzana Macek-Jilkova, Ayca Zeybek, Giovanni Abbadessa, Yi Yu, Patrice Marche, Vincent Leroy, Thomas Decaens, France
FRI-052  THE MACROPHAGE PROTEIN CD5L ACTS AS A PRO-Oncogenic Factor in Hepatocytes
Gemma Aran*, Lucía Sanjurjo, Cristina Bárcena, Mahak Javid, Marina Simon, Maria Vázquez, Esther Díaz, Carlos Huertas, Maria Varela, Mireia Miquel, Susana Coll, Isabel Ojanguren, Ramon Bartoli, Margarita Sala, Ramon Planas, Carolina Armengol, María-Rosa Sarrias, Spain

FRI-053  A TGF-B Receptor I Kinase Inhibitor, Galunisertib (LY2157299) Inhibits Hepatocellular Carcinoma Progression in In Vivo Experimental Models
Cinzia Buccoliero, Dario Consolante, Francesco Dituri, Serena Mancarella, Nemany Hanafy, Angelo Mancinelli, Paolo Trerotoli, Stefano Leporatti, Claudio Pisano, Gianluigi Giannelli*, Italy

FRI-054  SUMOYLATION CONTROLS THE LOCALIZATION AND ACTIVITY OF LKB1 IN LIVER CANCER
Imanol Zubiete-Franco*, Fernando Lopitz-Otsoa, Pablo Fernández-Tussy, Teresa Delgado, María Martínez-Chantar, Spain

FRI-055  TREATMENTS OF EXPERIMENTAL HEPATOCELLULAR CARCINOMA USING A NOVEL ENGINEERED HOST DEFENCE PEPTIDE
Ji Hua Shi*, Clara Loise Hammarström, Øystein Rekdal, Pål Dag Line, Norway

FRI-057  CROSS-TALK BETWEEN TGF-B AND EGFR PATHWAYS IN THE REGULATION OF HEPATOCELLULAR CARCINOMA CELL MIGRATION AND INVASION
Judit López Luque*, Esther Bertran, Eva Crosas Molist, Daniel Caballero Diaz, Isabel Fabregat, South Georgia and the Islands

FRI-058  MIR-21 AND MIR-150 DOWNREGULATION IS ASSOCIATED WITH OXALIPLATIN-RELATED SINUSOIDAL OBSTRUCTION SYNDROME AND IMPAIRED SURVIVAL
Junfang Zhao*, Sander Rensen, Celien Vreuls, Maartje van den Broek, Ann Driessen, Marcel van Herwijnen, Marlon Jetten, Danyel Jennen, Cornelis Dejong, Steven Olde Damink, Netherlands
Liver tumours: Experimental (Cont.)

FRI-059  YI  NUCLEAR LOCALIZATION OF IMPDH2, THE PRIMARY TARGET OF MYCOPHENOLIC ACID, CONSTRAINS HEPATOCELLULAR CARCINOMA
Kan Chen*, Kostandinos Sideras, Buyun Ma, Wanlu Cao, Luc J van der Laan, Dave Sprengers, Ron Smits, Herold J Metselaar, Jaap Kwekkeboom, Maikel P Peppelenbosch, Qiuwei Pan, Netherlands

FRI-060  YI  HEPATOCELLULAR CARCINOMA DIFFERENTIALLY MODULATES AMPK ACTIVITY AND INDUCES AUTOPHAGY IN HEPATIC STELLATE CELLS IN A PARACRINE MANNER
Katrin Schözel*, Lisa Longato, Massimo Pinzani, Krista Rombouts, United Kingdom

FRI-061  YI  STANNIOCALCIN 1 OVEREXPRESSION PROMOTES METASTASIS IN HEPATOCELLULAR CARCINOMA
Kristy Chan*, Carmen Leung, Carmen Wong, Irene Ng, Regina Lo, Hong Kong, China

FRI-062  YI  INFLAMMATION AND FIBROSIS IN THE LIVERS OF TNFR1/MDR2KO MICE
Laura K. Berkhout*, Till Krech, Gisa Tiegs, Roja Barikbin, Germany

FRI-063  YI  RESTORING MIR122 IN HUMAN STEM-LIKE HEPATOCARCINOMA CELLS, PROMPTS TUMOR DORMANCY THROUGH SMAD-INDEPENDENT TGF-B PATHWAY
Loreto Boix*, Juan Manuel Lopez-Oliva, Ana Carolina Rhodes, Jordi Bruix, Spain

FRI-064  YI  REGULATION OF P53 FAMILY GENE EXPRESSION AND AKT/JNK CELL SIGNALING PATHWAYS BY SORAFENIB IN HEPATOCARCINOMA CELL LINES
**FRI-065**

**SOX17 REGULATES CHOLANGIOCYTE DIFFERENTIATION AND ACTS AS A TUMOUR SUPPRESSOR IN CHOLANGIOCARCINOMA**


**FRI-066**

**MULTI-OMICS LANDSCAPE OF PRECANCEROUS LIVER DISEASE**

Magdalena Budzinska*, Thomas Tu, Robert Cheng, William D’Avigdor, Nicholas Shackel, Australia

**FRI-067**

**COMBINATION OF 4-METHYLUMBELLIFERONE AND ADENOVIRAL GENE TRANSFER OF INTERLEUKIN-12 REDUCED THE EXPRESSION OF CANCER STEM CELLS MARKERS, AND SHOWED A POTENT ANTITUMOR EFFECT IN AN EXPERIMENTAL HEPATOCellular CARCINOMA MODEL WITH FIBROSIS**

Marcelo M. Rodriguez*, Mariana Malvicini, Esteban Fiore, Sofia Gomez Bustillo, Flavia Piccioni, Estanislao Peixoto, Catalina Atorrasagasti, Mariana Garcia, Laura Alaniz, Guillermo Mazzolini, Argentina

**FRI-068**

**IMPACT OF CANCER STEM CELL-ASSOCIATED MACROPHAGES ON CHOLANGIOCARCINOMA ONSET AND PROGRESSION**

Margherita Correnti*, Pietro Invernizzi, Chiara Raggi, Italy

**FRI-069**

**STEREOTACTIC ABLATIVE RADIOTHERAPY IN THE TREATMENT OF HEPATOCellular CARCINOMA LESIONS LARGER THAN 3 CENTIMETERS**

Margherita Diotallevi*, Patrizia Carucci, Alessia Guarneri, Elisabetta Trino, Daniela Campion, Pierfrancesco Franco, Stefano Mirabella, Riccardo Ragona, Silvia Gaia, Mauro Salizzoni, Umberto Ricardi, Mario Rizzetto, Italy

**FRI-070**

**HIGH EXPRESSION OF IL-17 AND ELEVATED HIGH-SENSITIVITY C-REACTIVE PROTEIN PREDICT TUMOR PROGRESSION IN UNRESECTABLE HEPATOCellular CARCINOMA PATIENTS TREATED WITH TRANSARTERIAL CHEMOEMBOLIZATION**

Myeong Jun Song*, Si Hyun Bae, Hyo Jun Ahn, Jeong Won Jang, Jong Young Choi, Seung Kew Yoon, Korea, South
Liver tumours: Experimental (Cont.)

**FRI-071**  
**YI**  
**TOLL-LIKE RECEPTOR 3: A POTENTIAL TUMOR SUPPRESSOR GENE IN HEPATOCELLULAR CARCINOMA?**  
Nadim Fares*, Marc Bonnin, Amandine Garcia, Barbara Testoni, Lydie lefrancois, Brigitte Bancel, Valerie Hervieu, Toufic Renno, Philippe Merle, Serge Lebecque, France

**FRI-072**  
**HEPATOCELLULAR CARCINOMA VIA ACTIVATION OF STAT3 SIGNALING**  
Teng Feng, Johanna Dzieran, Thorsten Maass, Andreas Teufel, Silke Marhenke, Arndt Vogel, Steven Dooley, Nadja Meindl-Beinker*, Germany

**FRI-073**  
**PROFILING OF INFILTRATING IMMUNE CELL IN TUMOR TISSUE OF HEPATOCELLULAR CARCINOMA PATIENTS.**  
Nataliya Rohr-Udilova*, Michael Trauner, Markus Peck-Radosavljevic, Austria

**FRI-074**  
**YI**  
**ENCAPSULATION OF SHT-DNA, SIRNA AND POLYPEPTIDE -17 INSIDE HYBRID POLYMERIC NANO-PROTEIN FOLIC ACID (HPNP-FA) CARRIER AS TARGETED TGFB INHIBITOR FOR HEPATOCELLULAR CARCINOMA**  
Nemany A. N. Hanafy*, Alessandra Quarta, Riccardo Di Corato, Luciana Dini, Concetta Nobile, Maria Luisa De Giorgi, Vittorianna Tasco, Sonia Carallo, Mariafrancesca Cascione, Rosaria Rinaldi, Isabel Fabregat, Stefano Leporatti, Italy

**FRI-075**  
**A PANEL OF 3 MARKERS (H4K20ME2, H4K16AC AND PIVKA-II) FOR PREDICTION OF MICROVASCULAR INVASION IN HEPATOCELLULAR CARCINOMA**  
Nicolas Pote*, François Cauchy, Miguel Albuquerque, Olivier Soubrane, Pierre Bedossa, Valérie Paradis, France

**FRI-076**  
**MELATONIN’S EFFECT ON THE SECONDARY BILIARY CIRRHOSIS INDUCED BY LIGATION OF BILIARY DUCT**  
Norma Anair Possa Marroni*, Josieli Raskopf Coares, Elizangela Gonçalves Schemitt, Renata Minuzzo Hartmann, Francielli Licks, Mariana Do Couto Soares, Adriane DalBosco, Brazil
FRI-077
YI
MER TYROSINE KINASE POSITIVE TUMOUR ASSOCIATED MACROPHAGES ARE A NOVEL THERAPEUTIC TARGET IN HEPATOCELLULAR CARCINOMA
Sujit K. Mukherjee, Oltin T. Pop*, Evangelos Triantafyllou, Wafa Khamri, Christine Bernsmeyer, Ka-Kit Li, Abid Suddle, Christopher Weston, Stuart Curbishley, Mark Thursz, David Adams, Nigel Heaton, Alberto Quaglia, Charalambos G. Antoniades, United Kingdom

FRI-078
THE POTENT PAN-CASPASE INHIBITOR IDN-7314 DOES NOT AFFECT TUMOR GROWTH RATE NOR DOES IT ANTAGONIZE THE EFFICACY OF SORAFENIB IN MODELS OF HEPATOCELLULAR CARCINOMA
Alfred Spada, Patricia Contreras*, United States

FRI-079
A HEPATIC STEM CELL VACCINE IS SUPERIOR TO AN EMBRYONIC STEM CELL VACCINE IN THE PROPHYLAXIS AND TREATMENT OF MURINE HEPATOCARCINOMA
Qi Zheng*, Yichao Zheng, Jing Chen, Jiaji Jiang, China

FRI-080
GLOBAL ANALYSIS OF DNA METHYLATION IN HEPATOCELLULAR CARCINOMA BY A LIQUID HYBRIDIZATION CAPTURE-BASED BISULFITE SEQUENCING APPROACH
Qian Chen*, Fei Gao, Huifang Liang, Xiaoping Chen, China

FRI-081
COEXPRESSION OF BTLA AND PD-1 IDENTIFIES A NOVEL CD4 T-CELL EXHAUSTION PHENOTYPE IN HUMAN HEPATOCELLULAR CARCINOMA.
Qiyi Zhao*, Zhan-Lian Huang, Liang Peng, Peipei Wang, Chaoshuang Lin, Dong-Ming Kuang, Limin Zheng, Zhiliang Gao, China

FRI-082
NON-INVASIVE IN VIVO IMAGING OF HYPOXIA-INDUCIBLE FACTOR 1 FUNCTION IN THE GROWTH OF COLORECTAL LIVER METASTASES
Roben G. Gieling*, Brian A. Telfer, Kaye J. Williams, United Kingdom

FRI-083
DIFFERENTIAL MICRORNA EXPRESSION IN PLASMA MICROVESICLES PREDICT HEPATOCELLULAR CARCINOMA REGULATORY PATHWAYS
Robert Cheng*, Magdalena Budzinska, Thomas Tu, Geoff McCaughan, Susan McLennan, Nicholas Shackel, Australia
Liver tumours: Experimental (Cont.)

FRI-084 YI

THE “FIBROUS NEST”: A BIOTYPE INCLUDING WNT SIGNALS, EXTRACELLULAR MATRIX REMODELING AND STEMNESS IN HEPATOCELLULAR CARCINOMA
Romain Désert*, Sihem Mebarki, Mireille Desille, Marie Sicard, Elise Lavergne, Stéphanie Renaud, Damien Bergeat, Laurent Sulpice, Christine Perret, Bruno Turlin, Bruno Clément, Orlando Musso, France

FRI-085

TREATMENT OF CHOLANGIOCARCINOMA BY BROMELAIN AND PAPAIN
Ruben Plentz*, Alena Müller, Samarpita Barat, Xi Chen, Cuong Bui, Przemyslaw Bozko, Nisar Malek, Germany

FRI-086 YI

NOTCH2 REGULATES SELF-RENEWAL AND TUMORIGENICITY OF HUMAN HEPATOCELLULAR CARCINOMA CELLS
Wen rui, Shi Xiang de, Lei Xu bo, Chao liu, Rui Zhang*, Germany

FRI-087 YI

BMI1 DRIVES MALIGNANT TRANSFORMATION OF HEPATIC PROGENITOR CELLS VIA ACTIVATION OF RAS/MAPK SIGNALING PATHWAY
Rui Zhang*, Li Fei Tang, Wen Rui wu, Qi Bing tang, Jie wang, Chao liu, Germany

FRI-088

GENOTYPE-PHENOTYPE CORRELATION OF CTNNB1 MUTATIONS REVEALS DIFFERENT B-CATENIN ACTIVATION LEVELS IN HEPATOCELLULAR TUMORS WITH HIGH ACTIVITY ASSOCIATED WITH MALIGNANCY
Sandra Rebouissou*, Andrea Franconi, Julien Calderaro, Eric Letouzé, Sandrine Imbeaud, Camilla Pilati, Jean-Charles Nault, Gabrielle Couchy, Alexis Laurent, Charles Balabaud, Paulette Bioulac-Sage, Jessica Zucman-Rossi, France

FRI-089 YI

MOLECULAR HETEROGENEITY AND TRUNK DRIVER MUTATIONS IN HEPATOCELLULAR CARCINOMA
Daniela Sia, Andrew N Harrington, Sara Torrecilla’, Zhongyang Zhang, Genis Camprecios, Agrin Moeini, Sara Toffanin, Isabel Fiel, Ke Hao, Monica Higuera, Laia Cabellos, Helena Cornella, Milind Mahajan, Yujin Hoshida, Augusto Villanueva, Sander Florman, Myron Schwartz, Josep M Llovet, Spain
FRI-090  FUNCTIONAL GENOMICS ON TUMOR INVASION OF HUMAN HEPATOMA: A NOVEL TIS1-HIF-NOTCH SIGNALING PATHWAY REGULATES HEPATOCELLULAR CARCINOMA INVASION
Sen-Yung Hsieh*, Taiwan

FRI-091  SERPINB3 UP-REGULATES HYPOXIA INDUCIBLE FACTORS -1ALPHA AND -2ALPHA IN LIVER CANCER CELLS THROUGH DIFFERENT MECHANISMS
Stefania Cannito*, Gianmarco Villano, Cristian Turato, Elisabetta Morello, Beatrice Foglia, Erica Novo, Santina Quarta, Sebastiano Colombatto, Fernando Lopiz-Otsoa, Teresa Cardoso, M Luz Martinez-Chantar, Patrizia Pontisso, Maurizio Parola, Italy

FRI-092  DICKKOPF-1 ENHANCES TUMOR ANGIOGENESIS AND ENDOTHELIAL MESENCHYMAL TRANSITION
Sung Hoon Choi*, Hyun Gyu Lee, Hyemi Kim, Jun Young Park, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Seung Up Kim, Korea, South

FRI-093  A COSTIMULATION-ASSISTED PRIME-BOOST VACCINATION DRIVES POTENT IMMUNE RESPONSES TO HEPATOCELLULAR CARCINOMA NEOANTIGENS
Supot Nimanong*, Dimitrij Ostroumov, Jessica Heemcke, Thailand

FRI-094  RADIOFREQUENCY ABLATION OF SOLID TUMORS IN COMBINATION WITH BORTEZOMIB CAUSES ER-STRESS
Sonja Gehring, Malte Zumblick, Thomas Gress, Th. Till Wissniowski*, Germany

FRI-095  TRANSFORMING GROWTH FACTOR-BETA TRIGGERS TRANSENDOTHELIAL MIGRATION DURING HEPATOCELLULAR CARCINOMA PROGRESSION
Petra Koudelkova, Gerhard Weber, Victor Costina, Steven Dooley, Rahul Agarwal, Peter Winter, Peter Findeisen, Wolfgang Mikulits*, Austria

FRI-096  HEPATOCYTE-DERIVED OSTEOPONTIN PROMOTES THE DEVELOPMENT OF HEPATOCELLULAR CARCINOMA
Xiaodong Ge*, Ioana Abraham-Enachescu, Yu Chen, Xiaochen Sun, Anna Koh, Grace Guzman, Yujin Hoshida, Natalia Nieto, United States
Liver tumours: Experimental (Cont.)

**FRI-097**

**IMPACT OF THE COMBINATION OF DIPEPTIDYL PEPTIDASE IV INHIBITOR AND ANGIOTENSIN-II TYPE 1 RECEPTOR BLOCKER ON HEPATOCARCINOGENESIS IN A RAT MODEL OF NONALCOHOLIC STEATOHEPATITIS**

Yasushi Okura*, Tadashi Namisaki, Ryuichi Noguchi, Kosuke Takeda, Kei Moriya, Mitsuteru Kitade, Norihisa Nishimura, Shinya Sato, Yasuhiko Sawada, Hideto Kawaratani, Kenichiro Seki, Kosuke Kaji, Hitoshi Yoshiji, Japan

**FRI-098**

**GENOME-WIDE HIGH-THROUGHPUT SCREENING UNVEIL BIOMARKERS CORRELATED WITH GALUNISERTIB (LY2157299) EFFECTIVENESS IN HEPATOCELLULAR CARCINOMA**

Yuan Cao*, Rahul Agarwal, Francesco Dituri, Bhavna Rani, Luigi Lupo, Peter Winter, Gianluigi Giannelli, Italy

**FRI-099**

**ACTIVATION OF YAP-1 BY C-MYC PATHWAY IS A THERAPEUTIC TARGET IN HEPATOCELLULAR CARCINOMA UNDER HYPOXIC CONDITION**

Yuri Cho*, Dong Hyeon Lee, Eun Ju Cho, Jeong-Hoon Lee, Su Jong Yu, Yoon Jun Kim, Jung-Hwan Yoon, Korea, South

**FRI-100**

**NEXT-GENERATION PROTEASOME INHIBITOR OPROZOMIB SYNERGIZES WITH MODULATORS OF THE UNFOLDED PROTEIN RESPONSE TO SUPPRESS HEPATOCELLULAR CARCINOMA**


**FRI-101**

**THE UNFOLDED PROTEIN RESPONSE UNDERLIES MICROENVIRONMENTAL STRESS-INDUCED PHENOTYPE SWITCHING LEADING TO STEMNESS AND CHEMORESISTANCE IN HUMAN HEPATOCELLULAR CARCINOMA**

Yves-Paul Vandewynckel*, Olivier Govaere, Astrid Vandierendonck, Debby Laukens, Lindsey Devisscher, Annelies Paridaens, Eliene Bogaerts, Sarah Raevens, Xavier Verhelst, Christophe Van Steenkiste, Louis Libbrecht, Christophe Ampe, Marleen Van Troys, Anja Geerts, Tania Roskams, Hans Van Vlierberghe, Belgium
Viral hepatitis: Hepatitis B & D – clinical (therapy, new compounds, resistance)

**FRI-103**

**THE PRESENCE OF BCP / PC VARIANTS REDUCES THE RATE OF HBSAG LOSS AMONG HBEAG-POSITIVE CHB PATIENTS TREATED WITH LONG-TERM TENOFOVIR DF THERAPY**

Alex Thompson*, Julianne Bayliss, Lilly Yuen, Margaret Littlejohn, Kathleen Jackson, Darren Wong, Anuj Gaggar, Kathryn Kitrinos, Mani Subramanian, Patrick Marcellin, Ed Gane, Henry Chan, Scott Bowden, Stephen Locarnini, Peter Revill, *Australia*

**FRI-104**

**PRECLINICAL CHARACTERIZATION OF POTENT CORE PROTEIN ASSEMBLY MODULATORS FOR THE TREATMENT OF CHRONIC HEPATITIS B**

Qi Huang, Alexandre Mercier*, Yi Zhou, Kirk Henne, G. Renuka Kumar, Shawn Sun, Lida Guo, Jean Liu, Yuhua Zong, Tian Sun, Katherine Nabel, Pao-Chen Li, Cathal Mahon, Geoffrey Chen, Mark Bures, Lichun Li, Earl May, Emily Connelly, Jason Deer, Sarah Kate, Samson Francis, William W. Turner, Adam Zlotnick, Lee D. Arnold, Uri Lopatin, *United States*

**FRI-105**

**UPDATE ON THE SAFETY AND EFFICACY OF REP 2139 MONOTHERAPY AND SUBSEQUENT COMBINATION THERAPY WITH PEGYLATED INTERFERON ALPHA-2A IN CAUCASIAN PATIENTS WITH CHRONIC HBV / HDV CO-INFECTION**

Michel Bazinet, Victor Pantea, Valentin Cebotaescu, Lilia Cojuhari, Paulina Jimbei, Jeffery Albrecht, Peter Schmid, Adalbert Krawczyk, Hadi Karimzadeh, Michael Roggendorf, Andrew Vaillant*, *Canada*

**FRI-106**

**CIRCULATING IL-17 AND IP-10 AS POTENTIAL FACTORS TO INFLUENCE HBV INFECTION OUTCOME**

Bei Cai*, Junlong Zhang, Jie Chen, Yun Liao, Qi Zhang, Chuanmin Tao, Lanlan Wang, *China*

**FRI-107 YI**

**CLINICAL UTILITY OF HEPATITIS B CORE-RELATED ANTIGEN (HBCRAG) IN THE TREATMENT OF HEPATITIS DELTA**

Benjamin Maasoumy*, Michael Wöbse, Svenja Hardtke, Patrick Lehmann, Birgit Bremer, Benjamin Heidrich, Markus Cornberg, Cihan Yurdaydin, Michael P. Manns, Heiner Wedemeyer, *Germany*
**Viral hepatitis: Hepatitis B & D – clinical (therapy, new compounds, resistance) (Cont.)**

**FRI-108** NUCLEOSIDE ANALOGUES IMPROVE THE SHORT-TERM PROGNOSIS OF CHRONIC HEPATITIS B PATIENTS WHEN THEY SUFFERED AN ACUTE-ON-CHRONIC LIVER FAILURE
Chao Ye*, Juan Lu, Lanjuan Li, China

**FRI-109** UGT2B28 GENOMIC VARIATION IS ASSOCIATED WITH HEPATITIS B E-ANTIGEN SEROCONVERSION IN RESPONSE TO ENTECAVIR OR PEGINTERFERON THERAPY
Chau-Ting Yeh*, Chih-Lang Lin, Rong-Nan Chien, Kung-Hao Liang, Chao-Wei Hsu, Ming-Wei Lai, Taiwan

**FRI-110** RANDOMIZED CONTROLLED TRIAL OF ENTECAVIR PROPHYLAXIS IN PATIENTS WITH INFLAMMATORY ARTHRITIS AND INACTIVE HBV INFECTION UNDERGOING BIOLOGICS TREATMENT: THE FIRST INTERIM REPORT
Chieh-Ju Lee*, Yi-Hsiang Huang, Hsiao-Yi Lin, Chung-Tei Chou, Chang-Youh Tsai, Wei-Sheng Chen, Ming-Han Chen, Han-Chieh Lin, Taiwan

**FRI-111** HEPATITIS DELTA VIRUS KINETICS UNDER THE PRENYLATION INHIBITOR LONAFARNIB SUGGEST HDV-MEDIATED SUPPRESSION OF HBV REPLICATION

**FRI-112** MIR-B-INDEX: A CANDIDATE BIO-MARKER TO IDENTIFY THE IMMUNE CONTROL OF HBV INFECTION IN CHRONIC HEPATITIS B PATIENTS TREATED WITH NUCLEOS(T)IDE-ANALOGUES
Daniela Cavallone*, Filippo Oliveri, Piero Colombatto, Barbara Coco, Veronica Romagnoli, Lidia Surace, Silvia Fabiani, Gabriele Ricco, Francesco Moriconi, Ferruccio Bonino, Maurizia R. Brunetto, Italy
FRI-113  TREATMENT DISCONTINUATION AFTER HBSAG LOSS IS SAFE IN CHRONIC HEPATITIS B PATIENTS TREATED WITH NUCLEOS/TIDE ANALOGS: A RETROSPECTIVE MULTICENTER STUDY (HEBESAS)
Emilio Suárez*, Miguel A. Simón, Maria Buti, Martin Prieto, Juan M. Pascasio, Manuel Rodriguez, Teresa Casanovas, Javier Crespo, Juan Arenas, Rafael Gómez, Blanca Figueruela, Moises Diago, Rosa Mª Morillas, Jose M. Zozaya, Jose L Calleja, Marta Casado, Esther Molina, Javier Fuentes, Spain

FRI-114  NO BENEFICIAL OF LONG-TERM ANALOGUE TREATMENT ON THE CLINICAL OUTCOME OF PATIENTS WITH CHRONIC HEPATITIS DELTA AND ADVANCED LIVER DISEASE. A CASE-CONTROL STUDY
Giuseppina Brancaccio, Massimo Fasano, Adriano Grossi, Teresa Santantonio, Giovanni B. Gaeta*, Italy

FRI-115  PHARMACOKINETICS AND PHARMACODYNAMICS MODELING OF LONAFARNIB IN PATIENTS WITH CHRONIC HEPATITIS DELTA VIRUS INFECTION
Laetitia Canini, Christopher Koh, Scott J. Cotler, Susan L. Uprichard, Mark A. Winters, Ma Ali Thanda Han, David E. Kleiner, Ramazan Idilman, Cihan Yurdaydin, Jeffrey S. Glenn, Theo Heller, Harel Dahari*, United States

FRI-116  USING OFF-TREATMENT HBV DNA LEVELS TO PREDICT ALT RELAPSE AFTER NUCLEOS(T)IDE ANALOGUE DISCONTINUATION: A PROSPECTIVE COHORT STUDY
Heng Chi*, Jiawei Cao, Bettina E. Hansen, Tao Yu, Shaohang Cai, Zhandong Li, Harry L. Janssen, Jie Peng, Netherlands

FRI-117  A GENOTYPE-SPECIFIC BASELINE SCORE TO PREDICT POST-TREATMENT RESPONSE TO PEGINFERON ALFA-2A IN HBEAG-POSITIVE PATIENTS WITH HEPATITIS B VIRUS GENOTYPE B OR C INFECTION
Henry Lik-Yuen Chan*, Diethelm Messinger, George V. Papatheodoridis, Markus Cornberg, Qing Xie, Teerha Piratsivuth, Hong Ren, Patrick Kennedy, Alex J. Thompson, Antonietta Caputo, Georgios Bakalos, Vedran Pavlovic, Pietro Lampertico, China
FRI-118 TENOFOVIR DF MONOTHERAPY IS SUPERIOR TO ENTECAVIR-ADEFOVIR COMBINATION IN CHRONIC HEPATITIS B PATIENTS WHO ARE SUBOPTIMAL RESPONDER FOR LAMIVUDINE-ADEFOVIR THERAPY WITH RT204I/V MUTATION: A INTERIM ANALYSIS OF PROSPECTIVE MULTICENTER TRIAL
Hong Soo Kim*, Sae Hwan Lee, Sang Gyune Kim, Young Seok Kim, Soung Won Jeong, Jae Young Jang, Boo Sung Kim, Dae Won Jun, Tae Yeob Kim, Joo Hyun Sohn, Young Don Kim, Gab Jin Cheon, Byung Seok Lee, Korea, South

FRI-119 FIVE-YEAR OUTCOME OF TELBIVUDINE VERSUS ENTECAVIR IN TREATING HIGH VIRAL LOAD CHRONIC HEPATITIS B PATIENTS
Hong-Ying Pan*, Ze-Ze Ren, Hai-Jun Huang, Hai Zou, Yong-Xi Tong, Dan-Hong Yang, Hong-Yi Pan, Mei-Juan Chen, Ming-Shan Wang, Yi-Cheng Huang, Jia-Jie Zhang, China

FRI-120 ANTIVIRAL THERAPY FOR THE PREVENTION OF LONG-TERM CIRRHOSIS RISK IN PATIENTS WITH CHRONIC HEPATITIS B

FRI-121 FIBROTIC BURDEN, NOT ANTIVIRAL AGENT, DETERMINES CLINICAL OUTCOME IN CHRONIC HEPATITIS B PATIENTS: A PROPENSITY-SCORE MATCHED ANALYSIS
Hye Soo Kim*, Beom Kyung Kim, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Ki Jun Song, Jung Won Park, Yeong Jin Kim, Oidov Baatarkhuu, Kwang Hyub Han, Korea, South

FRI-122 ANALYSIS OF HEPATITIS B SURFACE ANTIGEN (HBsAg) LEVELS USING THE HIGHLY SENSITIVE LUMIPULSE HBsAg-HQ ASSAY IN HEPATITIS B VIRUS PATIENTS WITH HBsAg SEROCLEARANCE ACCORDING TO THE CONVENTIONAL ASSAY
Itaru Ozeki*, Tomoaki Nakajima, Shuhei Hige, Yoshiyasu Karino, Joji Toyota, Japan
FRI-123  OUTCOME OF 3-YEAR CONSOLIDATION THERAPY FOLLOWING HBEAG LOSS IN HBEAG-POSITIVE CHRONIC HEPATITIS B PATIENTS TREATED WITH NUCLEOS(T)IDE ANALOGUES
Ja Kyung Kim, Kwan Sik Lee*, Jung Il Lee, Ah Young Kang, Hye Young Chang, Korea, South

FRI-124  EFFECTS OF ETV OR TDF ON RENAL FUNCTION IN PATIENTS WITH HBV-RELATED CIRRHOSIS: OUTCOME AT 2 YEARS
Jihye Park*, Jun Yong Park, Korea, South

FRI-125  RANDOMIZED TRIAL OF TELBIVUDINE VERSUS ENTECAVIR IN REDUCING SERUM HBSAG LEVELS IN HBEAG-POSITIVE ENTECAVIR-TREATED PATIENTS WHO HAVE ACHIEVED HBV DNA UNDETECTABILITY BY PRECEDING ENTECAVIR TREATMENT
Young-Suk Lim, Jihyun An*, Gi-Ae Kim, Hyung Don Kim, Han Chu Lee, Ju Hyun Shim, Korea, South

FRI-126  PERSISTENCE TO ENTECAVIR TREATMENT FOR CHRONIC HEPATITIS B IN A REAL-LIFE SETTING: 2 YEAR RESULTS OF A GERMAN PROSPECTIVE MULTICENTRE OBSERVATIONAL STUDY
Jörg Petersen*, Thomas Wilke, Stefan Mauss, Renate Heyne, Christoph Herold, Manfred Wiese, Klaus Böker, Tanja Pichl, Anja Meier, Dietrich Hüppe, Germany

FRI-127  PHARMACOKINETICS AND SAFETY OF TENOFOVIR ALAFENAMIDE IN SUBJECTS WITH SEVERE HEPATIC IMPAIRMENT
Joseph M. Custodio*, Grace Ma, Jennifer Cuvin, Lillian Ting, John Flaherty, Julia Z. Zack, United States

FRI-128  TENOFOVIR VERSUS TENOFOVIR PLUS ENTECAVIR FOR CHRONIC HEPATITIS B WITH LAMIVUDINE-RESISTANCE AND ENTECAVIR-RESISTANCE
Sangheun Lee, Sang Hoon Ahn, Kyu Sik Jung, Do Young Kim, Beom Kyung Kim, Seung Up Kim, Oidov Baatarkhuu, Hye Jin Ku, Kwang-Hyub Han, Jun Yong Park*, Korea, South
Viral hepatitis: Hepatitis B & D – clinical (therapy, new compounds, resistance) (Cont.)

FRI-129  **ENTECAVIR VERSUS LAMIVUDINE FOR PREVENTION OF LIVER-RELATED EVENTS IN PATIENTS WITH HBV-RELATED ADVANCED LIVER DISEASE: A MULTICENTER, PROSPECTIVE STUDY**
Jun Yong Park*, Sang Gyun Kim, Won Young Tak, Hyung Joon Yim, Byoung Kuk Jang, Moon Young Kim, Byung Ik Kim, Jin-Woo Lee, Ki Tae Yoon, Jae Youn Cheong, So Young Kwon, Tae Yeob Kim, Si Hyun Bae, Yeon Seok Seo, Jung Hyun Kwon, Dong Joon Kim, Ja-Kyung Kim, Soung Won Jeong, Sang Hoon Ahn, Kwang-Hyub Han, Korea, South

FRI-130  **TWENTY-FIVE YEARS OF CHRONIC HEPATITIS B – CLINICAL OUTCOME**
Liliane C. Meireles*, Sofia Vitor, Luis Carlos Freitas, Joana Granada, Iolanda Santos, Rui Tato Marinho, José Velosa, Portugal

FRI-131  **COST-EFFECTIVENESS ANALYSIS OF HEPATITIS B VIRUS SCREENING TO PREVENT HEPATITIS B VIRUS REACTIVATION IN PATIENTS RECEIVING RITUXIMAB BASED CHEMOTHERAPY FOR HEMATOLOGIC MALIGNANCY**
Maria Buti*, Javier Crespo, Rafael Esteban, Covadonga Torres, Itziar Oyagüez, Miguel Ángel Casado, Spain

FRI-132  **QUANTIFICATION OF SERUM HBSAG IS A USEFUL PARAMETER TO OPTIMIZE ANTIVIRAL NUC THERAPY SCHEDULE IN CHRONIC HEPATITIS B**
Maria Guarino*, Giuseppe Portella, Raffaele Bonavolta, Francesco Auriemma, Valentina Cossiga, Rocco Granata, Laura Donnarumma, Nicola Caporaso, Filomena Morisco, Italy

FRI-133  **BASELINE HBSAG AND HBCRAG TITERS ALLOW PEGINTERFERON BASED “PRECISION MEDICINE” IN HBEAG-NEGATIVE CHRONIC HEPATITIS B**
Michelle Martinot Peignoux*, Martine Lapalus, Nathalie Boyer, Corinne Castelnau, Nathalie Giuily, Michelle Pouteau, Tarik Asselah, Patrick Marcellin, France
FRI-134

PREVIOUS INTERFERON TREATMENT FAILURE IS ASSOCIATED WITH A VERY LOW CHANCE OF RESPONSE TO PEGINTERFERON RETREATMENT IN HBEAG-POSITIVE CHRONIC HEPATITIS B: POOLED ANALYSIS OF TWO RANDOMIZED TRIALS
Milan J. Sonneveld*, Jun Cheng, Qing Xie, Bettina Hansen, Jinlin Hou, Fehmi Tabak, Harry L. Janssen, Netherlands

FRI-135

EFFICACY OF COMBINATION WITH INTERFERON AND NUCLEOS(T)IDE ANALOGUES AS SIMULTANEOUS OR SEQUENTIAL THERAPY IN PATIENTS WITH CHRONIC HEPATITIS B
Nan Jiang*, Jia Pan, Xingxiang Yang, Jianmei Lin, Rengang Huang, Shuqiang Wang, Xiaoxia Geng, Renguo Yang, Tingting Luo, Jiazhen Wu, Kaijv Xu, China

FRI-136

COMPLETE BLOCKAGE OF HBV VIRUS REPLICATION AND INHIBITION OF CCCDNA FORMATION BY CORE PROTEIN ALLOSTERIC MODIFIERS
Pao-Chen Li*, Emily Connelly, Yuhua Zong, Yi Zhou, Shawn Sun, Adam Zlotnick, Lee Arnold, Uri Lopatin, Qi Huang, United States

FRI-137

EFFECTIVENESS OF PEGINTERFERON ALFA-2A THERAPY IN HBEAG-POSITIVE AND HBEAG-NEGATIVE PATIENTS WITH CHRONIC HEPATITIS B: FINAL RESULTS 3 YEARS POST-TREATMENT OF THE PROSPECTIVE, GLOBAL, OBSERVATIONAL S-COLLATE STUDY
Patrick Marcellin*, Qing Xie, Seung Woon Paik, Robert Flisiak, Teerha Piratvisuth, Jörg Petersen, Tarik Asselah, Markus Cornberg, Denis Ouzan, Graham R. Foster, George V. Papatheodoridis, Diethelm Messinger, Loredana Regep, Georgios Bakalos, Ulrich Alshuth, Heiner Wedemeyer, France

FRI-138

A GENOTYPE-SPECIFIC BASELINE SCORE TO PREDICT RESPONSE AT 48 WEEKS POST-TREATMENT TO PEGINTERFERON ALFA-2A IN PATIENTS WITH HBEAG-NEGATIVE CHRONIC HEPATITIS B
Pietro Lampertico*, Diethelm Messinger, Markus Cornberg, Maurizia Brunetto, Jörg Petersen, Patrick Kennedy, Tarik Asselah, Vivien Rothe, Antonietta Caputo, Georgios Bakalos, Vedran Pavlovic, George V. Papatheodoridis, Italy
Viral hepatitis: Hepatitis B & D – clinical (therapy, new compounds, resistance) (Cont.)

FRI-139 AN EASY-TO-USE BASELINE SCORE TO PREDICT RESPONSE TO PEGINTERFERON ALFA-2A IN PATIENTS WITH CHRONIC HEPATITIS B IN RESOURCE-LIMITED SETTINGS
Pietro Lampertico*, Diethelm Messinger, Hameed Oladipupo, Georgios Bakalos, Tarik Asselah, Italy

FRI-140 INTERACTIONS STUDY OF NON-NUCLEOSIDE INHIBITORS WITH HEPATITIS B VIRUS E ANTIGEN TOWARD BETTER DESIGN OF NEW INHIBITORS BASED ON MOLECULAR DOCKING AND PHARMACOPHORE METHODS
Reza Aalizadeh*, Greece

FRI-141 HIGH RATES OF SURFACE ANTIGEN LOSS AND SUSTAINED VIRAL SUPPRESSION IN ASIAN CHRONIC HEPATITIS B PATIENTS TREATED WITH ORAL ANTIVIRAL THERAPY: COMMUNITY-BASED REAL WORLD OUTCOMES
Robert Wong*, My Nguyen, Chuck Chan, Huy Trinh, Andrew Huynh, Mytop Ly, Huy Nguyen, Khanh Nguyen, Sharon Torres, Jenny Yang, Benny Liu, Ruel Garcia, Taft Bhuket, Brian Levitt, Eduardo DaSilvera, Robert Gish, United States

FRI-142 THE ANALYSIS OF EFFICACY OF TENOFOVIR BASED-RESCUE THERAPY IN CHRONIC HEPATITIS B PATIENTS ACCORDING TO GENOTYPIC RESISTANT MUTATION TO NUCLEOS(T)IDE ANALOGUES
Seong Hee Kang*, Jong Eun Yeon, Young Sun Lee, Tae Suk Kim, Yang Jae Yoo, Sang Jun Suh, Young Kul Jung, Ji Hoon Kim, Yeon Seok Seo, Hyung Joon Yim, Kwan Soo Byun, Korea, South

FRI-143 ANTIVIRAL EFFICACY AND HOST IMMUNE RESPONSE INDUCTION WITH SB 9200, AN ORAL PRODRUG OF THE DINUCLEOTIDE SB 9000, IN COMBINATION WITH ENTECAVIR IN THE WOODCHUCK MODEL OF CHRONIC HEPATITIS B
Kyle Korolowicz, Maria Balarezo, Radhakrishnan Iyer, Seetharamaiyer Padmanabhan, Dillon Cleary, Rayomand Gimi, Anjaneyulu Sheri, Manasa Suresh, Changsuek Yon, Robin Tucker, Nezam Afdhal, Stephan Menne*, United States
FRI-144  PREDICTING HBSAG CLEARANCE RESPONSES DURING ARC-520 RNA INTERFERENCE (RNAI) THERAPY BASED ON HBSAG EPITOPE PROFILE ANALYSIS
Renae Walsh, Rachel Hammond, Lilly Yuen, Joshua Deerain, Bruce Given, Thomas Schluep, Man-Fung Yuen, Henry Lik-Yuen Chan, Ching-Lung Lai, James Hamilton, Johnson Yn Lau, Carlo Ferrari, Robert G Gish, Stephen A. Locarnini*, Australia

FRI-145  DELAYED SEROLOGIC RESPONSE IN MULTI-DRUG RESISTANT CHB PATIENTS WITH TENOFOVIR AND ENTECAVIR COMBINATION THERAPY IN REAL CLINICAL PRACTICE
Sung Won Lee*, Jung Hyun Kwon, Young Woon Kim, Jeong Won Jang, Soon Woo Nam, Nam Ik Han, Korea, South

FRI-146  GENETIC VARIATION IN FCER1A GENE PREDICTS SUSTAINED HBSAG CLEARANCE IN EAST-ASIAN PATIENTS TREATED WITH PEGYLATED INTERFERON ALFA-2A (40KD): THE ‘PEG-BE-YOND’ STUDY
Lai Wei, Vedran Pavlovic*, Aruna T. Bansal, Xiao-Ping Chen, Graham R. Foster, Hua He, Jia-Horng Kao, Pietro Lampertico, Yun-Fan Liaw, Adriana Motoc, George Papatheodoridis, Teerha Piratvisuth, Robert Plesniak, Cynthia Wat, United Kingdom

FRI-147  LONG-TERM FOLLOW-UP OF EUROPEAN HBEAG-NEGATIVE CHRONIC HEPATITIS B-INFECTED PATIENTS ON ANTIVIRAL TREATMENT
Viola Knop*, Tania Welzel, Charlotte Schreiber, Ursula Hubrich, Kathrin Sprinzl, Bernd Kronenberger, Stefan Zeuzem, Christoph Sarrazin, Germany

FRI-148  HBEAG SEROCONVERSION RATES AFTER FIVE YEARS OF FOLLOW-UP IN PATIENTS TREATED WITH PEGINTERFERON ALFA-2A (40KD) IN NEPTUNE: FINAL RESULTS OF THE SON OF NEPTUNE LONG-TERM FOLLOW-UP STUDY
Wan-Long Chuang*, Jidong Jia, Henry Lik-Yuen Chan, Kwang-Hyub Han, Tawesak Tanwandee, Deming Tan, Xinyue Chen, Edward Gane, Teerha Piratvisuth, Liang Chen, Qing Xie, Joseph Jao-Yiu Sung, Diethelm Messinger, Cynthia Wat, Georgios Bakalos, Yun-Fan Liaw, Taiwan
<table>
<thead>
<tr>
<th>POSTERS / FRIDAY 15 APRIL 2016</th>
</tr>
</thead>
</table>

**Viral hepatitis: Hepatitis B & D – clinical (therapy, new compounds, resistance) (Cont.)**

<table>
<thead>
<tr>
<th>FRI-149</th>
<th>IL-33 CLEAR HEPATITIS B VIRUS IN HYDRODYNAMIC HBV MOUSE MODEL THROUGH ST2 EXPRESSED ON NK CELL</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Xiuzhu Gao*, Xiumei Chi, Xiaomei Wang, Hongxin Xu, Ruihong Wu, Dong Li, Damo Xu, Junqi Niu, China</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>FRI-150</th>
<th>MULTICENTER RANDOMIZED CONTROLLED TRIAL OF SWITCHING TO TENOFOVIR DISOPROXIL FUMARATE MONOTHERAPY IN LAMIVUDINE-RESISTANT CHRONIC HEPATITIS B PATIENTS WITH UNDETECTABLE HBV VIRAL LOAD UNDER LAMIVUDINE/ADEFOVIR ADD-ON THERAPY: INTERIM ANALYSIS</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>FRI-151</th>
<th>SEQUENTIAL COMBINATION TREATMENT OF PEGYLATED INTERFERON CAN ACHIEVE FURTHER SEROLOGICAL RESPONSE IN LONG-TERM ENTECAVIR TREATMENT EXPERIENCED HBEAG-POSITIVE PATIENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Yiqi Yu*, Guojun Li, Shaoling Chen, Jing Wang, Lingyun Shao, Wenhong Zhang, China</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>FRI-152</th>
<th>SWITCHING TENOFOVIR DISOPROXIL FUMARATE (TDF) PLUS ENTECAVIR COMBINATION THERAPY TO TDF MONOTHERAPY IS SAFE AND EFFICACIOUS IN PATIENTS WITH MULTIPLE DRUG-RESISTANT CHRONIC HEPATITIS B: RANDOMIZED TRIAL</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Young-Suk Lim*, Byung Chul Yoo, Kwan Soo Byun, So Young Kwon, Yoon Jun Kim, Jihyun An, Han Chu Lee, Yung Sang Lee, Korea, South</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>FRI-153</th>
<th>THE EFFICACY AND SAFETY OF PEGINTERFERONA-2A AND NUCLEOS(T)IDE ANALOGUES TREATMENTS IN HBEAG POSITIVE CHRONIC HEPATITIS B WITH ACUTE EXACERBATION</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Su Lin, Qiaoxia Ye, Mingfang Wang, Zhiyuan Weng, Jiajing Jiang, Yueyong Zhu*, China</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>FRI-154</th>
<th>THE EFFICACY AND SAFETY OF TELBIVUDINE OR TENOFOVIR IN PREGNANCY FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HBV</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Yanqiong Zhang, Quanxin Wu, Hongfei Huang, Yuming Wang*, China</td>
</tr>
</tbody>
</table>
Viral hepatitis: Hepatitis C – clinical (except therapy)

FRI-155 INCREASING INCIDENCE OF CANCER IN PERSONS LIVING WITH HIV COINFECTED WITH HCV: AN ADDITIONAL IMPACT OF HCV INFECTION?
Alvaro Mena*, Héctor Meijide, Iria Rodríguez-Osorio, Ángeles Castro-Iglesias, Sonia Pértega, Guillermo Rodríguez-Martínez, Berta Pernas, Josefa Baliñas, José D. Pedreira, Eva Poveda, Spain

FRI-156 STATIN USE IS ASSOCIATED WITH A LOWER RATE OF LIVER CANCER IN PATIENTS WITH CHRONIC HEPATITIS C
Anders Nyberg*, Ekaterina Sadikova, Jiaxiao Shi, T. Craig Cheetham, Kevin Chiang, Zobair Younossi, Lisa Nyberg, United States

Barbara Rossetti*, Francesca Bai, Alessandro Tavelli, Massimo Galli, Andrea Antinori, Francesco Castelli, Giampietro Pellizzer, Alessandro Cozzi Lepri, Stefano Bonora, Antonella d’Arminio Monforte, Massimo Puoti, Andrea De Luca, Italy

FRI-158 GENETIC AND METABOLIC FACTORS RELATED WITH INSULIN RESISTANCE IN CHRONIC HEPATITIS C
Beatriz Mateos-Muñoz*, Elena Garcia-Martin, Maria J Torrecjón, Maria J Devesa-Medina, Gara Esguevillas, Maria C Cárdenas, Cristina Fernandez, Miguel Carballo, Jose A. Agundez, Jose M. Ladero, Spain

FRI-159 PATIENTS WITH CHRONIC HEPATITIS C CAN BE IDENTIFIED BY THEIR GUT MICROBIOTA
Benjamin Heidrich*, Marius Vital, Iris Plumeier, Silke Kahl, Janina Kirchner, Lisa Sollik, Szilvia Ziegert, Michael Manns, Heiner Wedemeyer, Dietmar Pieper, Germany

FRI-160 RISKS OF LIVER COMPLICATIONS AFTER A LONG-TERM FOLLOW-UP IN PATIENTS WITH CHRONIC HEPATITIS C WITH SUSTAINED VIROLOGIC RESPONSE
Blaise Kutala*, Marie-Pierre Ripault, Emilie Estrabaud, Feryel Khelifa-Mouri, Reda Nait, Nathalie Boyer, Nathalie Giuily, Corinne Castelnau, Tarik Asselah, Patrick Marcellin, France
FRI-161  LONG-TERM ASSESSMENT OF RENAL FUNCTION IN PATIENTS FOLLOWING ANTIVIRAL THERAPY FOR CHRONIC HEPATITIS C VIRUS INFECTION
Chen-Hua Liu*, Chih-Lin Chen, Chun-Jen Liu, Tung-Hung Su, Hung-Chih Yang, Pei-Jer Chen, Ding-Shinn Chen, Jia-Horng Kao, Taiwan

FRI-162  EFFECT OF AMIODARONE AND HCV DIRECT-ACTING ANTIVIRAL AGENTS ON CARDIAC CONDUCTION IN NONCLINICAL STUDIES
Gongxin Liu, Chin H. Tay*, Sridharan Rajamani, Adrian Ray, Luisa Stamm, Jonathan Vick, Megan Wilichinsky, John McHutchison, Diana Brainard, United States

FRI-163  THE ADDITION OF RIBAVIRIN IS ASSOCIATED WITH A SIGNIFICANTLY REDUCED QUALITY OF LIFE IN PATIENTS TREATED WITH IFN-FREE DIRECT-ACTING ANTIVIRAL THERAPY
Christoph Hoener Zu Siederdissen*, Katja Deterding, Kerstin Port, Michael P. Manns, Heiner Wedemeyer, Markus Cornberg, Germany

FRI-164  GLOMERULAR AND TUBULAR KIDNEY INVOLVEMENT IN HCV CHILD-A CIRRHOSIS
Donatella Palazzo*, Elisa Biliotti, Francesca Tinti, Alessandra Bachetoni, Paola Perinelli, Andrea Cappoli, Maria Domenica D’Alessandro, Stefania Grieco, Raffaella Labriola, Miroslava Subic, Ilaria Umbro, Paola Rucci, Anna Paola Mitterhofer, Gloria Taliani, Italy

FRI-165  COBAS(R) HCV GT FOR USE ON THE COBAS(R) 4800 SYSTEM: A HIGHLY ACCURATE HCV GENOTYPING TEST
Steven A. Herman, Elizabeth Perez, Ed G. Marins*, Tanja Schneider, Annemarie Berger, Christoph Sarrazin, United States

FRI-166  LONG-TERM FOLLOW-UP OF PATIENTS WITH CHRONIC HCV INFECTION FOLLOWING TREATMENT WITH DIRECT ACTING ANTIVIRAL REGIMENS: MAINTENANCE OF SVR, PERSISTENCE OF RESISTANCE MUTATIONS AND CLINICAL OUTCOMES
Eric J. Lawitz’, Peter Ruane, Catherine Stedman, Graham Foster, Robert H. Hyland, Sarah Coogan, Stephanie Moody, Hadas Dvory-Sobol, Steven J. Knox, Diana M. Brainard, Armand Abergel, Kosh Agarwal, Ziad Younes, Christian Schwabe, United States
FRI-167  THE EFFECT OF RENAL OR HEPATIC IMPAIRMENT ON THE PHARMACOKINETICS OF GS-9857, A PAN-GENOTYPIC HCV NS3/4A PROTEASE INHIBITOR
Eric Lawitz*, Thomas Marbury, Brian J. Kirby, Nicholas T. Au, Anita Mathias, Luisa M. Stamm, Helen Wei, Karim Sajwani, Gernot Klein, Ed Gane, Richard Robson, United States

FRI-168  DRUG-DRUG INTERACTION PROFILE OF SOFOSBUVIR/VELPATASVIR FIXED-DOSE COMBINATION
Erik Mogalian*, John McNally, Gong Shen, Lisa Moorehead, Karim Sajwani, Bill Smith, John Ling, Anita Mathias, United States

FRI-169  STEADY-STATE PHARMACOKINETICS OF SOFOSBUVIR AND VELPATASVIR IN HCV-INFECTED SUBJECTS WITHOUT CIRRHOSIS, WITH COMPENSATED CIRRHOSIS, OR WITH DECOMPENSATED CIRRHOSIS IN THE PHASE 3 ASTRAL STUDIES
Erik Mogalian*, Di An, Yanni Zhu, Yvonne Maruca, Cara Casey, John McNally, John Ling, Anita Mathias, United States

FRI-170  NEX t-GENERATION SEQUENCING ANALYSIS OF NS5A AND NS5B MINOR RESISTANCE-ASSOCIATED VARIANTS IN PATIENTS WITH HCV GENOTYPE 3 INFECTION WHO FAILED TREATMENT WITH DACLATASVIR PLUS SOFOSBUVIR
Fiona McPhee*, Dennis Hernandez, Nannan Zhou, United States

FRI-171  NEXT GENERATION SEQUENCING FOR HCV GENOTYPING AND OPTIONAL IDENTIFICATION OF RESISTANCE-ASSOCIATED VARIANTS
Elian Rakhmanaliev, Zhang Rui, Wen Huang, Kok Siong Poon, Wen Chua Cui, Joo Khoo Mui, Evelyn Koay, Ekawat Passomsombut, Wasun Chanratita, Gerd Michel*, Singapore
### Viral hepatitis: Hepatitis C – clinical (except therapy) (Cont.)

<table>
<thead>
<tr>
<th>Code</th>
<th>Title</th>
<th>Authors</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>FRI-173</td>
<td>HCV ERADICATION DOES NOT IMPACT GUT DYSBIOSIS OR SYSTEMIC INFLAMMATION IN CIRRHOTIC PATIENTS</td>
<td>Jasmohan S S. Bajaj*, Richard Sterling, Phillip Hylemon, Daniel Nixon, Michael Fuchs, Douglas Heuman, Masoumeh SIkaroodi, Patrick Gillevet, United States</td>
<td>United States</td>
</tr>
<tr>
<td>FRI-174</td>
<td>HEPATOTOXICITY WITH CHEMOTHERAPY IN PATIENTS INFECTED WITH HEPATITIS C</td>
<td>Jean-Luc Szpakowski*, Lue-Yen Tucker, David Baer, Marypat Pauly, United States</td>
<td>United States</td>
</tr>
<tr>
<td>FRI-175</td>
<td>LIVER STIFFNESS MEASUREMENT AFTER SUCCESSFUL ANTI-VIRAL THERAPY IN HEPATOCELLULAR CARCINOMA RISK ASSESSMENT FOR CHRONIC HEPATITIS C PATIENTS</td>
<td>Jing-Houng Wang*, Yi-Hao Yen, Chao-Hung Hung, Chien-Hung Chen, Chuan-Mo Lee, Sheng-Nan Lu, Taiwan</td>
<td>Taiwan</td>
</tr>
<tr>
<td>FRI-176</td>
<td>HIGH RESOLUTION ANALYSIS FOR GENOTYPES AND SUB-GENOTYPES IDENTIFICATION IN HEPATITIS C REVEALS THE IMPORTANCE OF MIXED INFECTIONS FOR OPTIMAL THERAPY</td>
<td>Jose A Del Campo*, Manuel Parra, Silvia Delgado, Marta Garcia-Valdecasas, Josep Gregori, Josep Quer, Samuel Bernal, José C Palomares, Lourdes Grande, Manuel Romero-Gómez, Spain</td>
<td>Spain</td>
</tr>
<tr>
<td>FRI-177</td>
<td>HIV/HCV COINFECTION IN SPAIN: PREVALENCE AND PATIENT CHARACTERISTICS</td>
<td>Juan Berenguer*, Antonio Rivero, Inmaculada Jarrin, Maria J Núñez, Carmen Quereda, Manel Crespo, Maria J Téllez, Pere Domingo, José A Iribarren, Juan González-García, Spain</td>
<td>Spain</td>
</tr>
<tr>
<td>FRI-178</td>
<td>HIGH RISK FOR HEPATOCELLULAR CARCINOMA IN CIRRHOTIC PATIENTS WITH SVR FOLLOWING IFN-FREE DAA TREATMENT WITHIN 1 YEAR FOLLOW-UP</td>
<td>Karin Kozbial*, Rafael Stern, Clarissa Freissmuth, Sandra Beinhardt, Albert Friedrich Stättermayer, Petra Munda, Michael Trauner, Peter Ferenci, Harald Hofer, Austria</td>
<td>Austria</td>
</tr>
</tbody>
</table>
FRI-179  SUSTAINED VIROLOGICAL RESPONSE AFTER INTERFERON-BASED THERAPY FOR CHRONIC HEPATITIS C AND ITS ASSOCIATION WITH REDUCED ALL-CAUSE MORTALITY AND LIVER-RELATED MORTALITY

Lisa M. Nyberg*, Xia Li, Su-Jau Yang, T. Craig Cheetham, Kevin Chiang, Jose Pio, Susan Caparosa, Zobair Younossi, Anders Nyberg, United States

FRI-180  GENDER DIFFERENCES IN HCV CHRONIC LIVER DISEASE: A REAL LIFE EVALUATION IN PITER (PIATTAFORMA ITALIANA PER LO STUDIO DELLA TERAPIA DELLE EPATITI VIRALI) COHORT STUDY

Loreta Kondili*, Maria Giovanna Quaranta, Loredana Falzano, Massimiliano Di Gregorio, Maurizia Brunetto, Anna Linda Zignego, Alessia Ciancio, Alfredo Di Leo, Maria Rendina, Giovanni Raimondo, Carlo Ferrari, Antonio Craxi, Gloria Taliani, Guglielmo Borgia, Ivan Gentile, Teresa Antonia Santantonio, Adele Giammario, Pierluigi Blanc, Giovanni Battista Gaeta, Antonio Gasbarrini, Massimo Siciliano, Luchino Chessa, Elke Maria Erne, Donatella Ieluzzi, Francesco Paolo Russo, Pietro Andreone, Maria Vinci, Carmine Coppola, Liliana Chemello, Salvatore Madonia, Gabriella Verucchi, Marcello Persico, Massimo Zuin, Alfredo Alberti, Massimo Puoti, Gerardo Nardone, Vincenzo De Maria, Marco Massari, Giuseppe Montalto, Giuseppe Foti, Maria Grazia Rumi, Andrea Giacometti, Antonio Benedetti, Gianpiero D’Offizi, Mario Strazzabosco, Sivia Fargion, Gioacchino Angarano, Alessandro Federico, Nicola Caporaso, Claudio Mastroianni, Pierluigi Toniutto, Massimo Colombo, Adriano Lazzarin, Carlo Torti, Massimo Andreoni, Floriano Rosina, Claudio Viscoli, Stefano Vella, Erica Villa, Italy
FRI-181  **HCV-RELATED MIXED CRYOGLOBULINEMIA: DATA FROM PITER, A NATIONWIDE ITALIAN HCV COHORT STUDY**
Loretta Kondili*, Liliana Elena Weimer, Alessandra Mallano, Luca Fucili, Maurizio Massella, Maria Vinci, Guglielmo Borgia, Maurizia Brunetto, Lidia Surace, Giovanni Battista Gaeta, Liliana Chemello, Pietro Andreone, Giovanni Raimondo, Roberto Filomnia, Marcello Persico, Massimo Puoti, Maria Grazia Rumi, Antonio Benedetti, Silvia Fargion, Donatella Ieluzzi, Gerardo Nardone, Foti Giuseppe, Alessia Ciancio, Gloria Taliani, Elisa Biliotti, Salvatore Madonia, Brigida Stagno, Alfredo Alberti, Marco Massari, Floriano Rosina, Giuseppe Mazzella, Alfredo Di Leo, Andrea Iannone, Carlo Ferrari, Alessandra Orlandini, Monica Monti, Teresa Antonia Santantonio, Luchino Chessa, Elke Maria Erne, Carmine Coppola, Massimo Andreoni, Franco Baldelli, Mario Mondelli, Pierluigi Blanc, Antonio Gasbarrini, Gabriella Verucchi, Massimo Colombo, Marta Borghi, Antonio Craxì, Salvatore Petta, Erica Villa, Olga Patti, Francesco Paolo Russo, Mario Strazzabosco, Stefano Vella, Anna Linda Zignego, Italy

FRI-182  **THE IL10-819C/T IS ASSOCIATED WITH MAJOR DEPRESSIVE DISORDER IN PATIENTS WITH CHRONIC HEPATITIS C**
Luciana R. Cunha, Diego A. Vieira, Yala G. Giampietro, Adriana D. Gomes, César Faria Jr, Rosângela Teixeira, Olindo A. Martins Filho, Fernando S. Neves, Gifone A. Rocha, Dulciene M. Queiroz, Luciana D. Silva*, Brazil

FRI-183  **THE PRESENCE OF DIABETES MELLITUS IS A STRONG RISK FACTOR FOR HEPATOCELLULAR CARCINOMA IN HEPATITIS C INFECTED PATIENTS WITH ADVANCED FIBROSIS OR CIRRHOSIS WHO HAVE ACHIEVED SUSTAINED VIROLOGICAL RESPONSE**
Magnus Hedenstierna*, Ali Nangarhari, Ola Weiland, Soo Aleman, Sweden

FRI-184  **INCIDENCE OF HCV REINFECTION AMONG TREATED INDIVIDUALS WITH RECENTLY ACQUIRED INFECTION**
Marianne Martinello*, Kathy Petoumenos, Jason Grebely, Ed Gane, Margaret Hellard, David Shaw, Joe Sasdeusz, Tanya Applegate, Francois Lamoury, Barbara Yeung, Laurence Maire, Gregory Dore, Gail Matthews, Australia
FRI-185  
**PREDICTION OF HEPATOCELLULAR CARCINOMA AFTER SUCCESSFUL ERADICATION OF HEPATITIS C BY SIMPLE AND READILY AVAILABLE FACTORS: NATIONWIDE MULTICENTER STUDY BY JAPANESE RED CROSS LIVER STUDY GROUP**
Masayuki Kurosaki*, Nobuharu Tamaki, Yutaka Yasui, Namiki Izumi, Japan

FRI-186  
**THE APPLICABILITY OF HEPATOCELLULAR CARCINOMA RISK PREDICTION SCORING SYSTEM IN A US PATIENT COHORT WITH CHRONIC HEPATITIS C INFECTION**
Mingjuan Jin, Changqing Zhao’, Mei-Hsuan Lee, An K. Le, Joseph Hoang, Nghiem B. Ha, Vanessa Trieu, Hwai-I Yang, Chien-Jen Chen, Mindie Nguyen, United States

FRI-187  
**THE BC HEPATITIS TESTERS COHORT: THE POPULATION LEVEL HEPATITIS C CASCADE OF CARE IN BRITISH COLUMBIA, CANADA**
Naveed Janjua’, Margot Kuo, Amanda Yu, Wong Stanley, Maria Alvarez, Jason Wong, Mark Tyndall, Mel Krajden, Canada

FRI-188  
**THE ASSOCIATION BETWEEN PNPLA3 POLYMORPHISMS AND FIBROSIS PROGRESSION AND HEPATOCELLULAR CARCINOMA DEVELOPMENT IN PATIENTS WITH CHRONIC HEPATITIS C**
Nobuharu Tamaki’, Masayuki Kurosaki, Mayu Higuchi, Hitomi Takada, Natsuko Nakakuki, Yutaka Yasui, Shoko Suzuki, Hiroyuki Nakanishi, Jun Itakura, Namiki Izumi, Japan

FRI-189  
**INSIGHT INTO HEPATITIS C VIRUS INFECTION; A COHORT STUDY OF WOMEN INFECTED WITH CONTAMINATED ANTI-D IMMUNOGLOBULIN IN IRELAND BETWEEN 1977 AND 1979**
Patricia Garvey’, Lelia Thornton, Niamh Murphy, Paula Flanagan, Suzanne Norris, Ireland

FRI-190  
**INTERFERON-FREE DAA REGIMENS DECREASE PORTAL PRESSURE AND HALT HISTOLOGICAL NECROINFLAMMATION IN HIV/HCV-COINFECTED PATIENTS**
Philipp Schwabl’, Mattias Mandorfer, Sebastian Steiner, Bernhard Scheiner, Theresa Bucsics, Maximilian Aichelburg, Katharina Grabmeier-Pfistershammer, Wolfgang Sieghart, Arnulf Fertilisch, Michael Trauner, Thomas Reiberger, Markus Peck-Radosavljevic, Austria
Viral hepatitis: Hepatitis C – clinical (except therapy) (Cont.)

**FRI-191** IMPAIRED ANTI-HBV VACCINE RESPONSE IN NON-CIRRHOTIC CHRONIC HCV PATIENTS IS NOT OVERCOME BY DOUBLE DOSE REGIMEN: A RANDOMIZED CONTROL TRIAL
Mario G. Pessoa, Roseane Porto*, Daniel Mazo, Claudia P. Oliveira, Norah Terrault, Jennifer Dodge, Patricia M. Zitelli, Joao R. Pinho, Marta Lopes, Flair J. Carrilho, Brazil

**FRI-192** HEPATITIS C VIRUS SPREAD AMONG FAMILY MEMBERS OF HCV INFECTED CHILDREN IN EGYPT
Sana Barakat*, Amel Mansour, Marsail Shenoda, Egypt

**FRI-193** THE ADDITIONAL IMPACT OF CHRONIC KIDNEY DISEASE ON CARDIOVASCULAR OUTCOMES AND DEATH AMONG HCV PATIENTS
Sara Tartof*, Jean Marie Arduino, Rong Wei, Jin-Wen Hsu, Kevin Rubenstein, Haihong Hu, Michael Horberg, Stephen Derose, Carla Rodriguez, United States

**FRI-194** MORTALITY AMONG PATIENTS WITH CHRONIC HEPATITIS C AND CIRRHOSIS IN DENMARK – A NATIONWIDE DANHEP COHORT STUDY
Sofie Hallager*, Peer Brehm Christensen, Anne Mette Rye Clausen, Alex Lund Laursen, Axel Møller, Poul Schlichting, Lone Galmstrup Madsen, Jan Gerstoft, Suzanne Lunding, Karin Elmegaard Grønbæk, Henrik Bygum Krarup, Nina Magrethe Weis, Denmark

**FRI-195** HEPATITIS C VIRUS CORE ANTIGEN: A SIMPLIFIED TREATMENT MONITORING TOOL, INCLUDING FOR POST-TREATMENT RELAPSE
Francois Lamoury, Angelica Soker, Danica Martinez, Behzad Hajarizadeh, Evan Cunningham, Philip Bruggmann, Graham Foster, Olav Dalgard, Brian Conway, Geert Robaeyts, Tracy Swan, Markus Backmund, Pip Marks, Jason Grebely, Gregory J. Dore, Tanya L. Applegate*, Australia
FRI-196
YI

**BIPHASIC KINETICS OF HCV-RNA DECAY IS ACCOMPANIED BY AN EVEN FASTER AMINOTRANSFERASES NORMALIZATION IN ALL-DAA TREATED CIRRHOTIC PATIENTS: A DIFFERENT SCENARIO FROM INTERFERON-BASED THERAPIES**

Valeria Cento, Domenico Di Carlo, Thi Huyen Tram Nguyen, Elisa Biliotti, Caterina Pasquazzi, Laura Gianserra, Daniele Di Paolo, Vincenza Calvaruso, Elisabetta Teti, Maddalena Cerrone, Dante Romagnoli, Michela Melis, Elena Danieli, Barbara Menzaghi, Ennio Polilli, Massimo Siciliano, Laura Ambra Nicolini, Antonio Di Biagio, Carlo Federico Magni, Francesco Paolo Antonucci, Velia Chiara Di Maio, Roberta Alfieri, Loredana Sarmati, Paolo Casalino, Sergio Bernardini, Valeria Micheli, Giuliano Rizzardini, Erica Villa, Giustino Parruti, Tiziana Quirino, Massimo Puoti, Sergio Babudieri, Antonella D’Arminio Monforte, Massimo Andreoni, Antonio Craxi, Ilaria Lenci, Mario Angelico, Gloria Taliani, Jeremie Guedj, Francesca Ceccherini-Silberstein, Carlo Federico Perno, Italy

FRI-197

**DXN VERIS SYSTEM FOR HCV VIRAL LOAD MONITORING IN THE ERA OF SECOND WAVE DIRECT-ACTING ANTIVIRAL AGENTS**

Valeria Micheli, Alessandra Lombardi, Alessandro Mancon, Davide Mileto, Nadia Zanchetta, Carlo Federico Magni, Laura Milazzo, Elena Angeli, Guido Gubertini, Massimo Galli, Maria Rita Gismondo, Italy

FRI-198
YI

**MODEL FOR ENDSTAGE LIVER DISEASE (MELD) SCORE CHANGES DURING HEPATITIS C VIRUS TREATMENT OF PATIENTS WITH CIRRHOSIS PREDICTS LONG-TERM PORTAL HYPERTENSIVE COMPLICATIONS**

Varun Saxena, Lisa Nyberg, Aditi Dasgupta, Stephanie Straley, Lisa Catalli, Anders Nyberg, Norah Terrault, United States

FRI-199

**CHARACTERIZATION OF THE LONGITUDINAL FIBROSIS CHANGES IN HEPATITIS C PATIENTS AFTER VIROLOGIC CURE: A META-ANALYSIS OF THE HISTOLOGIC DATA**

Yan Wang, Zhipeng Liu, Xuewu Wei, Ting Chen, Chuhong Huang, China
FRI-200 IMPRESSIVE GAINS IN PATIENT-REPORTED OUTCOMES ARE OBSERVED IN CHRONIC HEPATITIS C PATIENTS WITH OR WITHOUT CIRRHOSIS WHO ARE TREATED WITH SOFOSBUVIR AND VELPATASVIR: RESULTS FROM ASTRAL-1, -2, -3 AND -4
Zobair M. Younossi*, Maria Stepanova, Jordon Feld, Stefan Zeuzem, Mark Sulkowski, Graham R. Foster, Alessandra Mangia, Michael Charlton, Jacqueline G. O’Leary, Michael P. Curry, Sharon Hunt, United States

FRI-201 THE LEVELS OF MONOAMINE NEUROTRANSMITTERS IN HCV PATIENTS TREATED WITH LEDIPASVIR (LDV)/ SOFOSBUVIR (SOF)
Pegah Golabi, Elzafir Elsheikh, Azza Karrar, James M. Estep, Issah Younossi, Maria Stepanova, Lynn Gerber, Zobair M. Younossi*, United States
POSTERS

SATURDAY 16 APRIL 2016
<table>
<thead>
<tr>
<th>SAT-344</th>
<th>AUTOIMMUNE HEPATITIS HAS BEEN EMERGING IN JAPAN</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kazunari Tanaka*, Jong-Hon Kang, Takeshi Matsui, Yuhshi Kimura, Kunihiko Tsuji, Yuhki Yosino, Yoshihisa Kodama, Yasuo Sakurai, Akihiro Takiyama, Toshiya Shinohara, Hiroyuki Maguchi, Japan</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>SAT-345</th>
<th>CD14 IS ASSOCIATED WITH BILIARY STRICTURE FORMATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kilian Friedrich*, Karl-Heinz Weiss, Wolfgang Stremmel, Peter Schemmer, Daniel N. Gotthardt, Germany</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>SAT-346</th>
<th>THE EFFECT OF B-CELL DEPLETION ON B-CELL ACTIVATING FACTOR IN PRIMARY BILIARY CHOLANGITIS/CIRRHOSIS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Laura Jopson*, Jeremy Palmer, Achilleas Floudas, David Jones, United Kingdom</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>SAT-347</th>
<th>LIPID ANTIGENS IN BILE FROM PATIENTS WITH LIVER DISEASES ACTIVATE NATURAL KILLER T CELLS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Laura Valestrand*, Natalie Lie Berntsen, Elisabeth Schrumpf, Tom H. Karlsen, Richard S. Blumberg, Espen Melum, Norway</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>SAT-348</th>
<th>REDUNDANT TOLERANCE MECHANISMS PREVENT AUTOIMMUNE LIVER INFLAMMATION IN MICE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lisa Leypoldt*, Alena Laschtowitz, Dorothee Schwinge, Christoph Schramm, Samuel Huber, Ansgar W. Lohse, Antonella Carambia, Johannes Herkel, Germany</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>SAT-349</th>
<th>AUTOIMMUNE HEPATITIS: CLINICAL, LABORATORY AND SURVIVAL ANALYSIS IN CHILDREN AND ADULTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lisa Perini*, Irene Franceschet, Nora Cazzagon, Chiara Mangini, Vincenzo Baldo, Annarosa Floreani, Italy</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>SAT-350</th>
<th>TIME COURSE OF CHOLESTATIC ALTERATIONS IN SEPTIC AND SURGICAL CRITICAL ILLNESSES</th>
</tr>
</thead>
<tbody>
<tr>
<td>Marc Jenniskens*, Sarah Derde, Sarah Vander Perre, Steven Thiessen, Thomas Durfour, Fabian Güiza, Greet Vanden Berghe, Lies Langouche, Belgium</td>
<td></td>
</tr>
</tbody>
</table>
| SAT-351  | **BEHAVIORAL PATTERNS OF TOTAL SERUM BILIRUBIN PRIOR TO MAJOR CLINICAL ENDPOINTS IN 3529 PATIENTS WITH PRIMARY BILIARY CHOLANGITIS**  
| SAT-352  | **IMPROVEMENT IN ESTIMATED LIVER TRANSPLANT FREE SURVIVAL AFTER 1 YEAR OF OBETICHOLIC ACID TREATMENT**  
Maren H. Harms*, Willem J. Lammers, Tonya Marmon, Richard Pencek, Henk R. van Buuren, Bettina E. Hansen, David Shapiro, Netherlands |
| SAT-353  | **PRESENTATION OF PRIMARY BILIARY CHOLANGITIS IN CLINICAL PRACTICE**  
Margaret Corrigan*, James Eden, Robert Mitchell-Thain, Gideon Hirschfield, Riadh Jazrawi, United Kingdom |
| SAT-354  | **BONE METABOLISM AND BONE MINERAL DENSITY IN PATIENTS WITH CHOLESTATIC AUTOIMMUNE LIVER DISEASES**  
Mariya Prashnova*, Karina Raikhelson, Natalya Marchenko, Andrey Baranovskiy, Lyudmila Palgova, Russia |
| SAT-355  | **ALTERATIONS IN BRAIN STRUCTURE AND FUNCTION IDENTIFIED IN CHOLESTATIC MICE USING MANGANESE-ENHANCED MRI NEUROIMAGING**  
Shannon Churchill-Smith, Anca Toma, Tom Johnson, Jeff Dunn, Mark G. Swain*, Canada |
| SAT-356  | **NEUROIMAGING EVIDENCE OF HIPPOCAMPAL CHANGES IN PRIMARY BILIARY CIRRHOSIS CONSISTENT WITH TISSUE INJURY OR STRESS**  
Victoria Mosher, Mark G. Swain*, Glenda MacQueen, Bradley G. Goodyear, Canada |
| SAT-357  | **MITIGATION OF PRURITUS DURING OBETICHOLIC ACID TREATMENT IN PATIENTS WITH PRIMARY BILIARY CIRRHOSIS: STRATEGIES AND SUCCESSES**  
Marlyn J Mayo*, Andreas Kremer, Ulrich Beuers, Tonya Marmon, Roya Hooshmand-Rad, Richard Pencek, David Shapiro, United States |
Autoimmune and hepato biliary disease 2 (Cont.)

SAT-358 MODULATION OF THE TRANSCRIPTION FACTORS SNAIL, SLUG AND TWIST IN RESPONSE TO BILIARY INJURY IN PRIMARY BILIARY CIRRHOSIS
Maryam Jan*, John Kirby, John Brain, United Kingdom

SAT-359 FEMALE PREDOMINANCE, LOW RATE OF PRIMARY SCLEROSING CHOLANGITIS-IBD PHENOTYPE, LOW RATE OF DOMINANT STRICTURES, CHOLANGIOCARCINOMA AND NEED FOR TRANSPLANTATION
Mihaela Lita*, Speranta Iacob, Razvan Iacob, Carmen Ester, Razvan Cerban, Liana Gheorghe, Romania

SAT-360 LOSS OF CELLULAR FLICE-INHIBITORY PROTEIN PROMOTES CHOLESTASIS-INDUCED HEPATOCELLULAR INJURY AND INFLAMMATION IN BILE DUCT LIGATED MICE
Nadine Gehrke*, Yvonne Alt, Michael Nagel, Marcus Schuchmann, Peter R. Galle, Jörn M. Schattenberg, Germany

SAT-361 HEPATOBILIARY SECRETION OF CONJUGATED BILE ACIDS IN HEALTHY HUMANS QUANTIFIED BY 11C-CHOLYLSARCOSINE PET
Nikolaj W. Orntoft*, Ole L. Munk, Kim Frisch, Peter Ott, Ludvik Bass, Susanne Keiding, Michael Sørensen, Denmark

SAT-362 HEPATOBILIARY SECRETION OF CONJUGATED BILE ACIDS IN PATIENTS WITH CHOLESTASIS QUANTIFIED BY 11C-CHOLYLSARCOSINE PET
Nikolaj W. Orntoft*, Ole L. Munk, Kim Frisch, Peter Ott, Ludvik Bass, Susanne Keiding, Michael Sørensen, Denmark

SAT-363 COMBINED DELETION OF HEPATIC ZO-1 AND ZO-2 INDUCES LOSS OF BILE DUCTS
Jianliang Xu, Noémi Van Hul*, Matias Caldez, Matthew Dewhurst, Philipp Kaldis, Walter Hunziker, Singapore

SAT-364 EXTRAHEPATIC AUTOIMMUNITY IN PATIENTS WITH AUTOIMMUNE HEPATITIS
Nora Cazzagon’, Irene Franceschet, Lisa Perini, Chiara Mangini, Laura Costa, Annarosa Floreani, Italy
SAT-365 YI
OVEREXPRESSION OF MIRNA-506 IN HUMAN CHOLANGIOCYTES CAUSES PRIMARY BILIARY CHOLANGITIS-LIKE FEATURES INCLUDING MITOCHONDRIAL DYSFUNCTION AND INCREASED SENSITIVITY TO APOPTOSIS

SAT-366 YI
MYCOPHENOLATE MOFETIL FOR THE TREATMENT OF AUTOIMMUNE HEPATITIS IN CHILDREN
Olena Kostyrko*, Petr Shumilov, Natalia Shigoleva, Russia

SAT-367
CORRELATION OF NON-INVASIVE MARKERS OF LIVER FIBROSIS IN PATIENTS WITH PRIMARY SCLEROSING CHOLANGITIS: A VALIDATION COHORT
Peter Eddowes*, Palak Trivedi, Margaret Corrigan, James Ferguson, Gideon Hirschfield, United Kingdom

SAT-368 YI
MODULATION OF T CELL RESPONSES IN PRIMARY BILIARY CHOLANGITIS PATIENTS BY BILE ACID RECEPTOR SIGNALLING
Rachel E. Etherington*, Benjamin Millar, Claire Hardie, Barbara Innes, John Brain, David Jones, John Kirby, United Kingdom

SAT-369
MEDICAL TREATMENTS IN PATIENTS WITH PRIMARY SCLEROSING CHOLANGITIS DIFFER BETWEEN EUROPE AND NORTH AMERICA
Rachel Gomel*, Ricky Safer, Keith Lindor, Greg Everson, Christopher Bowlus, Canada

SAT-370 YI
ANALYSIS OF PREDICTIVE FACTORS OF NON RESPONSE TO THERAPY IN AUTOIMMUNE HEPATITIS-PRIMARY BILIARY CIRRHOSIS OVERLAP SYNDROMES A RETROSPECTIVE SINGLE-CENTER EXPERIENCE
Raffaele Licinio*, Antonio Facciorusso, Nicola Maurizio Castellaneta, Maria Rendina, Sonia Carparelli, Alfredo Di Leo, Italy
Autoimmune and hepato biliary disease 2 (Cont.)

SAT-371

YI

NEUROFUNCTIONAL CHARACTERIZATION OF PATIENTS WITH PRIMARY BILIARY CHOLANGITIS AND FATIGUE

Roman Zenouzi*, Janina von der Gablentz, Marcus Heldmann, Martin Göttlich, Anja Fellbrich, Christina Weiler-Normann, Marcial Sebode, Christoph Schramm, Thomas F. Münte, Ansgar W. Lohse, Germany

SAT-372

GENOTYPE-PHENOTYPE ANALYSIS ACROSS 130,422 GENETIC VARIANTS IDENTIFIES RSPO3 AS THE FIRST GENOME-WIDE SIGNIFICANT MODIFIER GENE IN PRIMARY SCLEROSING CHOLANGITIS


SAT-373

A NOVEL COMMON VARIANT IN CLDN14 IS ASSOCIATED WITH PRIMARY BILIARY CIRRHOSIS

Ruqi Tang*, Yiran Wei, Zhiqiang Li, Haoyan Chen, Michael F. Seldin, M. Eric Gershwin, Wilson Liao, Yongyong Shi, Xiong Ma, China
SAT-374 DECREASED MIR-425 INDUCED INFLAMMATORY CYTOKINE PRODUCTION VIA N-RAS UPREGULATION IN CD4+ T CELLS OF PRIMARY BILIAR CHOLANGITIS

Ryo Nakagawa*, Ryosuke Muroyama, Kazuhiko Koike, Chisato Saeki, Sayaka Ito, Sayuri Morimoto, Kaku Goto, Yasuo Matsubara, Naoya Kato, Mikio Zeniya, Japan

SAT-375 GP210 AND/OR SP100 AUTOANTIBODIES IN PRIMARY BILIARY CIRRHOSIS: PREDICTORS OF CIRRHOSIS/AUTOIMMUNE (AIH) OVERLAP SYNDROME?

Oluwatosin Taiwo, Sanju Mathew*, Jeremy Van Vlymen, Sarah Deacock, Aftab Ala, United Kingdom

SAT-376 HELICOBACTER PYLORI AS A MICROBIAL ANTIGEN IN IGG4-RELATED DISEASE

Emma L. Culver*, Wouter Smit, Caroline Evans, Ross Sadler, Tamsin Cargill, Lai-Mun Wang, Paul Klenerman, Berne Ferry, Eleanor Barnes, United Kingdom

SAT-377 RESCUE WITH STEROIDS IN PATIENTS WITH AUTOIMMUNE ACUTE JAUNDICED HEPATITIS

Victorio Cervera, Maria Eugenia Serio, Valeria Descalzi, Sebastian Raffa*, Argentina

SAT-378 CHANGES IN NUCLEAR RECEPTOR EXPRESSION INDUCED BY CHOLESTASIS IN MOUSE LIVER CELLS

Ester Gonzalez-Sanchez*, Delphine Firrincieli, Chantal Housset, Nicolas Chignard, France

SAT-379 GUT-LIVER AXIIS IN CYSTIC FIBROSIS: LACK OF ASSOCIATION BETWEEN INTESTINAL INFLAMMATION AND LIVER DISEASE IN ADULT CYSTIC FIBROSIS PATIENTS AFTER LUNG TRANSPLANTATION

Emina Halilbasic*, Katharina Staufer, Daniela Schmidt, Simon Schick, Andrea Brichta, Peter Jaksch, Walter Klepetko, Harald Vogelsang, Michael Trauner, Lili Kazemi-Shirazi, Austria

SAT-380 HUMAN LEUCOCYTE ANTIGEN ASSOCIATIONS IN IGG4-RELATED DISEASE AND PRIMARY SCLEROSING CHOLANGITIS STRATIFIED BY IGG4 LEVELS, IN A MULTICENTER UK COHORT

Emma L. Culver*, Jacob M. Hurst, Tamsin Cargill, Deepak Joshi, Manu Nayar, Matthew Huggett, Kofi Oppong, Sinisa Savic, Adrian Bateman, Roger W. Chapman, George J. Webster, Eleanor Barnes, United Kingdom
Autoimmune and hepato biliary disease 2 (Cont.)

**SAT-381**

**YI**

IMMUNOGLOBULIN E, EOSINOPHILS AND MAST CELLS IN ATOPIC INDIVIDUALS PROVIDE NOVEL INSIGHTS IN IGG4-RELATED DISEASE
Emma L. Culver*, Ross Sadler, Adrian Bateman, Mateusz Makuch, Berne Ferry, Rob Aalberse, Eleanor Barnes, Theo Rispens,
United Kingdom

**SAT-382**

**YI**

AN EARLY DEFINITION OF RESPONSE TO CORTICOSTEROIDS IN ACUTE SEVERE AUTOIMMUNE HEPATITIS
Francesca Saffioti*, Emma Culver, Aileen Marshall, David Patch, James O’Beirne, Douglas Thorburn, Rachel Westbrook,
United Kingdom

**SAT-387**

**YI**

AUTOREACTIVE IGA ANTIBodies AGAINST THE PANCREATIC MAJOR GLYCOPROTEIN 2 ARE ASSOCIATED WITH PRIMARY SCLEROSING CHOLANGITIS AND RELATED BILIARY TRACT CANCER

**SAT-388**

**YI**

PROTECTIVE ROLE OF SPECIFIC PATHOGEN FREE MICROBIOTA IN BILE DUCT Ligated MICE
Sheida Moghadamrad*, Kathy D McCoy, Jorum Kirundi, Philipp Kellmann, Andrea DeGottardi, Switzerland

**SAT-389**

**YI**

URSODEOXYCHOLIC ACID MODULATES THE EFFECTS OF LITHOCHOLIC ACID AND BILIRUBIN ON THE GENE EXPRESSION PROFILING IN OSTEOBLASTIC CELLS
Silvia Ruiz-Gaspà*, Nuria Guañabens, Marta Dubreuil, Pilar Peris, Ana Monegal, Albert Pares, Spain

**SAT-390**

**YI**

THE LITHOGENIC VARIANT D19H OF THE CHOLESTEROL TRANSPORTER ABCG8 LEADS TO INCREASED BILIARY CHOLESTEROL TO PHOSPHOLIPID COUPLING IN MICE
Charlotte Rebholz*, Rabea N. Hall, Marcin Krawczyk, Frank Lammert, Susanne N. Weber, Germany
SAT-391

YI

Top 10%

IGG4-RELATED DISEASE IS ASSOCIATED WITH CD4+ T CELL ACTIVATION AND REGULATION
Tamsin Cargill*, Emma Culver, Mateusz Makuch, Charis Manganis, Chris Willberg, Ross Sadler, Ellen Vermeulen, Laura Ligham, Alba Llibre, Leo Swadling, Caroline Evans, Christopher Green, Ayako Kurioka, Anthony Brown, Catherine de Lara, Marieke van Ham, Paul Klenerman, Theo Rispens, Eleanor Barnes, United Kingdom

SAT-392

YI

IDENTIFICATION OF THE NOVEL INFLAMMATION REGULATORY MECHANISM THROUGH MIR-139-5P IN PRIMARY BILIARY CIRRHOSIS
Tomohiro Katsumi*, Taketo Nishina, Kei Mizuno, Hiroaki Haga, Kazuo Okumoto, Takafumi Saito, Yoshiyuki Ueno, Japan

SAT-393

A FUT2 POLYMORPHISM INFLUENCES RESPONSIVENESS TO VANCOMYCIN IN PATIENTS WITH PRIMARY SCLEROSING CHOLANGITIS
Travis Murdoch*, John Oshiomogho, Tina Vo, Gilaad Kaplan, Bertus Eksteen, Canada

SAT-394

YI

POLYMORPHISMS OF IL12RB2 MAY AFFECT THE NATURAL HISTORY OF PRIMARY BILIARY CIRRHOSIS: A SINGLE CENTRE STUDY
Urszula Wasik*, Katarzyna Kozieł, Ewa Wunsch, Gary L. Norman, Piotr Milkiewicz, Małgorzata Milkiewicz, Poland

SAT-395

IMPACT OF GENDER AND RACE/ETHNICITY ON HEPATOCELULAR CARCINOMA, INTRAHEPATIC CHOLANGIOCARCINOMA AND EXTRAHEPATIC CHOLANGIOCARCINOMA
Vicky Bhagat*, Ponnandai Somasundar, United States

SAT-396

THE UK MULTICENTRE AUDIT OF MANAGEMENT AND OUTCOME OF AUTOIMMUNE HEPATITIS: PRELIMINARY OUTCOME RESULTS
Vikki M. Gordon*, United Kingdom

SAT-397

LONG TERM THERAPY WITH FENOFIBRATE AND URSODEOXYCHOLIC ACID DOES NOT IMPROVE PROJECTED SURVIVAL IN PRIMARY BILIARY CHOLANGITIS (CIRRHOSIS)
Vinod S. Hegade*, Amardeep Khanna, Lin Lee Wong, Jessica K Dyson, David Jones, United Kingdom
Autoimmune and hepato biliary disease 2 (Cont.)

SAT-398 VITAMIN D SUPPLEMENTATION THERAPY FOR PRIMARY BILIARY CIRRHOSIS: A RETROSPECTIVE CLINICAL STUDY
Lu Wang, Yong Q. Shi, Xin M. Zhou, Ying Han*, China

SAT-399 YI CLINICAL MANAGEMENT OF AUTOIMMUNE HEPATITIS IN THE REAL WORLD
Rodrigo Liberal, Ynto de Boer*, Raul J. Andrade, Gerd Bouma, George N. Dalekos, Annarosa Floreani, Dermot Gleeson, Gideon Hirschfield, Pietro Invernizzi, Marco Lenzi, Ansgar Lohse, Guilherme Macedo, Piotr Milkiewicz, Benedetta Terzioli, Bart van Hoek, John Vierling, Michael A. Heneghan, Netherlands

SAT-400 CORRELATIONS BETWEEN HEPATIC MORPHOMETRIC COLLAGEN CONTENT, HISTOLOGIC FIBROSIS STAGE, AND SERUM MARKERS IN PATIENTS WITH PRIMARY SCLerosing CHOLANGITIS (PSC)
### Cirrhosis: Bleeding, hepatorenal syndrome and ascites

#### SAT-001

**HEPATIC VENOUS OUTFLOW TRACT OBSTRUCTION: TREATMENT OUTCOMES AND UTILITY OF PROGNOSTIC SCORES**

Shalimar*, Ajay Kumar, Baibaswata Nayak, Shivananad Ramachandra Gamanagatti, Gurpreet Singh Gulati, Subrat Kumar Acharya, India

#### SAT-002

**ADDING RIFAXIMIN AND MIDODRINE ENHANCES DIURESIS IN REFRACTORY OR RECURRENT ASCITES WITH IMPROVEMENT IN CLINICAL OUTCOME INCLUDING RENAL FUNCTION, WEIGHT LOSS AND SHORT TERM SURVIVAL**

Amr S. Hanafy*, Egypt

#### SAT-003

**THE COMBINATION OF HEPATIC ELASTOGRAPHY AND DOPPLER ULTRASOUND CAN PREDICT THE RISK OF UPPER GASTROINTESTINAL BLEEDING IN PATIENTS WITH CIRRHOSIS**

Anda C. Achim*, Eugen Dumitru, Romania

#### SAT-004

**SELF-EXPANDING METAL STENTS IN PATIENTS WITH CIRRHOSIS AND SEVERE OR REFRACTORY ESOPHAGEAL VARICEAL BLEEDING: A SYSTEMATIC REVIEW AND META-ANALYSIS**

Astrid Marot*, Eric Trépo, Christopher Doerig, Christophe Moreno, Darius Moradpour, Pierre Deltenre, Switzerland

#### SAT-005

**LOW DOSE OF NONSELECTIVE B BLOCKERS MAY REDUCE RISK OF DEATH IN PATIENTS WITH CIRRHOSIS AFTER AN EPISODE OF SPONTANEOUS BACTERIAL PERITONITIS**

Bjørn S. Madsen*, Annette D. Fialla, Kristina F. Nielsen, Aleksander Krag, Denmark

#### SAT-006

**HOME-BASED MANAGEMENT OF REFRACTORY ASCITES BY PERMANENT TUNNELED PERITONEAL CATHETER IS AN EFFECTIVE REPLACEMENT FOR RECURRENT LARGE VOLUME PARACENTESIS**

Christoph Hoener Zu Siederdissen*, Philipp Solbach, Richard Taubert, Szilvia Ziegert, Kerstin Port, Andrea Schneider, Katja Hueper, Michael Manns, Heiner Wedemeyer, Elmar Jäckel, Germany
### Cirrhosis: Bleeding, hepatorenal syndrome and ascites (Cont.)

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>SAT-007</td>
<td>THE BENEFITS OF VIROSUPPRESSION ON PROGRESSION OF PORTAL HYPERTENSION IN PATIENTS WITH COMPENSATED VIRAL CIRRHOSIS (ANRS CO12 CIRVIR COHORT)</td>
<td>Christophe Bureau*, Dominique Thabut, Richard Layese, Valerie Bourcier, Linda Corvy, Ventzi Petrov-Sanchez, Patrick Marcellin, Dominique Guyader, Stanislas Pol, Dominique Larrey, Fabien Zoulim, Dominique Roulot, Victor De Ledinghen, Denis Ouzan, Albert Tran, Jean-Pierre Bronowicki, Ghassan Riachi, Paul Cales, Jean-Marie Peron, Laurent Alric, Marc Bourliere, Philippe Mathurin, Jean-Pierre Zarski, Françoise Roudot-Thoraval, Pierre Nahon, France</td>
</tr>
<tr>
<td>SAT-008</td>
<td>THE MICROSCOPICAL DETECTION OF BACTERIA COMPONENTS IN CLINICAL SAMPLES MIGHT BE USEFUL TO PREDICT THE RISK OF INFECTION</td>
<td>Cristina Lucidi*, Vincenza Di Gregorio, Barbara Lattanzi, Francesco Castellani, Marzia Boaretti, Maria LLeo, Manuela Merli, Italy</td>
</tr>
<tr>
<td>SAT-009</td>
<td>COMPARISON OF LONG-TERM SURVIVAL IN BRTO (BALLOON-OCLUDED RETROGRADE TRANSVENOUS OBLITERATION) VERSUS ENDOSCOPIC CYANOACRYLATE FOR MANAGEMENT OF BLEEDING GASTRIC VARICES</td>
<td>Daniel Stein*, Rose Onyeali, Saher Sabri, Zachary Henry, Stephen Caldwell, United States</td>
</tr>
<tr>
<td>SAT-010</td>
<td>INFECTION-ASSOCIATED ACUTE TUBULAR NECROSIS IN CRITICALLY ILL PATIENTS WITH CIRRHOSIS</td>
<td>Dzmitry Haurylenka*, Belarus</td>
</tr>
<tr>
<td>SAT-011</td>
<td>PREDICTORS OF MORTALITY AFTER TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT INSERTION</td>
<td>Eva Efsen*, Lise Hobolth, Lise Lotte Gluud, Susanne Frevert, Jens Otto Clemmesen, Denmark</td>
</tr>
<tr>
<td>SAT-012</td>
<td>OUTCOMES OF PREGNANCY IN PATIENTS WITH BUDD–CHIARI SYNDROME</td>
<td>Faisal I. Khan*, Ian Rowe, Bill Martin, Eilen Knox, Simon Olliff, Homoyon Mehrzad, Zergham Zia, Frederick Chen, Will Lester, Dhiraj Tripathi, United Kingdom</td>
</tr>
</tbody>
</table>
SAT-013
YI
STANDARDISATION OF PORTAL PRESSURE GRADIENTS MEASUREMENTS AFTER TIPS. DOES IT MATTER?
Gilberto Silva-Junior*, Fanny Turon, Anna Baiges, Eira Cerda Reyes, Luis Tellez, Virginia Hernandez-Gea, Jaume Bosch, Juan Carlos Garcia-Pagan, Brazil

SAT-014
RENALASE, A NEW PROTAGONIST OF ABNORMAL ADRENERGIC ACTIVATION IN LIVER CIRRHOSIS?
Giovanni Sansoe*, Manuela Aragno, Raffaella Mastrocola, Maurizio Parola, Italy

SAT-015
PROOF OF MULTIPLE MECHANISMS OF SOLUTE-FREE WATER RETENTION IN EXPERIMENTAL ASCITIC CIRRHOSIS
Giovanni Sansoe*, Manuela Aragno, Raffaella Mastrocola, Maurizio Parola, Italy

SAT-016
TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT FOR SYMPTOMATIC PORTAL HYPERTENSION WITH OR WITHOUT PORTAL VEIN THROMBOSIS IN 1171 PATIENTS WITH CIRRHOSIS A 14-YEAR RETROSPECTIVE STUDY FROM A SINGLE CENTER
Yong Lv, Bojing Zhang, Wengang Guo, Chuangye He, Zhengyu Wang, Zhanxin Yin, Jianhong Wang, Shuyao Ren, Xiangchen Meng, Jingzhi Cai, Xingshun Qi, Ming Bai, Jing Niu, Daiming Fan, Guohong Han*, China

SAT-017
FAVORABLE OUTCOMES FOLLOWING TIPS IN IDIOPATHIC NON-CIRRHTIC PORTAL HYPERTENSION WITH VARICEAL BLEEDING: A CASE-CONTROL STUDY FROM A SINGLE CENTER
Bojing Zhang, Yong Lv, Xiangchen Meng, Wengang Guo, Bohan Luo, Zhengyu Wang, Chuangye He, Zhanxin Yin, Jianhong Wang, Shuyao Ren, Jingzhi Cai, Jing Niu, Daiming Fan, Zengshan Li, Guohong Han*, China

SAT-018
PRESEPSIN (SOLUBLE CD14 SUBTYPE) LEVELS IN CIRRHOTIC PATIENTS WITH COMPENSATED OR DECOMPENSATED LIVER DISEASE WITH OR WITHOUT PORTAL HYPERTENSION RELATED BLEEDING
Ioannis S Elefsiniotis*, Stefanos Tsakiris, Eftychia Evangelidou, Georgia Barla, Athanasia Tasovasili, Ioanna Stathopoulou, Elefteria Giannakouloupoulou, Dimitrios Vrachatis, Christos Mavrogiannis, Greece
Cirrhosis: Bleeding, hepatorenal syndrome and ascites (Cont.)

SAT-019  REVERSAL OF TYPE I HEPATO-RENAL SYNDROME WITH TERLIPRESSIN AND OCTREOTIDE
Ionel Copaci*, Laurentiu Micu, Grethi Chiriac, Romania

SAT-020  TERLIPRESSIN-INDUCED HYponATREMIA IN CIRRHOTIC PATIENTS WITH VARICEAL BLEEDING
Irina Girleanu*, Anca Trifan, Oana Cristina Stoica, Ana Maria Singeap, Camelia Cojocariu, Stefan Chiriac, Carol Stanciu, Romania

SAT-021  NORFLOXACIN ESTIMULATES TREG-MEDIATED MODULATION OF PROINFLAMMATORY SIGNALLING IN EXPERIMENTAL CIRRHOSIS
Isabel N. Gomez-Hurtado*, Oriol Juanola, Pedro Zapater, Alba Moratalla, Jose Manuel Gonzalez-Navajas, Jose Such, Ruben Frances, Spain

SAT-022  SELF-REPORTED QUALITY OF LIFE IN PATIENTS TREATED WITH COVERED TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) VERSUS ENDOSCOPIC + B-BLOCKER TREATMENT FOR SECONDARY PREVENTION OF GASTRO-ÖESOPHAGEAL VARICEAL BLEEDING
Jihan Harki*, I. Lisanne Holster, Suzanne Polinder, Adriaan Moelker, Henk van Buuren, Ernst J. Kuipers, Eric T. T. L. Tjwa, Netherlands

SAT-023  ASSESSING THE BLEEDING RISK AFTER LIVER BIOPSY USING NEW CLINICAL AND BIOLOGICAL TOOLS: A PROSPECTIVE ANALYSIS OF 162 PROCEDURES
Julien Bissonnette*, Emmanuelle de Raucourt, Elia Gigante, Larbi Boudaoud, François Durand, Dominique Valla, Valérie Vilgrain, Pierre-Emmanuel Rautou, Canada

SAT-024  VASOACTIVE DRUGS FOR HEPATORENAL SYNDROME: A META-ANALYSIS
Mads E. Israelsen*, Andrew S. Allegretti, Aleksander Krag, Manol Jovani, Alison H. Goldin, Allison Schulman, Lise Lotte Gluud, Denmark

SAT-025  INCREASED BIOMARKERS OF CELL DEATH ARE ASSOCIATED WITH DEVELOPMENT AND CLINICAL OUTCOME IN PATIENTS WITH CIRRHOSIS AND HEPATORENAL SYNDROME
Marc Nguyen-Tat*, Thomas Austgen, Visvakanth Sivanathan, Juliane Ahrens, Daniel Sollinger, Johannes Rey, Marcus Wörns, Peter Galle, Jens Marquardt, Germany
SAT-026  LOW MOLECULAR WEIGHT HEPARIN TREATMENT DOES NOT INCREASE THE RISK OF BLEEDING AFTER PROPHYLACTIC ENDOSCOPIC VARICEAL BAND LIGATION IN PATIENTS WITH CIRRHOSIS
Marcello Bianchini*, Giulia Cavani, Ambra Bonaccorso, Laura Turco, Alberto Merighi, Erica Villa, Filippo Schepis, Italy

SAT-028  SELECTIVE INTESTINAL DECONTAMINATION WITH NORFLOXACIN IS ASSOCIATED WITH AN INCREASED PERCENTAGE OF REGULATORY T CELLS AND SERUM IL-10 LEVELS
Oriol Juanola Juárez*, Isabel Gómez-Hurtado, Pedro Zapater, Alba Moratalla, José M González-Navajas, José Such, Rubén Francés, Spain

SAT-029  EVALUATION AND IMPROVEMENT OF BAVENO 6 RECOMMENDATION FOR NON-INVASIVE DIAGNOSIS OF ESOPHAGEAL VARICES
Paul Cales*, Sylvie Sacher-Huvelin, Dominique Valla, Christophe Bureau, Emmanuel Coron, France

SAT-030  FREQUENCY OF RESISTANCE TO COMMONLY USED ANTIBIOTICS AMONG A GERMAN COHORT OF PATIENTS WITH SPONTANEOUS BACTERIAL PERITONITIS CHALLENGES CURRENT TREATMENT RECOMMENDATIONS
Philipp Lutz*, Hans-Dieter Nischalke, Benjamin Krämer, Felix Goeser, Dominik J Kaczmarek, Marijo Parcina, Jacob Nattermann, Achim Hoerauf, Christian P Strassburg, Ulrich Spengler, Germany

SAT-031  CIRRHOTIC PATIENTS WITH TLR-9 RS187084 POLYMORPHISM DO NOT INCREASE SERUM LEVELS OF CYTOKINES, DOPAMINE AND NORADRENALINE IN RESPONSE TO BACTERIAL DNA
Piñero Paula*, Zapater Pedro, Juanola Oriol, Giménez Paula, Caparrós Esther, González-Navajas Jose Manuel, Francés Rubén, Spain

SAT-032  URINARY BIOMARKER NGAL IN PATIENTS WITH CIRRHOSIS AND BACTERIAL INFECTIONS: ACCURACY STUDY IN ACUTE KIDNEY INJURY PREDICTION DEFINED BY KDIGO CRITERIA
Rafael O. Ximenes*, Claudia Helou, Marcio Diniz, Denise Barbeiro, Heraldo Souza, Luiz Augusto D’Albuquerque, Flair Carrilho, Alberto Farias, Brazil
Cirrhosis: Bleeding, hepatorenal syndrome and ascites (Cont.)

SAT-033 YI

URINARY BIOMARKER NGAL IN PATIENTS WITH HEPATORENAL SYNDROME: ACCURACY STUDY IN PREDICTION OF NO RESPONSE TO THERAPY WITH ALBUMIN AND TERLIPRESSIN
Rafael O. Ximenes*, Claudia Helou, Marcio Diniz, Denise Barbeiro, Heraldo Souza, Luiz Augusto D’Albuquerque, Flair Carrilho, Alberto Farias, Brazil

SAT-034

INCIDENCE, PREDICTORS AND OUTCOME OF ACUTE KIDNEY INJURY IN PATIENTS WITH NOSOCOMIAL SPONTANEOUS BACTERIAL PERITONITIS
Rakhi Maiwall*, Shiv K. Sarin, India

SAT-037

MID-INFRARED SPECTROSCOPY HAS A HIGH SENSITIVITY AND SPECIFICITY FOR POINT-OF-CARE DIAGNOSIS OF SPONTANEOUS BACTERIAL PERITONITIS
Rodolphe Anty*, Maëna Le Corvec, Christophe Renou, Anie Raoult, Jean-Baptiste Nousbaum, Florence Tanne, Claire Triboulot, Patrick Hastier, Cristel Fissore-Magdelein, Marie-Line Peritore, Véronique Blanc-Amrane, Eugénia Mariné-Barjoan, Jenny Vibert, Emmanuel Lemichez, Olivier Sire, Philippe Gual, Hugues Tariel, Albert Tran, Olivier Loréal, Luce Landraud, France

SAT-038 YI

CHANGES IN MICROBIOLOGICAL FLORA CAUSING SPONTANEOUS BACTERIAL PERITONITIS OVER THE LAST DECADE IN THE NETHERLANDS
Rosalie C. Oey*, Henk R. van Buuren, Annelies Verbon, Rob A. de Man, Netherlands

SAT-039 YI

INCIDENCE, PREDICTORS AND OUTCOMES OF ACUTE ON CHRONIC LIVER FAILURE IN OUTPATIENTS WITH CIRRHOSIS
Salvatore Piano*, Marta Tonon, Chiara Pilutti, Elia Vettore, Maria Luisa Stanco, Filippo Morando, Silvia Rosi, Antonietta Romano, Elisabetta Gola, Antonietta Sticca, Silvano Fasolato, Paolo Angeli, Italy

SAT-040

THE LONG-TERM OUTCOME OF 154 PATIENTS RECEIVING BALLOON-OCLLED RETROGRADE TRANS-VENOUS OBLITERATION (B-RTO) FOR GASTRIC FUNDAL VARICES
Satsuki Ando*, Yukinori Imai, Manabu Nakazawa, Kayoko Sugawara, Satoshi Mochida, Japan
**SAT-041**

**YI**

**NON-SELECTIVE BETA BLOCKERS (NSBBs): USE IS ASSOCIATED WITH IMPROVED SURVIVAL IN CIRRHOTIC PATIENTS WITH ASCITES: A SINGLE CENTRE RETROSPECTIVE STUDY**

Simona Onali*, Maria Kalafateli, Avik Majumdar, Rachel Westbrook, James O’Beirne, David Patch, Emmanuel Tsochatzis, *Italy*

**SAT-042**

**YI**

**MONITORING THE EFFECT OF LARGE VOLUME PARACENTHESIS ON SYSTEMIC HEMODYNAMICS PARAMETERS USING THE NON-INVASIVE CARDIAC SYSTEM. A PILOT STUDY**


**SAT-043**

**YI**

**AQUAPORIN-2 IN CIRRHOSIS: RELATION TO DISEASE SEVERITY, MARKERS OF RENAL FUNCTION AND IMPACT ON DEVELOPMENT OF RENAL INSUFFICIENCY AND MORTALITY**

Troels M. Busk*, Søren Møller, Erling Pedersen, Alexander Gerbes, Aleksander Krag, Markus Peck-Radosavljevic, Sona Frankova, Minneke J. Coenraad, Flemming Bendtsen, *Denmark*

**SAT-044**

**YI**

**SAFETY AND EFFICACY OF EARLY INITIATION OF BETA BLOCKERS IN CIRRHOTIC PATIENTS PREsenting WITH ACUTE VARICEAL BLEEDING**

Adnan Salim, Umair Butt*, Salman Afzal, Arshad Butt, Kashif Malik, Altaf Alam, *Pakistan*

**SAT-045**

**YI**

**HEPATIC ENCEPHALOPATHY IN PATIENTS WITH NON-CIRRHOTIC PORTAL HYPERTENSION: GRADE, PREVALENCE AND RISK FACTORS**

Valeria Nicoletti, Stefania Gioia*, Pierleone Lucatelli, Silvia Nardelli, Chiara Pasquale, Ilaria Pentassuglio, Stefano Nogas Sobrinho, Francesca Greco, Manuela Merli, Oliviero Riggio, *Italy*
**Fatty liver disease: Experimental**

**SAT-292**

**YI**

**CAFFEINE AMELIORATES HIGH-FAT-DIET INDUCED NONNALCHOLIC STEATOHEPATITIS BY ACTIVATING A MUSCLE-LIVER AXIS**

Xianbin Cai*, Chongye Fang, Shuhei Hayashi, Shumei Hao, Shuhei Nishiguchi, Hiroko Tsutsui, Jun Sheng, *China*

**SAT-293**

**DUAL PHOTON MICROSCOPY-BASED QUANTITATION OF FIBROSIS-RELATED COLLAGEN PROPERTIES (Q-FP) TO MODEL DISEASE PROGRESSION IN STEATOHEPATITIS**

Yan Wang*, Robert Vincent, Jinping Zhang, Jinlian Yang, Faridoddin Mirshahi, Arun Sanyal, *China*

**SAT-294**

**YI**

**SATURATED FATTY ACID, PALMITATE, INDUCED LIVER INFLAMMATION AND FIBROSIS IN VIVO**

Yuji Ogawa*, Yasushi Honda, Takaomi Kessoku, Wataru Tomeno, Shingo Kato, Kento Imao, Hironori Mawatari, Koji Hujita, Satoru Saito, Atsushi Nakajima, *Japan*

**SAT-295**

**COMPUTER ASSISTED MORPHOMETRIC ANALYSIS OF HEPATIC SONIC HEDGEHOG EXPRESSION CORRELATES WITH CIRCULATING MARKERS OF CELL DEATH AND KEY HISTOLOGIC FEATURES OF NON-ALCOHOLIC STEATOHEPATITIS**


**SAT-296**

**PHOSPHOPROTEOMIC ANALYSIS OF INTRACELLULAR SIGNALING IN THE HUMAN HEPATIC TISSUE OF PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE AND FIBROSIS**

Zobair M. Younossi*, Azza Karrar, Mariaelena Pierobon, Maria Stepanova, Kianoush Jeiran, Kimberly Reeder, Thomas Jeffers, Zahra Younoszai, Zachary Goodman, Emanuel F. Petricoin, United States

**SAT-297**

**HYPOXIA ACCELERATES FATTY ACID UPTAKE LEADING TO INCREASED FAT ACCUMULATION IN MICE AND IN CULTURED HUMAN HEPATOCYTE-DERIVED CELLS**

Agueda Gonzalez-Rodriguez*, Gloria Mateo, Esther Rey, Ines Soro-Arnaiz, Mar Capelli-Torres, Ainara Elorza, Julian Aragones, Carmelo Garcia-Monzon, *Spain*
SAT-298

YI

PERILIPIN A IS A NOVEL BIOMARKER OF CIRCULATING ADIPOCYTE-DERIVED EXTRACELLULAR VESICLES IN BOTH MURINE MODELS OF OBESITY AND OBESE HUMANS
Akiko Eguchi*, Milos Lazic, Aaron M. Armando, Susan A. Phillips, Oswald Quehenberger, Dorothy D. Sears, Arile E. Feldstein, United States

SAT-299

YI

INHIBITION OF PLASMINOGEN ACTIVATOR INHIBITOR 1 ATTENUATES DIET-INDUCED HEPATIC STEATOSIS IN MICE
Anne S. Henkel*, Sadiya Khan, Shantel Olivares, Douglas E. Vaughan, United States

SAT-300

YI

PRO-RESOLVING LIPID MEDIATORS MODULATE THE NLRP3 INFLAMMASOME IN CHRONIC LIVER DISEASE
Aritz Lopategi*, Bibiana Rius, López-Vicario Cristina, José Alcaraz-Quiles, Verónica García-Alonso, Esther Titos, Vicente Arroyo, Joan Clària, Spain

SAT-301

YI

PRO-RESOLVING LIPID MEDIATORS MODULATE HYPOXIA-INDUCED AND LIPOTOXIC ER STRESS IN PRIMARY HEPATOCYTES
Bibiana Rius*, Esther Titos, Cristina López-Vicario, Aritz Lopategi, Mireia Casulleras, José Alcaraz-Quiles, Vicente Arroyo, Joan Clària, Spain

SAT-302

YI

ADIPOSE TISSUE-LIVER AXIS: INVOLVEMENT OF THE TH17 PATHWAY IN THE PROGRESSION OF HUMAN NAFLD
Carla M. Chackelevicius*, Pablo J. Giraudi, Sabrina E. Gambaro, Silvia Palmisano, Michela Giuricin, Nicolò de Manzini, Deborah Bonazza, Fabrizio Zanconati, Claudio Tiribelli, Natalia Rosso, Italy

SAT-303

YI

IMPACT OF MITOCHONDRIAL UNCOUPLING ON HEPATIC METABOLISM AND NOVEL HUMAN HEPATIC SYSTEM FOR TYPE 2 DIABETES
Jessica E. Jones, Brandon A. Pabst, Rushi Patel, Nicholas B Vera, Emily Cokorinos, Jeffrey A Pfefferkorn, Cecile Vernochet*, United States

SAT-304

YI

A METABOLIC CIRCUITRY COMPRISING FREE FATTY ACIDS, MIR-122 AND TRIGLYCERIDES
Chofit Chai*, Mila Rivkin, Alina Simerzin, Hilla Giladi, Eithan Galun, Israel
<table>
<thead>
<tr>
<th>SAT-305</th>
<th>YI</th>
<th>Fatty liver disease: Experimental (Cont.)</th>
</tr>
</thead>
<tbody>
<tr>
<td>SAT-305</td>
<td>YI</td>
<td><strong>HIGH-FAT DIET AND GLYCATION IMPAIR LIPID AND GLUCOSE METABOLISM REGULATION IN RAT LIVERS</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Christian Neves*, José Sereno, Cláudia Simões, Tiago Rodrigues, João Castelhano, Judith Gonçalves, Guida Bento, Sónia Gonçalves, Rita Fonseca, Maria R. Domingues, Paulo Matafome, Miguel Castelo-Branco, Raquel Seiça, <em>Portugal</em></td>
</tr>
</tbody>
</table>

| SAT-306 | YI | **ACID SPHINGOMYELINASE TARGETING REDUCES THE PROGRESSION OF DIET-INDUCED NON-ALCOHOLIC STEATOHEPATITIS IN MICE WITH DISRUPTED METHIONINE HOMEOSTASIS** |
|         |    | Cristina Alarcon*, Anna Baulies, Vicent Ribas, Jose Maria Mato, Susana Núñez, Joan Caballeria, Carmen Garcia-Ruiz, Jose Carlos Fernandez-Checa, *Spain* |

| SAT-307 | YI | **TUDCA PROTECTS AGAINST ENDOPLASMIC RETICULUM STRESS-INDUCED INFLAMMASOME ACTIVATION AND HEPATOCYTE DEATH IN NON-ALCOHOLIC STEATOHEPATITIS** |
|         |    | Cynthia Lebeauvin*, Emma Proics, Charles-Henri Desnoyer de Bieville, Déborah Rousseau, Stéphanie Bonnafous, Stéphanie Patouraux, Albert Tran, Philippe Gual, Béatrice Bailly-Maitre, *France* |

| SAT-308 | YI | **VITAMIN D3 TREATMENT IMPROVES LIVER HISTOLOGY AND HEPATIC GENE EXPRESSION IN A MURINE OBESITY/NASH MODEL INDEPENDENT OF INTESTINAL FGF15 INDUCTION** |
|         |    | Daniel Jahn*, Donata Dorbath, Stefan Kircher, Heike M. Hermanns, Andreas Geier, *Germany* |

| SAT-309 | YI | **LIVER REGENERATION CAPACITY AFTER PARTIAL HEPATECTOMY IN RATS WITH NON-ALCOHOLIC STEATOHEPATITIS** |
|         |    | David Haldrup*, Sara Heebøll, Karen L. Thomsen, Kasper J. Andersen, Michelle Meier, Frank V. Mortensen, Jens R. Nyengaard, Steven J. H. Dutoit, Henning Grønbæk, *Denmark* |
MODULATION OF INTESTINAL MICROBIOTA AND GUT-LIVER AXIS BY QUERCETIN IMPROVE HFD-INDUCED METABOLIC SYNDROME AND NON-ALCOHOLIC FATTY LIVER DISEASE IN MICE
David Porras-Sanabria*, Maria Victoria Garcia-Mediavilla, Susana Martinez-Flórez, Esther Nistal, José Luis Olcoz, Ramiro Jover, Javier González-Gallego, Sonia Sánchez-Campos, Spain

OBETICHOLIC ACID AMELIORATES NON-ALCOHOLIC FATTY LIVER DISEASE BY IMPROVING METABOLIC PROFILE IN DIETARY OBESITY, BUT NOT IN OBESE, DIABETIC FOZ/FOZ MICE
Fahrettin Haczeyni, Laurence Poekes, Vanessa Barn, Auvro R Mridha, W Geoffrey Haigh, George N Ioannou, Matthew M Yeh, Isabelle A Leclercq, Narci C Teoh, Geoffrey C Farrell*, Australia

GENETIC AND HORMONAL CONTROL OF HEPATIC STEATOSIS IN FEMALE AND MALE MICE
Frode Norheim*, Simon Hui, Jake Lusis, United States

EXPLORING NOVEL LINKS BETWEEN ANGIGENESIS AND LIPID METABOLISM IN NON-ALCOHOLIC FATTY LIVER DISEASES
Savneet Kaur, Mohsin H. Bhat, Hamda Siddiqui*, Maria Thomas, Rania Dayoub, Shiv K. Sarin, Thomas Weiss, India

GALECTIN-3 DEFICIENCY EXACERBATES LIVER STEATOSIS BUT PROTECTS FROM STEATOHEPATITIS AND IL-33/IL-13 DEPENDENT FIBROSIS IN HFD-INDUCED OBESITY MOUSE MODEL
Ilija Jeftic*, Nemanja Jovicic, Jelena Pantic, Nebojsa Arsenijevic, Miodrag L. Lukic, Nada Pejnovic, Republic of Serbia

LACK OF NLRP3-INFLAMMASOME LEADS TO GUT-LIVER AXIS DERANGEMENT AND INCREASES HEPATIC INJURY IN A MOUSE MODEL OF NON-ALCOHOLIC FATTY LIVER DISEASE
Irene Pierantonelli*, Laura Agostinelli, Chiara Rychlicki, Melania Gaggini, Cristina Fraumene, Eleonora Mingarelli, Chiara Saponaro, Valeria Manghina, Emma Buzzigoli, Claudio Pinto, Luciano Trozzi, Stefania Saccomanno, Antonio Benedetti, Marco Marzioni, Samuele De Minicis, Sergio Uzzau, Amalia Gastaldelli, Gianluca Svegliati-Baroni, Italy
Fatty liver disease: Experimental (Cont.)

SAT-316
YI

A NUCLEAR MESSENGER LINKS CANNABINOID-1 (CB1) SIGNALLING TO FATTY LIVER

SAT-318
YI

PROTEIN KINASE STK25 CONTROLS LIPID PARTITIONING IN HUMAN HEPATOCYTES AND CORRELATES WITH LIVER FAT CONTENT IN MAN
Margit Mahlapuu*, Manoj Amrutkar, Matthias Kern, Estehr Nuñez-Durán, Marcus Ståhlman, Jan Borén, Matthias Blüher, *Sweden

SAT-319
YI

PNPLA3 IS INVOLVED IN HEPATIC LIPIDS METABOLISM THROUGH XBP1 AND MODULATION OF ENDOPLASMIC RETICULUM STRESS IN MICE
Masafumi Ono*, Tsunehiro Ochi, Kensuke Munekage, Mitsunari Ogasawara, Akira Hirose, Yasuko Nozaki-Fujimura, Nobuto Okamoto, Shinji Iwasaki, Jude Oben, Toshiji Saibara, *Japan

SAT-321
YI

EFFECT OF NUTRITIONAL WHEAT AMYLASE TRYPSIN INHIBITORS ON THE PROGRESSION OF NON-ALCOHOLIC FATTY LIVER DISEASE
Muhammad Ashfaq Khan*, Misbah Aslam, Victor zevallos, Yong Ook Kim, Xiaoyu Wang, Detlef Schuppan, *Germany

SAT-322
YI

CHANGES IN LXR PHOSPHORYLATION ATTENUATE DIET-INDUCED LIVER INFLAMMATION AND FIBROSIS
Natalia Becares*, Matthew Gage, Tu Vinh Luong, Benoit Pource, Rachel Chambers, Inês Pineda-Torra, *United Kingdom

SAT-323
YI

MIR-21 INHIBITION AND OBETICHOLIC ACID AMELIORATE NON-ALCOHOLIC STEATOHEPATITIS IN DIETARY ANIMAL MODELS

SAT-324
YI

VITAMIN D RECEPTOR IS UP-REGULATED IN NAFLD HEPATOCYTES AND IS REQUIRED FOR HIGH FAT DIET-INDUCED STEATOSIS IN APOE/-/- MICE LIVER
Ramiro Jover*, Milica Bozic, Carla Guzmán, Sonia Sánchez-Campos, Carmelo García-Monzón, José Manuel Valdivielso, *Spain
SAT-325  
ADAPTIVE IMMUNE RESPONSES PROMOTE LIVER FIBROGENESIS DURING THE PROGRESSION OF NONALCOHOLIC STEATOHEPATITIS THROUGH IL-33  
Salvatore Sutti*, Stefania Bruzzì, Cristina Mombello, Cristina Bozzola, Emanuele Albano, Italy

SAT-326  
HYPOXIA-INDUCIBLE FACTOR-2A AFFECTS FIBROGENIC PROGRESSION OF EXPERIMENTAL NON-ALCOHOLIC FATTY LIVER DISEASE  
Salvatore Sutti*, Elisabetta Morello, Stefania Cannito, Erica Novo, Claudia Bocca, Beatrice Foglia, Stefania Bruzzì, Gianmarco Villano, Patrizia Pontisso, Elisabetta Bugianesi, Emanuele Albano, Maurizio Parola, Italy

SAT-327  
IDENTIFICATION OF MOLECULAR PATHWAYS FOR STEM CELL THERAPY OF NON-ALCOHOLIC STEATOHEPATITIS IN AN IMMUNODEFICIENT MOUSE MODEL  
Sandra Winkler*, Stefan Kalkhof, Sandra Brückner, Madlen Hempel, Sven Baumann, Martin von Bergen, Bruno Christ, Germany

SAT-328  
RELATIONSHIPS BETWEEN CHANGING GUT MICROBIOTA AND THE PATHOGENESIS OF FATTY AND BILE ACIDS IN A MOUSE MODEL OF NON-ALCOHOLIC STEATOHEPATITIS  
Shoji Yamada*, Mitsuhiro Watanabe, Hidetsugu Saito, Japan

SAT-329  
PROGRESSION OF NON-ALCOHOLIC FATTY LIVER DISEASE TOWARDS STEATOHEPATITIS IS DIFFERENTIALLY MEDIATED BY INFLAMMASOME-INDUCED DOWNSTREAM PATHWAYS IL-1 AND IL-18  
Simon Hohenester*, Claudia Einer, Ralf Wimmer, Jutta Nagel, Florian P. Reiter, Sabine Schulz, Christian Rust, Alexander L. Gerbes, Hans Zischka, Gerald Denk, Germany

SAT-330  
MITOCHONDRIAL ADAPTATION TO HIGH CALORIC CHALLENGE PROTECTS AGAINST FATTY ACID-INDUCED HEPATOTOXICITY BUT PROMOTES LIVER STEATOSIS IN NASH  
Claudia Einer, Ralf Wimmer, Christian Rust, Alexander L. Gerbes, Gerald Denk, Hans Zischka, Simon Hohenester*, Germany

SAT-331  
CAFESTOL BUT NOT RESVERATROL IS A PARTIAL AGONIST OF FARNESOID X RECEPTOR AND STIMULATES FGF19 IN HUMAN ILEAL EXPLANTS  
Sina Jamei-Oskooei*, Richard Appleby, Jenna Geers, Julian Walters, United Kingdom
Fatty liver disease: Experimental (Cont.)

SAT-332
YI

THE INSULIN-LIKE GROWTH FACTOR 2 MRNA BINDING PROTEIN P62 INDUCES LIVER PROGENITOR CELL OCCURRENCE
Sonja M. Kessler*, Beate Czepukojc, Ahmad Barghash, Cristina Cadenas, Jan G. Hengstler, Volkhard Helms, Isabelle Leclercq, Johannes Haybaeck, Alexandra K. Kiemer, Germany

SAT-333

OMEGA-3 CARBOXYLIC ACIDS, EPANOVA®, AND THE SODIUM-GLUCOSE CO-TRANSPORTER 2 INHIBITOR, DAPAGLIFLOZIN®, IMPROVE STEATOHEPATITIS AND FIBROSIS SCORING IN A MOUSE MODEL OF NON-ALCOHOLIC STEATOHEPATITIS
Sophie Cazanave*, Bubu Banini, Amon Asgharpour, Robert Vincent, Mulugeta Seneshaw, Divya Prassana Kumar, Faridoddin Mirshahi, Kalyani Daita, Puneet Puri, Jan Oscarsson, Pierre Bedossa, Arun Sanyal, United States

SAT-334

COMBINED ACTIVITY OF NTCP AND OATPS GOVERNS HEPATIC UPTAKE OF CONJUGATED BILE ACIDS IN VIVO
Davor Slijepcevic, Dagmar Tolenaars, Dirk R. de Waart, Ulrich Beuers, Ronald Oude Elferink, Alfred Schinkel, Stan Van De Graaf*, Netherlands

SAT-335
YI

ROLE OF B-LYMPHOCYTES IN SUPPORTING ADAPTIVE IMMUNE RESPONSES ASSOCIATED WITH THE PROGRESSION OF NONALCOHOLIC STEATOHEPATITIS
Stefania Bruzzi*, Salvatore Sutti, Gabriele Giudici, Michela Emma Burlone, Cristina Mombello, Cristina Bozzola, Mario Pirisi, Emanuele Albano, Italy

SAT-336

ANTIFIBROTIC EFFECTS OF COMBINED TREATMENT WITH FARNESOID X RECEPTOR AGONIST AND ANGIOTENSIN-II TYPE1 RECEPTOR BLOCKER ON HEPATIC FIBROGENESIS IN THE RAT MODEL OF NONALCOHOLIC STEATOHEPATITIS
Tadashi Namisaki*, Yasushi Okura, Shinya Sato, Ryuichi Noguchi, Kei Moriya, Mitsuteru Kitade, Kosuke Takeda, Norihisa Nishimura, Yasuhiko Sawada, Kenichiro Seki, Hideto Kawaratani, Kosuke Kaji, Hitoshi Yoshiji, Japan
SAT-337 DUODENAL-JEJUNAL BYPASS SURGERY ATTENUATES NONALCOHOLIC FATTY LIVER DISEASE VIA DOWNREGULATION OF FATTY ACID SYNTHESIS IN MICE
Tae Kyoung Ha*, Jin Hyouk Lim, Sung Ho Jang, Doo In Lee, Dongho Choi, E Y HA, Korea, South

SAT-338 THREE-DIMENSIONAL HUMAN CELL CULTURE MODEL FOR STUDYING NON-ALCOHOLIC FATTY LIVER DISEASE
Tomasz Kostrzewski*, Terri Cornforth, Mohsen Shaeri, Sophie Snow, Larissa Ouro, David Hughes, United Kingdom

SAT-339 HEPATOCYTE SPECIFIC EXPRESSION OF A DOMINANT STABLE FORM OF B-CATENIN RESULTS IN EARLY LETHALITY DUE TO DISTURBANCES IN LIPID AND GLUCOSE METABOLISM
Ursula Lemberger*, Claudia Fuchs, Matthias Karer, Tatjana Stojakovic, Samuel Meier, Christian Schöfer, Gerda Egger, Fritz Wrba, Christoph Gerner, Makoto Taketo, Michael Trauner, Christoph H. Oesterreicher, Austria

SAT-340 HEPATIC RESPONSE OF MAGNESIUM-RESTRICTION IN C57BL/6 MICE
Vera H. I. Fengler*, Tanja Macheiner, Walter Goessler, Christoph Magnies, Johannes Haybaeck, Carolin Lackner, Karine Sargsyan, Austria

SAT-341 DIVERSE FUNCTIONAL ROLE OF LIVER DENDRITIC CELL SUBTYPES IN NON-ALCOHOLIC STEATOHEPATITIS
Eva-Carina Heier, Christoph Eckert, Thomas Tschernig, Miroslaw Kornek, Frank Lammert, Veronika Lukacs-Kornek*, Germany

SAT-342 COFFEE AND INTESTINAL PERMEABILITY IN A MICE MODEL OF NON-ALCOHOLIC FATTY LIVER DISEASE
Giovanna Mazzone, Vincenzo Lembo*, Giuseppe D’Argenio, Paola Vitaglione, Antonella Rossi, Ilenia Piscosquito, Marcella Savoia, Maria Guido, Filomena Morisco, Nicola Caporaso, Italy

SAT-343 HEPATOCELLULAR AUTOPHAGY DEFICIENCY IN MICE MODULATES THE UNFOLDED PROTEIN RESPONSE IN A PATHWAY SELECTIVE MANNER
**Liver tumours: Management**

**SAT-055**  
PROGNOSTIC RELEVANCE OF STAGE MIGRATION IN PATIENTS WITH HEPATOCELLULAR CARCINOMA: A MULTICENTER COHORT STUDY  
Alessandro Vitale*, Fabio Farinati, Marina Polacco, Patrizia Burra, Franco Trevisani, Umberto Cillo, Italy

**SAT-058**  
HIGH-POWERED MICROWAVES ABLATION OF INTERMEDIATE HEPATOCELLULAR CARCINOMA IN CIRRHOSIS: A MULTICENTER, PROSPECTIVE STUDY  
Antonio Giorgio*, Piero Gatti, Carmine Coppola, Gaetano Iaquinto, Bruno Santoro, Ferdinando Amendola, Valentina Giorgio, Italy

**SAT-059**  
YI  
ADHERENCE TO BCLC TREATMENT ALGORITHM AND SURVIVAL PREDICTORS IN SINGLE NODE HCC IN ITALY  
Caterina Pozzan*, Maria Angela Di Vasto, Gemma Maddalo, Alessandro Vitale, Franco Trevisani, Fabio Farinati, Italy

**SAT-060**  
YI  
AN OBJECTIVE MODEL TO OPTIMIZE TREATMENT DECISIONS IN ADVANCED HEPATOCELLULAR CARCINOMA AFTER SORAFENIB FAILURE: THE SORFA SCORE  
David James Pinato*, Clarence Yen, Tadaaki Arizumi, Paola Giarda, Jessica Howell, Pierluigi Toniutto, Ramya Ramaswami, Michela E. Burlone, Masatoshi Kudo, Mario Pirisi, Rohini Sharma, United Kingdom

**SAT-061**  
VITAMIN K1 PLUS SORAFENIB COMBINATION IS MORE EFFECTIVE THAN SORAFENIB ALONE IN ADVANCED HEPATOCELLULAR CARCINOMA - A PROSPECTIVE RANDOMIZED CONTROLLED TRIAL  
Devaraja Rangegowda*, Madhumita Premkumar, Manoj Kumar sharma, Amar Mukund, Shiva Kumar Sarin, India

**SAT-062**  
PERCUTANEOUS RADIOFREQUENCY ABLATION VERSUS ETHANOL INJECTION IMPACT ON OVERALL SURVIVAL RATE IN SMALL HEPATOCELLULAR CARCINOMA PATIENTS, A META-ANALYSIS  
Diego Ledro-Cano*, Spain
SAT-071  
**YI**

**SARCOPENIA AS A PROGNOSTIC FACTOR IN PATIENTS WITH EXTENSIVE FIBROSIS/CIRRHOSIS AND HEPATOCELLULAR CARCINOMA**  
Elia Gigante*, Mohamed Bouattour, Laurent Castera, Maxime Ronot, Onorina Bruno, Claire Francoz, Valerie Vilgrain, Olivier Soubranne, François Durand, *Italy*

SAT-072

**PROGNOSIS AFTER INTRAHEPATIC RECURRENCE IN THE PATIENTS WHO UNDERWENT CURATIVE RESECTION FOR HEPATOCELLULAR CARCINOMA**  
Eung-Ho Cho*, Sang Bum Kim, Jung I. Choi, Ryounggo Kim, Chang-Sup Lim, Su-Cheol Park, *Korea, South*

SAT-073

**SAFETY AND EFFECTIVENESS OF SORAFENIB FOR THE TREATMENT OF HEPATOCELLULAR CARCINOMA IN PATIENTS WITH DIABETES**  
Giovan Giuseppe Di Costanzo*, Raffaella Tortora, Filomena Morisco, Luigi Addario, Filippo Lampasi, Alfonso Galeota Lanza, Maria Guarino, Gabriella Cordone, Luigia Falco, Nicola Caporaso, *Italy*

SAT-074

**THREE-DIMENSIONAL CONFORMAL RADIOTHERAPY FOR PORTAL VEIN TUMOR THROMBOSIS IN ADVANCED HEPATOCELLULAR CARCINOMA**  
Hyun Young Woo*, Jeong Heo, Won Lim, Ki Tae Yoon, Young Mi Hong, Won Young Tak, Soo Young Park, Mong Cho, *Korea, South*

SAT-075

**REMNANT LIVER ISCHEMIA IS ASSOCIATED WITH EARLY RECURRENCE AND POORER SURVIVAL AFTER LIVER RESECTION IN PATIENTS WITH HEPATOCELLULAR CARCINOMA**  
Jai Young Cho*, Youngrok Choi, Jae Seong Jang, Haeryoung Kim, Korea, *South*

SAT-076

**RAMUCIRUMAB AS SECOND-LINE TREATMENT IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA: ANALYSIS OF REACH PATIENTS BY ALBUMIN-BILIRUBIN (ALBI) GRADE**  
Jean-Frédéric Blanc*, Stephen L. Chan, Joon Oh Park, Baek-Yeol Ryoo, Chia-Jul Yen O, Masatoshi Kudo, Ronnie Poon, Davide Pastorelli, Ari Baron, Tulio Flesch Pfiffer, Takuji Okusaka, Katerina Kubackova, Jorg Trojan, Javier Sastre, Ian Chau, Paolo Abada, Shao-Chun Chang, Ling Yang, Andrew Zhu, *France*
Liver tumours: Management (Cont.)

SAT-077
YI
VALIDATION AND PERFORMANCE OF THE HONG KONG LIVER CANCER STAGING SYSTEM IN A WESTERN COHORT
Jonathan Umbel’, Asrar AlAhmadi, Selim Gebran, Christopher Siegel, Pierre M. Gholam, United States

SAT-078
YI
ORAL MEDICATIONS IMPROVE THE COMPLIANCE TO REGULAR SURVEILLANCE FOR HEPATOCELLULAR CARCINOMA IN CHRONIC HEPATITIS B PATIENTS
Joon Yeul Nam’, Jeong-Hoon Lee, Dong Hyeon Lee, Young Chang, Hongkeun Ahn, Hyeki Cho, Jung-Ju Yoo, Minjong Lee, Young Youn Cho, Eunju Cho, Su Jong Yu, Yoon Jun Kim, Jung-Hwan Yoon, Korea, South

SAT-079
YI
PERFORMANCE OF THE HAP SCORE AMONG PATIENTS WITH HEPATOCELLULAR CARCINOMA TREATED BY RADIOEMBOLIZATION
Juan Buades Mateu’, Diego Martinez-Urbistondo, Manuel De la Torre Alaez, Mercedes Iñarrairaegui, Jose I. Bilbao, Bruno Sangro, Spain

SAT-080
HIGHER SERUM BILIRUBIN LEVELS OF LIVING LIVER DONORS MAY BE ASSOCIATED WITH DECREASED RISK OF POST-TRANSPLANT HEPATOCELLULAR CARCINOMA RECURRENCE
Sangbin Han, Ju Dong Yang, Dong Hyun Sinn, Justin Ko, Jong Man Kim, Jun Chul Shin’, Hee Jung Son, Jae-Won Joh, Gaabsoo Kim, Korea, South

SAT-081
PRIMARY PROPHYLAXIS FOR VARICEAL BLEEDING SHOULD BE DONE FOR PATIENTS WITH HEPATOCELLULAR CARCINOMA
Jung Hee Kim’, Dong Hyun Sinn, Ji Hyeon Lee, Wonseok Kang, Geum-Youn Gwak, Yong-Han Paik, Moon Seok Choi, Joon Hyeok Lee, Kwang Cheol Koh, Seung Woon Paik, Korea, South

SAT-082
PERCUTANEOUS ELECTROCHEMOTHERAPY OF MALIGNANT MAIN PORTAL VEINS THROMBOSIS: A PROSPECTIVE CASE SERIES
Luciano Tarantino’, Giuseppina Busto, Aurelio Nasto, Raffaele Fristachi, Luigi Cacace, Maria Talamo, Pasquale Ambrosino, Paolo Gallo, Paolo Tarantino, Catello Accardo, Italy
SAT-083 SHORT-TERM EFFICACY OF TRANSARTERIAL CHEMOEMBOLIZATION WITH EPIRUBICIN-LOADED SUPERABSORBENT POLYMER MICROSPHERES FOR HEPATOCELLULAR CARCINOMA: COMPARISON WITH CONVENTIONAL TRANSARTERIAL CHEMOEMBOLIZATION
Manabu Morimoto*, Satoshi Kobayashi, Satoshi Moriya, Makoto Ueno, Shun Teduka, Shinichi Ohkawa, Japan

SAT-084 PROGNOSTIC IMPACT OF INCIDENTAL HEPATOCELLULAR CARCINOMA AFTER LIVER TRANSPLANTATION
Manuel Rodríguez-Perálvarez*, Pablo Pérez, Lourdes Guerrero, Víctor González, Rafael Sánchez, Maria Centeno, Antonio Poyato, Pilar Barrera, Rubén Ciria, Javier Briceño, Jose Luis Montero, Manuel De la Mata, Spain

SAT-085 OPTIMIZATION OF SURVIVAL PREDICTION IN PATIENTS UNDER SORAFENIB TREATMENT: USEFULNESS OF CARBONIC ANHYDRASE IX BASELINE AND BASELINE AND EVOLUTIVE ANGIOPOYETIN 2
Maria Reig*, Boix Loreto, Ferran Torres, Juan Manuel Lopez-Oliva, Jordi Rimola, Anna Darnell, Alejandro Forner, Álvaro Diaz, Andrea Ribeiro, Neus Llarch, Carmen Ayuso, Jordi Bruix, Spain

SAT-086 THE ACCURACY OF THE BASELINE PERIPHERAL LYMPHOCYTE VALUE IN PREDICTING OVERALL SURVIVAL IN HEPATOCELLULAR CARCINOMA PATIENTS TREATED WITH SORAFENIB REINFORCES THE IMPACT OF THE IMMUNE RESPONSE ON TUMOR PROGRESSION
Maria Reig*, Andrea Ribeiro, Alessia Gazzola, Álvaro Diaz, Neus Llarch, Gemma Iserte, Alejandro Forner, Loreto Boix, Juan Manuel Lopez-Oliva, Anna darnell, Jordi Rimola, Carmen Ayuso, Jordi Bruix, Spain

SAT-087 PREDICTION OF POST-OPERATIVE LIVER FAILURE IN CIRRHOTICS UNDERGOING SURGICAL RESECTION FOR HEPATOCELLULAR CARCINOMA: THE ROLE OF LIVER STIFFNESS MEASURED BY ACOUSTIC RADIATION FORCE IMPULSE AND THE PROPOSAL FOR A NEW MATHEMATICAL MODEL SCORE
Claudia Iegri, Adriano De Santis, Gianluca Grazi, Massimo Rossi, Marinella Lupo*, Giulia Gallusi, Mariana Forlino, Simona Di Filippo, Fabio Melandro, Italy
Liver tumours: Management (Cont.)

SAT-088

RESULTS OF RADIOFREQUENCY ABLATION IN A COHORT OF CIRRHOTIC PATIENTS AT LIVER TRANSPLANTATION
Marta Hernández Conde*, Fernando Pons, Elba Llop, Christie Perelló, Juan De la Revilla, Natalia Fernández Puga, Jose Luis Martínez Porras, Maria Traperó, Santiago Méndez, Valentin Cuervas-Mons, Victor Sánchez-Turrión, José Luis Calleja Panero, Spain

SAT-089

SEX DIFFERENCES IN DISEASE PRESENTATION, TREATMENT, AND CLINICAL OUTCOMES OF PATIENTS WITH HEPATOCELULAR CARCINOMA
Maya Ladenheim, Nathan Kim*, Pauline Nguyen, An Le, Marcia Stefanick, Gabriel Garcia, Mindie Nguyen, United States

SAT-090

MULTIMODALITY TREATMENT OF HEPATOCELULAR CARCINOMA: HOW FIELD PRACTICE COMPLIES WITH INTERNATIONAL RECOMMENDATIONS
Michela Triolo*, Angelo Sangiovanni, Vincenzo La Mura, Massimo Iavarone, Cristina Della Corte, Antonio Nicolini, Giorgio Rossi, Massimo Colombo, Italy

SAT-091

ALBI GRADE DETERMINES POST-PROGRESSION SURVIVALS AFTER SORAFENIB TREATMENT FAILURE IN ADVANCED HEPATOCELULAR CARCINOMA PATIENTS: A MODEL FOR SECOND-LINE TRIAL SELECTION
Pei-Chang Lee*, Yi-Hsiang Huang, Yi-Tzen Chen, Chien-Wei Su, Han-Chieh Lin, Yee Chao, Taiwan

SAT-092

MANAGEMENT OF HEPATIC EPITHELIOID HAEMANGIOENDOTHELIOMA: 5 YEAR SINGLE-CENTER EXPERIENCE
Razvan C. Cerban*, Adina Croitoru, Irinel Popescu, Speranta Iacob, Corina Pietrareanu, Vlad Herlea, Florin Botea, Gabriel Becheanu, Radu Dumitru, Cristian Gheorghe, Ioana Lupescu, Liliana Gheorghe, Romania

SAT-093

ANALYSIS OF THE EFFECTIVENESS OF SORAFENIB TAKING INTO ACCOUNT THE CLINICAL COURSE IN PATIENTS WITH HEPATOCELULAR CARCINOMA
Sadahisa Ogasawara*, Tetsuhiro Chiba, Yoshihiko Ooka, Eiichiro Suzuki, Akinobu Tawada, Osamu Yokosuka, Japan
<table>
<thead>
<tr>
<th>SAT-094</th>
<th>VITAMIN C ENHANCES EPIGENETIC MODIFICATIONS INDUCED BY 5-AZACYTIDINE ON CELL CYCLE ARREST IN HEPATOCELLULAR CARCINOMA</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Sahar Olsadat Sajadian*, tripura Chaturvedula, Andreas K Nüssler, Germany</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>SAT-095</th>
<th>OUTCOMES OF PURE LAPAROSCOPIC VERSUS OPEN HEPATIC RESECTION FOR HEPATOCELLULAR CARCINOMA IN CIRRHOTIC PATIENTS: A CASE-CONTROLLED STUDY WITH PROPENSITY SCORE MATCHING</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Shogo Tanaka*, Shigekazu Takemura, Genya Hamano, Masahiko Kinoshita, Tokuji Ito, Shoji Kubo, Japan</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>SAT-096</th>
<th>MICROWAVE ABLATION VERSUS RADIOFREQUENCY ABLATION FOR HEPATOCELLULAR CARCINOMA: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMISED CONTROLLED TRIALS</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Stuart K. Roberts*, Obaid Fazli, Australia</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>SAT-097</th>
<th>TARGETED PROTEOMICS PREDICTS SUSTAINED COMPLETE RESPONSE AFTER TRANSARTERIAL CHEMOEMBOLIZATION IN PATIENTS WITH HEPATOCELLULAR CARCINOMA</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Su Jong Yu*, Hophil Min, Young Youn Cho, Jeong-Ju Yoo, Dong Hyeon Lee, Eun-Ju Cho, Jeong-Hoon Lee, Yoon Jun Kim, Chung Yong Kim, Jung-Hwan Yoon, Youngsoo Kim, Korea, South</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>SAT-098</th>
<th>EVALUATION OF EFFICACY AND SAFETY OF PERCUTANEOUS ASPIRATION SCLEROTHERAPY OF SIMPLE HEPATIC CYSTS, A SYSTEMATIC REVIEW</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Titus F. Wijnands*, Alena P. Gortjes, Tom J. Gevers, Sjoerd Jenniskens, Leo J. Schultze Kool, Andrej Potthoff, Maxime Ronot, Joost P. Drenth, Netherlands</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>SAT-099</th>
<th>THERAPEUTIC STRATEGIES IN THE REAL LIFE IN BCLC-C HEPATOCELLULAR CARCINOMA IN ITALY: ASSESSMENT IN THE ITALIAN LIVER CANCER AND VALIDATION IN THE ITALIAN ASSOCIATION OF HOSPITAL GASTROENTEROLOGISTS DATABASE</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Veronica Vanin*, Angela Imondi, Caterina Pozzan, Francesca Murer, Alessandro Vitale, Umberto Cillo, Elena Dionigi, Mauro Borzio, Franco Trevisani, Fabio Farinati, Italy</td>
</tr>
</tbody>
</table>
Liver tumours: Management (Cont.)

SAT-100  RESPONSE AT FIRST CHEMOEMBOLIZATION IS A ROBUST PREDICTOR OF FAVORABLE OUTCOME IN HEPATOCELLULAR CARCINOMA
Wei Teng, Yi-Chung Hsieh, Ka-Wai Liu, Chen-Fu Hung, Wen-Juei Jeng, Chien-Hao Huang, Wei-Ting Chen, Yi-Cheng Chen, Chen-Chun Lin, Chun-Yen Lin, Shi-Ming Lin, I-Shyan Sheen, Taiwan

SAT-101  COMPARISON OF SURGERY WITH TRANSARTERIAL CHEMOEMBOLIZATION FOR SOLITARY LARGE HEPATOCELLULAR CARCINOMA OF BCLC STAGE A; ANALYSES OF DATABASE FROM NATIONAL CANCER REGISTRY OF SOUTH KOREA
Young-Joo Jin, Ji Taek Hong, Jin-Woo Lee, Korea, South
Molecular and cellular biology: HSCs and fibrosis

SAT-383
TRANSDUCTION OF HEPATIC STELLATE CELLS WITH GENES OF HGF AND FGF4 BEFORE TRANSPLANTATION ENHANCES REPOPULATION OF TRANSPLANTED CELLS IN DAMAGED RAT LIVER
Anisa Gumerova*, Angelina Titova, Elwira Sharipova, Guzel Burganova, Georgiy Pevnev, Aygul Shafigullina, Iliaz Gazizov, Michail Mavlikeev, Maxim Kaligin, Marina Titova, Andrey Kiassov, Russia

SAT-384
SURVIVAL OF APOPTOSIS-PRIMED ACTIVATED HEPATIC FIBROBLASTS IS BCL-XL DEPENDENT
Anja Moncsek*, Achim Weber, Beat Müllhaupt, Christian Fingas, Joachim Mertens, Switzerland

SAT-385
TGF-B2 – TARGET TO TACKLE CHRONIC LIVER DISEASES USING ANTISENSE OLGONUCLEOTIDES
Anne Dropmann*, Hanna Korhonen, Michel Janicot, Steven Dooley, Nadja Meindl-Beinker, Germany

SAT-386
MELATONIN IMPAIRS THE INFLAMMATORY RESPONSE AND INHIBITS THE SPHINGOSINE KINASE SIGNALING PATHWAY IN AN ANIMAL MODEL OF LIVER FIBROSIS
Bárbara González-Fernández*, Diana I. Sanchéz, Beatriz San-Miguel, Irene Crespo, Juan Ortiz de Urbina, Marcelino Álvarez, Javier González-Gallego, María J. Tuñón, Spain

SAT-401
A NOVEL TISSUE PERFUSION TOOL TO SIMPLIFY AND STANDARDIZE LIVER DISSOCIATION
Timo Adams, Sylvia Däubel, David Kemmer, Wolfgang Stöters, Andreas Bosio, Carsten Poggel*, Germany

SAT-402
ELUCIDATING THE BIOMECHANICAL RESPONSE OF HUMAN HEPATIC STELLATE CELLS ON SUBSTRATES MIMICKING HEALTHY AND FIBROTIC MATRIX RIGIDITY
Dariusz Lachowski*, Ernesto Cortes, Benjamin Robinson, Krista Rombouts, Armando del Rio Hernandez, United Kingdom

SAT-403
INHIBITION OF MATRIX ACCUMULATION USING SMALL PEPTIDES REVERSES LIVER FIBROSIS
Eva Altrock*, Jane Sottile, Inaa A. Nakchbandi, Germany
Molecular and cellular biology: HSCs and fibrosis (Cont.)

SAT-404  
YI  
CARTILAGE OLIGOMERIC MATRIX PROTEIN PARTICIPATES IN THE PATHOGENESIS OF LIVER FIBROSIS  
Fernando M. Magdaleno Verduzco*, Elena Arriazu, Marina Ruiz de Galarreta, Yu Chen, Xiaodong Ge, Laura Conde de la Rosa, Natalia Nieto, United States

SAT-405  
PBI-4050 DECREASES HEPATIC STELLATE CELL ACTIVATION AND AMELIORATES FIBROSIS IN CARBON TETRACHLORIDE (CCL4)-INDUCED HEPATIC FIBROSIS MODEL  
François Sarra-Bournet*, Brigitte Grouix, Kathy Hince, Alexandra Felton, Mikaël Tremblay, Shaun Abbott, Jean-Simon Duceppe, Boulos Zacharie, Pierre Laurin, Lyne Gagnon, Canada

SAT-406  
YI  
MICRORNA-221 INHIBITION IN HEPATOCYTES: A NOVEL STRATEGY TO TREAT LIVER FIBROSIS  
Hsin-Chieh Tsay*, Qinggong Yuan, Asha Balakrishnan, Michael P. Manns, Michael Ott, Amar Deep Sharma, Germany

SAT-407  
YI  
THE BILE ACID-PHOSPHOLIPID CONJUGATE URSODEOXYCHOLYL LYSOPHOSPHATIDYLETHANOLAMIDE DISTURBS PRO-FIBROGENIC INTEGRIN AND TGFβ SIGNALING  
Jie Su*, Hongying Gan-Schreier, Walee Chamulitrat, Wolfgang Stremmel, Anita Pathil, Germany

SAT-408  
YI  
TH2-POLARIZATION OF CD4+ T-CELLS IS LOCALLY INDUCED AND DRIVES LIVER FIBROGENESIS  
Johanna A. Reissing*, Daniela Kroy, Pavek Strnad, Marie Berres, Christian Trautwein, Henning Zimmermann, Germany

SAT-409  
TARGETING LIVER FIBROSIS BY RNAI - MEDIATED INHIBITION OF CYCLIN E1  
Jörg-Martin Bangen*, Linda Hammerich, Roland Sonntag, Ute Haas, Daniela Lambertz, Frank Tacke, Christian Trautwein, Christian Liedtke, Germany

SAT-410  
HEPATOCYTE SENESCEENCE ACTIVATES HEPATIC STELLATE CELLS TO DRIVE LIVER FIBROSIS  
Jude Heaney*, Fiona Oakley, Fabienne Hanton, Roger Williams, Graeme Alexander, United Kingdom
SAT-411  YI  INCREASED EXPRESSION OF HISTONE DEACETYLASE 7 DURING HEPATIC STELLATE CELL ACTIVATION PROMOTES PRO-FIBROGENIC GENE EXPRESSION
Kim Freese*, Christoph Dorn, Wolfgang Thasler, Martina Müller, Claus Hellerbrand, Germany

SAT-412  YI  NOVEL LOW-COST AND EFFICIENT METHOD FOR THE ISOLATION OF MOUSE LIVER SINUSOIDAL CELLS
Leslie Stradiot*, Ivan Moya, Inge Mannaerts, George Halder, Leo L A van Grunsven, Belgium

SAT-413  YI  DEVELOPMENT AN IN VITRO MODEL CULTURE FOR TESTING OF ANTI-FIBROTIC DRUGS USING HUMAN PRECISION CUT LIVER SLICES
Lynda Aoudjehane*, Margaux Legrand, Fabiano Perdigao, Olivier Scatton, Jérôme Becquart, Chantal Housset, Yvon Calmus, Filomena Conti, France

SAT-414  YI  DIRECTED DIFFERENTIATION OF IPS CELLS TO HEPATIC STELLATE CELLS
Mar Coll*, Luis Perea, Ruben Boon, Julia Vallverdú, Daniel Rodrigo-Torres, Delia Blaya, Marta Llopis, Isabel Graupera, Beatriz Aguilar, Catherine Verfaillie, Pere Ginés, Pau Sancho-Bru, Spain

SAT-415  YI  RIVAROXABAN REDUCES PORTAL HYPERTENSION IN CIRRHOTIC RATS BY DEACTIVATING HEPATIC STELLATE CELLS AND REDUCING INTRAHEPATIC MICROTHROMBOSIS
Marina Vilaseca*, Cristina Isabel López-Sanjurjo, Erica Lafoz, Héctor García-Calderó, Oihane Garcia-Irigoyen, Matías Ávila, Juan Carlos Reverter, Jaime Bosch, Virginia Hernández-Gea, Jordi Gracia-Sanco, Juan Carlos García-Pagan, Spain

SAT-416  YI  HANDLING OF ACTIVATION STATUS OF HUMAN HEPATIC STELLATE CELLS BY LOW-MOLECULAR-WEIGHT FGF2 VIA THE INDUCTION OF CYTOGLOBIN
Misako Sato-Matsubara, Tsutomu Matsubara, Atsuko Daikoku, Kazuo Ikeda, Krista Rombouts, Massimo Pinzani, Norifumi Kawada*, Japan
INTERPLAY OF MATRIX STIFFNESS AND C-SRC IN HEPATIC FIBROSIS
Jan Görtzen, Robert Schierwagen, Jeanette Bierwolf, Sabine Klein, Frank Erhard Uschner, Peter van der Ven, Dieter Fürst, Christian Strassburg, Wim Laleman, Jörg-Matthias Pollok, Jonel Trebicka, Germany

THE IDENTIFICATION OF NOVEL SMALL MOLECULE COMPOUNDS WITH POTENT ANTI-FIBROTIC PROPERTIES BY PHENOTYPIC SCREENING OF PRIMARY HUMAN STELLATE CELLS
Carole BELANGER, Mathieu DUBERNET, Emilie NEGRO, Raphaël DARTEIL, Dean W. HUM, Bart STAELS, Robert WALCZAK, France

INTEGRIN ALPHA 11 SIGNIFICANCE IN PHENOTYPIC TRANSFORMATION OF HEPATIC STELLATE CELLS IN LIVER FIBROSIS
Ruchi Bansal, Shigeki Nakagawa, Scott L. Friedman, Yujin Hoshida, Jai Prakash, Netherlands

NEPRILYSIN CONTROLS THE SWITCH BETWEEN HEPATIC VASOCONSTRICTION AND FIBROGENESIS IN LIVER DISEASE
Sabine Klein, Winfried Reul, Robert Schierwagen, Frank Uschner, Christian Strassburg, Thomas Walther, Jonel Trebicka, Germany

THE HISTOLOGICAL QUANTIFICATION OF ALPHA-SMOOTH MUSCLE ACTIN PREDICTS FUTURE GRAFT FIBROSIS IN PEDIATRIC LIVER TRANSPLANT RECIPIENTS
Sharat Varma, Xavier Stephenne, Mina Komuta, Caroline Bouzin, Jerome Ambroise, Francoise Smets, Raymond Reding, Etienne Sokal, Belgium

IL-4/IL13 SIGNALING ACTS THROUGH M2 MACROPHAGES, BUT NOT TH2 T CELLS OR HEPATOCYTES TO DRIVE PROGRESSION OF CCL4-INDUCE LIVER FIBROSIS
Shih Yen Weng, Xiaoyu Wang, Santosh Vijayan, Yong Ook Kim, Leonard Kaps, Yilang Tang, Jeff Crosby, Michael Mccaleb, Frank Brombacher, Ari Waisman, Detlef Schuppan, Germany
SAT-423  YI

DISSECTING THE MOLECULAR ANTIFIBROTIC EFFECT OF THE TGF-BETA(I) RECEPTOR KINASE INHIBITOR GALUNISERTIB IN PRECISION-CUT LIVER SLICES
Theerut Luangmonkong*, Suriguga Suriguga, Emilia Bigaeva, Dorenda Oosterhuis, Koert de Jong, Detlef Schuppan, Henricus Mutsaers, Peter Olinga, Netherlands

SAT-424

LOSS OF NUMB IN HEPATIC PROGENITOR CELL PROMOTES LIVER FIBROSIS IN MICE
Xufeng Lu*, Lei Zhang, Hongjie Ji, Yongjie Zhou, Gang Guo, Shuiliang Luo, Keting Zhu, Xiaoyue Cao, Zhenru Wu, Li Li, Hong Bu, Yujun Shi, China
Non-invasive markers of liver fibrosis

SAT-425 NEW CIRCULATING METABONOMIC AND MIRNOMIC BIOMARKERS TO PREDICT STEATOSIS, INFLAMMATION AND FIBROSIS SEVERITY IN NON-ALCOHOLIC FATTY LIVER DISEASE
Aitor Carretero, Mireia Lopez-Riera, Estebán Saez, Teresa Blazquez, Isabel Conde, Angela Zaragoza, Ramiro Jover, Agustín Lahoz*, Spain

SAT-426 CD49A- CD49B+ NK1.1 CELLS IN C57/BL FIBROTIC LIVERS ARE DISTINCT FROM PERIPHERAL NATURAL KILLER CELLS IN THEIR NEUROLOGIN4/CD107A ACTIVATORY MARKER
Ahmad Salhab*, Johnny Amer, Rifaat Safadi, Israel

SAT-427 THE RELATIONSHIP BETWEEN FIB-4 INDEX VARIATIONS AND OUTCOME IN PATIENTS WITH CHRONIC HEPATITIS C AND CIRRHOSIS: COMPARISON WITH LIVER STIFFNESS MEASUREMENT
Anais Vallet-Pichard*, Philippe SULTANIK, Jean Francois MERITET, Samir BOUAM, Hélène FONTAINE, Marion COROUGE, Anne LAURAIN, Philippe SOGNI, Stanislas POL, Vincent MALLET, France

SAT-428 USEFULNESS OF COMMON FIBROSIS MARKERS TO PREDICT VIREMIA IN PATIENTS WITH REACTIVE HEPATITIS C ANTIBODY TEST
Anja De Weggheleire*, Sokkab An, Jozefien Buyze, Sopheak Thai, Sven Francque, Lutgarde Lynen, Belgium

SAT-429 NATIONAL SURVEY INVESTIGATING THE POTENTIAL ROLE OF NON-INVASIVE LIVER FIBROSIS TESTS IN THE UK
Ankur Srivastava*, Ruth Gailer, Emmanouil Tsocchatzis, Julie Parkes, William Rosenberg, United Kingdom

SAT-430 INFLUENCE OF HIV-1 CO-RECEPTOR TROPISM ON LIVER FIBROSIS IN HIV-INFECTED PATIENTS
Annalisa Saracino*, Alessandro Cozzi-Lepri, Francesca Ceccherini Silberstein, Silvia Nozza, Antonio Di Biagio, Giovanni Cassola, Giuseppe Bruno, Maria Capobianchi, Laura Monno, Antonella d’Arminio Monforte, Italy
SAT-431  A NEW METHOD INCLUDING THE QUANTIFICATION OF CIRCULATING MIRNAS ALLOWS THE EFFICIENT IDENTIFICATION OF NASH PATIENTS AT RISK WHO SHOULD BE TREATED
Arun Sanyal*, Genevieve Cordonnier, John Brozek, Alice Roudot, Sylvie Deledicque, Martin Barbazanges, Emilie Praca, Fouad Ben Sudrik, Sophie Megnien, Remy Hanf, Bart Staels, Pierre Bedossa, Vlad Ratziu, Dean Hum, Raphael Darteil, United States

SAT-432  A HIGHER ASPARTATE AMINOTRANSFERASE TO PLATELET RATIO INDEX AS A POTENTIAL FIBROSIS MARKER PREDICTS LIVER DISEASE MORTALITY IN THE UNITED STATES POPULATION
Aynur Unalp-Arida*, Constance Ruhl, United States

SAT-433  TRANSIENT ELASTOGRAPHY IS SUPERIOR TO FIB-4 IN ASSESSING THE RISK OF HEPATOCELLULAR CARCINOMA IN PATIENTS WITH CHRONIC HEPATITIS B
Beom Kyung Kim*, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kijun Song, Kwang-Hyub Han, Korea, South

SAT-434  ALGORITHM TO RULE-OUT CLINICALLY SIGNIFICANT PORTAL HYPERTENSION COMBINING SHEAR-WAVE ELASTOGRAPHY OF LIVER AND SPLEEN: A PROSPECTIVE MULTI-CENTER STUDY
Christian Jansen, Christopher K.-P. Bogs*, Wim Verlinden, Maja Thiele, Philip Moeller, Jan Goertzen, Jennifer Lehmann, Michael Praktiknjo, Johannes Chang, Aleksander Krag, Christian Strassburg, Sven Franque, Jonel Trebicka, Germany

SAT-435  TRANSIENT ELASTOGRAPHY AND COMBINATION OF FIBROTEST® AND TRANSIENT ELASTOGRAPHY FOR DIAGNOSIS OF ADVANCED FIBROSIS AND CIRRHOSIS IN PATIENTS WITH ALCOHOLIC LIVER DISEASE: A PROSPECTIVE MULTICENTER COHORT STUDY
Cosmin Sebastian Voican*, Alexandre Louvet, Jean-Baptiste Trabut, Micheline Njiké-Nakseu, Sébastien Dharancy, Andrea Sanchez, Marion Corouge, Karima Lamouri, Amandine Lebrun, Axel Balian, Sophie Prévot, Mounia Lachgar, Sophie Maitre, Hélène Agostini, Philippe Mathurin, Gabriel Perlemuter, Sylvie Naveau, France
### Non-invasive markers of liver fibrosis (Cont.)

| SAT-436 | LIVER STIFFNESS MEASURED BY ACOUSTIC RADIATION FORCE IMPULSE QUANTIFICATION IN PRIMARY SCLEROSING CHOLANGITIS: A COMPARISON WITH TRANSIENT ELASTOGRAPHY PERFORMED BY FIBROSCAN® AND OTHER NON-INVASIVE TESTS  
Davide Roccarina’, Francesca Saffioti, Matteo Rosselli, Massimo Pinzani, Aileen Marshall, Douglas Thorburn, Italy |
| SAT-437 | TRUE COLLAGEN TYPE III FORMATION (PRO-C3) IS PREDICTIVE OF OUTCOME IN HCV PATIENTS WITH ADVANCED LIVER FIBROSIS WITHIN THE TRENT STUDY  
| SAT-438 | RAPID AND SUSTAINED IMPROVEMENTS OF LIVER STIFFNESS VALUES IN HCV-INFECTED PATIENTS TREATED WITH DIRECT ANTIVIRAL DRUGS  
Dina Attia’, Katja Deterding, Janet Cornberg, Michael Manns, Michael Gebel, Markus Cornberg, Heiner Wedemeyer, Andrej Potthoff, Egypt |
| SAT-439 | SIMPLE NON INVASIVE FIBROSIS SCORES PREDICT LONG TERM MORTALITY IN PATIENTS WITH NON ALCOHOLIC FATTY LIVER DISEASE  
Elena Buzzetti’, Roberta Manguerra, Andrew Hall, Laura De Luca, Pinelopi Manousou, Massimo Pinzani, Amar P. Dhillon, Emmanuel Tsochatzis, United Kingdom |
| SAT-440 | CHOLESTASIS IS NOT ASSOCIATED WITH LIVER STIFFNESS IN A POPULATION-BASED COHORT  
Elisabeth Plompen’, Sarwa Darwish Murad, Bettina Hansen, Jeoffrey Schouten, Pavel Taimr, Albert Hofman, Bruno Stricker, Harry Janssen, Netherlands |
| SAT-441 | EUROPEAN MITOCHONDRIAL DNA HAPLOGROUPS IMPACT ON LIVER FIBROSIS PROGRESSION AMONG HCV AND HIV/HCV COINFECTED PATIENTS FROM NORTHWEST SPAIN  
Andres Tabernilla, Ignacio Rego-Pérez, Marta Grandal, Berta Pernas, Sonia Pértiga, Alvaro Mena, Iria Rodríguez-Osorio, Manuel Delgado, Ana Marino, Hortensia Álvarez, Jose Domingo Pedreira, Francisco Javier Blanco, Eva Poveda’, Spain |
PHYSICAL EXERCISE INCREASES LIVER STIFFNESS IN HUMANS
Felix Piecha*, Teresa Peccerella, Helmut Karl Seitz, Vanessa Rausch, Sebastian Mueller, Germany

PHARMACOLOGICAL VASODILATATION EFFICIENTLY DECREASES LIVER STIFFNESS IN RATS WITH TAA-INDUCED LIVER CIRRHOSIS
Felix Piecha*, Teresa Peccerella, Helmut Karl Seitz, Vanessa Rausch, Sebastian Mueller, Germany

BILIARY TRACT CANCER WITH OR WITHOUT PRIMARY SCLEROSING CHOLANGITIS IS ASSOCIATED WITH A RAISED ENHANCED LIVER FIBROSIS TEST RESULT COMPARED WITH PSC ALONE
Francesca Saffioti*, Davide Roccarina, Mette Vesterhus, Johannes Roksund Hov, William Rosenberg, Massimo Pinzani, Tom Hemming Karlsen, Stephen P Pereira, Kirsten Muri Boberg, Douglas Thorburn, United Kingdom

ACCURACY OF THE LATEST RELEASE OF A POINT SHEAR WAVE ELASTOGRAPHY METHOD FOR STAGING LIVER FIBROSIS IN PATIENTS WITH CHRONIC HEPATITIS C
Giovanna Ferraioli*, Laura Maiocchi, Raffaella Lissandrin, Carmine Tinelli, Carlo Filice, Italy

PROLONGED ENTECAVIR THERAPY IMPROVES LIVER FIBROSIS ESTIMATED BY APRI IN MAJORITY OF NAÏVE PATIENTS WITH A PARTIAL VIROLOGICAL RESPONSE
Hee Yeon Kim*, Chang Wook Kim, Chang Don Lee, Seung Kew Yoon, Jong Young Choi, Si Hyun Bae, Korea, South

RED BLOOD CELL DISTRIBUTION WIDTH AND GLOBULIN, NONINVASIVE INDICATORS OF FIBROSIS AND INFLAMMATION IN CHRONIC HEPATITIS PATIENTS
Huan Wang*, Hongqin Xu, Junqi Niu, China

RISK ASSESSMENT OF HEPATOCELLULAR CARCINOMA USING WISTERIA FLORIBUNDA AGGLUTININ-POSITIVE HUMAN MAC-2 BINDING PROTEIN IN CHRONIC HEPATITIS B PATIENTS
Ja Yoon Heo*, Sung Soo Ahn, Seung Up Kim, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Hyon-Suk Kim, Young Nyun Park, Kwang-Hyub Han, Korea, South
Non-invasive markers of liver fibrosis (Cont.)

**SAT-449 YI**

DIRECT ANTIVIRAL AGENT TREATMENT OF CHRONIC HCV INFECTION RESULTS IN RAPID REGRESSION OF TRANSIENT ELASTOGRAPHY (FIBROSCAN®) AND VALIDATED FIBROSIS MARKERS FIB-4 AND APRI
Jacqueline A. Bachofner*, Piero V. Valli, Arne Kröger, Beat Müllhaupt, Joachim C. Mertens, Switzerland

**SAT-450 YI**

THE BAVENO VI GUIDELINES: CAN WE CONFIDENTLY IDENTIFY LOW RISK CIRRHOTIC PATIENTS NOT REQUIRING ENDOSCOPIC SURVEILLANCE FOR VARICES?
James B. Maurice*, Edgar Brodkin, Frances Arnold, Heidi Paine, A M. D. Navaratnam, Sabrina Khawar, Emmanouil Tsocchatzis, David Patch, James O’Beirne, Ameet Dhar, Massimo Pinzani, Rachel H. Westbrook, United Kingdom

**SAT-451 YI**

Top 10%

PDGF-BB AS A POTENTIAL BIOMARKER FOR NON-INVASIVE ASSESSMENT OF LIVER FIBROSIS IN PATIENTS WITH CHRONIC HEPATITIS B
Jiyuan Zhou*, Yongqiong Deng, Hong Zhao, Guiqiang Wang, China

**SAT-452 YI**

OPPORTUNISTIC FIBROSCAN® TESTING IN A DUBLIN GENERAL PRACTICE (GP) MANAGING OPIATE SUBSTITUTION THERAPY: THE HEPCARE STUDY
John S. Lambert*, Carol Murphy, Anjali Patel, Des Crowley, Stephen Stewart, Jeremy Farrell, Walter Cullen, Matthew McKenna-Barry, Ireland

**SAT-453 YI**

THE DUBLIN HEPCHECK STUDY: COMMUNITY BASED TESTING OF HCV BY POINT OF CARE ORAQUICK® HCV SALIVA TEST IN HOMELESS POPULATIONS
John S. Lambert*, Carol Murphy, Austin O’Carroll, Jeremy Farrell, Anjali Patel, Gordana Avramovic, Walter Cullen, Clíona Ni Cheallaigh, Ireland

**SAT-454 YI**

NON-INVASIVE EVALUATION OF CHRONIC HEPATITIS C PATIENTS WITH MODERATE FIBROSIS (F2). LONG-TERM IMPACT OF ANTIVIRAL TREATMENT
Jose A. Carrión*, Nuria Cañete, Marc Puigvehi, Mar Garcia, Montserrat Garcia-Retortillo, Javier Gimeno, Teresa Broquetas, Susanna Coll, Rosa Fernández, Beatriz Cabrero, Maria Dolors Giménez, Felipe Bory, Ricard Solà, Spain
SAT-455  RAPID DECREASE OF THE NON-INVASIVE SERUM LIVER FIBROSIS MARKER WFA+-M2BP BY IFN-FREE THERAPY  
Kazuya Ura*, Norihiro Furusyo, Eiichi Ogawa, Hideyuki Nomura, Nobuyuki Yamashita, Hironori Tanimoto, Jun Hayashi, Japan

SAT-456  AN ONTARIO BASED DIAGNOSTIC REFERRAL PROGRAM USING TRANSIENT ELASTOGRAPHY – A RETROSPECTIVE ANALYSIS  
Kerstina H. Boctor*, Magdy Elkhashab, Marzena Magnes, Canada

SAT-457  A MICRORNA-BASED DIAGNOSTIC TOOL TO PREDICT ADVANCED FIBROSIS AND CIRRHOSIS IN PATIENTS WITH CHRONIC HEPATITIS B AND C  
Kevin Appourchaux, Emilie Estrabaud*, Matthieu Resche-Rigon, Martine Lapalus, Michelle Martinot-Peignoux, Safi Dokmak, Xavier Treton, Nathalie Boyer, Michel Vidaud, Pierre Bedossa, Patrick Marcellin, Tarik Asselah, France

SAT-458  NONINVASIVE ASSESSMENT OF LIVER FIBROSIS AND STEATOSIS IN HIV-MONOINFECTED SUBJECTS  
Giovanna Ferraioli, Laura Maiocchi*, Raffaella Lissandrini, Carmine Tinelli, Carlo Filice, Italy

SAT-459  THE UTILITY OF FIBROELASTOGRAPHY TO DETECT ALCOHOL-RELATED LIVER DISEASE IN A NURSE-LED OUTPATIENT ALCOHOL TREATMENT CLINIC  
Lynn Owens*, Andrew Thompson, Kevin Mannix, Elaine Lewis, Gill O’Hare, Laura Richardson, Paul Richardson, United Kingdom

SAT-460  LIVERTRAIL.COM: A SMARTPHONE APP TO PREDICT PRESENCE OF LIVER FIBROSIS IN PATIENTS WITH ALCOHOL OVERUSE  
Maja Thiele*, Bjørn S. Madsen, Janne Hansen, Linda Møller, Katrine Lindvig, Sönke Detlefsen, Aleksander Krag, Denmark

SAT-461  A LIVER SCORE THAT COMBINES DIRECT MARKERS OF EXTRACELLULAR MATRIX FORMATION WITH PLATELET COUNT, INR AND AGE ACCURately DIAGNOSE LIVER FIBROSIS AND CIRRHOSIS IN PATIENTS WITH ALCOHOL OVERUSE  
Maja Thiele*, Bjørn S. Madsen, Mette Nielsen, Janne Hansen, Linda Møller, Sönke Detlefsen, Diana Leeming, Ove Schaffalitzky de Muckadell, Morten Karsdal, Aleksander Krag, Denmark
### Non-invasive markers of liver fibrosis (Cont.)

<table>
<thead>
<tr>
<th>SAT-462</th>
<th>ENHANCED LIVER FIBROSIS (ELF) TEST QUANTIFICATION IN HBEAG-NEGATIVE PATIENTS WITH NUCLEOS(T)IDE ANALOGUES 1, 3, 5 AND 8 YEARS AFTER LIVER BIOPSY</th>
</tr>
</thead>
<tbody>
<tr>
<td>Marc Puigvehí*, Teresa Broquetas, Montserrat Garcia-Detortillo, Juan José Hernández, Rosa Fernández, Nuria Cañete, Susanna Coll, Beatriz Cabrero, Javier Gimeno, Maria Dolors Giménez, Felipe Bory, Ricard Solà, Jose A. Carrión, Spain</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>SAT-463</th>
<th>CARRIERS OF THE ABCB4 P.T175A ALLELE MIGHT BE AT-RISK OF INCREASED LIVER INJURY: ANALYSIS OF TWO INDEPENDENT COHORTS OF PATIENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Marcin Krawczyk*, Monika Rau, Jörn Schattenberg, Frank Grünhage, Heike Bantel, Anita Pathil, Münevver Demir, Johannes Kluwe, Tobias Boettler, Andreas Geier, Frank Lammert, Germany</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>SAT-464</th>
<th>BAVENO VI RECOMMENDATION ON AVOIDANCE OF SCREENING ENDOSCOPY IN CIRRHTIC PATIENTS BASED ON LIVER ELASTOGRAPHY AND PLATELET COUNT – ARE WE THERE YET?</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mário J. Silva*, Pedro Duarte, Milena Mendes, Carlos Bernardes, João Pinto, Rafaela Loureiro, Jorge Esteves, Filipe Calinas, Portugal</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>SAT-465</th>
<th>SUSTAINED VIROLOGICAL RESPONSE RESULTS IN REGRESSION OF LIVER STIFFNESS IN PATIENTS WITH CHRONIC HEPATITIS C VIRUS INFECTION</th>
</tr>
</thead>
<tbody>
<tr>
<td>Marjolein van Tilborg*, Raoel Maan, Nadine Haddo, Bettina E. Hansen, Robert J. de Knegt, Netherlands</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>SAT-466</th>
<th>ARE NON INVASIVE TEST GOOD ENOUGH TO PREDICT GASTROESOPHAGEAL VARICES IN PATIENTS WITH COMPENSATED ADVANCED CHRONIC LIVER DISEASE?</th>
</tr>
</thead>
<tbody>
<tr>
<td>Marta Lopez Gomez*, Elba Llop Herrera, Juan De la Revilla Negro, Natalia Fernández Puga, Maria Trapero Marugán, Marta Hernández Conde, Carlos Fernández Carrillo, Fernando Pons Renedo, Jose Luis Martinez Porras, Jose Luis Calleja Panero, Spain</td>
<td></td>
</tr>
</tbody>
</table>
PRECORE AND BASAL CORE PROMOTER MUTANTS IMPROVE THE DIAGNOSTIC PERFORMANCE OF FIBROSCAN® OR FIBROTEST® TO PREDICT SIGNIFICANT FIBROSIS IN CHRONIC HEPATITIS B PATIENTS
Martine Lapalus, Koubdi Jean Nana, Cédric Laouenan, Lucile Larrouy, Emilie Estrabaud*, Michelle Martinot-Peignoux, Alice Marlu, Juliette Cronfalt, Kevin Appourchaux, Nathalie Boyer, Pierre Bedossa, Patrick Marcellin, Vincent Leroy, Tarik Asselah, France

UTILITY OF MAC-2 BINDING PROTEIN GLYCOSYLATION ISOMER (M2BPGI) FOR ADVANCED FIBROSIS AND HEPATOCELLULAR CARCINOMA IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE
Masaaki Korenaga*, Keiko Korenaga, Masatoshi Imamura, Yoshihiko Aoki, Masaya Sugiyama, Tatsuya Kanto, Masashi Mizokami, Japan

ACCURACY OF A POINT SHEAR WAVE ELASTOGRAPHY TECHNIQUE (ELASTPQ) IN THE NON-INVASIVE ASSESSMENT OF LIVER FIBROSIS IN A LARGE COHORT OF LIVER PATIENTS
Matteo Garcovich*, Maurizio Pompili, Enrico Di Stasio, Barbara E. Dyrda, Laura Riccardi, Maria E. Ainora, Antonio Grieco, Gian L. Rapaccini, Massimo Siciliano, Antonio Gasbarrini, Maria A. Zocco, Italy

A SEROLOGICAL MARKER OF COLLAGEN TYPE III CROSSLINKING CORRELATES STRONGLY WITH SEVERITY OF LIVER DISEASE
Morten A. Karsdal*, Mette J. Nielsen, Maja Thiele, Federica Genovese, Bjørn S. Madsen, Janne F. Hansen, Linda Møller, Sónke Detlefsen, Ove Schaffalitzky de Muckadell, Diana J. Leeming, Aleksander Krag, Denmark

CIRCULATING MICRONANAS AS BIOMARKERS FOR DISEASE PROGRESSION IN CHRONIC HEPATITIS C VIRUS INFECTION
Naomi Bulteel*, Dagmara McGuinness, Paul G. Shiels, John McLauchlan, United Kingdom
### Non-invasive markers of liver fibrosis (Cont.)

**SAT-472**

**EXHALED BREATH PROFILING BY ELECTRONIC NOSE AS A NOVEL NON-INVASIVE METHOD FOR ASSESSMENT OF CHRONIC LIVER DISEASE: PROOF OF PRINCIPLE STUDY**

Natasha McDonald*, Rohit Sinha, Rianne de Vries, Peter Hayes, Robert Chamuleau, Jonathan Fallowfield, John Plevris, *United Kingdom*

**SAT-473**

**LIVER STIFFNESS IMPROVEMENT IN SUBJECTS WITH ADVANCED CHRONIC HEPATITIS C TREATED WITH DIRECT ANTIVIRAL AGENTS**

Nesrine Gamal*, Fabio Conti, Marianna Mastro Roberto, Alessandra Scuteri, Carmela Cursaro, Valeria Guarneri, Roberto Di Donato, Giovanni Vitale, Pietro Andreone, *Italy*

**SAT-474**

**THE UTILITY OF FIBROSCAN AND PLATELET COUNT TO IDENTIFY PATIENTS WHO CAN OMIT VARICEAL SURVEILLANCE ENDOSCOPY: VALIDATION OF THE BAVENO GUIDELINES IN A SCOTTISH COHORT**

Omar F. Ahmed*, Ewan H Forrest, Adrian J Stanley, Ruth Gillespie, Stephen T Barclay, *United Kingdom*

**SAT-475**

**IN SILICO IDENTIFICATION AND IN VIVO VALIDATION OF NON-INVASIVE BIOMARKERS FOR LIVER FIBROSIS**

Pablo J. Giraudi*, Sabrina E. Gambaro, Carla M. Chackelevicius, Michela Giuricin, Lory S. Crocè, Deborah Bonazza, Giorgio Soardo, Nicolò de Manzini, Claudio Tiri belli, Silvia Palmisano, Natalia Rosso, *Italy*

**SAT-476**

**LIVER SURFACE DEFORMABILITY: A NOVEL ULTRASOUND TECHNIQUE IN THE NON-INVASIVE ASSESSMENT OF HEPATIC FIBROSIS**

Paolo Del Poggio*, Daniela Di Mauro, Davide Resta, Sara Cecchin, Mario Mattiello, Anna Del Poggio, Andrea D’Alessio, *Italy*

**SAT-477**

**LIVER FIBROSIS DIAGNOSIS BY BLOOD TEST AND ELASTOGRAPHY: AGREEMENT OR COMBINATION?**

Paul Cales*, Vincent Leroy, Victor de Ledinghen, Jérôme Boursier, Isabelle Hubert, Frédéric Oberti, *France*
SAT-478 | POTENTIAL MRI BIOMARKERS OF LIVER FIBROSIS AND INFLAMMATION IN NAFLD WITH DUAL R2 AND R2* MAPPING
Paul Clark*, Hilton Leao Filho, Wanida Chua-anusorn, Paula P. Fabrega, Claudia P. Oliveira, Australia

SAT-479 | INVESTIGATION OF POTENTIAL SMALL RNA BASED BIOMARKERS RELATED WITH TGF-β FOR COMPANION DIAGNOSTICS AND STRATIFICATION OF HCC PATIENTS USING SMALL RNA-SEQ DATA
Rahul Agarwal*, Yuan Cao, Gianluigi Gianelli, Klaus Hoffmeier, Björn Rotter, Peter Winter, Germany

SAT-480 | LIVER TEST ABNORMALITIES IN PATIENTS WITH HIV MONO-INFECTION: ASSESSMENT WITH SIMPLE NON-INVASIVE FIBROSIS MARKERS
Rosa Lombardi*, Robert Lever, Colette Smith, Neal Marshall, Alison Rodger, Sanjay Bhagani, Emmanuel Tsochatzis, Italy

SAT-481 | REDUCED CIRCULATING LEVELS OF SIPA1L1 ENABLES THE DETECTION OF EARLY LIVER FIBROSIS IN CCL4-TREATED RATS
Santiago Marfa*, Manuel Morales-Ruiz, Denise Orò, Jordi Ribera, Guillermo Fernández-Varo, Wladimiro Jiménez, Spain

SAT-482 | IDENTIFICATION OF ADVANCED FIBROSIS IN HEPATITIS C PATIENTS FOLLOWING SUSTAINED VIROLOGIC RESPONSE: A NEW PREDICTIVE MODEL
Sarah Berhane*, Yoshihiko Tachi, Toshifumi Tada, Philip Johnson, Takashi Kumada, Hidenori Toyoda, United Kingdom

SAT-483 | A PROSPECTIVE STUDY OF PREVALENCE, RISK FACTORS, AND SEVERITY OF INTESTINAL FAILURE-ASSOCIATED LIVER DISEASE
Sofie H. Skadegaard*, Aleksander Krag, Palle Bekker Jeppesen, Mette Juul Nielsen, Morten Karsdal, Jens Kjeldsen, Denmark

SAT-484 | COMMUNITY APPROACH TARGETING CIRRHOSIS AND HEPATOCELLULAR CARCINOMA – CATCH
Stephen D. Bloom*, William Kemp, Anouk Dev, Amanda Nicoll, Stuart Roberts, Sally Bell, Ian Kronborg, Virginia Knight, Siddharth Sood, John Lubel, Australia
Non-invasive markers of liver fibrosis (Cont.)

SAT-485  
HEPATIC ENHANCEMENT OF GD-EOB-DTPA-ENHANCED 3-T MR IMAGING: PREDICTION OF SEVERITY OF LIVER CIRRHOSIS  
Sunyoung Lee*, Korea, South

SAT-486  
SPECTRUM OF NAFLD SEVERITY IN A LARGE POPULATION USING SOFTWARE-COMBINED TESTS OF STEATOSIS, NECROINFLAMMATORY ACTIVITY, AND FIBROSIS (FIBROMAX) IN COMPARISON WITH PATIENTS WITH CHRONIC HEPATITIS C  
Thierry Poynard*, Olivier Deckmyn, Mona Munteanu, Yen Ngo, Fabienne Drane, Jean Marie Castille, Chantal Housset, Vlad Ratziu, France

SAT-487  
INTEROBSERVER REPRODUCIBILITY OF A 2D-SHEAR WAVE ELASTOGRAPHY (2D-SWE) TECHNIQUE AND THE IMPACT OF ULTRASOUND EXPERIENCE IN ACHIEVING RELIABLE DATA  
Tudor V. Moga*, Ana Maria Stepan, Corina Pienar, Alina Popescu, Roxana Sirli, Mirela Danila, Ioan Sporea, Romania

SAT-488  
BASELINE LOW LIVER STIFFNESS VALUE CAN PREDICT A FAVORABLE REGRESSION OF FIBROSIS AFTER 5 YEARS OF ANTIVIRAL THERAPY IN PATIENTS WITH CHRONIC HEPATITIS B  
Young Eun Chon*, Myung Sung Min, Kyu Sik Jung, Kwang-Hyub Han, Beom Kyung Kim, Seung Up Kim, Do Young Kim, Sang Hoon Ahn, Jun Yong Park, Korea, South

SAT-489  
PREDICTION OF HEPATOCELLULAR CARCINOMA RECURRENCE AFTER RADIOFREQUENCY ABLATION USING LIVER STIFFNESS MEASUREMENT (FIBROSCAN)  
Yu Rim Lee*, Soo Young Park, Seung Up Kim, Sun Kyung Jang, Suhyun Lee, Se Young Jang, Won Young Tak, Young Oh Kweon, Jung Gil Park, Korea, South
**Viral hepatitis: Hepatitis C – clinical (therapy)**

**SAT-103**

**TREATMENT WITH SOFOSBUVIR + SIMEPREVIR FOR 12 WEEKS IN HCV COMPENSATED CIRRHOSIS (GENOTYPES 1 AND 4); THE USE OF RIBAVIRIN DOES NOT INFLUENCE SUSTAINED VIRAL RESPONSE**

Adolfo Gallego*, Edilmar Alvarado, Cristina Gely, Neus Pagès, Montserrat Masip, Núria Margall, Xavier Torras, Carlos Guarner, Spain

**SAT-104**

**SOFOSBUVIR PLUS VELPATASVIR FOR CHRONIC HCV GENOTYPE 1, 2, 3, AND 4 INFECTION**

Hussien Ahmed, Attia Attia, Arwa Mohamed, Ahmed Elgebaly, Ahmed Negida*, Egypt

**SAT-105**

**THE COMBINATION OF DACLATASVIR AND SOFOSBUVIR FOR CURING GENOTYPE 2 PATIENTS WHO CANNOT TOLERATE RIBAVIRIN**

Alessandra Mangia*, Andrea Arleo, Massimiliano Copetti, Maria Miscio, Valeria Piazzolla, Rosanna Santoro, Maria Maddalena Squillante, Italy

**SAT-106**

**INTERFERON-FREE TREATMENT OF CHRONIC HEPATITIS C WITH DIRECT-ACTING ANTIVIRAL AGENTS: AGE IS NO LONGER AN UNFAVORABLE PROGNOSTIC FACTOR**

Alexandre Pariente*, André-Jean Rémy, Jean-Pierre Arpurt, Christophe Renou, Frédéric Heluwaert, Hortensia Lison, Ramuntxo Arotcarena, Isabelle Rosa-Hézode, Arnaud Pauwels, François Bourhis, Gilles Macaigne, Xavier Causse, Georges Barjonet, Stéphanie de Montigny-Lenhardt, Hatem Salloum, Christophe Pilette, Séverine Hommel, Matthieu Schnee, Edmond Geagea, Éric Maringe, Yann Le Bricquin, Hélène Labadie, Jean Henrion, Hervé Hagège, Bruno Lesgourgues, France
**Viral hepatitis: Hepatitis C – clinical (therapy) (Cont.)**

**SAT-107**

**INTERFERON-FREE, DIRECT-ACTING ANTIVIRAL AGENTS REGIMENS IN HEPATITIS C ARE MORE EFFECTIVE, BETTER TOLERATED, AND DECREASE FATIGUE DURING TREATMENT IN REAL-LIFE CONDITIONS**


**SAT-108**

**REDUCTIONS IN LIFETIME RISKS OF LIVER-RELATED MORBIDITY AND MORTALITY ASSOCIATED WITH NOVEL DIRECT-ACTING ANTIVIRAL REGIMENS RECOMMENDED FOR TREATING GENOTYPE 4 NON-CIRRHOTIC HEPATITIS C PATIENTS IN THE UNITED STATES**

Sammy Saab, Hélène Parisé, Suchin Virabhak, Alice Wang*, Steven Marx, Scott Johnson, *United States*

**SAT-109**

**CHARACTERISTICS AND PREVALENCE OF CHRONIC KIDNEY DISEASE AMONG PATIENTS WITH HEPATITIS C WHO ARE TREATED WITH INTERFERON-FREE DIRECT-ACTING ANTIVIRAL REGIMENS**

Amy Puenpatom*, Michael Hull, Jeff McPheeters, Kay Schwebke, *United States*

**SAT-110**

**ADHERENCE TO EXPECTED TREATMENT DURATION FOR PATIENTS WITH HEPATITIS C TREATED WITH LEDIPASVIR/SOFOSBUVIR**

Amy Puenpatom*, Michael Hull, Jeff McPheeters, Kay Schwebke, *United States*

**SAT-111**

**LOW CORRELATION BETWEEN SUSTAINED VIROLOGIC RESPONSE AND CLINICAL OUTCOMES IN PATIENTS WITH HCV DECOMPENSATED CIRRHOSIS**

Ana Arencibia Almeida*, Antonio González, Elena Otón, Antonia Moreno, Elisa Borja, Dácil Díaz, Francisco Pérez Hernández, *Spain*
SAT-112 “REAL LIFE” SAFETY AND EFFICACY OF IFN/RBV-FREE, FULL-DOSE SOF-BASED THERAPY IN KIDNEY TRANSPLANTED PATIENTS
Ana Moreno*, Ana Fernandez, Maria J Vivancos, Maria J Pérez-Elias, Carmen Quereda, Sandra Elías, Fernando Liaño, Miguel García-González, Javier Graus, Santos del Campo, Alberto Díaz de Santiago, Maria L. Mateos, Rafael Bárcena, Santiago Moreno, Spain

SAT-113 “REAL LIFE” DATA ON DAAS USE AMONG HCV-PATIENTS WITH MODERATE TO SEVERE CHRONIC KIDNEY DISEASE NOT ON HEMODIALYSIS
Ana Moreno*, Maria J. Vivancos, Carmen Quereda, Maria J. Pérez-Elias, Alberto Díaz de Santiago, José L. Casado, Sara Bañón, Rafael Bárcena, Miguel García-González, Matilde Sánchez-Conde, Santos del Campo, María L. Mateos, Santiago Moreno, Spain

SAT-114 SIGNIFICANT REDUCTIONS IN COSTS OF GENERIC PRODUCTION OF SOFOSBUVIR AND DACLATASVIR FOR HEPATITIS C TREATMENT IN LOW- AND MIDDLE-INCOME COUNTRIES
Andrew Hill*, Bryony Simmons, Dzintars Gotham, Joseph Fortunak, United Kingdom

SAT-115 INTEGRATED, CO-LOCATED, TELEMEDICINE-BASED TREATMENT APPROACHES FOR HEPATITIS C VIRUS (HCV) MANAGEMENT FOR INDIVIDUALS ON OPIOID AGONIST TREATMENT
Andrew Talal’, Phyllis Andrews, Anthony McLeod, Marija Zeremski, Yang Chen, Clewert Sylvester, Lawrence Brown, United States

SAT-116 COMORBIDITIES, COMEDICATION AND POTENTIAL DRUG TO DRUG INTERACTIONS IN CHRONIC HEPATITIS C PATIENTS: IMPLICATIONS FOR ADEQUATE HCV TREATMENT SELECTION
Antoni Sicras’, Veronica Ferrer, Ruth Navarro, Marc Saez-Zafra, Spain

SAT-117 COMORBIDITIES, RESOURCE UTILIZATION AND HEALTH CARE COSTS OF PATIENTS WITH CHRONIC HEPATITIS C IN A SPANISH POPULATION
Antoni Sicras’, Veronica Ferrer, Ruth Navarro, Marc Saez-Zafra, Spain
Viral hepatitis: Hepatitis C – clinical (therapy) (Cont.)

**SAT-118**
**REASONS FOR DENIAL OF DIRECTLY ACTING ANTIVIRALS (DAA’S) FOR CHRONIC HEPATITIS C IN A UNITED STATES TREATMENT COHORT**

**SAT-119**
**HIGH EFFICACY OF LEDIPASVIR/SOFOSBUVIR PLUS RIBAVIRIN AMONG PATIENTS WITH DECOMPENSATED CIRRHOSIS WHO UNDERWENT LIVER TRANSPLANT DURING PARTICIPATION IN THE SOLAR-1 AND -2 STUDIES**
Beat Müllhaupt*, Paul Kwo, Kosh Agarwal, Christophe Duvoux, Francois Durand, Marcus Peck-Radosavljevic, Eric M. Yoshida, Leslie Lilly, Bernard Willems, Hugo Vargas, Princy Kumar, Robert S. Brown, Yves Horsmans, Shampa De-Oertel, Sarah Arterburn, Hadas Dvory-Sobol, Diana M. Brainard, John G. McHutchison, Norah Terrault, Mario Rizzetto, *Switzerland*

**SAT-120**
**OMBITASVIR/PARITAPREVIR/RITONAVIR + DASABUVIR + RIBAVIRIN (3D+RBV) TREATMENT OF HEPATITIS C (HCV) GENOTYPE 1 (GT1) INFECTED PATIENTS (PTS) AFTER FAILURE TO PREVIOUS FIRST GENERATION PROTEASE-INHIBITOR (PI) THERAPY. INTERIM ANALYSIS**
Bela Hunyady*, Margit Abonyi, Judit Gervain, Gábor Horváth, Zsuzsanna Gerlei, Gabriella Lengyel, Erzsébet Makkai, Zoltán Péter, Margit Pusztyay, Pál Ribiczey, László Rókus, Christoph Sarrazin, Ferenc Schneider, Maximilian Schneider, Ferenc Szalay, István Tornai, Anna Tusnádi, Eszter Újhelyi, Mihály Makara, *Hungary*

**SAT-121**
**WEIGHT GAIN AFTER IFN-FREE CURE OF CHRONIC HEPATITIS C: A POTENTIAL CONCERN?**
Bernhard Schlevogt*, Katja Deterding, Kerstin Port, Janina Kirschner, Lisa Sollik, Carola Mix, Michael P. Manns, Markus Cornberg, Heiner Wedemeyer, *Germany*
SAT-122  CAN WE CONTINUE AFTER LIVER TRANSPLANTATION WITH HCV TREATMENT STARTED ON LIST? (HEPA-C REGISTRY CASE SERIES)
Carlos Fernández-Carrillo*, Gonzalo Crespo, Juan de la Revilla, Lluis Castells, Maria Buti, José Luis Montero, Javier Crespo, Inmaculada Fernández, Cristina Serrano-Millán, Victoria Hernández, Maria Carlota Londoño, Spain

SAT-123  TREATMENT OF HCV WITH SIMEPREVIR ASSOCIATED TO DACLATASVIR IN PATIENTS WITH STAGE 4 AND 5 CHRONIC RENAL FAILURE
Carme Baliellas*, Paqui Marquez-Rodriguez, José Castellote, Teresa Casanovas-Taltavull, Rosa Rota, Anna Girbau, Eva Dueñas, Alba Cachero, Xavier Xiol, Spain

SAT-124  REAL LIFE EXPERIENCE IN TREATING CHRONIC HEPATITIS C WITH DIRECT ACTING ANTIVIRALS: GENOTYPING AND SUBTYPE MATTER
Christophe Ramière, Marianne Maynard, Kerstin Hartig-Lavie, François Bailly, Victor Virlogeux, Fabien Zoulim, Patrick Mialhès, Laurent Cotte, Olivier Guillaud, Jérôme Dumortier, Jacques Ritter, Patrice André, Caroline Scholtès*, France

SAT-125  HIGHER GENETIC BARRIER REVEALED IN HCV GT-1B/2/4/6 SUBJECTS THAN GT-1A PATIENTS – A PROOF OF CONCEPT TRIAL OF TG-2349 (FURAPREVIR)
Chau-Ting Yeh*, Shih-Jer Hsu, Tsung-Hui Hu, Chun-Jen Liu, Chen-En Tsai, Chih-Ming Chen, Li-Wen Chang, Chu-Chung Lin, Chi-Hsin R. King, Ming-Chu Hsu, Taiwan

SAT-126  HIGH SVR12 RATES WITH COMBINATION OF NS5A- AND NS5B- INHIBITORS FOR 24 WEEKS IN LIVER TRANSPLANTED PATIENTS
Christian Rupp*, Karl-Heinz Weiss, Theresa Hippchen, Wolfgang Stremmel, Peter Schemmer, Daniel N. Gotthardt, Germany

SAT-127  “REAL-LIFE”-EXPERIENCE WITH 2ND GENERATION DIRECT ACTING ANTIVIRAL (DAA) TREATMENT IN HCV PATIENTS (N=207)
Christoph R. Werner*, Nisar Malek, Ulrich Lauer, Christoph Berg, Germany
Viral hepatitis: Hepatitis C – clinical (therapy) (Cont.)

SAT-128  C-EDGE IBLD: EFFICACY AND SAFETY OF ELBASVIR/GRAZOPREVIR (EBR/GZR) IN SUBJECTS WITH CHRONIC HEPATITIS C VIRUS INFECTION AND INHERITED BLOOD DISORDERS
Christophe Hezode*, Massimo Colombo, Ulrich Spengler, Ziv Ben-Ari, Simone Strasser, William M. Lee, Leslie Morgan, Jingjun Qiu, Peggy Hwang, Michael Robertson, Bach-Yen Nguyen, Eliav Barr, Janice Wahl, Barbara Haber, Rohit Talwani, Vito Di Marco, France

SAT-129  DACLATASVIR PLUS SOFOSBUVIR PLUS RIBAVIRIN FOR 12 OR 16 WEEKS IN TREATMENT-EXPERIENCED PATIENTS WITH HCV GENOTYPE 3 INFECTION AND ADVANCED FIBROSIS OR CIRRHOSIS
Christophe Hezode*, Gregory Dore, Stephen Pianko, Stanislas Pol, Katherine Stuart, Alexander Thompson, Edmund Tse, Rafia Bhore, Maria Jesus Jimenez-Exposito, France

SAT-130  EFFICACY AND TOLERABILITY OF SIMEPREVIR AND DACLATASVIR FOR 12 OR 24 WEEKS IN HCV GENOTYPE 1B-INFECTED TREATMENT-NAÏVE PATIENTS WITH ADVANCED FIBROSIS OR COMPENSATED CIRRHOSIS
Christophe Hezode*, Piero Almasio, Stefan Bourgeois, Peter Buggisch, Ashley Brown, Moises Diago, Yves Horsmans, Lawrence Serfaty, Ferenc Szalay, Giovanni Battista Gaeta, Ramon Planas, Michael Schlag, Isabelle Lonjon-Domanec, Leen Gilles, Ralph DeMasi, Stefan Zeuzem, France

SAT-131  SUSTAINED VIROLOGIC RESPONSE TO DACLATASVIR AND SOFOSBUVIR, WITH OR WITHOUT RIBAVIRIN, AMONG PATIENTS IN THE FRENCH DACLATASVIR ATU PROGRAMME INFECTED WITH HCV GENOTYPES 4, 5 AND 6
Christophe Hézode*, Armand Abergel, Julie Chas, Filomena Conti, Laurent Cotte, Mariagrazia Tateo, Laurent Alric, Julien Vergniol, Christelle Tomei, Pierre-Henri Bernard, Véronique Loustaud-Ratti, Jean-Pierre Arpurt, Dominique Blaison, Dominique Larrey, Larysa Fedchuk, Yacia Bennai, Anne Filipovics, Hélène Fontaine, Georges-Philippe Pageaux, France
SAT-132 FAILURE TO FIRST-LINE DIRECT ANTIVIRAL (DAA) TREATMENT OF HCV INFECTION IN AN ITALIAN REAL-LIFE URBAN SETTING
Daniele Di Paolo*, Piera Rossi, Ilaria Lenci, Martina Milana, Chiara Masetti, Francesco Santopaoio, Raffaella Lionetti, Gianpiero D’Offizi, Adriano Pellicelli, Lucia Fondacaro, Massimo Siciliano, Annalisa Tortora, Francesca Chiesara, Alessandra Moretti, Francesca Ceccherini-Silberstain, Valeria Cento, Carlo Federico Perno, Mario Angelico, Italy

SAT-133 A MEMORY-LIKE SUBSET DOMINATES THE HCV-SPECIFIC CD8+ T-CELL COMPARTMENT AFTER DAA-MEDIATED ANTIGEN REMOVAL
Dominik Wieland*, Anita Schuch, Werner Held, Dietmar Zehn, Maike Hofmann, Robert Thimme, Germany

SAT-134 LEDIPASVIR/SOFOSBUVIR+/-RIBAVIRIN IN PATIENTS CO-INFECTED WITH HCV AND HIV: REAL-WORLD HETEROGENEOUS POPULATION FROM THE TRIO NETWORK
Douglas Dieterich*, Bruce Bacon, Michael Curry, Steven Flamm, Lauren Guest, Kris Kowdley, Yoori Lee, Naoky Tsai, Zobair Younossi, Nezam Afdhal, United States

SAT-135 HIGH EFFICACY AND FAVORABLE SAFETY OF ABT-493 AND ABT-530 CO-ADMINISTRATION FOR 12 WEEKS IN HCV GENOTYPE 1-INFECTED PATIENTS WITH CIRRHOSIS (SURVEYOR-I)
Ed Gane*, Fred Poordad, Armen Asatryan, Jacob Lalezari, Tarek Hassanein, Humberto Aguilar, Teresa I. Ng, Ran Liu, Chih-Wei Lin, Jens Kort, Federico Mensa, New Zealand

SAT-136 EFFICACY AND SAFETY OF OMBITASVIR/ PARITAPREVIR/RITONAVIR AND DASABUVIR, WITH OR WITHOUT RIBAVIRIN, IN ADULTS TREATED WITH THE REGIMEN APPROVED IN AUSTRALIA, CANADA, NEW ZEALAND, AND SWITZERLAND
Edward Gane*, Simone I. Strasser, Jordan Feld, Jean-Francois Dufour, Darrell Crawford, Stuart Roberts, Tara Satyanand, Mudra Kapoor, Lois Larsen, Thomas Podsadecki, New Zealand
Viral hepatitis: Hepatitis C – clinical (therapy) (Cont.)

SAT-137 100% SVR4 AND FAVORABLE SAFETY OF ABT-493 + ABT-530 ADMINISTERED FOR 12 WEEKS IN NON-CIRRHOTIC PATIENTS WITH GENOTYPES 4, 5, OR 6 INFECTION (SURVEYOR-I)
Edward Gane*, Jacob Lalezari, Armen Asatryan, Susan Greenbloom, Tarek Hassanein, Teresa Ng, Ran Liu, Chih-Wei Lin, Jens Kort, Federico Mensa, New Zealand

SAT-138 SHORT DURATION TREATMENT WITH SOFOSBUVIR/VELPATASVIR PLUS GS-9857 IN TREATMENT-NAIVE GENOTYPE 1-6 HCV-INFECTED PATIENTS WITH OR WITHOUT CIRRHOSIS

SAT-139 HIGH EFFICACY OF AN 8-WEEK 3-DRUG REGIMEN OF GRAZOPREVIR/MK-8408/MK-3682 IN HCV GENOTYPE 1, 2 AND 3-INFECTED PATIENTS: SVR24 DATA FROM THE PHASE 2 C-CREST 1 AND 2 STUDIES

SAT-140 EFFECTIVENESS AND SAFETY OF SOFOSBUVIR AND RIBAVIRIN FOR ELDERLY PATIENTS WITH HCV GENOTYPE 2 INFECTION
Eiichi Ogawa*, Norihiro Furusyo, Hideyuki Nomura, Naoki Yamashita, Kazufumi Dohmen, Akira Kawano, Kazuhiro Takahashi, Koichi Azuma, Takeaki Sato, Makoto Nakamuta, Toshimasa Koyanagi, Kazuhiro Kotoh, Shinji Shimoda, Jun Hayashi, Japan
COST-EFFECTIVENESS OF ELBASVIR (EBR, MK-8742)/GRAZOPREVIR (GZR, MK-5172) USE IN TREATMENT-NAIVE AND TREATMENT-EXPERIENCED PATIENTS WITH HEPATITIS C VIRUS (HCV) GENOTYPE 1 INFECTION AND CHRONIC KIDNEY DISEASE (CKD) IN THE UNITED STATES
Elamin Elbasha*, Wayne Greaves, Chizoba Nwankwo, United States

VIROLOGIC RESPONSE FOLLOWING ASUNAPREVIR/DACLATASVIR WITH OR WITHOUT BECLABUVIR FOR TREATMENT OF HCV GENOTYPE 1 IN PATIENTS CO-INFECTED WITH HIV
Elana S. Rosenthal, M.D.*, Louisa Howard, B.A., Julia Purdy, MSN, CRNP, Mary McLaughlin, RN, BSN, Sarah Kattakuzhy, M.D., Anita Kohli, M.D., Eleanor Wilson, M.D., Henry Masur, M.D., Shyam Kotttilil, M.D., Ph.D., United States

PREVALENCE AND MANAGEMENT OF DRUG-DRUG INTERACTIONS (DDIS) WITH OMBITASVIR (OBV), PARITAPREVIR/R (PRV/R) ± DASABUVIR (DBV) ± RIBAVIRIN (RBV) IN PATIENTS WITH CHRONIC HEPATITIS C IN REAL-LIFE CLINICAL PRACTICE
Elena González-Colominas*, María-Carlota Londoño, Rosa M. Morillas, Xavier Torras, Sergi Mojal, Sabela Lens, Dulce López, Adolfo Gallego, Zoe Mariño, Mercé Ardèvol, Neus Pagès, Ricard Solà, Jose A. Carrión, Spain

HIGH SVR RATES WITH SMV+SOF IN HCV GT1 AND GT4 PATIENTS WITH CIRRHOSIS OR ADVANCED FIBROSIS: A REAL PRACTICE ANALYSIS FROM A LARGE REGIONAL DATABASE IN TUSCANY, ITALY
Elena Salomoni*, Elena Gianni, Laura Gragnani, Filippo Oliveri, Maurizia R. Brunetto, Sauro Luchi, Dario Bartolozzi, Paolo Forte, Spartaco Sani, Pierluigi Blanc, Rodolfo Sacco, Anna Linda Zignego, Andrea De Luca, Danilo Tacconi, Donatella Aquilini, Francesco Menichetti, Corrado Catalani, Cesira Nencioni, Paola Carrai, Silvia Chigiotti, Piero Colombatto, Italy

CORE ANTIGEN QUANTIFICATION TO MONITOR TREATMENT EFFICACY IN PATIENTS WITH CHRONIC HEPATITIS C REceiving DIRECTLY ACTING ANTIVIRALS
Elisabetta Degasperi*, Alessio Aghemo, Stella De Nicola, Patrizia Bono, Anna Orlandi, Roberta D’Ambrosio, Roberta Soffredini, Riccardo Perbellini, Giovanna Lunghi, Massimo Colombo, Italy
**Viral hepatitis: Hepatitis C – clinical (therapy) (Cont.)**

**SAT-146**
HEPATITIS C CORE ANTIGEN ASSAY FOR THE MONITORING OF TREATMENT WITH DIRECT ANTIVIRAL AGENTS IN PATIENTS WITH CHRONIC HEPATITIS C
Elisabetta Loggi*, Carmela Cursaro, Alessandra Scuteri, Ranka Vukotic, Elena Grandini, Marzia Margotti, Valeria Guarneri, Mauro Stanzani, Silvia Galli, Giuliano Furlini, Claudio Galli, Maria Paola Landini, Pietro Andreone, *Italy*

**SAT-147**
DASABUVIR AND OMBITASVIR/PARITAPREVIR/RITONAVIR WITH OR WITHOUT RIBAVIRIN IN PATIENTS WITH HIV-HCV COINFECTION: REAL LIFE INTERIM ANALYSIS OF AN ITALIAN MULTICENTRE COMPASSIONATE USE PROGRAM
Elisabetta Teti*, Alessandra Ricciardi, Andrea Antinori, Massimo Galli, Giuliano Rizzardini, Antonio Di Biagio, Gioacchino Angarano, Raffaele Bruno, Cristina Mussini, Andrea De Luca, Annamaria Cattelan, Adriano Lazzarin, Gloria Taliani, Antonella D’Arminio Monforte, Claudio Maria Mastroianni, Giovanni Di Perri, Franco Maggiolo, Massimo Puoti, Francesco Castelli, Andrea Gori, Nicola Boffa, Bruno Cacopardo, Andrea Giammetti, Giustino Parruti, Vincenzo Vullo, Antonio Chirianni, Alfredo Pennica, Caterina Pasquazzi, Laura Sighinolgi, Elisa Gentilotti, Loredana Sarmati, Massimo Andreoni, *Italy*

**SAT-148**
C-SWIFT RETREATMENT FINAL RESULTS: HIGHLY SUCCESSFUL RETREATMENT OF GT1-INFECTED PATIENTS WITH 12 WEEKS OF ELBASVIR/GRAZOPREVIR PLUS SOFOSBUVIR AND RIBAVIRIN AFTER FAILURE OF SHORT-DURATION ALL-ORAL THERAPY
Eric J. Lawitz*, Fred Poordad, Julio Gutierrez, Jennifer Wells, Carmen Landaverde, Joseph Reiling, Jerry Jing Li, Hsieh-Cheng Huang, Michael Robertson, Janice Wahl, Eliav Barr, Barbara Haber, *United States*
SAT-149  LEDIPASVIR/SOFOSBUVIR IN NS3/4A PROTEASE INHIBITOR-EXPERIENCED SUBJECTS WITH HCV GENOTYPE 1 AND HIV-CO-INFECTION. FINAL RESULTS OF THE ANRS HC31 SOFTRIH STUDY
Eric Rosenthal*, Claire Fougerou-Leurent, Alain Renault,
Elina Teicher, Stéphanie Dominguez, Alissa Naqvi, Sophie Metivier,
Laurent Cotte, Jacques Reyne, Marc-Antoine Valantin,
Vincent Leroy, Georges-Philippe Pageaux, Stanislas Pol, Lionel Piroth,
Philippe Perre, Philippe Morlat, Dominique Salmon-Ceron,
Julie Chas, Vincent Jeantils, Pierre de Truchis, Thierry Allègre,
Michel Dupon, François Raffi, Yazdan Yazdanpanah,
Isabelle Poizot-Martin, Didier Néau, Pierre-Marie Girard,
David Zucman, Rodolphe Garraffo, Stéphane Chevaliez,
Patrizia Carrieri, Hugues Aumaitre, Karine Lacombe, Francois Bailly,
Eric Billaud, Aurélie Pailhé, Imane Amri, Marc Bourlière,
Eric Bellissant, Jean-Michel Molina, *France

SAT-150  HIGH EFFICACY OF INTERFERON-FREE TREATMENTS IN REAL-WORLD PATIENTS WITH CHRONIC HEPATITIS C. A MULTICENTRIC STUDY
Huascar Ramos, Ester Badia*, Pedro Linares, Isabel Martín,
Carolina Almohalla, Francisco Jorquera, Isidro García, Mónica Vásquez,
Pilar Conde, Begoña Alvarez, Guillermo Karpman, Judith Gómez,
Sara Lorenzo, Visitación Gozalo, Diana Joao, Marina de Benito,
Lourdes Ruiz, Felipe Jiménez, Federico Sáez-Royuela, *Spain

SAT-151  EFFICACY OF INTERFERON-FREE THERAPY IN CIRRHOTIC AND NON-CIRRHOTIC CHRONIC HEPATITIS C PATIENTS IN CLINICAL PRACTICE
Ester Badia*, Huascar Ramos, Pedro Linares, Isabel Martín,
Carolina Almohalla, Francisco Jorquera, Isidro García, Mónica Vásquez,
Pilar Conde, Begoña Alvarez, Guillermo Karpman, Visitación Gozalo,
Sara Lorenzo, Judith Gómez, Diana Joao, Marina de Benito,
Lourdes Ruiz, Felipe Jiménez, Federico Sáez-Royuela, *Spain

SAT-152  SIMEPREVIR AND SOFOSBUVIR WITH OR WITHOUT RIBAVIRIN IN GENOTYPE 1 CHRONIC HEPATITIS C PATIENTS: EFFICACY AND SAFETY IN REAL LIFE
Huascar Ramos, Judith Gómez, Pedro Linares, Isabel Martín,
Carolina Almohalla, Francisco Jorquera, Isidro García,
Mónica Vásquez, Pilar Conde, Ester Badía*, Begoña Alvarez,
Guillermo Karpman, Sara Lorenzo, Visitación Gozalo, Diana Joao,
Marina de Benito, Lourdes Ruiz, Felipe Jiménez,
Federico Sáez-Royuela, *Spain
Viral hepatitis: Hepatitis C – clinical (therapy) (Cont.)

SAT-153  INTRODUCTION OF DIRECTLY OBSERVED COMMUNITY PHARMACY DISPENSING OF DIRECTING ACTING ANTIVIRALS ACHIEVES HIGH SUSTAINED VIRAL RESPONSE RATES IN A DIFFICULT TO TREAT COHORT
Fiona Marra*, Shouren Datta, Matthew Priest, Mathis Heydtmann, Ray Fox, Stephen T. Barclay, United Kingdom

SAT-154  SOFOSBUVIR / LEDIPASVIR IN SPANISH PRISON POPULATION WITH CHRONIC HEPATITIS C
Francisco Fernandez-Gonzalez*, Ana Maria Matilla-Peña, Paloma Gijón-Vidaurreta, Enrique Acín-García, Diego Rincón-Rodríguez, Elena Reigadas-Ramirez, Gerardo Clemente Ricote, Spain

SAT-155  TREATMENT OF HCV GENOTYPE 2 WITH SOFOSBUVIR AND RIBAVIRIN RESULTS IN LOW SVR RATES IN A REAL WORLD COHORT (GERMAN HEPATITIS C-REGISTRY, DHC-R)
Frank Tacke*, Rainer Günther, Peter Buggisch, Hartwig Klinker, Andreas Schober, Christine John, Thomas Lutz, Heike Pfeiffer-Vornkahl, Claus Niederau, Markus Cornberg, Christoph Sarrazin, Stefan Mauss, German Hepatitis C-Registry, Germany

SAT-156  OMBITASVIR/PARITAPREVIR/R, DASABUVIR, AND SOFOSBUVIR TREATMENT OF PATIENTS WITH HCV GENOTYPE 1-INFECTION WHO FAILED A PRIOR COURSE OF DAA THERAPY: THE QUARTZ-I STUDY
Fred Poordad*, Michael Bennett, Thomas E. Sepe, Eric Cohen, Robert W. Reindollar, Gregory Everson, Raymond W. Phillips, Asma Siddique, J. Greg Sullivan, Terry D. Box, Bo Fu, Tami Pilot-Matias, Manal Abunimeh, Daniel E. Cohen, Ziad Younes, United States

SAT-157  HIGH SVR RATES WITH THE COMBINATION OF ABT-493 + ABT-530 FOR 8 WEEKS IN NON-CIRRHOTIC PATIENTS WITH HCV GENOTYPE 1 OR 2 INFECTION
Fred Poordad*, Franco Felizarta, Stanley Wang, Armen Asatryan, Tarek Hassanain, Humberto Aguilar, Jacob Lalezari, J. Scott Overcash, Teresa I. Ng, Sandra S. Lovell, Chih-Wei Lin, Jens Kort, Federico J. Mensa, United States
SAT-158 FACTORS IMPACTING SVR12 FOR PATIENTS WITH ADVANCED CIRRHOSIS RECEIVING DACLATASVIR AND SOFOSBUVIR WITH RIBAVIRIN IN THE ALLY-1 STUDY
Frederick Poordad*, Robert Fontana, Eugene Schiff, John M. Vierling, Charles Landis, Yue Zhao, Yash Gandhi, Tushar Garimella, Tim Eley, Stephanie Noviello, Eugene S. Swenson, United States

SAT-159 INTEGRATED ANALYSIS OF SOF+RBV OR LDV/SOF FOR THE TREATMENT OF GENOTYPE 4 CHRONIC HCV INFECTION
Gamal E. Esmat*, Gamal Shiha, Armand Abergel, Tarik Asselah, Anita Kohli, Shyam Kotttilil, Peter J. Ruane, Susanna Naggie, Wahid H. Doss, Thomas A. Hahambis, Cathleen Letterio, Macky Natha, Bruce Kreter, Kathryn Kersey, Diana Brainard, Steven J. Knox, Egypt

SAT-160 SOFOSBUVIR PLUS SIMEPREVIR IN TREATMENT-NAIVE AND TREATMENT-EXPERIENCED EGYPTIAN PATIENTS WITH HEPATITIS C VIRUS INFECTION: A REAL LIFE EXPERIENCE

SAT-161 FINAL RESULTS OF THE PYRAMID 1 STUDY, A PHASE 3 REGISTRATIONAL TRIAL OF RAVIDASVIR (PPI-668) AND SOFOSBUVIR IN HCV GENOTYPE-4 PATIENTS: HIGH RATES OF SUSTAINED VIRAL CLEARANCE IN CIRRHOTIC AND NON-CIRRHOTIC PATIENTS

SAT-162 EFFECTIVENESS OF SIMEPREVIR TREATMENT FOR HEPATITIS C IN REAL PRACTICE: PRELIMINARY RESULTS FROM THE STILY ITALIAN OBSERVATIONAL STUDY
Giovanni B. Gaeta*, Barbara Menzaghi, Gianpiero D’Offizi, Alessia Giorgini, Adriano Lazzarin, Sergio Babudieri, Maurizia Brunetto, Stefano Fagiuli, Lucia Simoni, Maria Palma, Roberta Termini, Italy
Viral hepatitis: Hepatitis C – clinical (therapy) (Cont.)

SAT-163  C-EDGE CO-STAR: RISK OF REINFECTION FOLLOWING SUCCESSFUL THERAPY WITH ELBASVIR AND GRAZOPREVR IN PERSONS WHO INJECT DRUGS (PWID) RECEIVING OPIOID AGONIST THERAPY (OAT)

SAT-164  SOfosbuvir-based, RIBAVIRIN-Freeregimens IN PATIENTS WITH CHRONIC HEPATITIS C AND END-Stage renal disease: A look at safety, tolerability and efficacy
Hector E. Nazario*, Apurva Modi, Milka Ndungu, Ruben Ramirez, Lauren Tujague, Jeffrey Weinstein, United States

SAT-165  Real-life results of sofosbuvir based therapy FOR EGYPTIAN PATIENTS WITH HEPATITIS C AND advanced fibrosis-cirrhosis
Wahid Doss, Gamal Esmat, Magdy El-Serafy, Wafaa El-Akel, Ayman Yosry, Manal El-Sayed, Mohamed Hassany, Mohamed El-Kassas, Khaled Kabil, Imam Waked*, Egypt

SAT-166  Ombitasvir/paritaprevir/ritonavir with ribavirin achieves high sustained virologic response (SVR) rates in Egyptian adults with CHRONIC HCV genotype 4 infection (AGATE-II)
Imam Waked*, Gamal Shiha, Roula B. Qaqish, Gamal Esmat, Ayman Yosry, Wahid Doss, Mohamed Hassany, Reham Soliman, Mohammad A. Mohey, Naglaa Allam, Naglaa Zayed, Carolyn M. Setze, Rebecca Redman, Niloufar Mobashery, Egypt

SAT-167  Effectiveness of simeprevir-containing regimens among patients with chronic hepatitis C virus in various US practice settings: the SONET study
SAT-168  THE TOLERABILITY OF SOF/VEL FOR 12 WEEKS IN >1000 PATIENTS TREATED IN THE ASTRAL-1, ASTRAL -2, AND ASTRAL -3 STUDIES: AN INTEGRATED SAFETY ANALYSIS
Ira Jacobson*, Norbert Brau, Stefan Bourgeois, Phillippe Mathurin, Paul Thuluvath, W. Jeffrey Fessel, Stephen Ryder, Guido Gerken, Lin Liu, Xiao Ding, John McNally, Anu Osinusi, Diana Brainard, Mani Subramanian, Graham Foster, United States

SAT-169  BASELINE CLINICAL AND LABORATORY PARAMETERS ASSOCIATED WITH CLINICAL BENEFITS OF SUCCESSFUL HCV TREATMENT WITH SOFOSBUVIR/VELPATASVIR IN DECOMPENSATED CIRRHOTIC PATIENTS

SAT-170  COST-EFFECTIVENESS OF DIRECT-ACTING ANTIVIRALS FOR HEPATITIS C TREATMENT: A SYSTEMATIC REVIEW OF 227 ANALYSES
Jagpreet Chhatwal*, Tianhua He, Chin Hur, Maria Lopez-Olivo, United States

SAT-171  HEPATITIS C TREATMENT AS PREVENTION: FOCUSING ON UNITED STATES PRISONS
Jagpreet Chhatwal*, Kan Li, Tianhua He, Mark S. Roberts, Turgay Ayer, Sumeyye S. Samur, John J. Grefenstette, Anne C. Spaulding, United States

SAT-172  A RETROSPECTIVE ANALYSIS OF HEPATITIS C INFECTED PATIENTS TREATED THROUGH A COMMUNITY-BASED INTEGRATED CARE MODEL
James M. Levin*, Eric Huckins, Katherine Zimny, United States

SAT-173  SOF/VEL FOR 12 WEEKS IS WELL TOLERATED AND RESULTS IN HIGH SVR12 RATES IN PEOPLE RECEIVING OPIOID SUBSTITUTION THERAPY
Jason Grebely*, Gregory J. Dore, Richard Aspinall, Maribel Rodriguez-Torres, Raymond Fox, Lin Liu, Xiao Ding, John McNally, Anu Osinusi, Diana Brainard, Mani Subramanian, Mark Sulkowski, Jordan Feld, Australia
### Viral hepatitis: Hepatitis C – clinical (therapy) (Cont.)

<table>
<thead>
<tr>
<th>SAT-174</th>
<th>ON-TREATMENT ILLICIT DRUG USE DID NOT IMPACT TREATMENT OUTCOME DURING THERAPY WITH LEDIPASVIR-SOFOSBUVIR WITH OR WITHOUT RIBAVIRIN IN THE PHASE 3 ION-1 STUDY</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Jason Grebely*, Steve Flamm, Stefan Zeuzem, Robert Hyland, Paul Chang, Xiao Ding, Chohee Yun, Diana Brainard, John McHutchison, Xavier Forns, Alessandra Mangia, Gregory Dore, Australia</td>
</tr>
</tbody>
</table>

**SAT-175**  
YI  
**HCV GENOTYPE 3: META-ANALYSIS WITH AVAILABLE TREATMENT OPTIONS**  
Javier Ampuero*, Rajender Reddy, Manuel Romero-Gomez, Spain

**SAT-176**  
YI  
**IMPACT OF BASAL COMORBIDITIES ON THE OVERALL BENEFIT OF DAA THERAPY IN HEPATITIS C**  
Javier Ampuero*, Carlota Jimeno, Nieves Palomo, Rosa Quiles, Aida Ortega, Guillermo Ontanilla, Patricia Cordero, Jose Maria Rosales, Marta Hernandez, Francisco Javier Serrano, Martin Bonacci, Marta Maraver, Lourdes Grande, Xavier Forns, Manuel De la Mata, Jose Luis Calleja, Jose Maria Navarro, Isabel Carmona, Juan Manuel Pascasio, Raul Andrade, Javier Salmeron, Maria Buti, Javier Crespo, Manuel Romero-Gomez, Spain

**SAT-177**  
**REAL-WORD EFFECTIVENESS OF 8, 12 AND 24 WEEKS LEDIPASVIR (LDV)/SOFOBUVIR (SOF)-BASED THERAPY FOR HEPATITIS C VIRUS (HCV) GENOTYPE 1: ANALYSIS IN A LARGE INTEGRATED HEALTH CARE SYSTEM**  
Jennifer Lai*, Maxwell Witt, David Witt, United States

**SAT-178**  
**LONG-TERM EFFECT OF THE PORTUGUESE UNIVERSAL ACCESS PROGRAM TO NEW GENERATION DIRECT-ACTING ANTIVIRALS FOR THE TREATMENT OF HEPATITIS C**  
SAT-179
EFFICACY AND SAFETY OF HCV-TREATMENT WITH DIRECT-ACTING ANTIVIRAL AGENTS INTERFERON-FREE, IN PATIENTS WITH SEVERE RENAL IMPAIRMENT IN CLINICAL PRACTICE
Joaquin Cabezas*, Maria Carlota Londoño, Susana Llerena, Raquel Muñoz, Carmen Ballellas, Maria Buti, Juan Manuel Pascasio, Federico Saez-Royuela, Javier García-Samaniego, Juan de la Vega, Pilar Sanchez-Pobre, Carmen Alvarez-Navascues, Jose Antonio Carrión, Francisco Gea, Rosa Maria Morillas, Miguel Fernandez-Bermejo, Angeles Castro, Maria Rivero, Jose Ramon Fernandez, Marina Berenguer, Jose J Moreno, Diego Rincon, Jose Luis Calleja, Javier Crespo, Spain

SAT-180
TREATMENT OF HEPATITIS C ASSOCIATED MIXED CRYOglobulinemia WITH DIRECT ACTING ANTIVIRAL THERAPY
Joel S. Emery*, Magdalena Kuczynski, Dani La, Matthew Kowgier, Jordan Feld, Canada

SAT-181
LARGE SINGLE CENTER EXPERIENCE OF SOFOSBUVIR AND LEDIPASVIR THERAPY FOR THE TREATMENT OF PATIENTS WITH HEPATITIS C VIRUS
Joel Wedd*, Ryan Ford, Jp Norvell, Samir Parekh, Nicole Cheng, Nikita Young, Anisha Patel, Rahul Maheshwari, Ravi Vora, Okechukwu Mgbemena, James Spivey, Anjana Pillai, United States

SAT-182
REAL WORLD EVALUATION OF VIEKIRA PAK (RITONAVIR BOOSTED PARITAPREVIR, OMBITASVIR AND DASABUVIR +/- RIBAVIRIN) IN HCV GENOTYPE 1 TARGETING ADVANCED LIVER DISEASE (THE REV1TAL STUDY)
John S. Lubel’, Stephen Pianko, Alexander Thompson, Simone Strasser, Katherine Stuart, Paul Gow, Joanne Mitchell, Alessia Gazzola, Sarah Chivers, Gauri Mishra, Saroj Nazareth, Tracey Jones, John Gough, Steven Bollipo, Amanda Wade, Edmund Tse, Gerry MacQuillan, Jacob George, Stuart Roberts, Australia
Viral hepatitis: Hepatitis C – clinical (therapy) (Cont.)

SAT-183  LEDIPASVIR/SOFOSBUVIR WITH RIBAVIRIN FOR 12 WEEKS IS EFFECTIVE AND SAFE IN TREATMENT-NAÏVE GENOTYPE-3 HEPATITIS C-INFECTED PATIENTS IN CANADA

SAT-184  DACLATASVIR PLUS SOFOSBUVIR WITH OR WITHOUT RIBAVIRIN FOR THE TREATMENT OF CHRONIC HCV INFECTION IN PATIENTS WITH DECOMPENSATED CIRRHOSIS: RESULTS OF A EUROPEAN MULTICENTRE COMPASSIONATE USE PROGRAM
Jorg Petersen’, Tania Welzel, Kerstin Herzer, Peter Ferenci, Michael Gschwantler, Markus Cornberg, Patrick Ingiliz, Thomas Berg, Ulrich Spengler, Ola Weiland, Marc van der Valk, Hartwig Klinker, Jurgen Rockstroh, Markus Peck-Radosavljevic, Yue Zhao, Maria Jesus Jimenez-Exposito, Stefan Zeuzem, Germany

SAT-185  FAILURE WITH DAA REGIMENS IN A HIGH VOLUME TREATMENT CENTER UNDER REAL LIFE CONDITIONS
Jorg Petersen’, Karsten Wursthorn, Karen Olah, Thore Lorenzen, Andreas Plettenberg, Stefan Unger, Christine Czaja-Harder, Kathrin Matschenz, Albrecht Stoehr, Peter Buggisch, Germany

SAT-186  HEPATIC FIBROSIS MEASURED BY ELASTOGRAPHY AMONG PEOPLE WHO INJECT DRUGS WITH CHRONIC HCV IN COMMUNITY SETTINGS: THE TAP STUDY
Joseph S. Doyle’, Paul Dietze, Paul Desmond, David M. Iser, Mark Stoove, Emma McBryde, Peter Higgs, Margaret E. Hellard, Alexander J. Thompson, Australia

SAT-187  REDUCING THE BURDEN OF HEPATOCELLULAR CARCINOMA IN JAPAN THROUGH TREATMENT OF CHRONIC HEPATITIS C VIRUS INFECTION
Junko Tanaka’, Christopher R. Estes, Homie Razavi, Japan
SAT-188 AN INTEGRATED SAFETY AND EFFICACY ANALYSIS OF SOFOSBUVIR-BASED REGIMENS IN PATIENTS WITH HEREDITARY BLEEDING DISORDERS
K. Rajender Reddy*, Catherine Stedman, Kimberly Workowski, Jenny C. Yang, Luisa M. Stamm, Ming Lin, Diana M. Brainard, John G. McHutchison, Gayle P. Balba, Edward J. Gane, Christopher Walsh, United States

SAT-189 SAFETY AND EFFICACY OF NEW DAA REGIMENS IN KIDNEY AND LIVER TRANSPLANT RECIPIENTS WITH HEPATITIS C: INTERVAL RESULTS FROM THE HCV-TARGET STUDY

SAT-190 RENAL FUNCTION DECLINE IS FREQUENT IN PATIENTS UNDERGOING HEPATITIS C TREATMENT POST KIDNEY TRANSPLANT
Kalyan R. Bhamidimarri*, Paul Martin, Cynthia Levy, David Roth, United States

SAT-191 TREATMENT OF CHRONIC HEPATITIS C AFTER DECEASED DONOR RENAL TRANSPLANTATION WITH DIRECT ACTING ANTIVIRAL REGIMENS: INTERIM DATA
Hani El-Halawany, Kamran Qureshi*, United States

SAT-192 REAL-LIFE OUTCOMES OF 8 WEEKS REGIMEN OF SOFOSBUVIR AND LEDIPASVIR WITHOUT RIBAVIRIN, IN NON-CIRRHOTIC TREATMENT-NAIVE HEPATITIS C GENOTYPE 1 PATIENTS WITH LESS THAN 6 MILLION IU/ML VIRAL LOAD
Kamran Qureshi*, Jennifer Andres, John Regester, Stephen Lott, Joshua Halladay, Cassandra Peleckis, Paul Urick, United States

SAT-193 LOW SUSTAINED VIROLOGIC RESPONSE (SVR) RATES IN GENOTYPE (GT) 2 AND 3 PATIENTS WITH QUANTIFIABLE HEPATITIS C VIRUS (HCV) AT WEEK 4 OF TREATMENT WITH SOFOSBUVIR (SOF) CONTAINING REGIMENS
Karla Thornton*, Paulina Deming, Miranda Sedillo, Clifford Qualls, Terry Box, John Scott, Paula Cox, Jorge Mera, Anna Miller, Richard Manch, Anita Kohli, Robert Gish, Ann Moore, Norman Sussman, Saira Khaderi, Sanjeev Arora, United States
Viral hepatitis: Hepatitis C – clinical (therapy) (Cont.)

**SAT-194 SAFETY AND EFFICACY OF IFN- FREE ANTIVIRAL THERAPIES IN ADVANCED HCV- ASSOCIATED LIVER CIRRHOSIS: RESULTS FROM THE GERMAN HEPATITIS C-REGISTRY (DHC-R)**

Katja Deterding*, Peter Buggisch, Hartwig Klinker, Karl-Georg Simon, Klaus H. W. Böker, Eckart Schott, Tim Zimmermann, Markus Cornberg, Rainer Günther, Heike Pfeiffer-Vornkahl, Christoph Sarrazin, Michael P. Manns, Dietrich Hüppe, Heiner Wedemeyer, Thomas Berg, German Hepatitis C-Registry, Germany

**SAT-195 SOF/VEL FOR 12 WEEKS RESULTS IN HIGH SVR12 RATES IN SUBJECTS WITH NEGATIVE PREDICTORS OF RESPONSE TO TREATMENT: AN INTEGRATED ANALYSIS OF EFFICACY FROM THE ASTRAL-1, ASTRAL-2 AND ASTRAL-3 STUDIES**

Kaushik Agarwal*, Keyur Patel, Didier Samuel, Marc Bourliere, Ziad Younes, Tim Morgan, Simone Strasser, Barbara Leggett, Lin Liu, Xiao Ding, John McNally, Anu Osinusi, Diana Brainard, Mani Subramanian, Nezam Afdhal, United Kingdom

**SAT-196 OUTCOME, SAFETY AND TOLERABILITY OF TREATING HEPATITIS C IN DECOMPENSATED CIRRHTICS WITH LEDIPASVIR/SOFOSBUVIR WITH OR WITHOUT RIBAVIRIN OR SOFOSBUVIR WITH RIBAVIRIN: REAL LIFE DATA. PRELIMINARY RESULTS OF RETROSPECTIVE SINGLE CENTER EXPERIENCE**

Khaled Selim*, Wen long, Bridgeida Elhazin, Jennifer Salazar, Marina Karmanova, Micheal Volk, United States

**SAT-197 SAFETY AND TOLERABILITY OF RECURRENT HEPATITIS C TREATMENT IN POST LIVER AND LIVER/KIDNEY TRANSPLANT PATIENTS TREATED WITH LEDIPASVIR/SOFOSBUVIR WITH AND WITHOUT RIBAVIRIN OR SOFOSBUVIR WITH RIBAVIRIN: SINGLE CENTER EXPERIENCE**

Khaled Selim*, Bridgeida Elhazin, Wen long, Marina Karmanova, Jennifer Salazar, Micheal Volk, United States
SAT-198  PHARMACOKINETIC ANALYSES OF LEDIPASVIR/SOFOSBUVIR IN HCV-INFECTED SUBJECTS WITH ADVANCED LIVER DISEASE AND/OR FOLLOWING LIVER TRANSPLANTATION
Kimberly L. Garrison*, Polina German, Sarah Arterburn, Shampa De-Oertel, Diana Brainard, John Ling, Feng Jin, Anita Mathias, United States

SAT-199  ALL-ORAL TREATMENT WITH DACLATASVIR PLUS SOFOSBUVIR ± RIBAVIRIN IN HCV GENOTYPE 3-INFECTED PATIENTS WITH ADVANCED FIBROSIS OR CIRRHOSIS: AN ANALYSIS OF ALLY-3 AND ALLY-3+
Kris Kowdley*, Peter Angus, David Bernstein, Jean-Pierre Bronowicki, Vincent Leroy, Paul Pockros, Rafia Bhore, Khurram Rana, Maria Jesus Jimenez-Exposito, United States

SAT-200  INFLUENCE OF PROTON PUMP INHIBITORS AND H2 RECEPTOR ANTAGONISTS ON DIRECT ACTING ANTIVIRAL HCV SUSTAINED VIROLOGIC RESPONSE
Lacey DeVreese*, Pierre Giguère, Daniel Corsi, Curtis Cooper, Canada

SAT-201  RAPID CHANGES IN CHOLESTEROL IN CHRONIC HEPATITIS C PATIENTS TREATED WITH ANTIVIRALS AND POTENTIAL IMPACT ON CARDIOVASCULAR RISK
Laura M. Benitez*, Isabella Esposito, Isolina Baños, Ana Duca, Maria Jesus Citores, Pablo Barreiro, Alicia Royuela, Valentin Cuervas-Mons, Vicente Soriano, Carmen De Mendoza, Spain

SAT-202  IMPACT OF DAA THERAPY ON THE CANDIDACY TO LIVER TRANSPLANTATION. AN ANALYSIS ON PUBLISHED DATA
Luigi G. Lupo*, Maria Rendina, Maria F. Valentini, Stefania Roselli, Italy

SAT-203  HIGH TOLERABILITY AND SUSTAINED VIROLOGIC RESPONSE WITH SOFOSBUVIR-BASED THERAPY AMONG PATIENTS WITH MENTAL HEALTH DISEASE
Lydia Tang*, Jack Masur, Zayani Sims, Shyam Kotttilil, United States
Viral hepatitis: Hepatitis C – clinical (therapy) (Cont.)

SAT-204  
**EFFICACY AND SAFETY OF DIRECT ACTING ANTIVIRAL THERAPY FOR HCV GENOTYPE 4 IN EGYPT; MULTICENTER REAL LIFE EXPERIENCE**

SAT-205  
**REAL-LIFE EXPERIENCE OF DAA-BASED REGIMENS PLUS RIBAVIRIN IN CIRRHOTIC PATIENTS COINFECTED WITH HCV AND HIV-1**
Emanuela Messina, Caterina Uberti-Foppa, Marco Merli*, Laura Galli, Diletta Barbanotti, Andrea Poli, Stefania Salpietro, Giulia Morsica, Sabrina Bagaglio, Andrea Andolina, Antonella Castagna, Adriano Lazzarin, Hamid Hasson, *Italy*

SAT-206  
**DIFFERENCES BETWEEN HEPATITIS HCV-MONOINFECTED AND HCV-HIV-COINFECTED PATIENTS TREATED WITH NEW DAA-BASED THERAPIES**
Maria Luisa Montes*, Adriana Ahumada, Teresa Aldamiz, Antonio Olveira, Lucia Bailón, Javier Garcia-Samaniego, Juan Berenguer, Dolores Perez-Valderas, Victoria Moreno, Pilar Miralles, Pilar Castillo, Diego Rincón, Eulalia Valencia, Miriam Romero, Juan Carlos López Bernaldo de Quirós, Maria Vega Catalina, Araceli Garcia, Francisco Parras, Ana Matilla, Marta Abadia, Mikel Rico, Luz Martin-Carbonero, *Spain*

SAT-207  
**EFFICACY AND TOLERABILITY OF INTERFERON-FREE ANTIVIRAL THERAPY IN KIDNEY TRANSPLANT (KT) RECIPIENTS WITH CHRONIC HEPATITIS C: REAL-LIFE DATA FROM THE SPANISH NATIONAL REGISTRY (HEPA-C)**
Maria-Carlota Londoño*, Inmaculada Fernández, Raquel Muñoz-Gómez, Juan-Manuel Pascasio, Carmen Bariellas, Natalia Polanco, Nuria Esforzado, Martín Prieto, Lluís Castells, Javier Crespo, Jose-Luis Calleja, Francisco Gea, Xavier Forns, *Spain*
SAT-208 TREATMENT OF PATIENTS WITH HEPATITIS C VIRUS (HCV) GENOTYPE 3 INFECTION IN THE ERA OF DIRECT ACTING ANTIVIRALS (DAA): DATA FROM THE GERMAN HEPATITIS C-REGISTRY (DHC-R)
Markus Cornberg*, Peter Buggisch, Andreas Schober, Günther Schmutz, Klaus H. W. Böker, Ralph Link, Stefan Christensen, Karl-Georg Büscher, Heike Pfeiffer-Vornkahl, Michael P. Manns, Christoph Sarrazin, Dietrich Hüppe, Thomas Berg, Claus Niederau, German Hepatitis C-Registry, Germany

SAT-209 LEDIPASVIR/SOFOSBUVIR FOR RECURRENT HEPATITIS C IN LIVER TRANSPLANT RECIPIENTS: A REAL-LIFE SPANISH MULTICENTRE EXPERIENCE
Martin Prieto*, Inmaculada Fernández, Maria-Carolita Londoño, Manuel Abradelo, Juan Manuel Pascasio, Francisco Gea, Diego Rincón, Valentin Cuervas-Mons, Gonzalo Crespo, José Luis Montero, Vanessa Hontangas, Carme Baliellas, José Manuel Sousa, Miguel García, Sonia Pascual, José Antonio Pons, Lluis Castells, Milagros Testillano, Miguel Jimenez, Alejandra Otero, Esther Molina, Antonio González, Flor Nogueras, Luisa González-Diequez, Sara Lorente, Gloria Sánchez-Antolin, José Ignacio Herrero, Fernando Casafont, Spain

SAT-210 MODELING EARLY HCV KINETICS TO INDIVIDUALIZE DIRECT ACTING ANTIVIRALS TREATMENT DURATION IN PATIENTS WITH ADVANCED CIRRHOSIS
Martina Gambato*, Laetitia Canini, Sabela Lens, Frederik Graw, Maria C. Londoño, Susan L. Uprichard, Zoe Mariño, Enric Reverter, Concepcio Bartres, Patricia González, Scott J. Cotler, Xavier Forns, Harel Dahari, Spain

SAT-211 EFFICACY OF DACLATASVIR/ASUNAPREVIR FOR PATIENTS WITH CHRONIC HEPATITIS C 1B COMPLICATED WITH RENAL INSUFFICIENCY
Masanori Atsukawa*, Noritomo Shimada, Akihito Tsubota, Hiroshi Abe, Tomomi Okubo, Ai Nakagawa, Taeang Arai, Notio Itokawa, Chisa Kondo, Yasuhiro Tanaka, Yoshio Aizawa, Katsuhiko Iwakiri, Japan

SAT-212 SAFETY OF SIMEPREVIR-BASED TREATMENT FOR HEPATITIS C IN REAL PRACTICE: PRELIMINARY RESULTS FROM THE STILY OBSERVATIONAL STUDY
Massimo Colombo*, Maurizio Russello, Paolo Forte, Gennaro Lettieri, Laura Milazzo, Antonio Gasbarrini, Alessandra Ori, Maria Palma, Roberta Termini, Giovanni Battista Gaeta, Italy
### SAT-213
**YI**

**INTERFERON-FREE TREATMENT WITH SOFOSBUVIR PLUS DACLATASVIR ACHIEVES SUSTAINED VIROLOGIC RESPONSE IN 100% OF DIFFICULT-TO-TREAT HIV/HCV-COINFECTED PATIENTS AND DECREASES LIVER STIFFNESS**

Mattias Mandorfer*, Philipp Schwabl, Sebastian Steiner, Bernhard Scheiner, David Chromy, Theresa Bucsics, Albert Friedrich Staettermayer, Maximilian Christopher Aichelburg, Katharina Grabmeier-Pfistershammer, Michael Trauner, Thomas Reiberger, Markus Peck-Radosavljevic, *Austria*

### SAT-214

**REAL WORLD EFFECTIVENESS OF LEDIPASVIR/SOFOSBUVIR (LDV/SOF) IN TREATMENT-EXPERIENCED CIRRHOTIC GENOTYPE 1 PATIENTS WITH CHRONIC HEPATITIS C: A COMPARATIVE ANALYSIS OF GILEAD SPONSORED TRIALS WITH 4 REAL-WORLD COHORTS**


### SAT-215

**THE EFFECT OF SUSTAINED VIROLOGIC RESPONSE ON CEREBRAL METABOLISM AND NEUROCOGNITION IN PATIENTS WITH CHRONIC GENOTYPE 1 HCV INFECTION**

Michael P. Curry*, Nancy P. Moczynski, Lin Liu, Luisa Stamm, Chohee Yun, Diana M. Brainard, John G. McHutchison, David Alsop, Nezam H. Afdhal, *United States*

### SAT-216

**EFFECTIVENESS OF LEDIPASVIR/SOFOSBUVIR AND OMBITASVIR/PARITAPREVIR/RITONAVIR/DASABUVIR IN TREATMENT-NAÏVE AND –EXPERIENCED U.S. VETERANS WITH GENOTYPE 1 HEPATITIS C INFECTION**


### SAT-217

**SUSTAINED VIROLOGIC RESPONSE AMONG PATIENTS WITH GENOTYPE 1 HEPATITIS C AND TREATED WITH INTERFERON-FREE DIRECT-ACTING ANTIVIRAL REGIMENS**

Michael Hull*, Amy Puenpatom, Jeff McPheeters, Kay Schwebke, *United States*
SAT-218  PRIORITIZING TREATMENT CANDIDATES BY TIME DEGENERATIVE FACTORS IN PATIENTS WITH CHRONIC HEPATITIS C INFECTION
Ming-Lung Yu*, Chung-Feng Huang, Chia-Yen Dai, Jee-Fu Huang, Wan-Long Chuang, Taiwan

SAT-219  TG-2349, A POTENT PROTEASE INHIBITOR, PLUS PEGIFN/RBV PROVIDES EXCELLENT VIROLOGICAL RESPONSES FOR HARDER-TO-TREAT SUBPOPULATIONS OF HCV-1B NON-CIRRHOTIC PATIENTS
Ming-Lung Yu*, Shih-Jer Hsu, Chau-Ting Yeh, Chao-Hung Hung, Ming-Yao Chen, Pei-Jer Chen, Yi-Hsiang Huang, Pin-Nan Cheng, Chih-Ming Chen, Li-Wen Chang, Chu-Chung Lin, Felice Sheen, Chi-Hsin R. King, Edward Kuo, Ming-Chu Hsu, Taiwan

SAT-220  EFFICACY AND SAFETY OF OMBITASVIR/ PARITAPREVIR/RITONAVIR, WITH OR WITHOUT RIBAVIRIN, IN PATIENTS WITH HCV GENOTYPE 4 INFECTION — REAL-WORLD EXPERIENCE FROM QATAR
Moutaz F. Derbala*, Aliaa M. Amer, Saad Alkaabi, Omr Aljyli, Yasser Kamel, Khaleel Sultan, Elham A. Elsayad, Ashraf Amin, Fuad I. Pasic, Mohamed Elshaikh, Mohamed Elshaikh, Qatar

SAT-221  A RISK FACTORS FOR DE NOVO DIABETES MELLITUS IN PATIENTS WITH CHRONIC HEPATITIS C AND SUSTAINED VIROLOGICAL RESPONSE
Nasser Mousa*, Ahmed Abdel-Razik, Sherif Elbaz, Narmin Effat, Niveen El-Wakeel, Mahmoud Awad, Waleed Eldars, Wagdi Elkashef, Egypt

SAT-222  THE OPTIMAL TIMING OF HEPATITIS C THERAPY IN TRANSPLANT ELIGIBLE PATIENTS WITH CHILD B AND C CIRRHOSIS: A COST-EFFECTIVENESS ANALYSIS
Elliot B. Tapper, Michael Hughes, Maria Buti, Jean-Francois Dufour, Steven Flamm, Michael Curry, Nezam Afzal, United States

SAT-223  COMPARISON OF FREQUENCIES OF DRUG-DRUG INTERACTIONS BETWEEN SOFOSBUVIR/LEDIPASVIR AND OMBITASVIR/DASABUVIR/PARITAPREVIR/ RITONAVIR +/- RIBAVIRIN AMONG HIV/HCV COINFECTED PATIENTS
Christopher Schriever, Alisha Ahmed, Kelly Rose Delehanty, Jenna Yager, Georgina Farrow, Rachel Kashtan, Thomas Lodise, Nimish Patel, United States
Viral hepatitis: Hepatitis C – clinical (therapy) (Cont.)

SAT-224  **EFFECTIVENESS OF DACLATASVIR BASED THERAPY IN PATIENTS WITH CHRONIC HEPATITIS C IN EUROPE: EXPERIENCE FROM THE NAMED PATIENT PROGRAM**
Nina Weis', Jim Young, Harald Hofer, William Irving, Ola Weiland, Emiliano Giostra, Juan Manuel Pascasio, Lluís Castells, Martin Prieto, Cinira Lefevre, David Evans, Heiner Bucher, Jose Luis Calleja, Denmark

SAT-225  **THE SAFETY AND EFFICACY OF DIRECT-ACTING ANTIVIRAL TREATMENT FOR PATIENTS WITH GENOTYPE 1 CHRONIC HEPATITIS C AND RENAL IMPAIRMENT**

SAT-226  **LEDIPASVIR/SOFOSBUVIR THERAPY IS SAFE AND EFFECTIVE IN LIVER TRANSPLANT RECIPIENTS WITH RECURRENT HCV INFECTION: SINGLE CENTER, REAL LIFE EXPERIENCE**
Nyan L. Latt*, Rita Gevorkyan, Amandeep Sahota, United States

SAT-227  **LEDIPASVIR/SOFOSBUVIR FOR 8 WEEKS IN NON-CIRRHOTIC, TREATMENT NAIVE PATIENTS WITH GENOTYPE 1 HEPATITIS C INFECTION: REAL LIFE EXPERIENCE IN A COMMUNITY SETTING**
Nyan L. Latt*, Rita Gevorkyan, Beshoy T. Yanny, Amandeep Sahota, United States

SAT-228  **THE EFFECT OF SOFOSBUVIR CONTAINING REGIMES IN PATIENTS WITH HCV GENOTYPE 3 INFECTION-A SCANDINAVIAN REAL-LIFE EXPERIENCE**
Olav Dalgard*, Ola Weiland, Geir Noraberg, Lars Karlsen, Martin Lagging, Lars Heggelund, Martti Färkkilä, Nina Weiss, Ulla Balslev, Erika Belard, Anne L.h. Øvrehus, Mette S. Kjaer, Henrik Krarup, Birgit T Roege, Sofie Hallager, Lone Madsen, Nina M Weiss, Norway

SAT-229  **QUANTITATIVE SYSTEMS PHARMACOLOGY MODEL OF HEPATITIS C: PREDICTION OF RESULTS OF ONGOING CLINICAL TRIALS OF DIRECT ANTIVARAL AGENTS COMBINATION THERAPIES**
Oleg Demin Jr*, Russia
SAT-230  **EFFICACY OF TREATMENT USING DIRECT ACTING ANTIVIRAL DRUGS (DAAS) IN HEPATITIS C VIRUS-INFECTED PATIENTS WITH HEPATOCELLULAR CARCINOMA – REAL LIFE DATA**
Oliver Waidmann*, Martin-Walter Welker, Nina Weiler, Stefan Zeuzem, Christoph Sarrazin, Johannes Vermehren, *Germany*

SAT-231  **SOFOSBUVIR/DACLATASVIR/RIBAVIRIN FOR 12 WEEKS IN PATIENTS WITH GENOTYPE 3 HEPATITIS C AND ADVANCED FIBROSIS/CIRRHOSIS: RESULTS FROM A REAL WORLD COHORT**
Omar F. Ahmed*, Fiona Marra, Ray Fox, Matthew Priest, Shouren Datta, Mathis Heydmann, Stephen T Barclay, *United Kingdom*

SAT-232  **EFFICACY OF SOFOSBUVIR/LEDIPASVIR IN TREATING GENOTYPE 1 AND 4 HEPATITIS C FOR 8/12 WEEKS: RESULTS FROM A DIFFICULT TO TREAT COHORT**
Omar F. Ahmed*, Emma Thomson, Shouren Datta, Ray Fox, Matthew Priest, Mathis Heydmann, Fiona Marra, Stephen T. Barclay, *United Kingdom*

SAT-233  **DETERMINATION OF LEDIPASVIR CONCENTRATIONS IN PATIENTS WITH DECOMPENSATED CIRRHOSIS RECEIVING LOW DOSE PROTON PUMP INHIBITORS DURING SOFOSBUVIR-LEDIPASVIR TREATMENT FOR HCV GENOTYPE 1 INFECTION**
Omar El-Sherif*, Stephen Stewart, Colm Bergin, Susan McKiernan, Orla Crosbie, Saye Khoo, Suzanne Norris, *Ireland*

SAT-234  **SOFOSBUVIR AND LEDIPASVIR VERSUS SOFOSBUVIR AND SIMEPREVIR COMBINATION THERAPY IN THE MANAGEMENT OF ACUTE HEPATITIS C: A RANDOMIZED OPEN LABEL PROSPECTIVE CLINICAL PILOT STUDY. SLAM C STUDY**

SAT-235  **SOFOSBUVIR AND LEDIPASVIR IN ATTAINMENT OF SVR12 IN SICKLE CELL DISEASE (SCD) SUBPOPULATION WITH CHRONIC HEPATITIS C (CHC). A SINGLE CENTER PROSPECTIVE OPEN LABEL CLINICAL PILOT STUDY - SLASH C TRIAL**
Viral hepatitis: Hepatitis C – clinical (therapy) (Cont.)

**SAT-236**
SOFOSBUVIR, LEDIPASVIR IN IBD TREATED PATIENTS WITH ADVANCED BIOLOGICS INCLUDING RIBAVIRIN ERADICATING CHRONIC HEPATITIS C: SOLATAIRE C TRIAL. A MULTI-CENTER CLINICAL PROSPECTIVE PILOT STUDY

**SAT-237**
OMBITASVIR (ABT 267), RITANAVIR BOOST WITH DASTASBUVIR (ABT 333) AND PRATASPRAVIR (ABT 450) WITH OR WITHOUT RIBAVIRIN (RBV) IN G1 SPECIAL POPULATION IN HEMODIALYSIS (HD) IN CHRONIC HEPATITIS C (HCV) PATIENTS. DROP C TRIAL
P Patrick Basu*, Niraj J. Shah, Mark Aloysius, L Kavali, E Shehi, United States

**SAT-238**
PARAMETERS ASSOCIATED WITH TREATMENT FAILURE WITH DIRECT ACTING ANTIVIRALS AGAINST THE HEPATITIS C VIRUS (HCV) – RESULTS FROM THE GERMAN HEPATITIS C COHORT (GECCO)
Patrick Ingiliz*, Stefan Christensen, Torben Kimhofer, Dietrich Hueppe, Knud Schewe, Thomas Lutz, Christoph Boesecke, Karl-Georg Simon, Axel Baumgarten, Stefan Mauss, Germany

**SAT-239**
SAFETY OF ABT-493 AND ABT-530 CO-ADMINISTERED IN PATIENTS WITH HCV GENOTYPE 1 – 6 INFECTION: RESULTS FROM THE SURVEYOR-I AND SURVEYOR-II STUDIES
Paul Kwo*, Fred Poordad, Ariel Porcalla, Edward Gane, Jacob Lalezari, David Wyles, Ran Liu, Jens Kort, Federico J. Mensa, United States

**SAT-240**
REAL-WORLD EFFECTIVENESS AND COST PER SUSTAINED VIRAL RESPONSE OF LEDIPASVIR/ SOFOSBUVIR CHRONIC HEPATITIS C TREATMENT
Peter Buggisch*, Karsten Wursthorn, Albrecht Stoehr, Aline Gauthier, Petar K. Atanasov, Joerg Petersen, Germany
SAT-241  LEDIPASVIR/SOFOSBUVIR TREATMENT FOR 8 WEEKS IN TREATMENT-NAÏVE HCV GENOTYPE 1 INFECTED PATIENTS UNDER REAL LIFE CONDITIONS: DATA FROM THE GERMAN HEPATITIS C-REGISTRY (DHC-R)
Peter Buggisch*, Klaus H. W. Böker, Rainer Günther, Gerlinde Teuber, Hartwig Klinker, Anita Pathil, Stefan Christensen, Heike Peiffer-Vornkahl, Karl-Georg Simon, Claus Niederau, Heiner Wedemeyer, Stefan Zeuzem, German Hepatitis C-Registry, Germany

SAT-242  LEDIPASVIR/SOFOSBUVIR (LDV/SOF) FOR 8 WKS IN GENOTYPE 1 (GT1) TREATMENT-NAÏVE NON-CIRRHOTIC PATIENTS WITH HCV VIRAL LOAD <6 MILLION IU/ML (6M); A COMPARATIVE ANALYSIS OF THE PHASE-3 ION-3 DATA TO REAL WORLD EFFECTIVENESS
Peter Buggisch*, Jorg Peterson, Stefan Mauss, Kris Kowdley, Micheal Curry, Peter Ruane, Dani Ain, Naoky Tsai, Yoori Lee, Edward Eggleton, Macky Natha, Bruce Kreter, Diana Brainard, Patrick Ingiliz, Germany

SAT-243  REAL-WORLD EFFECTIVENESS OF LEDIPASVIR/ SOFOSBUVIR 8 WEEKS CHRONIC HEPATITIS C TREATMENT
Peter Buggisch*, Karsten Wursthorn, Albrecht Stoehr, Aline Gauthier, Petar K. Atanasov, Joerg Petersen, Germany

SAT-244  INCARCERATION OF PEOPLE WHO INJECT DRUGS - MODELLING ITS ROLE IN HCV TRANSMISSION AND THE IMPACT OF SCALED-UP HCV TREATMENT IN PRISONS
Jack Stone, Natasha K. Martin, Matthew Hickman, Sharon Hutchinson, Esther Aspinall, Avril Taylor, Alison Munro, Karen Dunleavy, Erica Peters, Peter Bramley, Peter Hayes, David Goldberg, Peter Vickerman*, United Kingdom

SAT-245  LONG-TERM IMPACT OF RESPONSE TO INTERFERON-BASED THERAPY IN PATIENTS WITH CHRONIC HEPATITIS C VIRUS IN RELATION TO LIVER FUNCTION, SURVIVAL AND CAUSE OF DEATH
Philip Johnson*, Emily de Groot, Sarah Berhane, Toshifumi Tada, Takashi Kumada, Hidenori Toyoda, United Kingdom

SAT-246  IMPACT OF SUSTAINED VIRAL RESPONSE ON RENAL FUNCTION IN PATIENTS WITH CHRONIC INFECTION BY HEPATITIS C VIRUS (HCV)
Rafael Granados*, Miriam Serrano, Nidia Santana, Shaila Alonso, Marta Hernández, Raquel García, José María Martín, Spain
Viral hepatitis: Hepatitis C – clinical (therapy) (Cont.)

**SAT-247**  
**SAFETY OF DIRECT-ACTING ANTIVIRALS -BASED THERAPY FOR THE TREATMENT OF PATIENTS WITH CHRONIC HEPATITIS C VIRUS INFECTION AND CIRRHOSIS: RESULTS FROM AN INTERNATIONAL MULTICENTER COHORT STUDY**  

**SAT-248**  
**OMBITASVIR/PARITAPREVIR/RITONAVIR PLUS DASABUVIR ARE SAFETY AND EFFICACY FOR TREATING HCV GT1 AND 4 INFECTION IN PATIENTS WITH SEVERE RENAL IMPAIRMENT OR END-STAGE RENAL DISEASE: A MULTICENTER EXPERIENCE**  
Raquel Muñoz Gómez*, Diego Rincón, Enrique Hernández, Adriana Ahumada, M. Dolores Pérez Valderas, M. José Devesa, Francisca Cuencia, Conrado Fernández, M. Luisa Gutierrez, María Ortiz, Marta Calvo, Gregorio Castellano, Inmaculada Fernández, Spain

**SAT-249**  
**IMPACT OF COMORBIDITIES AND POLYMEDICATION IN THE SELECTION OF DIRECT-ACTING ANTIVIRALS IN PATIENTS WITH CHRONIC HEPATITIS C IN SPAIN**  
Raul J. Andrade*, Eric Yu, Maria Isabel Lucena, Spain

**SAT-250**  
**EXCELLENT EFFICACY AND TOLERANCE OF INTERFERON FREE REGIMEN BASED SOFOSBUVIR AND THEIR IMPACT IN ALCOHOL WITHDRAWAL IN HEAVY DRINKERS INFECTED WITH HCV**  
Régine Truchi*, Eve Gelsi, Faredj Cherikh, Nathalie Le Dantec, Pascale Tomasi, Rodolphe Anty, Albert Tran, France

**SAT-251**  
**DACLATASVIR AND SOFOSBUVIR THERAPY FOR PATIENTS WITH DECOMPENSATED CIRRHOSIS OR POST-LIVER TRANSPLANT HCV RECURRENCE AND ADVANCED FIBROSIS OR CIRRHOSIS: UNITED STATES MULTICENTRE TREATMENT PROTOCOL**  
Robert Brown*, Michael Fried, Rajender K. Reddy, Consuelo Soldevila Pico, Soro Khemichian, Jama Darling, Andrew A. Napoli, Beatrice Anduze-Faris, Paul Kwo, United States
SAT-252  PREDICTORS OF FAST RESPONSE TO OMBITASVIR/ PARITAPREVIR/RITONAVIR ±DASABUVIR ±RIBAVIRIN IN REAL LIFE AMBER STUDY IN GENOTYPE 1 AND 4 HCV INFECTED PATIENTS AS A RATIONALE FOR SHORTENING OF TREATMENT

SAT-253  PREDICTORS OF HEPATIC DECOMPENSATION DURING OMBITASVIR/PARITAPREVIR/RITONAVIR ±DASABUVIR ±RIBAVIRIN TREATMENT OF GENOTYPE 1 AND 4 HCV INFECTED PATIENTS (REAL LIFE AMBER STUDY)
Robert Flisiak*, Jerzy Jaroszewicz, Ewa Janczewska, Marta Wawrzynowicz-Syczewska, Anna Grabinska, Beata Bolewska, Arkadiusz Pisula, Ewa Karpinska, Iwona Mozer-Lisewska, Grzegorz Madej, Poland

SAT-254  SOFOSBUVIR/LEDIPASVIR WITHOUT RIBAVIRIN IN THE TREATMENT OF ASIANS WITH CHRONIC HEPATITIS C VIRUS GENOTYPE 6 IN THE UNITED STATES: COMMUNITY-BASED REAL WORLD OUTCOMES
Robert Wong*, My Nguyen, Huy Trinh, Andrew Huynh, Mytop Ly, Huy Nguyen, Khanh Nguyen, Jenny Yang, Ruel Garcia, Eduardo DaSilvera, Robert Gish, United States

SAT-255  NEW TREATMENTS FOR HCV: SCOPE FOR PREVENTING LIVER DISEASE AND HCV TRANSMISSION IN ENGLAND
Ross J. Harris*, Natasha Kaleta Martin, Eleanor Rand, Sema Mandal, David Mutimer, Mary Ramsay, Daniela De Angelis, Matthew Hickman, Helen Harris, United Kingdom

SAT-256  UNIVERSAL ACCESS TO NEW GENERATION DIRECT-ACTING ANTIVIRALS TO REDUCE THE BURDEN OF HEPATITIS C IN PORTUGAL
Viral hepatitis: Hepatitis C – clinical (therapy) (Cont.)

SAT-257 ON TREATMENT HCV RNA AS A PREDICTOR OF SVR12 IN PATIENTS WITH GENOTYPE 1-6 HCV INFECTION TREATED WITH SOFOSBUVIR/VELPATASVIR FIXED DOSE COMBINATION FOR 12 WEEKS: AN ANALYSIS OF THE ASTRAL-1, ASTRAL-2, AND ASTRAL-3 STUDIES
Saleh Alqatani*, Stefan Zeuzem, Stefan Bourgeois, Phillippe Mathurin, Sergio Roijer, Gregory Everson, Armand Abergel, Victor De Ledinghen, Lin Liu, Xiao Ding, John McNally, Anu Osinusi, Diana Brainard, Mani Subramanian, Alessandra Mangia, Mark Sulkowski, United States

SAT-258 FEASIBILITY OF RECRUITING PEOPLE WHO INJECT DRUGS INTO A NURSE-LED MODEL OF CARE TRIAL: THE TAP STUDY
Sally von Bibra*, Joseph S. Doyle, Peter Higgs, Paul Dietze, Paul Desmond, Mark Stoove, Emma McBryde, Leona Burke, Josi Lupi, Mellissa Bryant, Alexander J. Thompson, Margaret E. Hellard, Australia

SAT-259 SAFETY AND EFFICACY OF IFN&RBV-FREE DAA-BASED REGIMENS IN HCV-RECURRENCE AFTER ORTHOTOPIC LIVER TRANSPLANTATION
Sandra Beinhardt*, Ramonana Al-Zoairy, Clarissa Freissmuth, Karin Kozbial, Rafael Stern, Albert F. Stäthermayer, Heinz Zoller, Andreas Maieron, Rudolf Stauber, Katharina Stauffer, Michael Strasser, Wolfgang Vogel, Markus Peck-Radosaljevic, Michael Trauner, Peter Ferenci, Harald Hofer, Austria

Fawaz Georgie, Shirin Nafisi*, Anita Kohli, Karla Thornton, Justin Reynolds, Ann Moore, Robert Gish, John Scott, Paulina Deming, Miranda Sedillo, Clifford Qualls, Terry Box, Paula Cox, Jorge Mera, Anna Miller, Norman Sussman, Saira Khaderi, Richard Manch, Sanjeev Arora, United States
SAT-261 THE REAL WORLD EXPERIENCE OF DACLATASVIR AND ASUNAPREVIR COMBINATION THERAPY FOR MORE ELDERLY PATIENTS THAN THE CLINICAL TRIAL SUBJECTS WITH GENOTYPE 1B CHRONIC HEPATITIS C
Shuhei Hige*, Yoshiyasu Karino, Itaru Ozeki, Masakatsu Yamaguchi, Mutsuumi Kimura, Tomohiro Arakawa, Tomoaki Nakajima, Yasuaki Kuwata, Takahiro Sato, Takumi Ohmura, Joji Toyota, Japan

SAT-262 BASELINE CREATININE CLEARANCE IS A PREDICTOR OF WORSENING RENAL FUNCTION WHILE ON HCV TREATMENT WITH SOFOSBUVIR-LEDIPASVIR
Russell Rosenblatt, Amit Mehta, Michael Wagner, Sonal Kumar*, United States

SAT-263 TREATMENT OUTCOMES FOR HEPATITIS C GENOTYPE 1 INFECTION WITH DIRECT ACTING ANTIVIRALS: DATA FROM THE GERMAN HEPATITIS C-REGISTRY
Stefan Mauss*, Peter Buggisch, Klaus H. W. Böker, Eckart Schott, Hartwig Klinker, Rainer Günther, Heike Pfeiffer-Vornkahl, Thomas Berg, Christoph Sarrazin, Dietrich Hüppe, Michael P. Manns, German Hepatitis C-Registry, Germany

SAT-264 PHARMACOKINETIC INTERACTIONS BETWEEN SIMEPREVIR AND LEDIPASVIR IN TREATMENT-NAÏVE HEPATITIS C VIRUS GENOTYPE 1-INFECTED PATIENTS WITHOUT CIRRHOSIS TREATED WITH A SIMEPREVIR/SOFOSBUVIR/LEDIPASVIR REGIMEN
Stefan Bourgeois*, Yves Horsmans, Frederik Nevens, Hans van Vlierberghe, Christophe Moreno, Maria Beumont, Jolanda van de Logt, Leen Vijgen, Veerle van Eygen, Donghan Luo, Vera Hillewaert, Pieter Van Remoortere, Sivi Ouwerkerk-Mahadevan, Belgium

SAT-265 RELAPSE AND TREATMENT-EMERGENT RAVS WITH DAA-BASED REGIMENS IN HEPATITIS C VIRUS (HCV) MONO- OR HUMAN IMMUNODEFICIENCY VIRUS (HIV)-HCV CO-INFECTED PATIENTS – A REAL CONCERN IN CLINICAL PRACTICE? RESULTS FROM THE GERMAN HEPATITIS C COHORT (GECCO)
Stefan Christensen*, Patrick Ingiliz, Knud Schewe, Juergen Rockstroh, Dietrich Huppe, Axel Baumgarten, Thomas Lutz, Guenther Schmutz, Karl Georg Simon, Heiner Busch, Torben Kimhofer, Stefan Mauss, Germany
Viral hepatitis: Hepatitis C – clinical (therapy) (Cont.)

SAT-266

FINAL SVR24 DATA FROM THE PHASE 3 C-EDGE TREATMENT-NAIVE STUDY OF ELBASVIR (EBR)/GRAZOPREVIR (GZR) IN PATIENTS WITH CHRONIC HCV GENOTYPE 1, 4 OR 6 INFECTION
Stefan Zeuzem*, Reem Ghalib, K. Rajender Reddy, Paul Pockros, Ziv Ben Ari, Yue Zhao, Deborah Brown, Mark DiNubile, Michael Robertson, Janice Wahl, Eliav Barr, Joan Butterton, Elizabeth Martin, Germany

SAT-267

INOSINE TRIPHOSPHATASE DEFICIENCY DOES NOT PREDICT ANAEMIA DURING RIBAVIRIN CONTAINING DAA ALL ORAL REGIMENS FOR HCV
Stella De Nicola*, Enrico Galmozzi, Alessio Aghemo, Roberta D'Ambrosio, Elisabetta Degasperi, Marta Borghi, Massimo Colombo, Italy

SAT-268

DIRECT OBSERVED THERAPY OF CHRONIC HEPATITIS C WITH INTERFERON-FREE ALL-ORAL REGIMENS AT A LOW-THRESHOLD DRUG TREATMENT FACILITY – A NEW CONCEPT FOR TREATMENT OF PATIENTS WITH BORDERLINE COMPLIANCE RECEIVING OPIOID SUBSTITUTION THERAPY
Stephan Moser*, Angelika Schütz, Katharina Marchart, Sabrina Ambrosch, Asia Karpi, Enisa Gusic, Hans Haltmayer, Michael Gschwantler, Austria

SAT-269

LEDIPASVIR/SOFOSBUVIR+/RIBAVIRIN IN HCV POST-TRANSPLANT PATIENTS: REAL-WORLD HETEROGENEOUS POPULATION FROM THE TRIO NETWORK
Steven Flamm*, Bruce Bacon, Michael Curry, Douglas Dieterich, Lauren Guest, Kris Kowdley, Yoori Lee, Naoky Tsai, Zobair Younossi, Nezam Afdhal, United States

SAT-270

DECREASE IN LIVER STIFFNESS IN CHRONIC HEPATITIS C PATIENTS AFTER DIRECT- ACTING ANTIVIRAL THERAPY
Sumeet Kainth*, Ankur Jindal, Shiv K. Sarin, India
SAT-271
YI
ENDOTHELIAL DYSFUNCTION, MACROPHAGE DYSFUNCTION AND EMERGING CARDIOVASCULAR RISK FACTORS IN PATIENTS WITH HEPATITIS C VIRUS INFECTION. CHARACTERIZATION AND POTENTIAL REVERSIBILITY WITH DIRECT ACTING ANTIVIRAL AGENTS
Susana Llerena*, Christie Perello, Marta Hernandez, Maria Jose Garcia, David Ramos, Angel Estebanez, Joaquin Cabezas, Antonio Cuadrado, Marcos Lopez-Hoyos, Jose Luis Calleja, Javier Crespo, Spain

SAT-272
HCV RE-INFECTION IN HIGH-RISK PEOPLE WHO INJECT DRUGS
Syune Hakobyan*, Canada

SAT-273
EFFECTIVENESS AND SAFETY OF OMBITASVIR, PARITAPREVIR/RITONAVIR, AND DASABUVIR WITHOUT RIBAVIRIN IN PATIENTS WITH HCV GENOTYPE 1B WITH OR WITHOUT COMPENSATED CIRRHOSIS: POOLED ANALYSIS ACROSS 5 CLINICAL TRIALS
Tania M Welzel*, Vasily Isakov, Roger Trinh, Adrian Streinu-Cercel, Jean-Francois Dufour, Rui T Marinho, Christophe Moreno, Li Liu, Wangang Xie, Fernando Tatsch, Nancy Shulman, Antonio Craxi, Germany

SAT-274
EFFECTIVENESS AND SAFETY OF DAA COMBINATION THERAPIES FOR TREATMENT OF HCV IN ELDERLY PATIENTS (>70 YRS.): RESULTS FROM THE GERMAN HEPATITIS C-REGISTRY
Tania Welzel*, Eckart Schott, Jörg Petersen, Stefan Mauss, Tim Zimmermann, Karl-Georg Simon, Holger Hinrichsen, Thomas Berg, Heike Pfeiffer-Vornkahl, Stefan Zeuzem, Dietrich Hüppe, Heiner Wedemeyer, Klaus H. W. Böker, German Hepatitis C-Registry, Germany

SAT-275
DACLATASVIR PLUS SOFOSBUVIR WITH OR WITHOUT RIBAVIRIN FOR TREATMENT OF CHRONIC HCV INFECTION IN PATIENTS WITH ADVANCED LIVER DISEASE: RESULTS OF A EUROPEAN COMPASSIONATE USE PROGRAM
Tania Welzel*, Jörg Petersen, Kerstin Herzer, Peter Ferenci, Michael Gschwantler, Markus Cornberg, Patrick Ingiliz, Thomas Berg, Ulrich Spengler, Ola Weiland, Marc van der Valk, Hartwig Klinker, Jurgen Rockstroh, Markus Peck-Radosavljevic, Yue Zhao, Maria Jesus Jimenez-Exposito, Stefan Zeuzem, Germany
Viral hepatitis: Hepatitis C – clinical (therapy) (Cont.)

SAT-276 REAL-WORLD DATA ON THE USE OF RIBAVIRIN WITH OMBITASVIR/PARITAPREVIR/R WITH OR WITHOUT DASABUVIR IN HCV GENOTYPE 1 OR 4-INFECTED PATIENTS FROM THE GERMAN HEPATITIS C REGISTRY
Tania M. Welzel*, Peter Buggisch, Thomas Berg, Kerstin Stein, Jan Hettinger, Henning Kleine, Germany

SAT-277 IMPROVEMENT IN MARKERS OF LIVER FIBROSIS AND FUNCTION IN HCV GENOTYPE 4-INFECTED PATIENTS WITH COMPENSATED CIRRHOSIS RECEIVING OMBITASVIR/PARITAPREVIR/RITONAVIR WITH RIBAVIRIN (AGATE-I)
Tarek I. Hassanein*, Tariq Asselah, Roula B. Qaqish, Christophe Hezode, Jean-Pierre Mulkay, Christophe Moreno, Magdy ElKhashab, Saleh Alqahtani, Yao Yu, Rebecca Redman, Niloufar Mobashery, United States

SAT-278 HIGH SVR RATES IN PATIENTS WITH GENOTYPE 4 CHRONIC HEPATITIS C INFECTION AND COMPENSATED CIRRHOSIS WITH OMBITASVIR/PARITAPREVIR/RITONAVIR CO-ADMINISTERED WITH RIBAVIRIN (AGATE-I)
Tariq Asselah*, Christophe Hezode, Roula B. Qaqish, Magdy ElKhashab, Tarek Hassanein, Georgios Papatheodoridis, Jordan Feld, Saleh Alqahtani, Tami Pilot-Matias, Yao Yu, Rebecca Redman, Niloufar Mobashery, France

SAT-279 SOFOSBUVIR/VELPATASVIR FIXED DOSE COMBINATION FOR 12 WEEKS IN HCV INFECTED PATIENTS PREVIOUSLY TREATED WITH PLACEBO: RESULTS OF THE DEFERRED TREATMENT STUDY (GS-US-342-1446 STUDY)

SAT-280 GENDER AND IFNL4 RS12979860 GENOTYPE PREDICT RESPONSE TO LEDIPASVIR/SOFOSBUVIR
Thomas R. O’Brien*, Jordan Feld, Ruth Pfeiffer, United States
<table>
<thead>
<tr>
<th>SAT-281</th>
<th>LOW SERUM 25(OH) D3 LEVEL AFFECTS THE EXISTENCE OF DRUG-RESISTANT MUTATIONS AT THE NSSA REGION IN PATIENTS WITH CHRONIC HEPATITIS C 1B</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tomomi Okubo*, Masanori Atsukawa, Noritomo Shimada, Hiroshi Abe, Teang Arai, Ai Nakagawa, Norio Itokawa, Chisa Kondo, Yoshio Aizawa, Katsuhiko Iwakiri, Japan</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>SAT-282</th>
<th>DACLATASVIR PLUS SOFOSBUVIR WITH OR WITHOUT RIBAVIRIN IN PATIENTS WITH HCV INFECTION AND DECOMPENSATED CIRRHOSIS: INTERIM ANALYSIS OF A FRENCH MULTICENTRE COMPASSIONATE USE PROGRAMME</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vincent Leroy*, Christophe Hézode, Sophie Métivier, Mariagrazia Tateo, Filoména Conti, Eric Nguyen-Khac, Denis Lacoste, Julien Vergniol, Régine Truchi, Dominique Guyader, Ghassan Riachi, Christophe Michau, Dominique Blaison, Frédéric Oberti, Hélène Fontaine, Vincent Di Martino, Jean-Pierre Bronowicki, Raoudha Akremi, Yacia Bennai, Anne Filipovics, Georges-Philippe Pageaux, France</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>SAT-283</th>
<th>SUSTAINED VIROLOGIC RESPONSE PREDICTS FIBROSIS REGRESSION MEASURED BY FIBROTEST IN HCV-INFECTED PATIENTS</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>SAT-284</th>
<th>ACTIVE ANTIVIRAL TREATMENT FOR CHRONIC HEPATITIS C VIRUS INFECTION NEEDS TO BE RECOMMENDED FOR DECREASING HEPATITIS C-ASSOCIATED HEPATOCELLULAR CARCINOMA RISK IN THE NEW ERA OF HIGHLY EFFECTIVE ORAL ANTIVIRAL DRUGS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Young-Joo Jin*, Ji Taek Hong, Jin-Woo Lee, Korea, South</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>SAT-285</th>
<th>EFFICACY AND PATIENT-REPORTED OUTCOMES IN DECOMPENSATED CIRRHOTIC WITH CHRONIC HEPATITIS C TREATED WITH SOFOSBUVIR AND VELPATASVIR WITH OR WITHOUT RIBAVIRIN: RESULTS FROM ASTRAL-4 CLINICAL TRIAL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Zobair M. Younossi*, Maria Stepanova, Michael Charlton, Jacqueline G. O’Leary, Michael P. Curry, Robert S. Brown, Sharon Hunt, United States</td>
<td></td>
</tr>
</tbody>
</table>
Viral hepatitis: Hepatitis C – clinical (therapy) (Cont.)

SAT-286  SAFETY AND EFFICACY OF SOFOSBUVIR PLUS SIMEPREVIR IN A SPANISH COHORT OF 622 CIRRHOTIC PATIENTS INFECTED WITH GENOTYPES 1 OR 4
Zoe Mariño*, Juan Manuel Pascasio, Gloria Sánchez-Antolín, Carme Baliellas, Martín Prieto, José Maria Moreno, José Antonio Carrión, Immaculada Fernández, Alexandra Gomez, Jose Luis Montero, Angeles Castro, Sonia Pascual, Joaquin Cabezas, Ana Del Carmen Arencibia, Jose Luis Calleja, Juan Jose Sanchez-Ruano, Lluis Castells, Agustín Albillos, Manuel Romero, Javier García-Samaniego, Isidoró Narváez, Trinidad Serrano, Alvaro Giraldez, Xavier Xiol, Vanessa Hontangas, Valentín Cuervas-Mons, Javier Crespo, Xavier Forns, Spain
EASL thanks all abstract reviewers for their time and effort, and appreciates their contribution towards the success of The International Liver Congress™.

Abrahades Juan G., Canada
Adams David, United Kingdom
Akarca Ulus, Turkey
Alasawi William, United Kingdom
Andrade Raul Jesús, Spain
Androni Pietro, Italy
Barnes Ellie, United Kingdom
Bartosch Birke, France
Baumert Thomas, France
Bechman Lars, Germany
Berzigotti Annalisa, Spain
Bhouri Sherrie, Italy
Bourlière Marc, France
Bruno Savino, Italy
Bruns Tony, Germany
Buti Maria, Spain
Calleja José Luis, Spain
Canbay Ali, Germany
Castro Rui, Portugal
Chevaliez Stephane, France
Colle Isabelle, Belgium
Colnot Sabine, France
Cornberg Markus, Germany
Crespo Gonzalo, Spain
Cucchetti Alessandro, Italy
Dahlke Marc, Germany
Dalgard Olav, Norway
Dalton Harry, United Kingdom
D’Antiga Lorenzo, Italy
De Francesco Raffaele, Italy
de Gottardi Andrea, Switzerland
Diepolder Helmut, Germany
Diepolder Helmut, Germany
Dooley Steven, Germany
Durantel David, France
Eferl Robert, Austria
Ferenc Peter, Austria
Fernandez Javier, Spain
Fickert Peter, Austria
Flisiak Robert, Poland
Fondevila Constantino, Spain
Fraquelli Mirella, Italy
Friedrich-Rust Mireen, Germany
Galle Peter, Germany
Geier Andreas, Germany
Genesca Ferrer Juan, Spain
Germani Giacomo, Italy
Gheorghe Liliana, Romania
Giannini Edoardo, Italy
Gschwantler Michael, Austria
Hezode Christophe, France
Hirschfield Gideon, United Kingdom
Isoniemi Helena, Finland
Jacquemin Emmanuel, France
Jaroszевич Jerzy, Poland
Keitel Verena, Germany
Krag Aleksander, Denmark
La Mura Vincenzo, Italy
Lavanchy Daniel, Switzerland
Leroy Vincent, France
Levrero Massimo, Italy
ACKNOWLEDGEMENTS

Liberal Rodrigo, United Kingdom
Lucifora Julie, France
Luedde Tom, Germany
Machado Mariana, Portugal
Majno Pietro, Switzerland
Mandorfer Mattias, Austria
Mangia Alessandra, Italy
Mann Jelena, United Kingdom
Marra Fabio, Italy
Martinez-Chantar Maria, Spain
Marzioni Marco, Italy
McPherson Stuart, United Kingdom
Meyer Tim, United Kingdom
Mookerjee Raj, United Kingdom
Moradpour Darius, Switzerland
Neuman-Haefelin Christoph, Germany
Newsome Philipp, United Kingdom
Nobili Valerio, Italy
Oakley Fiona, United Kingdom
Oliveira Claudia, Brazil
Paradis Valérie, France
Peck-Radosavljevic Markus, Austria
Petersen Jörg, Germany
Petta Salvatore, Italy
Pinzani Massimo, United Kingdom
Pischke Sven, Germany
Pontisso Patrizia, Italy
Protzer Ulrike, Germany
Puoti Massimo, Italy
Ratziu Vlad, France
Rimola Jordi, Spain
Ripoll Cristina, Germany
Roeb Elke, Germany
Rowe Ian, United Kingdom
Salomone Federico, Italy
Samuel Didier, France
Sancho-Bru Pau, Spain
Sarobe Pablo, Spain
Schramm Christoph, Germany
Schwabl Philipp, Austria
Semmo Nasser, Switzerland
Shetty Shishir, United Kingdom
Sibila Maria, Austria
Soubrane Olivier, France
Thabut Dominique, France
Thompson Alexander, Australia
Tilg Herbert, Austria
Toffani Sarah, Germany
Tokat Yaman, Turkey
Toso Christian, Switzerland
Toy Mehlika, United States
Trauner Michael, Austria
Triantos Christos, Greece
Valenti Luca, Italy
van Bommel Florian, Germany
van Damme Pierre, Belgium
Viganò Mauro, Italy
Villa Erica, Italy
Vitale Alessandro, Italy
Vogel Arndt, Germany
Wedemeyer Heiner, Germany
Weinmann Arndt, Germany
Weiskirchen Ralf, Germany
Wekerle Thomas, Austria
Welzel Tania, Germany
Wörns Marcus-Alexander, Germany
Zoller Heinz, Austria
Zucman-Rossi Jessica, France
SPONSORS

PLATINUM SPONSORS

GILEAD

MSD

GOLD SPONSOR

NORGINE

SILVER SPONSORS

Bristol-Myers Squibb

sequana medical
OTHER SPONSORS

GE Healthcare

Alexion

Genfit

Novartis

Philips

Resoundant

Shire

Siemens

Supersonic

Toshiba

Univar

BIOTECH COMPANIES

Owl

Sanyal

Wilson
EASL photographers and film crew will be present throughout The International Liver Congress™ 2016 - you can find all official footage at the ILC website.
INDUSTRY SATELLITE SYMPOSIA

INTERCEPT PHARMACEUTICALS

Wednesday 13 April 2016 – Room B3

Understanding the role of evolving targets in NASH
Chair: Kris V. Kowdley, United States

18:00-18:05 Introduction and opening remarks
Kris V. Kowdley, United States

18:05-18:20 NASH: Unmet therapeutic needs & risk stratification
Stephen A. Harrison, United States

18:20-18:35 Goals for treatment response
Kris V. Kowdley, United States

18:35-18:55 Making sense of therapeutic targets for NASH
Stephen A. Harrison, United States

18:55-19:15 What new therapies are on the horizon; efficacy and safety profiles
Vlad Ratziu, France

19:15-19:30 Expert panel discussion
Faculty Panel

NORGINE

Wednesday 13 April 2016 – Room D1

Driving change in the management of hepatic encephalopathy
Chair: Jasmohan Bajaj, United States

18:00-18:05 Welcome and overview of agenda
Jasmohan Bajaj, United States

18:05-18:20 A unifying hypothesis: How do bacterial translocation, ammonia and inflammation contribute to hepatic encephalopathy?
Rajiv Jalan, United Kingdom

18:20-18:45 Translating the pathophysiology of HE into clinical practice
Kevin Mullen, United States
18:45-18:55  Q&A and panel discussion  
All

18:55-19:10  Individualising quality care – a case-based discussion  
Case study 1  
All

19:10-19:20  Case study 2 – the patient perspective  
All

19:20-19:30  Q&A and panel discussion  
All

19:30  Closing remarks and symposium close  
Jasmohan Bajaj, United States

GENFIT

Thursday 14 April, 2016 – Room B2

NASH: Optimizing therapy for progressive disease  
Chair: Vlad Ratziu, France

07:30-07:40  Introduction by chairman – Case study: A 47-year-old woman with insidious progression of NASH  
Vlad Ratziu, France

07:40-07:55  NAFLD: Who are the patients in need of therapy and when do we need drugs  
Stephen A. Harrison, United States

07:55-08:15  Targeting different stages of disease: Hepatic and metabolic management of NASH patients  
Sven Francque, Belgium

08:15-08:30  Discussion and Q&A
GILEAD SCIENCES EUROPE LTD

Thursday 14 April 2016 – Room D1

Expanding the horizon for hepatitis B management
Chair: Maria Buti, Spain

07:30-07:40 Expanding the horizon: the changing face of hepatitis B
Maria Buti, Spain

07:40-08:00 Expanding the horizon: understanding more about natural
history and management
Pietro Lampertico, Italy

08:00-08:20 Expanding the horizon: achieving the potential of therapy
Kosh Agarwal, United Kingdom

08:20-08:30 Panel discussion and close
Maria Buti, Spain
All

UNIVAR BV

Thursday 14 April 2016 – Room C1

A multi-disciplinary approach to the management of Wilson’s disease
Chair: Peter Ferenci, Austria

07:30-07:35 Chair and opening remarks
Peter Ferenci, Austria

07:35-07:55 The perspective of the neurologist
Aurelia Poujois, France

07:55-08:15 The perspective of the hepatologist
Gideon Hirschfield, United Kingdom

08:15-08:25 Question and answer session

08:25-08:30 Close and summary
ABBVIE

Thursday 14 April, 2016 – Room A1

Welcome to the real world: HCV clinical trials to patient realities
Chairs: Heiner Wedemeyer, Germany
Ira Jacobson, USA

18:30-18:40 Welcome and introductions
Heiner Wedemeyer, Germany

18:40-19:00 Real world experience: What have we learned overall?
Heiner Wedemeyer, Germany

19:00-19:20 Real world experience: What have we learned about advanced liver disease?
Robert Brown, United States

19:20-19:40 Real world experience: What have we learned about chronic kidney disease?
Antonio Craxi, Italy

19:40-20:00 Q&A, summary and close
Ira Jacobson, United States

GILEAD SCIENCES EUROPE LTD

Thursday 14 April 2016 – Hall 6

Leaving no one behind: Leading the way to HCV elimination
Chair: Rafael Esteban, Spain

18:30-18:40 Changing realities for patients with HCV
Rafael Esteban, Spain

18:40-18:50 Achievements in patient care
Stefano Fagiuoli, Italy

18:50-19:00 Achievements in the real world
Nezam Afdhal, United States

19:00-19:10 Achievements in broadening care
Ashley Brown, United Kingdom

19:10-19:20 Achievements in reality
Patrice Cacoub, France

19:20-19:30 Achievements in society
Stefan Zeuzem, Germany

19:30-19:40 Achievements in practice
Panel

19:40-19:50 Achievements towards elimination
Rafael Esteban, Spain

19:50-20:00 Summary
Rafael Esteban, Spain

INTERCEPT PHARMACEUTICALS

Friday 15 April 2016 – Room D1

Answering the unmet medical need in primary biliary cholangitis (PBC)
Chair: Gideon Hirschfield, United Kingdom

18:30-18:40 Introduction and opening remarks
Gideon Hirschfield, United Kingdom

18:40-18:55 New developments in PBC: Early diagnosis and potential targets for therapy
Michael Trauner, Austria

18:55-19:10 The PBC challenge: Appropriate endpoints to assess clinical efficacy
Albert Pares, Spain

19:10-19:30 New therapies on the horizon for PBC
Gideon Hirschfield, United Kingdom

19:30-19:55 Addressing the unmet needs in PBC: Patient and clinician perspectives
Expert faculty panel

19:55-20:00 Summary and concluding remarks
Gideon Hirschfield, United Kingdom
MSD

Friday 15 April 2016 – Room A1

Challenges in treating my HCV patients – An interactive symposium
Chairs: Rafael Esteban, Spain  
Stefan Zeuzem, Germany

18:30-18:35  Welcome and opening comments  
Rafael Esteban, Spain  
Stefan Zeuzem, Germany

18:35-18:55  Challenges in treating cirrhotic patients  
Ira Jacobson, United States

18:55-19:15  Challenges in treating people who inject drugs  
Greg Dore, Australia

19:15-19:35  Challenges in treating patients with special conditions  
Stanislas Pol, France

19:35-19:55  Challenges in treating patients who have failed previous treatments  
Paul Kwo, United States

19:55-20:00  Closing remarks  
Rafael Esteban, Spain  
Stefan Zeuzem, Germany

ABBVIE

Saturday 16 April 2016 – Room D1

HCV emerging data and trending topics: An interactive debate and case discussion  
Chair: Jean-Michel Pawlotsky, France

07:30-07:35  Welcome and introduction  
Jean-Michel Pawlotsky, France

07:35-08:15  “What’s trending and what’s not?” – discussion and informal debate  
Jean-Michel Pawlotsky, France  
Fred Poordad, United States  
Erica Villa, Italy
ALEXION

Saturday 16 April 2016 – Room CI

Can you figure it out? Differential diagnosis beyond the usual
Chair: Vlad Ratziu, France

07:30-07:35 Chair’s introduction
Vlad Ratziu, France

07:35-07:45 Early cirrhosis seen in an adolescent patient, what might you suspect?
Case presentation
Jesus Quintero, Spain

07:45-07:55 A Pathologist’s perspective: optimizing diagnosis in metabolic liver disease
Case presentation
Uta Drebber, Germany

07:55-08:05 A case of pronounced malnutrition in an adult with metabolic disease
Case presentation
Patrick Gerner, Germany

08:05-08:15 An infant with failure to thrive & severe liver disease – what do you suspect?
Case presentation
Suresh Vijay, United Kingdom

08:15-08:30 Panel discussion
Chair moderates with faculty
NOVARTIS PHARMACEUTICAL

Saturday 16 April 2016 – Room B1

**Shaping the future of liver disease management: What lies ahead?**
**Chair: Clifford A. Brass, United States**

07:30-07:35  Novartis and new therapies in liver disease  
Nikolai Naoumov, Switzerland

07:35-07:50  Non-bile acid FXR agonists for the treatment of NASH  
Bryan Laffitte, United States

07:50-08:05  Renal dysfunction in cirrhosis – treatment of AKI/HRS  
Jonathan Fallowfield, United Kingdom

08:05-08:20  Addressing emerging unmet medical needs in liver transplantation  
Faouzi Saliba, France

08:20-08:30  Questions and answers  
Clifford A. Brass, United States

SEQUANA MEDICAL AG

Saturday 16 April 2016 – Room C2

**Therapeutic advances in refractory ascites**
**Chair: Thomas Berg, Germany**

07:30-07:50  alfpump® vs. standard of care in ascites treatment – RCT results  
Rajiv Jalan, United Kingdom

07:50-08:10  ‘Real World Data’ for the alfpump system  
Andrea De Gottardi, Switzerland

08:10-08:30  TIPS or alfpump? That is the question  
Thomas Berg, Germany
MINI-WORKSHOPS

RESOUNDANT, INC.

Thursday 14 April 2016 – Room E2

MR elastography of the liver: The essentials
Speaker: Sudhakar K. Venkatesh

07:30-08:30 A practical overview of magnetic resonance elastography (MRE) will be presented. The workshop is intended for clinicians and researchers who are looking for an introduction to the technology and are interested in learning more about this remarkable diagnostic tool.

1. Clinical rationale
2. Basic physics
3. Indications for use
4. Clinical evidence
5. Practical tips for performing the exam
6. Practical tips for analyzing the data
7. Troubleshooting
8. Future applications
9. Q&A

ONE WAY LIVER S.L. (OWL)

Friday 15 April 2016 – Room E2

“Accurate & non-invasive NAFLD/NASH diagnostic methods: a metabolomics perspective”
Chair: José M. Mato, Spain

18:30-18:35 Welcome & introduction
José M. Mato, Spain

18:35-18:50 Identification and quantification of fat in the liver by MRI and its correlation with lipidomics analysis
Jesus Bañales, Spain
18:50-19:05  Blind validation of OWLiver, a non-invasive lipidomic test for the diagnosis of NASH  
Cristina Alonso, Spain

19:05-19:20  The lipidomic signature of disease progression in NAFLD  
Puneet Puri, United States

19:20-19:30  Chairman’s questions, summary and group discussion
EXHIBITION INFO

EXHIBITION – HALL 8.1

Thursday 14 April  09:30-16:30  
Friday 15 April  09:30-16:30  
Saturday 16 April  09:30-16:30

OFFICIAL SET-UP

Monday 11 April  08:00-22:00 (Booths 50m² and larger)  
Tuesday 12 April  08:00-22:00  
Wednesday 13 April  08:00-16:00

OFFICIAL DISMANTLING

Saturday 16 April  18:00-24:00*  
Sunday 17 April  07:00-18:00

*No truck loading will be permitted after 21:30.
## EXHIBITORS’ LIST

<table>
<thead>
<tr>
<th>COMPANIES</th>
<th>BOOTH NUMBER</th>
</tr>
</thead>
<tbody>
<tr>
<td>AbbVie</td>
<td>1500</td>
</tr>
<tr>
<td>AbbVie</td>
<td>2600 A</td>
</tr>
<tr>
<td>Advanced Bio. Lab (ABL)</td>
<td>2600 C</td>
</tr>
<tr>
<td>Alexion</td>
<td>2500 A</td>
</tr>
<tr>
<td>ALFA WASSERMANN S.p.A</td>
<td>3000 D</td>
</tr>
<tr>
<td>BAXTER</td>
<td>2300 J</td>
</tr>
<tr>
<td>BioPredictive</td>
<td>2600 E</td>
</tr>
<tr>
<td>Biotest AG</td>
<td>2500 K</td>
</tr>
<tr>
<td>Bristol-Myers Squibb Company</td>
<td>2000 B</td>
</tr>
<tr>
<td>Cepheid</td>
<td>1900 K</td>
</tr>
<tr>
<td>Committed To Cure</td>
<td>2700 G</td>
</tr>
<tr>
<td>Dr. Falk Pharma GmbH</td>
<td>2100 A</td>
</tr>
<tr>
<td>Echosens</td>
<td>2200 H</td>
</tr>
<tr>
<td>Epistem</td>
<td>1900 E</td>
</tr>
<tr>
<td>Elsevier</td>
<td>3200 B</td>
</tr>
<tr>
<td>Fresenius Medical Care</td>
<td>2300 A</td>
</tr>
<tr>
<td>Fujirebio Europe NV</td>
<td>2200 B</td>
</tr>
<tr>
<td>GE Healthcare</td>
<td>2200 A</td>
</tr>
<tr>
<td>Genetic Analysis AS</td>
<td>2300 L</td>
</tr>
<tr>
<td>Genfit</td>
<td>2900 E</td>
</tr>
<tr>
<td>Gilead Sciences, Inc.</td>
<td>1700</td>
</tr>
<tr>
<td>Gore &amp; Associates</td>
<td>2100 K</td>
</tr>
<tr>
<td>Hepatology- clinical textbook</td>
<td>3200 A</td>
</tr>
<tr>
<td>Humedics GmbH</td>
<td>2600 K</td>
</tr>
<tr>
<td>IC-HEP</td>
<td>1900 D</td>
</tr>
<tr>
<td>Intercept</td>
<td>1200</td>
</tr>
<tr>
<td>Jansszen Pharamaceutica</td>
<td>1800 A</td>
</tr>
<tr>
<td>Mendes SA</td>
<td>3000 A</td>
</tr>
<tr>
<td>MSD</td>
<td>1600</td>
</tr>
<tr>
<td>New Insights into HE</td>
<td>1900 O</td>
</tr>
<tr>
<td>Norgine</td>
<td>2900 A</td>
</tr>
<tr>
<td>COMPANIES</td>
<td>BOOTH NUMBER</td>
</tr>
<tr>
<td>----------------------------------------</td>
<td>--------------</td>
</tr>
<tr>
<td>Novartis Pharmaceutical</td>
<td>3100K</td>
</tr>
<tr>
<td>Orasure Technologies</td>
<td>1900 N</td>
</tr>
<tr>
<td>Perspectum Diagnostics Ltd</td>
<td>2100 C</td>
</tr>
<tr>
<td>PHILIPS</td>
<td>2200 I</td>
</tr>
<tr>
<td>PhoenixBio</td>
<td>2600 D</td>
</tr>
<tr>
<td>PRO.MED.CS Praha a.s.</td>
<td>1100 M</td>
</tr>
<tr>
<td>Resoundant, Inc.</td>
<td>2300 D</td>
</tr>
<tr>
<td>Roche Molecular Systems, Inc</td>
<td>1100 A</td>
</tr>
<tr>
<td>Sequana Medical AG</td>
<td>2000 N</td>
</tr>
<tr>
<td>Siemens</td>
<td>3000 F</td>
</tr>
<tr>
<td>Sirtex Medical Europe GmbH</td>
<td>2600 M</td>
</tr>
<tr>
<td>SuperSonic Imagine SA</td>
<td>2200 C</td>
</tr>
<tr>
<td>Toshiba Medical Systems Europe</td>
<td>2300 E</td>
</tr>
<tr>
<td>Vital Therapies, Inc.</td>
<td>2500 N</td>
</tr>
<tr>
<td>Wako Chemicals GmbH</td>
<td>3200 K</td>
</tr>
<tr>
<td>Wiley</td>
<td>2600 J</td>
</tr>
<tr>
<td>Wisepress Medical Bookshop</td>
<td>3200 F</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ASSOCIATIONS</th>
<th>BOOTH NUMBER</th>
</tr>
</thead>
<tbody>
<tr>
<td>AASLD – American Association for the Study of Liver Disease</td>
<td>2400 K</td>
</tr>
<tr>
<td>ALEH – Latin American Association for the Study of the Liver</td>
<td>2400 J</td>
</tr>
<tr>
<td>M3 Medical</td>
<td>2300 C</td>
</tr>
<tr>
<td>Paris Hepatitis Conference</td>
<td>2300 B</td>
</tr>
<tr>
<td>Systems Medicine of the Liver – LiSyM</td>
<td>2400 B</td>
</tr>
<tr>
<td>The Cochrane Hepato-Biliary Group</td>
<td>2400 B</td>
</tr>
<tr>
<td>UEG – United European Gastroenterology</td>
<td>2400 E</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>BIOTECH COMPANIES</th>
<th>BOOTH NUMBER</th>
</tr>
</thead>
<tbody>
<tr>
<td>OWL Metabolomics</td>
<td>Biotech Village</td>
</tr>
<tr>
<td>Sanyal Biotechnology</td>
<td>Biotech Village</td>
</tr>
<tr>
<td>Wilson Therapeutics AB</td>
<td>Biotech Village</td>
</tr>
</tbody>
</table>
COMPANY PROFILES

AbbVie

1 North Waukegan Road
North Chicago 60064
United States

www.abbvie.com

AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott Laboratories. The company’s mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world’s most complex and serious diseases. AbbVie employs approximately 25,000 people worldwide and markets medicines in more than 170 countries. For further information on the company and its people, portfolio and commitments, please visit www.abbvie.com. Follow @abbvie on Twitter or view careers on our Facebook or LinkedIn page.

Advanced Bio. Lab (ABL)

Rue des Jardiniers, 17
Luxembourg Ville 1835
Luxembourg

www.ablsa.com

ABL offer researchers, clinicians and laboratories efficient diagnostics and IT solutions for sequencing, clinical genotyping and patient management in liver diseases.

HepatiC® is a collaborative, multi-user, patient registry for monitoring HCV-infected patients. Updated on a regular basis with latest drugs and new features. Your daily routine and research database.

ViroScore®, SeqHepB, DeepChek® and VisibleChek® are IT systems designed for molecular analysis and automated dashboard reporting for HCV and HBV infected patients.

DeepChek® SingleRound HCV assays are for Research Use. These genotyping and drug resistance tests are easy-to-perform and ready for Sanger or next generation sequencing (NGS) with clinical reporting included.
Alexion Pharma

Giesshübelstrasse 30
Zürich 8045
Switzerland

www.alexionpharma.eu

Alexion is a global biopharmaceutical company focused on developing and delivering life-transforming therapies for patients with devastating and rare diseases. Patients with these life-threatening diseases often have no effective treatment options, and they and their families suffer with little hope. Our goal is to deliver medical breakthroughs where none currently exist. We are driven because we know people’s lives depend on our work.

ALFA WASSERMANN S.p.A

Via Ragazzi Del ’99, 5
Bologna 40133
Italy

www.alfawassermann.com

Alfa Wassermann was founded in 1948 in Bologna (Italy). It has grown abroad via the establishment of a network of distributors and the setting up of 11 subsidiaries. Alfa Wassermann employs more than 1,500 people. Alfa Wassermann and its subsidiaries are companies of Alfasigma Group.

By believing and investing in research and development, Alfa Wassermann has been able to generate more than 60% of its turnover from original products, manufactured in its GMP-certified production plant. Our major achievement is Rifaximin-α (Normix®, Xifaxan® and others), an innovative intestine-targeted, non-absorbable antibiotic, now available in most countries worldwide, including the USA.

BAXTER

Thurgauerstrasse 130
Glattpark (Opfikon) 8152
Switzerland

www.baxter.com

Every day, around the world, thousands of patients with end-stage renal disease (ESRD) and acute kidney injury (AKI) rely on Baxter for access to essential
treatment. Baxter is dedicated to providing renal patients with the best possible life by elevating the standards of care across all therapeutic options, whether that be in-centre or home for chronic care, or in the ICU or hospital setting for acute care. Baxter Acute Care offers an integrated product and service offering to support critically ill patients requiring extracorporeal blood purification and fluid management to manage one or more failing organs, including the lungs, kidneys and liver.

**BioPredictive**

218 Bld Saint Germain
Paris 75007
France

www.biopredictive.com

BioPredictive offers diagnostic and prognostic blood tests for liver diseases. BioPredictive is dedicated to improve the management of liver diseases. Over a million tests performed worldwide. BioPredictive’s diagnosis and prognosis patented tests (FiboTest-ActiTest, FibroMax, HCV-GenoFibroTest which combines IL28b and surrogate markers, ElastoFibroTest combines surrogate markers and transient elastography) are available on line via a secured and anonymous Internet connection www.biopredictive.com.

FibroTest App (free) including ElastoFibroTest and DAAFibroTest is also available on iPhone and Android.

We invite you to take a look at our online scientific library: http://library.biopredictive.com/

**Biotest AG**

Landsteinerstr. 5
Dreieich 63303
Germany

www.biotest.com

Biotest is a specialist in innovative haematology, clinical immunology and intensive care medicine with headquarters in Germany. Biotest develops, manufactures and markets plasma proteins and biotherapeutic drugs.

These medications are used to treat life-threatening diseases such as blood coagulation disorders (haemophilia), severe infections and immune system disorders. As the global market leader in hyperimmunoglobulins and the
exclusive manufacturer of an IgM-enriched immunoglobulin, Biotest considers itself as a provider of special solutions for the prevention and therapy of life-threatening and rare diseases.

Biotest currently employs more than 2,200 people worldwide.

**Bristol-Myers Squibb Company**

777 Scudders Mill Rd  
Plainsboro Township, New Jersey  
United States

[www.bms.com](http://www.bms.com)

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. Our medicines are helping millions of patients around the world in their fight against cancer, cardiovascular disease, hepatitis C, HIV and rheumatoid arthritis. The Bristol-Myers Squibb Foundation’s philanthropic programs seek to promote health equity and improve the health outcomes among populations disproportionately affected by serious diseases and conditions, giving new hope to some of the world’s most vulnerable people.

**Cepheid**

Vira Solelh  
Maurens Scopont 81470  
France


Cepheid is a leading molecular diagnostics company that is dedicated to improving healthcare by developing, manufacturing, and marketing accurate yet easy-to-use molecular systems and tests. By automating highly complex and time-consuming manual procedures, the company’s solutions deliver a better way for institutions of any size to perform sophisticated genetic testing for organisms and genetic-based diseases. Through its strong molecular biology capabilities, the company is focusing on those applications where accurate, rapid, and actionable test results are needed most, in fields such as critical and healthcare-associated infections, virology, sexual health, genetic diseases and cancer.
Committed To Cure

Hill & Knowlton Limited (Committed to Cure secretariat)
The Buckley Building
49 Clerkenwell Green
London EC1R 0EB
United Kingdom

www.committedtocure.org

Committed to Cure is a new European initiative supporting a future free from hepatitis C by raising awareness of the disease, highlighting the significance of cure, and why it matters.

Lead by a coalition of experts, the initiative aims to achieve two main objectives:

• Create a community of support around hepatitis C cure by sharing real stories of people living with hepatitis C.

• Support people affected by hepatitis C with high quality educational information and practical tools.

www.CommittedtoCure.org

The Committed to Cure initiative has been funded by Gilead Sciences Europe Ltd. Gilead has had no input into the content of the Committed to Cure Initiative.

Dr. Falk Pharma GmbH

Leinenweberstrasse 5
Freiburg 79108
Germany

www.drfalkpharma.de

Dr. Falk Pharma GmbH is an independent family-owned enterprise based in Freiburg/Germany with affiliates in UK and Ireland, the BeNeLux countries, Spain, Portugal and Russia. Dr. Falk Pharma and its over 200 employees are specialised in the development and distribution of pharmaceuticals for hepatological and gastroenterological diseases. These, mainly prescription drugs, are marketed in Germany and more than 60 countries worldwide.

The Falk Foundation e.V. is an independent organisation associated with Dr. Falk Pharma, offering a wide variety of congresses and media to support product independent postgraduate education for doctors on a national and international level.
Echosens

30 place d’Italie
Paris 75013
France

www.echosens.com

Echosens develops, manufactures and markets non-invasive diagnostic products and services: FibroScan, FibroMeter and FibroView. FibroScan, based on proprietary Vibration Control Transient Elastography, is used worldwide in routine clinical practice and research. It has made radical changes to the way hepatologists. The advantages of the technology have been demonstrated in more than 1,000 peer-reviewed publications since 2003. FibroMeter is a range of scores combining several blood biomarkers to measure the degree of fibrosis in the liver. This complete range of blood tests has been the subject of numerous publications in internationally renowned scientific journals and is covered by a series of patents. FibroView offers a broad range of smart connectivity solutions linking FibroScan to the Hospital Information Systems.

Elsevier

Radarweg 29
Amsterdam 1034NX
Netherlands

www.elsevier.com

Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Elsevier Research Intelligence and ClinicalKey — and publishes over 2,500 journals, including The Lancet, Cell and the Journal of Hepatology, plus more than 33,000 book titles, including a number of iconic reference works. Elsevier is part of RELX Group plc, a world-leading provider of information solutions for professional customers across industries.
Epistem Ltd.

48 Grafton Street
Manchester M13 9XX
United Kingdom

www.epistem.co.uk or www.genedrive.com

Epistem is a leading biotechnology and diagnostic company developing near patient PCR assays on our Genedrive platform. Genedrive is a major advance in molecular diagnostic testing by providing a rapid, low cost, simple to use ‘Point of Care’ device with high sensitivity and specificity for use in the diagnosis of infectious diseases and companion diagnostic tests. Epistem has developed an IL28B genotyping test which is conducted from buccal swabs with results obtained in 50 minutes of sample collection. Viral detection, viral load and HepC genotyping tests are in development.

Fresenius Medical Care

Else-Kroener-Str. 1
Bad Homburg 61352
Germany

www.freseniusmedicalcare.com

Fresenius Medical Care is the world’s largest integrated provider of products and services for individuals undergoing dialysis because of chronic kidney failure, a condition that affects more than 1,500,000 individuals worldwide. In patients suffering from severe liver failure (like acute or “acute-on-chronic”), elimination of toxins by dialysis is not enough because here albumin-bound toxins have to be removed, too. With Prometheus®, Fresenius Medical Care offers a therapy system that combines a procedure where a fraction of plasma is separated from blood to remove albumin bound toxins by adsorption with hemodialysis to clear the blood from water soluble substances.

Fujirebio Europe NV

Technologiepark 6
Zwijnaarde 9052
Belgium

www.fujirebio-europe.com

Fujirebio is a leading international healthcare company specialized in high quality IVD testing solutions. The company is world-wide leader in oncology
for routine and novel markers, has solid experience with immunoassay testing solutions and has, as Innogenetics (now Fujirebio Europe), been pioneering the field of molecular diagnostics and multiparameter testing.

Fujirebio Europe’s products in the area of infectious diseases are focused on chronic liver disease, providing molecular monitoring tools for HBV (genotyping, drug resistance mutations, basal core/precore mutations). The LUMIPULSE® G1200 and G600II offers fully automated screening solutions for specialty infectious diseases (HBcrAg, ...) and markers for HCC (AFP/PIVKA-II).

**GE Healthcare**

Beethovenstrasse 239
Solingen 42665
Germany

www.gehealthcare.com

GE Healthcare provides transformational medical technologies and services to meet the demand for increased access, enhanced quality and more affordable healthcare around the world. GE (NYSE: GE) works on things that matter – great people and technologies taking on tough challenges. From medical imaging, software & IT, patient monitoring and diagnostics to drug discovery, biopharmaceutical manufacturing technologies and performance improvement solutions, GE Healthcare helps medical professionals deliver great healthcare to their patients.

**Genetic Analysis AS**

Nycoveien 2
Oslo 0401
Norway

www.genetic-analysis.com

Genetic Analysis AS is a Norwegian biotech company providing a CE-marked gut microbiota analysis for testing gut bacterial imbalance. The analysis allow standardized information for identifying correlations between gut bacteria profiles and disease.
Genfit

885, Avenue Eugène Avinée
Loos 59120
France

www.genfit.com

GENFIT is a biopharmaceutical company focused on the discovery and development of drug candidates in areas of high unmet medical needs corresponding to a lack of suitable treatment. GENFIT’s R&D efforts are focused on bringing therapeutic and diagnostic solutions to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases, that affect the liver (such as NASH – Nonalcoholic steatohepatitis) and more generally the gastro-intestinal arena. GENFIT’s research programs have resulted in the creation of a rich and diversified pipeline of drug candidates. Its lead proprietary compound, Elafibranor, reverses NASH to prevent progression to cirrhosis.

Gilead

333 Lakeside Drive
Foster City CA 94404
United States

www.gilead.com

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. With each new discovery and investigational drug candidate, we seek to improve the care of patients living with life-threatening diseases around the world. Gilead’s therapeutic areas of focus include HIV/AIDS, liver diseases, haematology and oncology, inflammatory and respiratory diseases, and cardiovascular conditions.

Gore & Associates

Europe

www.goremedical.com/eu/

At Gore Medical, we have provided creative therapeutic solutions to complex medical problems for 40 years. During that time, 40 million innovative Gore
Medical Devices have been implanted, saving and improving the quality of lives worldwide.

For more information, visit www.goremedical.com/eu/

**Hepatology- clinical textbook**

Grafenberger Allee 128a
Duesseldorf 40237
Germany

www.hepatologytextbook.com

Hepatology – A Clinical Textbook is an up-to-date source of information for physicians, residents and advanced medical students seeking a broader understanding of liver disease. It is available free of charge at www.hepatologytextbook.com.

**Humedics GmbH**

Marie-Elisabeth-Lüders- Str.1
Berlin 10625
Germany

www.humedics.de

Humedics specializes in real-time liver function measurement. The Germany based company has an innovative breath test, LiMAx, measuring liver function and identifying underlying hepatic impairment. LiMAx serves a role to assist surgeons to optimize the surgical planning, and to provide all clinicians a better and safer basis in the clinical decision-making. The test result from LiMAx together with a well-established LiMAx algorithm for liver surgery provides a new way to estimate the surgical risks. LiMAx test is a new liver function test for predicting postoperative outcome in liver surgery.

**IC-HEP**

The International Coalition of Hepatology Education Providers

7 Century Drive - Suite 104
Parsippany NJ 07054
United States
www.ic-hep.org

IC-HEP (The International Coalition of Hepatology Education Providers) is a global collaboration of leading educational providers that is dedicated to providing healthcare professionals the most current information and clinically meaningful education on hepatitis, with special focus on chronic hepatitis C. With partners from medical societies and global medical education providers, it is our goal to make IC-HEP the premier platform for dissemination of education and information to healthcare providers across the globe.

IC-HEP will identify and prioritize global medical education needs through a collaboration of leading medical experts, medical education providers, universities and communications companies.

For additional information, please visit www.ic-hep.org

infohep.org

Acorn House, 314-320 Grays Inn Road
London WC1X 8DP
United Kingdom

www.infohep.org

infohep.org is a resource for health professionals and advocates working in the hepatitis field across Europe. Launched at the International Liver Congress in 2013, it is a high quality, online resource developed to increase awareness of viral hepatitis, its treatment and the needs of people living with viral hepatitis in Europe.

infohep.org provides cutting edge news reported from major conferences, a directory of hepatitis services across Europe and a free news bulletin, it is a quick, reliable and easy way to keep on top of the issues and developments.

Intercept

450 W 15th St, Ste 505
New York NY 10011
United States

www.interceptpharma.com/

Intercept is a biopharmaceutical company focused on developing and commercializing novel therapeutics to treat underserved chronic liver diseases such as primary biliary cirrhosis, nonalcoholic steatohepatitis, primary
sclerosing cholangitis, and biliary atresia. Our product candidates have the potential to treat liver diseases for which there currently are limited therapeutic options.

**Janssen Pharmaceutica**

Turnhoutseweg 30
Beerse B-2340
Belgium


The Janssen Pharmaceutical Companies of Johnson & Johnson are dedicated to addressing and solving the most important unmet medical needs of our time, including oncology, immunology, neuroscience, infectious disease, and cardiovascular and metabolic diseases. Driven by our commitment to patients, Janssen develops innovative products, services and healthcare solutions to help people throughout the world.

Janssen believes to effectively fight hepatitis, a serious commitment is required from all stakeholders to improve the healthcare infrastructure across the continuum of care, increase awareness, provide education and ensure access to effective treatment. Janssen is working around the world to be a positive catalyst in the fight towards eradication of this deadly disease and serious public health problem.

**Mendes SA**

Via Giacometti 1
Lugano 6900
Switzerland

[www.vivomixx.eu](http://www.vivomixx.eu)

Mendes SA is a pharmaceutical company that commercializes probiotic food supplements. Vivomixx® is the main product, a food supplement containing a combination of 8 different strains of live lactic acid bacteria and bifidobacteria and present in the market with two different formulation: boxes of 10 sachets, providing 450 billion bacteria per sachet, and boxes of 10 capsules, providing 112 billion bacteria per capsule.
Today’s MSD is a global healthcare leader working to help the world be well. Merck is known as MSD outside the United States and Canada. Through our prescription medicines, vaccines, biologic therapies, and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programs and partnerships. For more information, visit www.merck.com and connect with us on Twitter, Facebook and YouTube.

New Insights into HE

New Insights into HE is an educational website developed for HCPs with an interest in improving the identification and management of patients with hepatic encephalopathy (HE).

Educational resources include modules reviewing the pathogenesis of HE, the burden on patients and healthcare resources and appropriate diagnosis and management. There are also interactive, case-based activities, and a Journal Club.

FastFacts discusses identifying patients with HE, initiating appropriate management and the need for better identification and management of patients with HE.

The website is appropriate for those with a primary interest in liver disease and those with more diverse clinical responsibilities.

Norgine

Norgine is a European specialist pharmaceutical company that has been established for over 100 years. Norgine provides expertise and ‘know how’
in Europe to develop, manufacture and market products that offer real value to healthcare professionals, payers and patients. Norgine’s approach and infrastructure is integrated and focused upon ensuring that Norgine wins partnership opportunities for growth. Norgine is headquartered in the Netherlands and its global operations are based in Amsterdam and in Harefield, UK.

Join us for our symposium on Wednesday 13th April at 6:00pm – “Driving change in the management of hepatic encephalopathy.”

For more information, please visit www.norgine.com

**Novartis Pharmaceutical**

Novartis Campus  
Basel CH-4002  
Switzerland

www.novartis.com

Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care and cost-saving generic pharmaceuticals.

Novartis products are available in more than 180 countries around the world. For more information, please visit http://www.novartis.com.

**One Way Liver S.L. (OWL)**

502 bldng, Bizkaia Science and Technology Park  
Derio (Bizkaia) 48160  
Spain

www.owlmetabolomics.com

OWL is a biotechnology company in the field of metabolomics and liver disease. Metabolomics uncovers metabolite alterations in biological samples and provides an overall picture of human or animal health.

OWL’s expertise in detecting subtle metabolite changes has resulted in the discovery of new liver disease biomarkers and the development of unique diagnostic products. In particular, a novel non-invasive test for non-alcoholic fatty liver disease (NAFLD) and its more severe form (steatohepatitis or NASH) has been recently developed.
OWL also offers its unique know-how in metabolomics to provide the scientific community with R&D services in biomarker research and companion diagnostics.

**Orasure Technologies**

220 East 1st Street  
Bethlehem PA 18015  
United States

www.orasure.com

OraSure Technologies manufactures oral fluid devices and other technologies designed to detect or diagnose critical medical conditions. Its innovative products include rapid tests for HIV and HCV antibodies, influenza antigens, testing solutions for detecting drugs of abuse, and oral fluid sample collection, stabilization and preparation products for molecular diagnostic applications.

**Perspectum Diagnostics Ltd**

Oxford Centre for Innovation, New Road  
Oxford OX1 1BY  
United Kingdom

www.perspectum-diagnostics.com

Perspectum Diagnostics delivers medical software solutions and services to aid in the detection and staging of early liver disease and for quantifying disease progression and response to therapy.

Harnessing the power of magnetic resonance imaging (MRI), our first product, LiverMultiScan is a safe, non-invasive alternative to liver biopsy.

Our service model is beneficial to patients and healthcare professional alike, providing a fully supported, next-day analysis service with patient-friendly reports.

Since formation in 2012, Perspectum Diagnostics has analysed over 5000 images, installed on three continents and partnered with pharmaceutical companies in both clinical and preclinical trials.
**PHILIPS**

VB-4 Boschdijk 525 PO Box 80014
Eindhoven 5600JJ
Netherlands

[www.philips.com/healthcare](http://www.philips.com/healthcare)

Creating a healthier future, together at Philips, we look beyond technology to the experiences of patients, providers and caregivers across the health continuum from healthy living to prevention, diagnosis, treatment, recovery and home care. We unlock insights leading to meaningful innovations from hospital to home. Our solutions combine clinical breadth and depth of expertise, technology and services, actionable data, consultative new business models and partnerships. Together, with our customers, we take risks and share responsibility – so that we can transform how care is delivered and experienced. It’s a unique perspective empowering us all to create a healthier future.

**PhoenixBio**

3-4-1 Kagamiyama
Higashi – Hiroshima 739-0046
Japan


PhoenixBio is a Japanese-based company that produces the PXB-Mouse® chimeric animal model, a unique in-vivo research tool for drug discovery and development with a humanized liver consisting of up to 95% human hepatocytes. In order to match the growing need for more accurate and relevant preclinical data in the field of drug discovery and development, we apply this model in the fields of virology, ADME, Toxicology, and Pharmacology to accurately predict human responses. We provide high quality in-house in-vivo drug efficacy evaluations of anti-HBV entry and replication inhibitors together with ADME, Toxicology, and Pharmacology study services.

**PRO.MED.CS Praha a.s**

Telcska 1
Prague 140 00
Czech Republic

[www.promedcs.eu](http://www.promedcs.eu)
PRO.MED.CS Praha a.s. is a leading independent Czech manufacturer of medicinal products for human use with its own research and development facilities. PRO.MED.CS specialises in producing tablets, coated tablets and capsules, manufacturing over 1.5 million units daily. The portfolio primarily focuses on gastrointestinal and cardiovascular medicine. PRO.MED.CS exports to 30 countries around the world, especially the Russian Federation, Central and Eastern Europe and Central Asia. In recent years it has also been gaining a foothold on West European markets. The company's main goal is to bring proven, effective, safe and affordable products to market.

Resoundant, Inc.

221 1st Ave SW, Suite 205
Rochester, Minnesota 55902
United States

www.resoundant.com

Resoundant, Inc. produces magnetic resonance imaging, MRE, technology that is available as an upgrade to MRI scanners manufactured by Philips, GE and Siemens. MRE was developed by Dr. Richard Ehman and his team at the Mayo Clinic. It is available in over 500 locations around the world.

For more information, visit booth #2300D.

507-266-4211 mreinfo@resoundant.com

Roche Molecular Systems, Inc

4300 Hacienda Drive
Pleasanton 94588
United States

www.molecular.roche.com

Headquartered in Pleasanton, California, Roche Molecular Diagnostics (RMD) is a business area of Roche Diagnostics (Basel, Switzerland) that develops, manufactures and supplies a wide array of innovative medical diagnostic products, services, tests, platforms and technologies. With its broad portfolio of oncology, virology, microbiology and blood screening tests, RMD’s clients include researchers, physicians, patients, hospitals, laboratories and blood banks around the world.
The business was founded in the early 1990s following the acquisition of the revolutionary, Nobel-prize winning Polymerase Chain Reaction Technology (PCR). PCR quickly replicates a single specific fragment of DNA or RNA to quantities sufficient for accurate laboratory analysis.

**Sanyal Biotechnology**

800 East Leigh St  
Richmond 23236  
United States  

www.sanyalbio.com

Sanyal Biotechnology is a contract research organization specializing in pre-clinical small animal model screening of drugs. We have developed a proprietary isogenic mouse model, the DIAMOND™ mouse, that develops NAFLD and NASH solely as a result of Western Diet. The progression of the pathology and physiological changes exactly parallel development of human liver disease due to metabolic syndrome. The DIAMOND™ mice develop symptoms of metabolic syndrome including obesity, dyslipidemia, and insulin resistance; additionally, their liver pathology also progresses to cirrhosis and HCC. Our CRO services are performed in an AAALAC-accredited GLP environment.

**Sequana Medical AG**

Technoparkstrasse 1  
Zurich 8005  
Switzerland  

www.sequanamedical.com

Sequana Medical is a Swiss medical device company dedicated to improving patient lives through innovative technologies to manage fluid balance within the body. Sequana Medical’s alfapump® (automated low-flow ascites) system is a fully implantable battery-powered pump system for the management of ascites. The alfapump system automatically and continually moves ascites as it forms to the bladder, significantly reducing the need for large volume paracentesis and improving patient quality of life. Sequana Medical has recently launched its next generation product, alfapump® with DirectLink Technology, which allows clinicians to monitor the alfapump® remotely.
Shire International GmbH

Zählerweg 10
Zug 6300
Switzerland

www.shire.com

Shire enables people with life-altering conditions to lead better lives.

Shire’s strategy is to focus on developing and marketing innovative specialty medicines to meet significant unmet patient needs.

Shire’s focus is on providing treatments in Rare Diseases, Neuroscience, Gastrointestinal, and Internal Medicine and we are developing treatments for symptomatic conditions treated by specialist physicians in other targeted therapeutic areas, such as Ophthalmics.

Siemens Healthcare GmbH

Hartmannstrasse 16
Erlangen 91052
Germany

www.healthcare.siemens.com

Siemens Healthcare is one of the world’s largest suppliers of technology to the healthcare industry and a leader in medical imaging, laboratory diagnostics and healthcare IT. All supported by a comprehensive portfolio of clinical consulting, training, and services available across the globe and tailored to customers’ needs.

Sirtex Medical Europe GmbH

Joseph-Schumpeter-Allee 33
Bonn 53227
Germany

www.sirtex.com

Sirtex Medical is actively engaged in the field of liver-directed therapies for cancer patients. The innovative technology, SIR-Spheres® microspheres (Yttrium-90 resin beads), was approved in 2002 for use in the treatment of a variety of unresectable liver tumours as well as in hepatocellular carcinoma within the European Union under a CE Mark. SIR-Spheres® microspheres
are presently used at 290+ institutions in Europe and the Middle East. Data from SIRFLOX, a RCT evaluating SIR-Spheres Y-90 resin microspheres in combination with a current chemotherapy regimen for the first-line treatment of unresectable colorectal liver metastases, have been published at ASCO in 2015.

**SuperSonic Imagine SA**

510 rue René Descartes; Les Jardins de la Duranne Bat F
Aix en Provence 13857
France

www.supersonicimagine.com

SuperSonic Imagine designs, develops and markets a revolutionary ultrasound system, Aixplorer®, which can acquire images 200 times faster than conventional systems. ShearWave™ Elastography, enabled by the Aixplorer UltraFast platform, is the only technology that provides robust liver stiffness measurements with real-time image guidance. Clinical studies in Hep B, C and NASH patients have demonstrated that SuperSonic Imagine’s ShearWave Elastography is reliable and easy to use. It provides maps and measurements of liver stiffness that help assess the stage of liver fibrosis and monitor disease progression. This non-invasive technology helps reduce the number of liver biopsies.

**Toshiba Medical Systems Europe**

Zilverstraat 1
Zoetermeer 2718RP
Netherlands

www.toshiba-medical.eu/

For over 140 years Toshiba’s research and development has improved the health and welfare of people around the world. Today, Toshiba Medical Systems offers a full range of diagnostic imaging products and is a reliable service partner in more than 135 countries around the globe.

Our Mission is to deliver the best quality products and services, as well as the industry’s best after-sales support through long-term, customer focused partnerships.
Univar BV

Schouwburgplein 30 – 34
Rotterdam 3012 CL
Netherlands

www.univar.com

Founded in 1924, Univar is a leading global distributor of specialty and basic chemicals from a global network of premier suppliers. Univar operates one of the most extensive distribution networks in the world with more than 700 distribution facilities throughout North America, Europe, the Asia-Pacific region, and Latin America, supported by a global network of sales and technical professionals. With a broad portfolio of products and innovative services, and deep technical and market expertise, Univar connects customers with the tailored solutions they need through one of the most extensive distribution networks in the world. Univar is Chemistry DeliveredSM.

Vital Therapies, Inc.

250 0 N 15010 Avenue of Science, Ste. 200
San Diego CA 92128
United States

www.vitaltherapies.com

Vital Therapies®, Inc. (VTL) is a biotherapeutic company developing ELAD®, an extracorporeal human hepatic cell-based liver treatment currently in Phase 3 clinical trials. ELAD is designed to improve survival in patients with liver failure by providing hepatic support continuously for up to five days. We believe that use of ELAD allows time for the patient’s native liver to recover from an acute decompensation, stabilize, and then potentially regenerate, or to maintain the patient until liver transplantation can occur. The ELAD® System is the only bio-artificial liver support system containing immortal human liver-derived cells to enter phase 3 clinical trials.

Wako Chemicals GmbH

3200 K Fuggerstrasse 12
Neuss 41468
Germany

www.wako-chemicals.de
Wako Chemicals GmbH is a leading manufacture of diagnostic reagents. Our products are the result of more than 90 years of dedication to In Vitro Diagnostics.

In the field of hepatology Wako offers biomarkers AFP-L3 and DCP to aid in the early recognition of hepatocellular carcinoma (HCC) in at-risk patients. Implementing the tests to clinical routine increases the possibility of timely application of curative therapies and improved patient outcomes. Both blood tests are CE-marked and available at reference laboratories. Our reagent for Hyaluronic Acid (HA LT) allows automated determination of this marker to be used alone or in fibrosis scores.

**Wiley**

111 River Street  
Hoboken NJ 07030-5774  
United States

www.wiley.com

It’s the knowledge age – and it’s Wiley’s customers who lead the world’s knowledge economy.

Our customers drive progress by providing quality education, the right skills to fulfil global demand and scientific research to fuel innovation. Our customers care, their organizations succeed and the world benefits.

Wiley develops digital education, learning, assessment and certification to help universities, businesses and individuals bridge between education and employment and achieve their ambitions.

We partner with learned societies and support researchers to communicate discoveries that make a difference. Our digital content, books and 1600 online journals build on a 200 year heritage of quality publishing.

**Wilson Therapeutics**

Västra trädgårdsgatan 15  
Stockholm SE-11153  
Sweden

www.wilsontherapeutics.com

Wilson Therapeutics is a privately-held biopharmaceutical company focused on developing novel treatments for Wilson Disease, a rare genetic disease that affects approximately 1 in 15,000.
Wilson Therapeutics is committed to advancing WTX101 through clinical trials with the aim of helping to improve the lives of patients with Wilson Disease.

WTX101, is the proprietary bis-choline salt of tetrathiomolybdate. Tetrathiomolybdate is a novel de-coppering agent – meaning it reduces the body’s level of copper – with high affinity and selectivity for copper.

**Wisepress Medical Bookshop**  
25 High Path  
Merton Abbey  
London SW19 2JL  
United Kingdom

www.wisepress.com

Wisepress.com, Europe’s leading conference bookseller, has a range of books and journals relevant to the themes of the meeting. In addition to attending 200 conferences per year, Wisepress has a comprehensive medical and scientific bookshop online with great offers. Follow us on Twitter for the latest news @WisepressBooks.
ASSOCIATIONS’ PROFILES

AASLD – American Association for the Study of Liver Disease

1001 N Fairfax St., Suite 400
Alexandria VA 22314
United States

www.aasld.org

With 5,000 members from around the world—including hepatologists, surgeons, scientists, trainees, and other health care professionals—AASLD is the leader in education, advocacy, and career development. Become a member at stand 2400K and receive free registration for The Liver Meeting® 2016 (Nov. 11-15, Boston) and a free trial of LiverLearning®, our online education portal.

ALEH – Latin American Association for the Study of the Liver

Estoril 50, of.1005, Las Condes
Santiago 7591047
Chile

www.alehlatam.org

A non-profit scientific association founded in 1968, whose main objective is to promote and disseminate the study of Hepatology in Latin America, through training and the exchange of scientific knowledge and experiences, to reduce current gaps in the world. Through academic activities, ALEH seeks to establish a solid leadership within the field at an international and Latin American level. ALEH is also a member of GLOBAL LIVER SUMMIT. Member countries are: Argentina, Brazil, Bolivia, Chile, Colombia, Costa Rica, Cuba, Ecuador, Guatemala, Mexico, Paraguay, Panama, Peru, Dominican Republic, Uruguay, and Venezuela.

EASL – The European Association for the Study of the Liver

EASL is a medical society and the leading liver association in Europe. It aims to promote liver research and improve the treatment of liver disease throughout the world.
In the 50 plus years since it was founded, EASL has grown from a small organisation to becoming the Home of Hepatology – a leading liver association with over 4,000 hepatology experts as members, and attracting in excess 10,000 delegates at its annual meeting, The International Liver Congress™.

**M3 Medical**

20 Western Avenue  
Milton Park OX14 4SH  
United Kingdom

www.m3medical.com

M3 Medical is a free online community for doctors throughout Europe, designed to offer a secure online platform for discussion and debate.

This exciting new online community has been developed following the feedback of hundreds of physicians across Europe, and delivers the type of collaborative, knowledge-sharing experiences that they have been asking for.

Content is delivered in German, French, Spanish, Italian and English. In addition to blogs and a closed forum exclusively for verified physicians, the portal also offers conference coverage and listings, clinical articles and the latest news and journal summaries.

**Paris Hepatitis Conference Systems Medicine of the Liver – LiSyM**

Hôpital Beaujon  
100 Boulevard du Général Leclerc  
Clichy 92110  
France

www.aphc.info/home

The Paris Hepatitis Conference (PHC) is a high level international meeting that has been providing the state of the art about the management of hepatitis B and C by an outstanding faculty, for the last 11 years. In 2016, 1000 specialists (80 countries) were attending. The conference is held on the behalf of University of Paris. The main purpose of the meeting is to encourage interactivity between the faculty and delegates in order to apply the up to date knowledge to the management of patients (through discussions and workshops). We are looking forward to welcoming you to Paris!
The Cochrane Hepato-Biliary
The CHBG

Blegdamsvej 9
Copenhagen DK 2100
Denmark

www.hbg.cochrane.org

The CHBG, part of Cochrane, is a non-profit, international clinical research group with about 2500 members. Cochrane systematic reviews of interventions for hepatic and biliary diseases are our main product. In issue 1, 2016 of The Cochrane Library, we published 310 peer-reviewed protocols for systematic reviews and 186 systematic reviews. A CHBG Register with about 15500 references on randomised or controlled clinical trials is maintained in the CENTRAL database in The Cochrane Library. Cochrane reviews are not industry funded.

You are welcome to work with us! Come to booth 2400A!

UEG – United European Gastroenterology

Wickenburggasse 1
Vienna 1080
Austria

www.ueg.eu

Together, we are advancing gastroenterological care.

UEG, or United European Gastroenterology, is a professional non-profit organisation combining all the leading European societies concerned with digestive disease.

Together, our member societies represent over 22,000 specialists, working across medicine, surgery, paediatrics, GI oncology and endoscopy. This makes UEG the most comprehensive organisation of its kind in the world, and a unique platform for collaboration and the exchange of knowledge.

Our mission is continually to improve standards of care in gastroenterology, and promote ever greater understanding of digestive and liver disease – among the public and medical experts alike.

Visit www.ueg.eu
# NATIONAL ASSOCIATIONS’ VILLAGE

The Home of Hepatology – Hall 8.0

<table>
<thead>
<tr>
<th>Country</th>
<th>Association</th>
<th>Abbreviation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Armenia</td>
<td>Armenian Hepatological Forum</td>
<td>AHF</td>
</tr>
<tr>
<td>Belgium</td>
<td>Belgian Association for the Study of the Liver</td>
<td>BASL</td>
</tr>
<tr>
<td>United Kingdom</td>
<td>British Liver Trust</td>
<td></td>
</tr>
<tr>
<td>Bulgaria</td>
<td>Bulgarian Association for the Study of the Liver</td>
<td>BgASL</td>
</tr>
<tr>
<td>Denmark</td>
<td>Danish Society of Gastroenterology and Hepatology</td>
<td>DSGH</td>
</tr>
<tr>
<td>France</td>
<td>Association Française pour l’Etude du Foie</td>
<td>AFEF</td>
</tr>
<tr>
<td>Germany</td>
<td>German Association for the Study of the Liver</td>
<td>GASL</td>
</tr>
<tr>
<td>Greece</td>
<td>Hellenic Association for the Study of the Liver</td>
<td>HASL</td>
</tr>
<tr>
<td>Israel</td>
<td>Israel Association for the Study of Liver</td>
<td>IsASL</td>
</tr>
<tr>
<td>Italy</td>
<td>Associazione Italiana per lo Studio del Fegato</td>
<td>A.I.S.F</td>
</tr>
<tr>
<td></td>
<td>Mediterranean Association for Study of the Liver</td>
<td>MASL</td>
</tr>
<tr>
<td>The Netherlands</td>
<td>Netherlands Association for the Study of the Liver</td>
<td>NASL</td>
</tr>
<tr>
<td>Poland</td>
<td>Polish Association for the Study of the Liver</td>
<td>PASL</td>
</tr>
<tr>
<td>Portugal</td>
<td>Associação Portuguesa para o Estudo do Figado</td>
<td>APEF</td>
</tr>
<tr>
<td>Romania</td>
<td>Romanian Association for the Study of the Liver</td>
<td>RASL</td>
</tr>
<tr>
<td>Russia</td>
<td>Russian Scientific Liver Society</td>
<td>RSLS</td>
</tr>
<tr>
<td>Serbia</td>
<td>Hepatology Section of the Serbian Medical Society</td>
<td>HSSMS</td>
</tr>
<tr>
<td>Spain</td>
<td>Asociacion Española para el Estudio del Higado</td>
<td>AEEH</td>
</tr>
<tr>
<td>Switzerland</td>
<td>Swiss Association for the Study of the Liver</td>
<td>SASL</td>
</tr>
<tr>
<td>Turkey</td>
<td>Turkish Association for the Study of the Liver</td>
<td>TASL</td>
</tr>
<tr>
<td>Ukraine</td>
<td>Ukrainian Association for the Study of the Liver Diseases</td>
<td>UASLD</td>
</tr>
</tbody>
</table>
For the reduction in recurrence of overt hepatic encephalopathy (OHE)

Just because they're home, doesn't mean they're out of danger

Xifaxan®550
Targaxan®550
Rifaximin–α

Long-term secondary prophylaxis in HE

Information about this product, including adverse reactions, precautions, contra-indications and method of use can be found at www.medicines.org.uk/emc. Please consult the Summary of Product Characteristics (SmPC) before prescribing, particularly in relation to side-effects, precautions and contra-indications. Further information is available on request from the marketing authorisation holder; Norgine Pharmaceuticals Ltd. Norgine House, Widewater Place, Moorhall Road, Harefield, Middlesex UB9 6NS, UK. Product licence number: PL20011/0020. ATC code: A07AA11. Company reference: GL/XIF/1214/0080. Product under licence from Alfa Wassermann S.p.A. XIFAXAN and TARGAXAN are registered trademarks of the Alfa Wassermann group of companies, licensed to the Norgine group of companies. NORGINE and the sail logo are registered trademarks of the Norgine group of companies. GL/XIF/0116/0134a. Date of preparation: January 2016.

Adverse events should be reported to your regulatory agency. Adverse events should also be reported to your local distributor or Norgine Limited, Norgine House, Moorhall Road, Harefield, Uxbridge, Middlesex UB9 6NS, United Kingdom. Email: globalmedinfo@norgine.com

XIFAXAN®/TARGAXAN® has varying availability and licensing internationally. Before prescribing, consult your country approved prescribing information, available from your local distributor or Norgine Ltd.
Intercept Pharmaceuticals is focused on developing therapies for liver diseases that have few therapeutic options.

You are invited to visit Booth #1200 while attending EASL, The International Liver Congress™, 2016 Barcelona, Spain | 13-17 April 2016

interceptpharma.com
Where a 25-year legacy of innovation in chronic HEPATITIS C treatment\textsuperscript{1,2} meets

AN UNWAVERING COMMITMENT TO THE TASK AT HAND

HEPATITIS C IS A SERIOUS BURDEN THAT CAN HAVE DIRE CONSEQUENCES\textsuperscript{3}

According to the World Health Organization, the human cost of hepatitis C–related liver diseases is staggering: it claims the lives of approximately 500,000 people per year.\textsuperscript{4} However, recent advances in care have led many to believe that elimination of hepatitis C is possible. MSD remains committed more than ever to providing innovative solutions for advancement of chronic hepatitis C treatment and to working towards the ultimate goal of hepatitis C elimination.

Learn more about how MSD is addressing the task at hand by visiting Booth 1600

For more than 25 years, Gilead has worked to develop medicines that address areas of unmet medical need for people around the world.

Our portfolio of medicines and pipeline of investigational drugs include treatments for HIV/AIDS, liver diseases, cancer and inflammation, and serious respiratory and cardiovascular conditions.

Every day we strive to transform and simplify care for people with life-threatening illnesses.
Welcome to EASL
Come Visit Us At Booth 1500
GET NOTIFIED FOR ANY NEWS AND DEVELOPMENTS

Visit easl.eu for more information

SEE YOU NEXT YEAR!